,gender,indications,nctId,phase,recruitment,sponsors,therapies,title,updateDate,variantRequirementDetails,variantRequirements
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT00002651,Phase III,Completed,Southwest Oncology Group ,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}]",Hormone Therapy in Treating Men With Stage IV Prostate Cancer,04/18/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT00002651,Phase III,Completed,Southwest Oncology Group ,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}]",Hormone Therapy in Treating Men With Stage IV Prostate Cancer,04/18/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT00003553,Phase II,Unknown status,"National Heart, Lung, and Blood Institute (NHLBI)","[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer,06/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT00006199,Phase I,Unknown status, National Center for Research Resources (NCRR) ,"[{'id': 938, 'therapyName': 'Tipifarnib'}, {'id': 942, 'therapyName': 'Topotecan'}]","Study of the Farnesyl Transferase Inhibitor, R115777, in Combination With Topotecan (NYU 99-32)",06/20/2017,[],no
0,both,"[{'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}]",NCT00020566,Phase III,Unknown status,University of Leicester ,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2670, 'therapyName': 'Vincristine + Doxorubicin + Dactinomycin + Ifosfamide + Etoposide'}]","Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma",06/20/2017,[],no
0,both,"[{'id': 5151, 'name': 'plexiform neurofibroma', 'source': 'DOID'}]",NCT00030264,Phase II,Completed,Children's Hospital of Philadelphia ,"[{'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Combination Chemotherapy in Treating Patients With Neurofibromatosis and Progressive Plexiform Neurofibromas,06/03/2016,[],no
0,,[],NCT00040222,,"Active, not recruiting",,[],"Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer",04/12/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT00054496,Phase II,Unknown status,The Cleveland Clinic ,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme,06/20/2017,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 2226, 'name': 'myeloproliferative neoplasm', 'source': 'DOID'}]",NCT00074490,Phase II,Completed,National Cancer Institute (NCI),"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers,08/19/2017,[],no
0,both,"[{'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 8584, 'name': 'Burkitt lymphoma', 'source': 'DOID'}, {'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}, {'id': 50458, 'name': 'juvenile myelomonocytic leukemia', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT00084695,Phase II,Unknown status,Milton S. Hershey Medical Center ,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases,06/20/2017,[],no
0,both,"[{'id': 8632, 'name': ""Kaposi's sarcoma"", 'source': 'DOID'}]",NCT00092222,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1187, 'therapyName': 'Alpha 2 Interferon'}, {'id': 2211, 'therapyName': 'EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1008, 'therapyName': 'Doxil'}]",Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity,03/03/2015,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT00114738,Phase II,"Active, not recruiting",National Cancer Institute (NCI) ,"[{'id': 3395, 'therapyName': 'R-EPOCH'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}]",EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma,02/06/2016,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT00129740,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 829, 'therapyName': 'Nilotinib'}]",Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML),07/24/2015,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT00150657,Phase II,Unknown status,St. John Providence Health System,"[{'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}]",Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer,06/20/2017,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT00167180,Phase II,Completed,"Masonic Cancer Center, University of Minnesota ","[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}]",Post Transplant Donor Lymphocyte Infusion,07/12/2017,[],no
0,both,"[{'id': 263, 'name': 'kidney cancer', 'source': 'DOID'}]",NCT00184015,,"Active, not recruiting",University of Southern California,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 688, 'therapyName': 'Bortezomib'}]","Bortezomib and Bevacizumab (""BB-mib-mab"") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)",03/17/2015,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT00223665,Phase II,Unknown status,University of Washington ,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 742, 'therapyName': 'Flutamide'}]",Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy,06/20/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT00254319,Phase II,Unknown status,The Cooper Health System ,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}]",Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC),06/20/2017,[],no
0,both,"[{'id': 3234, 'name': 'central nervous system lymphoma', 'source': 'DOID'}]",NCT00267865,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma,05/06/2015,[],no
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}]",NCT00290485,Phase II,Unknown status,Maisonneuve-Rosemont Hospital ,"[{'id': 770, 'therapyName': 'Imatinib'}]",Gleevec Administered Preoperatively to Reduce Gastrointestinal Stromal Tumor (GIST),06/20/2017,[],no
0,female,"[{'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}]",NCT00292955,Phase II,Unknown status,University of Virginia ,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma",06/20/2017,[],no
0,both,"[{'id': 3234, 'name': 'central nervous system lymphoma', 'source': 'DOID'}]",NCT00293475,Phase Ib/II,Recruiting,OHSU Knight Cancer Institute ,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2669, 'therapyName': 'Carboplatin + Methotrexate + Rituximab'}]",Rituximab and Methotrexate Chemotherapy w/Blood-Brain Barrier Disruption (BBBD) &amp; Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL,05/13/2015,[],no
0,both,"[{'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT00301418,Phase Ib/II,Completed,Weill Medical College of Cornell University ,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma,04/24/2015,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT00301990,Phase II,Unknown status,Jonsson Comprehensive Cancer Center ,"[{'id': 2098, 'therapyName': 'Aldesleukin + Bevacizumab'}]",Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer,06/20/2017,[],no
0,both,"[{'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}, {'id': 5076, 'name': 'mixed glioma', 'source': 'DOID'}]",NCT00303849,Phase Ib/II,Recruiting,OHSU Knight Cancer Institute ,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2562, 'therapyName': 'Etoposide + Melphalan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Combination Chemotherapy With BBBD Followed By Sodium Thiosulfate in Treating Patients With Anaplastic Oligodendroglioma or Oligoastrocytoma,04/22/2015,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT00305682,Phase II,Recruiting,"Masonic Cancer Center, University of Minnesota","[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant,03/04/2015,[],no
0,both,[],NCT00313599,,Completed,"University of California, San Francisco",[],Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors,07/24/2014,[],no
0,both,"[{'id': 5525, 'name': 'anal squamous cell carcinoma', 'source': 'DOID'}]",NCT00316888,Phase II,"Active, not recruiting",Eastern Cooperative Oncology Group ,"[{'id': 1928, 'therapyName': 'Cetuximab + Cisplatin + Fluorouracil + Radiotherapy'}]","Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer",08/30/2016,[],no
0,female,[],NCT00318513,Phase I,Unknown status,Premiere Oncology of Arizona ,[],Safety Study of Bevacizumab to Treat Women With a History of Breast Cancer and Suffering From Upper Extremity Lymphedema,06/20/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT00338377,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization,10/08/2015,[],no
0,both,"[{'id': 3382, 'name': 'liposarcoma', 'source': 'DOID'}, {'id': 1967, 'name': 'leiomyosarcoma', 'source': 'DOID'}, {'id': 4415, 'name': 'fibrous histiocytoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 5485, 'name': 'synovial sarcoma', 'source': 'DOID'}, {'id': 3355, 'name': 'fibrosarcoma', 'source': 'DOID'}]",NCT00356031,Phase II,Completed,Massachusetts General Hospital,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab and Radiation Therapy for Sarcomas,05/20/2017,[],no
0,both,"[{'id': 5660, 'name': 'lymphoepithelioma-like carcinoma', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT00368082,Phase I,"Active, not recruiting",Baylor College of Medicine ,[],"Autologous/Allogeneic TGFbeta-resistant LMP2A-specific CTL, Lymphoma (TGF-beta)",07/28/2015,[],no
0,both,"[{'id': 263, 'name': 'kidney cancer', 'source': 'DOID'}]",NCT00375674,,"Active, not recruiting",Pfizer,"[{'id': 930, 'therapyName': 'Sunitinib'}]", A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer,03/15/2016,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT00378638,Phase II,Unknown status,"Chap, Linnea I., M.D.","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer,06/20/2017,[],no
0,,[],NCT00406445,,Recruiting,,[],Role of p53 Gene in Metabolism Regulation in Patients With Li-Fraumeni Syndrome,02/26/2015,[],no
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT00408772,Phase II,Withdrawn,"University of California, Davis","[{'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}]","Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Cannot Be Removed By Surgery",01/19/2017,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT00411788,Phase II,Completed,Yale University,"[{'id': 1979, 'therapyName': 'Sirolimus + Trastuzumab'}]",A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer,09/22/2016,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT00461773,Phase II,Unknown status,Yale University ,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer,06/20/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT00463060,Phase Ib/II,Unknown status,Mount Sinai School of Medicine ,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer,06/20/2017,[],no
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT00489944,Phase II,Unknown status,San Diego Pacific Oncology & Hematology Associates ,"[{'id': 1963, 'therapyName': 'Sunitinib + Tamoxifen + Cisplatin'}]","Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma",06/20/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT00492505,Phase II,Unknown status,San Diego Pacific Oncology and Hematology Associates ,"[{'id': 2212, 'therapyName': 'Cisplatin + Sorafenib + Tamoxifen'}]","Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma",06/20/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}]",NCT00492687,Phase II,Unknown status,San Diego Pacific Oncology & Hematology Associates ,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas",06/20/2017,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT00513474,Phase I,Completed,Massachusetts General Hospital ,"[{'id': 2313, 'therapyName': 'Rasburicase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2314, 'therapyName': 'Busulfan + Cyclophosphamide + Etoposide'}]",Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant,05/13/2015,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT00520130,Phase Ib/II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2305, 'therapyName': 'Alemtuzumab + Cyclosporine'}, {'id': 2306, 'therapyName': 'Rituximab + Fludarabine + EPOCH'}, {'id': 2307, 'therapyName': 'Fludarabine + EPOCH'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,10/30/2015,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT00536991,Phase Ib/II,Terminated,Roswell Park Cancer Institute ,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2889, 'therapyName': 'calcitriol'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]","Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer",10/28/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT00538005,Phase Ib/II,Unknown status,San Diego Pacific Oncology & Hematology Associates,"[{'id': 2132, 'therapyName': 'Sorafenib + Bevacizumab + Oxaliplatin'}]","Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma",06/20/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT00541047,Phase III,"Active, not recruiting",Medical Research Council ,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS),10/14/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT00547105,Phase II,Unknown status,"Simmons Cancer Center, National Cancer Institute (NCI)","[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib and Stereotactic Body Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Non-Small Call Lung Cancer,06/20/2017,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT00549848,Phase III,"Active, not recruiting",St. Jude Children's Research Hospital ,"[{'id': 1781, 'therapyName': 'Vincristine + Pegaspargase + Daunorubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1782, 'therapyName': 'Clofarabine + Etoposide + Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia,04/12/2017,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT00550992,Phase I,Unknown status,Dutch Childhood Oncology Group ,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia,06/20/2017,[],yes
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 7438, 'name': 'ovarian clear cell cystadenocarcinoma', 'source': 'DOID'}, {'id': 5746, 'name': 'ovarian serous cystadenocarcinoma', 'source': 'DOID'}, {'id': 3604, 'name': 'ovarian mucinous cystadenocarcinoma', 'source': 'DOID'}, {'id': 4217, 'name': 'malignant ovarian Brenner tumor', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT00565851,Phase III,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel and Gemcitabine With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer",06/20/2017,[],no
0,both,[],NCT00566800,Phase I,Unknown status,Kansas City Veteran Affairs Medical Center ,[],Erlotinib in Treating Patients With Barrett Esophagus,06/20/2017,[],no
0,both,[],NCT00566995,,Completed,National Cancer Institute (NCI),[],Phase II Study of Vandetanib in Individuals With Kidney Cancer,04/08/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT00569296,,Terminated,Roger Williams Medical Center,"[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}]"," Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer",03/25/2015,"[{'molecularProfile': {'id': 1102, 'profileName': 'EGFR positive'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 60077, 'name': 'progesterone-receptor positive breast cancer', 'source': 'DOID'}]",NCT00570323,Phase II,"Active, not recruiting",Baylor Breast Care Center,"[{'id': 1911, 'therapyName': 'Anastrozole  + Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer,08/12/2017,[],yes
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT00573378,Phase II,Withdrawn,University of Michigan Cancer Center ,"[{'id': 2467, 'therapyName': 'Imatinib + Interferon alfa-2b '}, {'id': 2468, 'therapyName': 'Interferon alfa-2b + Nilotinib '}]",Imatinib or Nilotinib With Pegylated Interferon-alpha2b in Chronic Myeloid Leukemia,06/25/2016,[],yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT00573989,Phase Ib/II,Terminated,Comprehensive Cancer Center of Wake Forest University ,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}]","Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer",09/01/2016,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT00574587,Phase Ib/II,Unknown status,Montefiore Medical Center ,"[{'id': 1983, 'therapyName': 'vorinostat + Paclitaxel'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]","Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis",07/03/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT00576654,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 954, 'therapyName': 'Veliparib'}]",Irinotecan Hydrochloride and Veliparib in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery,12/02/2016,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}]",NCT00577278,Phase II,"Active, not recruiting",City of Hope Medical Center ,"[{'id': 767, 'therapyName': 'Ibritumomab'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma",06/03/2015,[],no
0,,[],NCT00579683,,Completed,Memorial Sloan Kettering Cancer Center ,[],Registry for Patients With Acquired Resistance to Small Molecule Kinase Inhibitors in Non-Small-Cell Lung Cancer,02/05/2016,[],no
0,both,"[{'id': 50744, 'name': 'anaplastic large cell lymphoma', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT00585195,Phase I,Recruiting,Pfizer,"[{'id': 1526, 'therapyName': 'Crizotinib + Itraconazole\t'}, {'id': 1483, 'therapyName': 'Crizotinib + Rifampin'}]","A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer",12/06/2016,"[{'molecularProfile': {'id': 1240, 'profileName': 'MET positive'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1771, 'profileName': 'ROS1 positive'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1629, 'profileName': 'MET amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2096, 'profileName': 'MET act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT00588770,Phase III,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1832, 'therapyName': 'Carboplatin + Fluorouracil\t'}]",Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,03/17/2015,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT00589420,Phase II,Unknown status,University of Pennsylvania ,"[{'id': 2390, 'therapyName': 'Docetaxel + Sorafenib'}]",Sorafenib and Docetaxel in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy,06/20/2017,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}]",NCT00602329,Phase II,Unknown status,University of Pennsylvania ,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer,06/20/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT00602602,Phase II,"Active, not recruiting",University of Pennsylvania ,"[{'id': 2102, 'therapyName': 'Bevacizumab + Fluorouracil + Oxaliplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer",02/08/2017,[],no
0,both,"[{'id': 4794, 'name': 'ependymoblastoma', 'source': 'DOID'}, {'id': 60108, 'name': 'brain glioma', 'source': 'DOID'}, {'id': 3869, 'name': 'childhood medulloblastoma', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 1664, 'name': 'pineoblastoma', 'source': 'DOID'}, {'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 2129, 'name': 'atypical teratoid rhabdoid tumor', 'source': 'DOID'}, {'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}, {'id': 4791, 'name': 'supratentorial primitive neuroectodermal tumor', 'source': 'DOID'}]",NCT00602667,Phase I,"Active, not recruiting",St. Jude Children's Research Hospital,"[{'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 2450, 'therapyName': 'Cyclophosphamide + Etoposide + Topotecan'}, {'id': 2451, 'therapyName': 'Erlotinib + Cyclophosphamide + Topotecan'}]","Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma",05/05/2017,[],no
0,both,"[{'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 1039, 'name': 'prolymphocytic leukemia', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 12603, 'name': 'acute leukemia', 'source': 'DOID'}, {'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT00602693,Phase I,Completed,"Masonic Cancer Center, University of Minnesota ","[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2311, 'therapyName': 'Allopurinol + Cyclophosphamide + Fludarabine'}]",T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer,02/11/2017,[],no
0,both,[],NCT00608361,,Completed,National Cancer Institute (NCI),[], Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery,06/27/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT00610948,Phase I,Completed,UNC Lineberger Comprehensive Cancer Center,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 845, 'therapyName': 'Panitumumab'}]","Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment",01/26/2016,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT00618657,Phase II,"Active, not recruiting","University of California, Irvine","[{'id': 1490, 'therapyName': 'Nab-paclitaxel + Carboplatin + Trastuzumab'}, {'id': 1489, 'therapyName': 'Nab-paclitaxel + Carboplatin + Bevacizumab'}]","Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting",12/01/2016,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 1240, 'name': 'leukemia', 'source': 'DOID'}]",NCT00620633,Phase I,"Active, not recruiting",Memorial Sloan Kettering Cancer Center ,"[{'id': 2901, 'therapyName': 'WT1 senstized T cells'}]",Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation,04/01/2016,[],yes
0,,"[{'id': 3234, 'name': 'central nervous system lymphoma', 'source': 'DOID'}]",NCT00621036,Phase II,Unknown status,Simmons Cancer Center ,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma,06/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT00625378,Phase III,Recruiting,Bayer,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Long Term Extension Program (STEP),08/31/2015,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT00651976,Phase I,Suspended,Vanderbilt-Ingram Cancer Center ,"[{'id': 794, 'therapyName': 'Letrozole'}]","Letrozole in Treating Postmenopausal Women With Stage I, II or III Breast Cancer That Can Be Removed by Surgery",07/20/2017,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT00658658,Phase I,Completed,Amgen,"[{'id': 845, 'therapyName': 'Panitumumab'}]",Panitumumab Pediatric Study,10/09/2015,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT00660218,Phase Ib/II,Unknown status,State University of New York - Upstate Medical University ,"[{'id': 1988, 'therapyName': 'Paclitaxel + Cetuximab'}]","A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer",06/20/2017,[],no
0,both,"[{'id': 60108, 'name': 'brain glioma', 'source': 'DOID'}]",NCT00660621,Phase II,Unknown status,"Kentuckiana Cancer Institute, Eisai Inc.","[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]","A Phase II Study Of Gliadel, Concomitant Temozolomide And Radiation, Followed By Dose Dense Therapy With Temozolomide Plus Bevacizumab For Newly Diagnosed Malignant High Grade Glioma",06/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 7757, 'name': 'childhood leukemia', 'source': 'DOID'}]",NCT00665990,Phase I,Completed,St. Jude Children's Research Hospital,"[{'id': 1119, 'therapyName': 'Sorafenib + Avastin + Cyclophosphamide'}]",Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia,09/09/2014,[],no
0,both,"[{'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT00669669,Phase Ib/II,"Active, not recruiting",Fred Hutchinson Cancer Research Center,"[{'id': 2556, 'therapyName': 'O6-benzylguanine'}, {'id': 2555, 'therapyName': 'Carmustine + Filgrastim + Plerixafor + Temozolomide'}]",Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas,08/13/2016,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT00670046,Phase II,Unknown status,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 1076, 'therapyName': 'Valproic acid'}]","Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer",06/20/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 50744, 'name': 'anaplastic large cell lymphoma', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 285, 'name': 'hairy cell leukemia', 'source': 'DOID'}, {'id': 60061, 'name': 'cutaneous T cell lymphoma', 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT00671112,Phase I,Terminated,"Brian Hill, MD, PhD ","[{'id': 2234, 'therapyName': 'Bortezomib + Everolimus'}]",Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma,10/29/2015,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT00679536,Phase Ib/II,Unknown status,Ann & Robert H Lurie Children's Hospital of Chicago,"[{'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}]",Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors,06/20/2017,[],no
0,both,"[{'id': 4305, 'name': 'bone giant cell tumor', 'source': 'DOID'}]",NCT00680992,Phase II,"Active, not recruiting",Amgen ,"[{'id': 1198, 'therapyName': 'Denosumab'}]",Study of Denosumab in Subjects With Giant Cell Tumor of Bone,04/22/2016,[],no
0,both,[],NCT00690924,Phase I,"Active, not recruiting",Roswell Park Cancer Institute ,[],Calcitriol in Preventing Lung Cancer in Smokers and Former Smokers at High Risk of Lung Cancer,04/08/2017,[],no
0,female,[],NCT00694759,,Unknown status,Oregon Health and Science University ,[],Cortisol Regulation in Polycystic Ovary Syndrome (PCOS),06/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT00697632,Phase I,Recruiting,MethylGene Inc.,"[{'id': 809, 'therapyName': 'MGCD265'}]",Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies,08/31/2015,"[{'molecularProfile': {'id': 1112, 'profileName': 'MET alterations'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1240, 'profileName': 'MET positive'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1629, 'profileName': 'MET amp'}, 'requirementType': 'partial'}]",yes
0,,[],NCT00700414,,Recruiting,,[],International Pediatric Adrenocortical Tumor Registry,02/24/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT00700882,Phase II,Unknown status,Eastern Cooperative Oncology Group,"[{'id': 717, 'therapyName': 'Dasatinib'}]","Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery",06/20/2017,[],no
0,both,"[{'id': 1107, 'name': 'esophageal carcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT00702884,Phase II,Completed,Ohio State University Comprehensive Cancer Center ,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib in Treating Patients With Relapsed or Refractory Esophageal or Gastroesophageal Junction Cancer,04/24/2015,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT00717587,Phase II,Unknown status,Abramson Cancer Center of the University of Pennsylvania ,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2129, 'therapyName': 'girentuximab'}, {'id': 2128, 'therapyName': 'motexafin gadolinium'}]",Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer,06/20/2017,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT00718263,Phase III,Recruiting,Novartis Pharmaceuticals,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}]",Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase),03/26/2015,[],yes
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT00719875,Phase Ib/II,Completed,Yale University ,"[{'id': 1077, 'therapyName': 'Vorinostat'}]",HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer,03/04/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT00730158,Phase II,Suspended,University of Pittsburgh ,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1699, 'therapyName': 'KD018'}]","A Phase II Multicenter, Randomized, Placebo Controlled, Double Blinded Clinical Study of KD018 as a Modulator of Irinotecan Chemotherapy in Patients With Metastatic Colorectal Cancer",08/02/2017,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT00733408,Phase II,"Active, not recruiting",University of Washington,"[{'id': 1496, 'therapyName': 'Abraxane + Bevacizumab + Erlotinib'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer,01/08/2016,"[{'molecularProfile': {'id': 530, 'profileName': 'ERBB2 wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT00734877,Phase III,Recruiting,University of Arkansas,"[{'id': 1851, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide + Etoposide'}, {'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}]","UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma",12/24/2014,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT00740805,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 2989, 'therapyName': 'Aldoxorubicin + Cyclophosphamide + Veliparib'}]","Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma",07/31/2015,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT00747305,Phase I,Terminated,Medical University of South Carolina ,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery,10/23/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT00756340,Phase I,Completed,St. Jude Children's Research Hospital,"[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]",A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors,10/15/2015,[],no
0,female,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}, {'id': 60077, 'name': 'progesterone-receptor positive breast cancer', 'source': 'DOID'}]",NCT00759642,Phase II,"Active, not recruiting",University of Kansas ,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy,05/24/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT00761644,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1121, 'therapyName': 'Bevacizumab + Temsirolimus + Doxil'}]","Doxil, Bevacizumab and Temsirolimus Trial",06/01/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT00764972,Phase Ib/II,Unknown status,McGill University ,"[{'id': 2357, 'therapyName': 'Sorafenib + Vinorelbine'}]",Phase IB/II Trial Combining Vinorelbine With Sorafenib as First-Line Treatment in Patients With Metastatic Breast Cancer,06/20/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,[],NCT00770263,,Completed,Washington University School of Medicine,[], Erlotinib and Temsirolimus for Solid Tumors,12/08/2014,[],yes
0,female,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT00776867,Phase I,Completed,Memorial Sloan-Kettering Cancer Center,"[{'id': 855, 'therapyName': 'Perifosine'}]",Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors,08/02/2017,[],no
0,,"[{'id': 1240, 'name': 'leukemia', 'source': 'DOID'}]",NCT00777036,,"Active, not recruiting",,"[{'id': 717, 'therapyName': 'Dasatinib'}]",A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib,12/19/2014,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT00780494,Phase II,Unknown status,Pamela L. Kunz ,"[{'id': 2096, 'therapyName': 'Bevacizumab + Capecitabine + Carboplatin'}]","Ph II of Capecitabine, Carboplatin and Bevacizumab for Gastroesophageal Junction and Gastric Carcinoma",06/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT00781612,Phase II,Recruiting,"Genentech, Inc.","[{'id': 5471, 'therapyName': 'Trastuzumab + trastuzumab emtansine'}, {'id': 5470, 'therapyName': 'Paclitaxel + trastuzumab emtansine'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 3930, 'therapyName': 'Docetaxel + T-DM1'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies,03/23/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT00790816,Phase I,Completed,GlaxoSmithKline ,"[{'id': 1410, 'therapyName': 'Lapatinib + Paclitaxel'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1497, 'therapyName': 'Lapatinib + Letrozole'}, {'id': 1498, 'therapyName': 'Lapatinib + Oxaliplatin + Capecitabine'}, {'id': 1499, 'therapyName': 'Lapatinib + Gemcitabine'}, {'id': 1500, 'therapyName': 'Lapatinib + Docetaxel'}, {'id': 1501, 'therapyName': 'Lapatinib + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1502, 'therapyName': 'Lapatinib + Irinotecan + Leucovorin + Fluorouracil'}]",Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents,11/03/2016,[],no
0,both,"[{'id': 6166, 'name': 'prostatic urethra urothelial carcinoma', 'source': 'DOID'}, {'id': 6571, 'name': 'non-invasive bladder urothelial carcinoma', 'source': 'DOID'}]",NCT00794950,Phase II,"Active, not recruiting",University of Michigan,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma,08/11/2015,[],no
0,female,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT00796978,Phase II,Unknown status,"Cynthia Owusu, MD ","[{'id': 947, 'therapyName': 'Trastuzumab'}]",Trastuzumab in Treating Older Women With Early-Stage Breast Cancer,07/03/2017,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 120, 'name': 'female reproductive organ cancer', 'source': 'DOID'}]",NCT00800345,Phase I,Completed,Accelerated Community Oncology Research Network,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors,04/14/2016,[],no
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}]",NCT00812240,Phase III,Unknown status,AB Science ,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 770, 'therapyName': 'Imatinib'}]",A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment,06/20/2017,"[{'molecularProfile': {'id': 851, 'profileName': 'KIT positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 350, 'name': 'mastocytosis', 'source': 'DOID'}]",NCT00814073,Phase III,Unknown status,AB Science ,"[{'id': 804, 'therapyName': 'Masitinib'}]","A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap",06/20/2017,[],no
0,both,"[{'id': 60108, 'name': 'brain glioma', 'source': 'DOID'}]",NCT00823459,Phase II,Completed,"University of California, San Francisco ","[{'id': 735, 'therapyName': 'Everolimus'}]",Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma,06/19/2017,[],no
0,female,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT00826085,Phase Ib/II,Completed,Celsion,"[{'id': 1054, 'therapyName': 'ThermoDox'}]",Phase 1/2 Study of ThermoDox With Approved Hyperthermia in Treatment of Breast Cancer Recurrence at the Chest Wall,03/03/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT00828009,Phase II,Unknown status,Eastern Cooperative Oncology Group ,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 2142, 'therapyName': 'Emepepimut-S  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery,06/20/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT00828919,Phase I,"Active, not recruiting",Pfizer,"[{'id': 649, 'therapyName': 'Axitinib'}]",Continuing Access To AG- 013736 (A406) For Patients Previously Receiving AG 013736 In Clinical Trials,05/04/2016,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT00829647,Phase Ib/II,Withdrawn,Scripps Health,"[{'id': 1825, 'therapyName': 'Dasatinib + lenalidomide'}]",A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia,07/20/2017,[],no
0,both,"[{'id': 4471, 'name': 'chromophobe renal cell carcinoma', 'source': 'DOID'}, {'id': 4465, 'name': 'papillary renal cell carcinoma', 'source': 'DOID'}, {'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT00831480,Phase II,Terminated,Gilad Amiel ,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus(RAD001) For Advanced Renal Cell Carcinoma(RCC)Before Kidney Removal,03/22/2016,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT00838955,Phase II,Unknown status,Loyola University ,"[{'id': 936, 'therapyName': 'Temsirolimus'}]",Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma,06/20/2017,[],no
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT00842257,Phase II,Completed,Massachusetts General Hospital ,"[{'id': 845, 'therapyName': 'Panitumumab'}]",Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer,05/17/2017,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50773, 'name': 'paraganglioma', 'source': 'DOID'}, {'id': 5719, 'name': 'adrenal medulla cancer', 'source': 'DOID'}]",NCT00843037,Phase II,Completed,"University Health Network, Toronto ","[{'id': 930, 'therapyName': 'Sunitinib'}]",Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma,04/05/2017,[],no
0,both,[],NCT00854152,,Completed,Genentech,"[{'id': 750, 'therapyName': 'GDC-0980'}]", A Study Evaluating GDC-0980 Administered Once Daily in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma,01/08/2015,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT00857389,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies,08/07/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT00858377,Phase I,"Active, not recruiting",Amgen,"[{'id': 983, 'therapyName': 'AMG 900'}]",A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors,07/28/2014,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT00859781,Phase II,Recruiting,Weill Medical College of Cornell University ,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer,06/19/2015,[],no
0,both,[],NCT00863122,Phase I,Unknown status,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Concentration and Activity of Lapatinib in Vestibular Schwannomas,06/20/2017,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT00866281,Phase Ib/II,Terminated,Novartis Pharmaceuticals,"[{'id': 810, 'therapyName': 'Midostaurin'}]",A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia,12/23/2015,[],no
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT00871169,Phase II,Completed,New Mexico Cancer Care Alliance ,"[{'id': 1919, 'therapyName': 'Irinotecan + Oxaliplatin + Cetuximab'}]","Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer",12/04/2015,[],no
0,both,[],NCT00875238,Phase II,Unknown status,Vanderbilt University ,[],Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab,06/20/2017,[],no
0,both,"[{'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}, {'id': 5509, 'name': 'pediatric ependymoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT00876993,Phase I,Completed,All Children’s Hospital Johns Hopkins Medicine ,"[{'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]",Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors,06/14/2016,[],no
0,both,"[{'id': 4202, 'name': 'brain stem glioma', 'source': 'DOID'}, {'id': 6128, 'name': 'gliomatosis cerebri', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT00879437,Phase II,"Active, not recruiting",Baylor College of Medicine ,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas,01/22/2016,[],no
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT00885326,Phase I,"Active, not recruiting",New Approaches to Neuroblastoma Therapy Consortium ,"[{'id': 2072, 'therapyName': 'Bevacizumab + Cyclophosphamide + Zoledronic acid'}]","N2007-02:Bevacizumab,Cyclophosphamide,and Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma",03/19/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT00887068,Phase III,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 651, 'therapyName': 'Azacitidine'}]",Randomized Allogeneic Azacitidine Study,04/18/2017,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT00889954,Phase I,"Active, not recruiting",Baylor College of Medicine ,"[{'id': 1403, 'therapyName': 'Autologous TGF beta resistant HER2 EBV CTLs'}]",Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy,07/29/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT00892190,Phase I,Completed,University of Pittsburgh,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome,02/11/2016,[],no
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT00892736,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 954, 'therapyName': 'Veliparib'}]",Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy,07/31/2015,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,[],NCT00900744,FDA approved,Completed,Mount Sinai School of Medicine ,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6,08/26/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}]",NCT00902044,Phase I,Recruiting,Baylor College of Medicine ,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2940, 'therapyName': 'HER2 sensitized T-cells'}]",Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma,07/21/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}]",NCT00903461,Phase Ib/II,Terminated,Jennifer Rubin Grandis ,"[{'id': 2130, 'therapyName': 'EGFR Antisense DNA'}]",Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma,02/16/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT00903968,Phase Ib/II,Completed,Dana-Farber Cancer Institute ,"[{'id': 3348, 'therapyName': 'Bortezomib + Plerixafor'}]",Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma,09/30/2017,[],no
0,both,"[{'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}]",NCT00904345,Phase II,"Active, not recruiting",University of Michigan Cancer Center ,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC),10/04/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}]",NCT00906516,Phase II,Unknown status,Bradmer Pharmaceuticals Inc. ,"[{'id': 2146, 'therapyName': 'Neuradiab + Bevacizumab'}]",Neuradiab Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme,06/20/2017,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT00908167,Phase I,Completed,St. Jude Children's Research Hospital ,"[{'id': 2374, 'therapyName': 'Clofarabine + Cytarabine + Sorafenib'}]",Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies,07/14/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT00909831,Phase I,"Active, not recruiting",University of Pennsylvania ,"[{'id': 2302, 'therapyName': 'Hydroxychloroquine + Temsirolimus '}]",Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment,02/11/2016,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT00912340,Phase II,"Active, not recruiting",Emory University,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer,11/10/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT00915993,Phase I,Unknown status,University of Pennsylvania ,"[{'id': 930, 'therapyName': 'Sunitinib'}]",MRI in Predicting Response to Sunitinib Malate in Patients With Stage IV Kidney Cancer,06/20/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT00918333,Phase Ib/II,"Active, not recruiting",Mayo Clinic ,"[{'id': 1964, 'therapyName': 'Panobinostat + Everolimus'}]","Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma",06/26/2015,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT00918463,Phase II,Completed,Weill Medical College of Cornell University,"[{'id': 717, 'therapyName': 'Dasatinib'}]",A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL),02/10/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT00921115,Phase II,"Active, not recruiting",University of Kansas ,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.,12/02/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 263, 'name': 'kidney cancer', 'source': 'DOID'}]",NCT00923130,Phase II,Completed,National Cancer Institute (NCI),"[{'id': 1122, 'therapyName': 'Bevacizumab + Ixabepilone'}]",Bevacizumab Plus Ixabepilone to Treat Patients With Advanced Kidney Cancer,06/18/2016,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT00923845,Phase II,Completed,National Cancer Institute (NCI),"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2308, 'therapyName': 'Cyclophosphamide + Pentostatin'}]",Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer,09/30/2017,[],no
0,both,"[{'id': 8632, 'name': ""Kaposi's sarcoma"", 'source': 'DOID'}]",NCT00923936,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1673, 'therapyName': 'Doxil + Bevacizamub'}]",Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposi s Sarcoma,06/20/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT00925132,Phase Ib/II,Terminated,University of Iowa ,"[{'id': 1737, 'therapyName': 'Decitabine + Temozolomide + Panobinostat'}]","Treatment of Resistant Metastatic Melanoma Using Decitabine, Temozolomide and Panobinostat",07/03/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT00926640,Phase I,Completed,National Cancer Institute (NCI),"[{'id': 1123, 'therapyName': 'Belinostat + Cisplatin + Etoposide'}]",A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers,06/20/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT00932451,Phase II,Completed,Pfizer,"[{'id': 706, 'therapyName': 'Crizotinib'}]","An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene",02/09/2016,"[{'molecularProfile': {'id': 2446, 'profileName': 'ALK fusion'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT00936390,Phase III,"Active, not recruiting",Radiation Therapy Oncology Group ,"[{'id': 742, 'therapyName': 'Flutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer,03/10/2016,[],no
0,both,"[{'id': 2994, 'name': 'germ cell cancer', 'source': 'DOID'}]",NCT00936936,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2100, 'therapyName': 'Docetaxel + Gemcitabine + Melphalan'}, {'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors,02/19/2015,[],no
0,both,"[{'id': 1785, 'name': 'pituitary cancer', 'source': 'DOID'}, {'id': 5394, 'name': 'prolactinoma', 'source': 'DOID'}]",NCT00939523,Phase II,Recruiting,Cedars-Sinai Medical Center ,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy,03/20/2015,[],no
0,both,"[{'id': 10000004, 'name': 'Pediatric Solid Tumors', 'source': 'JAX'}, {'id': 50744, 'name': 'anaplastic large cell lymphoma', 'source': 'DOID'}, {'id': 3620, 'name': 'central nervous system cancer', 'source': 'DOID'}, {'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT00939770,Phase Ib/II,"Active, not recruiting",Children's Oncology Group,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,01/16/2016,"[{'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1760, 'profileName': 'ALK amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT00940316,Phase II,"Active, not recruiting",Northwestern University ,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1940, 'therapyName': 'Panitumumab + Erlotinib'}]",Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer,04/14/2015,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,[],NCT00940381,,Completed,M.D. Anderson Cancer Center,[], Sirolimus and Cetuximab in Advanced Malignancies,07/27/2014,[],no
0,both,"[{'id': 734, 'name': 'urethra cancer', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 4011, 'name': 'prostate transitional cell carcinoma', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 11819, 'name': 'ureter cancer', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 4007, 'name': 'bladder carcinoma', 'source': 'DOID'}]",NCT00942331,Phase III,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer,12/09/2014,[],no
0,both,"[{'id': 4239, 'name': 'alveolar soft part sarcoma', 'source': 'DOID'}]",NCT00942877,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1001, 'therapyName': 'Cediranib'}]",Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma,09/14/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}]",NCT00946647,Phase II,"Active, not recruiting",Novartis Pharmaceuticals ,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).",07/13/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT00950365,Phase II,Unknown status,"Montefiore Medical Center, Eli Lilly and Company, OSI Pharmaceuticals","[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Pharmacodynamic Separation of Pemetrexed and Erlotinib as Second-line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC),06/20/2017,[],no
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 6170, 'name': 'ovarian carcinosarcoma', 'source': 'DOID'}, {'id': 5165, 'name': 'uterine corpus sarcoma', 'source': 'DOID'}]",NCT00954174,Phase III,"Active, not recruiting",Gynecologic Oncology Group,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1125, 'therapyName': 'Paclitaxel + Ifosfamide'}]","Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritorium Cavity Cancer",08/05/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT00956007,Phase III,Recruiting,Radiation Therapy Oncology Group,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer,01/06/2015,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT00957853,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 701, 'therapyName': 'Cixutumumab'}]",Preoperative Treatment With Cetuximab and/or IMC-A12,04/24/2015,[],no
0,both,"[{'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}]",NCT00959868,Phase I,Unknown status,Vancouver Coastal Health ,"[{'id': 1807, 'therapyName': 'OGX-427'}]",A Study for Treatment of Superficial Bladder Cancer Using OGX-427,06/20/2017,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT00967655,Phase II,Unknown status,"Loma Linda Oncology Medical Group, Incorporated ","[{'id': 1960, 'therapyName': 'Capecitabine + Panitumumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}]","Capecitabine, Panitumumab, and Radiation Therapy With or Without Irinotecan Hydrochloride in Treating Patients Undergoing Surgery for Localized Rectal Cancer",06/20/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}]",NCT00968240,Phase I,Completed,Weill Medical College of Cornell University ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab),04/24/2015,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT00968968,Phase III,"Active, not recruiting",GlaxoSmithKline,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}]",Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone,12/03/2014,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}]",NCT00970502,Phase Ib/II,Completed,Mount Sinai School of Medicine,"[{'id': 2125, 'therapyName': 'Celecoxib + Erlotinib'}]","Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer",04/11/2017,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT00971737,Phase II,Unknown status,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer,09/02/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT00975767,Phase Ib/II,Terminated,MethylGene Inc.,"[{'id': 1127, 'therapyName': 'MGCD265 + Docetaxel'}, {'id': 1126, 'therapyName': 'MGCD265 + Erlotinib'}]",A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer,09/04/2014,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT00976573,,Completed,North Central Cancer Treatment Group,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma",03/08/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}, {'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT00978250,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 3789, 'therapyName': 'FdCyd + THU'}]",A Multi-Histology Phase II Study of 5-Fluoro-2-Deoxycytidine With Tetrahydrouridine (FdCyd + THU),03/20/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT00978432,Phase II,Terminated,"Anne Beaven, MD","[{'id': 1964, 'therapyName': 'Panobinostat + Everolimus'}]",Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL),06/08/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT00979212,Phase II,"Active, not recruiting",Radiation Therapy Oncology Group,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10),01/22/2016,[],no
0,both,"[{'id': 687, 'name': 'hepatoblastoma', 'source': 'DOID'}]",NCT00980460,Phase III,Recruiting,National Cancer Institute (NCI),"[{'id': 2298, 'therapyName': 'Irinotecan + Temsirolimus + Vincristine'}, {'id': 2297, 'therapyName': 'Cisplatin + Fluorouracil + Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer,03/05/2015,[],no
0,female,"[{'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}]",NCT00980954,Phase III,Recruiting,Radiation Therapy Oncology Group ,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy,12/25/2014,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT00981890,Phase I,"Active, not recruiting","University Health Network, Toronto ","[{'id': 930, 'therapyName': 'Sunitinib'}]",Stereotactic Radiosurgery With Sunitinib for Brain Metastases,06/17/2015,[],no
0,both,"[{'id': 2994, 'name': 'germ cell cancer', 'source': 'DOID'}, {'id': 2129, 'name': 'atypical teratoid rhabdoid tumor', 'source': 'DOID'}, {'id': 1664, 'name': 'pineoblastoma', 'source': 'DOID'}, {'id': 4794, 'name': 'ependymoblastoma', 'source': 'DOID'}, {'id': 4790, 'name': 'medulloepithelioma', 'source': 'DOID'}, {'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}]",NCT00983398,Phase Ib/II,Recruiting,OHSU Knight Cancer Institute ,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2587, 'therapyName': 'Carboplatin + Melphalan'}]","Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors",09/07/2016,[],no
0,both,[],NCT00983580,Phase II,"Active, not recruiting",National Cancer Institute (NCI),[],Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer,10/14/2015,[],no
0,both,[],NCT00984048,Phase I,Recruiting,Jewish General Hospital ,[],Study to Identify Mechanisms of Resistance to Standard Therapy in Patients With Metastatic Colorectal Cancer,07/15/2015,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT00986661,Phase I,Recruiting,Provectus Pharmaceuticals ,"[{'id': 879, 'therapyName': 'PV-10'}]",A Study to Assess PV-10 Chemoablation of Cancer of the Liver,02/04/2016,[],no
0,female,"[{'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 6170, 'name': 'ovarian carcinosarcoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1970, 'name': 'fallopian tube carcinosarcoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}]",NCT00989651,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 3047, 'therapyName': 'Bevacizumab + Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","Carboplatin, Paclitaxel, Bevacizumab, and ABT-888 in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",08/04/2016,[],no
0,both,"[{'id': 12603, 'name': 'acute leukemia', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 1037, 'name': 'lymphoblastic leukemia', 'source': 'DOID'}]",NCT00990249,Phase II,Completed,M.D. Anderson Cancer Center,"[{'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}]",Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation,05/13/2016,[],no
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT00993655,Phase III,Completed,NCIC Clinical Trials Group,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]"," Comparing Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",07/13/2016,[],no
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}, {'id': 1788, 'name': 'peritoneal mesothelioma', 'source': 'DOID'}]",NCT00996385,Phase II,Unknown status,Columbia University ,"[{'id': 3064, 'therapyName': 'Bortezomib + Oxaliplatin'}]",Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma,06/20/2017,[],no
0,both,[],NCT00996892,,Terminated,Genentech,[],"A Study Evaluating the Safety, Tolerability and Pharmacokinetics of GDC-0973 in Combination With GDC-0941 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors",12/31/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT00997334,Phase II,Completed,"David M. Jackman, MD ","[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC,04/12/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT00998010,Phase II,"Active, not recruiting",Jonsson Comprehensive Cancer Center,"[{'id': 3055, 'therapyName': 'Bortezomib + Temozolomide'}]","Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma",01/09/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT00999401,Phase I,Recruiting,"Cyclacel Pharmaceuticals, Inc.","[{'id': 1130, 'therapyName': 'Sapacitabine + Seliciclib'}]",A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors,05/04/2016,[],no
0,both,"[{'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01004224,Phase I,"Active, not recruiting",Novartis Pharmaceuticals ,"[{'id': 674, 'therapyName': 'BGJ398'}]",A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies,03/25/2017,"[{'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 812, 'profileName': 'FGFR1 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3147, 'profileName': 'FGFR2 amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01004861,Phase I,"Active, not recruiting",Plexxikon,"[{'id': 874, 'therapyName': 'PLX3397'}]",Safety Study of PLX108-01 in Patients With Solid Tumors,04/08/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 263, 'name': 'kidney cancer', 'source': 'DOID'}]",NCT01005797,Phase I,Completed,Medical University of South Carolina,"[{'id': 1131, 'therapyName': 'Panobinostat + Sorafenib'}]","Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers",03/04/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01006369,Phase II,Completed,"Rutgers, The State University of New Jersey","[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]","Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer",02/16/2017,[],no
0,female,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT01007695,Phase I,Terminated,University of Utah ,"[{'id': 1076, 'therapyName': 'Valproic acid'}]",Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot,05/07/2015,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01008150,Phase II,Unknown status,NSABP Foundation Inc ,"[{'id': 1504, 'therapyName': 'Paclitaxel + Trastuzumab + Neratinib + Doxorubicin + Cyclophosphamide'}, {'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer,10/03/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,[],NCT01009918,Phase II,"Active, not recruiting",University of South Florida ,[],Lisinopril or Coreg CR in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab,07/10/2015,[],yes
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT01010958,Phase I,Terminated,Columbia University ,"[{'id': 1076, 'therapyName': 'Valproic acid'}]",Adjuvant Valproate for High Grade Sarcomas,05/22/2015,[],no
0,both,"[{'id': 3275, 'name': 'thymoma', 'source': 'DOID'}, {'id': 3284, 'name': 'thymic carcinoma', 'source': 'DOID'}]",NCT01011439,Phase II,"Active, not recruiting",Nerviano Medical Sciences ,"[{'id': 2654, 'therapyName': 'PHA-848125AC'}]",Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma,05/05/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT01012817,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 1132, 'therapyName': 'Veliparib + Topotecan'}]","Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer",10/26/2016,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01013649,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 2381, 'therapyName': 'Erlotinib + Gemcitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery,03/20/2015,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01014065,Phase II,Completed,AHS Cancer Control Alberta ,"[{'id': 930, 'therapyName': 'Sunitinib'}]",A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect),02/26/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 2784, 'name': 'lung sarcoma', 'source': 'DOID'}, {'id': 1324, 'name': 'lung cancer', 'source': 'DOID'}]",NCT01014598,Phase I,"Active, not recruiting",Roswell Park Cancer Institute,"[{'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin in Treating Patients With Lung Cancer,06/11/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01014936,,Completed,EMD Serono,"[{'id': 726, 'therapyName': 'EMD 1214063'}]"," First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors",12/18/2015,"[{'molecularProfile': {'id': 1112, 'profileName': 'MET alterations'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01015222,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1032, 'therapyName': 'methylnaltrexone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies",12/23/2014,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01015833,Phase III,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer,05/30/2015,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01016886,Phase Ib/II,"Active, not recruiting",University of Alberta ,"[{'id': 1897, 'therapyName': 'Bisoprolol'}, {'id': 1896, 'therapyName': 'Perindopril'}]",Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research,02/10/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01017640,Phase I,Completed,National Cancer Institute (NCI),"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1134, 'therapyName': 'Veliparib + Mitomycin C'}]"," Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors",07/12/2016,[],no
0,both,[],NCT01022086,Phase I,Recruiting,"St. Michael's Hospital, Toronto ",[],Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving Trastuzumab,07/15/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01023737,Phase I,Recruiting,Devalingam Mahalingam,"[{'id': 1135, 'therapyName': 'Vorinostat + Hydroxychloroquine'}]",Hydroxychloroquine + Vorinostat in Advanced Solid Tumors,08/24/2015,[],no
0,both,"[{'id': 3275, 'name': 'thymoma', 'source': 'DOID'}, {'id': 3284, 'name': 'thymic carcinoma', 'source': 'DOID'}]",NCT01025089,Phase II,"Active, not recruiting",Memorial Sloan-Kettering Cancer Center,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1927, 'therapyName': 'Cisplatin + Doxorubicin + Cyclophosphamide'}]",Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma,04/07/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01026337,Phase I,"Active, not recruiting",Abramson Cancer Center of the University of Pennsylvania ,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer,12/16/2015,[],no
0,female,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}]",NCT01027416,Phase I,Completed,Roswell Park Cancer Institute ,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients,06/19/2017,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01028222,Phase II,Completed,Novartis Pharmaceuticals,"[{'id': 829, 'therapyName': 'Nilotinib'}]",A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation,05/20/2015,"[{'molecularProfile': {'id': 1214, 'profileName': 'KIT mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1650, 'profileName': 'KIT D820Y'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1652, 'profileName': 'KIT Y823D'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT01031381,Phase II,Completed,University of Pittsburgh,"[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]","Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer",04/16/2015,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT01032148,Phase I,Terminated,Roswell Park Cancer Institute ,"[{'id': 1080, 'therapyName': 'Panobinostat'}]","Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lymphoma",01/13/2017,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01035099,Phase I,Recruiting,Weill Medical College of Cornell University ,"[{'id': 794, 'therapyName': 'Letrozole'}]",RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF,04/24/2015,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01036087,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1984, 'therapyName': 'Panitumumab + Abraxane + Carboplatin'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}]","Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer",09/17/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5041, 'name': 'esophageal cancer', 'source': 'DOID'}, {'id': 2994, 'name': 'germ cell cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3382, 'name': 'liposarcoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01037790,Phase II,Recruiting,Abramson Cancer Center of the University of Pennsylvania,"[{'id': 850, 'therapyName': 'Palbociclib'}]",PD 0332991 in Treating Patients With Refractory Solid Tumors,04/21/2016,[],yes
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT01038778,Phase Ib/II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1541, 'therapyName': 'Entinostat'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer,02/10/2017,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01042379,Phase II,Recruiting,QuantumLeap Healthcare Collaborative,"[{'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1494, 'therapyName': 'MK2206 + Trastuzumab'}, {'id': 1493, 'therapyName': 'Trebananib + Trastuzumab'}, {'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer,09/18/2014,[],no
0,female,"[{'id': 192, 'name': 'sex cord-gonadal stromal tumor', 'source': 'DOID'}]",NCT01042522,Phase II,Recruiting,Gynecologic Oncology Group,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1137, 'therapyName': 'Bleomycin'}]","Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors",08/24/2015,[],no
0,both,[],NCT01042535,,"Active, not recruiting",National Cancer Institute (NCI),[], Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer,07/28/2014,[],yes
0,both,"[{'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT01052363,Phase I,Withdrawn,West Virginia University ,"[{'id': 2109, 'therapyName': 'Bevacizumab + Fosbretabulin'}]",OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas,02/10/2017,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT01058239,Phase II,"Active, not recruiting",Massachusetts General Hospital ,"[{'id': 1649, 'therapyName': 'Rituximab + Bortezomib'}]",Bortezomib Plus Rituximab for EBV+ PTLD,02/12/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01058707,Phase I,"Active, not recruiting","Millennium Pharmaceuticals, Inc.","[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Dose Escalation Study of MLN0128 in Subjects With Advanced Malignancies,04/24/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01059552,Phase I,"Active, not recruiting",Fox Chase Cancer Center ,"[{'id': 1077, 'therapyName': 'Vorinostat'}]",Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC),01/25/2017,[],no
0,both,"[{'id': 3608, 'name': 'appendix adenocarcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT01061515,Phase I,Recruiting,Washington University School of Medicine,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}]",Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer,08/24/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01061788,Phase I,Recruiting,Duke University,"[{'id': 1138, 'therapyName': 'AMG479 + Everolimus + Panitumumab'}]","A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer",12/23/2014,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01063075,Phase II,Completed,Eli Lilly and Company,"[{'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}]",A Study in Advanced Solid Tumors,01/27/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01064479,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center ,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Docetaxel And Cisplatin With or Without Erlotinib For Metastatic Or Recurrent Squamous Cell Carcinoma Of Head And Neck,01/14/2016,[],no
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT01064648,Phase Ib/II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 2432, 'therapyName': 'Cediranib + Cisplatin + Pemetrexed'}]",Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma,02/19/2016,[],no
0,both,"[{'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT01064921,Phase I,"Active, not recruiting",Ohio State University Comprehensive Cancer Center ,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma,10/27/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01067469,Phase II,Completed,M.D. Anderson Cancer Center,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2118, 'therapyName': 'Bevacizumab + Lomustine'}]",Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM),11/01/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01075113,Phase I,"Active, not recruiting",Virginia Commonwealth University ,"[{'id': 2356, 'therapyName': 'Sorafenib + Vorinostat'}]",Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer,02/10/2017,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT01076543,Phase Ib/II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 2280, 'therapyName': 'Temsirolimus + Lenalidomide'}]",Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma,04/08/2015,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01077544,Phase I,Completed,Novartis Pharmaceuticals,"[{'id': 829, 'therapyName': 'Nilotinib'}]",A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL),08/05/2015,[],yes
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT01079780,Phase II,Unknown status,Pam Cogliano ,"[{'id': 1920, 'therapyName': 'Irinotecan + Cetuximab + Ramucirumab'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}]",Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy,06/20/2017,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01081808,Phase I,Terminated,Roger Williams Medical Center,"[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}]","Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors",03/25/2015,"[{'molecularProfile': {'id': 1102, 'profileName': 'EGFR positive'}, 'requirementType': 'required'}]",yes
0,both,[],NCT01083966,Phase I,Suspended,Weill Medical College of Cornell University,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Intraarterial Cerebral Infusion of Avastin for Vestibular Schwannoma (Acoustic Neuroma),09/18/2015,[],no
0,,[],NCT01084252,,Recruiting,,"[{'id': 1390, 'therapyName': 'Dexamethasone'}]",Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies,10/19/2017,[],
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01087554,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer,05/20/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01087983,Phase I,Completed,M.D. Anderson Cancer Center,"[{'id': 1139, 'therapyName': 'Lapatinib + Sirolimus'}, {'id': 1140, 'therapyName': 'Lapatinib + Metformin'}]",Lapatinib With Sirolimus or Metformin,09/25/2015,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01088815,Phase II,Unknown status,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 1799, 'therapyName': 'Vismodegib + Gemcitabine + Abraxane'}]",Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas,06/20/2017,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 4992, 'name': 'optic nerve glioma', 'source': 'DOID'}, {'id': 4851, 'name': 'pilocytic astrocytoma', 'source': 'DOID'}]",NCT01089101,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma,06/19/2017,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01093573,Phase Ib/II,"Active, not recruiting","Brenda Cooper, MD ","[{'id': 2471, 'therapyName': 'Azacitidine + Midostaurin'}]",Midostaurin and Azacitidine in Treating Elderly Patients With Acute Myelogenous Leukemia,06/11/2016,[],no
0,,[],NCT01097278,,"Active, not recruiting",Southwest Oncology Group,[], S0812 High Dose Cholecalciferol in Premenopausal Women at High-Risk for Breast Cancer,01/09/2015,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01099358,Phase II,Completed,Eli Lilly and Company,"[{'id': 1915, 'therapyName': 'Cetuximab + Cisplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}]",Study in Advanced Solid Tumors,12/14/2016,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT01099423,Phase III,"Active, not recruiting",European Organisation for Research and Treatment of Cancer - EORTC ,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer,07/13/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01104922,Phase II,"Active, not recruiting",University of Pittsburgh ,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck,12/03/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01106599,Phase I,Completed,"Genentech, Inc. ","[{'id': 748, 'therapyName': 'GDC-0623'}]","A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors",12/29/2014,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT01106872,Phase Ib/II,Completed,University of Iowa,"[{'id': 1466, 'therapyName': 'Bevacizumab + Gemcitabine + Docetaxel + Valproic Acid '}]","Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas",08/25/2017,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01106898,Phase II,Unknown status,University of Nebraska,"[{'id': 1980, 'therapyName': 'Cyclophosphamide + Paclitaxel'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery,06/20/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT01107522,Phase I,"Active, not recruiting","Tactical Therapeutics, Inc.","[{'id': 1142, 'therapyName': 'CTO + Temozolomide'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar&#174; in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar&#174; and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas,01/07/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01107626,Phase III,"Active, not recruiting",Eastern Cooperative Oncology Group ,"[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,02/10/2017,[],no
0,both,"[{'id': 8923, 'name': 'skin melanoma', 'source': 'DOID'}]",NCT01107665,Phase II,"Active, not recruiting","University of California, Irvine","[{'id': 1143, 'therapyName': 'Pazopanib + Paclitaxel'}]",Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma,12/09/2016,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}]",NCT01108055,Phase II,Completed,Stanford University,"[{'id': 1143, 'therapyName': 'Pazopanib + Paclitaxel'}]",Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer,06/10/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01111058,Phase II,"Active, not recruiting",University of Chicago,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus Versus Placebo in Head and Neck Cancer,04/08/2015,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT01111188,,"Active, not recruiting",,"[{'id': 1730, 'therapyName': 'Palbociclib + Velcade'}]", Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma,02/08/2017,[],yes
0,both,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT01111825,Phase Ib/II,Completed,"Puma Biotechnology, Inc.","[{'id': 1527, 'therapyName': 'Temsirolimus + Neratinib'}]",Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer,10/08/2016,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3073, 'name': 'brain glioblastoma multiforme', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01112527,Phase II,"Active, not recruiting","Massachusetts General Hospital, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Henry Ford Hospital, Pfizer","[{'id': 714, 'therapyName': 'Dacomitinib'}]",PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma,09/29/2015,"[{'molecularProfile': {'id': 447, 'profileName': 'EGFR amp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01113476,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1144, 'therapyName': 'Abraxane + Avastin + Gemcitabine'}]","Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies",07/08/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01116336,Phase I,Recruiting,"Emory University, Astellas Pharma Inc, Polyphenon Pharma","[{'id': 4, 'therapyName': 'Erlotinib'}]",Phase I Chemoprevention Trial With Green Tea Polyphenon E and Erlotinib in Patients With Premalignant Lesions of the Head and Neck,03/26/2015,[],no
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT01116648,Phase Ib/II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer",02/13/2016,[],yes
0,both,[],NCT01118975,,Terminated,University of Maryland,[],GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers,07/28/2014,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01120249,Phase III,"Active, not recruiting",Southwest Oncology Group ,"[{'id': 735, 'therapyName': 'Everolimus'}]","S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery",10/07/2016,[],no
0,,[],NCT01121588,,"Active, not recruiting",,"[{'id': 706, 'therapyName': 'Crizotinib'}]","An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase (ALK)",10/02/2014,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01122199,Phase I,Completed,Indiana University,"[{'id': 1145, 'therapyName': 'Everolimus + AMG479'}]",Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors,05/11/2017,[],no
0,both,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT01124695,Phase II,Unknown status,Eastern Cooperative Oncology Group ,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer,06/20/2017,[],yes
0,both,"[{'id': 5041, 'name': 'esophageal cancer', 'source': 'DOID'}]",NCT01128387,Phase Ib/II,Completed,"University of Wisconsin, Madison","[{'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 845, 'therapyName': 'Panitumumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Trial of Panitumumab/Cisplatin/Fluorouracil With XRT in Esophageal Cancer,11/19/2016,[],no
0,both,"[{'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 4202, 'name': 'brain stem glioma', 'source': 'DOID'}]",NCT01130077,Phase I,Recruiting,University of Pittsburgh ,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas,08/11/2015,[],no
0,both,"[{'id': 4465, 'name': 'papillary renal cell carcinoma', 'source': 'DOID'}]",NCT01130519,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}]",A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer,05/09/2015,[],no
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT01132014,Phase I,"Active, not recruiting",Abramson Cancer Center of the University of Pennsylvania,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1154, 'therapyName': 'Dacarbazine'}]",Autologous OC-DC Vaccine in Ovarian Cancer,02/10/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01133678,Phase II,"Active, not recruiting",University of Chicago,"[{'id': 1790, 'therapyName': 'Cetuximab + Cisplatin + Paclitaxel'}, {'id': 735, 'therapyName': 'Everolimus'}]",Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck,06/24/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01138085,Phase I,Completed,GlaxoSmithKline,"[{'id': 1150, 'therapyName': 'GSK1120212 + GSK2141795'}]","Safety, Pharmacokinetics (PK) of AKT and MEK Combination",06/06/2015,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 4, 'profileName': 'BRAF wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01139723,Phase I,Completed,Genentech,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1616, 'therapyName': 'MINT1526A'}]","A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors",12/23/2014,[],no
0,both,"[{'id': 7912, 'name': 'mixed oligodendroglioma-astrocytoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}]",NCT01140568,Phase II,Recruiting,"Santosh Kesari, M.D., Ph.D. ","[{'id': 829, 'therapyName': 'Nilotinib'}]",Study of Platelet Derived Growth Factor Receptor (PDGFR) in Recurrent Malignant Gliomas,03/26/2015,"[{'molecularProfile': {'id': 1417, 'profileName': 'PDGFRA amp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01141478,Phase I,Recruiting,Loma Linda University ,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria,03/12/2015,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT01145430,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 2167, 'therapyName': 'pegylated liposomal doxorubicin + Veliparib'}]","Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer",07/27/2016,[],yes
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT01146795,Phase II,Terminated,Jason D. Wright,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",Neoadjuvant Therapy for Ovarian Cancer,11/03/2015,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01146834,Phase III,Recruiting,Weill Medical College of Cornell University,"[{'id': 3345, 'therapyName': 'Bortezomib + Filgrastim'}, {'id': 5459, 'therapyName': 'Bortezomib + Cyclophosphamide + G-CSF'}, {'id': 5460, 'therapyName': 'Bortezomib + Cyclophosphamide'}]",Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma,03/16/2017,[],no
0,both,"[{'id': 305, 'name': 'carcinoma', 'source': 'DOID'}]",NCT01148849,Phase I,"Active, not recruiting",MacroGenics ,"[{'id': 808, 'therapyName': 'MGAH22'}]",Safety Study of MGAH22 in HER2-positive Carcinomas,09/16/2015,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01149850,Phase II,"Active, not recruiting",Jonsson Comprehensive Cancer Center,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma,03/09/2016,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT01154452,Phase Ib/II,Completed,National Cancer Institute (NCI),"[{'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1096, 'therapyName': 'Vismodegib + RO4929097'}, {'id': 902, 'therapyName': 'RO4929097'}]",Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma,05/27/2015,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT01156584,Phase I,"Active, not recruiting",Tocagen Inc. ,"[{'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}]",A Study of a Retroviral Replicating Vector Administered to Subjects With Recurrent Malignant Glioma,02/26/2016,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT01158521,Phase II,Completed,Case Comprehensive Cancer Center,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer,01/08/2016,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01160211,Phase III,"Active, not recruiting",GlaxoSmithKline,"[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]","A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer",04/20/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT01162551,Phase II,Completed,Children's Hospital of Philadelphia ,"[{'id': 2304, 'therapyName': 'Sirolimus + Methotrexate'}]",Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma,10/04/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01163357,Phase I,Recruiting,City of Hope Medical Center ,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2288, 'therapyName': 'Bortezomib + Fludarabine + Melphalan'}]","Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma",07/22/2017,[],no
0,both,"[{'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}, {'id': 7757, 'name': 'childhood leukemia', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01164163,Phase I,Completed,Children's Oncology Group|National Cancer Institute (NCI),"[{'id': 907, 'therapyName': 'Ruxolitinib'}]","INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease",11/17/2014,"[{'molecularProfile': {'id': 1181, 'profileName': 'JAK2 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01164228,Phase II,Recruiting,Eastern Cooperative Oncology Group,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery,08/24/2015,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT01169636,Phase Ib/II,Completed,M.D. Anderson Cancer Center ,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}]","Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma",05/20/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01173679,Phase II,Terminated,Massachusetts General Hospital,"[{'id': 1821, 'therapyName': 'Dasatinib + Rituximab + Fludarabine'}]",Dasatinib With Fludarabine and Rituximab in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL),01/07/2015,[],no
0,,"[{'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 4948, 'name': 'gallbladder carcinoma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 5517, 'name': 'stomach carcinoma', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 4905, 'name': 'pancreatic carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 3459, 'name': 'breast carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}]",NCT01174121,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,06/21/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01174199,Phase I,Terminated, Roswell Park Cancer Institute ,"[{'id': 2263, 'therapyName': 'Temsirolimus + vorinostat'}]",Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer,09/14/2016,[],no
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 4163, 'name': 'ganglioneuroblastoma', 'source': 'DOID'}]",NCT01175356,Phase I,Completed,Children's Oncology Group ,"[{'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}]","Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin",02/10/2017,[],yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01176474,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma,09/03/2015,[],no
0,both,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}, {'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}, {'id': 60077, 'name': 'progesterone-receptor positive breast cancer', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01177397,Phase Ib/II,Completed,Celgene Corporation,"[{'id': 693, 'therapyName': 'CC-223'}]","Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",05/13/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01177683,Phase Ib/II,"Active, not recruiting","Sherif Farag, MB, BS ","[{'id': 3349, 'therapyName': 'Bendamustine + Bortezomib + pegylated liposomal-doxorubicin'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma,08/24/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01179269,Phase II,Withdrawn,Loyola University ,"[{'id': 1143, 'therapyName': 'Pazopanib + Paclitaxel'}]",Stage IIIB/IV Non-Small Cell Lung Cancer,10/14/2016,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT01180049,FDA approved,"Active, not recruiting",Pfizer ,"[{'id': 936, 'therapyName': 'Temsirolimus'}]",Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma,05/20/2017,[],no
0,both,"[{'id': 3996, 'name': 'urinary system cancer', 'source': 'DOID'}]",NCT01182168,Phase I,Completed,Memorial Sloan Kettering Cancer Center,"[{'id': 2296, 'therapyName': 'Cisplatin + Everolimus + Gemcitabine'}]",Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies,04/01/2016,[],no
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT01182285,Phase II,Completed,National Cancer Institute (NCI),"[{'id': 2674, 'therapyName': 'liothyronine sodium  '}, {'id': 1076, 'therapyName': 'Valproic acid'}]",A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin,05/03/2016,[],no
0,both,"[{'id': 6383, 'name': 'childhood brain stem glioma', 'source': 'DOID'}]",NCT01182350,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}, {'id': 2116, 'therapyName': 'Bevacizumab + Erlotinib + Temozolomide'}, {'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG),10/21/2015,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 1107, 'name': 'esophageal carcinoma', 'source': 'DOID'}, {'id': 5517, 'name': 'stomach carcinoma', 'source': 'DOID'}]",NCT01183559,Phase I,Unknown status,Fox Chase Cancer Center ,"[{'id': 2071, 'therapyName': 'Carboplatin + Fluorouracil + Paclitaxel + Vandetanib'}]","A Trial of ZD6474 (Zactima), Paclitaxel, Carboplatin, 5-Fluorouracil, and XRT Followed by Surgery",06/20/2017,[],no
0,both,"[{'id': 263, 'name': 'kidney cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01184326,Phase I,Completed,Dana-Farber Cancer Institute ,"[{'id': 1806, 'therapyName': 'everolimus + pazopanib'}]",An Expanded Phase I Study of Pazopanib and Everolimus in Patients With Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer,10/05/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01187199,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer",07/16/2016,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT01187810,Phase I,"Active, not recruiting",South Plains Oncology Consortium ,"[{'id': 2731, 'therapyName': 'Fenretinide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}]","Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL",05/25/2017,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}, {'id': 6811, 'name': 'juvenile pilocytic astrocytoma', 'source': 'DOID'}]",NCT01188096,Phase II,Recruiting,"Donald Durden, M.D. ","[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas,08/11/2015,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01188889,Phase Ib/II,Withdrawn,University of Michigan Cancer Center ,"[{'id': 2198, 'therapyName': 'Everolimus + Imatinib'}]",RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease,05/16/2015,[],no
0,,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT01189643,Phase I,"Active, not recruiting",Memorial Sloan-Kettering Cancer Center,"[{'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]","Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor",07/01/2016,[],no
0,both,"[{'id': 1107, 'name': 'esophageal carcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT01191697,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute,"[{'id': 1596, 'therapyName': 'Trastuzumab + Bevacizumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]","CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer",07/13/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT01193842,Phase Ib/II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas,07/29/2016,[],yes
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01194869,Phase II,Terminated,Emory University,"[{'id': 1534, 'therapyName': 'Sorafenib + Cisplatin + Paclitaxel'}]","Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast Cancer",08/08/2015,[],yes
0,both,"[{'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}]",NCT01195922,Phase Ib/II,Completed,National Institute of Dental and Craniofacial Research (NIDCR),"[{'id': 917, 'therapyName': 'Sirolimus'}]",Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma,11/13/2015,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}]",NCT01196390,Phase III,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1887, 'therapyName': 'Paclitaxel + Carboplatin + Trastuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer",11/14/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}]",yes
0,female,[],NCT01196936,Phase II,"Active, not recruiting",University of Alabama at Birmingham ,[],Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors,12/02/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01197170,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Hormone Blockade in Combination With Targeted Agents,04/29/2016,[],yes
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT01200238,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute ,"[{'id': 745, 'therapyName': 'Ganetespib'}]",STA-9090(Ganetespib) in Metastatic Ocular Melanoma,05/13/2015,[],no
0,both,[],NCT01201538,Phase II,Terminated,"University Health Network, Toronto ","[{'id': 829, 'therapyName': 'Nilotinib'}]",A Study of Nilotinib in Growing Vestibular Schwannomas,03/15/2016,[],no
0,both,[],NCT01201850,Phase I,Completed,"University of Colorado, Denver ","[{'id': 667, 'therapyName': 'Bevacizumab'}]",The Role of Bevacizumab in the Treatment of Radiation Necrosis in Children With Central Nervous System Tumors,09/19/2017,[],no
0,both,"[{'id': 4906, 'name': 'small intestine adenocarcinoma', 'source': 'DOID'}, {'id': 3502, 'name': 'ampulla of Vater adenocarcinoma', 'source': 'DOID'}]",NCT01202409,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 845, 'therapyName': 'Panitumumab'}]",CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater,04/29/2016,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT01203722,Phase Ib/II,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}]","Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies",03/04/2015,[],no
0,both,"[{'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}, {'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT01206530,Phase Ib/II,"Active, not recruiting",Abramson Cancer Center of the University of Pennsylvania ,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]",FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer,04/06/2017,[],no
0,both,"[{'id': 314, 'name': 'tenosynovial giant cell tumor', 'source': 'DOID'}]",NCT01207492,Phase II,"Active, not recruiting","Andrew J. Wagner, MD, PhD ","[{'id': 829, 'therapyName': 'Nilotinib'}]",Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor,03/30/2015,[],no
0,both,"[{'id': 3963, 'name': 'thyroid carcinoma', 'source': 'DOID'}]",NCT01208051,Phase Ib/II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 2437, 'therapyName': 'Cediranib + Lenalidomide'}, {'id': 1001, 'therapyName': 'Cediranib'}]",Cediranib Maleate With or Without Lenalidomide in Treating Patients With Thyroid Cancer,03/25/2015,[],no
0,both,"[{'id': 4906, 'name': 'small intestine adenocarcinoma', 'source': 'DOID'}, {'id': 3502, 'name': 'ampulla of Vater adenocarcinoma', 'source': 'DOID'}]",NCT01208103,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1601, 'therapyName': 'Capecitabine + Oxaliplatin + Bevacizumab'}]",Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater,02/19/2015,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01208662,Phase III,Recruiting,"Paul G. Richardson, MD ","[{'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65  (DFCI 10-106)",12/29/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01210378,Phase II,Completed,Maastricht Radiation Oncology ,"[{'id': 2924, 'therapyName': 'Nitroglycerin'}]",Nitroglycerin in Non-small Cell Lung Cancer,03/29/2017,[],no
0,both,"[{'id': 1107, 'name': 'esophageal carcinoma', 'source': 'DOID'}, {'id': 6270, 'name': 'gastric cardia carcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT01212822,Phase II,"Active, not recruiting",Fox Chase Cancer Center ,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer,03/05/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01213238,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab",09/16/2015,[],no
0,both,"[{'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}]",NCT01215136,Phase II,"Active, not recruiting",Hoosier Cancer Research Network ,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma,01/07/2016,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01216176,Phase Ib/II,"Active, not recruiting",Joyce Marie Slingerland ,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 912, 'therapyName': 'Saracatinib'}]",A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZDO530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer,02/08/2017,[],yes
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT01216683,Phase II,Unknown status,Eastern Cooperative Oncology Group ,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1164, 'therapyName': 'lenalidomide'}]","Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma",06/20/2017,[],no
0,both,"[{'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}, {'id': 1664, 'name': 'pineoblastoma', 'source': 'DOID'}]",NCT01217437,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1462, 'therapyName': 'Temozolomide + Irinotecan'}, {'id': 1463, 'therapyName': 'Temozolomide + Irinotecan + Bevacizumab'}]",Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors,09/07/2016,[],no
0,both,"[{'id': 263, 'name': 'kidney cancer', 'source': 'DOID'}]",NCT01217931,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy,09/11/2014,[],no
0,both,"[{'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}, {'id': 8618, 'name': 'oral cavity cancer', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 2596, 'name': 'larynx cancer', 'source': 'DOID'}]",NCT01218048,Phase II,"Active, not recruiting",University of Pittsburgh ,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",ERBITUX; Followed by Adjuvant Treatment With Chemoradiation and ERBITUX; for Locally Advanced Head and Neck Squamous Cell Carcinoma,01/09/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01218555,Phase I,"Active, not recruiting",Emory University,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 735, 'therapyName': 'Everolimus'}]",Study of Everolimus (RAD001)in Combination With Lenalidomide,03/19/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 263, 'name': 'kidney cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1324, 'name': 'lung cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01218867,Phase Ib/II,Completed,National Cancer Institute (NCI),"[{'id': 984, 'therapyName': 'Anti-VEGFR2 CAR CD8 lymphocytes'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes,03/01/2016,[],no
0,both,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01219699,Phase I,"Active, not recruiting",Novartis Pharmaceuticals,"[{'id': 691, 'therapyName': 'BYL719'}, {'id': 744, 'therapyName': 'Fulvestrant'}]"," A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene",07/28/2014,"[{'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01221506,Phase I,Completed,Abramson Cancer Center of the University of Pennsylvania,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib/DCE-MRIs in Renal Cell Carcinoma (RCC),09/27/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01222143,Phase Ib/II,Terminated,"University Health Network, Toronto ","[{'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}]","Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia",06/23/2015,"[{'molecularProfile': {'id': 851, 'profileName': 'KIT positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01226316,Phase I,Recruiting,AstraZeneca ,"[{'id': 655, 'therapyName': 'AZD5363'}]","Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules",12/15/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1213, 'profileName': 'PTEN mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1209, 'profileName': 'AKT1 mutant'}, 'requirementType': 'partial'}]",yes
0,,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT01231412,Phase III,"Active, not recruiting",Fred Hutchinson Cancer Research Center ,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2272, 'therapyName': 'Cyclosporine + Mycophenolate mofetil'}]",Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant,08/09/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01231594,Phase I,Recruiting,GlaxoSmithKline,"[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}]",A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors,10/07/2015,"[{'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01233687,Phase Ib/II,Completed,Ahmad Tarhini,"[{'id': 629, 'therapyName': 'AMG102'}, {'id': 4, 'therapyName': 'Erlotinib'}]",AMG 102 and Erlotinib for Advanced Non-Small Cell Lung Cancer,06/23/2017,[],no
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT01236547,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer,01/05/2017,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01237236,Phase I,Completed,Novartis Pharmaceuticals,"[{'id': 790, 'therapyName': 'Ribociclib'}]",A Trial of LEE011 in Patients With Advanced Solid Tumors or Lymphoma.,03/16/2017,[],no
0,both,"[{'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01238237,Phase I,Completed,Weill Medical College of Cornell University ,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Super-Selective Intraarterial Cerebral Infusion of Cetuximab for the Treatment of Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma,12/14/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01239134,Phase I,Recruiting,"GITR, Inc.","[{'id': 3613, 'therapyName': 'TRX518'}]",Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors,03/20/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01239368,Phase I,Completed,National Cancer Institute (NCI),[],Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma,08/19/2017,[],no
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT01239732,Phase III,Completed,Hoffmann-La Roche,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",A Study of the Addition of Avastin (Bevacizumab) to Carboplatin and Paclitaxel Therapy in Patients With Ovarian Cancer,05/13/2015,[],no
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01240590,Phase Ib/II,Completed,National Cancer Institute (NCI),"[{'id': 1461, 'therapyName': 'Crolibulin + Cisplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC),04/11/2017,[],no
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}, {'id': 5485, 'name': 'synovial sarcoma', 'source': 'DOID'}, {'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}, {'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}]",NCT01241162,Phase I,Completed,University of Louisville ,"[{'id': 650, 'therapyName': 'Decitabine'}]",Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma,10/07/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01241708,Phase III,Recruiting,Hackensack University Medical Center ,"[{'id': 688, 'therapyName': 'Bortezomib'}]",Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma ((Mel/MelVel)),08/10/2017,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01244750,Phase I,"Active, not recruiting",Bristol-Myers Squibb,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}]",Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting,03/22/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01246986,Phase II,"Active, not recruiting",Eli Lilly and Company,"[{'id': 2421, 'therapyName': 'Galunisertib + Sorafenib'}, {'id': 2409, 'therapyName': 'Galunisertib'}]",A Study of LY2157299 in Participants With Hepatocellular Carcinoma,12/13/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01248247,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center|AstraZeneca|Bayer|Merck Sharp & Dohme Corp.|National Cancer Institute (NCI)|OSI Pharmaceutic,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1098, 'therapyName': 'MK2206 + Selumetinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1097, 'therapyName': 'Erlotinib + MK2206'}]",BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study,12/30/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT01248949,Phase I,Completed,MedImmune LLC,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study to Evaluate the Safety and Antitumor Activity in Subjects With Advanced Solid Tumors,12/06/2015,[],no
0,female,"[{'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT01248962,Phase II,"Active, not recruiting",Memorial Sloan Kettering Cancer Center,"[{'id': 1092, 'therapyName': 'Carboplatin'}]","Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer",06/17/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01249443,Phase I,Terminated,AIDS Malignancy Consortium ,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Vorinostat in Combination With Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection,08/26/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT01251575,Phase II,Recruiting,Fred Hutchinson Cancer Research Center ,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2270, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Sirolimus'}]","Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant",03/02/2015,[],no
0,both,"[{'id': 1752, 'name': 'ocular melanoma', 'source': 'DOID'}]",NCT01252251,Phase II,Completed,"Memorial Sloan Kettering Cancer Center, Novartis Pharmaceuticals","[{'id': 2261, 'therapyName': 'Everolimus + Pasireotide'}]",RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma,06/18/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01252667,Phase II,Recruiting,Fred Hutchinson Cancer Research Center ,"[{'id': 2272, 'therapyName': 'Cyclosporine + Mycophenolate mofetil'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant,10/30/2015,[],no
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT01253460,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 3215, 'therapyName': 'Rituximab + sapacitabine'}]","Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)",10/05/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01253707,Phase I,Completed,Amgen,"[{'id': 1064, 'therapyName': 'AMG 337'}]",A Study of AMG 337 in Subjects With Advanced Solid Tumors,12/24/2016,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01254864,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1817, 'therapyName': 'Abiraterone + Sunitinib'}, {'id': 1818, 'therapyName': 'Abiraterone + Dasatinib\t'}]",Maximum Androgen Depletion,02/24/2015,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT01256398,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia,07/13/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01258855,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 624, 'therapyName': 'Aflibercept'}]",Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,02/18/2016,[],no
0,both,"[{'id': 4007, 'name': 'bladder carcinoma', 'source': 'DOID'}]",NCT01259063,Phase Ib/II,Completed,"Memorial Sloan Kettering Cancer Center, Novartis Pharmaceuticals, New York University, University of Hawaii ","[{'id': 2279, 'therapyName': 'Everolimus + Gemcitabine'}]",RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder,06/09/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01260415,Phase II,Completed,"University Health Network, Toronto ","[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of Perioperative Chemotherapy Plus Panitumumab in Patients With Colorectal Cancer Liver Metastases,07/08/2015,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT01260506,Phase Ib/II,Unknown status,Vascular Biogenics Ltd. operating as VBL Therapeutics ,"[{'id': 2277, 'therapyName': 'Bevacizumab + VB-111'}]",Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme,10/03/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01262027,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center|Novartis,"[{'id': 721, 'therapyName': 'Dovitinib'}]", TKI258 for Metastatic Inflammatory Breast Cancer Patients,06/20/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01263782,Phase II,Completed,M.D. Anderson Cancer Center,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 701, 'therapyName': 'Cixutumumab'}]",BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer,08/26/2017,[],no
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT01263951,Phase II,"Active, not recruiting",Abramson Cancer Center of the University of Pennsylvania ,"[{'id': 2299, 'therapyName': 'Everolimus + Sorafenib'}]",Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone,12/16/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT01264432,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 954, 'therapyName': 'Veliparib'}]","Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer",03/31/2015,[],no
0,both,[],NCT01265030,Phase Ib/II,Recruiting,Maine Medical Center ,"[{'id': 917, 'therapyName': 'Sirolimus'}]",A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis,03/02/2015,[],no
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT01265433,Phase II,Completed,Memorial Sloan Kettering Cancer Center ,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 2893, 'therapyName': 'WT1 vaccine'}]",Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy,08/19/2017,[],yes
0,both,"[{'id': 7912, 'name': 'mixed oligodendroglioma-astrocytoma', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3186, 'name': 'adult oligodendroglioma', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT01266031,Phase Ib/II,Completed,M.D. Anderson Cancer Center,"[{'id': 2110, 'therapyName': 'Bevacizumab + Vorinostat'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma,03/25/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01266057,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1135, 'therapyName': 'Vorinostat + Hydroxychloroquine'}, {'id': 1177, 'therapyName': 'Sirolimus + Hydroxychloroquine'}]",Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer,07/15/2017,[],no
0,both,[],NCT01266070,,Terminated,M.D. Anderson Cancer Center|Novartis,"[{'id': 721, 'therapyName': 'Dovitinib'}]", TKI 258 in Von Hippel-Lindau Syndrome (VHL),12/30/2015,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01266083,Phase II,"Active, not recruiting",Memorial Sloan Kettering Cancer Center ,"[{'id': 2893, 'therapyName': 'WT1 vaccine'}]",Trial of a WT-1 Analog Peptide Vaccine in Patients With Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL),10/17/2015,"[{'molecularProfile': {'id': 1325, 'profileName': 'FLT3 rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 8907, 'profileName': 'NPM1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT01267812,Phase II,"Active, not recruiting",City of Hope Medical Center ,"[{'id': 1649, 'therapyName': 'Rituximab + Bortezomib'}]",Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation,03/04/2017,[],yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01269424,Phase I,Suspended,Stanton Gerson MD ,"[{'id': 2972, 'therapyName': 'O6-benzylguanine + Temozolomide'}]",O6-Benzylguanine and Temozolomide With MGMTP140K Genetically Modified Blood Stem Cells in Untreated Glioblastoma,12/23/2016,[],no
0,both,"[{'id': 7912, 'name': 'mixed oligodendroglioma-astrocytoma', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01269853,Phase Ib/II,Recruiting,North Shore Long Island Jewish Health System ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA,02/20/2015,[],no
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT01270321,Phase II,"Active, not recruiting",Emory University ,"[{'id': 2260, 'therapyName': 'Pasireotide'}, {'id': 735, 'therapyName': 'Everolimus'}]",A Trial of Pasireotide and Everolimus in Adult Patients With Radioiodine-Refractory Differentiated and Medullary Thyroid Cancer,04/15/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01272037,Phase III,Recruiting,National Cancer Institute (NCI),"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]","Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",04/28/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01273155,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1078, 'therapyName': 'Belinostat'}]",Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction,08/25/2015,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01273610,Phase II,"Active, not recruiting",City of Hope Medical Center,"[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}]",Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Metastatic Breast Cancer,05/27/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01274338,Phase III,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}]",Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery,07/29/2016,[],no
0,both,"[{'id': 219, 'name': 'colon cancer', 'source': 'DOID'}, {'id': 1993, 'name': 'rectum cancer', 'source': 'DOID'}]",NCT01274624,Phase I,"Active, not recruiting",Oncolytics Biotech ,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2099, 'therapyName': 'Bevacizumab + Reolysin'}]",Study of REOLYSIN; in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer,03/29/2017,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01275677,Phase III,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1503, 'therapyName': 'Paclitaxel + Trastuzumab + Doxorubicin + Cyclophosphamide'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1882, 'therapyName': 'Docetaxel + Cyclophosphamide + Trastuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}]",Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer,02/23/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01276041,Phase II,"Active, not recruiting",Memorial Sloan Kettering Cancer Center ,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]","Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer",07/13/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01276210,Phase I,Completed,Vanderbilt-Ingram Cancer Center,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases,07/18/2017,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01281150,Phase I,Completed,National Cancer Institute (NCI),"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors,05/27/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01281176,,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors,07/28/2014,[],no
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT01281514,Phase I,Recruiting,Fox Chase Cancer Center ,"[{'id': 2168, 'therapyName': 'Carboplatin + Doxil + Everolimus'}]","Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",02/26/2015,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT01282502,Phase I,"Active, not recruiting",Massachusetts General Hospital,"[{'id': 810, 'therapyName': 'Midostaurin'}]",Midostaurin (PKC412) for Locally Advanced Rectal Cancer,06/22/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01283048,Phase I,Completed,"Toni Choueiri, MD","[{'id': 1178, 'therapyName': 'BKM120 + Bevacizumab'}]",Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma,09/22/2016,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT01283789,Phase II,"Active, not recruiting",University of Kansas,"[{'id': 1539, 'therapyName': 'Everolimus + Lapatinib'}]",Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer,02/10/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01283945,Phase Ib/II,Completed,Ethical Oncology Science,"[{'id': 1029, 'therapyName': 'Lucitanib'}]","Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors",05/16/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01285037,Phase I,"Active, not recruiting",Eli Lilly and Company,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1030, 'therapyName': 'LY2801653'}]",A Study of LY2801653 in Advanced Cancer,09/08/2017,[],no
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT01286272,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 3909, 'therapyName': 'Bendamustine + Ofatumumab'}, {'id': 3910, 'therapyName': 'Bendamustine + Bortezomib + Ofatumumab'}]",Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma,04/09/2016,[],no
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01286987,Phase I,Completed,BioMarin Pharmaceutical,"[{'id': 682, 'therapyName': 'Talazoparib'}]","Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors",07/19/2017,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01287546,Phase I,Completed,Eli Lilly and Company,"[{'id': 1179, 'therapyName': 'Emibetuzumab + Erlotinib'}, {'id': 1180, 'therapyName': 'Emibetuzumab + Trametinib'}, {'id': 803, 'therapyName': 'Emibetuzumab'}]",A Study of LY2875358 in Participants With Advanced Cancer,02/16/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01288430,Phase I,Terminated,Daiichi Sankyo Inc.,"[{'id': 1181, 'therapyName': 'DS-2248'}]","A Study of DS-2248, in Subjects With Advanced Solid Tumors",03/03/2015,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01290263,Phase Ib/II,Completed,Dana-Farber Cancer Institute,"[{'id': 1219, 'therapyName': 'Trebananib + Bevacizumab'}, {'id': 1218, 'therapyName': 'Trebananib'}]",Amgen 386 for Recurrent Glioblastoma,07/03/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01292655,Phase I,Completed,Bristol-Myers Squibb,"[{'id': 2545, 'therapyName': 'BMS-906024'}]",Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors,10/19/2017,"[{'molecularProfile': {'id': 2334, 'profileName': 'NOTCH1 act mut'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 3459, 'name': 'breast carcinoma', 'source': 'DOID'}]",NCT01293032,Phase I,Completed,Virginia Commonwealth University,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer,07/13/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01294670,Phase Ib/II,"Active, not recruiting",Memorial Sloan-Kettering Cancer Center,"[{'id': 1182, 'therapyName': 'Vorinostat + Etoposide'}]",Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients &lt; 21 Years at Diagnosis With Refractory Solid Tumors,04/28/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01294826,Phase I,Completed,Swedish Medical Center ,"[{'id': 1996, 'therapyName': 'AUY922 + Cetuximab'}]",Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,06/06/2015,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 7497, 'name': 'brain ependymoma', 'source': 'DOID'}, {'id': 5503, 'name': 'spinal cord ependymoma', 'source': 'DOID'}]",NCT01295944,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",Carboplatin and Bevacizumab for Recurrent Ependymoma,02/13/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01296555,Phase I,Recruiting,Genentech,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 794, 'therapyName': 'Letrozole'}]",A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer,12/23/2014,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01296581,Phase I,"Active, not recruiting",Tyrogenex,"[{'id': 962, 'therapyName': 'X-82'}]", Safety Study of X-82 in Patients With Advanced Solid Tumors,05/20/2015,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01296932,Phase I,Completed,Boehringer Ingelheim ,"[{'id': 4276, 'therapyName': 'BI 836826'}]",BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL),07/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01297452,Phase I,Completed,Memorial Sloan-Kettering Cancer Center,"[{'id': 1183, 'therapyName': 'BKM120 + Carboplatin + Paclitaxel'}]",BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors,04/01/2017,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}]",NCT01298570,Phase II,"Active, not recruiting",UNC Lineberger Comprehensive Cancer Center ,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer,02/12/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01299636,Phase I,Completed,PharmaMar,"[{'id': 1459, 'therapyName': 'PM060184'}]",Study of PM060184 in Patients With Advanced Solid Tumors,09/22/2015,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01300962,Phase I,"Active, not recruiting",UNC Lineberger Comprehensive Cancer Center,"[{'id': 1538, 'therapyName': 'BKM120 + Capecitabine + Lapatinib'}, {'id': 1537, 'therapyName': 'BKM120 + Capecitabine + Trastuzumab'}, {'id': 1536, 'therapyName': 'BKM120 + Capecitabine'}, {'id': 1535, 'therapyName': 'BYL719 + Capecitabine'}]",Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer,04/19/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3284, 'name': 'thymic carcinoma', 'source': 'DOID'}, {'id': 3275, 'name': 'thymoma', 'source': 'DOID'}]",NCT01301391,Phase II,"Active, not recruiting","Tiziana Life Sciences, PLC ","[{'id': 2654, 'therapyName': 'PHA-848125AC'}]",Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy,11/10/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01301807,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 3438, 'therapyName': 'Carfilzomib + Panobinostat'}]",Carfilzomib Plus Panobinostat in Relapsed/Refractory Multiple Myeloma (MM),08/27/2016,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01302379,Phase I,"Active, not recruiting","University of California, San Diego","[{'id': 1031, 'therapyName': 'Metformin'}]",Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors,12/11/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01302405,Phase I,Terminated,"Prism Pharma Co., Ltd.","[{'id': 1083, 'therapyName': 'Pri-724'}]",Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors,06/06/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01303341,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1724, 'therapyName': 'Rilutek + Sorafenib'}]",Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma,05/03/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01303796,Phase III,Unknown status,"Cyclacel Pharmaceuticals, Inc. ","[{'id': 1747, 'therapyName': 'Decitabine + Sapacitabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS),06/20/2017,[],no
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT01305213,Phase Ib/II,Completed,National Cancer Institute (NCI),"[{'id': 1186, 'therapyName': 'Fosbretabulin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Bevacizumab With or Without Fosbretabulin Tromethamine in Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",07/13/2017,[],no
0,both,"[{'id': 8747, 'name': 'subacute myeloid leukemia', 'source': 'DOID'}]",NCT01305499,Phase II,Recruiting,Case Comprehensive Cancer Center ,"[{'id': 2645, 'therapyName': 'Azacitidine + Entinostat'}]",A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML),03/20/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01305941,Phase II,"Active, not recruiting",UNC Lineberger Comprehensive Cancer Center,"[{'id': 1411, 'therapyName': 'Trastuzumab + Everolimus + Vinorelbine'}]","A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases",03/15/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 3277, 'name': 'thymus cancer', 'source': 'DOID'}]",NCT01306045,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 816, 'therapyName': 'MK2206'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 913, 'therapyName': 'Selumetinib'}]","Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies",10/07/2016,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 624, 'profileName': 'EGFR E746_A750del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1052, 'profileName': 'EGFR A763_Y764insFQEA'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1214, 'profileName': 'KIT mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1213, 'profileName': 'PTEN mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1208, 'profileName': 'HRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1209, 'profileName': 'AKT1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1216, 'profileName': 'ERBB2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1215, 'profileName': 'PDGFRA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1191, 'profileName': 'PIK3CA amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1417, 'profileName': 'PDGFRA amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01306058,Phase Ib/II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 2389, 'therapyName': 'Carotuximab + Sorafenib'}]",Sorafenib and TRC105 in Hepatocellular Cancer,04/12/2017,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT01306643,Phase Ib/II,Completed,Gilead Sciences,"[{'id': 1023, 'therapyName': 'Idelalisib'}]","Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma",10/17/2015,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01307267,Phase I,Recruiting,Pfizer ,"[{'id': 6111, 'therapyName': 'Utomilumab + Rituximab'}, {'id': 5086, 'therapyName': 'Utomilumab'}]",A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab,10/10/2017,[],yes
0,both,"[{'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT01307956,Phase II,Unknown status,University of Nebraska ,"[{'id': 1986, 'therapyName': 'Panitumumab + FOLFOX'}]","Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer",06/20/2017,[],no
0,both,"[{'id': 1993, 'name': 'rectum cancer', 'source': 'DOID'}, {'id': 1520, 'name': 'colon carcinoma', 'source': 'DOID'}]",NCT01309126,Phase III,Terminated,Biothera ,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 2065, 'therapyName': 'Cetuximab + Imprime PGG'}]",Study of Imprime PGG in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer,02/08/2017,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01310231,Phase II,"Active, not recruiting",Ozmosis Research Inc.,"[{'id': 1031, 'therapyName': 'Metformin'}]",A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer,05/03/2017,[],no
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT01312376,Phase I,"Active, not recruiting",Abramson Cancer Center of the University of Pennsylvania,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1227, 'therapyName': 'CD3/CD28 costimulated vaccine-primed autologous T-cells'}, {'id': 1222, 'therapyName': 'OC-DC vaccine'}]",Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer,07/20/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01312857,Phase II,Recruiting,Memorial Sloan-Kettering Cancer Center,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1941, 'therapyName': 'Floxuridine'}]","Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer",01/30/2015,"[{'molecularProfile': {'id': 1192, 'profileName': 'KRAS G12X'}, 'requirementType': 'excluded'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01313559,Phase II,Terminated,Thomas Jefferson University ,"[{'id': 2261, 'therapyName': 'Everolimus + Pasireotide'}, {'id': 2260, 'therapyName': 'Pasireotide'}]","Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer",07/16/2015,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01313897,Phase II,Completed,University of Arkansas ,"[{'id': 688, 'therapyName': 'Bortezomib'}]","UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma (NK2010-35)",01/14/2017,[],no
0,both,"[{'id': 8850, 'name': 'salivary gland cancer', 'source': 'DOID'}, {'id': 3752, 'name': 'larynx verrucous carcinoma', 'source': 'DOID'}, {'id': 8618, 'name': 'oral cavity cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01316757,Phase II,"Active, not recruiting",Fox Chase Cancer Center,"[{'id': 1921, 'therapyName': 'Cetuximab + Paclitaxel + Carboplatin + Erlotinib'}]","Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer",03/05/2016,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 1037, 'name': 'lymphoblastic leukemia', 'source': 'DOID'}]",NCT01319981,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia,09/11/2015,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01320592,Phase I,"Active, not recruiting",Abramson Cancer Center of the University of Pennsylvania ,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",PD0332991/Paclitaxel in Advanced Breast Cancer,07/20/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT01321346,Phase I,Completed,Therapeutic Advances in Childhood Leukemia Consortium ,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1080, 'therapyName': 'Panobinostat'}]",A Study Of Panobinostat In Children With Refractory Hematologic Malignancies,11/25/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01321437,Phase II,"Active, not recruiting","University of California, Irvine","[{'id': 649, 'therapyName': 'Axitinib'}]",Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma,12/09/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01323517,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 5900, 'therapyName': 'Dactinomycin + Ipilimumab + Melphalan'}]",Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity,06/16/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01323751,Phase Ib/II,Completed,Acetylon Pharmaceuticals Incorporated ,"[{'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1613, 'therapyName': 'ACY-1215'}]",Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma,01/25/2017,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT01324180,Phase I,Completed,H. Lee Moffitt Cancer Center and Research Institute,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]","Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL)",08/08/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01324479,Phase I,Completed,Novartis Pharmaceuticals,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors,09/15/2017,"[{'molecularProfile': {'id': 343, 'profileName': 'EGFR wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1240, 'profileName': 'MET positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01325207,Phase Ib/II,"Active, not recruiting",Northwestern University,"[{'id': 947, 'therapyName': 'Trastuzumab'}]",Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer,06/07/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 5041, 'name': 'esophageal cancer', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}]",NCT01325441,Phase Ib/II,Recruiting,"Boston Biomedical, Inc ","[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}]",A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies,04/24/2015,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01326702,Phase Ib/II,Completed,National Cancer Institute (NCI),"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1231, 'therapyName': 'Bendamustine'}]"," Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors",10/07/2015,[],no
0,both,"[{'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 6477, 'name': 'invasive bladder transitional cell carcinoma', 'source': 'DOID'}, {'id': 6845, 'name': 'infiltrating ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 50620, 'name': 'infiltrating renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}]",NCT01326871,Phase Ib/II,"Active, not recruiting","Altor Bioscience Corporation, National Cancer Institute (NCI)","[{'id': 2187, 'therapyName': 'ALT-801'}]",A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer,07/28/2015,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01327612,Phase II,"Active, not recruiting",Amgen,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 746, 'therapyName': 'Ganitumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1458, 'therapyName': 'Conatumumab'}]",Open Label Extension Study of Conatumumab and AMG 479,12/01/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01328054,,Completed,GlaxoSmithKline,"[{'id': 787, 'therapyName': 'Lapatinib'}]",A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval,09/16/2015,[],no
0,both,"[{'id': 60100, 'name': 'musculoskeletal system cancer', 'source': 'DOID'}]",NCT01330966,Phase II,"Active, not recruiting",Vector Oncology ,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma,09/09/2015,[],no
0,both,"[{'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}, {'id': 4233, 'name': 'clear cell sarcoma', 'source': 'DOID'}, {'id': 2154, 'name': 'nephroblastoma', 'source': 'DOID'}, {'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 768, 'name': 'retinoblastoma', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3672, 'name': 'rhabdoid cancer', 'source': 'DOID'}, {'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}, {'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}, {'id': 2129, 'name': 'atypical teratoid rhabdoid tumor', 'source': 'DOID'}, {'id': 2994, 'name': 'germ cell cancer', 'source': 'DOID'}, {'id': 5074, 'name': 'malignant ependymoma', 'source': 'DOID'}, {'id': 687, 'name': 'hepatoblastoma', 'source': 'DOID'}, {'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}]",NCT01331135,Phase I,"Active, not recruiting",Emory University,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors,12/23/2014,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01331291,Phase II,Completed,Massachusetts General Hospital ,"[{'id': 690, 'therapyName': 'Bosutinib'}]",Bosutinib in Adult Patients With Recurrent Glioblastoma,05/02/2015,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01331616,Phase I,Unknown status,West Penn Allegheny Health System,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Optic Neuropathy in 10 Patients With Glioblastoma Receiving Bevacizumab,06/20/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT01334502,Phase I,Completed,North Central Cancer Treatment Group ,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma",08/11/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01336634,Phase II,"Active, not recruiting",GlaxoSmithKline ,"[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.,06/16/2016,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01336842,Phase I,Completed,"University of California, Davis","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors,06/07/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT01338987,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation,12/31/2016,"[{'molecularProfile': {'id': 14079, 'profileName': 'KMT2A rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1214, 'profileName': 'KIT mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}, {'id': 7912, 'name': 'mixed oligodendroglioma-astrocytoma', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT01339039,Phase I,Terminated,"Patrick Y. Wen, MD ","[{'id': 2120, 'therapyName': 'Bevacizumab + Plerixafor'}]",Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma,01/20/2016,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01339871,Phase I,Completed,M.D. Anderson Cancer Center,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Phase I Study of Pazopanib and Vorinostat,06/20/2017,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01340300,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute,"[{'id': 1031, 'therapyName': 'Metformin'}]",Exercise and Metformin in Colorectal and Breast Cancer Survivors,01/22/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01342367,Phase I,Recruiting,University of Chicago ,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 2643, 'therapyName': 'Dutasteride'}, {'id': 2644, 'therapyName': 'Finasteride'}]",Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer,05/08/2015,[],no
0,both,"[{'id': 5485, 'name': 'synovial sarcoma', 'source': 'DOID'}]",NCT01343043,Phase Ib/II,Recruiting,Adaptimmune ,"[{'id': 5877, 'therapyName': 'NY-ESO-1-c259T'}]",A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patients With Synovial Sarcoma  (NY-ESO-1),08/14/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01344824,Phase II,Completed,UNC Lineberger Comprehensive Cancer Center,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]","Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Who Are Light or Never Smokers",04/19/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01345019,Phase III,"Active, not recruiting",Amgen ,"[{'id': 1198, 'therapyName': 'Denosumab'}, {'id': 2971, 'therapyName': 'Zoledronic acid'}]",Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma,05/21/2016,[],no
0,both,[],NCT01345136,Phase II,Recruiting,"University of California, Los Angeles ","[{'id': 735, 'therapyName': 'Everolimus'}]",Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma,03/26/2015,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01345669,Phase III,Terminated,Boehringer Ingelheim ,"[{'id': 623, 'therapyName': 'Afatinib'}]",LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy,08/11/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01346358,Phase I,"Active, not recruiting",Eli Lilly and Company ,"[{'id': 2004, 'therapyName': 'LY3022855'}]",A Study of IMC-CS4 in Subjects With Advanced Solid Tumors,04/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01347866,Phase I,Terminated,Pfizer,"[{'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 849, 'therapyName': 'PD-0325901'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer,09/16/2015,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01349660,Phase Ib/II,"Active, not recruiting","SCRI Development Innovations, LLC","[{'id': 1178, 'therapyName': 'BKM120 + Bevacizumab'}]",Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,07/22/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01351103,Phase I,Recruiting,Novartis Pharmaceuticals ,"[{'id': 1937, 'therapyName': 'LGK974'}]",A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands,03/01/2017,"[{'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01351415,Phase III,Completed,Hoffmann-La Roche,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of Avastin (Bevacizumab) in Combination With Standard of Care Treatment in Patients With Lung Cancer,09/20/2016,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01351909,Phase Ib/II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cyclophosphamide With or Without Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer,07/23/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01352650,Phase I,"Active, not recruiting",Weill Medical College of Cornell University,"[{'id': 1770, 'therapyName': 'Plerixafor + Decitabine'}]",Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML),03/04/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 1039, 'name': 'prolymphocytic leukemia', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 3368, 'name': ""bone Ewing's sarcoma"", 'source': 'DOID'}]",NCT01353625,Phase I,"Active, not recruiting",Celgene Corporation,"[{'id': 1000, 'therapyName': 'CC-115'}]","Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.",04/22/2016,[],no
0,both,"[{'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}]",NCT01356290,Phase II,Recruiting,Medical University of Vienna ,"[{'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 4418, 'therapyName': 'Fenofibrate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2124, 'therapyName': 'Celecoxib'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT),07/01/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01356628,Phase II,"Active, not recruiting",Thomas Jefferson University,"[{'id': 850, 'therapyName': 'Palbociclib'}]",A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer,04/21/2016,"[{'molecularProfile': {'id': 2395, 'profileName': 'RB1 positive'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT01357161,Phase II,Completed,Merck Sharp & Dohme Corp.,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 822, 'therapyName': 'MK-1775'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]", A Study of MK-1775 in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004),10/21/2016,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'required'}]",yes
0,,[],NCT01358331,,Terminated,Merck Sharp & Dohme Corp.,[],"A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)",07/15/2015,[],no
0,,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01358877,Phase III,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast Cancer,07/03/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01361113,Phase II,Completed,UNC Lineberger Comprehensive Cancer Center,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Neoadjuvant Pazopanib in Renal Cell Carcinoma,05/11/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01362374,Phase I,"Active, not recruiting",Genentech,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","Safety and Pharmacology Of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Patients With Advanced Solid Tumors",11/04/2015,[],no
0,both,"[{'id': 5151, 'name': 'plexiform neurofibroma', 'source': 'DOID'}]",NCT01362803,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 913, 'therapyName': 'Selumetinib'}]",AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors,03/04/2015,[],yes
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 5602, 'name': 'T-cell adult acute lymphocytic leukemia', 'source': 'DOID'}]",NCT01363817,Phase I,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2545, 'therapyName': 'BMS-906024'}]",Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma,01/27/2016,[],no
0,both,"[{'id': 11819, 'name': 'ureter cancer', 'source': 'DOID'}, {'id': 1324, 'name': 'lung cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 4007, 'name': 'bladder carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}, {'id': 12253, 'name': 'testicular lymphoma', 'source': 'DOID'}, {'id': 734, 'name': 'urethra cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 5041, 'name': 'esophageal cancer', 'source': 'DOID'}]",NCT01366144,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction",08/24/2015,[],no
0,female,"[{'id': 5750, 'name': 'uterine corpus serous adenocarcinoma', 'source': 'DOID'}]",NCT01367002,Phase II,"Active, not recruiting",Yale University,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer,08/23/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 2513, 'name': 'basal cell carcinoma', 'source': 'DOID'}]",NCT01367665,Phase II,Completed,Hoffmann-La Roche ,"[{'id': 956, 'therapyName': 'Vismodegib'}]",STEVIE: A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma,07/27/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01370109,Phase I,Recruiting,Abramson Cancer Center of the University of Pennsylvania ,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Cardiovascular Effects of Sunitinib Therapy (CREST),06/17/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01371981,Phase III,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 2391, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,08/10/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01375699,Phase I,"Active, not recruiting",Virginia Commonwealth University ,"[{'id': 1009, 'therapyName': 'Doxorubicin'}]","Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers",03/17/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01375829,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1263, 'therapyName': 'ixabepilone + temsirolimus'}]",Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,12/01/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT01375842,Phase I,"Active, not recruiting","Genentech, Inc. ","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase 1 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors,02/14/2017,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01376310,Phase II,"Active, not recruiting",GlaxoSmithKline,"[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}, {'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1266, 'therapyName': 'Pemetrexed + GSK1120212'}, {'id': 1267, 'therapyName': 'Carboplatin + GSK1120212'}, {'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}, {'id': 1269, 'therapyName': 'Gemcitabine + GSK1120212'}, {'id': 1271, 'therapyName': 'Everolimus + GSK1120212'}]",GSK1120212 Rollover Study,07/25/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01376505,Phase I,Recruiting,Pravin Kaumaya ,"[{'id': 1404, 'therapyName': 'HER2 Vaccine'}]",Vaccine Therapy in Treating Patients With Metastatic Solid Tumors,09/25/2014,[],no
0,both,[],NCT01379534,,Completed,Novartis|Novartis Pharmaceuticals,[], A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer,01/20/2015,"[{'molecularProfile': {'id': 543, 'profileName': 'FGFR2 wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1185, 'profileName': 'FGFR2 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01383148,Phase Ib/II,Terminated,Transgene,"[{'id': 1273, 'therapyName': 'MVA-MUC1-IL2 vaccine'}]",Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer,01/06/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01383538,Phase I,Completed,Andrew Ko ,"[{'id': 2498, 'therapyName': 'Fluorouracil + Leucovorin + Irinotecan + Oxaliplatin + Saridegib'}]",FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma,08/09/2017,[],no
0,both,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 3119, 'name': 'gastrointestinal system cancer', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT01384253,Phase I,Completed,Areva Med LLC,"[{'id': 1540, 'therapyName': '212Pb-TCMC-Trastuzumab + Trastuzumab '}]",Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy,10/01/2016,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 10286, 'name': 'prostate carcinoma', 'source': 'DOID'}]",NCT01385228,Phase I,Completed,"Daniel George, MD ","[{'id': 2042, 'therapyName': 'Docetaxel + Pazopanib + Pegfilgrastim'}]","Pazopanib, Docetaxel, Prednisone Prostate",04/06/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01386385,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}]","Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery",07/21/2016,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 1324, 'name': 'lung cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 1319, 'name': 'brain cancer', 'source': 'DOID'}]",NCT01386580,Phase Ib/II,Completed,to-BBB technologies B.V.,"[{'id': 974, 'therapyName': '2B3-101'}, {'id': 1274, 'therapyName': '2B3-101 + Trastuzumab'}]","An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.",01/22/2015,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 7912, 'name': 'mixed oligodendroglioma-astrocytoma', 'source': 'DOID'}]",NCT01386710,Phase Ib/II,Suspended,Weill Medical College of Cornell University ,"[{'id': 2074, 'therapyName': 'Bevacizumab + Carboplatin'}]",Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma,10/27/2015,[],no
0,,[],NCT01389778,,"Active, not recruiting",,[],Polycystic Ovary Syndrome Genetics and Treatment Response,10/08/2015,[],no
0,both,"[{'id': 60108, 'name': 'brain glioma', 'source': 'DOID'}]",NCT01390948,Phase II,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of Avastin (Bevacizumab) in Combination With Temolozomide (TMZ) and Radiotherapy in Paediatric and Adolescent Patients With High-Grade Glioma,05/13/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 10286, 'name': 'prostate carcinoma', 'source': 'DOID'}, {'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}, {'id': 4007, 'name': 'bladder carcinoma', 'source': 'DOID'}]",NCT01391143,Phase I,Recruiting,MacroGenics ,"[{'id': 2863, 'therapyName': 'MGA271'}]",Safety Study of MGA271 in Refractory Cancer,07/10/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01391533,Phase I,Completed,Sanofi ,"[{'id': 2159, 'therapyName': 'SAR125844'}]",Study of SAR125844 Single Agent Administered as Slow Intravenous Infusion in Adult Patients With Advanced Malignant Solid Tumors,04/14/2016,"[{'molecularProfile': {'id': 1629, 'profileName': 'MET amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1240, 'profileName': 'MET positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4239, 'name': 'alveolar soft part sarcoma', 'source': 'DOID'}]",NCT01391962,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1001, 'therapyName': 'Cediranib'}]",Sunitinib or Cediranib for Alveolar Soft Part Sarcoma,01/28/2015,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT01392183,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC),09/13/2017,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}, {'id': 5076, 'name': 'mixed glioma', 'source': 'DOID'}]",NCT01392209,Phase I,"Active, not recruiting",Memorial Sloan Kettering Cancer Center,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma,01/15/2016,[],no
0,both,[],NCT01392521,,Completed,Bayer,[], Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer,09/04/2014,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01393509,Phase I,"Active, not recruiting",Memorial Sloan-Kettering Cancer Center,"[{'id': 1162, 'therapyName': 'PU-H71'}]",The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies,06/20/2017,[],no
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}]",NCT01396148,Phase II,Completed,Pfizer ,"[{'id': 930, 'therapyName': 'Sunitinib'}]",A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor,10/06/2017,"[{'molecularProfile': {'id': 582, 'profileName': 'KIT wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 5015, 'name': 'fibrolamellar carcinoma', 'source': 'DOID'}, {'id': 5719, 'name': 'adrenal medulla cancer', 'source': 'DOID'}, {'id': 264, 'name': 'hemangiopericytoma', 'source': 'DOID'}, {'id': 1816, 'name': 'angiosarcoma', 'source': 'DOID'}, {'id': 5304, 'name': 'ovarian clear cell adenocarcinoma', 'source': 'DOID'}, {'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}, {'id': 5299, 'name': 'endometrial clear cell adenocarcinoma', 'source': 'DOID'}, {'id': 660, 'name': 'adrenal cortex cancer', 'source': 'DOID'}, {'id': 3284, 'name': 'thymic carcinoma', 'source': 'DOID'}, {'id': 3973, 'name': 'thyroid medullary carcinoma', 'source': 'DOID'}, {'id': 50773, 'name': 'paraganglioma', 'source': 'DOID'}]",NCT01396408,Phase II,"Active, not recruiting",NCIC Clinical Trials Group ,"[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours,05/13/2015,"[{'molecularProfile': {'id': 1191, 'profileName': 'PIK3CA amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1209, 'profileName': 'AKT1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2346, 'profileName': 'KDR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3110, 'profileName': 'AKT1 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1215, 'profileName': 'PDGFRA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1232, 'profileName': 'RET mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1213, 'profileName': 'PTEN mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1214, 'profileName': 'KIT mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1240, 'name': 'leukemia', 'source': 'DOID'}]",NCT01396499,Phase I,Completed,M.D. Anderson Cancer Center,"[{'id': 680, 'therapyName': 'BKM120'}]","Study to Assess Safety, Tolerability and Preliminary Efficacy of BKM120, PI3K Kinase Inhibitor, With Advanced Leukemias",11/02/2016,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01397734,Phase I,"Active, not recruiting",Beth Israel Deaconess Medical Center,"[{'id': 640, 'therapyName': 'Arsenic trioxide'}]",Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML),12/23/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4971, 'name': 'myelofibrosis', 'source': 'DOID'}, {'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}]",NCT01398462,Phase I,Completed,JW Pharmaceutical ,"[{'id': 3081, 'therapyName': 'CWP232291'}]",Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients,03/09/2016,"[{'molecularProfile': {'id': 1325, 'profileName': 'FLT3 rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01399918,Phase II,"Active, not recruiting",Memorial Sloan Kettering Cancer Center,"[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]",Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC),02/18/2017,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01401959,Phase II,"Active, not recruiting","SCRI Development Innovations, LLC ","[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 1981, 'therapyName': 'Eribulin + Trastuzumab'}]",Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy,03/20/2015,[],no
0,both,"[{'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}]",NCT01403610,Phase II,Completed,The University of Texas Health Science Center at San Antonio,"[{'id': 2144, 'therapyName': 'Bevacizumab + Evofosfamide'}, {'id': 1317, 'therapyName': 'Evofosfamide'}]",Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab,10/27/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01405391,Phase I,Completed,PharmaMar,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",Study of PM01183 in Non-Colorectal Cancer Patients as a Days 1 and 8 Intravenous Short Infusion Every 3 Weeks,01/16/2016,[],no
0,both,"[{'id': 3302, 'name': 'chordoma', 'source': 'DOID'}]",NCT01407198,Phase I,"Active, not recruiting",Massachusetts General Hospital ,"[{'id': 829, 'therapyName': 'Nilotinib'}]",Nilotinib With Radiation for High Risk Chordoma,03/11/2016,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01407562,Phase I,"Active, not recruiting","Rutgers, The State University of New Jersey","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}]","Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors",07/15/2016,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT01408043,Phase I,Terminated,Case Comprehensive Cancer Center ,"[{'id': 3222, 'therapyName': 'Etoposide + Filgrastim + Plerixafor'}]","Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma",12/08/2016,[],no
0,both,"[{'id': 60318, 'name': 'acute promyelocytic leukemia', 'source': 'DOID'}]",NCT01409161,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 3685, 'therapyName': 'Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin'}]","Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin",03/11/2016,[],yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01409174,Phase Ib/II,Terminated,M.D. Anderson Cancer Center,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}]",IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma,06/01/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01409200,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 649, 'therapyName': 'Axitinib'}]",Neoadjuvant Axitinib in Prostate Cancer,09/28/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01411410,Phase I,Completed,Bayer,"[{'id': 1276, 'therapyName': 'Copanlisib + Paclitaxel'}]",Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer,09/16/2015,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01412229,Phase II,"Active, not recruiting",UNC Lineberger Comprehensive Cancer Center,"[{'id': 1957, 'therapyName': 'Abraxane + Carboplatin + Cetuximab'}]",Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck,08/29/2015,[],no
0,both,"[{'id': 8618, 'name': 'oral cavity cancer', 'source': 'DOID'}]",NCT01414426,Phase II,Recruiting,University of Chicago ,"[{'id': 953, 'therapyName': 'Vandetanib'}]",Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions,02/13/2015,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT01415752,Phase II,Recruiting,Eastern Cooperative Oncology Group ,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1164, 'therapyName': 'lenalidomide'}]","Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma",01/10/2016,[],yes
0,both,[],NCT01416688,Phase I,"Active, not recruiting",Southwest Oncology Group ,[],"S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride",02/21/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT01418001,Phase Ib/II,Terminated,Memorial Sloan-Kettering Cancer Center,"[{'id': 1470, 'therapyName': 'Gemcitabine + Docetaxel + Pazopanib'}]",Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS),12/18/2014,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01420250,Phase I,"Active, not recruiting",Thomas Jefferson University ,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer,10/10/2015,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT01420874,Phase I,"Active, not recruiting",Barbara Ann Karmanos Cancer Institute,"[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Anti-CD3 x Anti-Erbitux Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer),02/05/2016,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT01421524,Phase I,Recruiting,Celgene Corporation ,"[{'id': 2358, 'therapyName': 'CC-122'}]","Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma",08/05/2015,[],no
0,,[],NCT01422746,,Recruiting,,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]", Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess,12/21/2016,[],
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT01424982,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 2048, 'therapyName': 'Cytarabine + Methotrexate + Ponatinib'}, {'id': 2049, 'therapyName': 'Ponatinib + Vincristine'}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),08/02/2016,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01425008,Phase I,"Active, not recruiting","Millennium Pharmaceuticals, Inc.","[{'id': 1034, 'therapyName': 'MLN2480'}]",Study of MLN2480 in Patients With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Patients With Metastatic Melanoma,12/16/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01427322,,Terminated,Virginia Commonwealth University,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease,07/09/2015,[],no
0,,[],NCT01427595,,"Active, not recruiting",,[], Effect of Metformin on Sensitivity of the Gonadotropin-releasing Hormone (GnRH) Pulse Generator to Suppression by Estradiol and Progesterone,12/21/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01428492,Phase I,Completed,GlaxoSmithKline,"[{'id': 625, 'therapyName': 'Afuresertib'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma,12/15/2015,[],no
0,both,"[{'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}]",NCT01430351,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1784, 'therapyName': 'Memantine'}, {'id': 1031, 'therapyName': 'Metformin'}, {'id': 1785, 'therapyName': 'Mefloquine'}]","Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM)",12/18/2015,[],no
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT01430416,Phase I,"Active, not recruiting",Novartis Pharmaceuticals,"[{'id': 621, 'therapyName': 'AEB071'}]",Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients,09/03/2016,[],no
0,both,"[{'id': 50749, 'name': 'peripheral T-cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT01431209,Phase II,Recruiting,University of Nebraska|Incyte Corporation,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma,08/25/2015,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01431794,Phase Ib/II,"Active, not recruiting",Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 2497, 'therapyName': 'Gemcitabine + nab-paclitaxel + Sonidegib'}]",Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma,07/30/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01433991,Phase Ib/II,"Active, not recruiting",Eisai Inc.,"[{'id': 1019, 'therapyName': 'Golvatinib'}, {'id': 792, 'therapyName': 'Lenvatinib'}]",E7050 in Combination With E7080 in Subjects With Advanced Solid Tumors (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2),07/30/2014,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01434303,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1542, 'therapyName': 'Entinostat + Lapatinib + Trastuzumab'}]","Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only",12/19/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01434316,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1277, 'therapyName': 'Veliparib + Dinaciclib'}, {'id': 1278, 'therapyName': 'Veliparib + Dinaciclib + carboplatin'}]",Veliparib and Dinaciclib With or Without Carboplatin in Treating Patients With Advanced Solid Tumors,10/03/2016,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}, {'id': 7912, 'name': 'mixed oligodendroglioma-astrocytoma', 'source': 'DOID'}]",NCT01434602,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 2299, 'therapyName': 'Everolimus + Sorafenib'}]",Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas,01/28/2016,[],no
0,both,"[{'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01435395,Phase I,Completed,Emory University ,"[{'id': 2122, 'therapyName': 'Bevacizumab + Bortezomib + Temozolomide'}]","Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme",04/28/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01436656,Phase I,"Active, not recruiting",Novartis Pharmaceuticals,"[{'id': 796, 'therapyName': 'Encorafenib'}]",A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma,07/31/2014,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01436968,Phase III,Recruiting,"Advantagene, Inc.","[{'id': 5171, 'therapyName': 'Valacyclovir'}, {'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer,06/19/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01437449,Phase II,"Active, not recruiting",Stanford University ,"[{'id': 1987, 'therapyName': 'Cisplatin + Docetaxel + Cetuximab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Weekly Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)",05/21/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01437566,Phase II,Completed,"Genentech, Inc.","[{'id': 750, 'therapyName': 'GDC-0980'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 749, 'therapyName': 'GDC-0941'}]",Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy,07/06/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4007, 'name': 'bladder carcinoma', 'source': 'DOID'}]",NCT01438112,,Terminated,"Cold Genesys, Inc.","[{'id': 2524, 'therapyName': 'Gemcitabine + interferon + Mitomycin C + Valrubicin '}, {'id': 2523, 'therapyName': 'CG0070'}]",Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer,07/29/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}, {'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT01438554,Phase I,"Active, not recruiting",Sidney Kimmel Comprehensive Cancer Center,"[{'id': 1310, 'therapyName': 'Pazopanib + Trametinib'}]","Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma",06/20/2015,[],no
0,female,[],NCT01439711,Phase II,"Active, not recruiting",Alliance for Clinical Trials in Oncology ,[],Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ,06/23/2016,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT01439750,Phase Ib/II,"Active, not recruiting",Milton S. Hershey Medical Center ,"[{'id': 3394, 'therapyName': 'Bortezomib + Cladribine + Rituximab'}]","Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)",02/08/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01440582,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 3362, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide + Panobinostat'}]",Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients,09/21/2016,[],no
0,female,"[{'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}]",NCT01440998,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1819, 'therapyName': 'Dasatinib + Paclitaxel + Carboplatin'}]","Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer",07/15/2015,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01441882,Phase II,"Active, not recruiting",OHSU Knight Cancer Institute,"[{'id': 717, 'therapyName': 'Dasatinib'}]",A Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity,08/12/2016,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01441947,Phase II,"Active, not recruiting",Massachusetts General Hospital,"[{'id': 1965, 'therapyName': 'cabozantinib + Fulvestrant'}]",Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer,04/18/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}, {'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT01442935,Phase II,"Active, not recruiting",UNICANCER,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}, {'id': 2181, 'therapyName': 'Bevacizumab + FOLFIRI'}, {'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2183, 'therapyName': 'Bevacizumab + FOLFIRINOX'}, {'id': 2184, 'therapyName': 'Cetuximab + FOLFIRINOX'}]",Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases,12/19/2015,[],no
0,,[],NCT01443468,,Recruiting,,[],Clinical and Genetic Studies of Li-Fraumeni Syndrome,02/24/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01443481,Phase I,Completed,Novartis Pharmaceuticals,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Pharmacokinetics (PK) of TKI258 in Cancer Patients With Normal and Impaired Hepatic Function,02/06/2015,[],no
0,both,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT01445418,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer,07/13/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01445509,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors,01/26/2015,[],no
0,both,"[{'id': 4231, 'name': 'histiocytoma', 'source': 'DOID'}, {'id': 3371, 'name': 'chondrosarcoma', 'source': 'DOID'}, {'id': 1967, 'name': 'leiomyosarcoma', 'source': 'DOID'}, {'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}, {'id': 4239, 'name': 'alveolar soft part sarcoma', 'source': 'DOID'}, {'id': 5485, 'name': 'synovial sarcoma', 'source': 'DOID'}, {'id': 3507, 'name': 'dermatofibrosarcoma protuberans', 'source': 'DOID'}, {'id': 8282, 'name': 'adult epithelioid sarcoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 1816, 'name': 'angiosarcoma', 'source': 'DOID'}, {'id': 3512, 'name': 'neurofibrosarcoma', 'source': 'DOID'}, {'id': 4415, 'name': 'fibrous histiocytoma', 'source': 'DOID'}, {'id': 3516, 'name': 'adult fibrosarcoma', 'source': 'DOID'}, {'id': 6332, 'name': 'adult malignant hemangiopericytoma', 'source': 'DOID'}, {'id': 5693, 'name': 'adult liposarcoma', 'source': 'DOID'}]",NCT01446809,Phase I,"Active, not recruiting",University of Washington,"[{'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}, {'id': 1471, 'therapyName': 'Pazopanib + Doxorubicin + Ifosfamide'}]",Pazopanib Hydrochloride Followed By Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma,04/08/2016,[],no
0,both,"[{'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01449058,Phase Ib/II,Completed,Novartis Pharmaceuticals,"[{'id': 1311, 'therapyName': 'BYL719 + MEK162'}]",A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors,10/03/2017,"[{'molecularProfile': {'id': 1208, 'profileName': 'HRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01449279,Phase I,"Active, not recruiting",Stanford University ,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy,09/22/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01449370,Phase I,Completed,"Millennium Pharmaceuticals, Inc.","[{'id': 1033, 'therapyName': 'MLN1117'}]",Dose Escalation Study of MLN1117 in Subjects With Advanced Cancer,11/09/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 50744, 'name': 'anaplastic large cell lymphoma', 'source': 'DOID'}]",NCT01449461,Phase Ib/II,"Active, not recruiting",Ariad Pharmaceuticals,"[{'id': 634, 'therapyName': 'AP26113'}]",A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113,06/22/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1249, 'profileName': 'ROS1 fusion'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01450384,Phase I,Completed,Virginia Commonwealth University,"[{'id': 1482, 'therapyName': 'Pemetrexed + Sorafenib'}]",Pemetrexed Disodium and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors,02/05/2016,[],no
0,both,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT01450696,Phase III,Terminated,Hoffmann-La Roche,"[{'id': 1899, 'therapyName': 'Capecitabine + Cisplatin + Trastuzumab'}]",HELOISE Study: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer,11/29/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT01450761,Phase III,Completed,Bristol-Myers Squibb ,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone,07/12/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01453088,Phase II,Recruiting,Hackensack University Medical Center,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older,08/10/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01453101,Phase II,"Active, not recruiting",Hackensack University Medical Center ,"[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma,06/20/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT01453205,Phase II,Completed,MedImmune LLC ,"[{'id': 2354, 'therapyName': 'Cisplatin + Cytarabine + Dexamethasone'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2407, 'therapyName': 'MEDI-551'}]","A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",08/09/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01454102,Phase I,"Active, not recruiting",Bristol-Myers Squibb,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)",08/21/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01455389,Phase Ib/II,Recruiting,"Genprex, Inc.","[{'id': 1313, 'therapyName': 'DOTAP:chol-Fus1'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer,08/06/2014,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01456325,Phase III,Completed,Genentech,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 838, 'therapyName': 'Onartuzumab'}]",A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung),04/07/2016,"[{'molecularProfile': {'id': 1240, 'profileName': 'MET positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01456689,Phase I,"Active, not recruiting",Novartis Pharmaceuticals ,"[{'id': 2685, 'therapyName': 'Midazolam'}, {'id': 2402, 'therapyName': 'LGH447 '}]",A Study of Oral LGH447 in Patients With Relapsed and/or Refractory Multiple Myeloma,07/21/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01458067,Phase I,Completed,GlaxoSmithKline,"[{'id': 765, 'therapyName': 'GSK2636771'}]"," A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency",04/26/2016,"[{'molecularProfile': {'id': 479, 'profileName': 'PTEN loss'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01459211,Phase II,Completed,"University College, London ","[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Pilot Study to Establish Safety and Efficacy of a Combination of Dexamethasone and Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia (CLL),11/09/2016,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT01459380,Phase I,Completed,National Cancer Institute (NCI),"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Veliparib, Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer",07/25/2017,[],no
0,both,"[{'id': 1816, 'name': 'angiosarcoma', 'source': 'DOID'}]",NCT01462630,Phase II,Recruiting,Fox Chase Cancer Center,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma,09/18/2014,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01463046,Phase I,"Active, not recruiting","University of California, San Francisco ","[{'id': 3185, 'therapyName': 'Cytarabine + Daunorubicin + Panobinostat'}]",Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome,01/13/2016,[],no
0,,[],NCT01464086,,Recruiting,,[],LIFSCREEN : Evaluation of Whole Body MRI for Early Detection of Cancers in Subjects With P53 Mutation (Li-Fraumeni Syndrome),07/13/2015,[],no
0,both,"[{'id': 1799, 'name': 'islet cell tumor', 'source': 'DOID'}]",NCT01465659,Phase Ib/II,Recruiting,Northwestern University ,"[{'id': 2040, 'therapyName': 'Pazopanib + Temozolomide'}]",Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery,02/11/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01465802,Phase II,Completed,Pfizer,"[{'id': 714, 'therapyName': 'Dacomitinib'}, {'id': 1392, 'therapyName': 'Alclometasone'}, {'id': 1391, 'therapyName': 'Doxycycline'}]",Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO,06/24/2015,"[{'molecularProfile': {'id': 1216, 'profileName': 'ERBB2 mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1798, 'name': 'pancreatic endocrine carcinoma', 'source': 'DOID'}, {'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT01466036,Phase II,"Active, not recruiting",Massachusetts General Hospital ,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors,09/17/2016,[],no
0,female,"[{'id': 3459, 'name': 'breast carcinoma', 'source': 'DOID'}]",NCT01466972,Phase II,"Active, not recruiting","Hope Rugo, MD ","[{'id': 848, 'therapyName': 'Pazopanib'}]",Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib,05/14/2016,[],yes
0,both,"[{'id': 8618, 'name': 'oral cavity cancer', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}]",NCT01467115,Phase II,Completed,Drexel University ,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 694, 'therapyName': 'Cetuximab'}]",INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER,05/10/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01467310,Phase I,Completed,UNC Lineberger Comprehensive Cancer Center ,"[{'id': 2, 'therapyName': 'Trametinib'}]",Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212,04/20/2016,[],yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01468896,Phase Ib/II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 694, 'therapyName': 'Cetuximab'}]","Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery",02/03/2016,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01468922,Phase I,Completed,National Cancer Institute (NCI),"[{'id': 636, 'therapyName': 'Tivantinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib and ARQ 197 for Advanced Solid Tumors,02/16/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01470131,Phase III,Unknown status,AB Science,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]",A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma,06/20/2017,[],no
0,both,"[{'id': 1324, 'name': 'lung cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01470209,Phase I,"Active, not recruiting",Emory University,"[{'id': 1314, 'therapyName': 'BKM120 + Everolimus'}]",A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies,03/04/2017,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1213, 'profileName': 'PTEN mutant'}, 'requirementType': 'partial'}]",yes
0,both,[],NCT01470404,,Unknown status,Samsung Medical Center ,[],Pharmacogenomic Study (Adjuvant Chemotherapy),06/20/2017,[],no
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT01471054,Phase II,Terminated,Arman Mashayekhi,"[{'id': 1480, 'therapyName': 'Dexamethasone intravitreal implant'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma,05/03/2016,[],no
0,female,"[{'id': 60076, 'name': 'estrogen-receptor negative breast cancer', 'source': 'DOID'}]",NCT01471106,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer,09/29/2016,[],yes
0,both,"[{'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}, {'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT01471353,Phase II,"Active, not recruiting",University of Florida,"[{'id': 2428, 'therapyName': 'Sorafenib + Capecitabine'}]",Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,06/26/2015,[],no
0,both,[],NCT01471964,Phase Ib/II,Suspended,Fox Chase Cancer Center,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 626, 'therapyName': 'Alisertib'}]","Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer",11/26/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01472016,Phase I,Completed,"AbbVie (prior sponsor, Abbott)","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1063, 'therapyName': 'ABT-700'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study of ABT-700 in Subjects With Advanced Solid Tumors,06/08/2017,"[{'molecularProfile': {'id': 1066, 'profileName': 'MET amp over exp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01473095,Phase I,"Active, not recruiting",ArQule,"[{'id': 635, 'therapyName': 'ARQ092'}]",Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma,05/04/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01473901,Phase I,Completed,Novartis Pharmaceuticals,"[{'id': 4474, 'therapyName': 'BKM120 + Temozolomide'}]",A Phase I Dose Escalation Study of BKM120 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma,09/14/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01473940,Phase I,"Active, not recruiting",Northwestern University ,"[{'id': 2970, 'therapyName': 'Gemcitabine + Ipilimumab'}]",Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery,03/23/2016,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT01476839,Phase I,Recruiting,City of Hope Medical Center ,"[{'id': 6258, 'therapyName': 'Basiliximab + 90Y basiliximab + Carmustine + Cytarbine + Etoposide + Melphalan'}]",Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma,09/29/2017,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01478178,Phase Ib/II,Completed,"DelMar Pharmaceuticals, Inc. ","[{'id': 2921, 'therapyName': 'VAL-083'}]",Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma or Progressive Secondary Brain Tumor,11/02/2016,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01478321,Phase II,"Active, not recruiting",Northwestern University ,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas,03/31/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01479244,Phase III,Completed,"Galena Biopharma, Inc. ","[{'id': 3766, 'therapyName': 'E75'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",Efficacy and Safety Study of NeuVax (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence,02/25/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 263, 'name': 'kidney cancer', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01480154,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1393, 'therapyName': 'MK2206 + hydroxychloroquine'}]","Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer",11/18/2015,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01480583,Phase II,Completed,Angiochem Inc ,"[{'id': 947, 'therapyName': 'Trastuzumab'}]",GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases,06/07/2016,[],no
0,,[],NCT01482286,,Completed,,[],Effect of Weight and Insulin Sensitivity on Reproductive Function in PCOS,02/08/2017,[],no
0,both,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT01482715,,"Active, not recruiting","Clovis Oncology, Inc.","[{'id': 906, 'therapyName': 'Rucaparib'}]",A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II),07/08/2016,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 2870, 'name': 'endometrial adenocarcinoma', 'source': 'DOID'}]",NCT01482728,Phase I,Completed,University of Virginia,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Bristol-Myers Squibb Dasatinib Src Inhibition in Endometrial Cancer,05/14/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01483274,Phase I,Withdrawn,University of Louisville,"[{'id': 650, 'therapyName': 'Decitabine'}]",Decitabine and Vaccine Therapy for Patients With Relapsed AML Following Allogeneic Stem Cell Transplantation,06/06/2015,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT01483690,Phase Ib/II,Terminated,Therapeutic Advances in Childhood Leukemia Consortium ,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}]",A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL,09/17/2015,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01484041,Phase Ib/II,Terminated,Georgetown University|Novartis Pharmaceuticals,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer,09/21/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01485042,Phase I,Completed,"Herbert Hurwitz, MD","[{'id': 1318, 'therapyName': 'Evofosfamide + Pazopanib'}]",Dose Escalation Study of Pazopanib Plus TH-302,09/02/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01485744,Phase I,"Active, not recruiting",Massachusetts General Hospital ,"[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 1428, 'therapyName': 'Sonidegib'}]","LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer",04/08/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01485861,Phase II,"Active, not recruiting","Genentech, Inc.","[{'id': 750, 'therapyName': 'GDC-0980'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",Study of GDC-0068 Or GDC-0980 With Abiraterone Acetate Versus Abiraterone Acetate in Patients With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy,05/07/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01487265,Phase II,"Active, not recruiting","SCRI Development Innovations, LLC","[{'id': 1319, 'therapyName': 'BKM120 + Erlotinib'}]",Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib,04/09/2016,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01488318,Phase II,Terminated,University of Pittsburgh,"[{'id': 1820, 'therapyName': 'Cetuximab + Dasatinib'}]",Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma,11/05/2016,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01488552,Phase Ib/II,Completed,Pancreatic Cancer Research Team ,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1031, 'therapyName': 'Metformin'}]",Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer,08/20/2016,[],no
0,both,"[{'id': 7371, 'name': 'superficial urinary bladder cancer', 'source': 'DOID'}]",NCT01489813,Phase II,Recruiting,Emory University ,"[{'id': 757, 'therapyName': 'Genistein'}]",Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment,06/01/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01489865,Phase Ib/II,Recruiting,Georgetown University ,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer,08/27/2015,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 3748, 'name': 'esophagus squamous cell carcinoma', 'source': 'DOID'}]",NCT01490749,Phase I,"Active, not recruiting",Emory University,"[{'id': 1924, 'therapyName': 'Everolimus + Paclitaxel + Carboplatin + Cetuximab'}]",Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer,03/22/2016,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01491737,Phase II,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Patients With Hormone Receptor-Positive, Metastatic HER2-positive Breast Cancer",04/07/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3368, 'name': ""bone Ewing's sarcoma"", 'source': 'DOID'}, {'id': 4232, 'name': ""extraosseous Ewing's sarcoma"", 'source': 'DOID'}, {'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT01492673,Phase II,"Active, not recruiting",Memorial Sloan-Kettering Cancer Center,"[{'id': 1479, 'therapyName': 'Cyclophosphamide + Topotecan + Bevacizumab'}]","Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma",04/27/2016,[],no
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT01493505,Phase III,Terminated,Amgen,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1218, 'therapyName': 'Trebananib'}]", TRINOVA-3,02/24/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01493843,Phase II,Completed,Genentech,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 749, 'therapyName': 'GDC-0941'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer,05/06/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01494662,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute,"[{'id': 1543, 'therapyName': 'Capecitabine + Neratinib'}, {'id': 828, 'therapyName': 'Neratinib'}]",HKI-272 for HER2-Positive Breast Cancer and Brain Metastases,05/31/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01494688,Phase I,"Active, not recruiting",Hoffmann-La Roche ,"[{'id': 2843, 'therapyName': 'Emactuzumab'}, {'id': 4249, 'therapyName': 'Emactuzumab + Paclitaxel'}]",A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Patients With Advanced Solid Tumors,07/06/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01495988,Phase II,Terminated,Melanoma Research Foundation Breakthrough Consortium,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 342, 'therapyName': 'Vemurafenib'}]",Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma,02/06/2016,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01497392,Phase I,Completed,Roswell Park Cancer Institute,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 721, 'therapyName': 'Dovitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]"," Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers",02/16/2017,[],no
0,both,"[{'id': 3571, 'name': 'liver cancer', 'source': 'DOID'}, {'id': 263, 'name': 'kidney cancer', 'source': 'DOID'}]",NCT01497444,Phase Ib/II,Suspended,North Central Cancer Treatment Group,"[{'id': 1320, 'therapyName': 'Evofosfamide + Sorafenib'}]",Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery,01/26/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01497626,Phase I,Terminated,Georgetown University,"[{'id': 1394, 'therapyName': 'Lapatinib + bortezomib'}]",Lapatinib and Bortezomib in Patients With Advanced Malignancies,10/01/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01497704,Phase Ib/II,Completed,LSK BioPartners Inc.,"[{'id': 986, 'therapyName': 'Apatinib'}]",Dose-Escalation and Safety Trial of YN968D1,05/15/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01497808,Phase Ib/II,"Active, not recruiting",Abramson Cancer Center of the University of Pennsylvania ,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",RADVAX: A Stratified Phase I/II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma,01/26/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01498445,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1760, 'therapyName': 'Dasatinib + Decitabine '}]",Phase I/II - Dasatinib and Decitabine,12/04/2014,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 1967, 'name': 'leiomyosarcoma', 'source': 'DOID'}]",NCT01498484,Phase II,"Active, not recruiting",Atara Biotherapeutics,"[{'id': 5057, 'therapyName': 'EB-VST cells'}]",Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies,03/15/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01498978,Phase II,"Active, not recruiting",OHSU Knight Cancer Institute ,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,02/16/2016,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT01499121,Phase II,"Active, not recruiting",Sunnybrook Health Sciences Centre ,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule,05/30/2015,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01501487,FDA approved,"Active, not recruiting",Agendia ,"[{'id': 1902, 'therapyName': 'Docetaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,03/30/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01503229,Phase II,"Active, not recruiting",University of Washington ,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,11/04/2015,[],no
0,female,"[{'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}]",NCT01504126,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1912, 'therapyName': 'Propranolol'}]",Beta-Blocker / Ovarian,02/05/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01505569,Phase I,Recruiting,"Masonic Cancer Center, University of Minnesota ","[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2101, 'therapyName': 'Etoposide + Ifosfamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Auto Transplant for High Risk or Relapsed Solid or CNS Tumors,05/13/2015,[],no
0,,[],NCT01506596,,Completed,"ACORN Research, LLC.","[{'id': 848, 'therapyName': 'Pazopanib'}]",Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma,05/26/2016,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01506609,Phase II,"Active, not recruiting","AbbVie (prior sponsor, Abbott)","[{'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",The Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide or In Combination With Carboplatin and Paclitaxel Versus Placebo in Subjects With BRCA1 and BRCA2 Mutation and Metastatic Breast Cancer,10/28/2015,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01506973,Phase Ib/II,Recruiting,Abramson Cancer Center of the University of Pennsylvania ,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy in Pancreatic Cancer,08/05/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01508104,Phase Ib/II,Terminated,University of Cincinnati,"[{'id': 1321, 'therapyName': 'BEZ235 + Everolimus'}, {'id': 735, 'therapyName': 'Everolimus'}]",Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors,08/24/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01508117,Phase II,Terminated,University of Cincinnati ,"[{'id': 649, 'therapyName': 'Axitinib'}]",Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients,09/20/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01510119,Phase Ib/II,"Active, not recruiting",Abramson Cancer Center of the University of Pennsylvania ,"[{'id': 2231, 'therapyName': 'Everolimus + Hydroxychloroquine'}]",Autophagy Inhibition to Augment mTOR Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine in Patients With Previously Treated Renal Cell Carcinoma,12/08/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01512251,Phase Ib/II,Completed,"University of California, San Francisco","[{'id': 1322, 'therapyName': 'BKM120 + Vemurafenib'}]",BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma,09/19/2017,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01513083,Phase I,Completed,Hoffmann-La Roche,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function,01/27/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01513733,Phase I,Completed,"Andrew J. Armstrong, MD ","[{'id': 2699, 'therapyName': 'Tasquinimod'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",The CATCH Prostate Cancer Trial Cabazitaxel And Tasquinimod in Men With Prostate Cancer,07/28/2016,[],no
0,both,"[{'id': 4203, 'name': 'brain stem cancer', 'source': 'DOID'}, {'id': 4202, 'name': 'brain stem glioma', 'source': 'DOID'}]",NCT01514201,Phase Ib/II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 954, 'therapyName': 'Veliparib'}]","Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas",02/04/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01514864,Phase II,Terminated,Bristol-Myers Squibb,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation,12/01/2015,"[{'molecularProfile': {'id': 1250, 'profileName': 'BRAF inact mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01515527,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS),12/04/2014,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}]",NCT01516216,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Vitamin D in Untreated Metastatic Colorectal Cancer,02/10/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01517243,Phase II,Unknown status,Dartmouth-Hitchcock Medical Center,"[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Phase II Study of Alternating Sunitinib and Temsirolimus,08/02/2017,[],no
0,both,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01517802,Phase III,Recruiting,"Janssen Research & Development, LLC","[{'id': 1805, 'therapyName': 'Abiraterone'}]",A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate,03/16/2017,[],no
0,both,"[{'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}, {'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}, {'id': 3368, 'name': ""bone Ewing's sarcoma"", 'source': 'DOID'}, {'id': 4232, 'name': ""extraosseous Ewing's sarcoma"", 'source': 'DOID'}, {'id': 1319, 'name': 'brain cancer', 'source': 'DOID'}, {'id': 10000004, 'name': 'Pediatric Solid Tumors', 'source': 'JAX'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT01518413,Phase I,Completed,Children's Research Institute,"[{'id': 1323, 'therapyName': 'Sorafenib + Irinotecan'}]",Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors,04/22/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01519323,Phase I,Terminated,Hoffmann-La Roche,"[{'id': 342, 'therapyName': 'Vemurafenib'}]", BRIM-P,07/29/2016,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT01519869,Phase I,"Active, not recruiting",Rachel Miller ,[],"Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma",01/14/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01520389,Phase I,Completed,Merrimack Pharmaceuticals ,"[{'id': 821, 'therapyName': 'MM-151'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment,03/19/2016,[],no
0,both,"[{'id': 5041, 'name': 'esophageal cancer', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}]",NCT01522768,Phase II,Recruiting,Memorial Sloan-Kettering Cancer Center|Boehringer Ingelheim Pharmaceuticals,"[{'id': 1106, 'therapyName': 'Afatinib + Trastuzumab'}]", Afatinib (BIBW 2992) and Trastuzumab in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer,07/27/2014,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01522820,Phase I,Completed,Roswell Park Cancer Institute,"[{'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 917, 'therapyName': 'Sirolimus'}]",Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors,10/05/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01522872,Phase Ib/II,"Active, not recruiting",Threshold Pharmaceuticals ,"[{'id': 1317, 'therapyName': 'Evofosfamide'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma,01/07/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01522989,Phase I,"Active, not recruiting",Georgetown University,"[{'id': 1703, 'therapyName': 'Palbociclib + Fluorouracil + Oxaliplatin'}]","PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies",12/21/2016,"[{'molecularProfile': {'id': 2395, 'profileName': 'RB1 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT01523977,Phase I,"Active, not recruiting",Dana-Farber Cancer Institute ,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL,03/15/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01524978,Phase II,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers,11/04/2015,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1799, 'name': 'islet cell tumor', 'source': 'DOID'}]",NCT01525082,Phase II,"Active, not recruiting",Stanford University ,"[{'id': 2073, 'therapyName': 'Bevacizumab + Capecitabine + Temozolomide'}]","Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors",07/15/2016,[],no
0,both,"[{'id': 1799, 'name': 'islet cell tumor', 'source': 'DOID'}]",NCT01525550,FDA approved,"Active, not recruiting",Pfizer ,"[{'id': 930, 'therapyName': 'Sunitinib'}]",A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors,03/15/2016,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01525589,Phase II,Recruiting,PharmaMar ,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",A Phase II Clinical Trial of PM01183 in BRCA 1/2-Associated or Unselected Metastatic Breast Cancer,11/10/2015,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01525602,Phase I,"Active, not recruiting",Plexxikon,"[{'id': 1395, 'therapyName': 'PLX3397 + Paclitaxel'}]",Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors,03/23/2017,[],no
0,,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01526096,Phase I,Recruiting,University of Chicago,"[{'id': 5985, 'therapyName': 'Basiliximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Stem Cell Transplantation for Patients With Multiple Myeloma,07/12/2017,[],no
0,both,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}]",NCT01526473,Phase I,"Active, not recruiting",H. Kim Lyerly ,"[{'id': 1068, 'therapyName': 'AVX901'}]",A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901,02/18/2016,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT01526603,Phase I,Recruiting,"Masonic Cancer Center, University of Minnesota ","[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1092, 'therapyName': 'Carboplatin'}]",High Dose Chemotherapy and Autologous Transplant for Neuroblastoma,05/06/2015,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01526837,Phase I,Terminated,Brain & Spine Surgeons of New York ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence,07/13/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01526928,Phase Ib/II,"Active, not recruiting","Clovis Oncology, Inc.","[{'id': 1003, 'therapyName': 'CO1686'}]","Study to Evaluate Safety, Pharmacokinetics, and Efficacy of CO-1686 in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients",08/04/2015,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01528046,Phase I,Recruiting,H. Lee Moffitt Cancer Center and Research Institute,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1826, 'therapyName': 'Vincristine + Irinotecan + Temozolomide '}]",Metformin in Children With Relapsed or Refractory Solid Tumors,12/22/2014,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01528345,Phase II,Terminated,Novartis Pharmaceuticals,"[{'id': 2189, 'therapyName': 'Fulvestrant + Dovitinib'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer",07/12/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01529593,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1325, 'therapyName': 'Temsirolimus + Metformin'}]",Temsirolimus in Combination With Metformin in Patients With Advanced Cancers,09/04/2015,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT01529827,Phase II,"Active, not recruiting",Roswell Park Cancer Institute,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",03/19/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01530984,Phase II,Withdrawn,Lawrence Fong ,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab and GMCSF Immunotherapy for Prostate Cancer,10/06/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01531361,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 1326, 'therapyName': 'Vemurafenib + Sorafenib'}]",Sorafenib or Crizotinib and Vemurafenib in Advanced Cancer,08/31/2015,"[{'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01531894,Phase II,"Active, not recruiting",GlaxoSmithKline,"[{'id': 625, 'therapyName': 'Afuresertib'}]",Continuation Study of the Oral AKT Inhibitor GSK2110183,03/04/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01532011,Phase I,Completed,M.D. Anderson Cancer Center,"[{'id': 1328, 'therapyName': 'Erlotinib + Pralatrexate'}]",Erlotinib in Combination With Pralatrexate in Advanced Malignancies,07/06/2016,"[{'molecularProfile': {'id': 624, 'profileName': 'EGFR E746_A750del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 343, 'profileName': 'EGFR wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1046, 'profileName': 'EGFR G719C'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01532089,Phase II,"Active, not recruiting",Academic and Community Cancer Research United,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations,10/15/2016,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT01532687,Phase II,Recruiting,OHSU Knight Cancer Institute,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}]",Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma,09/30/2016,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01532700,Phase II,"Active, not recruiting","""University Health Network, Toronto|GlaxoSmithKline""","[{'id': 1091, 'therapyName': 'Ofatumumab + GSK2110183'}]", An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL),11/02/2016,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01532960,Phase I,Terminated,University of Virginia ,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer (Breast 41),08/16/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01533948,Phase II,Terminated,Roswell Park Cancer Institute,"[{'id': 649, 'therapyName': 'Axitinib'}]",Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery,06/02/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01534260,Phase Ib/II,Recruiting,Hamid Sayar ,"[{'id': 2366, 'therapyName': 'Bortezomib + Sorafenib + vorinostat'}]","Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype",03/12/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01534598,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 3789, 'therapyName': 'FdCyd + THU'}]",FdCyd and THU for Advanced Solid Tumors,03/20/2016,[],no
0,both,"[{'id': 3969, 'name': 'papillary thyroid carcinoma', 'source': 'DOID'}]",NCT01534897,Phase I,Completed,Massachusetts General Hospital,"[{'id': 3, 'therapyName': 'Dabrafenib'}]",Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436,06/19/2015,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 3594, 'name': 'choriocarcinoma', 'source': 'DOID'}, {'id': 3590, 'name': 'gestational trophoblastic neoplasm', 'source': 'DOID'}]",NCT01535053,Phase III,"Active, not recruiting",Gynecologic Oncology Group ,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",Methotrexate or Dactinomycin in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia,05/05/2017,[],no
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT01535157,Phase Ib/II,"Active, not recruiting",South Plains Oncology Consortium ,"[{'id': 2858, 'therapyName': 'Ketoconazole'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer,08/01/2017,[],no
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT01536743,Phase II,"Active, not recruiting",Jonsson Comprehensive Cancer Center,"[{'id': 850, 'therapyName': 'Palbociclib'}]",A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression,08/20/2016,[],no
0,both,"[{'id': 4905, 'name': 'pancreatic carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 5742, 'name': 'pancreatic acinar cell adenocarcinoma', 'source': 'DOID'}]",NCT01537107,Phase I,Suspended,Mayo Clinic,"[{'id': 1329, 'therapyName': 'Sirolimus + Vismodegib'}]",Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery,10/31/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01537744,Phase I,Completed,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 1396, 'therapyName': 'Azacitidine + Romidepsin'}]","A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer",05/26/2017,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}]",NCT01538680,Phase III,No longer available,Bayer,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Subjects With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Therapy,07/01/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01540253,Phase I,Completed,Roswell Park Cancer Institute,"[{'id': 1330, 'therapyName': 'BKM120 + Docetaxel'}]","PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic",07/01/2016,[],no
0,both,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01540526,Phase I,Completed,"University of Wisconsin, Madison","[{'id': 649, 'therapyName': 'Axitinib'}]",Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib,12/15/2014,[],no
0,,[],NCT01540682,,"Active, not recruiting",,"[{'id': 694, 'therapyName': 'Cetuximab'}]",MLN8237 in Head and Neck Cancer,07/21/2016,[],no
0,,[],NCT01543581,,Completed,,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Vismodegib for Treatment of Basal Cell Carcinoma,12/18/2014,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01543698,Phase Ib/II,"Active, not recruiting",Novartis Pharmaceuticals,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}]",A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors,05/07/2016,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01543763,Phase I,"Active, not recruiting","University of California, San Francisco","[{'id': 3046, 'therapyName': 'Panobinostat + Pazopanib'}]","Phase I Tolerability, Efficacy, and Safety Study of Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors",08/02/2017,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01543776,Phase II,"Active, not recruiting",University of Chicago ,"[{'id': 1805, 'therapyName': 'Abiraterone'}]",Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer,04/02/2016,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01545648,Phase II,"Active, not recruiting","Hope Rugo, MD ","[{'id': 1198, 'therapyName': 'Denosumab'}]",Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer,05/14/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01545947,Phase I,Completed,Celgene Corporation,"[{'id': 1149, 'therapyName': 'Azacitidine + CC-223'}, {'id': 1147, 'therapyName': 'Erlotinib + CC-223'}]"," Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer",07/10/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01546038,Phase Ib/II,"Active, not recruiting",Pfizer,"[{'id': 1748, 'therapyName': 'PF-04449913'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]",A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome,05/10/2017,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT01547546,Phase I,Completed,"Genentech, Inc.","[{'id': 2018, 'therapyName': 'GDC-0084'}]",A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma,03/20/2015,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01547806,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1756, 'therapyName': 'Plerixafor'}]",Collection of Transplant Stem Cells for Plasma Cell Myeloma,09/14/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01548144,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1153, 'therapyName': 'Crizotinib + Pazopanib'}, {'id': 1151, 'therapyName': 'Crizotinib + Pemetrexed'}, {'id': 1156, 'therapyName': 'Pazopanib + Pemetrexed'}, {'id': 1155, 'therapyName': 'Crizotinib + Pazopanib + Pemetrexed'}]",Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer,01/27/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01548807,Phase I,Recruiting,Abramson Cancer Center of the University of Pennsylvania ,"[{'id': 735, 'therapyName': 'Everolimus'}]",Phase 1 Trial of the Mammalian Target of Rapamycin (mTOR) Inhibitor Everolimus Plus Radiation Therapy (RT) for Salvage Treatment of Biochemical Recurrence in Prostate Cancer Patients Following Prostatectomy,01/27/2016,[],no
0,both,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT01551745,Phase II,Completed,"Gradalis, Inc.","[{'id': 1158, 'therapyName': 'FANG vaccine + Bevacizumab'}]", Salvage Ovarian FANG Vaccine + Bevacizumab,08/05/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01552356,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors,01/09/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01552434,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1376, 'therapyName': 'Temsirolimus + Bevacizumab + Valproic Acid + Cetuximab'}]","Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab",04/25/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01553071,Phase I,Recruiting,University of Texas Southwestern Medical Center ,"[{'id': 1049, 'therapyName': 'Safingol'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Phase I Trial of IV Fenretinide (4-HPR) Plus IV Safingol for Patients With Relapsed Malignancies,12/20/2016,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01553188,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1218, 'therapyName': 'Trebananib'}]",AMG 386 and Abiraterone for Advanced Prostate Cancer,04/08/2016,[],no
0,both,"[{'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}]",NCT01553851,Phase II,Completed,Washington University School of Medicine ,"[{'id': 2, 'therapyName': 'Trametinib'}]",GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer,12/06/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01553942,Phase II,Recruiting,Massachusetts General Hospital,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Afatinib With CT and RT for EGFR-Mutant NSCLC,06/15/2015,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01555489,Phase II,Completed,Thomas Jefferson University ,[],Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca,06/22/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01556490,Phase III,Recruiting,BTG International Inc. ,[],Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer,03/17/2015,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01556776,Phase III,Terminated,German CLL Study Group ,"[{'id': 1164, 'therapyName': 'lenalidomide'}]",A Study of Lenalidomide Maintenance for High-risk Patients With CLL Following First-line Therapy,07/08/2016,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01560416,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute ,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 745, 'therapyName': 'Ganetespib'}]",Fulvestrant With or Without Ganetespib in HR+ Breast Cancer,04/05/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01560923,Phase II,"Active, not recruiting","Masonic Cancer Center, University of Minnesota ","[{'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer,11/09/2016,[],no
0,male,"[{'id': 10286, 'name': 'prostate carcinoma', 'source': 'DOID'}]",NCT01561482,Phase II,Withdrawn,Nicholas Mitsiades ,"[{'id': 1829, 'therapyName': 'Metformin + Simvastatin'}]",Study of Metformin With Simvastatin for Men With Prostate Carcinoma,07/23/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01562275,Phase I,Completed,Genentech,"[{'id': 1160, 'therapyName': 'Cobimetinib + GDC-0068'}]"," A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Patients With Locally Advanced or Metastatic Solid Tumors",02/02/2015,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01562873,,Terminated,Dana-Farber Cancer Institute,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]", Ruxolitinib in Patients With Breast Cancer,11/28/2015,[],no
0,both,[],NCT01562899,,Terminated,Novartis|Novartis Pharmaceuticals,[], A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors,02/16/2017,[],yes
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01564251,Phase I,"Active, not recruiting","Genentech, Inc. ","[{'id': 2113, 'therapyName': 'GDC-0575 + Gemcitabine'}, {'id': 2024, 'therapyName': 'GDC-0575'}]",A Study of GDC-0575 Alone And in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma,07/06/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01565083,Phase II,Completed,Hoffmann-La Roche ,"[{'id': 1666, 'therapyName': 'Pertuzumab + Trastuzumab + Vinorelbine'}]",A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer,12/03/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01565837,Phase II,Recruiting,Wolfram Samlowski ,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma,07/29/2015,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01566721,Phase III,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 947, 'therapyName': 'Trastuzumab'}]",A Safety and Tolerability Study of Assisted- and Self-Administered Subcutaneous Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With Early HER2-Positive Breast Cancer (SafeHer),12/03/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01567930,Phase II,Unknown status,University of Tennessee Cancer Institute ,"[{'id': 936, 'therapyName': 'Temsirolimus'}]",Temsirolimus as Second-line Therapy in HCC,06/20/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01569984,Phase II,Completed,Dr. Yoo-Joung Ko ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Radiosensitization of AVASTIN; (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis,03/31/2015,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01570036,Phase II,Recruiting,George E. Peoples ,"[{'id': 3766, 'therapyName': 'E75'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax,01/16/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01570868,Phase II,Terminated,M.D. Anderson Cancer Center,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP),05/17/2016,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01571024,Phase I,Completed,UNC Lineberger Comprehensive Cancer Center,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 680, 'therapyName': 'BKM120'}]", BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer,07/06/2016,[],no
0,both,"[{'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}, {'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}, {'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT01571284,Phase III,Completed,Sanofi,"[{'id': 2095, 'therapyName': 'Aflibercept + FOLFIRI'}]",Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen,03/02/2017,[],no
0,both,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT01572038,Phase III,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) and A Taxane in First-Line Treatment in Patients With HER2-Positive Advanced Breast Cancer (PERUSE),03/03/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01572727,Phase II,Completed,Novartis Pharmaceuticals ,"[{'id': 1545, 'therapyName': 'BKM120 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",10/15/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01573702,Phase II,"Active, not recruiting",UNC Lineberger Comprehensive Cancer Center,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Stereotactic Radiosurgery or Other Local Ablation Then Erlotinib in Epidermal Growth Factor Receptor (EGFR),09/29/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01574729,Phase II,Unknown status,"Shenzhen SiBiono GeneTech Co.,Ltd ","[{'id': 1680, 'therapyName': 'rAD-p53'}]",Surgery Combined With rAd-p53 Gene in Treatment Advanced Non-small-cell Carcinoma,06/20/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01575548,Phase III,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery,07/28/2017,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01576172,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 954, 'therapyName': 'Veliparib'}]",Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,12/15/2015,[],no
0,both,[],NCT01576185,,Completed,Children's Oncology Group ,[],Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia,05/19/2016,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01576406,Phase I,Completed,Pfizer,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients,07/08/2016,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01576666,Phase Ib/II,Completed,Novartis Pharmaceuticals,"[{'id': 1547, 'therapyName': 'BKM120 + Sonidegib'}]","Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",06/26/2015,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01577173,Phase II,Completed,"Genentech, Inc. ","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 806, 'therapyName': 'MEHD7945A'}]",A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck,02/03/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01577745,Phase I,Completed,MedImmune LLC ,"[{'id': 2546, 'therapyName': 'MEDI0639'}]","A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors",05/03/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01578109,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia,02/08/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01578551,Phase II,"Active, not recruiting",Sidney Kimmel Comprehensive Cancer Center,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.,10/14/2016,[],no
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT01579812,Phase II,"Active, not recruiting",Ronald Buckanovich ,"[{'id': 1031, 'therapyName': 'Metformin'}]","Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients",06/03/2016,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT01579929,Phase I,Completed,Memorial Sloan Kettering Cancer Center. ,"[{'id': 2504, 'therapyName': 'Cisplatin + Etoposide + Sonidegib'}]","Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)",08/18/2017,[],no
0,both,"[{'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}]",NCT01579994,Phase I,"Active, not recruiting",Memorial Sloan Kettering Cancer Center. ,"[{'id': 2190, 'therapyName': 'Ganetespib + Crizotinib'}]",Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers,03/17/2015,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 11239, 'name': 'appendix cancer', 'source': 'DOID'}]",NCT01580410,Phase II,"Active, not recruiting",Comprehensive Cancer Center of Wake Forest University,"[{'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}]",Surgery and Oxaliplatin or Mitomycin C in Treating Patients With Tumors of the Appendix,10/24/2015,[],no
0,both,"[{'id': 60108, 'name': 'brain glioma', 'source': 'DOID'}]",NCT01580969,Phase Ib/II,Recruiting,University of Utah,"[{'id': 667, 'therapyName': 'Bevacizumab'}]","Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma",02/22/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT01581541,Phase I,Terminated,National Cancer Institute (NCI),"[{'id': 1162, 'therapyName': 'PU-H71'}]", PU-H71 in Patients With Solid Tumors and Low-Grade Non-Hodgkin s Lymphoma That Have Not Responded to Standard Treatment,10/05/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01581970,Phase II,Completed,"Masonic Cancer Center, University of Minnesota ","[{'id': 1997, 'therapyName': 'Cyclophosphamide + Cetuximab'}]",Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head &amp; Neck Cancer,07/17/2015,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01582009,Phase Ib/II,Terminated,Roswell Park Cancer Institute ,"[{'id': 1964, 'therapyName': 'Panobinostat + Everolimus'}]",Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate,07/20/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01582191,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1163, 'therapyName': 'Vandetanib + Everolimus'}]",Vandetanib With Everolimus,02/11/2016,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT01582204,Phase I,Recruiting,Memorial Sloan-Kettering Cancer Center,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma,02/02/2015,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01582295,Phase I,Completed,Massachusetts General Hospital ,"[{'id': 998, 'therapyName': 'cabozantinib'}]",XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease,03/01/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01582672,Phase III,"Active, not recruiting",Argos Therapeutics ,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC),07/21/2015,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT01584531,Phase II,Completed,"Onconova Therapeutics, Inc. ","[{'id': 1046, 'therapyName': 'rigosertib'}]","Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome",04/07/2016,[],no
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT01585194,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma,05/29/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01585415,Phase I,Terminated,National Cancer Institute (NCI),"[{'id': 953, 'therapyName': 'Vandetanib'}]", Vemurafenib and White Blood Cell Therapy for Advanced Melanoma,07/26/2016,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01585805,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer,04/28/2015,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01586195,Phase II,Terminated,Genentech,"[{'id': 342, 'therapyName': 'Vemurafenib'}]"," Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E",02/03/2016,"[{'molecularProfile': {'id': 696, 'profileName': 'BRAF act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01586611,Phase III,Unknown status,AHS Cancer Control Alberta ,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study to See if hENT1 Testing on Tumour Tissue Can Predict Response to Treatment With Gemcitabine Chemotherapy and if a Different Chemotherapy Called FOLFOX is Better Than Gemcitabine in Metastatic Pancreas Cancer,06/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01587040,Phase Ib/II,"Active, not recruiting",Sanofi,"[{'id': 1050, 'therapyName': 'XL147'}, {'id': 1051, 'therapyName': 'SAR245409'}]",Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen,08/29/2015,[],no
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT01587352,Phase II,Suspended,National Cancer Institute (NCI),"[{'id': 1077, 'therapyName': 'Vorinostat'}]",Vorinostat in Treating Patients With Metastatic Melanoma of the Eye,01/20/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01587703,Phase I,Recruiting,GlaxoSmithKline ,"[{'id': 784, 'therapyName': 'GSK525762'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers",10/21/2015,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01588184,Phase III,Recruiting, Hoffmann-La Roche ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",An Extension Study to Provide Continued Avastin Therapy to Patients With Solid Tumours Who Were Previously Enrolled in a Roche/Genentech Sponsored Study,12/01/2015,[],no
0,both,"[{'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}]",NCT01588431,Phase II,"Active, not recruiting",Ahmad Wehbe ,"[{'id': 1987, 'therapyName': 'Cisplatin + Docetaxel + Cetuximab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer,07/21/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01588678,Phase I,Completed,Daiichi Sankyo Inc.,"[{'id': 1010, 'therapyName': 'DS-3078a'}]"," A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas",04/08/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01588821,Phase II,"Active, not recruiting",Massachusetts General Hospital,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Advanced Solid Malignancies,09/16/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01591421,Phase Ib/II,"Active, not recruiting",NCIC Clinical Trials Group ,"[{'id': 1990, 'therapyName': 'BKM120 + Panitumumab'}]",P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer.,07/17/2015,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT01591577,Phase II,Recruiting,Jonsson Comprehensive Cancer Center,"[{'id': 2440, 'therapyName': 'Lapatinib + Temozolomide'}]",Lapatinib With Temozolomide and Regional Radiation Therapy for Patients With Newly-Diagnosed Glioblastoma Multiforme,03/20/2015,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01592370,Phase I,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma,09/07/2017,[],no
0,both,"[{'id': 1790, 'name': 'malignant mesothelioma', 'source': 'DOID'}]",NCT01592383,Phase II,Completed,University of Chicago,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma,05/13/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01593228,Phase III,Completed,Sanofi,"[{'id': 1173, 'therapyName': 'Iniparib + doxorubicin + carboplatin'}, {'id': 1172, 'therapyName': 'Iniparib + Paclitaxel'}, {'id': 1171, 'therapyName': 'Iniparib + Irinotecan'}, {'id': 1170, 'therapyName': 'Iniparib + Topotecan'}, {'id': 1169, 'therapyName': 'Iniparib + Gemcitabine + Carboplatin'}, {'id': 1168, 'therapyName': 'Iniparib'}]", Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial,10/05/2016,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01593254,Phase II,"Active, not recruiting",Bristol-Myers Squibb,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Phase IIb Study of Dasatinib Versus Imatinib in Patients With CML-CP Who Have Not Achieved an Early Optimal Response to Imatinib,03/08/2017,[],yes
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT01593670,Phase II,Terminated,"Masonic Cancer Center, University of Minnesota","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes,06/20/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT01593748,Phase II,"Active, not recruiting",Medical University of South Carolina,"[{'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}, {'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}]",A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma,10/04/2017,[],no
0,female,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}]",NCT01594216,Phase II,"Active, not recruiting",Abramson Cancer Center of the University of Pennsylvania,"[{'id': 1108, 'therapyName': 'Ruxolitinib + Exemestane'}]", Ruxolitinib in Estrogen Receptor Positive Breast Cancer,09/27/2016,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01596140,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1175, 'therapyName': 'Vemurafenib + Temsirolimus'}, {'id': 1174, 'therapyName': 'Vemurafenib + Everolimus'}]",Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer,05/26/2016,"[{'molecularProfile': {'id': 696, 'profileName': 'BRAF act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01596270,Phase I,Completed,Sanofi,"[{'id': 1051, 'therapyName': 'SAR245409'}]",A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma,12/23/2014,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01596751,Phase Ib/II,"Active, not recruiting","Hope Rugo, MD ","[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 874, 'therapyName': 'PLX3397'}]",Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast Cancer,08/09/2017,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01597388,Phase I,"Active, not recruiting",AstraZeneca,"[{'id': 2199, 'therapyName': 'Vistusertib + Fulvestrant'}]",AZD2014 and Fulvestrant in Patients With ER+ Advanced Metastatic Breast Cancer,10/30/2015,[],yes
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT01599754,Phase III,"Active, not recruiting","SFJ Pharmaceuticals, Inc. ","[{'id': 649, 'therapyName': 'Axitinib'}]",Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients,05/14/2016,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT01599832,Phase I,Terminated,University of Chicago ,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer,06/09/2017,[],no
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT01601535,Phase Ib/II,"Active, not recruiting",New Approaches to Neuroblastoma Therapy Consortium ,"[{'id': 2628, 'therapyName': 'Alisertib + Irinotecan + Temozolomide'}]",Study of MLN8237 in Combination With Irinotecan and Temozolomide,07/09/2015,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01602315,Phase Ib/II,Terminated,Novartis Pharmaceuticals,"[{'id': 1837, 'therapyName': 'BYL719 + Cetuximab'}]",A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,12/01/2016,[],no
0,both,"[{'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01602406,Phase I,Completed,Novartis Pharmaceuticals,"[{'id': 2037, 'therapyName': 'LJM716 + Trastuzumab'}]",Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer,09/12/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1799, 'name': 'islet cell tumor', 'source': 'DOID'}]",NCT01603004,Phase I,Recruiting,Memorial Sloan-Kettering Cancer Center ,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Potential Imaging and Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors,02/02/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01603212,Phase Ib/II,Completed,M.D. Anderson Cancer Center,"[{'id': 1188, 'therapyName': 'Aldesleukin + Vemurafenib + IFN A2b'}]"," Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor",07/12/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01604031,Phase Ib/II,Terminated,Baylor College of Medicine ,"[{'id': 1164, 'therapyName': 'lenalidomide'}]",Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide,02/09/2016,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01606579,Phase Ib/II,Completed,"Prism Pharma Co., Ltd. ","[{'id': 2466, 'therapyName': 'Cytarabine + Pri-724'}, {'id': 2465, 'therapyName': 'Dasatinib + Pri-724'}, {'id': 1083, 'therapyName': 'Pri-724'}]",Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies,05/04/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 50744, 'name': 'anaplastic large cell lymphoma', 'source': 'DOID'}]",NCT01606878,Phase I,Recruiting,Children's Oncology Group,"[{'id': 2952, 'therapyName': 'Dexamethasone + Doxorubicin + Vincristine'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma,07/23/2015,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2893, 'name': 'cervix carcinoma', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01607905,Phase I,Completed,"Karyopharm Therapeutics, Inc ","[{'id': 1749, 'therapyName': 'Selinexor'}]",Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced or Metastatic Solid Tumor Cancer,04/05/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01609556,Phase I,"Active, not recruiting","ImmunoGen, Inc. ","[{'id': 3232, 'therapyName': 'IMGN853'}]","First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors",10/14/2016,[],yes
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT01609816,Phase Ib/II,Recruiting,Barbara Ann Karmanos Cancer Institute,"[{'id': 717, 'therapyName': 'Dasatinib'}]","Dasatinib in Treating Patients With Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma Previously Treated With Autologous Stem Cell Transplant",07/16/2016,[],no
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT01610206,Phase II,"Active, not recruiting",Linda R Duska,"[{'id': 1478, 'therapyName': 'Gemcitabine + Pazopanib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer,05/04/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01610284,Phase III,"Active, not recruiting",Novartis Pharmaceuticals,"[{'id': 1546, 'therapyName': 'Fulvestrant + BKM120'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor,03/09/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3368, 'name': ""bone Ewing's sarcoma"", 'source': 'DOID'}, {'id': 4232, 'name': ""extraosseous Ewing's sarcoma"", 'source': 'DOID'}]",NCT01610570,Phase Ib/II,Terminated,National Cancer Institute (NCI),"[{'id': 1397, 'therapyName': 'Mithramycin'}]",Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma,04/21/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}]",NCT01612351,Phase II,"Active, not recruiting",UNC Lineberger Comprehensive Cancer Center,"[{'id': 2477, 'therapyName': 'Lapatinib + Carboplatin + Cisplatin + Paclitaxel'}, {'id': 2476, 'therapyName': 'Lapatinib + Carboplatin + Paclitaxel'}]",Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery,04/26/2017,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT01614197,Phase I,Recruiting,Therapeutic Advances in Childhood Leukemia Consortium ,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1639, 'therapyName': 'Methotrexate'}]",A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma,12/01/2015,[],no
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT01616303,Phase II,"Active, not recruiting",Quest PharmaTech Inc.,"[{'id': 1190, 'therapyName': 'Oregovomab + Carboplatin + Paclitaxel'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]", A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer,10/21/2014,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT01619761,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1847, 'therapyName': 'lenalidomide + Fludarabine + Melphalan'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}]",Natural Killer (NK) Cells in Cord Blood Transplantation,04/19/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01619774,Phase II,Completed,M.D. Anderson Cancer Center,"[{'id': 1191, 'therapyName': 'GSK1120212 + Dabrafenib'}]", An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor,08/18/2015,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01619813,Phase II,Completed,NCIC Clinical Trials Group ,"[{'id': 2462, 'therapyName': 'Docetaxel + Prednisone'}, {'id': 893, 'therapyName': 'Reolysin'}]",Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer,05/26/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01620190,Phase II,"Active, not recruiting",University of Washington,"[{'id': 619, 'therapyName': 'Abraxane'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer,10/05/2017,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01620216,Phase II,Recruiting,OHSU Knight Cancer Institute,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Validation of an in Vitro Assay to Predict Targeted Therapies for Acute Leukemia Patients,12/19/2014,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01620593,Phase II,Completed,Devalingam Mahalingam ,"[{'id': 1031, 'therapyName': 'Metformin'}]",Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer,09/23/2016,[],no
0,both,"[{'id': 3587, 'name': 'pancreatic ductal carcinoma', 'source': 'DOID'}]",NCT01621243,Phase Ib/II,Terminated,"Momenta Pharmaceuticals, Inc. ","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 4251, 'therapyName': 'Necuparanib'}]",M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer,01/06/2017,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 50458, 'name': 'juvenile myelomonocytic leukemia', 'source': 'DOID'}]",NCT01621477,Phase II,Terminated,St. Jude Children's Research Hospital ,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 2469, 'therapyName': 'Busulfan + Clofarabine + Thymoglobulin'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}]",T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant,10/06/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01621490,Phase I,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (PD-1),03/30/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01621542,Phase I,Completed,Sunovion ,"[{'id': 2893, 'therapyName': 'WT1 vaccine'}]",Clinical Study of WT2725 in Patients With Advanced Malignancies,06/06/2017,[],yes
0,both,"[{'id': 3284, 'name': 'thymic carcinoma', 'source': 'DOID'}, {'id': 3275, 'name': 'thymoma', 'source': 'DOID'}]",NCT01621568,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib for Advanced Thymus Cancer Following Earlier Treatment,04/22/2016,[],no
0,both,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT01621906,,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 920, 'therapyName': 'Sorafenib'}]",18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib,07/23/2015,[],no
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT01622543,Phase II,"Active, not recruiting",NCIC Clinical Trials Group ,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 893, 'therapyName': 'Reolysin'}]",Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer,02/17/2015,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01622868,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 787, 'therapyName': 'Lapatinib'}]",Whole-Brain Radiation Therapy With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer,09/25/2014,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT01623349,Phase I,"Active, not recruiting",Dana-Farber Cancer Institute ,"[{'id': 2171, 'therapyName': 'BYL719 + Olaparib'}, {'id': 2170, 'therapyName': 'BKM120 + Olaparib'}]",Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer,03/24/2017,[],yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01624285,Phase II,Recruiting,Jonsson Comprehensive Cancer Center ,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer,07/23/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01624467,Phase II,Completed,Eli Lilly and Company,"[{'id': 826, 'therapyName': 'Necitumumab'}]",A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors,08/01/2015,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01624766,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1199, 'therapyName': 'Everolimus + Denosumab'}, {'id': 1192, 'therapyName': 'Anakinra + Everolimus'}]",Anakinra or Denosumab and Everolimus in Advanced Cancer,12/23/2014,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01625156,Phase I,Completed,National Cancer Institute (NCI),"[{'id': 1200, 'therapyName': 'Tivantinib + Temsirolimus'}]",Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed By Surgery,10/21/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01625234,Phase Ib/II,Recruiting,"Xcovery Holding Company, LLC ","[{'id': 961, 'therapyName': 'X-396'}]","Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer",04/22/2015,"[{'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT01625260,Phase Ib/II,"Active, not recruiting",Altor Bioscience Corporation,"[{'id': 2187, 'therapyName': 'ALT-801'}, {'id': 2191, 'therapyName': 'ALT-801 + Gemcitabine'}]",A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer,04/14/2016,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01625286,Phase Ib/II,"Active, not recruiting",AstraZeneca,"[{'id': 2192, 'therapyName': 'AZD5363 + Paclitaxel'}]","Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients",04/08/2016,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 3675, 'name': 'childhood kidney neoplasm', 'source': 'DOID'}, {'id': 3119, 'name': 'gastrointestinal system cancer', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 3571, 'name': 'liver cancer', 'source': 'DOID'}, {'id': 2994, 'name': 'germ cell cancer', 'source': 'DOID'}, {'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 3368, 'name': ""bone Ewing's sarcoma"", 'source': 'DOID'}, {'id': 4232, 'name': ""extraosseous Ewing's sarcoma"", 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01625351,Phase I,"Active, not recruiting",St. Jude Children's Research Hospital,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}]",A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas,08/23/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01625936,Phase I,Unknown status,Abramson Cancer Center of the University of Pennsylvania,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 708, 'therapyName': 'CRLX101'}]",CRLX101 Plus Bevacizumab in Advanced RCC,10/03/2017,[],no
0,both,"[{'id': 8864, 'name': 'acute monocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01627041,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1739, 'therapyName': 'Daunorubicin + Cytarabine + Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]","Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia",02/24/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01628471,Phase Ib/II,Completed,Uman Pharma,"[{'id': 1734, 'therapyName': 'Genistein + Decitabine'}]","MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer",09/24/2015,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01628640,Phase I,Recruiting,Mayo Clinic ,"[{'id': 2423, 'therapyName': 'VSV-IFN-beta'}]",Viral Therapy in Treating Patient With Liver Cancer,10/13/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01630590,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer,02/10/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01630733,Phase III,Recruiting,OncoGenex Technologies ,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 3648, 'therapyName': 'Custirsen + Docetaxel'}]","A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer",02/26/2016,[],no
0,,[],NCT01631279,,Terminated,"""Proacta, Incorporated""",[], A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors,07/28/2014,[],yes
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01633060,Phase III,"Active, not recruiting",Novartis Pharmaceuticals,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1546, 'therapyName': 'Fulvestrant + BKM120'}]","A Phase III Study of BKM120 With Fulvestrant in Patients With HR+, HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi",10/06/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}]",NCT01633541,Phase II,Recruiting,University of Michigan Cancer Center ,"[{'id': 644, 'therapyName': 'AT-101'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer,05/06/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01633970,Phase I,"Active, not recruiting",Genentech,"[{'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}, {'id': 1204, 'therapyName': 'Atezolizumab + Carboplatin + Pemetrexed'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Avastin (Bevacizumab) and/or With Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors,03/22/2017,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01634217,Phase I,"Active, not recruiting","Masonic Cancer Center, University of Minnesota ",[],Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation,12/09/2016,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT01634685,Phase I,"Active, not recruiting",University of Texas Southwestern Medical Center ,"[{'id': 3684, 'therapyName': 'Bavituximab + Capecitabine'}]","A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma",03/06/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01634893,Phase I,Completed,Tyler Curiel,"[{'id': 1208, 'therapyName': 'Sorafenib + Hydroxychloroquine'}]",Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors,03/26/2016,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT01635712,Phase I,Completed,Esanex Inc. ,"[{'id': 866, 'therapyName': 'SNX-5422'}]",Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies,04/27/2017,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01636479,Phase I,"Active, not recruiting",Sanofi ,"[{'id': 2078, 'therapyName': 'SAR405838'}]",Phase 1 Safety Testing of SAR405838,03/27/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01636622,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1209, 'therapyName': 'Vemurafenib + Carboplatin + Paclitaxel '}]"," Study of Vemurafenib, Carboplatin, and Paclitaxel",05/20/2016,"[{'molecularProfile': {'id': 696, 'profileName': 'BRAF act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60061, 'name': 'cutaneous T cell lymphoma', 'source': 'DOID'}]",NCT01637090,Phase II,Terminated,Boston Medical Center ,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus in Treating Cutaneous T-cell Lymphoma,04/27/2016,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01638533,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1075, 'therapyName': 'romidepsin'}]","Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction",08/24/2015,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT01638546,Phase II,Completed,National Cancer Institute (NCI),"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer,02/11/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01638676,Phase Ib/II,Recruiting,James Graham Brown Cancer Center,"[{'id': 1210, 'therapyName': 'Vemurafenib + Metformin '}]", A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients,07/29/2014,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT01639248,,Completed,"EntreMed|University of Colorado, Denver|Indiana University Melvin and Bren Simon Cancer Center","[{'id': 727, 'therapyName': 'ENMD-2076'}]", A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer,06/27/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01639508,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes,10/02/2016,"[{'molecularProfile': {'id': 2903, 'profileName': 'RET fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1112, 'profileName': 'MET alterations'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1249, 'profileName': 'ROS1 fusion'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01639911,Phase I,Completed,University of Illinois at Chicago,"[{'id': 1212, 'therapyName': 'Alisertib + Pazopanib'}]",MLN8237 and Pazopanib in Combination for Solid Tumors,04/21/2017,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01640301,Phase Ib/II,Suspended,Fred Hutchinson Cancer Research Center ,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 2901, 'therapyName': 'WT1 senstized T cells'}]","Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant",10/22/2016,"[{'molecularProfile': {'id': 1325, 'profileName': 'FLT3 rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3119, 'name': 'gastrointestinal system cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01640665,Phase I,Completed,Yale University ,"[{'id': 2428, 'therapyName': 'Sorafenib + Capecitabine'}]",Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors,09/09/2016,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}]",NCT01641939,Phase III,Terminated,Hoffmann-La Roche,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",A Study of Trastuzumab Emtansine Versus Taxane in Patients With Advanced Gastric Cancer,05/13/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50685, 'name': 'small cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT01642251,Phase Ib/II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer,07/21/2015,[],no
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 3121, 'name': 'gallbladder cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 1790, 'name': 'malignant mesothelioma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT01642342,Phase I,Recruiting,University of Southern California ,"[{'id': 3013, 'therapyName': 'sEphB4-HSA'}]",Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors,08/11/2015,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT01643278,Phase I,Completed,National Cancer Institute (NCI),"[{'id': 1803, 'therapyName': 'Dasatinib + Ipilimumab'}]",Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic,01/11/2017,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT01643603,Phase Ib/II,Recruiting,Barbara Ann Karmanos Cancer Institute,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Dasatinib in Treating Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant,03/10/2016,[],no
0,both,"[{'id': 200, 'name': 'giant cell tumor', 'source': 'DOID'}]",NCT01643850,Phase II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 2838, 'therapyName': 'MCS110'}]",MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS),06/19/2015,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01644253,Phase I,Recruiting,Aptevo Therapeutics ,"[{'id': 4745, 'therapyName': 'Idelalisib + Otlertuzumab + Rituximab'}, {'id': 4742, 'therapyName': 'Otlertuzumab + Rituximab'}, {'id': 4743, 'therapyName': 'Obinutuzumab + Otlertuzumab'}, {'id': 4744, 'therapyName': 'Ibrutinib + Otlertuzumab'}]","Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia",09/21/2016,[],yes
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT01644773,Phase I,Recruiting,St. Jude Children's Research Hospital,"[{'id': 1252, 'therapyName': 'Crizotinib + Dasatinib'}]",Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG),12/19/2014,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01646125,,Terminated,Novartis Pharmaceuticals,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 647, 'therapyName': 'AUY922'}, {'id': 854, 'therapyName': 'Pemetrexed'}]"," An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations",03/14/2017,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01647711,Phase I,Completed,Boehringer Ingelheim,"[{'id': 623, 'therapyName': 'Afatinib'}]","A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations",10/23/2015,"[{'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT01647828,Phase Ib/II,Completed,"OncoMed Pharmaceuticals, Inc. ","[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2547, 'therapyName': 'Tarextumab'}]",A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer,09/21/2016,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT01648348,Phase Ib/II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1242, 'therapyName': 'Carotuximab'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,09/10/2015,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01649180,Phase II,Terminated,"PrECOG, LLC. ","[{'id': 649, 'therapyName': 'Axitinib'}]",NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (PrE0801),04/21/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01649284,Phase I,Approved for marketing,Boehringer Ingelheim ,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib Expanded Access Program,12/01/2016,"[{'molecularProfile': {'id': 1102, 'profileName': 'EGFR positive'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT01649336,Phase I,Completed,Array BioPharma ,"[{'id': 2010, 'therapyName': 'MEK162 + Paclitaxel'}]","A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer",04/23/2016,[],no
0,both,[],NCT01649778,Phase III,Completed,GlaxoSmithKline ,[],Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma,07/14/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01649947,Phase II,Completed,"Rutgers, The State University of New Jersey ","[{'id': 1487, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Hydroxychloroquine'}, {'id': 1488, 'therapyName': 'Paclitaxel + Carboplatin + Hydroxychloroquine'}]",Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II,02/24/2017,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01650506,Phase I,Completed, Matthew A. Maurer ,"[{'id': 1828, 'therapyName': 'Metformin + Erlotinib'}]",Study of Erlotinib and Metformin in Triple Negative Breast Cancer,08/31/2017,[],yes
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT01652079,Phase II,"Active, not recruiting",Massachusetts General Hospital,"[{'id': 1213, 'therapyName': 'CRLX101 + Bevacizumab'}]",CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer,02/17/2017,[],no
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT01652196,Phase II,"Active, not recruiting",Richard Goldberg ,"[{'id': 2367, 'therapyName': 'Aflibercept + mFOLFOX-6'}]",Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer,07/19/2016,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}]",NCT01652482,Phase II,Completed,"Genentech, Inc. ","[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 806, 'therapyName': 'MEHD7945A'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,02/19/2015,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01652976,Phase II,"Active, not recruiting",University of Florida,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 717, 'therapyName': 'Dasatinib'}]","Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma",06/23/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01653470,Phase I,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2545, 'therapyName': 'BMS-906024'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors",01/26/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01654965,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1477, 'therapyName': 'Tivantinib + Topotecan + Pegfilgrastim'}]",Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors,11/17/2014,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT01655225,Phase I,Recruiting,Eli Lilly and Company,"[{'id': 1214, 'therapyName': 'LY3023414 + Midazolam '}, {'id': 1215, 'therapyName': ' LY3023414 + Letrozole '}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3023414 in Participants With Advanced Cancer,12/23/2014,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01655693,Phase III,"Active, not recruiting",Onxeo ,"[{'id': 1009, 'therapyName': 'Doxorubicin'}]",Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma (ReLive),03/01/2017,[],no
0,both,"[{'id': 3963, 'name': 'thyroid carcinoma', 'source': 'DOID'}]",NCT01655719,Phase II,Completed,University of Michigan ,"[{'id': 3125, 'therapyName': 'Pioglitazone'}]",Pioglitazone in Thyroid Cancers,05/12/2017,[],yes
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01656538,Phase II,"Active, not recruiting",NCIC Clinical Trials Group,"[{'id': 893, 'therapyName': 'Reolysin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer,04/22/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01656642,Phase I,"Active, not recruiting",Genentech,"[{'id': 1216, 'therapyName': 'Atezolizumab + vemurafenib'}]", A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Vemurafinib (Zelboraf&#174;) in Patients With Previously Untreated BRAFV600-Mutation Positive Metastatic Melanoma,02/24/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01657591,Phase I,"Active, not recruiting",H. Lee Moffitt Cancer Center and Research Institute,"[{'id': 1217, 'therapyName': 'XL888 + Vemurafenib'}]", Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma,06/01/2016,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01657682,Phase II,Recruiting,Arog Pharmaceuticals LLC,"[{'id': 705, 'therapyName': 'Crenolanib'}]",A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations,02/08/2017,"[{'molecularProfile': {'id': 2774, 'profileName': 'FLT3 act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5600, 'name': 'precursor lymphoblastic lymphoma/leukemia', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT01658007,Phase I,Terminated,"Children's Hospital Medical Center, Cincinnati ","[{'id': 917, 'therapyName': 'Sirolimus'}]",Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma,06/25/2016,[],no
0,both,[],NCT01658553,Phase I,Completed,GlaxoSmithKline,"[{'id': 2, 'therapyName': 'Trametinib'}]"," A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212",11/05/2014,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01658878,Phase I,Recruiting,Bristol-Myers Squibb ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma)",04/28/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01659151,Phase II,"Active, not recruiting",H. Lee Moffitt Cancer Center and Research Institute,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 342, 'therapyName': 'Vemurafenib'}]", Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer &amp; High Dose IL-2 Metastatic Melanoma,12/28/2016,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01660451,Phase II,"Active, not recruiting",Bayer ,"[{'id': 995, 'therapyName': 'Copanlisib'}]","Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas",03/24/2016,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01660906,Phase III,Completed,Bristol-Myers Squibb,"[{'id': 717, 'therapyName': 'Dasatinib'}]","This Study Will be a Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib",11/24/2015,[],yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01660971,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1816, 'therapyName': 'Gemcitabine + Dasatinib + Erlotinib'}]","Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery",12/18/2015,[],no
0,both,"[{'id': 3193, 'name': 'peripheral nerve sheath neoplasm', 'source': 'DOID'}]",NCT01661283,Phase II,"Active, not recruiting",Sarcoma Alliance for Research through Collaboration ,"[{'id': 1120, 'therapyName': 'Everolimus + Bevacizumab'}]",Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors,10/16/2015,[],no
0,both,"[{'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}, {'id': 6383, 'name': 'childhood brain stem glioma', 'source': 'DOID'}, {'id': 60108, 'name': 'brain glioma', 'source': 'DOID'}, {'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}, {'id': 3368, 'name': ""bone Ewing's sarcoma"", 'source': 'DOID'}, {'id': 4232, 'name': ""extraosseous Ewing's sarcoma"", 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2154, 'name': 'nephroblastoma', 'source': 'DOID'}, {'id': 3185, 'name': 'spinal cord glioma', 'source': 'DOID'}, {'id': 3869, 'name': 'childhood medulloblastoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 5509, 'name': 'pediatric ependymoma', 'source': 'DOID'}, {'id': 768, 'name': 'retinoblastoma', 'source': 'DOID'}]",NCT01661400,Phase I,Recruiting,Washington University School of Medicine,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors,04/22/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01661972,Phase Ib/II,Completed,"John Strickler, M.D. ","[{'id': 2368, 'therapyName': 'Aflibercept + Capecitabine'}]",Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer,07/12/2017,[],no
0,,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT01662869,Phase III,Completed,Hoffmann-La Roche,"[{'id': 838, 'therapyName': 'Onartuzumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic HER2-Negative And Met-Positive Gastroesophageal Cancer (MetGastric),01/05/2016,"[{'molecularProfile': {'id': 1240, 'profileName': 'MET positive'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT01663259,Phase I,"Active, not recruiting",Avraham Eisbruch ,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients,03/08/2017,[],no
0,both,"[{'id': 4905, 'name': 'pancreatic carcinoma', 'source': 'DOID'}]",NCT01663272,Phase I,"Active, not recruiting",University of Michigan Cancer Center ,"[{'id': 2070, 'therapyName': 'Cabozantinib + Gemcitabine'}]",A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer,03/22/2016,[],no
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT01663857,Phase Ib/II,"Active, not recruiting",Eli Lilly and Company ,"[{'id': 3296, 'therapyName': 'Ralimetinib'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",A Study of LY2228820 for Recurrent Ovarian Cancer,08/09/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01664000,Phase I,Completed,Cellceutix Corporation ,"[{'id': 2999, 'therapyName': 'thioureidobutyronitrile'}]","A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors",02/18/2016,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01664182,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1223, 'therapyName': 'Trebananib + Sunitinib'}, {'id': 1220, 'therapyName': 'Trebananib + Pazopanib'}, {'id': 1221, 'therapyName': 'Trebananib + Sorafenib'}, {'id': 1218, 'therapyName': 'Trebananib'}, {'id': 1219, 'therapyName': 'Trebananib + Bevacizumab'}]","Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer",11/14/2015,[],no
0,female,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01664754,Phase I,"Active, not recruiting",Jonsson Comprehensive Cancer Center ,"[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 738, 'therapyName': 'Exemestane'}]","Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer",09/10/2016,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT01665768,Phase II,"Active, not recruiting",Sidney Kimmel Comprehensive Cancer Center,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 735, 'therapyName': 'Everolimus'}]",Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma,07/14/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01666730,Phase II,Recruiting,Case Comprehensive Cancer Center,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1031, 'therapyName': 'Metformin'}]",Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer,12/22/2014,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01666756,Phase I,"Active, not recruiting","City of Hope Medical Center, National Cancer Institute (NCI)","[{'id': 2387, 'therapyName': 'Sorafenib + KD018'}]",Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer,06/05/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01667419,Phase III,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",BRIM8: A Study of Vemurafenib Adjuvant Therapy in Patients With Resected Cutaneous BRAF Mutant Melanoma,10/07/2016,[],yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01668719,Phase Ib/II,Recruiting,Southwest Oncology Group ,"[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma",12/31/2015,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01669343,Phase I,"Active, not recruiting","Samuel Lunenfeld Research Institute, Mount Sinai Hospital ","[{'id': 794, 'therapyName': 'Letrozole'}]",Aromatase Inhibitor Host Factors Study,10/21/2015,[],yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01669720,Phase II,Terminated,Brown University ,"[{'id': 624, 'therapyName': 'Aflibercept'}]",Adjuvant Aflibercept for Metastatic Colorectal Cancer,03/11/2016,[],no
0,female,"[{'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 4217, 'name': 'malignant ovarian Brenner tumor', 'source': 'DOID'}]",NCT01669798,Phase II,Recruiting,AA Secord ,"[{'id': 831, 'therapyName': 'Nintedanib'}]","BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer",02/18/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT01670175,Phase I,Completed,"University of California, San Francisco","[{'id': 1224, 'therapyName': 'Sirolimus + Cyclophosphamide + Topotecan'}]",Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors,06/22/2017,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01670877,Phase II,Recruiting,Washington University School of Medicine ,"[{'id': 828, 'therapyName': 'Neratinib'}]",Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer,04/24/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1216, 'profileName': 'ERBB2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01671904,Phase I,"Active, not recruiting","Genentech, Inc. ","[{'id': 3638, 'therapyName': 'Bendamustine + GDC-0199 + Obinutuzumab'}, {'id': 3637, 'therapyName': 'Bendamustine + GDC-0199 + Rituximab'}]","A Study of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Participants With Chronic Lymphocytic Leukemia",08/01/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01672736,Phase Ib/II,"Active, not recruiting","University Health Network, Toronto","[{'id': 1831, 'therapyName': 'Linsitinib + Bortezomib + Dexamethasone'}]",A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma,12/04/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT01673737,Phase I,Completed,Sanofi,"[{'id': 1052, 'therapyName': 'SAR260301'}, {'id': 1225, 'therapyName': 'SAR260301 + Vemurafenib'}]", A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer,04/11/2015,[],yes
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01674140,Phase III,Recruiting,Southwest Oncology Group ,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer,03/02/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01674270,Phase II,Completed,"University Health Network, Toronto ","[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1814, 'therapyName': 'Degarelix'}]",Degarelix Neo-Adjuvant Radical Prostatectomy Trial,12/23/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01676714,Phase II,Completed,"University of California, Davis ","[{'id': 721, 'therapyName': 'Dovitinib'}]",Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer,06/22/2016,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01676753,Phase Ib/II,Recruiting,Jo Chien,"[{'id': 4225, 'therapyName': 'Dinaciclib + Pembrolizumab'}]",Phase 1b Dose De-escalation Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer,03/30/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01677559,Phase I,"Active, not recruiting",Washington University School of Medicine,"[{'id': 1226, 'therapyName': 'Alisertib + Abraxane'}]",Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies,02/24/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01677741,Phase I,Recruiting,GlaxoSmithKline,"[{'id': 3, 'therapyName': 'Dabrafenib'}]"," The Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Pediatric Subjects",07/29/2014,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,[],NCT01678105,,Completed,Ontario Clinical Oncology Group (OCOG)|Novartis Pharmaceuticals,"[{'id': 721, 'therapyName': 'Dovitinib'}]", A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands,09/18/2015,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01681433,Phase II,Terminated,Costantine Albany ,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1807, 'therapyName': 'OGX-427'}]",OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone,09/09/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01682083,Phase III,"Active, not recruiting",GlaxoSmithKline,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]", A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.,04/24/2015,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01682213,Phase II,"Active, not recruiting",Memorial Sloan-Kettering Cancer Center,"[{'id': 3, 'therapyName': 'Dabrafenib'}]",Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation,05/20/2016,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01683149,Phase I,Completed,H. Lee Moffitt Cancer Center and Research Institute,"[{'id': 1228, 'therapyName': 'Topotecan + Sorafenib'}]", Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies,03/05/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01683188,Phase III,Terminated,Prometheus Laboratories,"[{'id': 1229, 'therapyName': 'Aldesleukin + Vemurafenib'}]", HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma,02/05/2015,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01683422,Phase II,Recruiting,Loma Linda University,"[{'id': 2473, 'therapyName': 'Erlotinib + Capecitabine + Gemcitabine'}]",Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer,03/26/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01683994,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 2069, 'therapyName': 'cabozantinib + Docetaxel'}]",Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer,08/09/2017,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT01684397,Phase Ib/II,Recruiting,Roswell Park Cancer Institute,"[{'id': 1230, 'therapyName': 'Pazopanib + Bevacizumab'}]",Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer,08/24/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01685125,Phase II,"Active, not recruiting",University of Southern California,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,07/08/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01685892,Phase I,"Active, not recruiting","Genentech, Inc. ","[{'id': 3636, 'therapyName': 'GDC-0199 + Obinutuzumab'}]",A Study of Venetoclax (GDC-0199; ABT-199) in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia,08/03/2016,[],no
0,both,"[{'id': 50744, 'name': 'anaplastic large cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT01686165,Phase II,"Active, not recruiting",University of Arizona ,"[{'id': 1078, 'therapyName': 'Belinostat'}, {'id': 897, 'therapyName': 'Rituximab'}]",Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Aggressive B-Cell Non-Hodgkin Lymphoma,04/16/2016,[],no
0,female,[],NCT01687179,Phase I,Completed,Brigham and Women's Hospital ,[],Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis,08/13/2016,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01687400,Phase II,"Active, not recruiting",Washington University School of Medicine,"[{'id': 650, 'therapyName': 'Decitabine'}]",Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes,08/23/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01687673,Phase II,"Active, not recruiting","University of California, San Francisco","[{'id': 2388, 'therapyName': 'Sorafenib + Temsirolimus'}]",Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma,12/06/2015,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01688492,Phase Ib/II,"Active, not recruiting",Memorial Sloan Kettering Cancer Center ,"[{'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-na&#239;ve Patients With Progressive Metastatic Castration-resistant Prostate Cancer,08/21/2015,[],no
0,both,"[{'id': 4939, 'name': 'ureter carcinoma', 'source': 'DOID'}, {'id': 734, 'name': 'urethra cancer', 'source': 'DOID'}, {'id': 4007, 'name': 'bladder carcinoma', 'source': 'DOID'}, {'id': 4919, 'name': 'renal pelvis carcinoma', 'source': 'DOID'}, {'id': 6166, 'name': 'prostatic urethra urothelial carcinoma', 'source': 'DOID'}]",NCT01688999,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Advanced Urothelial Cancer,02/16/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01689974,Phase II,Terminated,New York University School of Medicine ,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma,08/01/2015,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01689987,Phase I,Completed,OHSU Knight Cancer Institute ,"[{'id': 2385, 'therapyName': 'Sirolimus + Cyclophosphamide + Dexamethasone + Hydroxychloroquine'}]","Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma",09/08/2017,[],no
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT01690468,Phase Ib/II,Recruiting,"Prescient Therapeutics, Ltd. ","[{'id': 4566, 'therapyName': 'Carboplatin + Triciribine'}]",PTX-200 and Carboplatin in Ovarian Cancer,08/14/2016,[],no
0,,[],NCT01690624,,Recruiting,,"[{'id': 5537, 'therapyName': 'BI 836858'}]",BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse,04/17/2017,[],
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT01691898,Phase Ib/II,"Active, not recruiting","Genentech, Inc.","[{'id': 4415, 'therapyName': 'Obinutuzumab + Pinatuzumab Vedotin + Rituximab'}, {'id': 4416, 'therapyName': 'Polatuzumab Vedotin + Pinatuzumab Vedotin + Rituximab'}, {'id': 4417, 'therapyName': 'Obinutuzumab + Polatuzumab Vedotin'}]",A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (ROMULUS),02/08/2017,[],no
0,both,"[{'id': 8923, 'name': 'skin melanoma', 'source': 'DOID'}]",NCT01693068,Phase II,Completed,EMD Serono,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 871, 'therapyName': 'Pimasertib'}]",Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma,02/13/2016,"[{'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01693562,Phase Ib/II,"Active, not recruiting",MedImmune LLC ,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase 1/2 Study to Evaluate MEDI4736,06/03/2016,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT01695005,Phase I,Recruiting,Eli Lilly and Company ,"[{'id': 2958, 'therapyName': 'LY3039478'}]",A Study of LY3039478 in Participants With Advanced Cancer,07/30/2015,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01695330,Phase II,Terminated,Oncotherapeutics,"[{'id': 688, 'therapyName': 'Bortezomib'}]",Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens,03/11/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01695473,Phase II,"Active, not recruiting",Charles Ryan ,"[{'id': 680, 'therapyName': 'BKM120'}]",Neoadjuvant BKM120 in High-risk Prostate Cancer,10/06/2015,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT01695941,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 3581, 'therapyName': 'Alisertib + Bortezomib + Rituximab'}]","Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma",02/24/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01696045,Phase II,Terminated,Bristol-Myers Squibb ,"[{'id': 779, 'therapyName': 'Ipilimumab'}]","Phase 2 Study of Ipilimumab in Children and Adolescents (12 to <18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma",08/30/2017,[],no
0,both,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT01697293,Phase Ib/II,Recruiting,Albert Einstein College of Medicine of Yeshiva University ,"[{'id': 3054, 'therapyName': 'Paclitaxel + Triciribine'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]","Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer",09/03/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}]",NCT01697566,Phase III,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1031, 'therapyName': 'Metformin'}]",An Endometrial Cancer Chemoprevention Study of Metformin,02/06/2016,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01698905,Phase II,"Active, not recruiting",Novartis Pharmaceuticals,"[{'id': 829, 'therapyName': 'Nilotinib'}]",Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop),12/23/2015,[],yes
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01698918,Phase II,"Active, not recruiting",Novartis Pharmaceuticals ,"[{'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]","Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer",07/03/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 2513, 'name': 'basal cell carcinoma', 'source': 'DOID'}]",NCT01700049,Phase II,"Active, not recruiting",St. Louis University,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes,07/26/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01700270,Phase I,Completed,Novartis Pharmaceuticals,"[{'id': 1232, 'therapyName': 'Dovitinib + Fluvoxamine'}]", Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.,11/17/2014,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01700400,Phase I,Completed,"""Cancer Research and Biostatistics Clinical Trials Consortium|University of Arizona|Providence Cancer Center, Earle A. C","[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]"," Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer",11/24/2014,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01701037,Phase II,Terminated,Vanderbilt-Ingram Cancer Center,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]", Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery,06/24/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01701674,Phase I,"Active, not recruiting",H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts,04/12/2016,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT01701986,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 3992, 'therapyName': 'Busulfan + Clofarabine + Gemcitabine'}]",Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas,04/22/2016,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01702064,Phase I,"Active, not recruiting",H. Lee Moffitt Cancer Center and Research Institute|Incyte Corporation,"[{'id': 1116, 'therapyName': 'Ruxolitinib + Nilotinib'}]",Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients,10/27/2016,[],no
0,,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}]",NCT01702558,Phase II,Completed,Hoffmann-La Roche,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 1976, 'therapyName': 'trastuzumab emtansine + Capecitabine'}]",A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer,08/29/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01702571,Phase III,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",A Study of Kadcyla (Trastuzumab Emtansine) in Patients With HER2 Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment,09/12/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01703065,Phase I,"Active, not recruiting",University of Washington ,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Treating Men With Castration-Resistant Prostate Cancer,06/20/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01703390,Phase II,Unknown status,Arbeitsgemeinschaft medikamentoese Tumortherapie ,"[{'id': 2182, 'therapyName': 'Cetuximab + FOLFOX'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Biomarker Directed Treatment in Metastatic Colorectal Cancer,06/20/2017,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT01703481,Phase I,"Active, not recruiting","Janssen Research & Development, LLC","[{'id': 1028, 'therapyName': 'JNJ-42756493'}]","A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Patients With Advanced or Refractory Solid Tumors or Lymphoma",08/20/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01703507,Phase I,"Active, not recruiting",Thomas Jefferson University ,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Melanoma With Brain Metastases,10/07/2015,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 1240, 'name': 'leukemia', 'source': 'DOID'}]",NCT01703572,Phase I,Completed,"OncoMed Pharmaceuticals, Inc. ","[{'id': 839, 'therapyName': 'Brontictuzumab'}]",A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies,09/21/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01706458,Phase II,"Active, not recruiting","University of Wisconsin, Madison ","[{'id': 2698, 'therapyName': 'pTVG-HP plasmid DNA vaccine'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer,03/04/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01707004,Phase I,"Active, not recruiting","University of Wisconsin, Madison","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1206, 'therapyName': 'Busulfan'}]",Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,01/13/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01708161,Phase I,Completed,Novartis|Novartis Pharmaceuticals|Amgen,"[{'id': 1109, 'therapyName': 'BYL719 + AMG 479'}]",A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors,07/22/2017,"[{'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1191, 'profileName': 'PIK3CA amp'}, 'requirementType': 'required'}]",yes
0,female,[],NCT01708798,Phase II,Terminated,University of British Columbia ,[],Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer,01/06/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01708941,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,01/09/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01708993,Phase II,Completed,NCIC Clinical Trials Group|Oncolytics Biotech,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1110, 'therapyName': 'Reolysin + Pemetrexed'}, {'id': 1111, 'therapyName': 'Reolysin + Docetaxel'}]"," Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy",05/06/2016,[],no
0,both,"[{'id': 3969, 'name': 'papillary thyroid carcinoma', 'source': 'DOID'}]",NCT01709292,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center ,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer,08/23/2017,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01709435,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 998, 'therapyName': 'cabozantinib'}]", Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors,03/17/2015,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01709734,Phase II,"Active, not recruiting",Tokai Pharmaceuticals ,"[{'id': 1508, 'therapyName': 'galeterone'}]","A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer",09/03/2016,[],no
0,female,"[{'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}]",NCT01711515,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Chemoradiation Therapy and Ipilimumab in Treating Patients With Locally Advanced Cervical Cancer,03/10/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01711528,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 3437, 'therapyName': 'Bortezomib + Dexamethasone + Dinaciclib'}]","Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",02/08/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01711541,Phase Ib/II,Suspended,National Cancer Institute (NCI),"[{'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}, {'id': 1849, 'therapyName': 'Cisplatin + Fluorouracil + Hydroxyurea'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer,10/07/2017,[],no
0,both,"[{'id': 285, 'name': 'hairy cell leukemia', 'source': 'DOID'}]",NCT01711632,Phase II,"Active, not recruiting",Memorial Sloan-Kettering Cancer Center,"[{'id': 342, 'therapyName': 'Vemurafenib'}]","BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia",08/20/2016,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01711658,Phase II,"Active, not recruiting","Radiation Therapy Oncology Group, GlaxoSmithKline, NRG Oncology","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2475, 'therapyName': 'Lapatinib + Cisplatin'}]",TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer,07/22/2017,"[{'molecularProfile': {'id': 1806, 'profileName': 'CDKN2A loss'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01712217,Phase Ib/II,"Active, not recruiting",Astex Pharmaceuticals ,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 645, 'therapyName': 'AT13387'}]",A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib,07/02/2015,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50523, 'name': 'adult T-cell leukemia', 'source': 'DOID'}]",NCT01712659,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib for Adult T-Cell Leukemia,08/25/2015,[],no
0,both,[],NCT01713946,Phase III,"Active, not recruiting",Novartis Pharmaceuticals ,[],A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures (EXIST-3),10/07/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01713972,Phase I,"Active, not recruiting",Manisha Shah,"[{'id': 1233, 'therapyName': 'Dabrafenib + Pazopanib'}]", Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors,05/21/2015,"[{'molecularProfile': {'id': 696, 'profileName': 'BRAF act mut'}, 'requirementType': 'required'}]",yes
0,,[],NCT01714115,,No longer available,,[],Use of Eylea for the Treatment of an Optic Nerve Hemangioma,08/09/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01714739,Phase I,Recruiting,Bristol-Myers Squibb ,"[{'id': 2584, 'therapyName': 'Lirilumab + Nivolumab'}]",A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors,04/24/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01715285,Phase III,"Active, not recruiting","Janssen Research & Development, LLC","[{'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]","A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)",09/29/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01716416,Phase I,"Active, not recruiting",Washington University School of Medicine,"[{'id': 1838, 'therapyName': 'Pazopanib + Cetuximab'}]",Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC),06/28/2017,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT01716806,Phase II,Recruiting,"Seattle Genetics, Inc.","[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}, {'id': 5055, 'therapyName': 'Brentuximab vedotin + Bendamustine'}, {'id': 5056, 'therapyName': 'Brentuximab vedotin + Dacarbazine'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL),12/02/2016,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01717053,Phase II,"Active, not recruiting",Duke University ,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 759, 'therapyName': 'Goserelin'}]","Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer",09/14/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01717482,Phase II,"Active, not recruiting",Mayo Clinic,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer,10/08/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT01719250,Phase I,Completed,Mayo Clinic ,"[{'id': 680, 'therapyName': 'BKM120'}]",Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,03/29/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT01719302,Phase Ib/II,Completed,University of Vermont,"[{'id': 1470, 'therapyName': 'Gemcitabine + Docetaxel + Pazopanib'}]","Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma",06/17/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01719380,Phase Ib/II,"Active, not recruiting",Novartis Pharmaceuticals,"[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 1917, 'therapyName': 'LGX818 + Cetuximab + BYL719'}]","Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer",02/13/2016,"[{'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT01719744,,Completed,"""University Health Network, Toronto""","[{'id': 727, 'therapyName': 'ENMD-2076'}]", Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma,03/16/2016,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT01720225,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk,02/25/2016,[],no
0,both,"[{'id': 5074, 'name': 'malignant ependymoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT01721577,Phase Ib/II,Unknown status,Rush University Medical Center ,"[{'id': 2745, 'therapyName': 'AXL1717'}]",Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas,06/20/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01721603,Phase II,Completed,"University of California, San Francisco","[{'id': 3, 'therapyName': 'Dabrafenib'}]", A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases,11/02/2016,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01722162,Phase II,Completed,Washington University School of Medicine,"[{'id': 2097, 'therapyName': 'Bevacizumab + Capecitabine'}]",Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer,07/23/2016,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT01722292,Phase Ib/II,Terminated,Eli Lilly and Company,"[{'id': 1587, 'therapyName': 'Taladegib'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of LY2940680 in Small Cell Lung Cancer,12/01/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01723020,Phase I,Completed,Amgen ,"[{'id': 1452, 'therapyName': 'AMG 232'}]",A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma,10/07/2017,[],no
0,both,"[{'id': 3969, 'name': 'papillary thyroid carcinoma', 'source': 'DOID'}, {'id': 3962, 'name': 'follicular thyroid carcinoma', 'source': 'DOID'}]",NCT01723202,Phase II,"Active, not recruiting","National Comprehensive Cancer Network, Manisha Shah, Ohio State University Comprehensive Cancer Center","[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]",Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer,10/12/2016,"[{'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01723774,Phase II,Recruiting,Washington University School of Medicine,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}]",PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer,10/29/2014,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01723800,Phase I,Completed,City of Hope Medical Center|National Cancer Institute (NCI),"[{'id': 1112, 'therapyName': 'BKM120 + Pemetrexed + Carboplatin'}]"," PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer",09/21/2016,[],no
0,both,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT01724606,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM),03/12/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01725100,Phase I,Completed,GlaxoSmithKline,"[{'id': 2, 'therapyName': 'Trametinib'}]","A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies",03/27/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01725165,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,[],Oligometastatic Disease,02/05/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01726738,Phase II,"Active, not recruiting",UNC Lineberger Comprehensive Cancer Center,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations,03/07/2017,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 263, 'name': 'kidney cancer', 'source': 'DOID'}]",NCT01727089,Phase II,Completed,National Cancer Institute (NCI),"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1243, 'therapyName': 'Bevacizumab + TRC105'}]", Bevacizumab With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Kidney Cancer,09/07/2017,[],no
0,,[],NCT01727154,Phase I,Terminated,Dendreon ,[],Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T,07/12/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01727336,Phase II,"Active, not recruiting","Acceleron Pharma, Inc.","[{'id': 1245, 'therapyName': 'Dalantercept + Axitinib'}, {'id': 649, 'therapyName': 'Axitinib'}]", Study of Dalantercept in Patients With Advanced Renal Cell Carcinoma,07/18/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01727869,Phase I,Completed,Regeneron Pharmaceuticals,"[{'id': 1246, 'therapyName': 'REGN1400 + Erlotinib'}, {'id': 1247, 'therapyName': 'REGN1400 + Cetuximab'}, {'id': 1072, 'therapyName': 'REGN1400'}]", Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer,04/08/2015,[],no
0,both,[],NCT01728259,Phase I,Suspended,Barbara Ann Karmanos Cancer Institute ,"[{'id': 4501, 'therapyName': 'Bortezomib + Dexamethasone + Pomalidomide'}]","First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD",04/08/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01728311,Phase I,Completed,Bayer ,"[{'id': 666, 'therapyName': 'BAY1082439'}]",Open Label Study of BAY1082439 in Patients With Advanced Cancer,04/13/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01729091,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Study of Umbilical Cord Blood-derived Natural Killer Cells in Conjunction With High Dose Chemotherapy and Autologous Stem Cell Transplant for Patients With Multiple Myeloma,07/06/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01729338,Phase II,Terminated,Duke University,"[{'id': 3358, 'therapyName': 'Bortezomib + Cyclophosphamide + lenalidomide'}]",Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma,06/01/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01729845,Phase Ib/II,"Active, not recruiting",Fred Hutchinson Cancer Research Center ,"[{'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]","Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes",08/10/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01729923,Phase II,Terminated,University of Washington,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 2124, 'therapyName': 'Celecoxib'}]",A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer,05/05/2017,[],no
0,both,"[{'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 219, 'name': 'colon cancer', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT01730118,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1404, 'therapyName': 'HER2 Vaccine'}]",Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing,02/17/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01730833,Phase II,Recruiting,City of Hope Medical Center ,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]","Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Metastatic Breast Cancer",02/10/2015,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01730937,Phase III,Recruiting,"Radiation Therapy Oncology Group, National Cancer Institute (NCI)","[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer,05/06/2016,[],no
0,both,"[{'id': 3074, 'name': 'giant cell glioblastoma', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01730950,Phase II,"Active, not recruiting",Radiation Therapy Oncology Group ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma,06/19/2017,[],no
0,both,"[{'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}]",NCT01732640,Phase Ib/II,Completed,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 2442, 'therapyName': 'Afatinib + Carboplatin + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.,02/08/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT01732913,Phase III,Terminated,Gilead Sciences ,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,05/28/2016,[],no
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01732926,Phase III,Terminated,Gilead Sciences ,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}]",Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas,05/26/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01733004,Phase I,Completed,Merrimack Pharmaceuticals,"[{'id': 1248, 'therapyName': 'MM-141 + Everolimus'}, {'id': 1073, 'therapyName': 'MM-141'}, {'id': 1249, 'therapyName': 'MM-141 + Abraxane + Gemcitabine'}]",A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors,03/05/2016,[],no
0,both,"[{'id': 4851, 'name': 'pilocytic astrocytoma', 'source': 'DOID'}, {'id': 6726, 'name': 'fibrillary astrocytoma', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}]",NCT01734512,Phase II,Recruiting,"University of California, San Francisco, Novartis Pharmaceuticals, Pacific Pediatric Neuro-Oncology Consortium","[{'id': 735, 'therapyName': 'Everolimus'}]",PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children,05/11/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01734928,Phase III,"Active, not recruiting",Celgene Corporation ,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]","Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",05/26/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01736943,Phase II,Recruiting,"University of California, Davis ","[{'id': 3184, 'therapyName': 'Bortezomib + pegylated liposomal-doxorubicin'}]",Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia,11/05/2015,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01737008,Phase I,Completed,"University Health Network, Toronto ","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 714, 'therapyName': 'Dacomitinib'}]",Study of Dacomitinib With Radiotherapy With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck,06/14/2016,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}, {'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}]",NCT01737502,Phase II,Recruiting,Mayo Clinic ,"[{'id': 2301, 'therapyName': 'Auranofin + Sirolimus'}]",PKCi and mTOR Inhibition With Auranofin+Sirolimus for Squamous Cell Lung Cancer,03/05/2015,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1208, 'profileName': 'HRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01738139,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1250, 'therapyName': 'Ipilimumab + Imatinib Mesylate'}]",Ipilimumab and Imatinib Mesylate in Advanced Cancer,09/29/2016,"[{'molecularProfile': {'id': 26354, 'profileName': 'KIT D816X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1659, 'profileName': 'KIT V654A'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1214, 'profileName': 'KIT mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01738451,Phase I,Completed,GlaxoSmithKline,"[{'id': 3, 'therapyName': 'Dabrafenib'}]", A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors,04/15/2015,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}]",NCT01738815,Phase I,Unknown status,State University of New York - Upstate Medical University ,"[{'id': 1076, 'therapyName': 'Valproic acid'}]",Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer,06/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01739764,Phase III,Recruiting,Hoffmann-La Roche,"[{'id': 342, 'therapyName': 'Vemurafenib'}]", An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol,12/24/2014,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01740297,Phase Ib/II,"Active, not recruiting",Amgen ,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2695, 'therapyName': 'talimogene laherparepvec '}]",Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma,03/31/2016,[],no
0,both,"[{'id': 1993, 'name': 'rectum cancer', 'source': 'DOID'}]",NCT01740648,Phase I,"Active, not recruiting",Ohio State University Comprehensive Cancer Center|Evan Wuthrick|National Comprehensive Cancer Network|GlaxoSmithKline,"[{'id': 1113, 'therapyName': 'Trametinib + Fluorouracil'}]","Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer",10/07/2017,"[{'molecularProfile': {'id': 1194, 'profileName': 'KRAS Q61X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1192, 'profileName': 'KRAS G12X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1193, 'profileName': 'KRAS G13X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1198, 'profileName': 'NRAS Q61X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1196, 'profileName': 'NRAS G12X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1197, 'profileName': 'NRAS G13X'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}]",NCT01741727,Phase II,Completed,"AbbVie (prior sponsor, Abbott)","[{'id': 976, 'therapyName': 'ABT-414'}]",A Study of ABT-414 in Subjects With Solid Tumors,01/09/2016,"[{'molecularProfile': {'id': 447, 'profileName': 'EGFR amp'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01741753,Phase I,Terminated,Dana-Farber Cancer Institute ,"[{'id': 2499, 'therapyName': 'Abiraterone + BKM120 + Prednisone'}]",BKM120+Abiraterone Acetate for Metastatic CRPC,01/27/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01742286,Phase I,Recruiting,Novartis Pharmaceuticals,"[{'id': 789, 'therapyName': 'Ceritinib'}]","Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)",12/22/2014,"[{'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT01742988,Phase I,Recruiting,"Curis, Inc. ","[{'id': 709, 'therapyName': 'CUDC-907'}]","Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma",03/06/2015,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT01743950,Phase II,Recruiting,"University of Wisconsin, Madison ","[{'id': 667, 'therapyName': 'Bevacizumab'}]",A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab,07/18/2016,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT01744223,Phase Ib/II,Recruiting,Bellicum Pharmaceuticals,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6053, 'therapyName': 'BPX-501'}]",Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant,07/31/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01744340,Phase Ib/II,Completed,howard safran ,"[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer,02/11/2016,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01744652,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1252, 'therapyName': 'Crizotinib + Dasatinib'}]",Dasatinib and Crizotinib in Advanced Cancer,03/31/2016,"[{'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1112, 'profileName': 'MET alterations'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 4974, 'profileName': 'CDKN2A mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1760, 'profileName': 'ALK amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01744665,Phase II,"Active, not recruiting",Novartis Pharmaceuticals,"[{'id': 829, 'therapyName': 'Nilotinib'}]",Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5.,04/11/2015,[],yes
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT01745354,Phase I,Terminated,Robert Lowsky ,"[{'id': 3084, 'therapyName': 'SD-101'}]",Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT),11/19/2016,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT01746238,Phase I,"Active, not recruiting",Massachusetts General Hospital,"[{'id': 1473, 'therapyName': 'Doxorubicin + Bevacizumab'}]",Bevacizumab/Doxorubicin/Radiation for Sarcoma,02/25/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01746251,Phase II,"Active, not recruiting",Massachusetts General Hospital,"[{'id': 623, 'therapyName': 'Afatinib'}]",Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation,03/15/2017,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01746849,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation,12/08/2015,[],no
0,both,"[{'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT01747551,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute,"[{'id': 624, 'therapyName': 'Aflibercept'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer,05/11/2016,[],no
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 3672, 'name': 'rhabdoid cancer', 'source': 'DOID'}]",NCT01747876,Phase I,Completed,Novartis Pharmaceuticals,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma,08/12/2017,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT01748149,Phase I,Recruiting,Theodore Nicolaides MD ,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas,02/02/2015,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01748825,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 822, 'therapyName': 'MK-1775'}]",MK-1775 for Advanced Solid Tumors,12/23/2014,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01749384,Phase I,Completed,National Cancer Institute (NCI),"[{'id': 1254, 'therapyName': 'Bevacizumab + Tivantinib'}]",Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery,10/13/2017,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT01749397,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 2009, 'therapyName': 'Floxuridine + Veliparib'}]","Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer",02/04/2015,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01750073,Phase II,Recruiting,University of Nebraska ,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1980, 'therapyName': 'Cyclophosphamide + Paclitaxel'}]",Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Stage I-III Breast Cancer,02/05/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01750281,Phase II,"Active, not recruiting",AstraZeneca ,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}]",Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.,11/14/2015,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01750567,Phase II,Recruiting,University of Michigan Cancer Center,"[{'id': 1031, 'therapyName': 'Metformin'}]",A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL,12/22/2014,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01750918,Phase II,"Active, not recruiting",GlaxoSmithKline ,"[{'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1718, 'therapyName': 'Panitumumab + Dabrafenib'}, {'id': 1992, 'therapyName': 'Panitumumab + Trametinib + Dabrafenib'}, {'id': 1991, 'therapyName': 'Panitumumab + Trametinib'}]",BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC),08/27/2016,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01750983,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center ,"[{'id': 2992, 'therapyName': 'Ipilimumab + lenalidomide'}]",Ipilimumab and Lenalidomide in Advanced Cancer,07/12/2016,[],no
0,both,"[{'id': 1240, 'name': 'leukemia', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01751425,Phase II,Recruiting,M.D. Anderson Cancer Center|Incyte Corporation,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD),11/03/2014,[],yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01751451,Phase II,"Active, not recruiting",Memorial Sloan Kettering Cancer Center ,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1814, 'therapyName': 'Degarelix'}]","3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy",10/07/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01752400,Phase II,"Active, not recruiting",Massachusetts General Hospital ,"[{'id': 647, 'therapyName': 'AUY922'}]",AUY922 for Advanced ALK-positive NSCLC,09/05/2015,"[{'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01752920,Phase I,"Active, not recruiting",ArQule ,"[{'id': 2900, 'therapyName': 'ARQ 087'}]",Phase 1 Dose Escalation Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors,12/28/2016,[],no
0,both,"[{'id': 1319, 'name': 'brain cancer', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT01753713,Phase II,"Active, not recruiting","Case Comprehensive Cancer Center|Manmeet Ahluwalia, MD|National Cancer Institute (NCI)|Novartis","[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma,10/10/2014,[],no
0,,[],NCT01754025,,Recruiting,Dana-Farber Cancer Institute ,[],INHERIT EGFR - Studying Germline EGFR Mutations,07/17/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01754376,Phase II,Terminated,Massachusetts General Hospital,"[{'id': 1229, 'therapyName': 'Aldesleukin + Vemurafenib'}]",Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma,03/10/2017,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01754987,Phase Ib/II,Completed,Thomas Jefferson University ,"[{'id': 920, 'therapyName': 'Sorafenib'}]",A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective,06/22/2016,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT01755195,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Adults With Advanced Soft Tissue Sarcoma,02/22/2015,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01755767,Phase III,Completed,Daiichi Sankyo Inc. ,"[{'id': 636, 'therapyName': 'Tivantinib'}]",Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy,06/09/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01756352,Phase II,"Active, not recruiting",Brigham and Women's Hospital ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",FET-PET for Evaluation of Response of Recurrent GBM to Avastin,01/30/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01757327,Phase II,Withdrawn,Washington University School of Medicine ,"[{'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer,04/07/2015,[],yes
0,both,"[{'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}]",NCT01758731,Phase I,"Active, not recruiting","University of Colorado, Denver ","[{'id': 1999, 'therapyName': 'Olaparib + Cetuximab'}]",Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History,02/10/2017,[],no
0,both,"[{'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}]",NCT01759303,Phase II,"Active, not recruiting",Vector Oncology ,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung,12/07/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01760525,Phase I,"Active, not recruiting",Novartis Pharmaceuticals,"[{'id': 2077, 'therapyName': 'CGM097'}]",A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors,06/24/2016,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 642, 'profileName': 'TP53 wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT01760655,Phase II,Recruiting,Thomas Jefferson University,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1842, 'therapyName': 'Fludarabine + Thiotepa + Cyclophosphamide'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]",Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies,12/23/2014,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01761266,Phase III,"Active, not recruiting",Eisai Limited ,"[{'id': 792, 'therapyName': 'Lenvatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}]","A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma",09/09/2015,[],no
0,both,[],NCT01762592,Phase III,Not yet recruiting,Wilex ,[],REDECT 2 REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT,09/04/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01763164,Phase III,"Active, not recruiting",Novartis|Novartis Pharmaceuticals,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 807, 'therapyName': 'Binimetinib'}]",Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma,08/31/2015,"[{'molecularProfile': {'id': 1198, 'profileName': 'NRAS Q61X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01764477,Phase I,Completed,"Prism Pharma Co., Ltd. ","[{'id': 2566, 'therapyName': 'Gemcitabine + Pri-724'}]",Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma,10/22/2015,[],no
0,,[],NCT01764607,,Terminated,,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma,03/12/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01765543,Phase I,Completed,Hoffmann-La Roche,"[{'id': 1256, 'therapyName': 'Rifampin + Vemurafenib'}]",A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy,07/06/2016,"[{'molecularProfile': {'id': 696, 'profileName': 'BRAF act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01765582,Phase II,Terminated,Hoffmann-La Roche,"[{'id': 1523, 'therapyName': 'Fluorouracil + Capecitabine + Irinotecan + Leucovorin + Oxaliplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]",STEAM: A Study of Sequential and Concurrent FOLFOXIRI/Avastin (Bevacizumab) Regimens Versus FOLFOX/Avastin in First-Line in Patients With Metastatic Colorectal Cancer,09/19/2017,[],no
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT01767194,Phase II,Suspended,National Cancer Institute (NCI),"[{'id': 2286, 'therapyName': 'Dinutuximab  '}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1462, 'therapyName': 'Temozolomide + Irinotecan'}]",Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma,05/23/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01767454,Phase I,Completed,GlaxoSmithKline,"[{'id': 1258, 'therapyName': 'Dabrafenib + Ipilimumab + Trametinib'}, {'id': 1257, 'therapyName': 'Dabrafenib + Ipilimumab'}]",Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma,08/27/2016,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01767623,Phase I,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 342, 'therapyName': 'Vemurafenib'}]", A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients,07/08/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01767636,Phase II,Recruiting,Mayo Clinic,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib in Treating Patients With Metastatic Non-Clear Cell Kidney Cancer,09/12/2017,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT01767766,Phase I,"Active, not recruiting","TG Therapeutics, Inc. ","[{'id': 2022, 'therapyName': 'TGR-1202'}]",Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies,02/04/2016,[],no
0,both,[],NCT01767792,Phase II,"Active, not recruiting",University of Alabama at Birmingham ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas,05/05/2017,[],yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT01769209,Phase II,Terminated,Stanford University ,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1830, 'therapyName': 'Vincristine + Dexamethasone + Pegaspargase + Doxorubicin'}]",Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,10/18/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01769391,Phase II,"Active, not recruiting",Eli Lilly and Company,"[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer,07/23/2015,[],no
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT01769547,Phase II,Terminated,Ontario Clinical Oncology Group (OCOG)|Novartis Pharmaceuticals,"[{'id': 721, 'therapyName': 'Dovitinib'}]",A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy,12/01/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01769768,Phase I,Completed,Novartis Pharmaceuticals ,"[{'id': 1428, 'therapyName': 'Sonidegib'}, {'id': 2505, 'therapyName': 'Warfarin'}, {'id': 2506, 'therapyName': 'Bupropion'}]",Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients,08/18/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01772004,Phase I,Recruiting,EMD Serono ,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor),10/29/2015,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01772472,Phase III,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE),11/03/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01772797,Phase I,Completed,Novartis Pharmaceuticals ,"[{'id': 789, 'therapyName': 'Ceritinib'}, {'id': 647, 'therapyName': 'AUY922'}]",Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer,06/09/2016,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60108, 'name': 'brain glioma', 'source': 'DOID'}]",NCT01774253,Phase II,Terminated,Giselle Sholler ,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma,10/06/2015,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01774344,Phase III,"Active, not recruiting",Bayer ,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma (RESORCE),03/12/2016,[],no
0,both,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT01774786,Phase III,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1894, 'therapyName': 'Capecitabine + Fluorouracil + Cisplatin + Trastuzumab'}]",A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or Gastric Cancer,07/06/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT01774851,Phase II,Terminated,Merrimack Pharmaceuticals ,"[{'id': 1892, 'therapyName': 'Paclitaxel + Trastuzumab + MM-111'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]","A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach",06/23/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,,[],NCT01775176,,Completed,,[], Effect of Weight and Insulin Sensitivity on Reproductive Function in Polycystic Ovary Syndrome,06/18/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01775423,Phase Ib/II,Unknown status,"Boston Biomedical, Inc ","[{'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 in Adult Patients With Advanced Malignancies,10/03/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01775501,Phase II,Recruiting,Massachusetts General Hospital ,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Sorafenib + mFOLFOX for Hepatocellular Carcinoma,03/12/2015,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01776008,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1548, 'therapyName': 'Goserelin + MK2206'}]",Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer,11/21/2015,"[{'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01776307,Phase II,Recruiting,"Boston Biomedical, Inc ","[{'id': 2090, 'therapyName': 'BBI608 + Cetuximab'}, {'id': 2091, 'therapyName': 'BBI608 + Capecitabine'}, {'id': 2092, 'therapyName': 'BBI608 + Panitumumab'}]",A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer,02/18/2015,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01776723,Phase II,"Active, not recruiting",H. Lee Moffitt Cancer Center and Research Institute|Incyte Corporation,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib,12/13/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01777776,Phase Ib/II,Terminated,Novartis Pharmaceuticals,"[{'id': 796, 'therapyName': 'Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}]",Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.,09/14/2016,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01778439,Phase I,Completed,"OncoMed Pharmaceuticals, Inc. ","[{'id': 839, 'therapyName': 'Brontictuzumab'}]",A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors,09/21/2016,[],no
0,both,[],NCT01778920,Phase I,Completed,University of Pennsylvania ,[],Intraoperative Folate-fluorescein Conjugate (EC17) Lung Cancer (CA),05/19/2016,[],no
0,both,[],NCT01778933,Phase I,Recruiting,University of Pennsylvania ,[],Intraoperative Imagery of Renal Nodules With Folate-fluorescein Conjugate(EC17),12/10/2015,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01779050,Phase II,"Active, not recruiting",Washington University School of Medicine,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1982, 'therapyName': 'Fluorouracil + Epirubicin + Cyclophosphamide'}, {'id': 1834, 'therapyName': 'Docetaxel + Carboplatin'}, {'id': 1881, 'therapyName': 'Docetaxel + Cyclophosphamide'}]",Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells,01/07/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}]",NCT01780545,Phase II,Completed,"Noah Hahn, M.D. ","[{'id': 1807, 'therapyName': 'OGX-427'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer,10/06/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01781026,Phase II,Completed,Yale University,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases,04/08/2015,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01781429,Phase Ib/II,"Active, not recruiting","BioMed Valley Discoveries, Inc","[{'id': 997, 'therapyName': 'BVD-523'}]","Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies",01/06/2017,"[{'molecularProfile': {'id': 1238, 'profileName': 'MAP2K1 mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01781455,Phase Ib/II,Recruiting,"Boston Biomedical, Inc ","[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Adult Patients With Advanced Solid Tumors,05/05/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01781572,Phase Ib/II,"Active, not recruiting",Novartis,"[{'id': 5, 'therapyName': 'Binimetinib + Ribociclib'}]",A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma,12/13/2016,"[{'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01783171,Phase I,Completed,National Cancer Institute (NCI),"[{'id': 2193, 'therapyName': 'Dinaciclib + MK2206'}]",Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery,08/23/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01783197,Phase I,"Active, not recruiting",NCIC Clinical Trials Group|AstraZeneca,"[{'id': 913, 'therapyName': 'Selumetinib'}]", Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC,10/21/2015,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT01783587,Phase I,Recruiting,Dana-Farber Cancer Institute,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer,03/20/2015,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01783756,Phase Ib/II,"Active, not recruiting",Jonsson Comprehensive Cancer Center,"[{'id': 1552, 'therapyName': 'Lapatinib + Capecitabine + Everolimus'}]","Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis",09/29/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01784068,Phase II,"Active, not recruiting",Novartis Pharmaceuticals ,"[{'id': 829, 'therapyName': 'Nilotinib'}]",Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients,07/20/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01784640,Phase I,"Active, not recruiting",Jonsson Comprehensive Cancer Center,"[{'id': 1270, 'therapyName': 'AUY922 + Pemetrexed'}]",Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer,03/09/2016,"[{'molecularProfile': {'id': 343, 'profileName': 'EGFR wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 391, 'profileName': 'ALK wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1799, 'name': 'islet cell tumor', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01784861,Phase Ib/II,"Active, not recruiting",Washington University School of Medicine,"[{'id': 1272, 'therapyName': 'X-82 + Everolimus'}]",VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors,07/20/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01786265,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone,07/28/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01786343,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 650, 'therapyName': 'Decitabine'}]",Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML),12/04/2014,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01787331,Phase II,"Active, not recruiting","University of California, San Francisco ","[{'id': 1026, 'therapyName': 'Itraconazole'}]",A Phase II Study of Itraconazole in Biochemical Relapse,06/20/2017,[],no
0,both,"[{'id': 1240, 'name': 'leukemia', 'source': 'DOID'}]",NCT01787487,Phase III,Recruiting,M.D. Anderson Cancer Center,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}]",Evaluation of RUX and AZA Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm,06/18/2016,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01787500,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1331, 'therapyName': 'Vemurafenib + Cetuximab + Irinotecan '}]","Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers",09/22/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01788280,Phase I,Not yet recruiting,University of Utah,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab,07/23/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01788566,Phase II,Completed,Eli Lilly and Company,"[{'id': 2882, 'therapyName': 'Necitumumab + Gemcitabine + Cisplatin'}]",A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Lung Cancer,06/28/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01789281,Phase III,Recruiting,Novartis Pharmaceuticals,"[{'id': 1333, 'therapyName': 'Everolimus + Sandostatin LAR Depot'}]",Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.,12/23/2014,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01790126,Phase II,"Active, not recruiting","Aragon Pharmaceuticals, Inc. ","[{'id': 1947, 'therapyName': 'ARN-509'}]",The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer,10/04/2016,[],no
0,both,"[{'id': 8618, 'name': 'oral cavity cancer', 'source': 'DOID'}]",NCT01790204,Phase Ib/II,Completed,Georgetown University,"[{'id': 1457, 'therapyName': 'phenethyl isothiocyanate'}]",A Study of the Effects of PEITC on Oral Cells With Mutant p53,03/23/2015,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT01790503,Phase Ib/II,"Active, not recruiting",Plexxikon ,"[{'id': 874, 'therapyName': 'PLX3397'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma,10/22/2015,[],no
0,both,[],NCT01790568,Phase II,"Active, not recruiting",University of Michigan Cancer Center ,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant,07/06/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01791088,Phase I,"Active, not recruiting",University of Chicago ,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery,12/23/2014,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01791478,Phase I,"Active, not recruiting",Vanderbilt-Ingram Cancer Center ,"[{'id': 1553, 'therapyName': 'Letrozole + BYL719'}]",BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer,07/12/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01792050,Phase II,"Active, not recruiting",NewLink Genetics Corporation ,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 2976, 'therapyName': 'indoximod'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer,03/16/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,female,[],NCT01793948,Phase I,"Active, not recruiting",Indiana University School of Medicine,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer,03/16/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01794507,Phase I,"Active, not recruiting","AbbVie (prior sponsor, Abbott) ","[{'id': 3436, 'therapyName': 'Bortezomib + Dexamethasone + GDC-0199\t'}]",A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy,05/13/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01794520,Phase I,"Active, not recruiting","AbbVie (prior sponsor, Abbott) ","[{'id': 1562, 'therapyName': 'Venetoclax'}]",Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma,12/30/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01794702,Phase Ib/II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]","Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia",05/23/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01794845,Phase II,Terminated,University of Miami ,"[{'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}]",Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma,05/12/2017,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01796197,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute,"[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa,07/03/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01797120,Phase II,Completed,"PrECOG, LLC. ","[{'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI",09/15/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}]",NCT01797523,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1031, 'therapyName': 'Metformin'}]",RAD/Letrozole/Metformin,07/26/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01798485,Phase III,Terminated,Synta Pharmaceuticals Corp. ,"[{'id': 745, 'therapyName': 'Ganetespib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC,11/06/2015,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01798901,Phase I,"Active, not recruiting",Alison Walker,"[{'id': 1751, 'therapyName': 'AR-42 + Decitabine'}]",AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia,02/12/2015,[],no
0,male,"[{'id': 2992, 'name': 'prostate neuroendocrine neoplasm', 'source': 'DOID'}]",NCT01799278,Phase II,"Active, not recruiting",Weill Medical College of Cornell University ,"[{'id': 626, 'therapyName': 'Alisertib'}]",A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer,09/03/2015,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01799889,Phase II,"Active, not recruiting",Gilead Sciences ,"[{'id': 2522, 'therapyName': 'Entospletinib  '}]",A Phase 2 of Entospletinib in Subjects With Relapsed or Refractory Hematologic Malignancies,06/20/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01800695,Phase I,Completed,AbbVie ,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 976, 'therapyName': 'ABT-414'}]",Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme,07/08/2017,"[{'molecularProfile': {'id': 447, 'profileName': 'EGFR amp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01801111,Phase II,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment,07/31/2015,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01801163,Phase I,Withdrawn,Indiana University ,"[{'id': 920, 'therapyName': 'Sorafenib'}]",A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC),04/16/2015,[],no
0,both,"[{'id': 1752, 'name': 'ocular melanoma', 'source': 'DOID'}]",NCT01801358,Phase Ib/II,Terminated,Novartis|Novartis Pharmaceuticals,"[{'id': 807, 'therapyName': 'Binimetinib'}, {'id': 1114, 'therapyName': 'MEK162 + AEB071'}]", A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma,12/01/2015,[],no
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT01802320,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 816, 'therapyName': 'MK2206'}]",Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,12/01/2015,"[{'molecularProfile': {'id': 4, 'profileName': 'BRAF wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01802632,Phase Ib/II,"Active, not recruiting",AstraZeneca,"[{'id': 660, 'therapyName': 'Osimertinib'}]", AZD9291 First Time In Patients Ascending Dose Study,06/25/2015,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT01803282,Phase I,Recruiting,Gilead Sciences ,"[{'id': 3320, 'therapyName': 'GS-5745'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Safety and Tolerability Study in Solid Tumors,12/20/2015,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 4138, 'profileName': 'EML4-ALK'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT01804101,Phase I,"Active, not recruiting",Fred Hutchinson Cancer Research Center,"[{'id': 4341, 'therapyName': 'CPX-351'}]",Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia,01/13/2017,[],yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01804465,Phase II,Recruiting,"University of California, San Francisco ","[{'id': 779, 'therapyName': 'Ipilimumab'}]",A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer,08/05/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01804530,Phase I,"Active, not recruiting",Plexxikon ,"[{'id': 2651, 'therapyName': 'PLX7486'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors,09/29/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01804634,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 1373, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Sirolimus'}]",A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors,11/07/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01804686,Phase III,Recruiting,"Janssen Research & Development, LLC ","[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Long-term Extension Study of PCI-32765 (Ibrutinib),09/01/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01806064,Phase I,"Active, not recruiting",Tracon Pharmaceuticals Inc.,"[{'id': 1243, 'therapyName': 'Bevacizumab + TRC105'}]", A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma,10/07/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01806571,Phase II,Recruiting,Mayo Clinic ,"[{'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}]","Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",11/08/2015,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01807065,Phase II,"Active, not recruiting",City of Hope Medical Center ,"[{'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer,01/30/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01808573,Phase III,"Active, not recruiting","Puma Biotechnology, Inc.","[{'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}, {'id': 1543, 'therapyName': 'Capecitabine + Neratinib'}]",A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting,10/12/2017,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01809691,Phase III,"Active, not recruiting",Southwest Oncology Group ,"[{'id': 2671, 'therapyName': 'Orteronel '}, {'id': 1507, 'therapyName': 'Bicalutamide'}]","S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer",08/18/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01810016,Phase I,Terminated,Ludwig Institute for Cancer Research ,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]",NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma,06/18/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}]",NCT01810913,Phase II,"Active, not recruiting",Radiation Therapy Oncology Group ,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}]","Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer",03/19/2016,[],no
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT01811212,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer,08/23/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01811498,Phase Ib/II,Recruiting,North Shore Long Island Jewish Health System ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM,02/19/2015,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT01812252,Phase II,Recruiting,Fred Hutchinson Cancer Research Center,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 1798, 'therapyName': 'Decitabine + Azacitidine'}]",Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant,12/18/2014,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01812668,Phase I,"Active, not recruiting",Barbara Ann Karmanos Cancer Institute ,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer,04/24/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01813214,Phase II,Terminated,Georgetown University,"[{'id': 342, 'therapyName': 'Vemurafenib'}]", The Effects of Vemurafenib on Immunity in Patients With Melanoma,03/07/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01813734,Phase II,Recruiting,Massachusetts General Hospital ,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib in Advanced NSCLC w/ RET Translocations,02/10/2015,"[{'molecularProfile': {'id': 1326, 'profileName': 'RET rearrange'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}, {'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT01814501,Phase II,Recruiting,Christina Wu ,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab,02/09/2015,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 481, 'profileName': 'NRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}]",NCT01814553,Phase III,Completed,Boehringer Ingelheim,"[{'id': 1374, 'therapyName': 'Afatinib + Loperamide'}]", ADAM-Afatinib Diarrhea Assessment and Management,08/01/2015,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01814813,Phase II,"Active, not recruiting",Alliance for Clinical Trials in Oncology ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery,03/08/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01814826,Phase I,"Active, not recruiting","Millennium Pharmaceuticals, Inc. ","[{'id': 1688, 'therapyName': 'MLN4924'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older,04/19/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01815294,Phase I,Completed,"Janssen Research & Development, LLC","[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1008, 'therapyName': 'Doxil'}]", A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer,04/28/2015,[],no
0,both,"[{'id': 2513, 'name': 'basal cell carcinoma', 'source': 'DOID'}]",NCT01815840,Phase II,Completed,Hoffmann-La Roche,"[{'id': 956, 'therapyName': 'Vismodegib'}]",A Study of Two Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas,07/03/2017,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01816035,Phase I,Completed,University of Washington,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery,05/24/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01816984,Phase Ib/II,"Active, not recruiting",University of Chicago ,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 680, 'therapyName': 'BKM120'}]",PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,01/09/2016,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT01817751,Phase II,Recruiting,Virginia Commonwealth University ,"[{'id': 1076, 'therapyName': 'Valproic acid'}, {'id': 920, 'therapyName': 'Sorafenib'}]","Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma",03/17/2015,[],no
0,both,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01818986,Phase II,Recruiting,University of Texas Southwestern Medical Center ,"[{'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC),05/20/2015,[],no
0,female,"[{'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}]",NCT01820325,Phase II,Terminated,Novartis|Novartis Pharmaceuticals,"[{'id': 680, 'therapyName': 'BKM120'}]", Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer,05/28/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01820364,Phase II,Terminated,Novartis Pharmaceuticals,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 1260, 'therapyName': 'Encorafenib + Ribociclib'}, {'id': 1337, 'therapyName': 'Encorafenib + BKM120'}, {'id': 1336, 'therapyName': 'BGJ398 + Encorafenib'}, {'id': 1338, 'therapyName': 'Capmatinib + Encorafenib'}]", LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma,01/10/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01820754,Phase II,"Active, not recruiting",Duke University ,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC),09/24/2016,[],no
0,both,"[{'id': 3587, 'name': 'pancreatic ductal carcinoma', 'source': 'DOID'}]",NCT01821729,Phase II,Recruiting,Massachusetts General Hospital ,"[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 2998, 'therapyName': 'Losartan'}]",Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer,01/20/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01822015,Phase I,"Active, not recruiting",Thomas Jefferson University,"[{'id': 2232, 'therapyName': 'Cytarabine + Idarubicin + Sirolimus'}]","Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia",05/12/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01822496,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1375, 'therapyName': 'Cisplatin + Etoposide + Paclitaxel + Carboplatin + Erlotinib'}]",Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer,06/15/2015,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 12603, 'name': 'acute leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01822509,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant,05/27/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01822522,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus,08/31/2015,[],no
0,both,"[{'id': 3748, 'name': 'esophagus squamous cell carcinoma', 'source': 'DOID'}]",NCT01822613,Phase Ib/II,Completed,Novartis Pharmaceuticals ,"[{'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}, {'id': 2283, 'therapyName': 'BYL719 + LJM716'}]",Study of Safety and Efficacy of the Combination of LJM716 and BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC),07/28/2016,[],no
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT01822652,Phase I,"Active, not recruiting",Baylor College of Medicine ,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN",11/03/2015,[],no
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01822756,Phase I,Terminated,Incyte Corporation,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors,04/14/2017,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01823198,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1846, 'therapyName': 'Busulfan + Fludarabine + anti-thymocyte globulin'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies,12/23/2014,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01823835,Phase II,"Active, not recruiting","Genentech, Inc. ","[{'id': 2150, 'therapyName': 'GDC-0810'}]",A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer,05/31/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01824823,Phase II,Terminated,Eastern Cooperative Oncology Group ,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence,09/15/2015,[],no
0,female,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT01824836,Phase I,Recruiting,Eastern Cooperative Oncology Group ,"[{'id': 633, 'therapyName': 'Anastrozole'}]",Anastrozole in Treating Aromatase Inhibitor Musculoskeletal Symptoms in Female Patients With Stage I-III Breast Cancer,05/05/2015,[],yes
0,both,"[{'id': 3500, 'name': 'gallbladder adenocarcinoma', 'source': 'DOID'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 4896, 'name': 'bile duct adenocarcinoma', 'source': 'DOID'}, {'id': 4932, 'name': 'ampulla of Vater carcinoma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT01825603,Phase I,Recruiting,University of Nebraska ,"[{'id': 4952, 'therapyName': 'ADH-1 + Cisplatin + Gemcitabine'}]","ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery",11/13/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01826448,Phase I,Terminated,Plexxikon,"[{'id': 1339, 'therapyName': 'PLX3397 + Vemurafenib'}]"," A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma",10/10/2014,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01827111,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 2978, 'therapyName': 'Ipilimumab + nab-paclitaxel'}]",Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma,05/03/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01827137,Phase I,"Active, not recruiting",Memorial Sloan Kettering Cancer Center ,"[{'id': 2893, 'therapyName': 'WT1 vaccine'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation,02/11/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01827384,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1193, 'therapyName': 'Veliparib + Temozolomide'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 2, 'therapyName': 'Trametinib'}]",Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors,10/20/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01828021,Phase II,Completed,MacroGenics ,"[{'id': 808, 'therapyName': 'MGAH22'}]",Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer,07/28/2017,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}]",NCT01828034,Phase Ib/II,"Active, not recruiting","Memorial Sloan Kettering Cancer Center, Novartis","[{'id': 2218, 'therapyName': 'MEK162 + Gemcitabine + Cisplatin'}]","First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma",01/12/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01828112,Phase III,"Active, not recruiting",Novartis Pharmaceuticals,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 789, 'therapyName': 'Ceritinib'}]",LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib,04/27/2016,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01828476,Phase II,Terminated,"Rutgers, The State University of New Jersey ","[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 2597, 'therapyName': 'Abiraterone + Navitoclax'}]",Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer,04/01/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01828554,Phase III,Recruiting,"University of Wisconsin, Madison","[{'id': 1105, 'therapyName': 'Capecitabine'}]",Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight,09/21/2014,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01829217,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute ,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib in Never-Smokers With Lung Adenocarcinoma,01/24/2017,"[{'molecularProfile': {'id': 343, 'profileName': 'EGFR wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 391, 'profileName': 'ALK wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1326, 'profileName': 'RET rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01829503,Phase II,"Active, not recruiting",University of Pittsburgh,"[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}]",Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),01/16/2016,[],no
0,both,"[{'id': 3571, 'name': 'liver cancer', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01829971,Phase I,Terminated,"Mirna Therapeutics, Inc.","[{'id': 1035, 'therapyName': 'MRX34'}]","A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection",09/28/2016,[],no
0,both,"[{'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 120, 'name': 'female reproductive organ cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT01831089,Phase I,Completed,PharmaMar,"[{'id': 1196, 'therapyName': 'Lurbinectedin + Paclitaxel + Bevacizumab'}, {'id': 1197, 'therapyName': 'Lurbinectedin + Paclitaxel'}]","Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors",07/28/2016,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01831726,Phase II,Completed,Novartis Pharmaceuticals,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib,02/05/2016,"[{'molecularProfile': {'id': 1327, 'profileName': 'CSF1R rearrange'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1326, 'profileName': 'RET rearrange'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1232, 'profileName': 'RET mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1276, 'profileName': 'FGFR1 rearrange'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1215, 'profileName': 'PDGFRA mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1214, 'profileName': 'KIT mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1185, 'profileName': 'FGFR2 mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1221, 'profileName': 'FGFR1 mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1317, 'profileName': 'FGFR2 rearrange'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1318, 'profileName': 'FGFR3 rearrange'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1320, 'profileName': 'PDGFRA rearrange'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1325, 'profileName': 'FLT3 rearrange'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1228, 'profileName': 'CSF1R mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1324, 'profileName': 'KIT rearrange'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01832259,Phase II,"Active, not recruiting",University of Utah ,"[{'id': 848, 'therapyName': 'Pazopanib'}]",A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection,03/09/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01833143,Phase II,"Active, not recruiting","Memorial Sloan-Kettering Cancer Center|Millennium Pharmaceuticals, Inc.","[{'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D,10/10/2014,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 746, 'profileName': 'KRAS G12D'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT01833169,Phase II,Completed,Novartis Pharmaceuticals,"[{'id': 680, 'therapyName': 'BKM120'}]",BKM120 for Patients With PI3K-activated Tumors,11/09/2016,"[{'molecularProfile': {'id': 1281, 'profileName': 'AKT1 act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 743, 'profileName': 'PIK3CA act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT01834248,Phase I,Completed,Roswell Park Cancer Institute,"[{'id': 1795, 'therapyName': 'DEC-205-NY-ESO-1 + Decitabine '}]",DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia,07/22/2017,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01834651,Phase II,Completed,"Edwin Posadas, MD ","[{'id': 998, 'therapyName': 'cabozantinib'}]",A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases,04/20/2017,[],no
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT01835145,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye,05/11/2016,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01835158,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1236, 'therapyName': 'Cabozantinib + Sunitinib'}]",Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer,04/15/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01835184,Phase I,Terminated,National Cancer Institute (NCI),"[{'id': 1235, 'therapyName': 'Cabozantinib + Vemurafenib'}]",Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery,10/10/2014,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01835223,Phase Ib/II,"Active, not recruiting",Roswell Park Cancer Institute ,"[{'id': 1055, 'therapyName': 'Tivozanib'}]",Tivozanib in Treating Patients With Liver Cancer That is Metastatic or Cannot Be Removed by Surgery,02/25/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01835288,Phase II,Withdrawn,Stanford University ,"[{'id': 640, 'therapyName': 'Arsenic trioxide'}]",Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,10/06/2016,[],no
0,both,"[{'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}]",NCT01835626,Phase II,Recruiting,Sue Yom ,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma,12/18/2014,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01836029,Phase II,"Active, not recruiting",VentiRx Pharmaceuticals Inc. ,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2000, 'therapyName': 'Fluorouracil + Cetuximab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,08/28/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01837329,Phase I,Recruiting,University of Rochester ,"[{'id': 3147, 'therapyName': 'Tetrathiomolybdate'}]",Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer,10/20/2015,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01837602,Phase I,"Active, not recruiting",Abramson Cancer Center of the University of Pennsylvania,[],cMet CAR RNA T Cells Targeting Breast Cancer,08/23/2016,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01837667,Phase I,Completed,"Lixte Biotechnology Holdings, Inc. ","[{'id': 3683, 'therapyName': 'Docetaxel + LB-100'}]",Phase I Study of LB-100 With Docetaxel in Solid Tumors,10/01/2016,[],no
0,both,"[{'id': 6726, 'name': 'fibrillary astrocytoma', 'source': 'DOID'}, {'id': 4852, 'name': 'pleomorphic xanthoastrocytoma', 'source': 'DOID'}, {'id': 4851, 'name': 'pilocytic astrocytoma', 'source': 'DOID'}, {'id': 3073, 'name': 'brain glioblastoma multiforme', 'source': 'DOID'}, {'id': 3185, 'name': 'spinal cord glioma', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 4845, 'name': 'pilomyxoid astrocytoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01837862,Phase Ib/II,Recruiting,Mark Atlas,"[{'id': 2134, 'therapyName': 'Mebendazole + Vincristine + Carboplatin + Temozolomide'}, {'id': 2133, 'therapyName': 'Mebendazole + Bevacizumab + Irinotecan'}]",A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas,04/25/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01838395,Phase II,Completed,"BioLineRx, Ltd. ","[{'id': 3168, 'therapyName': 'BKT140 + Cytarabine'}]",Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients,06/16/2016,[],no
0,both,[],NCT01838577,,Recruiting,European Organisation for Research and Treatment of Cancer - EORTC ,[],Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study,04/24/2015,[],no
0,both,"[{'id': 3973, 'name': 'thyroid medullary carcinoma', 'source': 'DOID'}]",NCT01838642,Phase II,Terminated,National Cancer Institute (NCI),"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib for Advanced Medullary Thyroid Cancer,03/19/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01839955,Phase Ib/II,Completed,Neelesh Sharma MD PhD,"[{'id': 1237, 'therapyName': 'Erlotinib + Quinacrine'}]",Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer,11/01/2016,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 343, 'profileName': 'EGFR wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01840592,Phase II,"Active, not recruiting",Memorial Sloan Kettering Cancer Center.,"[{'id': 2363, 'therapyName': 'Doxorubicin + Sorafenib'}]",Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib,06/21/2016,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01841333,Phase II,Recruiting,"University of Colorado, Denver ","[{'id': 1748, 'therapyName': 'PF-04449913'}]",PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant,09/17/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01841463,Phase Ib/II,Suspended,Piramal Enterprises Limited,"[{'id': 1238, 'therapyName': 'Vemurafenib + Voruciclib'}]",Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation,09/04/2014,"[{'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 285, 'name': 'hairy cell leukemia', 'source': 'DOID'}]",NCT01841723,Phase II,Recruiting,National Cancer Institute (NCI) ,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia,04/07/2016,[],no
0,both,"[{'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT01841736,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors,10/30/2016,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01842646,Phase II,"Active, not recruiting",H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 1748, 'therapyName': 'PF-04449913'}]",Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS),09/25/2015,[],no
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT01843062,Phase III,"Active, not recruiting",AstraZeneca,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer,04/16/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01843738,Phase I,Withdrawn,University of Utah,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",Radiation Use During Vemurafenib Treatment,05/25/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60061, 'name': 'cutaneous T cell lymphoma', 'source': 'DOID'}]",NCT01843998,Phase II,Withdrawn,Stefan Schieke MD ,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL),06/05/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT01844583,Phase I,Completed,"Millennium Pharmaceuticals, Inc.","[{'id': 1239, 'therapyName': 'Alisertib  + Esomeprazole'}, {'id': 1240, 'therapyName': 'Alisertib + Rifampin'}, {'id': 626, 'therapyName': 'Alisertib'}]","Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib",10/01/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01844674,Phase I,Completed,Hoffmann-La Roche,"[{'id': 1241, 'therapyName': 'Vemurafenib + Tizanidine'}]",A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies,09/16/2015,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01844765,Phase II,"Active, not recruiting",Novartis Pharmaceuticals,"[{'id': 829, 'therapyName': 'Nilotinib'}]","Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.",07/08/2017,[],yes
0,female,"[{'id': 6212, 'name': 'ovarian endometrial cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT01844986,Phase III,"Active, not recruiting",AstraZeneca,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.,12/11/2015,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01845792,Phase II,Completed,"University of Colorado, Denver ","[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer,03/09/2017,[],no
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT01846611,Phase III,Recruiting,"Janssen Research & Development, LLC ","[{'id': 1008, 'therapyName': 'Doxil'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",02/26/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01846624,Phase II,"Active, not recruiting",Bruno C. Medeiros,"[{'id': 1769, 'therapyName': 'Decitabine + Midostaurin'}]",Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,04/28/2016,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01847001,Phase II,"Active, not recruiting",Columbia University ,"[{'id': 1912, 'therapyName': 'Propranolol'}, {'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]",Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy,09/01/2017,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT01847274,Phase III,Completed,"Tesaro, Inc. ","[{'id': 832, 'therapyName': 'Niraparib'}]",A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer,07/06/2016,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01848067,Phase Ib/II,"Active, not recruiting",Thomas Jefferson University ,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 626, 'therapyName': 'Alisertib'}]","Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",05/12/2016,[],no
0,both,"[{'id': 3996, 'name': 'urinary system cancer', 'source': 'DOID'}, {'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}, {'id': 5041, 'name': 'esophageal cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01848756,Phase Ib/II,Terminated,Esanex Inc. ,"[{'id': 866, 'therapyName': 'SNX-5422'}]",Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers,04/24/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01849146,Phase I,Suspended,National Cancer Institute (NCI),"[{'id': 2713, 'therapyName': 'MK-1775 + Temozolomide'}]","WEE1 Inhibitor MK-1775, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme",10/18/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01849276,Phase I,"Active, not recruiting",Northwestern University,"[{'id': 1792, 'therapyName': 'Metformin + Cytarabine'}]",Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML,02/25/2016,[],yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01849588,FDA approved,Terminated,Massachusetts General Hospital ,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib for Hepatocellular Cancer With Chronic Hepatitis C,03/14/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01849744,Phase I,Terminated,"Verastem, Inc.","[{'id': 1933, 'therapyName': 'VS-4718'}]",Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies,07/29/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01849783,Phase II,Recruiting,University of Iowa ,"[{'id': 1852, 'therapyName': 'Melphalan + Bortezomib + Thalidomide + Dexamethasone'}, {'id': 3435, 'therapyName': 'Aldoxorubicin + Cisplatin + Cyclophosphamide + Dexamethasone + Etoposide'}]",Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma,01/27/2016,[],no
0,female,"[{'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT01849874,Phase III,"Active, not recruiting",Array BioPharma ,"[{'id': 807, 'therapyName': 'Binimetinib'}]","A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer",05/07/2016,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01850004,Phase II,"Active, not recruiting",Bristol-Myers Squibb,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response,11/10/2016,[],no
0,female,[],NCT01850628,,Recruiting,NSABP Foundation Inc ,[],NSABP Biospecimen Discovery Project,07/23/2015,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01852292,Phase II,Completed,Novartis Pharmaceuticals ,"[{'id': 1545, 'therapyName': 'BKM120 + Paclitaxel'}]",Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy,06/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01853046,Phase I,Completed,Bayer,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment,08/11/2015,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 5744, 'name': 'ovary serous adenocarcinoma', 'source': 'DOID'}]",NCT01853306,Phase I,Completed,AbbVie,"[{'id': 954, 'therapyName': 'Veliparib'}]","A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors",07/22/2017,"[{'molecularProfile': {'id': 1282, 'profileName': 'BRCA1 inact mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1283, 'profileName': 'BRCA2 inact mut'}, 'requirementType': 'required'}]",yes
0,both,[],NCT01853423,Phase I,Completed,Le Bonheur Children's Hospital ,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Tuberou Sclerosis Complex: Facial Angiofibroma Skin Cream,08/20/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}]",NCT01853618,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1652, 'therapyName': 'Tremelimumab'}]",Tremelimumab With Chemoembolization or Ablation for Liver Cancer,04/06/2017,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT01853644,Phase II,Recruiting,Northwestern University ,"[{'id': 1055, 'therapyName': 'Tivozanib'}]","Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer",02/24/2017,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01853748,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial),09/25/2014,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01854034,Phase II,Completed,Massachusetts General Hospital ,"[{'id': 647, 'therapyName': 'AUY922'}]",Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR,03/15/2017,"[{'molecularProfile': {'id': 4039, 'profileName': 'EGFR exon 20 ins'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT01854606,Phase Ib/II,Completed,Novartis Pharmaceuticals,"[{'id': 1951, 'therapyName': 'AEB071 + Everolimus'}]",Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma,02/15/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT01855750,Phase III,"Active, not recruiting","Janssen Research & Development, LLC ","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",04/12/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01855828,Phase II,Recruiting,Lajos Pusztai,"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1550, 'therapyName': 'Pertuzumab + Trastuzumab + Fluorouracil + Epirubicin + Cyclophosphamide'}]",Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer,09/25/2014,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 60077, 'name': 'progesterone-receptor positive breast cancer', 'source': 'DOID'}, {'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}]",NCT01857193,Phase Ib/II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 2265, 'therapyName': 'LEE011 + Everolimus + Exemestane'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 2266, 'therapyName': 'LEE011 + Exemestane'}]",Phase Ib/II Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of ER+ Her2- Advanced Breast Cancer,12/02/2016,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01857271,Phase II,Recruiting,Albert Einstein College of Medicine of Yeshiva University,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer,06/15/2015,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT01857934,Phase II,Recruiting,St. Jude Children's Research Hospital ,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 2627, 'therapyName': 'Levetiracetam'}, {'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 2458, 'therapyName': 'Hu14.18K322A'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}]",Therapy for Children With Advanced Stage Neuroblastoma,05/06/2015,[],yes
0,both,"[{'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}]",NCT01858168,Phase I,Recruiting,Massachusetts General Hospital,"[{'id': 1438, 'therapyName': 'Olaparib + Temozolomide'}]",Phase I Study of Olaprib and Temozolomide for Ewings Sarcoma,04/22/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01858389,Phase II,Completed,Pfizer,"[{'id': 714, 'therapyName': 'Dacomitinib'}]",A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer,10/20/2015,"[{'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01858883,Phase I,Completed,Incyte Corporation ,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2406, 'therapyName': 'INCB039110'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Safety Study of INCB039110 in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors,04/20/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1324, 'name': 'lung cancer', 'source': 'DOID'}]",NCT01859026,Phase I,Recruiting,H. Lee Moffitt Cancer Center and Research Institute,"[{'id': 1253, 'therapyName': 'MEK162 + Erlotinib'}]",A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation,09/26/2017,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT01859741,Phase Ib/II,"Active, not recruiting","OncoMed Pharmaceuticals, Inc. ","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2547, 'therapyName': 'Tarextumab'}]",A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE),09/21/2016,[],no
0,both,"[{'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 2600, 'name': 'laryngeal carcinoma', 'source': 'DOID'}, {'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT01860430,Phase I,"Active, not recruiting",University of Pittsburgh ,"[{'id': 1926, 'therapyName': 'Cetuximab + Ipilimumab'}]",A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer,01/24/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01860638,Phase III,Completed,Hoffmann-La Roche ,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2075, 'therapyName': 'Lomustine'}]",A Comparison of Continuous Avastin (Bevacizumab) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Patients With Glioblastoma,07/29/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01861314,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1793, 'therapyName': 'Bortezomib + Sorafenib + Decitabine   '}]","Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia",10/09/2015,[],no
0,female,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT01862081,Phase I,Completed,"Genentech, Inc.","[{'id': 2321, 'therapyName': 'Docetaxel + GDC-0032 '}, {'id': 2322, 'therapyName': 'GDC-0032 + Paclitaxel'}]","A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer",08/26/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01862900,Phase Ib/II,"Active, not recruiting",Providence Health & Services ,"[{'id': 1653, 'therapyName': 'MEDI6469'}]",Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions,08/11/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01863550,Phase III,Recruiting,ECOG-ACRIN Cancer Research Group,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma,01/21/2016,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01864096,Phase III,Recruiting,"University Health Network, Toronto ","[{'id': 1031, 'therapyName': 'Metformin'}]",The Metformin Active Surveillance Trial (MAST) Study,12/22/2014,[],no
0,female,"[{'id': 3459, 'name': 'breast carcinoma', 'source': 'DOID'}]",NCT01864746,Phase III,Recruiting,German Breast Group ,"[{'id': 850, 'therapyName': 'Palbociclib'}]",A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery,04/21/2016,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01865747,Phase III,"Active, not recruiting",Exelixis,"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}]",A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma,11/17/2014,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01866293,Phase Ib/II,Completed,Memorial Sloan Kettering Cancer Center,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma,09/24/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01866410,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1255, 'therapyName': 'Cabozantinib + Erlotinib'}]",Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer,07/30/2014,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01867333,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 3069, 'therapyName': 'PROSTVAC-F/TRICOM '}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer,12/30/2016,[],no
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01868022,Phase I,"Active, not recruiting",GlaxoSmithKline ,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 2899, 'therapyName': 'GSK3052230'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling",12/17/2016,"[{'molecularProfile': {'id': 812, 'profileName': 'FGFR1 amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01868503,Phase II,Terminated,Stanford University,"[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer,11/19/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT01869114,Phase II,Recruiting,Thomas Jefferson University ,"[{'id': 2233, 'therapyName': 'Azacitidine + Sirolimus'}]",Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy,09/07/2017,[],no
0,both,"[{'id': 60318, 'name': 'acute promyelocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01869803,Phase I,Suspended,Comprehensive Cancer Center of Wake Forest University ,"[{'id': 756, 'therapyName': 'Gemtuzumab ozogamicin'}]",Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia,04/15/2017,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01870505,Phase I,"Active, not recruiting",Memorial Sloan Kettering Cancer Center. ,"[{'id': 2318, 'therapyName': 'BYL719 + Exemestane'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]",BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer,02/18/2017,[],yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01870596,Phase II,Completed,National Cancer Institute (NCI),"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2027, 'therapyName': 'MK-8776'}]",Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia,09/02/2016,[],no
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT01870609,Phase II,Terminated,"Verastem, Inc. ","[{'id': 958, 'therapyName': 'VS-6063'}]",Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma,10/08/2015,[],no
0,,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01870726,Phase Ib/II,Completed,Novartis Pharmaceuticals ,"[{'id': 2461, 'therapyName': 'BKM120 + INC280'}]",Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma,02/15/2017,"[{'molecularProfile': {'id': 479, 'profileName': 'PTEN loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1213, 'profileName': 'PTEN mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2077, 'profileName': 'PTEN negative'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01871311,Phase I,Recruiting,Georgetown University ,"[{'id': 1929, 'therapyName': 'Nilotinib + Cetuximab'}]",A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab,02/02/2015,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT01871571,Phase II,Recruiting,University of Southern California,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}]","Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer",09/18/2014,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT01871675,Phase I,Completed,"SCRI Development Innovations, LLC","[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1024, 'therapyName': 'Duvelisib'}, {'id': 1231, 'therapyName': 'Bendamustine'}]","Phase Ib Study of IPI-145 in Combination With Bendamustine, Rituximab or Bendamustine/Rituximab in Hematologic Malignancies",07/12/2016,[],no
0,both,"[{'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}]",NCT01871766,Phase II,Recruiting,St. Jude Children's Research Hospital,"[{'id': 1119, 'therapyName': 'Sorafenib + Avastin + Cyclophosphamide'}, {'id': 1436, 'therapyName': 'Vincristine + Dactinomycin'}, {'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}]","Treatment of Localized Rhabdomyosarcoma With Chemotherapy, Radiotherapy, and Surgery",09/10/2014,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01871805,Phase Ib/II,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 698, 'therapyName': 'Alectinib'}]",A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer,05/13/2015,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}]",NCT01872260,Phase Ib/II,Recruiting,Novartis Pharmaceuticals,"[{'id': 1553, 'therapyName': 'Letrozole + BYL719'}, {'id': 1569, 'therapyName': 'LEE011 + BYL719 + Letrozole'}, {'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer",09/30/2014,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'excluded'}]",yes
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01873833,Phase II,Recruiting,University of Southern California,"[{'id': 1559, 'therapyName': 'Capecitabine + Cyclophosphamide + Lapatinib + Trastuzumab'}]","Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer",09/25/2014,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}]",NCT01874353,Phase III,"Active, not recruiting",AstraZeneca ,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy,12/01/2015,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}]",NCT01874665,Phase II,Completed,Ariad Pharmaceuticals,"[{'id': 877, 'therapyName': 'Ponatinib'}]",A Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor,12/13/2016,"[{'molecularProfile': {'id': 1668, 'profileName': 'KIT act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01874860,Phase I,Recruiting,James Graham Brown Cancer Center ,"[{'id': 1391, 'therapyName': 'Doxycycline'}]",Skin Rash Study Before Chemotherapy in Colorectal &amp; Head and Neck Cancer Patients,02/02/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01875250,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 4884, 'therapyName': 'Enzalutamide + PROSTVAC-F/TRICOM + PROSTVAC-V/TRICOM'}]",Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer,11/26/2016,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01875666,Phase I,"Active, not recruiting",UNC Lineberger Comprehensive Cancer Center,"[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]","Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",04/19/2017,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01875705,Phase I,Completed,"Genentech, Inc. ","[{'id': 2149, 'therapyName': 'GDC-0994'}]",A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors,05/10/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01876212,Phase II,Recruiting,Hussein Tawbi,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma,12/19/2014,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT01876251,,Terminated,Pfizer,"[{'id': 1115, 'therapyName': 'PF-03084014 + Docetaxel'}]", A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer,07/18/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01876511,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors,05/13/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01876641,Phase Ib/II,Recruiting,University of Iowa,"[{'id': 1259, 'therapyName': 'Vemurafenib + Decitabine'}]",Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib,07/30/2014,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT01876784,Phase III,Completed,AstraZeneca ,"[{'id': 953, 'therapyName': 'Vandetanib'}]","Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer",09/07/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01876953,Phase Ib/II,"Active, not recruiting",City of Hope Medical Center ,"[{'id': 1850, 'therapyName': 'Cytarabine + Idarubicin + Dasatinib'}]","Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia",04/12/2016,[],no
0,both,"[{'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}]",NCT01877083,Phase II,"Active, not recruiting","Eisai Co., Ltd.","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung,04/21/2016,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 2882, 'profileName': 'RET positive'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1326, 'profileName': 'RET rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01877382,Phase I,Recruiting,Daiichi Sankyo Inc.,"[{'id': 2079, 'therapyName': 'DS-3032b'}]","A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas",02/20/2015,[],no
0,female,"[{'id': 2870, 'name': 'endometrial adenocarcinoma', 'source': 'DOID'}]",NCT01877564,Phase II,Recruiting,University of Arkansas ,"[{'id': 1031, 'therapyName': 'Metformin'}]",A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women,12/23/2014,[],no
0,both,"[{'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}, {'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01877811,Phase Ib/II,"Active, not recruiting",Teva Pharmaceutical Industries,"[{'id': 1002, 'therapyName': 'CEP-32496'}]",CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2,08/05/2017,"[{'molecularProfile': {'id': 1232, 'profileName': 'RET mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1326, 'profileName': 'RET rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1273, 'profileName': 'BRAF rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}]",NCT01878617,Phase II,Recruiting,St. Jude Children's Research Hospital,"[{'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1800, 'therapyName': 'Cyclophosphamide + Cisplatin + Vincristine '}, {'id': 1801, 'therapyName': 'Pemetrexed + Gemcitabine'}]",A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma,12/18/2014,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT01879085,Phase Ib/II,Recruiting,Hussein Tawbi ,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma,05/13/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT01880437,Phase II,Terminated,Hoffmann-La Roche,"[{'id': 1802, 'therapyName': 'Cytarabine + Vismodegib'}]",A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myleodysplastic Syndrome,12/01/2015,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT01880567,Phase II,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 3280, 'therapyName': 'Ibrutinib + Rituximab'}]",Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL),05/19/2016,[],yes
0,both,"[{'id': 3565, 'name': 'meningioma', 'source': 'DOID'}]",NCT01880749,Phase I,"Active, not recruiting",New York University School of Medicine,"[{'id': 735, 'therapyName': 'Everolimus'}]",Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas,07/25/2017,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT01882803,Phase II,"Active, not recruiting","Infinity Pharmaceuticals, Inc. ","[{'id': 1024, 'therapyName': 'Duvelisib'}]",A Phase 2 Study of IPI-145 in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO),10/21/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01883362,Phase II,Recruiting,Novartis Pharmaceuticals,"[{'id': 810, 'therapyName': 'Midostaurin'}]",Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML,04/03/2015,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01884285,Phase I,Recruiting,AstraZeneca ,"[{'id': 992, 'therapyName': 'AZD8186'}]",AZD8186 First Time In Patient Ascending Dose Study,12/06/2016,"[{'molecularProfile': {'id': 2408, 'profileName': 'PTEN del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 479, 'profileName': 'PTEN loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2095, 'profileName': 'PTEN inact mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 4202, 'name': 'brain stem glioma', 'source': 'DOID'}]",NCT01884740,Phase Ib/II,Recruiting,Weill Medical College of Cornell University ,"[{'id': 1654, 'therapyName': 'Avastin + Cetuximab'}]",Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux and Bevacizumab For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age,01/07/2015,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01885195,Phase II,Completed,Novartis Pharmaceuticals,"[{'id': 807, 'therapyName': 'Binimetinib'}]",MEK162 for Patients With RAS/RAF/MEK Activated Tumors,06/07/2017,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1238, 'profileName': 'MAP2K1 mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1208, 'profileName': 'HRAS mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01885689,Phase II,Recruiting,City of Hope Medical Center ,"[{'id': 2236, 'therapyName': 'Clofarabine + Melphalan'}]",Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia or Acute Leukemia in Remission,03/02/2015,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 70004, 'name': 'myeloid neoplasm', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT01885897,Phase Ib/II,Recruiting,"Masonic Cancer Center, University of Minnesota ","[{'id': 3060, 'therapyName': 'ALT-803'}]",IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT,11/05/2015,[],yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01885949,Phase II,"Active, not recruiting",Massachusetts General Hospital ,"[{'id': 2395, 'therapyName': 'Enzalutamide + Tivozanib'}]",Tivozanib + Enzalutamide in Adv Prostate Cancer,10/21/2015,[],no
0,both,"[{'id': 1039, 'name': 'prolymphocytic leukemia', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT01886859,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 3580, 'therapyName': 'Ibrutinib + lenalidomide'}]",Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,09/09/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01887717,Phase III,"Active, not recruiting",BTG International Inc. ,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein,05/20/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01887886,Phase III,Completed,Hoffmann-La Roche,"[{'id': 1280, 'therapyName': 'Onartuzumab + Erlotinib'}]",A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating EGFR Mutation,09/03/2015,"[{'molecularProfile': {'id': 1240, 'profileName': 'MET positive'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT01888302,Phase I,Completed,Mayo Clinic ,"[{'id': 2289, 'therapyName': 'Cisplatin + Gemcitabine + Sirolimus '}]","Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery",06/22/2016,[],no
0,female,"[{'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}]",NCT01888562,Phase I,Withdrawn,Washington University School of Medicine ,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma,12/19/2015,"[{'molecularProfile': {'id': 816, 'profileName': 'FGFR2 C382R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1691, 'profileName': 'FGFR2 S373C'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3430, 'profileName': 'FGFR2 S252W'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3432, 'profileName': 'FGFR2 Y376C'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1219, 'profileName': 'FGFR2 act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 3427, 'profileName': 'FGFR2 N550H'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3413, 'profileName': 'FGFR2 K660E'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3429, 'profileName': 'FGFR2 P253R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3428, 'profileName': 'FGFR2 N550K'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT01888965,Phase II,Terminated,Georgetown University|Novartis,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Maintenance Dovitinib for Colorectal and Pancreas Cancer,08/18/2015,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01889186,Phase II,"Active, not recruiting","AbbVie, Genentech, Inc.","[{'id': 1562, 'therapyName': 'Venetoclax'}]",A Study of the Efficacy of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia With the 17p Deletion,05/28/2015,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01889420,Phase I,Terminated,New Mexico Cancer Care Alliance ,"[{'id': 2312, 'therapyName': 'Pomalidomide + Everolimus + Dexamethasone'}]","Phase I Trial of Everolimus, Pomalidomide and Dexamethasone Patients With Relapsed/Refractory Multiple Myeloma",08/01/2015,[],no
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT01890980,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 2893, 'therapyName': 'WT1 vaccine'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134,02/06/2016,[],yes
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT01891344,Phase II,"Active, not recruiting","Clovis Oncology, Inc. ","[{'id': 906, 'therapyName': 'Rucaparib'}]","A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)",07/08/2016,[],no
0,both,"[{'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}, {'id': 3187, 'name': 'brain oligodendroglioma', 'source': 'DOID'}, {'id': 3073, 'name': 'brain glioblastoma multiforme', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01891747,Phase Ib/II,"Active, not recruiting",Vanderbilt-Ingram Cancer Center,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]", A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma,12/22/2015,"[{'molecularProfile': {'id': 576, 'profileName': 'IDH1 wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT01892046,Phase I,Completed,Esanex Inc. ,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 866, 'therapyName': 'SNX-5422'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors,07/27/2017,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01892371,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",AC220 With 5-Aza or Low Dose Cytarabine,12/01/2015,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT01893320,Phase Ib/II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1766, 'therapyName': 'Decitabine + Vosaroxin'}]",Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome,06/17/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT01894061,Phase II,Recruiting,Case Comprehensive Cancer Center ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma,02/19/2015,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01894451,Phase I,Recruiting,Dana-Farber Cancer Institute ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy,07/23/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01894672,Phase II,Completed,Memorial Sloan-Kettering Cancer Center,"[{'id': 796, 'therapyName': 'Encorafenib'}]","BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation",04/12/2016,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT01895842,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center|Incyte Corporation,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS),02/10/2017,"[{'molecularProfile': {'id': 1181, 'profileName': 'JAK2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT01896531,Phase II,"Active, not recruiting","Genentech, Inc. ","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer,11/11/2016,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}]",NCT01896856,Phase Ib/II,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 2015, 'therapyName': 'SGI-110 + Irinotecan'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer,02/06/2015,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01896869,Phase II,Suspended,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 1903, 'therapyName': 'FOLFIRINOX'}, {'id': 779, 'therapyName': 'Ipilimumab'}]","A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer",03/25/2017,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT01896999,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 2487, 'therapyName': 'Brentuximab vedotin + Ipilimumab'}]",Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,12/01/2015,[],no
0,both,"[{'id': 8584, 'name': 'Burkitt lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT01897012,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1075, 'therapyName': 'romidepsin'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas,12/08/2015,[],yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01897116,Phase I,"Active, not recruiting",Abramson Cancer Center of the University of Pennsylvania,"[{'id': 1281, 'therapyName': 'Vemurafenib + Hydroxychloroquine'}]", A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma,01/26/2016,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT01897441,Phase I,Recruiting,Albert Einstein College of Medicine of Yeshiva University ,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer,01/28/2015,[],no
0,both,[],NCT01897571,Phase Ib/II,Recruiting,"Epizyme, Inc. ",[],Study of EPZ-6438 Formerly Known as E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas,08/10/2015,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01898078,Phase I,"Active, not recruiting","Millennium Pharmaceuticals, Inc.","[{'id': 626, 'therapyName': 'Alisertib'}]", Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas,02/26/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01898130,Phase II,"Active, not recruiting",Northwestern University,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy,04/26/2017,[],no
0,both,"[{'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT01898494,Phase II,"Active, not recruiting",Eastern Cooperative Oncology Group ,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer,07/12/2017,"[{'molecularProfile': {'id': 1974, 'profileName': 'CDKN2A positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 2513, 'name': 'basal cell carcinoma', 'source': 'DOID'}]",NCT01898598,Phase II,Terminated,Hoffmann-La Roche,"[{'id': 956, 'therapyName': 'Vismodegib'}]",A Study of Vismodegib With Surgery in Patients With Previously Untreated Basal Cell Carcinoma,05/09/2017,[],no
0,both,"[{'id': 3948, 'name': 'adrenocortical carcinoma', 'source': 'DOID'}]",NCT01898715,Phase I,Recruiting,"Millendo Therapeutics, Inc. ","[{'id': 4296, 'therapyName': 'ATR-101'}]",Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma,06/17/2016,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01898793,Phase Ib/II,Recruiting,Washington University School of Medicine,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 5300, 'therapyName': 'ALT-803 + Cyclophosphamide + Fludarabine phosphate'}]",Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS),05/19/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01899053,Phase I,"Active, not recruiting","Millennium Pharmaceuticals, Inc.","[{'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]",Phase 1b Study of MLN0128 in Combination With MLN1117 in Adult Patients With Advanced Nonhematologic Malignancies,11/11/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01900002,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center ,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC),02/11/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01900652,Phase II,Completed,Eli Lilly and Company,"[{'id': 1179, 'therapyName': 'Emibetuzumab + Erlotinib'}, {'id': 803, 'therapyName': 'Emibetuzumab'}]",A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants,05/25/2016,"[{'molecularProfile': {'id': 1240, 'profileName': 'MET positive'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01901146,Phase III,Completed,Amgen ,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac),02/08/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01902173,Phase Ib/II,Suspended,National Cancer Institute (NCI),"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 2200, 'therapyName': 'Dabrafenib + GSK2141795'}]","GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer",11/05/2016,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60061, 'name': 'cutaneous T cell lymphoma', 'source': 'DOID'}]",NCT01902225,Phase I,Unknown status,Weiyun Ai ,"[{'id': 3393, 'therapyName': 'Doxil + romidepsin '}]",Phase I Dose-finding and Preliminary Efficacy Study of the Istodax in Combination With Doxil for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma,09/06/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT01903330,Phase II,Recruiting,Daniela A. Bota ,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1873, 'therapyName': 'Sargramostim'}]",ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme,07/01/2016,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01903733,Phase I,Recruiting,Pfizer ,"[{'id': 690, 'therapyName': 'Bosutinib'}]",Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008,03/02/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01903993,Phase II,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Randomized Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - &quot;POPLAR&quot;,05/13/2015,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01904123,Phase I,Not yet recruiting,M.D. Anderson Cancer Center ,"[{'id': 2784, 'therapyName': 'WP1066'}]",A Phase I Trial of WP1066,06/05/2015,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01904903,Phase II,Recruiting,Washington Hospital Center,"[{'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cardiac Safety Study in Patients With HER2+ Breast Cancer (SAFE-HEaRt),09/25/2014,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,female,[],NCT01905046,Phase III,Recruiting,Alliance for Clinical Trials in Oncology ,[],Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer,08/10/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT01905228,Phase I,Recruiting,Incuron ,"[{'id': 3940, 'therapyName': 'CBL0137 '}]",A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm or Refractory Lymphomas,04/15/2016,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01905592,Phase III,"Active, not recruiting","Tesaro, Inc. ","[{'id': 832, 'therapyName': 'Niraparib'}]","A Phase III Trial of Niraparib Versus Physician's Choice in Her2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients",04/12/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 285, 'name': 'hairy cell leukemia', 'source': 'DOID'}]",NCT01905813,Phase I,"Active, not recruiting",Incyte Corporation ,"[{'id': 2420, 'therapyName': 'INCB039110 + INCB040093'}, {'id': 2021, 'therapyName': 'INCB040093'}]",Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies,01/15/2016,[],no
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT01907100,Phase III,Recruiting,Boehringer Ingelheim ,"[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib (BIBF 1120) in Mesothelioma,12/03/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01907802,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 3, 'therapyName': 'Dabrafenib'}]",Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction,12/19/2015,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01907815,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia,06/03/2016,"[{'molecularProfile': {'id': 1193, 'profileName': 'KRAS G13X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1194, 'profileName': 'KRAS Q61X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1192, 'profileName': 'KRAS G12X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1208, 'profileName': 'HRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1197, 'profileName': 'NRAS G13X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1198, 'profileName': 'NRAS Q61X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1196, 'profileName': 'NRAS G12X'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT01908413,Phase I,Terminated,"Curis, Inc. ","[{'id': 3639, 'therapyName': 'GDC-0917'}]","Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma",12/02/2016,[],no
0,,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01908426,Phase III,"Active, not recruiting",Exelixis ,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib,10/20/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01908478,Phase I,"Active, not recruiting",Cedars-Sinai Medical Center ,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer",08/27/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01909453,Phase III,"Active, not recruiting",Novartis Pharmaceuticals,"[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 796, 'therapyName': 'Encorafenib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}]",Study Comparing Combination of LGX818 Plus MEK162 and LGX818 Monotherapy Versus Vemurafenib in BRAF Mutant Melanoma,12/22/2015,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01910545,Phase I,Completed,"OncoTherapy Science, Inc. ","[{'id': 3951, 'therapyName': 'OTS167'}]",Phase 1 Study of OTS167 in Patients With Solid Tumors,04/13/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01911325,Phase Ib/II,Terminated,Novartis Pharmaceuticals ,"[{'id': 680, 'therapyName': 'BKM120'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients,11/19/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01911507,Phase I,Recruiting,"University of California, Davis","[{'id': 1284, 'therapyName': 'INCB028060 + Erlotinib'}]",INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer,07/31/2014,"[{'molecularProfile': {'id': 1240, 'profileName': 'MET positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01912625,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 2196, 'therapyName': 'Carboplatin + Paclitaxel + Trametinib'}]","Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery",04/19/2016,"[{'molecularProfile': {'id': 1194, 'profileName': 'KRAS Q61X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1192, 'profileName': 'KRAS G12X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1193, 'profileName': 'KRAS G13X'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01912963,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute,"[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer",08/31/2016,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT01913639,Phase II,"Active, not recruiting",Memorial Sloan-Kettering Cancer Center ,"[{'id': 2014, 'therapyName': 'Regorafenib + FOLFOX'}]",FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer,06/27/2015,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01914484,Phase II,Recruiting,"University Health Network, Toronto|Novartis","[{'id': 1116, 'therapyName': 'Ruxolitinib + Nilotinib'}]",Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia,06/24/2015,[],yes
0,female,"[{'id': 5304, 'name': 'ovarian clear cell adenocarcinoma', 'source': 'DOID'}]",NCT01914510,Phase II,Recruiting,"University Health Network, Toronto","[{'id': 727, 'therapyName': 'ENMD-2076'}]",A Study of ENMD-2076 in Ovarian Clear Cell Cancers,07/28/2014,[],no
0,both,"[{'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}]",NCT01914900,Phase II,Unknown status,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano ","[{'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}]",Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer,06/20/2017,"[{'molecularProfile': {'id': 642, 'profileName': 'TP53 wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT01915498,Phase I,"Active, not recruiting",Celgene Corporation ,"[{'id': 2982, 'therapyName': 'Enasidenib'}]",Phase 1 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation,05/05/2016,"[{'molecularProfile': {'id': 5912, 'profileName': 'IDH2 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01915576,Phase I,Completed,Bayer,"[{'id': 994, 'therapyName': 'BAY1125976'}]",Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients,12/29/2016,"[{'molecularProfile': {'id': 643, 'profileName': 'AKT1 E17K'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT01915602,Phase II,Completed,Bayer,"[{'id': 2221, 'therapyName': 'Refametinib + Sorafenib'}]",Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC),05/16/2017,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT01916109,Phase II,Terminated,Memorial Sloan-Kettering Cancer Center,"[{'id': 1943, 'therapyName': 'Gemcitabine + Carboplatin + Panitumumab'}]","Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer",07/22/2015,[],no
0,both,[],NCT01916135,Phase I,"Active, not recruiting",Memorial Sloan-Kettering Cancer Center,[],"PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative",06/23/2017,[],no
0,both,"[{'id': 3119, 'name': 'gastrointestinal system cancer', 'source': 'DOID'}]",NCT01916447,Phase I,Completed,"Taiho Oncology, Inc. ","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.,10/07/2017,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01918306,Phase Ib/II,Terminated,Vanderbilt-Ingram Cancer Center,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1554, 'therapyName': 'GDC-0941 + Cisplatin'}]",GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer,08/20/2015,[],yes
0,both,[],NCT01918930,Phase I,Terminated,MacroGenics ,[],Tissue Procurement Substudy for Participants in Study CP-MGA271-01,12/24/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01919086,Phase II,"Active, not recruiting",Memorial Sloan Kettering Cancer Center ,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]",Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma,03/31/2017,[],no
0,both,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01920061,Phase I,Recruiting,Pfizer,"[{'id': 1287, 'therapyName': 'PF-05212384 + Dacomitinib'}, {'id': 1286, 'therapyName': 'PF-05212384 + Cisplatin'}, {'id': 1285, 'therapyName': 'PF-05212384 + Docetaxel'}]",A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents,12/12/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01921335,Phase I,"Active, not recruiting",Dana-Farber Cancer Institute,"[{'id': 1560, 'therapyName': 'ARRY-380 + Trastuzumab'}]",Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer,04/05/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01921751,Phase II,Terminated,Radiation Therapy Oncology Group,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery,07/06/2016,[],no
0,both,"[{'id': 4202, 'name': 'brain stem glioma', 'source': 'DOID'}, {'id': 4860, 'name': 'brain stem astrocytic neoplasm', 'source': 'DOID'}]",NCT01922076,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 822, 'therapyName': 'MK-1775'}]",WEE1 Inhibitor MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas,02/10/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01922752,Phase I,Completed,"Teva Branded Pharmaceutical Products, R&D Inc","[{'id': 2147, 'therapyName': 'CEP-37440'}]",To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors,12/10/2015,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01922921,Phase Ib/II,"Active, not recruiting",University of Washington,"[{'id': 1556, 'therapyName': 'HER-2/neu intracellular domain protein + Trastuzumab '}, {'id': 1558, 'therapyName': 'HER-2/neu intracellular domain protein + Trastuzumab + Polysaccharide-K'}]",Vaccine Therapy and Trastuzumab With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer,10/03/2017,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01923168,Phase II,Completed,Novartis Pharmaceuticals,"[{'id': 1570, 'therapyName': 'BKM120 + Letrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]","Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women",08/01/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01923337,Phase I,"Active, not recruiting","University of California, Davis","[{'id': 1288, 'therapyName': 'Irinotecan + Alisertib'}]",Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer,02/19/2016,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01924260,Phase I,"Active, not recruiting","University of California, Davis","[{'id': 1289, 'therapyName': 'Alisertib + Gemcitabine'}]",Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer,05/02/2017,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01924351,Phase II,Withdrawn,University of Maryland,[],HER2-positive Breast Cancer With Brain Metastasis (GCC 1345),06/09/2016,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT01925131,Phase I,Recruiting,Southwest Oncology Group ,"[{'id': 3221, 'therapyName': 'Cyclophosphamide + Prednisone + Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]","S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia",11/16/2015,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT01925573,Phase I,Recruiting,University of Maryland ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",NOVOTTF-100A+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344),02/19/2015,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT01926587,Phase Ib/II,Recruiting,"Onconova Therapeutics, Inc. ","[{'id': 2320, 'therapyName': 'Azacitidine + Regorafenib'}]",Oral Rigosertib in Combination With Azacitidine,04/18/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01927341,Phase Ib/II,Completed,Novartis Pharmaceuticals,"[{'id': 807, 'therapyName': 'Binimetinib'}, {'id': 845, 'therapyName': 'Panitumumab'}]","Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors",03/12/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01927627,Phase II,"Active, not recruiting",Case Comprehensive Cancer Center ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in Patients With High-risk Prostate Cancer,07/09/2015,[],no
0,both,"[{'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}]",NCT01927744,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 2474, 'therapyName': 'Erlotinib + Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","Study of Chemotherapy With Cisplatin/CarboplatinAstellas Pharma Inc, OSI Pharmaceuticals, Kadoorie Foundation, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection",06/02/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01928160,Phase II,Withdrawn,Vanderbilt-Ingram Cancer Center,"[{'id': 1290, 'therapyName': 'Erlotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1291, 'therapyName': 'Erlotinib + Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1292, 'therapyName': 'Erlotinib + Cisplatin'}]",Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib,07/14/2015,"[{'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5041, 'name': 'esophageal cancer', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}]",NCT01928290,Phase II,Recruiting,Washington University School of Medicine ,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]","Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer",01/28/2015,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}]",NCT01928394,Phase Ib/II,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors",10/20/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01928459,Phase I,Completed,Novartis Pharmaceuticals,"[{'id': 1293, 'therapyName': 'BGJ398 + BYL719'}]",Phase 1b Trial of BGJ398/BYL719 in Solid Tumors,01/13/2017,"[{'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1185, 'profileName': 'FGFR2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1221, 'profileName': 'FGFR1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT01928537,Phase III,"Active, not recruiting","Onconova Therapeutics, Inc. ","[{'id': 1046, 'therapyName': 'rigosertib'}]",Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine,02/24/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01928576,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1541, 'therapyName': 'Entinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]",Phase II Anti-PD1 Epigenetic Priming Study in NSCLC.,05/07/2015,[],no
0,female,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT01928589,Phase Ib/II,Recruiting,Sidney Kimmel Comprehensive Cancer Center,[],Partial Breast Irradiation With Concurrent Chemotherapy for Women With Breast Cancer,01/29/2015,[],yes
0,both,[],NCT01929642,Phase II,Completed,"Hugo W. Moser Research Institute at Kennedy Krieger, Inc. ",[],Rapalogues for Autism Phenotype in TSC A Feasibility Study (RAPT),09/09/2016,[],no
0,both,"[{'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01931098,Phase II,Not yet recruiting,M.D. Anderson Cancer Center ,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase II Pazopanib Plus Topotecan for Recurrent Glioblastoma Multiforme (GBM),12/25/2015,[],no
0,both,[],NCT01931150,Phase III,Completed,Memorial Sloan-Kettering Cancer Center,[],Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT,09/15/2015,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT01931163,Phase II,Recruiting,The Methodist Hospital System ,"[{'id': 735, 'therapyName': 'Everolimus'}]",NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer,12/02/2016,[],yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01933815,Phase Ib/II,Recruiting,"Cortice Biosciences, Inc. ","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2274, 'therapyName': 'TPI 287'}]",Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma,03/03/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01933932,Phase III,"Active, not recruiting",AstraZeneca,"[{'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}]",Assess Efficacy and Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC,01/28/2016,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'required'}]",yes
0,both,[],NCT01933945,,"Active, not recruiting",Bayer ,[],"Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib",05/26/2016,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01934335,Phase I,Recruiting,NCT01934335,"[{'id': 953, 'therapyName': 'Vandetanib'}]",Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer,09/30/2014,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01934361,Phase Ib/II,Completed,Novartis Pharmaceuticals ,"[{'id': 2500, 'therapyName': 'BKM120 + Lomustine'}, {'id': 2501, 'therapyName': 'BKM120 + Carboplatin'}]",Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme,08/11/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01934894,Phase II,Terminated,"SCRI Development Innovations, LLC ","[{'id': 1572, 'therapyName': 'Cabazitaxel + Lapatinib'}]",Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases,06/03/2017,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1324, 'name': 'lung cancer', 'source': 'DOID'}]",NCT01935336,Phase II,Recruiting,"University of Colorado, Denver ","[{'id': 877, 'therapyName': 'Ponatinib'}]",Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers,05/16/2016,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 2882, 'profileName': 'RET positive'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 2596, 'name': 'larynx cancer', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT01935921,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1926, 'therapyName': 'Cetuximab + Ipilimumab'}]","Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer",10/14/2016,[],no
0,female,"[{'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}]",NCT01935934,Phase II,Suspended,National Cancer Institute (NCI),"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer,07/08/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01935947,Phase II,Terminated,National Cancer Institute (NCI),"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2645, 'therapyName': 'Azacitidine + Entinostat'}, {'id': 2646, 'therapyName': 'Docetaxel + Irinotecan + Pemetrexed '}]",Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer,04/15/2017,[],no
0,female,"[{'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}]",NCT01935973,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer,08/12/2015,[],no
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT01936974,Phase II,Terminated,Western Regional Medical Center,"[{'id': 1295, 'therapyName': 'Gemcitabine + Bevacizumab + Cisplatin'}, {'id': 1296, 'therapyName': 'Gemcitabine + Bevacizumab + Oxaliplatin'}, {'id': 1294, 'therapyName': 'Gemcitabine + Bevacizumab + Carboplatin'}, {'id': 1297, 'therapyName': 'Gemcitabine + Bevacizumab'}]","(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma",09/29/2017,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01937117,Phase II,"Active, not recruiting",Sidney Kimmel Comprehensive Cancer Center,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer,09/30/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01937715,Phase II,Terminated,Pfizer,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer,12/01/2015,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 481, 'profileName': 'NRAS wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4007, 'name': 'bladder carcinoma', 'source': 'DOID'}]",NCT01938573,Phase Ib/II,Completed,University of Washington ,"[{'id': 2289, 'therapyName': 'Cisplatin + Gemcitabine + Sirolimus '}]","Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer",03/15/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}]",NCT01938638,Phase I,Completed,Bayer,"[{'id': 4027, 'therapyName': 'BAY1143572'}]",Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer,11/24/2016,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}]",NCT01939223,Phase III,Completed,Bayer ,"[{'id': 890, 'therapyName': 'Regorafenib'}]","COlorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo?Controlled Phase-III STudy (COAST)",10/14/2016,[],no
0,both,[],NCT01939275,Phase I,Recruiting,City of Hope Medical Center,[],64Cu DOTA-Trastuzumab PET in Studying Patients With Gastric Cancer,02/10/2015,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}]",NCT01940172,Phase I,Completed,TetraLogic Pharmaceuticals ,"[{'id': 1458, 'therapyName': 'Conatumumab'}, {'id': 2647, 'therapyName': 'Birinapant  '}]",Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer,01/15/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01940276,Phase II,"Active, not recruiting",Duke University ,"[{'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer,10/26/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01940809,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 779, 'therapyName': 'Ipilimumab'}]","Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed By Surgery",05/13/2017,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01941927,Phase II,Unknown status,Adil Daud,"[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib With GSK2141795 in BRAF Wild-type Melanoma,06/20/2017,"[{'molecularProfile': {'id': 1241, 'profileName': 'NRAS BRAF wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01942837,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling,06/30/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01942993,Phase II,Terminated,Philip Friedlander,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma,03/19/2016,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01943422,Phase Ib/II,"Active, not recruiting",John Kirkwood,"[{'id': 1300, 'therapyName': 'Vemurafenib + Interferon alfa-2b'}]",Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma,02/10/2017,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01943682,Phase I,Recruiting,"Children's Hospital Medical Center, Cincinnati ","[{'id': 4341, 'therapyName': 'CPX-351'}]",Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma,07/01/2016,[],no
0,both,"[{'id': 712, 'name': 'refractory hematologic cancer', 'source': 'DOID'}]",NCT01943851,Phase I,Recruiting,GlaxoSmithKline ,"[{'id': 784, 'therapyName': 'GSK525762'}]","A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies",04/24/2015,[],no
0,both,"[{'id': 3459, 'name': 'breast carcinoma', 'source': 'DOID'}]",NCT01945775,Phase III,"Active, not recruiting",BioMarin Pharmaceutical ,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 682, 'therapyName': 'Talazoparib'}, {'id': 728, 'therapyName': 'Eribulin'}]","A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)",09/13/2017,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01946204,Phase III,"Active, not recruiting","Aragon Pharmaceuticals, Inc.","[{'id': 1947, 'therapyName': 'ARN-509'}]",A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer,12/28/2016,[],no
0,both,"[{'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT01946529,Phase II,"Active, not recruiting",St. Jude Children's Research Hospital,"[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 1434, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide + others'}]",Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors,04/22/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01946789,Phase I,Recruiting,Altor Bioscience Corporation ,"[{'id': 3060, 'therapyName': 'ALT-803'}]",A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors,09/04/2015,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT01947023,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 2478, 'therapyName': 'Dabrafenib + Lapatinib'}]",Dabrafenib and Lapatinib Ditosylate in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery,05/06/2016,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01947608,Phase I,Available,Novartis Pharmaceuticals ,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC,05/08/2015,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}]",NCT01948141,Phase II,Completed,Roswell Park Cancer Institute ,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens,06/09/2017,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01948297,Phase I,Recruiting,Debiopharm International SA ,"[{'id': 1014, 'therapyName': 'FF-284'}]",Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations,08/23/2017,"[{'molecularProfile': {'id': 2969, 'profileName': 'FGFR2 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3147, 'profileName': 'FGFR2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14910, 'profileName': 'FGFR1 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 812, 'profileName': 'FGFR1 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1185, 'profileName': 'FGFR2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3329, 'profileName': 'FGFR3 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1221, 'profileName': 'FGFR1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14903, 'profileName': 'FGFR3 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}, {'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT01949194,Phase II,Recruiting,Gerald Batist ,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers,02/02/2015,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01949337,Phase III,"Active, not recruiting",Alliance for Clinical Trials in Oncology ,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer,11/02/2016,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT01949883,Phase I,Recruiting,Constellation Pharmaceuticals ,"[{'id': 2033, 'therapyName': 'CPI-0610'}]",A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma,12/11/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01950195,Phase I,Terminated,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",SRS (Stereotactic Radiosurgery) Plus Ipilimumab,11/17/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01950390,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1301, 'therapyName': 'Ipilimumab + Bevacizumab'}]",Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot be Removed by Surgery,09/29/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01951690,Phase II,Completed,"Verastem, Inc.","[{'id': 958, 'therapyName': 'VS-6063'}]",Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer,02/08/2017,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 3459, 'name': 'breast carcinoma', 'source': 'DOID'}]",NCT01952054,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1198, 'therapyName': 'Denosumab'}]",Denosumab for Breast Cancer With Bone Mets,02/15/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT01952249,Phase Ib/II,Completed,"OncoMed Pharmaceuticals, Inc. ","[{'id': 2007, 'therapyName': 'Demcizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian,09/21/2016,[],no
0,,[],NCT01952847,,"Active, not recruiting",,[],Randomized Trial of Glutamine in Patients With Mucositis or Esophagitis,10/26/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01953588,Phase III,Recruiting,Alliance for Clinical Trials in Oncology ,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery,09/17/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01953692,Phase I,"Active, not recruiting",Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013),09/12/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01953926,Phase II,Recruiting,"Puma Biotechnology, Inc.","[{'id': 828, 'therapyName': 'Neratinib'}]","An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification",07/31/2014,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1243, 'profileName': 'ERBB2 act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 447, 'profileName': 'EGFR amp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT01954030,Phase Ib/II,Terminated,Annick Desjardins ,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure,02/20/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01954043,Phase I,Completed,GlaxoSmithKline,"[{'id': 1302, 'therapyName': 'Dabrafenib + Rabeprazole + Rifampin'}]",A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors,04/26/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01954316,Phase I,Recruiting,"University Health Network, Toronto ","[{'id': 4029, 'therapyName': 'CFI-400945'}]",A Study of CFI-400945 Fumarate in Patients With Advanced Cancer,04/29/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3073, 'name': 'brain glioblastoma multiforme', 'source': 'DOID'}]",NCT01954576,Phase II,Recruiting,Washington University School of Medicine,[],NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme,08/05/2017,[],no
0,both,"[{'id': 4905, 'name': 'pancreatic carcinoma', 'source': 'DOID'}]",NCT01954732,Phase I,Withdrawn,Case Comprehensive Cancer Center,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery,03/17/2015,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01954784,Phase I,Terminated,Case Comprehensive Cancer Center ,"[{'id': 3434, 'therapyName': 'Bortezomib + Cyclosporine + Mycophenolate'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma,02/18/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01955434,Phase II,Recruiting,Mayo Clinic,"[{'id': 4019, 'therapyName': 'Cyclophosphamide + LCL161'}]",SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma,04/29/2016,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}]",NCT01955499,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 3580, 'therapyName': 'Ibrutinib + lenalidomide'}]",Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,09/02/2016,[],no
0,both,"[{'id': 687, 'name': 'hepatoblastoma', 'source': 'DOID'}, {'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}, {'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT01956669,Phase II,Recruiting,GlaxoSmithKline,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors,11/17/2014,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01956812,Phase III,Terminated,"Immunomedics, Inc. ","[{'id': 3000, 'therapyName': 'Y90 clivatuzumab tetraxetan'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer (PANCRIT-1),03/19/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01957007,Phase I,Completed,"OncoMed Pharmaceuticals, Inc. ","[{'id': 4413, 'therapyName': 'Docetaxel + Vantictumab'}]",A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC,07/28/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01958021,Phase III,"Active, not recruiting", Novartis Pharmaceuticals ,"[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 794, 'therapyName': 'Letrozole'}]",Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2),11/18/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}]",NCT01958112,Phase II,Terminated,Dana-Farber Cancer Institute ,"[{'id': 1150, 'therapyName': 'GSK1120212 + GSK2141795'}]",GSK1120212+GSK2141795 for Cervical Cancer,08/13/2016,[],no
0,female,"[{'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}]",NCT01958658,Phase I,Suspended,National Cancer Institute (NCI),"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]","AZD1775, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer",05/19/2016,[],no
0,female,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT01959490,Phase II,Completed,Case Comprehensive Cancer Center,"[{'id': 1486, 'therapyName': 'Bevacizumab + Doxorubicin + Cyclophosphamide + Paclitaxel '}, {'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}]",Trastuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer,08/08/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT01959672,Phase II,Recruiting,University of Nebraska ,"[{'id': 827, 'therapyName': 'Nelfinavir'}, {'id': 1189, 'therapyName': 'Oregovomab'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer,08/05/2015,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT01959698,Phase Ib/II,Recruiting,Roswell Park Cancer Institute ,"[{'id': 2351, 'therapyName': 'Carfilzomib + Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}]","Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma",03/11/2015,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01960023,Phase Ib/II,"Active, not recruiting",National Surgical Adjuvant Breast and Bowel Project (NSABP),"[{'id': 1118, 'therapyName': 'Cetuximab + Neratinib'}]",Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer,02/20/2016,"[{'molecularProfile': {'id': 430, 'profileName': 'PIK3CA wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 481, 'profileName': 'NRAS wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 4, 'profileName': 'BRAF wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01961115,Phase II,"Active, not recruiting",Fred Hutchinson Cancer Research Center ,"[{'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 3016, 'therapyName': 'MELITAC 12.1 Peptide Vaccine '}]",INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma,01/24/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT01961765,Phase I,Completed,Massachusetts General Hospital ,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia,07/22/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01961843,Phase I,"Active, not recruiting",Massachusetts General Hospital ,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Abiraterone Acetate for Castrate Resistant Prostate Cancer,03/21/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01962792,Phase Ib/II,Recruiting,Pharmacyclics ,"[{'id': 3282, 'therapyName': 'Carfilzomib + Ibrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma",12/29/2015,[],no
0,both,"[{'id': 2994, 'name': 'germ cell cancer', 'source': 'DOID'}]",NCT01962896,Phase II,Recruiting,Theodore Laetsch ,"[{'id': 2253, 'therapyName': 'Erlotinib + Sirolimus'}]",A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors,03/02/2015,[],no
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT01962948,Phase II,"Active, not recruiting",Fox Chase Cancer Center ,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 745, 'therapyName': 'Ganetespib'}]","Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",03/05/2016,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01963481,Phase II,Completed,New York University School of Medicine ,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 738, 'therapyName': 'Exemestane'}]",Exemestane and Cyclophosphamide for Metastatic Breast Cancer,10/19/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3840, 'name': 'craniopharyngioma', 'source': 'DOID'}]",NCT01964300,Phase II,Recruiting,Pediatric Brain Tumor Consortium ,"[{'id': 2624, 'therapyName': 'peginterferon alfa-2b'}]",Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery,10/30/2016,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT01964924,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer,03/07/2017,[],yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01965353,Phase I,"Active, not recruiting",Dana-Farber Cancer Institute ,"[{'id': 3362, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide + Panobinostat'}]",A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma,02/08/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01966003,Phase III,Completed,Amgen,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2141, 'therapyName': 'Bevacizumab-awwb'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer,09/19/2015,[],no
0,both,"[{'id': 219, 'name': 'colon cancer', 'source': 'DOID'}, {'id': 1993, 'name': 'rectum cancer', 'source': 'DOID'}]",NCT01966289,Phase I,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1949, 'therapyName': 'SGI-110'}, {'id': 2977, 'therapyName': 'GVAX colorectal cancer vaccine'}]",SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC),07/29/2015,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 9036, 'name': 'parotid gland cancer', 'source': 'DOID'}, {'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}, {'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01966445,Phase I,Completed,GlaxoSmithKline ,"[{'id': 2919, 'therapyName': 'GSK2849330'}]","Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors",10/19/2017,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01966471,Phase III,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}, {'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}]",A Study of Kadcyla (Trastuzumab Emtansine) Plus Perjeta (Pertuzumab) Following Anthracyclines in Comparison With Herceptin (Trastuzumab) Plus Perjeta and a Taxane Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer,11/21/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01967095,Phase I,"Active, not recruiting",Memorial Sloan-Kettering Cancer Center,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer,11/26/2016,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50773, 'name': 'paraganglioma', 'source': 'DOID'}, {'id': 5719, 'name': 'adrenal medulla cancer', 'source': 'DOID'}]",NCT01967576,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 649, 'therapyName': 'Axitinib'}]","Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma",08/11/2015,[],no
0,both,"[{'id': 60108, 'name': 'brain glioma', 'source': 'DOID'}]",NCT01967810,Phase II,Completed,Angiochem Inc ,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2053, 'therapyName': 'GRN1005'}]",ANG1005 in Patients With Recurrent High-Grade Glioma,09/29/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}]",NCT01968109,Phase I,Recruiting,Bristol-Myers Squibb,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors,06/05/2016,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT01968213,Phase III,"Active, not recruiting","Clovis Oncology, Inc. ","[{'id': 906, 'therapyName': 'Rucaparib'}]","A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer",07/08/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT01969643,Phase I,Recruiting,"Seattle Genetics, Inc. ","[{'id': 3615, 'therapyName': 'SGN-LIV1A '}]",A Safety Study of SGN-LIV1A in Breast Cancer Patients,02/25/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01970358,Phase I,Recruiting,Dana-Farber Cancer Institute ,"[{'id': 3006, 'therapyName': 'NeoVax melanoma vaccine'}]",A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma,08/11/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01970527,Phase II,Recruiting,University of Washington ,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma,07/30/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01970865,Phase Ib/II,Recruiting,Pfizer ,"[{'id': 869, 'therapyName': 'PF-06463922'}, {'id': 706, 'therapyName': 'Crizotinib'}]",A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations,08/30/2015,"[{'molecularProfile': {'id': 11085, 'profileName': 'ROS1 rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}]",yes
0,,[],NCT01970930,,Recruiting,,[],Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV &amp; ET) Patients,02/25/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01971489,Phase I,Withdrawn,Roswell Park Cancer Institute,"[{'id': 1304, 'therapyName': 'BKM120 + Gemcitabine + Cisplatin'}]","PI3K Inhibitor BKM120, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors",08/14/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01971515,Phase I,Recruiting,EMD Serono,"[{'id': 1037, 'therapyName': 'MSC2363318A'}]",First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies,12/02/2016,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1209, 'profileName': 'AKT1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1213, 'profileName': 'PTEN mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'excluded'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01972217,Phase II,"Active, not recruiting",AstraZeneca ,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 837, 'therapyName': 'Olaparib'}]",Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer,08/14/2015,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT01972516,Phase II,Terminated,Dana-Farber Cancer Institute ,"[{'id': 1055, 'therapyName': 'Tivozanib'}]",Tivozanib As Maintenance Therapy In GYN,08/11/2015,[],no
0,female,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT01973309,Phase I,"Active, not recruiting","OncoMed Pharmaceuticals, Inc. ","[{'id': 4398, 'therapyName': 'Vantictumab + Paclitaxel'}]",A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer,05/31/2017,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01973868,Phase I,"Active, not recruiting",Bayer,"[{'id': 1305, 'therapyName': 'Regorafenib + Cetuximab'}]",Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination,10/06/2016,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT01974258,Phase I,Withdrawn,Hoffmann-La Roche,"[{'id': 1306, 'therapyName': 'Onartuzumab + Vemurafenib'}, {'id': 1307, 'therapyName': 'Onartuzumab + Cobimetinib'}, {'id': 1308, 'therapyName': 'Onartuzumab + Cobimetinib + Vemurafenib'}]","Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients",08/03/2016,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}]",NCT01974440,Phase III,"Active, not recruiting","Janssen Research & Development, LLC ","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}]","A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",12/23/2015,[],no
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT01974752,Phase III,Completed,AstraZeneca,"[{'id': 1432, 'therapyName': 'Selumetinib + Dacarbazine'}]",Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT),01/06/2017,[],no
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT01974765,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies",04/22/2015,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT01975519,Phase I,"Active, not recruiting",Tracon Pharmaceuticals Inc.,"[{'id': 1431, 'therapyName': 'TRC105 + Pazopanib'}]",A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma,09/12/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01975701,Phase II,"Active, not recruiting",Novartis Pharmaceuticals ,"[{'id': 674, 'therapyName': 'BGJ398'}]",A Phase 2 Study of BGJ398 in Patients With Recurrent GBM,10/07/2016,"[{'molecularProfile': {'id': 1217, 'profileName': 'FGFR3 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3329, 'profileName': 'FGFR3 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 812, 'profileName': 'FGFR1 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1276, 'profileName': 'FGFR1 rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3147, 'profileName': 'FGFR2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1318, 'profileName': 'FGFR3 rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1317, 'profileName': 'FGFR2 rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1218, 'profileName': 'FGFR1 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1219, 'profileName': 'FGFR2 act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01975831,Phase I,"Active, not recruiting",Ludwig Institute for Cancer Research ,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab,02/17/2017,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01976169,Phase I,Recruiting,University of Texas Southwestern Medical Center|Pfizer|University of Pennsylvania,"[{'id': 1731, 'therapyName': 'PD-0332991 + T-DM1'}]",Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1),11/19/2014,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 2007, 'profileName': 'RB1 loss'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 8691, 'name': 'mycosis fungoides', 'source': 'DOID'}, {'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}, {'id': 60061, 'name': 'cutaneous T cell lymphoma', 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT01976585,Phase Ib/II,Recruiting,Joshua Brody ,"[{'id': 4337, 'therapyName': 'CDX-301 + poly ICLC '}]",In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy,07/14/2016,[],no
0,both,"[{'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}, {'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}, {'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01976741,Phase I,Recruiting,Bayer ,"[{'id': 2030, 'therapyName': 'Rogaratinib'}]",Phase I Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor,09/25/2017,"[{'molecularProfile': {'id': 1217, 'profileName': 'FGFR3 act mut'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01977651,FDA approved,"Active, not recruiting","Astellas Pharma Global Development, Inc.","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide,11/21/2015,[],no
0,both,"[{'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01977677,Phase Ib/II,"Active, not recruiting",Stanford University ,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1756, 'therapyName': 'Plerixafor'}]",Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma,07/29/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01978236,Phase II,Completed,GlaxoSmithKline,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}]","Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",09/29/2017,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT01979211,Phase II,Recruiting,University of Cincinnati ,"[{'id': 694, 'therapyName': 'Cetuximab'}]",Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck,01/29/2015,[],no
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT01979523,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma,03/09/2017,[],no
0,both,"[{'id': 50744, 'name': 'anaplastic large cell lymphoma', 'source': 'DOID'}]",NCT01979536,Phase II,Suspended,National Cancer Institute (NCI),"[{'id': 706, 'therapyName': 'Crizotinib'}]",Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma,04/07/2017,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01980823,Phase I,Recruiting,Kevin Kalinsky,"[{'id': 1576, 'therapyName': 'Atorvastatin + Metformin'}]",Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer,09/30/2014,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01980875,Phase III,Terminated,Gilead Sciences ,"[{'id': 1647, 'therapyName': 'Idelalisib + Obinutuzumab'}, {'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}]",Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia,05/20/2016,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT01980888,Phase III,Terminated,Gilead Sciences ,"[{'id': 2324, 'therapyName': 'Bendamustine + Idelalisib + Rituximab'}]",Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia,06/29/2016,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01981187,Phase II,Completed,Novartis Pharmaceuticals,"[{'id': 796, 'therapyName': 'Encorafenib'}]",LGX818 for Patients With BRAFV600 Mutated Tumors,03/12/2016,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,[],NCT01981525,,Completed,,"[{'id': 1031, 'therapyName': 'Metformin'}]",A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome,04/26/2017,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3355, 'name': 'fibrosarcoma', 'source': 'DOID'}]",NCT01981551,Phase II,"Active, not recruiting",National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI),"[{'id': 859, 'therapyName': 'PF-03084014'}]",Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis,09/11/2014,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT01982448,Phase II,Recruiting,Dana-Farber Cancer Institute ,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin vs Paclitaxel for Triple Neg,08/05/2015,[],yes
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01983501,Phase I,"Active, not recruiting",Oncothyreon Inc.,"[{'id': 1573, 'therapyName': 'ARRY-380 + Trastuzumab emtansine'}]",A Phase 1b Study of ONT-380 Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer,09/04/2015,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT01983969,Phase Ib/II,"Active, not recruiting",M.D. Anderson Cancer Center ,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 2557, 'therapyName': 'Azacitidine + Gemcitabine + vorinostat'}]",Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma,06/19/2015,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT01984242,Phase II,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma,05/13/2015,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT01985256,Phase I,"Active, not recruiting",Tocagen Inc. ,"[{'id': 3209, 'therapyName': 'Toca 511'}]",Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor,02/26/2016,[],no
0,,[],NCT01985334,,Completed,,[],Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen,09/22/2016,[],no
0,both,"[{'id': 1520, 'name': 'colon carcinoma', 'source': 'DOID'}, {'id': 1993, 'name': 'rectum cancer', 'source': 'DOID'}]",NCT01985763,Phase Ib/II,Completed,Randall F. Holcombe ,"[{'id': 757, 'therapyName': 'Genistein'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Genistein in Treatment of Metastatic Colorectal Cancer,02/08/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01986166,Phase I,Completed,Genentech,"[{'id': 1342, 'therapyName': 'MEHD7945A + Cobimetinib'}]",A Study of MEHD7945A and Cobimetinib (GDC-0973) in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS,07/19/2016,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01986348,Phase II,"Active, not recruiting","Karyopharm Therapeutics, Inc ","[{'id': 1749, 'therapyName': 'Selinexor'}]",Phase 2 Study of Selinexor (KPT-330) in Patients With Recurrent Glioblastoma After Failure of Radiation and Temozolomide,04/05/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60463, 'name': 'NUT midline carcinoma', 'source': 'DOID'}]",NCT01987362,Phase I,"Active, not recruiting",Tensha Therapeutics ,"[{'id': 937, 'therapyName': 'TEN-010'}]","A Two Part, Multicenter, Open-label Study of TEN-010 Given Subcutaneously",04/06/2017,[],no
0,both,[],NCT01987375,Phase I,Suspended,University of Alabama at Birmingham ,[],Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures,07/18/2017,[],no
0,,[],NCT01987726,Phase I,"Active, not recruiting",Ohio State University Comprehensive Cancer Center,[],Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors,02/08/2017,[],no
0,both,[],NCT01987830,,Recruiting,Massachusetts General Hospital,[],Bevacizumab w / Temozolomide PET &amp; Vascular MRI For GBM,02/24/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01988896,Phase I,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Phase 1b Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors,10/19/2016,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01989052,Phase Ib/II,Terminated,Annick Desjardins ,"[{'id': 2075, 'therapyName': 'Lomustine'}, {'id': 999, 'therapyName': 'Carboxyamidotriazole Orotate'}]",Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma,06/17/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01989546,Phase Ib/II,Completed,National Cancer Institute (NCI),"[{'id': 682, 'therapyName': 'Talazoparib'}]","Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations",06/20/2017,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01989585,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 1303, 'therapyName': 'Trametinib + Dabrafenib + Navitoclax'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","Dabrafenib, Trametinib, and Navitoclax in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery",06/19/2017,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01989598,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1298, 'therapyName': 'Trametinib + GSK2141795'}]",Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma,07/28/2016,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT01989676,Phase III,"Active, not recruiting",Pfizer,"[{'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02),03/15/2017,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01990196,Phase II,Recruiting,Jonsson Comprehensive Cancer Center,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 1815, 'therapyName': 'Degarelix + Enzalutamide'}]",Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer,12/19/2014,[],no
0,both,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 60077, 'name': 'progesterone-receptor positive breast cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT01990209,Phase II,Recruiting,"SCRI Development Innovations, LLC ","[{'id': 2671, 'therapyName': 'Orteronel '}]",Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR),06/20/2016,[],yes
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT01990352,Phase II,Suspended,University of Arizona,"[{'id': 1008, 'therapyName': 'Doxil'}]",Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy,05/26/2017,[],no
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT01991210,Phase II,Terminated,"Genentech, Inc. ","[{'id': 1345, 'therapyName': 'DNIB0600A'}, {'id': 1008, 'therapyName': 'Doxil'}]",A Randomized Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer,08/22/2017,[],no
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}]",NCT01991379,Phase Ib/II,Recruiting,Memorial Sloan-Kettering Cancer Center,"[{'id': 1430, 'therapyName': 'MEK162 + Imatinib mesylate'}]",MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST),09/10/2014,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT01991938,Phase I,Terminated,"Verastem, Inc.","[{'id': 960, 'therapyName': 'VS-5584'}]",Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma,12/29/2016,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT01992653,Phase I,"Active, not recruiting","Genentech, Inc. ","[{'id': 4248, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma",02/10/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01992874,Phase I,Completed,EMD Serono,"[{'id': 871, 'therapyName': 'Pimasertib'}]",Relative Bioavailability of Pimasertib in Cancer Patients,04/24/2015,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT01993641,Phase II,Completed,"MEI Pharma, Inc.","[{'id': 1758, 'therapyName': 'Pracinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA,07/07/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT01993719,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Immunotherapy Using Tumor Infiltrating Lymphocytes Comparing 2 Different Conditioning Regimens for Patients With Metastatic Melanoma,06/21/2016,[],no
0,both,[],NCT01994369,Phase I,"Active, not recruiting",University of Pennsylvania ,[],Intraoperative Imagery of Breast Cancer With Folate-FITC (EC17),06/20/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}]",NCT01994382,Phase I,Recruiting,Portola Pharmaceuticals ,"[{'id': 2531, 'therapyName': 'Cerdulatinib'}]",Phase 1 Dose Escalation Study in Chronic Lymphocytic Leukemia and Non-hodgkin Lymphoma,12/08/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT01994590,Phase II,Terminated,M.D. Anderson Cancer Center|Novartis,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC),06/20/2017,[],no
0,both,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT01995188,Phase I,Completed,Genentech,"[{'id': 1347, 'therapyName': 'DNIB0600A + Carboplatin + Bevacizumab'}, {'id': 1346, 'therapyName': 'DNIB0600A + Carboplatin'}]",A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Patients With Ovarian Cancer,10/05/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01995708,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 2901, 'therapyName': 'WT1 senstized T cells'}]","CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation",07/21/2015,[],yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT01996696,Phase II,Recruiting,AHS Cancer Control Alberta,"[{'id': 1031, 'therapyName': 'Metformin'}]","A Study With or Without Metformin to Determine if Metformin Can Prevent Weight Gain and Other Problems (i.e. Diabetes, Increased Cholesterol, Etc.) That Can Arise From the Use of Hormonal Therapy in Combination With Radiation Therapy When Treating Aggressive Localized Prostate Cancer.",05/23/2015,[],no
0,both,[],NCT01997255,Phase II,Withdrawn,Baylor College of Medicine ,[],Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS),05/06/2016,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT01997333,Phase II,"Active, not recruiting",Celldex Therapeutics,"[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer",08/31/2017,[],yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01997840,Phase Ib/II,"Active, not recruiting",Acetylon Pharmaceuticals Incorporated,"[{'id': 1614, 'therapyName': 'ACY-1215 + Pomalidomide + Dexamethasone'}]",ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma,05/05/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01998126,Phase I,"Active, not recruiting",University of Utah,"[{'id': 1348, 'therapyName': 'Ipilimumab + Erlotinib'}, {'id': 1349, 'therapyName': 'Ipilimumab + Crizotinib'}]",Ipilimumab Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts,06/10/2016,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT01998971,Phase I,Recruiting,"Janssen Research & Development, LLC ","[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1475, 'therapyName': 'Thalidomide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 3323, 'therapyName': 'Montelukast'}]",A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma,12/21/2015,[],no
0,both,"[{'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}, {'id': 4817, 'name': 'ganglioneuroma', 'source': 'DOID'}, {'id': 4852, 'name': 'pleomorphic xanthoastrocytoma', 'source': 'DOID'}, {'id': 5076, 'name': 'mixed glioma', 'source': 'DOID'}, {'id': 4851, 'name': 'pilocytic astrocytoma', 'source': 'DOID'}, {'id': 5078, 'name': 'ganglioglioma', 'source': 'DOID'}, {'id': 5509, 'name': 'pediatric ependymoma', 'source': 'DOID'}, {'id': 5032, 'name': 'pineal gland cancer', 'source': 'DOID'}, {'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT01999270,Phase I,Completed,Washington University School of Medicine ,"[{'id': 2112, 'therapyName': 'Bevacizumab + Irinotecan'}]",Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors,10/01/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT01999738,Phase I,"Active, not recruiting",Endocyte,"[{'id': 1603, 'therapyName': 'EC1456'}]",Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors,08/24/2017,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT01999972,Phase I,"Active, not recruiting",Pfizer,"[{'id': 1350, 'therapyName': 'Axitinib + Crizotinib'}]",A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors,05/20/2017,[],no
0,both,"[{'id': 1324, 'name': 'lung cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT01999985,Phase I,"Active, not recruiting",H. Lee Moffitt Cancer Center and Research Institute,"[{'id': 1351, 'therapyName': 'Dasatinib + Afatinib'}]",Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC),03/31/2017,"[{'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02000596,Phase II,Terminated,Katherine Tkaczuk ,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1911, 'therapyName': 'Anastrozole  + Fulvestrant'}]",Trastuzmab and Pertuzumab Alone or in Combination With Hormonal Therapy or Chemotherapy With Eribulin in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced or MBC,03/05/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02000622,Phase III,"Active, not recruiting",AstraZeneca ,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.,01/27/2016,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'excluded'}]",yes
0,female,[],NCT02000778,Phase I,"Active, not recruiting",University of Pennsylvania ,[],EC17 for Intraoperative Imaging in Occult Ovarian Cancer,12/14/2016,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02000882,Phase II,"Active, not recruiting",US Oncology Research,"[{'id': 1536, 'therapyName': 'BKM120 + Capecitabine'}]",Capecitabine + BKM120 TNBC BC Brain Met,10/03/2017,[],yes
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02000934,Phase I,Recruiting,"Millennium Pharmaceuticals, Inc. ","[{'id': 3146, 'therapyName': 'TAK-659'}]",A Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies,10/21/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02000947,Phase Ib/II,"Active, not recruiting",MedImmune LLC ,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer,01/24/2017,[],no
0,both,"[{'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT02002182,Phase II,Recruiting,Andrew Sikora ,"[{'id': 3090, 'therapyName': 'ADXS11-001'}]","ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer",12/01/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02002689,Phase II,Terminated,Novartis Pharmaceuticals,"[{'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 for Patients With PTCH1 or SMO Mutated Tumors,05/03/2016,"[{'molecularProfile': {'id': 1664, 'profileName': 'SMO mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02003092,Phase I,Recruiting,"Rexahn Pharmaceuticals, Inc. ","[{'id': 6224, 'therapyName': 'RX-5902'}]",RX-5902 Treatment of Subjects With Solid Tumors,09/25/2017,[],yes
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02003209,Phase III,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]","Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer",03/03/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02003573,Phase I,Terminated,Boehringer Ingelheim ,"[{'id': 1745, 'therapyName': 'Volasertib + Decitabine'}]",Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML),12/16/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02003924,Phase III,"Active, not recruiting","Medivation, Inc. ","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer,07/18/2017,[],no
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT02004028,Phase II,Completed,"Verastem, Inc. ","[{'id': 958, 'therapyName': 'VS-6063'}]",Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma.,02/08/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}]",NCT02004106,Phase I,Completed,Hoffmann-La Roche ,"[{'id': 2886, 'therapyName': 'RO6895882'}]",A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors,09/03/2016,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02004262,Phase II,Completed,"Aduro BioTech, Inc. ","[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2383, 'therapyName': 'Capecitabine + Fluorouracil + Gemcitabine '}]",Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting,02/08/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02004522,Phase III,"Active, not recruiting","Infinity Pharmaceuticals, Inc. ","[{'id': 1024, 'therapyName': 'Duvelisib'}, {'id': 1090, 'therapyName': 'Ofatumumab'}]",A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO),11/19/2015,[],no
0,both,"[{'id': 1039, 'name': 'prolymphocytic leukemia', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02005289,Phase II,Recruiting,Ohio State University Comprehensive Cancer Center ,"[{'id': 5843, 'therapyName': 'Lenalidomide + MOR208'}, {'id': 5847, 'therapyName': 'Ibrutinib + MOR208'}]","Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL",06/02/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02005315,Phase I,"Active, not recruiting","OncoMed Pharmaceuticals, Inc.","[{'id': 4412, 'therapyName': 'Gemcitabine + nab-paclitaxel + Vantictumab'}]",A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer,04/18/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02005471,Phase III,"Active, not recruiting",Hoffmann-La Roche ,"[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}]",A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,05/06/2016,[],no
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}, {'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}]",NCT02006485,Phase I,Recruiting,"TG Therapeutics, Inc. ","[{'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ublituximab in Combination With TGR-1202 in Patients With B-cell Malignancies,03/06/2015,[],no
0,both,"[{'id': 1039, 'name': 'prolymphocytic leukemia', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02007044,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL),11/16/2015,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02007512,Phase II,"Active, not recruiting","Medivation, Inc. ","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 738, 'therapyName': 'Exemestane'}]",Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer,04/28/2015,"[{'molecularProfile': {'id': 530, 'profileName': 'ERBB2 wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02008227,Phase III,"Active, not recruiting",Hoffmann-La Roche ,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Randomized Phase 3 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) Compared to Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - OAK,06/02/2015,[],no
0,both,"[{'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}, {'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT02008383,Phase I,Recruiting,"John Strickler, M.D. ","[{'id': 1985, 'therapyName': 'Panitumumab + cabozantinib'}]",Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer,02/04/2015,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02008877,Phase Ib/II,"Active, not recruiting",Sarcoma Alliance for Research through Collaboration ,"[{'id': 2271, 'therapyName': 'Ganetespib + Sirolimus'}]",A Trial of Ganetespib Plus Sirolimus: Phase 1 Includes Multiple Sarcoma Subtypes and Phase 2 MPNST,03/05/2016,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT02009332,Phase Ib/II,Recruiting,"Aadi, LLC ","[{'id': 917, 'therapyName': 'Sirolimus'}]",Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer,03/06/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02009397,Phase Ib/II,Recruiting,James Graham Brown Cancer Center ,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients,07/29/2015,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 4905, 'name': 'pancreatic carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02009449,Phase I,"Active, not recruiting",ARMO BioSciences ,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 2621, 'therapyName': 'AM0010 '}, {'id': 619, 'therapyName': 'Abraxane'}]",A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,02/18/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02009631,Phase I,Completed,AbbVie,"[{'id': 954, 'therapyName': 'Veliparib'}]",A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors,12/12/2014,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02010021,Phase I,"Active, not recruiting",Dartmouth-Hitchcock Medical Center ,"[{'id': 794, 'therapyName': 'Letrozole'}]",Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.,05/10/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02010606,Phase I,"Active, not recruiting",Cedars-Sinai Medical Center ,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma,06/07/2017,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02010645,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1763, 'therapyName': 'Eltrombopag + Decitabine'}]",Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS),09/01/2015,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02011945,Phase I,"Active, not recruiting",Bristol-Myers Squibb,"[{'id': 1813, 'therapyName': 'Dasatinib + Nivolumab'}]",A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia,12/09/2016,[],no
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 285, 'name': 'hairy cell leukemia', 'source': 'DOID'}]",NCT02012231,Phase Ib/II,Terminated,Plexxikon,"[{'id': 1041, 'therapyName': 'PLX8394'}]","Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.",09/16/2014,"[{'molecularProfile': {'id': 696, 'profileName': 'BRAF act mut'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02012296,Phase Ib/II,Recruiting,University of Chicago ,"[{'id': 2603, 'therapyName': 'Mifepristone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer,03/17/2017,[],no
0,both,"[{'id': 3748, 'name': 'esophagus squamous cell carcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}]",NCT02013154,Phase I,Recruiting,"Leap Therapeutics, Inc.","[{'id': 6254, 'therapyName': 'DKN-01 + Paclitaxel'}]",A Study of DKN-01 in Combination With Paclitaxel,10/03/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02013219,Phase I,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 3490, 'therapyName': 'Alectinib + Atezolizumab'}, {'id': 1352, 'therapyName': 'Atezolizumab + Erlotinib'}]",A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer,06/30/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02013804,Phase I,Completed,MedImmune LLC ,"[{'id': 3120, 'therapyName': 'MEDI0680'}]",A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies,10/07/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02014116,Phase I,"Active, not recruiting",Eli Lilly and Company ,"[{'id': 3268, 'therapyName': 'LY3009120'}]",A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body,07/27/2016,[],no
0,both,"[{'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02014337,Phase I,"Active, not recruiting",Corcept Therapeutics ,"[{'id': 3053, 'therapyName': 'Eribulin + Mifepristone'}]",Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors,12/23/2016,[],yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02014636,Phase I,"Active, not recruiting",GlaxoSmithKline,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC),04/14/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}, {'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}, {'id': 219, 'name': 'colon cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02014909,Phase I,Completed,"Kolltan Pharmaceuticals, Inc. ","[{'id': 2054, 'therapyName': 'CDX-3379'}, {'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}, {'id': 2064, 'therapyName': 'CDX-3379 + Trastuzumab'}, {'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}, {'id': 2062, 'therapyName': 'CDX-3379 + Erlotinib'}]",A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors,07/25/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1102, 'profileName': 'EGFR positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}]",NCT02015065,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 953, 'therapyName': 'Vandetanib'}]",Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors,03/22/2016,"[{'molecularProfile': {'id': 1214, 'profileName': 'KIT mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1215, 'profileName': 'PDGFRA mutant'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02015117,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases,08/12/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02015208,Phase Ib/II,Completed,Sunnybrook Health Sciences Centre|Novartis,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia,09/27/2016,[],no
0,,[],NCT02015559,,Recruiting,,[],Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus,09/16/2015,[],no
0,both,"[{'id': 1319, 'name': 'brain cancer', 'source': 'DOID'}]",NCT02015728,Phase I,"Active, not recruiting",Seattle Children's Hospital,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1804, 'therapyName': 'Temozolomide + Etoposide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors,12/16/2016,[],no
0,both,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT02016534,Phase II,Terminated,Amgen,"[{'id': 1064, 'therapyName': 'AMG 337'}]",Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors,11/11/2016,"[{'molecularProfile': {'id': 1629, 'profileName': 'MET amp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02016729,Phase I,Completed,Amgen ,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1452, 'therapyName': 'AMG 232'}]",A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia,08/26/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02017717,Phase III,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143),07/14/2017,[],no
0,both,"[{'id': 3873, 'name': 'nodular medulloblastoma', 'source': 'DOID'}]",NCT02017964,Phase II,Completed,Children's Oncology Group ,"[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 2673, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine  '}]","Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma",05/18/2017,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 285, 'name': 'hairy cell leukemia', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}]",NCT02018861,Phase I,"Active, not recruiting",Incyte Corporation,"[{'id': 2406, 'therapyName': 'INCB039110'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 3088, 'therapyName': 'INCB050465 '}]","A Phase 1, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 Monotherapy and in Combination With INCB039110 in Subjects With Previously Treated B-Cell Malignancies",05/19/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02019069,Phase II,Recruiting,Bruno C. Medeiros ,"[{'id': 4341, 'therapyName': 'CPX-351'}]",CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,09/25/2017,[],no
0,both,[],NCT02019576,Phase II,Recruiting,Sunnybrook Health Sciences Centre ,[],Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib,02/10/2015,[],no
0,both,"[{'id': 4465, 'name': 'papillary renal cell carcinoma', 'source': 'DOID'}]",NCT02019693,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1065, 'therapyName': 'Capmatinib'}]",A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer,04/03/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02019979,Phase II,Terminated,Beth Israel Medical Center,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) (METRO),06/19/2017,"[{'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'excluded'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02020070,Phase II,"Active, not recruiting",Memorial Sloan Kettering Cancer Center ,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1814, 'therapyName': 'Degarelix'}]","Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy",08/12/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02020707,Phase I,Suspended,Mayo Clinic,"[{'id': 619, 'therapyName': 'Abraxane'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery,07/14/2017,[],no
0,female,[],NCT02022007,Phase I,Completed,Woman's ,[],Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis,11/02/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02022982,Phase Ib/II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1823, 'therapyName': 'PD-0325901 + Palbociclib'}]",PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors,12/06/2016,"[{'molecularProfile': {'id': 1208, 'profileName': 'HRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT02023333,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma,07/14/2015,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02023463,Phase I,"Active, not recruiting",Thomas Jefferson University ,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]","Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer",07/27/2017,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02023905,Phase II,Recruiting,"University of California, San Francisco ","[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 735, 'therapyName': 'Everolimus'}]",Everolimus With and Without Temozolomide in Adult Low Grade Glioma,03/04/2015,[],no
0,both,[],NCT02023996,Phase I,Recruiting,Memorial Sloan-Kettering Cancer Center ,[],PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer,02/11/2015,[],yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02024087,Phase Ib/II,"Active, not recruiting","Acceleron Pharma, Inc. ","[{'id': 2364, 'therapyName': 'Dalantercept + Sorafenib'}]",Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma,05/12/2016,[],no
0,both,"[{'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT02024607,Phase Ib/II,"Active, not recruiting","Boston Biomedical, Inc ","[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 2093, 'therapyName': 'BBI608 + Bevacizumab'}, {'id': 2094, 'therapyName': 'BBI608 + Regorafenib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer,10/10/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02025010,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute ,"[{'id': 1805, 'therapyName': 'Abiraterone'}]",Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates.,09/14/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02025192,Phase I,"Active, not recruiting",Oncothyreon Inc.,"[{'id': 1560, 'therapyName': 'ARRY-380 + Trastuzumab'}, {'id': 1577, 'therapyName': 'ARRY-380 + Capecitabine'}]",A Phase 1b Study of ONT-380 Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer,01/27/2016,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02025803,Phase I,"Active, not recruiting","Taiho Oncology, Inc.","[{'id': 4335, 'therapyName': 'Capecitabine + TAS-114'}]","A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors",06/20/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02027935,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4,08/05/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02027961,Phase Ib/II,"Active, not recruiting",MedImmune LLC,"[{'id': 1357, 'therapyName': 'Dabrafenib + Durvalumab + Trametinib'}, {'id': 1358, 'therapyName': 'Durvalumab + Trametinib'}]",Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone,11/04/2015,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,female,[],NCT02028221,Phase II,Recruiting,University of Arizona,[],Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk,06/28/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02028988,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide + External Beam Rt For Prostate,02/15/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02029417,Phase II,Terminated,Roswell Park Cancer Institute,"[{'id': 1794, 'therapyName': 'Omacetaxine + Cytarabine + Decitabine'}]","Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia",01/13/2016,[],no
0,both,"[{'id': 1039, 'name': 'prolymphocytic leukemia', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02029443,Phase Ib/II,"Active, not recruiting",Acerta Pharma BV ,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","ACP-196, a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia",06/24/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02030483,Phase I,Terminated,Weill Medical College of Cornell University,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma,02/15/2017,"[{'molecularProfile': {'id': 2395, 'profileName': 'RB1 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT02030964,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 2590, 'therapyName': 'Cyclophosphamide + Topotecan'}, {'id': 2124, 'therapyName': 'Celecoxib'}]",N2012-01 Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan,08/16/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02031419,Phase I,Recruiting,Celgene Corporation,"[{'id': 2376, 'therapyName': 'CC-122 + CC-292'}, {'id': 2377, 'therapyName': 'CC-223 + CC-292'}, {'id': 2375, 'therapyName': 'CC-122 + CC-223'}, {'id': 897, 'therapyName': 'Rituximab'}]","Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma",03/12/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02031458,Phase II,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase 2 Study of MPDL3280A (an Engineered Anti-PDL1 Antibody) in Patients With PD-L1 Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer - BIRCH,04/07/2016,[],yes
0,both,"[{'id': 1799, 'name': 'islet cell tumor', 'source': 'DOID'}]",NCT02031536,Phase II,Terminated,Eastern Cooperative Oncology Group ,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery,02/10/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02032277,Phase III,"Active, not recruiting",AbbVie ,"[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer,04/07/2016,[],yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02032810,Phase I,"Active, not recruiting",H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma,03/31/2017,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02032823,Phase III,Recruiting,AstraZeneca ,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer,06/13/2016,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02033148,Phase I,Withdrawn,Roswell Park Cancer Institute,"[{'id': 769, 'therapyName': 'Icotinib'}]",Icotinib Hydrochloride in Treating Patients With Advanced Cancers,08/04/2014,[],no
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}, {'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}, {'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}, {'id': 2994, 'name': 'germ cell cancer', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 285, 'name': 'hairy cell leukemia', 'source': 'DOID'}, {'id': 4906, 'name': 'small intestine adenocarcinoma', 'source': 'DOID'}]",NCT02034110,Phase II,Recruiting,GlaxoSmithKline ,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers,07/14/2015,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02034123,Phase I,Terminated,GlaxoSmithKline ,"[{'id': 3014, 'therapyName': 'GSK2879552 '}]",Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma,08/05/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02034552,Phase II,"Active, not recruiting",Bayer ,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC),02/16/2016,[],no
0,both,"[{'id': 3459, 'name': 'breast carcinoma', 'source': 'DOID'}]",NCT02034916,Phase II,"Active, not recruiting",BioMarin Pharmaceutical ,"[{'id': 682, 'therapyName': 'Talazoparib'}]","A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)",05/13/2016,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT02035137,,Recruiting,New Approaches to Neuroblastoma Therapy Consortium,"[{'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1426, 'therapyName': '131I-MIBG + Irinotecan + Vincristine'}, {'id': 1427, 'therapyName': '131I-MIBG + Vorinostat'}]",131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat,08/16/2017,[],no
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02035345,FDA approved,Terminated,Massachusetts General Hospital ,"[{'id': 1092, 'therapyName': 'Carboplatin'}]",Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment,11/02/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02035527,Phase Ib/II,"Active, not recruiting","Ohio State University Comprehensive Cancer Center, National Comprehensive Cancer Network","[{'id': 2431, 'therapyName': 'Sorafenib + Cisplatin + Docetaxel'}]","Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",12/01/2015,[],no
0,female,"[{'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}]",NCT02035787,Phase I,Recruiting,UNC Lineberger Comprehensive Cancer Center,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients,12/22/2014,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02036086,Phase II,Recruiting,Sunnybrook Health Sciences Centre ,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases,08/20/2015,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3965, 'name': 'Merkel cell carcinoma', 'source': 'DOID'}]",NCT02036476,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute ,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma,09/13/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02036502,Phase I,Recruiting,Merck Sharp & Dohme Corp. ,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3322, 'therapyName': 'lenalidomide + Pembrolizumab'}]",A Study of Pembrolizumab (MK-3475) in Combination With Lenalidomide and Dexamethasone in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023),12/21/2015,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02036918,Phase I,Recruiting,Duke University ,"[{'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer,05/15/2015,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02037230,Phase Ib/II,Recruiting,University of Michigan Cancer Center ,"[{'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}]",Dose Escalation Trial of MK1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas,04/22/2015,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02038010,Phase I,"Active, not recruiting",Northwestern University,"[{'id': 1575, 'therapyName': 'BYL719 + Trastuzumab emtansine'}]",BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx,02/18/2016,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02038647,Phase II,"Active, not recruiting","Millennium Pharmaceuticals, Inc. ","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}]",Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC),01/26/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02038673,Phase I,Completed,Astellas Pharma Inc ,"[{'id': 3584, 'therapyName': 'ASP5878'}]",An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors,09/15/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02038699,Phase Ib/II,Withdrawn,"Oncoceutics, Inc. ","[{'id': 1687, 'therapyName': 'ONC201'}]",A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer,12/23/2015,[],yes
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02038946,Phase II,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140),05/14/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02039674,Phase Ib/II,"Active, not recruiting",Merck Sharp & Dohme Corp.,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 2104, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}, {'id': 2107, 'therapyName': 'Erlotinib + Pembrolizumab '}, {'id': 2108, 'therapyName': 'Gefitinib + Pembrolizumab '}]",A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021),03/21/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02039726,Phase III,"Active, not recruiting",Daiichi Sankyo Inc. ,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 882, 'therapyName': 'Quizartinib'}]",An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects,09/29/2017,"[{'molecularProfile': {'id': 2774, 'profileName': 'FLT3 act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 5329, 'profileName': 'FLT3 D835X'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02039947,Phase II,"Active, not recruiting",GlaxoSmithKline,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain,08/27/2016,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}]",NCT02040376,Phase III,"Active, not recruiting",The Hospital for Sick Children,"[{'id': 1031, 'therapyName': 'Metformin'}]",Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma,09/29/2017,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02040857,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute|Pfizer,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Palbociclib + Endocrine Therapy for HR + BrCa,04/21/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT02041260,Phase II,Recruiting,Exelixis,"[{'id': 998, 'therapyName': 'cabozantinib'}]",A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting,02/17/2015,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02041429,Phase Ib/II,"Active, not recruiting",Dana-Farber Cancer Institute|Incyte Corporation,"[{'id': 1369, 'therapyName': 'Ruxolitinib + Paclitaxel'}]",Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca,05/27/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 1993, 'name': 'rectum cancer', 'source': 'DOID'}, {'id': 219, 'name': 'colon cancer', 'source': 'DOID'}]",NCT02041481,Phase I,"Active, not recruiting","City of Hope Medical Center, National Cancer Institute (NCI), Novartis","[{'id': 2217, 'therapyName': 'MEK162 + FOLFOX'}]","MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer",03/05/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02041533,Phase III,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)",10/07/2015,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'excluded'}]",yes
0,both,[],NCT02042144,Phase III,"Active, not recruiting",Bayer ,[],Safety and Effectiveness of Regorafenib,07/27/2017,[],no
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT02042378,Phase II,Completed,"Clovis Oncology, Inc. ","[{'id': 906, 'therapyName': 'Rucaparib'}]",A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation,06/18/2016,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT02042430,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 2575, 'therapyName': 'Epacadostat'}]","INCB024360 Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",03/03/2016,[],no
0,both,"[{'id': 4948, 'name': 'gallbladder carcinoma', 'source': 'DOID'}, {'id': 4897, 'name': 'bile duct carcinoma', 'source': 'DOID'}]",NCT02042443,Phase II,Completed,National Cancer Institute (NCI),"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery,09/13/2017,[],no
0,female,"[{'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}]",NCT02042495,Phase II,Withdrawn,Jewish General Hospital ,"[{'id': 1031, 'therapyName': 'Metformin'}]",Endometrial Cancer Biomarker Changes Following Exposure to Metformin,08/31/2016,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02042989,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1360, 'therapyName': 'Ixazomib + Vorinostat'}]",MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies,03/21/2017,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02043587,Phase II,Recruiting,"University of California, San Diego","[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia &amp; Lymphoblastic Lymphoma,12/15/2014,[],no
0,both,"[{'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02043665,Phase I,Recruiting,Viralytics ,"[{'id': 2974, 'therapyName': 'coxsackievirus A21'}]",Systemic Treatment Of Resistant Metastatic Disease Employing CVA21 and Pembrolizumab in Non-small Cell Lung Cancer and Bladder Cancer (STORM/ KEYNOTE-200) (STORM),05/26/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02043678,Phase III,"Active, not recruiting",Bayer ,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]","Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms",09/24/2016,[],no
0,both,"[{'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}]",NCT02044120,Phase I,Recruiting,Sarcoma Alliance for Research through Collaboration,"[{'id': 1437, 'therapyName': 'Niraparib + Temozolomide'}]","ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma",04/22/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02044601,Phase Ib/II,Withdrawn,M.D. Anderson Cancer Center,"[{'id': 1370, 'therapyName': 'Onartuzumab + Paclitaxel + Carboplatin'}, {'id': 1371, 'therapyName': 'Onartuzumab + Erlotinib + Paclitaxel + Carboplatin'}]",Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT),08/05/2014,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02044822,Phase II,Terminated,Gilead Sciences ,"[{'id': 2325, 'therapyName': 'Idelalisib + Rituximab'}]",Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion,05/21/2016,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}]",NCT02045030,Phase II,Terminated,CR-CSSS Champlain-Charles-Le Moyne ,"[{'id': 2095, 'therapyName': 'Aflibercept + FOLFIRI'}]",Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer,11/17/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02045446,Phase II,"Active, not recruiting",University of Texas Southwestern Medical Center,"[{'id': 1146, 'therapyName': 'Bevacizumab + Erlotinib'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC),12/30/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02046122,Phase I,Recruiting,Duke University ,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}]",Adoptive Transfer of Haplo-identical DLI for AML and MDS,10/02/2014,[],no
0,both,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT02046421,Phase I,"Active, not recruiting",University of Chicago ,"[{'id': 2603, 'therapyName': 'Mifepristone'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]","Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",05/13/2017,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}]",NCT02046538,Phase II,Withdrawn,Weill Medical College of Cornell University ,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 624, 'therapyName': 'Aflibercept'}]",Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer,02/08/2017,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02047149,Phase I,Terminated,"University of Massachusetts, Worcester ","[{'id': 1789, 'therapyName': 'Zileuton + Dasatinib'}]",Evaluating the Safety of Zileuton (Zyflo(R)) in Combination With Dasatinib (Sprycel (R) in Chronic Myelogenous Leukemia,10/01/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02047214,Phase II,Terminated,"Cortice Biosciences, Inc. ","[{'id': 2123, 'therapyName': 'Bevacizumab + Paclitaxel'}]",Safety and Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy,01/29/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02047344,Phase II,Recruiting,Golden Biotechnology Corporation ,"[{'id': 985, 'therapyName': 'Antroquinonol'}]","Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC",02/27/2015,[],no
0,both,"[{'id': 1324, 'name': 'lung cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}]",NCT02047747,Phase II,Terminated,"David Piccioni, M.D., Ph.D","[{'id': 714, 'therapyName': 'Dacomitinib'}]",A Phase II Study of Dacomitinib in Progressive Brain Metastases,06/17/2016,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02048059,Phase II,Completed,Angiochem Inc ,"[{'id': 2053, 'therapyName': 'GRN1005'}]",ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases,09/29/2017,[],no
0,both,"[{'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}, {'id': 3382, 'name': 'liposarcoma', 'source': 'DOID'}, {'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}]",NCT02048371,Phase II,Recruiting,Sarcoma Alliance for Research through Collaboration ,"[{'id': 890, 'therapyName': 'Regorafenib'}]","A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas",02/11/2015,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02048384,Phase Ib/II,Recruiting,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 1593, 'therapyName': 'Sirolimus + Metformin'}, {'id': 1031, 'therapyName': 'Metformin'}]",A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer,12/22/2014,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02048488,Phase Ib/II,"Active, not recruiting","Tesaro, Inc. ","[{'id': 949, 'therapyName': 'TSR-011'}]","A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas",03/10/2016,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02048709,Phase I,Completed,"Genentech, Inc. ","[{'id': 2888, 'therapyName': 'GDC-0919'}]",IDO Inhibitor in Advanced Solid Tumors,02/08/2017,[],no
0,both,"[{'id': 1816, 'name': 'angiosarcoma', 'source': 'DOID'}]",NCT02048722,Phase II,Recruiting,Northwestern University ,"[{'id': 890, 'therapyName': 'Regorafenib'}]","Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma",02/10/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT02048943,Phase I,Withdrawn,Roswell Park Cancer Institute,"[{'id': 1372, 'therapyName': 'Dovitinib + Gemcitabine + Abraxane'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 721, 'therapyName': 'Dovitinib'}]","Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer",01/09/2015,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02049515,Phase III,Enrolling by invitation,"Infinity Pharmaceuticals, Inc. ","[{'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1024, 'therapyName': 'Duvelisib'}]",A Phase 3 Extension Study of IPI-145 and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07,08/01/2017,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}]",NCT02049541,Phase I,"Active, not recruiting",Kami Maddocks ,"[{'id': 2502, 'therapyName': 'BKM120 + Rituximab'}]",Study of BKM120; Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma,09/15/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02049593,Phase I,"Active, not recruiting",Jonsson Comprehensive Cancer Center,"[{'id': 1377, 'therapyName': 'Talazoparib + Temozolomide'}, {'id': 1378, 'therapyName': 'Irinotecan + Talazoparib'}]",PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors,01/16/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02049801,Phase I,"Active, not recruiting","Bruno C. Medeiros, National Cancer Institute (NCI)","[{'id': 2220, 'therapyName': 'MEK162 + Idarubicin + Cytarabine'}]","MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",04/28/2016,"[{'molecularProfile': {'id': 1196, 'profileName': 'NRAS G12X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1197, 'profileName': 'NRAS G13X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1192, 'profileName': 'KRAS G12X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1193, 'profileName': 'KRAS G13X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1198, 'profileName': 'NRAS Q61X'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02049905,Phase III,Completed,CytRx,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Phase 3 Study to Treat Patients With Soft Tissue Sarcomas,06/08/2017,[],no
0,female,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}, {'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02049957,Phase Ib/II,Recruiting,"Millennium Pharmaceuticals, Inc.","[{'id': 1581, 'therapyName': 'MLN0128 + Fulvestrant'}, {'id': 1580, 'therapyName': 'MLN0128 + Exemestane'}]",Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer,09/30/2014,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT02050009,Phase I,Withdrawn,Fox Chase Cancer Center ,"[{'id': 1381, 'therapyName': 'Paclitaxel + Carboplatin + Metformin'}]","Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",05/06/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02050321,Phase II,Terminated,University of Arizona ,"[{'id': 1936, 'therapyName': 'Vemurafenib + Acitretin'}]",A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma,04/02/2016,"[{'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02050919,Phase II,Recruiting,OHSU Knight Cancer Institute ,"[{'id': 2365, 'therapyName': 'Epirubicin + Ifosfamide + Sorafenib'}]","Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma",03/12/2015,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}]",NCT02051751,Phase I,Completed,Novartis Pharmaceuticals,"[{'id': 1379, 'therapyName': 'BYL719 + Paclitaxel'}]",A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer,09/14/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4908, 'name': 'anal carcinoma', 'source': 'DOID'}]",NCT02051868,Phase II,Recruiting,Royal Marsden NHS Foundation Trust ,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel (InterAACT),07/05/2016,[],no
0,female,[],NCT02052102,Phase II,Recruiting,AHS Cancer Control Alberta ,[],A Study to See Whether Breath-Hold Techniques During Radiation Radiation Treatment Are Effective in Helping to Improve Sparing of the Heart,02/10/2015,[],no
0,both,"[{'id': 3073, 'name': 'brain glioblastoma multiforme', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT02052648,Phase Ib/II,Recruiting,NewLink Genetics Corporation ,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 2976, 'therapyName': 'indoximod'}]",Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors,08/05/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02052778,Phase Ib/II,Recruiting,"Taiho Oncology, Inc.","[{'id': 1053, 'therapyName': 'TAS-120'}]",A Dose Finding Study Followed by a Safety and Efficacy Study in Patients With Advanced Solid Tumors or Multiple Myeloma With FGF/FGFR-Related Abnormalities,12/11/2016,"[{'molecularProfile': {'id': 812, 'profileName': 'FGFR1 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3147, 'profileName': 'FGFR2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14910, 'profileName': 'FGFR1 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1185, 'profileName': 'FGFR2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3329, 'profileName': 'FGFR3 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1221, 'profileName': 'FGFR1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14903, 'profileName': 'FGFR3 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2969, 'profileName': 'FGFR2 fusion'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT02053376,Phase II,"Active, not recruiting",University of Pittsburgh ,"[{'id': 890, 'therapyName': 'Regorafenib'}]",A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy,09/29/2017,[],no
0,female,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT02053636,Phase II,Completed,Servier ,"[{'id': 1029, 'therapyName': 'Lucitanib'}]",A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer,04/21/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02054520,Phase II,Unknown status,NewLink Genetics Corporation ,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Immunotherapy Study for Patients With Stage IV Melanoma,10/03/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02054806,Phase I,"Active, not recruiting",Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28),09/04/2015,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02055820,Phase I,"Active, not recruiting",Hoffmann-La Roche ,"[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Safety and Pharmacokinetics Study of GDC-0199 (ABT-199) in Patients With Non-Hodgkin's Lymphoma,06/01/2017,[],no
0,both,[],NCT02056015,Phase I,Completed,"Millennium Pharmaceuticals, Inc. ",[],A Phase I Study of MLN6907 in Patients With Metastatic Colorectal,01/06/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02057107,Phase II,Recruiting,University of Pittsburgh ,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}]","Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)",01/29/2015,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02057133,Phase I,Recruiting,Eli Lilly and Company ,"[{'id': 2254, 'therapyName': 'Abemaciclib + Letrozole'}, {'id': 2257, 'therapyName': 'Abemaciclib + Exemestane'}, {'id': 2258, 'therapyName': 'Everolimus + Exemestane + LY2835219'}, {'id': 2255, 'therapyName': 'Abemaciclib + Anastrozole'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}, {'id': 2259, 'therapyName': 'Abemaciclib + Trastuzumab'}]",A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread,09/16/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02057640,Phase Ib/II,"Active, not recruiting",Case Comprehensive Cancer Center ,"[{'id': 4565, 'therapyName': 'Dexamethasone + Ixazomib + Panobinostat'}]",MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma,05/25/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02057770,Phase I,Recruiting,Washington University School of Medicine,"[{'id': 5724, 'therapyName': 'Busulfan + Fludarabine phosphate + Cyclophosphamide'}, {'id': 5647, 'therapyName': 'Tocilizumab'}]",Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,05/19/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02057939,Phase II,"Active, not recruiting",Duke University ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM),03/09/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02058706,Phase II,Recruiting,Barbara Ann Karmanos Cancer Institute ,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]",LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer,04/21/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02059213,Phase II,"Active, not recruiting",University of Michigan Cancer Center,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 795, 'therapyName': 'Leuprolide'}]", A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer,05/06/2017,"[{'molecularProfile': {'id': 2007, 'profileName': 'RB1 loss'}, 'requirementType': 'excluded'}]",yes
0,female,"[{'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT02059265,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 717, 'therapyName': 'Dasatinib'}]","Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer",03/22/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02060188,Phase Ib/II,Recruiting,Bristol-Myers Squibb ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",A Study of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Colon Cancer (CheckMate 142),05/06/2015,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02060253,Phase I,"Active, not recruiting",New York University School of Medicine,"[{'id': 1579, 'therapyName': 'Ganetespib + Paclitaxel + Trastuzumab'}]","Ganetespib, Paclitaxel and Trastuzumab for Advanced or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer",07/13/2016,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT02060370,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC),05/03/2016,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02061332,Phase Ib/II,"Active, not recruiting",University of Pennsylvania ,"[{'id': 5222, 'therapyName': 'HER2-pulsed DC1 vaccine'}]",DC Vaccine for Patients With Ductal Carcinoma In Situ,10/04/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,female,[],NCT02061397,Phase Ib/II,Recruiting,University of Pennsylvania ,"[{'id': 2239, 'therapyName': 'Simvastatin'}]",Safety of Simvastatin in LAM and TSC,03/02/2015,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02061761,Phase Ib/II,Recruiting,Bristol-Myers Squibb,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 4196, 'therapyName': 'BMS-986016'}]",Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies,06/05/2016,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02063724,Phase I,"Active, not recruiting",H. Lee Moffitt Cancer Center and Research Institute,"[{'id': 5222, 'therapyName': 'HER2-pulsed DC1 vaccine'}]",HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer (Adjuvant),07/12/2017,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT02063958,Phase I,"Active, not recruiting",Esanex Inc. ,"[{'id': 866, 'therapyName': 'SNX-5422'}]",Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors,05/25/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02064036,Phase I,Recruiting,"University of California, Davis ","[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate,04/21/2015,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02064582,Phase II,Recruiting,University of Texas Southwestern Medical Center ,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer",05/08/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02065063,Phase I,Completed,GlaxoSmithKline,"[{'id': 1368, 'therapyName': 'Palbociclib + Trametinib'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors",08/29/2017,"[{'molecularProfile': {'id': 1241, 'profileName': 'NRAS BRAF wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1299, 'profileName': 'BRAF wild-type NRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02065466,Phase Ib/II,Withdrawn,University of Arizona,"[{'id': 1380, 'therapyName': 'Abraxane + Temozolomide + Bevacizumab'}]","Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases",09/01/2015,[],no
0,female,[],NCT02065609,Phase I,Recruiting,Washington University School of Medicine ,[],89ZrTrastuzumab Breast Imaging With Positron Emission Tomography,02/11/2015,[],no
0,female,"[{'id': 5299, 'name': 'endometrial clear cell adenocarcinoma', 'source': 'DOID'}, {'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}, {'id': 2870, 'name': 'endometrial adenocarcinoma', 'source': 'DOID'}]",NCT02065687,Phase III,Recruiting,Gynecologic Oncology Group,"[{'id': 1381, 'therapyName': 'Paclitaxel + Carboplatin + Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer",02/25/2017,[],no
0,both,"[{'id': 5517, 'name': 'stomach carcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT02065765,Phase II,No longer available,Eli Lilly and Company ,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer,03/01/2017,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02065869,Phase Ib/II,Recruiting,Bellicum Pharmaceuticals,"[{'id': 6053, 'therapyName': 'BPX-501'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant,07/31/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02066181,Phase III,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis,12/06/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02066532,Phase Ib/II,Recruiting,Kevin Kalinsky,"[{'id': 1578, 'therapyName': 'Ruxolitinib + Trastuzumab'}]",Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer,09/30/2014,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02066636,Phase III,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen (CheckMate 153),09/01/2016,[],no
0,both,"[{'id': 2513, 'name': 'basal cell carcinoma', 'source': 'DOID'}]",NCT02067104,Phase II,Completed,University of Arizona,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention,01/22/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02067156,Phase II,Completed,"GenSpera, Inc. ","[{'id': 4338, 'therapyName': 'mipsagargin'}]","Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma",02/25/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02068079,Phase I,Withdrawn,Duke University,"[{'id': 1383, 'therapyName': 'Vemurafenib + Trientine'}]",A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma,11/19/2015,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT02068586,Phase II,Recruiting,Thomas Jefferson University,"[{'id': 1076, 'therapyName': 'Valproic acid'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma,11/24/2014,[],no
0,female,[],NCT02069093,Phase II,Completed,Novartis Pharmaceuticals ,[],"Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer",05/07/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02069145,Phase I,Completed,"OncoMed Pharmaceuticals, Inc.","[{'id': 2413, 'therapyName': 'Ipafricept + Sorafenib'}]",Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer,08/18/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02069730,Phase I,Recruiting,"University Health Network, Toronto ","[{'id': 1749, 'therapyName': 'Selinexor'}]",A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes,05/19/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02070406,Phase I,Recruiting,Jonsson Comprehensive Cancer Center ,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies",06/23/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02070549,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction,09/26/2017,[],no
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02071862,Phase I,Recruiting,"Calithera Biosciences, Inc ","[{'id': 1667, 'therapyName': 'CB-839'}]",Study of the Glutaminase Inhibitor CB-839 in Solid Tumors,07/07/2016,"[{'molecularProfile': {'id': 1781, 'profileName': 'IDH1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 5912, 'profileName': 'IDH2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02071927,Phase I,Completed,"Calithera Biosciences, Inc ","[{'id': 1667, 'therapyName': 'CB-839'}]",Study of the Glutaminase Inhibitor CB-839 in Leukemia,02/10/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02072486,Phase I,"Active, not recruiting",Roswell Park Cancer Institute ,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,07/03/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02073097,Phase Ib/II,Recruiting,Case Comprehensive Cancer Center ,"[{'id': 2351, 'therapyName': 'Carfilzomib + Rituximab'}, {'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}]","Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma",03/11/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02073123,Phase Ib/II,Recruiting,NewLink Genetics Corporation ,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2976, 'therapyName': 'indoximod'}]",Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma,07/29/2015,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02073487,Phase II,Recruiting,The Methodist Hospital System,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1583, 'therapyName': 'Trastuzumab emtansine + Lapatinib'}, {'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 619, 'therapyName': 'Abraxane'}]",Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab With Lapatinib and Paclitaxel,09/30/2014,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02073838,Phase II,Recruiting,Sarit Assouline ,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 3179, 'therapyName': 'Vismodegib + Ribavirin'}]",Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML,11/05/2015,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02073916,Phase I,Recruiting,The Methodist Hospital System ,"[{'id': 1907, 'therapyName': 'T-DM1 + Lapatinib + Abraxane'}]",TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer,01/29/2015,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02073994,Phase I,"Active, not recruiting","Agios Pharmaceuticals, Inc.","[{'id': 1491, 'therapyName': 'AG-120'}]","Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation",11/26/2016,"[{'molecularProfile': {'id': 1781, 'profileName': 'IDH1 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02074839,Phase I,"Active, not recruiting","Agios Pharmaceuticals, Inc. ","[{'id': 1491, 'therapyName': 'AG-120'}]",Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation,06/03/2017,"[{'molecularProfile': {'id': 1781, 'profileName': 'IDH1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02074878,Phase I,Terminated,Baylor Breast Care Center ,"[{'id': 1962, 'therapyName': 'Sunitinib + Crizotinib'}]",CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer,08/10/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT02075177,Phase I,Available,South Plains Oncology Consortium ,"[{'id': 2858, 'therapyName': 'Ketoconazole'}, {'id': 2731, 'therapyName': 'Fenretinide'}]",Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma,07/08/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02075840,Phase III,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 698, 'therapyName': 'Alectinib'}, {'id': 706, 'therapyName': 'Crizotinib'}]","ALEX Study: A Randomized, Phase III Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients",02/12/2016,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'required'}]",yes
0,both,[],NCT02076152,,Recruiting,Massachusetts General Hospital,[],FMISO PET Study of Glioblastoma,07/24/2015,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT02076191,Phase Ib/II,Recruiting,John Mascarenhas ,"[{'id': 1735, 'therapyName': 'Ruxolitinib + Decitabine'}]",Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML,11/20/2014,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02076997,Phase I,Recruiting,Baylor College of Medicine ,"[{'id': 1639, 'therapyName': 'Methotrexate'}]",Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate,09/16/2015,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02077166,Phase Ib/II,Recruiting,Pharmacyclics ,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]",Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,02/19/2016,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02077881,Phase Ib/II,Recruiting,NewLink Genetics Corporation ,"[{'id': 2976, 'therapyName': 'indoximod'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer,08/05/2015,[],no
0,both,"[{'id': 1798, 'name': 'pancreatic endocrine carcinoma', 'source': 'DOID'}, {'id': 263, 'name': 'kidney cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02077933,Phase I,"Active, not recruiting",Novartis Pharmaceuticals,"[{'id': 1384, 'therapyName': 'BYL719 + Everolimus'}, {'id': 1385, 'therapyName': 'BYL719 + Everolimus + Exemestane'}]","Study of Safety and Efficacy of BYL719 With Everolimus or BYL719 With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors",10/19/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02077959,Phase Ib/II,"Active, not recruiting",Yvonne Efebera,"[{'id': 3357, 'therapyName': 'lenalidomide + Pidilizumab'}]",Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma,02/08/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT02078609,Phase I,Recruiting,Novartis Pharmaceuticals ,"[{'id': 2402, 'therapyName': 'LGH447 '}]",A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS),09/22/2016,[],no
0,both,"[{'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3074, 'name': 'giant cell glioblastoma', 'source': 'DOID'}]",NCT02078648,Phase Ib/II,"Active, not recruiting","Stemline Therapeutics, Inc. ","[{'id': 3010, 'therapyName': 'SL-701'}, {'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 667, 'therapyName': 'Bevacizumab'}]","Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme",09/13/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02078752,Phase I,Completed,Pfizer ,"[{'id': 4324, 'therapyName': 'PF-06647263 '}]",A Study Of PF-06647263 In Patients With Advanced Solid Tumors,07/14/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02079636,Phase I,Recruiting,Eli Lilly and Company,"[{'id': 1069, 'therapyName': 'LY3023414'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY2835219 in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC),06/05/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02079740,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 1386, 'therapyName': 'Trametinib + Navitoclax'}]",Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors,01/24/2017,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02080078,Phase I,Recruiting,"AHS Cancer Control Alberta, Cross Cancer Institute","[{'id': 2436, 'therapyName': 'Erlotinib + Theophylline'}]",A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline,06/24/2015,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02080260,Phase II,"Active, not recruiting",Stuart Salmon ,"[{'id': 890, 'therapyName': 'Regorafenib'}]",A Study of Regorafenib in Advanced Pancreatic Cancer Patients,08/30/2017,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02081378,Phase I,Recruiting,Novartis Pharmaceuticals,"[{'id': 2484, 'therapyName': 'ABL001'}, {'id': 829, 'therapyName': 'Nilotinib'}]","A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)",04/03/2015,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02081495,Phase I,Completed,"Janssen Research & Development, LLC","[{'id': 1008, 'therapyName': 'Doxil'}]",A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer,05/24/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02081755,,Recruiting,Baylor Research Institute,"[{'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 735, 'therapyName': 'Everolimus'}]",Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer,03/13/2015,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT02082210,Phase Ib/II,"Active, not recruiting",Eli Lilly and Company,"[{'id': 1387, 'therapyName': 'Emibetuzumab + Ramucirumab'}]",A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer,07/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02082665,Phase I,Completed,GlaxoSmithKline,"[{'id': 1388, 'therapyName': 'Dabrafenib + Rosuvastatin + Midazolam'}]",Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam,09/27/2016,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02082977,Phase I,Terminated,GlaxoSmithKline ,"[{'id': 2734, 'therapyName': 'GSK2816126'}]","A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell and Transformed Follicular Lymphoma",08/01/2017,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02083250,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 3201, 'therapyName': 'Busulfan + Clofarabine + Fludarabine'}]",Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia,11/16/2015,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02083653,Phase II,"Active, not recruiting",EMD Serono ,"[{'id': 931, 'therapyName': 'SYM004'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer,11/03/2015,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02083692,,Completed,Thomas Jefferson University,"[{'id': 1031, 'therapyName': 'Metformin'}]",Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling,10/20/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02085070,Phase II,Recruiting,Yale University ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 in Melanoma and NSCLC Patients With Brain Metastases,05/06/2015,[],no
0,,[],NCT02085148,,"Active, not recruiting",,[], A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy,04/21/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02085408,Phase III,Recruiting,Eastern Cooperative Oncology Group,"[{'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}]",Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia,06/19/2017,[],no
0,,[],NCT02086526,,Recruiting,,[],Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET),09/16/2015,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02086552,Phase II,Recruiting,Mayo Clinic,"[{'id': 4445, 'therapyName': 'lenalidomide + Sonidegib'}]",Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma,07/14/2016,[],no
0,both,[],NCT02086695,Phase I,Completed,Mayo Clinic ,[],Early Detection of Broken Hearts in Cancer Patients,01/30/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02087176,Phase II,Terminated,AstraZeneca ,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer,06/15/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02087241,Phase II,Terminated,AstraZeneca ,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer,03/30/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02087423,Phase II,"Active, not recruiting",AstraZeneca ,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Global Study to Assess the Effects of MEDI4736 in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (ATLANTIC),12/22/2015,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02088112,Phase I,"Active, not recruiting",MedImmune LLC ,"[{'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC),07/16/2016,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02088541,Phase II,"Active, not recruiting","Karyopharm Therapeutics, Inc ","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}]",Selinexor (KPT-330) in Older Patients With Relapsed AML,04/05/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02088684,Phase Ib/II,"Active, not recruiting",Novartis Pharmaceuticals ,"[{'id': 2315, 'therapyName': 'BKM120 + Fulvestrant + LEE011'}, {'id': 2316, 'therapyName': 'Fulvestrant + LEE011'}, {'id': 2317, 'therapyName': 'BYL719 + Fulvestrant + LEE011'}]",Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer,01/24/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02089230,Phase Ib/II,Recruiting,"M.D. Anderson Cancer Center, Novartis","[{'id': 807, 'therapyName': 'Binimetinib'}]","Phase I/II MEK162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy",02/27/2015,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02089334,Phase Ib/II,Recruiting,"Rexahn Pharmaceuticals, Inc. ","[{'id': 2262, 'therapyName': 'Everolimus + RX-0201'}, {'id': 735, 'therapyName': 'Everolimus'}]","Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer",03/02/2015,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02089685,Phase Ib/II,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2624, 'therapyName': 'peginterferon alfa-2b'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29),02/10/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02090114,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 2591, 'therapyName': 'Andriol'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistant (The RESTORE Study),05/08/2015,[],no
0,female,[],NCT02090127,Phase I,No longer available,"AVEO Pharmaceuticals, Inc. ","[{'id': 740, 'therapyName': 'Ficlatuzumab'}]",Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient,12/01/2015,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02091063,Phase Ib/II,Recruiting,Jennifer Amengual ,"[{'id': 1613, 'therapyName': 'ACY-1215'}]",ACY-1215 for Relapsed/Refractory Lymphoid Malignancies,05/18/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02091141,Phase II,Recruiting,Genentech,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 698, 'therapyName': 'Alectinib'}, {'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors",09/26/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1271, 'profileName': 'SMO act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 4039, 'profileName': 'EGFR exon 20 ins'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1243, 'profileName': 'ERBB2 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1760, 'profileName': 'ALK amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9953, 'name': 'B- and T-cell mixed leukemia', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 1240, 'name': 'leukemia', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02091245,Phase I,Recruiting,Dana-Farber Cancer Institute ,"[{'id': 1749, 'therapyName': 'Selinexor'}]","Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML",06/01/2017,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02091531,Phase II,"Active, not recruiting",Memorial Sloan Kettering Cancer Center,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients,11/23/2016,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02091960,Phase II,"Active, not recruiting","Astellas Pharma Global Development, Inc. ","[{'id': 1878, 'therapyName': 'Enzalutamide + Trastuzumab'}]","A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) and Estrogen Receptor Negative (ER-) Metastatic or Locally Advanced Breast Cancer",02/21/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT02092324,Phase II,Recruiting,OHSU Knight Cancer Institute ,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia,03/11/2016,[],yes
0,both,"[{'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}]",NCT02092909,Phase Ib/II,"Active, not recruiting","Idera Pharmaceuticals, Inc. ","[{'id': 2866, 'therapyName': 'IMO-8400'}]",Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia (8400-401),10/06/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02093403,Phase I,"Active, not recruiting",Ramiro Garzon,"[{'id': 1768, 'therapyName': 'Decitabine + Selinexor'}]",Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,12/22/2016,[],no
0,,[],NCT02093546,,"Active, not recruiting",M.D. Anderson Cancer Center,[],Translational Companion Protocol to GOG229O,10/15/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02094573,Phase II,"Active, not recruiting",Ariad Pharmaceuticals ,"[{'id': 634, 'therapyName': 'AP26113'}]","A Phase 2, Multicenter, Randomized Study of AP26113",10/07/2015,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02094872,Phase II,"Active, not recruiting",Yale University ,"[{'id': 1009, 'therapyName': 'Doxorubicin'}]",Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic,02/21/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02095054,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1305, 'therapyName': 'Regorafenib + Cetuximab'}]",Regorafenib and Cetuximab in Patients With Advanced Malignancy,07/22/2017,[],no
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 3869, 'name': 'childhood medulloblastoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 4791, 'name': 'supratentorial primitive neuroectodermal tumor', 'source': 'DOID'}]",NCT02095132,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 1361, 'therapyName': 'MK-1775 + Irinotecan'}]",WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors,11/25/2014,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02095184,Phase I,Recruiting,University of Maryland ,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]",GCC 1366 Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients,05/12/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02096055,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1949, 'therapyName': 'SGI-110'}, {'id': 1022, 'therapyName': 'Idarubicin'}]",4-Arm Phase II Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML),10/27/2016,[],no
0,both,"[{'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}, {'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT02096354,Phase II,"Active, not recruiting","EpicentRx, Inc. ","[{'id': 890, 'therapyName': 'Regorafenib'}]","A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer",07/06/2017,[],no
0,both,"[{'id': 962, 'name': 'neurofibroma', 'source': 'DOID'}]",NCT02096471,Phase II,"Active, not recruiting",University of Alabama at Birmingham ,"[{'id': 849, 'therapyName': 'PD-0325901'}]",MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1,03/23/2016,[],yes
0,both,"[{'id': 4653, 'name': 'intraocular retinoblastoma', 'source': 'DOID'}]",NCT02097134,Phase I,"Active, not recruiting",Children's Oncology Group ,"[{'id': 1207, 'therapyName': 'Melphalan'}]",Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma,02/10/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02097225,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1362, 'therapyName': 'AT13387 + Dabrafenib + Trametinib'}]","Hsp90 Inhibitor AT13387, Dabrafenib, and Trametinib in Treating Patients With Recurrent Melanoma That is Metastatic or Cannot be Removed by Surgery",04/14/2016,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02097732,Phase II,"Active, not recruiting",University of Michigan Cancer Center ,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery,12/20/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02097810,Phase Ib/II,Recruiting,"Ignyta, Inc.","[{'id': 1455, 'therapyName': 'Entrectinib'}]","A Phase 1/2a Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer; Study Targeting ALK, ROS1, or TRKA/B/C",10/19/2016,[],yes
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02098109,Phase II,Completed,Washington University School of Medicine ,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma,12/24/2016,[],no
0,female,"[{'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}]",NCT02098343,Phase Ib/II,Recruiting,Aprea AB,"[{'id': 1953, 'therapyName': 'Carboplatin + Doxorubicin'}, {'id': 1952, 'therapyName': 'APR-246 + Carboplatin + Doxorubicin'}]","p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246",02/01/2016,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2836, 'profileName': 'TP53 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4866, 'name': 'salivary gland adenoid cystic carcinoma', 'source': 'DOID'}]",NCT02098538,Phase II,"Active, not recruiting",Memorial Sloan-Kettering Cancer Center,"[{'id': 890, 'therapyName': 'Regorafenib'}]","Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma",01/12/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02098967,Phase I,"Active, not recruiting",Hoffmann-La Roche ,"[{'id': 2155, 'therapyName': 'RO6839921'}]","A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.",10/28/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02099058,Phase I,Recruiting,AbbVie,"[{'id': 1743, 'therapyName': 'ABBV-399 + Carboplatin'}, {'id': 1364, 'therapyName': 'ABBV-399 + Erlotinib'}, {'id': 1363, 'therapyName': 'ABBV-399'}, {'id': 1366, 'therapyName': 'ABBV-399 + Bevacizumab'}, {'id': 1365, 'therapyName': 'ABBV-399 + Cetuximab'}]","A Phase 1/1b Study With ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",11/25/2014,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02099539,Phase Ib/II,Recruiting,Altor Bioscience Corporation ,"[{'id': 3060, 'therapyName': 'ALT-803'}]",A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma,01/21/2016,[],no
0,,[],NCT02099864,,Recruiting,OHSU Knight Cancer Institute ,[],Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy,04/21/2015,[],no
0,both,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02100007,Phase Ib/II,Terminated,"MEI Pharma, Inc. ","[{'id': 2174, 'therapyName': 'ME-344 + Topotecan'}]",ME-344 Given in Combination With Hycamtin in Patients With Solid Tumors,07/07/2016,[],no
0,,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02100423,Phase II,"Active, not recruiting",Case Comprehensive Cancer Center ,[],Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma,10/06/2016,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02100852,Phase I,"Active, not recruiting","TG Therapeutics, Inc. ","[{'id': 2342, 'therapyName': 'Chlorambucil + Obinutuzumab + TGR-1202'}]","TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)",10/09/2015,[],no
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT02101021,Phase II,Terminated,Gilead Sciences,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 823, 'therapyName': 'Momelotinib'}]",Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma,04/20/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02101034,Phase Ib/II,Recruiting,Washington University School of Medicine,"[{'id': 1705, 'therapyName': 'Palbociclib + Cetuximab'}]",PD 0332991 and Cetuximab in Patients With Incurable SCCHN,11/25/2014,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02101385,Phase II,Recruiting,Hoosier Cancer Research Network,[],Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer,09/30/2014,[],yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02101593,Phase I,Completed,Polaris Group ,"[{'id': 2424, 'therapyName': 'ADI-PEG 20'}]",Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer,03/05/2016,[],no
0,both,"[{'id': 5151, 'name': 'plexiform neurofibroma', 'source': 'DOID'}]",NCT02101736,Phase II,"Active, not recruiting",University of Alabama at Birmingham ,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +),09/14/2016,[],no
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT02101775,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}]","Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",09/29/2017,[],no
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}]",NCT02101788,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 2173, 'therapyName': 'Doxil + Letrozole + Tamoxifen + Paclitaxel'}, {'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer,05/17/2016,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02101853,Phase III,Recruiting,National Cancer Institute (NCI),"[{'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 2347, 'therapyName': 'Leucovorin + Pegaspargase  + Vincristine'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2348, 'therapyName': 'Asparaginase + Cyclophosphamide + Etoposide'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}]",Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia,12/01/2015,[],yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}, {'id': 5076, 'name': 'mixed glioma', 'source': 'DOID'}, {'id': 5074, 'name': 'malignant ependymoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT02101905,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 787, 'therapyName': 'Lapatinib'}]",Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma,08/05/2016,"[{'molecularProfile': {'id': 447, 'profileName': 'EGFR amp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1798, 'name': 'pancreatic endocrine carcinoma', 'source': 'DOID'}, {'id': 1799, 'name': 'islet cell tumor', 'source': 'DOID'}]",NCT02101918,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 624, 'therapyName': 'Aflibercept'}]",Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery,12/24/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02101944,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 2463, 'therapyName': 'Carfilzomib + Dexamethasone + Reolysin'}]","Viral Protein Production After Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients With Multiple Myeloma",04/25/2017,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT02103478,Phase Ib/II,"Active, not recruiting",Astex Pharmaceuticals,"[{'id': 1759, 'therapyName': 'ASTX727'}]",Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS,08/30/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02104427,Phase II,Completed,"TaiGen Biotechnology Co., Ltd. ","[{'id': 2853, 'therapyName': 'TG-0054'}, {'id': 1632, 'therapyName': 'Filgrastim'}]","PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients",01/13/2016,[],no
0,both,"[{'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}]",NCT02105350,Phase I,Suspended,"University Health Network, Toronto ","[{'id': 2210, 'therapyName': 'Gemcitabine + MEK162 + Oxaliplatin'}]",A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer,07/08/2015,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02105636,Phase III,"Active, not recruiting",Bristol-Myers Squibbb,"[{'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141),01/14/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02106507,Phase I,"Active, not recruiting",Memorial Sloan Kettering Cancer Center,"[{'id': 2303, 'therapyName': 'ARN-509 + Everolimus'}]",ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate,10/14/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02106546,Phase III,"Active, not recruiting",AbbVie ,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer",03/29/2016,[],no
0,both,"[{'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}]",NCT02107235,Phase I,Completed,"Onconova Therapeutics, Inc. ","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1046, 'therapyName': 'rigosertib'}]",Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer,04/07/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02107703,Phase III,"Active, not recruiting",Eli Lilly and Company ,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer,01/06/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02107755,Phase II,"Active, not recruiting",Ohio State University Comprehensive Cancer Center ,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma,11/17/2016,[],no
0,both,"[{'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}]",NCT02108652,Phase II,"Active, not recruiting",Hoffmann-La Roche ,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,05/13/2015,[],no
0,both,"[{'id': 1798, 'name': 'pancreatic endocrine carcinoma', 'source': 'DOID'}]",NCT02108782,Phase II,Withdrawn,Academic and Community Cancer Research United ,"[{'id': 721, 'therapyName': 'Dovitinib'}]",Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors,07/31/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02108964,Phase Ib/II,Recruiting,Novartis Pharmaceuticals,"[{'id': 1309, 'therapyName': 'EGF816'}]","A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies",10/16/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02109016,Phase II,Completed,"Clovis Oncology, Inc. ","[{'id': 1029, 'therapyName': 'Lucitanib'}]","A Study to Assess the Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGFR1-driven Lung Cancer",11/15/2016,"[{'molecularProfile': {'id': 812, 'profileName': 'FGFR1 amp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT02109445,Phase II,Terminated,Pfizer ,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 859, 'therapyName': 'PF-03084014'}]",Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies,07/18/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02109627,Phase I,Recruiting,C. Babis Andreadis ,"[{'id': 3183, 'therapyName': 'Cytarabine + Ficlatuzumab'}]",Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML,11/05/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02109744,Phase Ib/II,Recruiting,University of Rochester,"[{'id': 1796, 'therapyName': 'Decitabine + Sirolimus'}, {'id': 1797, 'therapyName': 'Decitabine + Ribavirin'}]",Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients,12/18/2014,[],no
0,both,[],NCT02110069,Phase II,Recruiting,"Children's Hospital Medical Center, Cincinnati, Pfizer","[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 917, 'therapyName': 'Sirolimus'}]",A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors,03/05/2015,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02110082,Phase I,Completed,Bristol-Myers Squibb,"[{'id': 2066, 'therapyName': 'Cetuximab + Urelumab'}]",Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer,04/01/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02110355,Phase Ib/II,Recruiting,Amgen,"[{'id': 1454, 'therapyName': 'AMG 232 + Trametinib'}, {'id': 1453, 'therapyName': 'AMG 232 + Trametinib + Dabrafenib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma,03/17/2015,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02110563,Phase I,Terminated,"Dicerna Pharmaceuticals, Inc.","[{'id': 3122, 'therapyName': 'DCR-MYC'}]","Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma",08/05/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02111187,Phase I,Completed,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 1428, 'therapyName': 'Sonidegib'}]",A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer,04/30/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02112032,Phase I,"Active, not recruiting","Hassane M. Zarour, MD ","[{'id': 2625, 'therapyName': 'peginterferon alfa-2b + Pembrolizumab'}]",Treatment of Advanced Melanoma With MK-3475 and Peginterferon,08/23/2017,[],no
0,both,"[{'id': 5599, 'name': 'precursor T-lymphoblastic lymphoma/leukemia', 'source': 'DOID'}, {'id': 5603, 'name': 'acute T cell leukemia', 'source': 'DOID'}]",NCT02112916,Phase III,Recruiting,National Cancer Institute (NCI),"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma,10/14/2014,[],no
0,male,"[{'id': 10286, 'name': 'prostate carcinoma', 'source': 'DOID'}]",NCT02113657,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer,07/29/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02113813,Phase I,"Active, not recruiting","Astellas Pharma Global Development, Inc. ","[{'id': 1082, 'therapyName': 'ASP8273'}]",A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations,01/24/2017,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 4039, 'profileName': 'EGFR exon 20 ins'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 2596, 'name': 'larynx cancer', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}, {'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}]",NCT02113878,Phase I,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1691, 'therapyName': 'BKM120 + Cisplatin'}]",Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck,10/30/2014,[],no
0,both,"[{'id': 3672, 'name': 'rhabdoid cancer', 'source': 'DOID'}, {'id': 2129, 'name': 'atypical teratoid rhabdoid tumor', 'source': 'DOID'}]",NCT02114229,Phase II,Recruiting,St. Jude Children's Research Hospital ,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2449, 'therapyName': 'Methotrexate + Cisplatin + Cyclophosphamide + Vincristine'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 942, 'therapyName': 'Topotecan'}]",Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors,10/15/2015,"[{'molecularProfile': {'id': 2085, 'profileName': 'SMARCB1 negative'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 13297, 'profileName': 'SMARCB1 loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 13296, 'profileName': 'SMARCB1 mut'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02115048,Phase II,"Active, not recruiting",Translational Research in Oncology ,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 794, 'therapyName': 'Letrozole'}]",Clinical Study for the Treatment of Breast Cancer the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone,03/22/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02115243,Phase I,"Active, not recruiting",Duke University ,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma,11/26/2016,[],no
0,both,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT02115282,Phase III,Recruiting,National Cancer Institute (NCI),"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1541, 'therapyName': 'Entinostat'}, {'id': 738, 'therapyName': 'Exemestane'}]",Exemestane With or Without Entinostat in Treating Postmenopausal Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic,05/01/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02115464,Phase II,Recruiting,Ontario Clinical Oncology Group (OCOG),"[{'id': 1031, 'therapyName': 'Metformin'}]",Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy,12/22/2014,[],no
0,both,"[{'id': 4897, 'name': 'bile duct carcinoma', 'source': 'DOID'}, {'id': 4948, 'name': 'gallbladder carcinoma', 'source': 'DOID'}]",NCT02115542,Phase II,Recruiting,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Single Agent Regorafenib in Refractory Advanced Biliary Cancers,02/08/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02115828,Phase I,"Active, not recruiting",Sidney Kimmel Comprehensive Cancer Center,"[{'id': 956, 'therapyName': 'Vismodegib'}]",A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy,10/18/2016,[],no
0,both,"[{'id': 1037, 'name': 'lymphoblastic leukemia', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}]",NCT02116777,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 1377, 'therapyName': 'Talazoparib + Temozolomide'}]",BMN-673 and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies,04/22/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02116803,Phase III,Completed,Novartis Pharmaceuticals,"[{'id': 721, 'therapyName': 'Dovitinib'}]",An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective,01/24/2017,[],no
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT02116894,Phase I,Completed,"Herbert Hurwitz, MD ","[{'id': 2035, 'therapyName': 'PF-03446962 + Regorafenib'}]",Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer,12/22/2016,[],no
0,both,"[{'id': 4653, 'name': 'intraocular retinoblastoma', 'source': 'DOID'}]",NCT02116959,Phase I,Unknown status,"University of California, San Francisco ","[{'id': 2559, 'therapyName': 'Carboplatin + Etoposide + Melphalan + Vincristine'}]",Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Intra-Ocular Retinoblastoma,07/04/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02117024,Phase II,"Active, not recruiting",Heat Biologics,"[{'id': 2472, 'therapyName': 'HS-110 + Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,09/03/2015,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02117219,Phase I,Recruiting,MedImmune LLC ,"[{'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Phase 1 Study to Evaluate MEDI4736 in MDS,07/12/2016,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02117297,Phase II,Recruiting,New York Medical College ,"[{'id': 756, 'therapyName': 'Gemtuzumab ozogamicin'}]",SCT Plus Immune Therapy in Average Risk AML/MDS,04/07/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02117362,Phase I,Recruiting,Providence Health & Services ,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2975, 'therapyName': 'GR-MD-02'}]",Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma,07/29/2015,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02117479,Phase III,Terminated,Incyte Corporation,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1),07/12/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02117648,,Completed,,"[{'id': 1690, 'therapyName': 'Abemaciclib + Clarithromycin'}, {'id': 802, 'therapyName': 'Abemaciclib'}]", A Study of LY2835219 in Participants With Cancer,09/22/2015,[],no
0,both,"[{'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02117817,Phase I,Withdrawn,"Rutgers, The State University of New Jersey","[{'id': 1367, 'therapyName': 'BKM120 + Abraxane'}]","Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer",03/20/2015,[],no
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT02118285,Phase I,Completed,"Masonic Cancer Center, University of Minnesota ","[{'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]","Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",08/25/2017,[],no
0,,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02118311,Phase II,Withdrawn,"Masonic Cancer Center, University of Minnesota ","[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease After a Non-Myeloablative Umbilical Cord Blood Transplantation,06/16/2016,"[{'molecularProfile': {'id': 582, 'profileName': 'KIT wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02118337,Phase I,Recruiting,MedImmune LLC ,"[{'id': 3121, 'therapyName': 'MEDI0680 + MEDI4736'}]","A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies",10/08/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02119650,Phase II,Terminated,Incyte Corporation,"[{'id': 1856, 'therapyName': 'Ruxolitinib + Cisplatin + Pemetrexed'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer,06/20/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02119663,Phase III,Terminated,Incyte Corporation,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1615, 'therapyName': 'Ruxolitinib + Capecitabine'}]",A Study of Ruxolitinib in Pancreatic Cancer Patients,10/05/2016,[],no
0,both,"[{'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}, {'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT02119676,Phase II,Terminated,Incyte Corporation ,"[{'id': 890, 'therapyName': 'Regorafenib'}, {'id': 907, 'therapyName': 'Ruxolitinib'}]",Study of Ruxolitinib in Colorectal Cancer Patients,06/20/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02120222,Phase I,Recruiting,Kari Kendra ,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery,07/13/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02120287,Phase II,Recruiting,University of Pittsburgh ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme,07/15/2015,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02120417,Phase II,Terminated,Incyte Corporation ,"[{'id': 1615, 'therapyName': 'Ruxolitinib + Capecitabine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer,07/13/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02120469,Phase I,Recruiting,City of Hope Medical Center ,"[{'id': 2252, 'therapyName': 'Eribulin + Everolimus'}]",Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer,12/02/2016,[],yes
0,both,"[{'id': 2513, 'name': 'basal cell carcinoma', 'source': 'DOID'}]",NCT02120677,Phase I,Recruiting,Johns Hopkins University ,"[{'id': 1026, 'therapyName': 'Itraconazole'}]",Topical Itraconazole in the Treatment of Basal Cell Carcinoma,02/27/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT02121418,Phase I,"Active, not recruiting",University of Washington,"[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}]","Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm",09/01/2016,[],no
0,female,"[{'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}]",NCT02121990,Phase I,"Active, not recruiting",Memorial Sloan-Kettering Cancer Center,"[{'id': 1451, 'therapyName': 'Cisplatin + Paclitaxel + Bevacizumab + Olaparib '}]","Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",02/10/2017,[],no
0,both,"[{'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT02122172,Phase II,Recruiting,University of Chicago ,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib in Advanced Refractory Urothelial Cancer,08/12/2017,[],no
0,female,"[{'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT02122185,Phase II,Recruiting,University of Chicago,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1827, 'therapyName': 'Paclitaxel + Carboplatin + Docetaxel'}]","Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",03/17/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02122770,Phase I,"Active, not recruiting","Millennium Pharmaceuticals, Inc.","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1688, 'therapyName': 'MLN4924'}, {'id': 1689, 'therapyName': 'Fluconazole'}]","Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors",03/11/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02122809,Phase I,Completed,"Chipscreen Biosciences, Ltd. ","[{'id': 1998, 'therapyName': 'Chiauranib'}]",Phase I Study of Chiauranib in Patients With Advanced Solid Tumors,06/18/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02122861,Phase I,"Active, not recruiting",Immune Design ,"[{'id': 3271, 'therapyName': 'ID-LV305'}]","A Phase 1 Safety Study of Intradermal ID-LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1",08/22/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02122913,Phase I,Recruiting,"Loxo Oncology, Inc.","[{'id': 2650, 'therapyName': 'LOXO-101'}]",Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Adult Solid Tumors,05/20/2015,[],yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02123758,Phase I,"Active, not recruiting","Aragon Pharmaceuticals, Inc. ","[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]",A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer,12/20/2016,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02124148,Phase I,Recruiting,Eli Lilly and Company,"[{'id': 1994, 'therapyName': 'Cisplatin + Prexasertib'}, {'id': 1993, 'therapyName': 'Cetuximab + Prexasertib'}, {'id': 6248, 'therapyName': 'Pemetrexed + Prexasertib'}, {'id': 6247, 'therapyName': 'LY3023414 + Prexasertib'}, {'id': 6246, 'therapyName': 'Fluoruracil + Leucovorin + Prexasertib'}]",A Study of LY2606368 With Cisplatin or Cetuximab in Participants With Advanced Cancer,10/16/2017,"[{'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT02124421,Phase II,Recruiting,Mercy Medical Center ,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1812, 'therapyName': 'Cisplatin + Paclitaxel'}]","Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer",02/26/2015,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02124707,Phase II,Recruiting,UNC Lineberger Comprehensive Cancer Center,"[{'id': 1989, 'therapyName': 'Carboplatin + Cetuximab + Paclitaxel'}]","Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN",01/29/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02124772,Phase I,Recruiting,GlaxoSmithKline,"[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations",08/31/2015,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1273, 'profileName': 'BRAF rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 8618, 'name': 'oral cavity cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 2596, 'name': 'larynx cancer', 'source': 'DOID'}]",NCT02124850,Phase I,Recruiting,VentiRx Pharmaceuticals Inc. ,"[{'id': 694, 'therapyName': 'Cetuximab'}]",A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With ERBITUX&#174; (Cetuximab) and VTX-2337,02/22/2015,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02125084,Phase I,"Active, not recruiting","SCRI Development Innovations, LLC ","[{'id': 2264, 'therapyName': 'Enzalutamide + Everolimus'}]",Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer,03/19/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02125357,Phase II,"Active, not recruiting",British Columbia Cancer Agency ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Sequencing Abiraterone and Enzalutamide in mCRPC,02/08/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02125461,Phase III,"Active, not recruiting",AstraZeneca ,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer (PACIFIC),04/09/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02126553,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1164, 'therapyName': 'lenalidomide'}]",Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in Remission,01/25/2015,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02126579,Phase Ib/II,Recruiting,"Craig L Slingluff, Jr ","[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 3009, 'therapyName': 'Long peptide vaccine 7'}]",Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists,08/11/2015,[],no
0,both,"[{'id': 4465, 'name': 'papillary renal cell carcinoma', 'source': 'DOID'}]",NCT02127710,Phase II,"Active, not recruiting",AstraZeneca ,"[{'id': 2161, 'therapyName': 'Savolitinib'}]",A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC),11/06/2015,[],no
0,both,"[{'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT02128282,Phase Ib/II,Recruiting,"Senhwa Biosciences, Inc. ","[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 6091, 'therapyName': 'Cisplatin + Gemcitabine + Silmitasertib'}]",Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma,08/04/2017,[],no
0,both,"[{'id': 2596, 'name': 'larynx cancer', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT02128906,Phase II,Recruiting,University of Pittsburgh ,"[{'id': 1925, 'therapyName': 'Docetaxel + Cetuximab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC,01/07/2015,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02129062,Phase II,Terminated,National Cancer Institute (NCI),"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia,12/04/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02129075,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 3006, 'therapyName': 'NeoVax melanoma vaccine'}, {'id': 3007, 'therapyName': 'CDX-301'}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}]",CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma,12/06/2015,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 8692, 'name': 'myeloid leukemia', 'source': 'DOID'}]",NCT02129101,Phase I,"Active, not recruiting",Mayo Clinic,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1428, 'therapyName': 'Sonidegib'}]",Azacitidine and Sonidegib in Treating Patients With Myeloid Malignancies,01/24/2017,[],no
0,both,[],NCT02129647,Phase II,Recruiting,New York University School of Medicine ,"[{'id': 649, 'therapyName': 'Axitinib'}]",Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas,02/24/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02130466,Phase Ib/II,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}, {'id': 1448, 'therapyName': 'Pembrolizumab + Dabrafenib'}, {'id': 1449, 'therapyName': 'Pembrolizumab + Dabrafenib + Trametinib'}]",A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022),09/11/2014,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 4, 'profileName': 'BRAF wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02130557,Phase III,"Active, not recruiting",Avillion Development 1 Limited ,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 770, 'therapyName': 'Imatinib'}]","A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia",09/19/2015,[],no
0,both,"[{'id': 2994, 'name': 'germ cell cancer', 'source': 'DOID'}, {'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 5176, 'name': ""renal Wilms' tumor"", 'source': 'DOID'}, {'id': 1319, 'name': 'brain cancer', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 768, 'name': 'retinoblastoma', 'source': 'DOID'}]",NCT02130869,Phase I,Recruiting,St. Jude Children's Research Hospital ,"[{'id': 2378, 'therapyName': 'Bendamustine + Cytarabine + Etoposide'}, {'id': 2460, 'therapyName': 'Busulfan + Hu14.18K322A'}, {'id': 2459, 'therapyName': 'Aldesleukin + Melphalan + Sargramostim'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,03/25/2015,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02131064,Phase III,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}, {'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]",A Study Comparing Kadcyla Plus Perjeta Treatment to Chemotherapy Combined With Herceptin Plus Perjeta in Patients With HER2-Positive Breast Cancer,07/07/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02131584,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL),05/23/2017,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT02131597,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1949, 'therapyName': 'SGI-110'}]",SGI-110 in Higher Risk Myelodysplastic Syndrome (MDS),12/17/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02132598,Phase II,Recruiting,"Liza Villaruz, MD ","[{'id': 998, 'therapyName': 'cabozantinib'}]",Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases,10/02/2016,"[{'molecularProfile': {'id': 1629, 'profileName': 'MET amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02132754,Phase I,Recruiting,Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2829, 'therapyName': 'MK-4166'}]",Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001),06/12/2015,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02132949,Phase II,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1895, 'therapyName': 'Cyclophosphamide + Fluorouracil + Docetaxel + Epirubicin  '}]","A Study Evaluating Perjeta (Pertuzumab) Combined With Herceptin (Trastuzumab) and Standard Anthracycline-based Chemotherapy in Patients With HER2-positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer.",07/06/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02133183,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",TORC1/2 Inhibitor INK128 Before and After Surgery in Treating Patients With Recurrent Glioblastoma,03/08/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02133742,Phase I,"Active, not recruiting",Pfizer ,"[{'id': 2494, 'therapyName': 'Axitinib + Pembrolizumab'}]","A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer",04/07/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02134015,Phase III,Terminated,"Daiichi Sankyo Inc., Parexel","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2530, 'therapyName': 'Patritumab + Erlotinib'}]",Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung),08/29/2017,"[{'molecularProfile': {'id': 343, 'profileName': 'EGFR wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02134067,Phase I,Recruiting,"Taiho Oncology, Inc.","[{'id': 1400, 'therapyName': 'TAS-119'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors",10/20/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02134886,Phase I,Terminated,National Cancer Institute (NCI),"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection,09/30/2015,"[{'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 2446, 'profileName': 'ALK fusion'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02134912,Phase II,Recruiting,Southwest Oncology Group,"[{'id': 1151, 'therapyName': 'Crizotinib + Pemetrexed'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib,01/25/2015,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02135133,Phase II,Suspended,Dana-Farber Cancer Institute ,"[{'id': 2326, 'therapyName': 'Idelalisib + Ofatumumab'}]","A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL",05/10/2016,[],no
0,both,[],NCT02135757,FDA approved,"Active, not recruiting",PeriPharm ,[],Study to Evaluate Real-world Pharmacoeconomics and Resistance Mechanisms of Panitumumab in Metastatic Colorectal Cancer Patients,01/15/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02136134,Phase III,"Active, not recruiting","Janssen Research & Development, LLC","[{'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]",Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma,01/28/2016,[],no
0,both,"[{'id': 8632, 'name': ""Kaposi's sarcoma"", 'source': 'DOID'}]",NCT02137564,Phase II,Withdrawn,AIDS Malignancy Clinical Trials Consortium ,"[{'id': 859, 'therapyName': 'PF-03084014'}]",Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma,07/24/2015,[],no
0,both,"[{'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02137759,Phase II,Recruiting,Emory University ,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",MRSI to Predict Response to RT/TMZ and Vorinostat in GBM,03/16/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02137837,Phase III,"Active, not recruiting",Southwest Oncology Group,"[{'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1590, 'therapyName': 'Fulvestrant + Everolimus + Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer",05/22/2015,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02138292,Phase I,"Active, not recruiting",University of Texas Southwestern Medical Center,"[{'id': 1446, 'therapyName': 'Trametinib + Digoxin'}]",A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma,06/03/2016,"[{'molecularProfile': {'id': 4, 'profileName': 'BRAF wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02138383,Phase I,"Active, not recruiting",H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer,01/25/2017,[],yes
0,both,"[{'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}, {'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT02138617,Phase II,Recruiting,UNC Lineberger Comprehensive Cancer Center,"[{'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1715, 'therapyName': 'Fluorouracil'}]",Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer,02/16/2015,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02138786,Phase II,Terminated,"Karyopharm Therapeutics, Inc ","[{'id': 1749, 'therapyName': 'Selinexor'}]",Study of Selinexor (KPT-330) in Patients With Refractory and/or Relapsed Richter's Transformation (RT),08/23/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02138812,Phase I,"Active, not recruiting",Bayer ,"[{'id': 3448, 'therapyName': 'BAY1161909 + Paclitaxel'}]",Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel,02/08/2017,[],yes
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}]",NCT02138929,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1871, 'therapyName': 'Everolimus + Sonidegib'}]",LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma,04/25/2017,[],yes
0,both,[],NCT02139215,FDA approved,"Active, not recruiting",PeriPharm ,[],Study to Evaluate Real-world Pharmacoeconomics of Panitumumab in Metastatic Colorectal Cancer Patients,01/15/2016,[],yes
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02139358,Phase Ib/II,"Active, not recruiting",H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 1592, 'therapyName': 'Gemcitabine + Trastuzumab + Pertuzumab'}]",Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer,01/25/2017,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT02139397,Phase Ib/II,Recruiting,Giselle Sholler ,"[{'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma,05/06/2015,[],no
0,,[],NCT02140723,,Recruiting,,[],p53 and Response to Preoperative Radiotherapy for T2 and T3,02/25/2015,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02140840,Phase II,Withdrawn,University of Arkansas,"[{'id': 2, 'therapyName': 'Trametinib'}]","A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib",04/08/2016,"[{'molecularProfile': {'id': 696, 'profileName': 'BRAF act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02141282,Phase II,"Active, not recruiting",AbbVie ,"[{'id': 1562, 'therapyName': 'Venetoclax'}]",A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy,10/14/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02141295,Phase II,Completed,Hoffmann-La Roche,"[{'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 1598, 'therapyName': 'RO5520985'}, {'id': 1599, 'therapyName': 'Bevacizumab + Fluorouracil + Leucovorin'}, {'id': 1600, 'therapyName': 'RO5520985 + Leucovorin + Fluorouracil'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study Comparing the Efficacy and Safety of RO5520985 and FOLFOX With Bevacizumab and FOLFOX in Patients With Untreated Metastatic Colorectal Cancer (McCAVE),04/27/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT02141477,Phase II,Terminated,M.D. Anderson Cancer Center,"[{'id': 1762, 'therapyName': 'Omacetaxine + Decitabine'}]",Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS),06/27/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02141542,Phase I,"Active, not recruiting","F. Stephen Hodi, MD ","[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1176, 'therapyName': 'MEDI3617'}]",Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma,07/22/2017,[],no
0,both,"[{'id': 12603, 'name': 'acute leukemia', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02141828,Phase I,Completed,"Epizyme, Inc. ","[{'id': 2855, 'therapyName': 'EPZ-5676'}]",A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene,08/04/2016,"[{'molecularProfile': {'id': 14079, 'profileName': 'KMT2A rearrange'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02142218,Phase I,No longer available,Bristol-Myers Squibb ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Expanded Access Program With Nivolumab to Treat Melanoma,09/30/2016,[],no
0,both,[],NCT02142296,FDA approved,Completed,Lawson Health Research Institute ,[],Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD),02/17/2017,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02142530,Phase I,Recruiting,Massachusetts General Hospital ,"[{'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1624, 'therapyName': 'Carfilzomib'}]",Carfilzomib Plus Belinostat in Relapsed/Refractory NHL,12/03/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02142738,Phase III,"Active, not recruiting",Merck Sharp & Dohme Corp. ,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024),10/09/2015,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02142803,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1444, 'therapyName': 'MLN0128 + Bevacizumab'}]",MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors,09/11/2014,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02142868,Phase III,No longer available,Pfizer ,"[{'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]","Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate",06/15/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02143050,Phase Ib/II,Recruiting,James Graham Brown Cancer Center,"[{'id': 1443, 'therapyName': 'Dabrafenib + Trametinib + Metformin'}]","Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients",10/10/2014,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02143401,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1872, 'therapyName': 'Navitoclax + Sorafenib'}]",Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors,07/22/2017,[],no
0,both,"[{'id': 7061, 'name': 'precursor B lymphoblastic lymphoma/leukemia', 'source': 'DOID'}]",NCT02143414,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1824, 'therapyName': 'Vincristine + Methotrexate + Mercaptopurine'}]","Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia",01/27/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02143466,Phase I,Recruiting,AstraZeneca,"[{'id': 2224, 'therapyName': 'Osimertinib + Savolitinib'}, {'id': 2225, 'therapyName': 'Osimertinib + Selumetinib'}, {'id': 2223, 'therapyName': 'AZD9291 + MEDI4736'}]",AZD9291 in Combination With Ascending Doses of Novel Therapeutics,02/01/2016,"[{'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02143635,Phase I,Recruiting,Novartis Pharmaceuticals,"[{'id': 2186, 'therapyName': 'HDM201'}]",Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt,02/27/2015,"[{'molecularProfile': {'id': 642, 'profileName': 'TP53 wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT02143726,Phase II,Recruiting,Alliance for Clinical Trials in Oncology,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 735, 'therapyName': 'Everolimus'}]","Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Thyroid Cancer",03/05/2015,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02144038,Phase Ib/II,Completed,Novartis Pharmaceuticals,"[{'id': 2419, 'therapyName': 'BYL719 + LGH447'}, {'id': 2402, 'therapyName': 'LGH447 '}]",Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma,01/28/2016,[],no
0,both,"[{'id': 3962, 'name': 'follicular thyroid carcinoma', 'source': 'DOID'}, {'id': 3969, 'name': 'papillary thyroid carcinoma', 'source': 'DOID'}]",NCT02145143,Phase I,"Active, not recruiting",Memorial Sloan-Kettering Cancer Center ,"[{'id': 342, 'therapyName': 'Vemurafenib'}]","Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib",02/27/2016,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02145559,Phase I,"Active, not recruiting",University of Chicago,"[{'id': 1593, 'therapyName': 'Sirolimus + Metformin'}, {'id': 917, 'therapyName': 'Sirolimus'}]",A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors,06/23/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02145910,Phase I,Withdrawn,Thomas Jefferson University,"[{'id': 342, 'therapyName': 'Vemurafenib'}]",Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases,03/19/2015,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02146066,Expanded access,Available,Northwest Biotherapeutics,"[{'id': 5205, 'therapyName': 'DCVax-L'}]",Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221,01/31/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02146222,Phase I,"Active, not recruiting","University of Wisconsin, Madison","[{'id': 1442, 'therapyName': 'X-82 + Docetaxel'}]",VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors,10/05/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02146833,Phase II,Terminated,"Karyopharm Therapeutics, Inc ","[{'id': 1749, 'therapyName': 'Selinexor'}]",Study of Selinexor (KPT-330) in Metastatic Castrate Resistant Prostate Adenocarcinoma,03/25/2016,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02146924,Phase I,Recruiting,City of Hope Medical Center ,[],Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia,06/17/2016,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02147990,Phase II,Unknown status,"Clovis Oncology, Inc. ","[{'id': 1003, 'therapyName': 'CO1686'}]",Open Label Safety and Efficacy Study of Rociletinib (CO-1686) in Patients With T790M Positive NSCLC Who Have Failed One Previous EGFR-Directed TKI,10/03/2017,"[{'molecularProfile': {'id': 4039, 'profileName': 'EGFR exon 20 ins'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT02149108,Phase III,Completed,Boehringer Ingelheim ,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer,08/30/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02150733,Phase I,Completed,Daiichi Sankyo Inc.,"[{'id': 636, 'therapyName': 'Tivantinib'}]",Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment,07/15/2016,[],no
0,both,"[{'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT02150967,Phase II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 674, 'therapyName': 'BGJ398'}]","A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma",03/22/2017,[],no
0,both,"[{'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}, {'id': 4948, 'name': 'gallbladder carcinoma', 'source': 'DOID'}]",NCT02151084,Phase II,Recruiting,"University Health Network, Toronto","[{'id': 2222, 'therapyName': 'Selumetinib + Cisplatin + Gemcitabine'}]",A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer,02/28/2015,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02151864,Phase I,"Active, not recruiting","Jason K. Sicklick, M.D.","[{'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A Cirrhosis,09/12/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02151981,Phase III,"Active, not recruiting",AstraZeneca,"[{'id': 660, 'therapyName': 'Osimertinib'}]",AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer,10/10/2015,"[{'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02152059,Phase II,Withdrawn,AHS Cancer Control Alberta ,"[{'id': 831, 'therapyName': 'Nintedanib'}]",A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy,07/07/2016,[],no
0,both,[],NCT02152254,Phase II,Recruiting,M.D. Anderson Cancer Center ,[],IMPACT 2: Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer,08/10/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02152631,Phase III,"Active, not recruiting",Eli Lilly and Company,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 802, 'therapyName': 'Abemaciclib'}]",A Study of LY2835219 in Participants With Previously Treated Lung Cancer,01/24/2017,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02152943,Phase I,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 1591, 'therapyName': 'Everolimus + Letrozole + Trastuzumab'}]","Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients",11/09/2016,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02152982,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,10/18/2017,[],no
0,both,"[{'id': 3962, 'name': 'follicular thyroid carcinoma', 'source': 'DOID'}]",NCT02152995,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer,04/14/2016,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02153450,Phase I,Recruiting,Case Comprehensive Cancer Center,"[{'id': 1031, 'therapyName': 'Metformin'}]",Stereotactic Radiosurgery and Metformin Hydrochloride in Treating Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer,05/15/2015,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}]",NCT02153580,Phase I,"Active, not recruiting",City of Hope Medical Center ,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 1231, 'therapyName': 'Bendamustine'}]","Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia",12/01/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02154490,Phase II,Recruiting,Southwest Oncology Group|National Cancer Institute (NCI),"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 1016, 'therapyName': 'GDC-0032'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 629, 'therapyName': 'AMG102'}]",Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer,02/16/2017,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 2446, 'profileName': 'ALK fusion'}, 'requirementType': 'excluded'}]",yes
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02154529,Phase Ib/II,Terminated,"Kadmon Corporation, LLC ","[{'id': 1880, 'therapyName': 'XL647 + Trastuzumab'}]",Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer,08/31/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT02154737,Phase I,Recruiting,"Tony Reid, M.D., Ph.D. ","[{'id': 2381, 'therapyName': 'Erlotinib + Gemcitabine'}]",Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer,03/19/2015,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02154776,Phase I,Completed,Novartis Pharmaceuticals,"[{'id': 1594, 'therapyName': 'LEE011 + BKM120 + Letrozole'}]","Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. (LeeBLet)",07/14/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02155088,Phase I,"Active, not recruiting",H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 1870, 'therapyName': 'BYL719 + Gemcitabine + Abraxane'}]",BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer,12/13/2016,[],no
0,both,"[{'id': 1324, 'name': 'lung cancer', 'source': 'DOID'}]",NCT02155465,Phase Ib/II,Completed,Memorial Sloan-Kettering Cancer Center,"[{'id': 1858, 'therapyName': 'Ruxolitinib + Erlotinib'}]",Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib,10/20/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02155582,Phase I,Completed,Bayer,"[{'id': 995, 'therapyName': 'Copanlisib'}]",Copanlisib Pharmacodynamic Study,04/08/2017,[],no
0,both,"[{'id': 3965, 'name': 'Merkel cell carcinoma', 'source': 'DOID'}]",NCT02155647,Phase II,Recruiting,EMD Serono ,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200),10/21/2016,[],no
0,both,"[{'id': 5509, 'name': 'pediatric ependymoma', 'source': 'DOID'}]",NCT02155920,Phase II,Recruiting,University of Texas Southwestern Medical Center ,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus for Children With Recurrent or Progressive Ependymomaildren With Recurrent or Progressive Ependymoma,03/12/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02156804,Phase II,"Active, not recruiting",Bristol-Myers Squibb,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)",03/15/2016,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02157051,Phase I,Recruiting,University of Washington ,[],Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer,06/09/2015,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02157103,Phase II,"Active, not recruiting",Emory University ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma,05/19/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02157636,Phase I,Recruiting,Constellation Pharmaceuticals ,"[{'id': 2033, 'therapyName': 'CPI-0610'}]",A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma,12/21/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02157792,Phase I,Recruiting,Vertex Pharmaceuticals Incorporated ,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy",07/13/2015,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02157883,Phase I,"Active, not recruiting",AstraZeneca ,"[{'id': 1026, 'therapyName': 'Itraconazole'}, {'id': 660, 'therapyName': 'Osimertinib'}]","Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)",08/20/2016,"[{'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02158091,Phase Ib/II,"Active, not recruiting",Dana-Farber Cancer Institute,"[{'id': 2339, 'therapyName': 'Cyclophosphamide + Fludarabine + Rituximab '}, {'id': 1024, 'therapyName': 'Duvelisib'}]","A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL",11/05/2016,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02158507,Phase I,"Active, not recruiting","University of Alabama at Birmingham, Scariot Foundation, GlaxoSmithKline, AbbVie","[{'id': 2543, 'therapyName': 'Lapatinib + Veliparib'}]","Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer",09/13/2017,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02158520,Phase II,"Active, not recruiting",Academic and Community Cancer Research United ,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1261, 'therapyName': 'Bevacizumab + Abraxane'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery,06/19/2017,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 12603, 'name': 'acute leukemia', 'source': 'DOID'}, {'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02158858,Phase I,Recruiting,Constellation Pharmaceuticals ,"[{'id': 2033, 'therapyName': 'CPI-0610'}]","A Phase 1 Study Evaluating CPI-0610 in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelodysplastic/Myeloproliferative Neoplasms",11/05/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02159066,Phase II,"Active, not recruiting",Novartis Pharmaceuticals ,"[{'id': 1101, 'therapyName': 'Binimetinib + Encorafenib + Ribociclib'}, {'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}, {'id': 2216, 'therapyName': 'LGX818 + MEK162 + INC280'}, {'id': 2215, 'therapyName': 'LGX818 + MEK162 + BKM120'}, {'id': 2214, 'therapyName': 'LGX818 + MEK162 + BGJ398'}]","LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma",02/13/2016,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02159365,Phase II,"Active, not recruiting",Bristol-Myers Squibb,"[{'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]",Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients,02/25/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02159495,Phase I,Recruiting,City of Hope Medical Center ,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,12/04/2015,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02159755,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1729, 'therapyName': 'ibrutinib + palbociclib'}]",Ibrutinib and Palbociclib Isethionate in Treating Patients With Previously Treated Mantle Cell Lymphoma,04/28/2017,[],yes
0,both,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02159950,Phase II,Completed,Roswell Park Cancer Institute ,"[{'id': 2648, 'therapyName': 'Sipuleucel-T'}, {'id': 2699, 'therapyName': 'Tasquinimod'}]",Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,05/21/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02159989,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1595, 'therapyName': 'Aflibercept + MLN0128'}]",MLN0128 and Ziv-Aflibercept in Treating Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery,12/01/2015,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02160015,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]","Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",05/17/2017,[],yes
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02160041,Phase II,Recruiting,Novartis Pharmaceuticals,"[{'id': 674, 'therapyName': 'BGJ398'}]",BGJ398 for Patients With Tumors With FGFR Genetic Alterations,09/22/2016,"[{'molecularProfile': {'id': 3329, 'profileName': 'FGFR3 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1185, 'profileName': 'FGFR2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1221, 'profileName': 'FGFR1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14903, 'profileName': 'FGFR3 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2969, 'profileName': 'FGFR2 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3147, 'profileName': 'FGFR2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 812, 'profileName': 'FGFR1 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14910, 'profileName': 'FGFR1 fusion'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02160106,Phase I,Recruiting,"MedPacto, Inc. ","[{'id': 3011, 'therapyName': 'TEW 7197'}]",First in Human Dose Escalation Study of TEW-7197 in Subjects With Advanced Stage Solid Tumors,08/11/2015,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02161419,Phase II,Terminated,Bayer ,"[{'id': 663, 'therapyName': 'BAY1000394'}]",RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer,05/21/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02161770,Phase I,Completed,AstraZeneca ,"[{'id': 660, 'therapyName': 'Osimertinib'}]",Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment,09/29/2017,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02162719,Phase II,"Active, not recruiting",Genentech,"[{'id': 1588, 'therapyName': 'Ipatasertib + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer,11/08/2016,[],yes
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02162888,Phase I,Completed,"Eagle Pharmaceuticals, Inc.","[{'id': 1231, 'therapyName': 'Bendamustine'}]","A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients",11/17/2014,[],no
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT02163356,Phase I,Recruiting,South Plains Oncology Consortium ,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2731, 'therapyName': 'Fenretinide'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma,07/08/2015,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02163694,Phase III,Recruiting,AbbVie ,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",05/05/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02163733,Phase I,"Active, not recruiting",AstraZeneca,"[{'id': 660, 'therapyName': 'Osimertinib'}]",Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer,05/07/2015,"[{'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02164006,Phase I,"Active, not recruiting","TG Therapeutics, Inc. ","[{'id': 2022, 'therapyName': 'TGR-1202'}]","Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients",02/04/2016,[],no
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}]",NCT02164240,Phase I,"Active, not recruiting",Dana-Farber Cancer Institute ,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST,03/24/2017,[],no
0,both,"[{'id': 2893, 'name': 'cervix carcinoma', 'source': 'DOID'}]",NCT02164461,Phase Ib/II,"Active, not recruiting","Advaxis, Inc. ","[{'id': 3090, 'therapyName': 'ADXS11-001'}]",ADXS11-001 High Dose HPV+ Cervical Cancer,06/21/2016,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02164838,Phase I,"Active, not recruiting",Children's Oncology Group,"[{'id': 649, 'therapyName': 'Axitinib'}]",VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors,06/23/2017,[],no
0,both,"[{'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}, {'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT02164916,Phase II,"Active, not recruiting",Southwest Oncology Group ,"[{'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 1331, 'therapyName': 'Vemurafenib + Cetuximab + Irinotecan '}]",S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer,04/07/2016,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT02166905,Phase Ib/II,Recruiting,Roswell Park Cancer Institute ,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission",08/11/2015,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02167854,Phase I,Recruiting,Memorial Sloan-Kettering Cancer Center,"[{'id': 2059, 'therapyName': 'BYL719 + LJM716 + Trastuzumab'}]","Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer",08/12/2016,"[{'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02168777,Phase Ib/II,Terminated,Bayer,"[{'id': 1424, 'therapyName': 'Regorafenib + Refametinib'}, {'id': 888, 'therapyName': 'Refametinib'}]","Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer",12/03/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4007, 'name': 'bladder carcinoma', 'source': 'DOID'}]",NCT02169284,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery,03/19/2015,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02170389,Phase I,Withdrawn,Roswell Park Cancer Institute ,"[{'id': 4075, 'therapyName': 'AGS-003'}]",Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer,09/19/2017,[],no
0,,[],NCT02171286,,Completed,,[],The OncoPanel Pilot (TOP) Study,04/15/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}, {'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02173093,Phase Ib/II,Recruiting,Barbara Ann Karmanos Cancer Institute,"[{'id': 2058, 'therapyName': 'Aldesleukin + GD2Bi-a ATC + Sargramostim '}]",Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma,06/09/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02174172,Phase I,Recruiting,Hoffmann-La Roche ,"[{'id': 6252, 'therapyName': 'Atezolizumab + Bevacizumab +Peg-interferon alfa-2a'}, {'id': 6253, 'therapyName': 'Atezolizumab + Interferon alfa-2b'}, {'id': 6250, 'therapyName': 'Atezolizumab + Peg-interferon alfa-2a'}, {'id': 6249, 'therapyName': 'Atezolizumab + Ipilimumab'}, {'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Study to Assess the Safety and Tolerability of MPDL3280A in Combination With Other Immune-modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors,09/26/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02174549,Phase I,Recruiting,Teclison Ltd. ,"[{'id': 3028, 'therapyName': 'tirapazamine'}]",Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer,09/06/2015,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02176161,Phase II,Recruiting,Winthrop University Hospital,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Prostate Cancer Adjuvant Trial,12/22/2014,[],no
0,both,"[{'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}]",NCT02177695,Phase II,Recruiting,Southwest Oncology Group ,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2564, 'therapyName': 'Aldoxorubicin + Cisplatin + Filgrastim + Methotrexate + Vinblastine'}]","S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer",04/22/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02177812,Phase I,Recruiting,GlaxoSmithKline ,"[{'id': 3014, 'therapyName': 'GSK2879552 '}]",A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML),02/25/2016,[],no
0,both,[],NCT02177825,Phase II,Recruiting,St. Justine's Hospital ,"[{'id': 770, 'therapyName': 'Imatinib'}]",Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas,03/26/2015,[],no
0,both,"[{'id': 2596, 'name': 'larynx cancer', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT02177838,Phase II,Suspended,"Rutgers, The State University of New Jersey","[{'id': 1915, 'therapyName': 'Cetuximab + Cisplatin'}]",Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer,09/29/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02178072,Phase II,Recruiting,Yale University ,"[{'id': 651, 'therapyName': 'Azacitidine'}]","Window Trial 5-aza in HNSCC, T-tare",07/20/2016,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02178436,Phase Ib/II,Suspended,Barbara Ann Karmanos Cancer Institute ,"[{'id': 2560, 'therapyName': 'Gemcitabine + nab-paclitaxel + Selinexor'}]","Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer",02/08/2017,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT02178644,Phase I,Recruiting,Yale University ,"[{'id': 1699, 'therapyName': 'KD018'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer,08/27/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 2870, 'name': 'endometrial adenocarcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02178722,Phase Ib/II,Recruiting,Incyte Corporation ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2575, 'therapyName': 'Epacadostat'}]","A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors and Advanced NSCLC (INCB 24360-202 / MK-3475-037 / KEYNOTE-037)",04/23/2015,[],yes
0,both,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT02178956,Phase III,"Active, not recruiting","Boston Biomedical, Inc ","[{'id': 2057, 'therapyName': 'BBI608'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer,12/21/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02179086,Phase II,Recruiting,NRG Oncology,"[{'id': 1141, 'therapyName': 'Temozolomide'}]",Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma,02/02/2015,[],no
0,,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02179671,Phase II,Completed,AstraZeneca,"[{'id': 1117, 'therapyName': 'Selumetinib + Docetaxel'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 660, 'therapyName': 'Osimertinib'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer",07/26/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02179918,Phase I,Completed,Pfizer,"[{'id': 5086, 'therapyName': 'Utomilumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036),10/10/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02180698,Phase I,Recruiting,Fred Hutchinson Cancer Research Center ,"[{'id': 3576, 'therapyName': 'GLA-SE'}]",TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery,03/20/2016,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02180711,Phase I,"Active, not recruiting",Acerta Pharma BV,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","An Open-label, Phase 1b Study of ACP 196 in Subjects With Follicular Lymphoma",12/06/2016,[],no
0,both,"[{'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}]",NCT02180724,Phase I,"Active, not recruiting",Acerta Pharma BV,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","An Open-label, Phase 1b Study of ACP 196 in Subjects With Waldenström Macroglobulinemia",01/21/2016,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02180867,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1472, 'therapyName': 'Doxorubicin + Ifosfamide'}]",Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can be Removed by Surgery (PAZNTIS),10/08/2014,[],no
0,both,"[{'id': 50749, 'name': 'peripheral T-cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02181218,Phase I,Recruiting,Washington University School of Medicine,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1611, 'therapyName': 'Gemcitabine + Oxaliplatin + Dexamethasone'}]","Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas",02/06/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02181478,Phase I,Recruiting,Case Comprehensive Cancer Center,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Intra-Osseous Co-Transplant of UCB and hMSC,07/25/2015,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02181738,Phase II,"Active, not recruiting",Bristol-Myers Squibb,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Subjects With Hodgkin's Lymphoma (Registrational) (CheckMate 205),12/02/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02182622,Phase I,Unknown status,Martin Gutierrez ,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1428, 'therapyName': 'Sonidegib'}]",LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel,06/20/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02184195,Phase III,Recruiting,AstraZeneca,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy,12/30/2014,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4556, 'name': 'lung large cell carcinoma', 'source': 'DOID'}, {'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}]",NCT02185690,Phase I,Not yet recruiting,"University Health Network, Toronto, Novartis","[{'id': 2213, 'therapyName': 'MEK162 + Carboplatin + Pemetrexed'}]","A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung",10/08/2016,"[{'molecularProfile': {'id': 343, 'profileName': 'EGFR wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02186249,Phase III,No longer available,Bristol-Myers Squibb,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Anti-CTLA-4 Treatment-Naïve Subjects With Unresectable or Metastatic Melanoma (CheckMate 218),02/10/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02186301,Phase II,Terminated,"Clovis Oncology, Inc.","[{'id': 1003, 'therapyName': 'CO1686'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR Mutant NSCLC Who Have Not Had Any Previous EGFR Directed Therapy,09/09/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 4039, 'profileName': 'EGFR exon 20 ins'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 4813, 'name': 'adult brain stem glioma', 'source': 'DOID'}]",NCT02186509,Phase I,Recruiting,Thomas Jefferson University,"[{'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas,02/02/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02186821,Phase II,Completed,Novartis Pharmaceuticals ,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE),11/30/2016,"[{'molecularProfile': {'id': 2097, 'profileName': 'ROS1 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1760, 'profileName': 'ALK amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1676, 'profileName': 'ROS1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02186834,Phase Ib/II,"Active, not recruiting",H. Lee Moffitt Cancer Center and Research Institute,"[{'id': 3356, 'therapyName': 'Dexamethasone + pegylated liposomal-doxorubicin + Selinexor'}]",Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma,10/05/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02186847,Phase II,"Active, not recruiting",NRG Oncology ,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer,12/23/2016,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02187302,Phase II,Completed,Cerulean Pharma Inc. ,"[{'id': 1213, 'therapyName': 'CRLX101 + Bevacizumab'}]",CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC),04/21/2017,[],no
0,,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02187744,Phase III,Completed,Pfizer,"[{'id': 1485, 'therapyName': 'Trastuzumab + Docetaxel + Carboplatin'}]",A Study Of PF-05280014 Or Trastuzumab Plus Taxotere&#174; And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04),05/03/2016,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02187783,Phase II,"Active, not recruiting",Novartis Pharmaceuticals,"[{'id': 790, 'therapyName': 'Ribociclib'}]",LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE),09/10/2016,"[{'molecularProfile': {'id': 4974, 'profileName': 'CDKN2A mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02187861,Phase II,"Active, not recruiting",Hoffmann-La Roche ,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3637, 'therapyName': 'Bendamustine + GDC-0199 + Rituximab'}, {'id': 3937, 'therapyName': 'GDC-0199 + Rituximab'}]",A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma,05/06/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02187991,Phase II,Recruiting,US Oncology Research,"[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer,07/09/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02188264,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer,06/20/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02188368,Phase II,Recruiting,Oncotherapeutics,"[{'id': 1625, 'therapyName': 'Bortezomib + Carfilzomib + Clarithromycin'}, {'id': 1674, 'therapyName': 'Doxil + Pomalidomide'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Pomalidomide for Lenalidomide for Failures,03/11/2016,[],no
0,female,"[{'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT02188550,Phase II,Unknown status,Sinai Hospital of Baltimore,"[{'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]",Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer,06/20/2017,[],no
0,both,"[{'id': 1240, 'name': 'leukemia', 'source': 'DOID'}]",NCT02188706,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1608, 'therapyName': 'Decitabine + Carboplatin'}, {'id': 1609, 'therapyName': 'Decitabine + Arsenic trioxide '}]","A Leukemia SPORE Phase II Clinical Trial Comparing Decitabine Versus Decitabine/Carboplatin and Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)",06/05/2015,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02188745,Phase II,Recruiting,Dartmouth-Hitchcock Medical Center,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 1643, 'therapyName': 'Estradiol'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]",ER Reactivation Therapy for Breast Cancer,12/09/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02189174,Phase Ib/II,Terminated,Novartis Pharmaceuticals,"[{'id': 1464, 'therapyName': 'CLR457'}]",Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies,01/16/2016,"[{'molecularProfile': {'id': 1191, 'profileName': 'PIK3CA amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2096, 'profileName': 'MET act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2095, 'profileName': 'PTEN inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02189343,Phase I,"Active, not recruiting",Acetylon Pharmaceuticals Incorporated ,"[{'id': 1614, 'therapyName': 'ACY-1215 + Pomalidomide + Dexamethasone'}]",Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed-and-Refractory Multiple Myeloma,04/09/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02190695,Phase II,Recruiting,Temple University,"[{'id': 1608, 'therapyName': 'Decitabine + Carboplatin'}, {'id': 1609, 'therapyName': 'Decitabine + Arsenic trioxide '}]","A Safety and Efficacy Study Using Decitabine, Decitabine/Carboplatin, Decitabine/Arsenic for the Treatment of Relapsed, Refractory, and Elderly Acute Myeloid Leukemia , Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia",10/02/2014,[],no
0,both,"[{'id': 60061, 'name': 'cutaneous T cell lymphoma', 'source': 'DOID'}]",NCT02192021,Phase I,Recruiting,University of Pittsburgh,"[{'id': 1009, 'therapyName': 'Doxorubicin'}]",Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL),02/18/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 3996, 'name': 'urinary system cancer', 'source': 'DOID'}, {'id': 3119, 'name': 'gastrointestinal system cancer', 'source': 'DOID'}]",NCT02192541,Phase I,Completed,National Cancer Institute (NCI),"[{'id': 1665, 'therapyName': 'Ganetespib + Aflibercept'}]","Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas",03/01/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02192775,Phase II,Recruiting,University of Arkansas ,"[{'id': 6125, 'therapyName': 'MV-NIS'}]",UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus,09/05/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02193152,Phase I,Recruiting,Washington University School of Medicine,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib in Molecularly Selected Patients With Advanced NSCLC,04/28/2015,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1215, 'profileName': 'PDGFRA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2346, 'profileName': 'KDR mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02193282,Phase III,Recruiting,National Cancer Institute (NCI),"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial),10/14/2014,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02193347,Phase I,Recruiting,Duke University,"[{'id': 1635, 'therapyName': 'PEPIDH1M vaccine'}]",RESIST: Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine,12/17/2015,"[{'molecularProfile': {'id': 1253, 'profileName': 'IDH1 R132H'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02194049,Phase I,Completed,"University of California, Davis","[{'id': 1626, 'therapyName': 'BKM120 + Etoposide + Cisplatin'}]","Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer",06/23/2016,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02194829,Phase Ib/II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 822, 'therapyName': 'MK-1775'}]",Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery,08/10/2017,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}]",NCT02195011,Phase II,"Active, not recruiting","SCRI Development Innovations, LLC","[{'id': 890, 'therapyName': 'Regorafenib'}]",Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases,05/09/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02195479,Phase III,Recruiting,"Janssen Research & Development, LLC","[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 1207, 'therapyName': 'Melphalan'}]",A Study of Combination of Daratumumanb and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma,01/24/2017,[],no
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT02195973,Phase Ib/II,"Active, not recruiting",University of Alabama at Birmingham,"[{'id': 1620, 'therapyName': 'Paclitaxel + Sonidegib'}]",Phase IB/II Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer,02/10/2017,[],no
0,both,"[{'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 50619, 'name': 'paranasal sinus cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT02196168,Phase II,Terminated,National Cancer Institute (NCI),"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer,08/05/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02196181,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery,06/19/2017,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02196857,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1633, 'therapyName': 'Sorafenib + Azacitidine'}]",Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation,02/10/2015,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT02197169,Phase I,"Active, not recruiting","DNAtrix, Inc. ","[{'id': 4407, 'therapyName': 'DNX-2401'}, {'id': 4444, 'therapyName': 'DNX-2401 + interferon gamma '}]",DNX-2401 With Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I),12/07/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02197234,Phase I,"Active, not recruiting",AstraZeneca,"[{'id': 1645, 'therapyName': 'Osimertinib + Simvastatin'}, {'id': 660, 'therapyName': 'Osimertinib'}]",Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC,07/15/2015,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02197247,Phase I,"Active, not recruiting",AstraZeneca,"[{'id': 1644, 'therapyName': 'Osimertinib + Rifampin'}, {'id': 660, 'therapyName': 'Osimertinib'}]","Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC",07/15/2015,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02197572,Phase I,"Active, not recruiting","Millennium Pharmaceuticals, Inc.","[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Effect of MLN0128 on the QTc Interval in Participants With Advanced Solid Tumors,09/19/2015,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT02197897,Phase II,Recruiting,Baylor College of Medicine,"[{'id': 1456, 'therapyName': 'Tamoxifen'}]",Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors,06/24/2015,[],no
0,,[],NCT02198417,,"Active, not recruiting",Massachusetts General Hospital ,[],Metformin Treatment in Polycystic Ovary Syndrome (PCOS),03/23/2017,[],no
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02199171,Phase I,Unknown status,"University of California, Irvine","[{'id': 1092, 'therapyName': 'Carboplatin'}]","Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer",06/20/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02199197,Phase II,Recruiting,University of Utah,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Radium Ra 223 With Enzalutamide in Men With Metastatic Castration Refractory Prostate Cancer,10/07/2014,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02199223,Phase I,Terminated,University of Utah ,"[{'id': 1617, 'therapyName': 'Regorafenib + Panitumumab'}]",Regorafenib + Panitumumab,09/23/2016,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1993, 'name': 'rectum cancer', 'source': 'DOID'}, {'id': 14110, 'name': 'anus cancer', 'source': 'DOID'}]",NCT02199236,Phase I,Recruiting,Memorial Sloan-Kettering Cancer Center,"[{'id': 1619, 'therapyName': 'Capecitabine + Fluorouracil'}]",Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management,10/07/2014,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02199665,Phase I,"Active, not recruiting",University of Chicago ,"[{'id': 2985, 'therapyName': 'Carfilzomib + Dexamethasone + Selinexor'}]","Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",11/30/2016,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02200380,Phase II,Terminated,Celldex Therapeutics ,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3007, 'therapyName': 'CDX-301'}]",A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs,05/25/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02200562,Phase Ib/II,Terminated,University of Utah,"[{'id': 1257, 'therapyName': 'Dabrafenib + Ipilimumab'}]",Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma,01/25/2017,"[{'molecularProfile': {'id': 654, 'profileName': 'BRAF V600R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02200614,Phase III,Recruiting,"Orion Corporation, Orion Pharma","[{'id': 836, 'therapyName': 'ODM-201'}]",Efficacy and Safety Study of ODM-201 in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer,10/10/2014,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02200757,Phase II,Recruiting,CytRx,"[{'id': 1440, 'therapyName': 'Aldoxorubicin'}, {'id': 942, 'therapyName': 'Topotecan'}]",Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer,11/17/2014,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02200848,Phase I,Terminated,Georgetown University ,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]","Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory CLL",05/12/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02201212,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus for Cancer With TSC1 or TSC2 Mutation,07/16/2015,[],yes
0,both,"[{'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT02201355,Phase I,"Active, not recruiting",University of Texas Southwestern Medical Center,"[{'id': 700, 'therapyName': 'Cisplatin'}]","Reduced-Volume Hypofractionated, PET-directed Intensity Modulated Radiotherapy Concurrent With Weekly Cisplatin Chemotherapy for Squamous Cell Carcinoma of the Head and Neck",12/30/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02201992,Phase III,Recruiting,Eastern Cooperative Oncology Group,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial),11/03/2014,[],yes
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02202746,Phase II,"Active, not recruiting","Clovis Oncology, Inc.","[{'id': 1029, 'therapyName': 'Lucitanib'}]","A Study to Assess the Safety and Efficacy of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With FGF Aberrant Metastatic Breast Cancer",04/07/2016,"[{'molecularProfile': {'id': 812, 'profileName': 'FGFR1 amp'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT02203513,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1651, 'therapyName': 'Prexasertib'}]","Chk1/2 Inhibitor (LY2606368) in Women With BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Non-High Risk Triple Negative Breast Cancer, and Grade Serous Ovarian Cancer at Low Genetic Risk",11/10/2015,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 3234, 'name': 'central nervous system lymphoma', 'source': 'DOID'}]",NCT02203526,Phase I,Suspended,National Cancer Institute (NCI),"[{'id': 1607, 'therapyName': 'Temozolomide + Etoposide + Doxil + Dexamethasone + Ibrutinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]","Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma",06/02/2016,[],no
0,both,"[{'id': 8923, 'name': 'skin melanoma', 'source': 'DOID'}]",NCT02203604,Phase II,"Active, not recruiting","Rutgers, The State University of New Jersey","[{'id': 1612, 'therapyName': 'Aldesleukin + Ipilimumab'}]",High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery,07/13/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02203695,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy,09/29/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02203773,Phase I,"Active, not recruiting",AbbVie ,"[{'id': 1636, 'therapyName': 'GDC-0199 + Decitabine'}, {'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}]",Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo),07/13/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02204020,Phase II,Withdrawn,University of Pittsburgh,"[{'id': 651, 'therapyName': 'Azacitidine'}]",Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS,07/08/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02204072,Phase I,Recruiting,Boehringer Ingelheim ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2916, 'therapyName': 'Xentuzumab'}]",BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC),12/10/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02204085,Phase Ib/II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 3426, 'therapyName': 'GO-203-2C'}]","A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia",01/29/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02204098,Phase I,Recruiting,Washington University School of Medicine,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy,01/08/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02204553,Phase I,No longer available,Novartis Pharmaceuticals,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}]",Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma,12/30/2015,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02204982,Phase III,Terminated,"Infinity Pharmaceuticals, Inc.","[{'id': 1024, 'therapyName': 'Duvelisib'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of IPI-145 in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma (DYNAMO + R),04/13/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02205333,Phase Ib/II,Terminated,MedImmune LLC ,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1653, 'therapyName': 'MEDI6469'}, {'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies,05/09/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02205398,Phase Ib/II,Terminated,Novartis Pharmaceuticals,"[{'id': 1618, 'therapyName': 'INC280 + Cetuximab '}]","Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy",07/26/2017,"[{'molecularProfile': {'id': 1240, 'profileName': 'MET positive'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 481, 'profileName': 'NRAS wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT02205515,Phase Ib/II,Recruiting,Sunnybrook Health Sciences Centre ,"[{'id': 735, 'therapyName': 'Everolimus'}]","An Open Label, Single-Centre, Phase II Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis",07/27/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02206763,Phase I,Terminated,Gilead Sciences ,"[{'id': 2380, 'therapyName': 'Erlotinib + Momelotinib'}]",Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC),03/23/2017,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 3457, 'name': 'invasive lobular carcinoma', 'source': 'DOID'}]",NCT02206984,Phase I,Recruiting,University of Pittsburgh ,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Endocrine Response in Women With Invasive Lobular Breast Cancer,09/28/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'excluded'}]",yes
0,both,[],NCT02207010,Phase I,"Active, not recruiting","St. Joseph's Hospital and Medical Center, Phoenix ",[],A Phase 0 Study of AZD1775 in Recurrent GBM Patients,03/19/2016,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}]",NCT02207062,Phase I,Recruiting,University of Washington ,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma,04/29/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02207504,Phase I,"Active, not recruiting",Dana-Farber Cancer Institute,"[{'id': 2446, 'therapyName': 'Crizotinib + Enzalutamide'}]",Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer,09/16/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02207530,Phase II,"Active, not recruiting",AstraZeneca,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Phase II Study of MEDI4736 Monotherapy in the Treatment of Patients With Recurrent or Metastatic SCCHN.,04/26/2016,[],no
0,both,"[{'id': 12603, 'name': 'acute leukemia', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02208037,Phase II,"Active, not recruiting","National Heart, Lung, and Blood Institute (NHLBI) ",[],Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203),06/18/2016,[],no
0,female,"[{'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 2870, 'name': 'endometrial adenocarcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02208375,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 655, 'therapyName': 'AZD5363'}, {'id': 991, 'therapyName': 'Vistusertib'}]",mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian Cancer,11/09/2016,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 5485, 'name': 'synovial sarcoma', 'source': 'DOID'}, {'id': 3382, 'name': 'liposarcoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02210104,Phase I,Withdrawn,M.D. Anderson Cancer Center,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Adoptive Therapy Using Antigen-Specific CD4 T-Cells,07/22/2017,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT02210117,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2111, 'therapyName': 'Bevacizumab + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC),02/21/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02211014,Phase I,"Active, not recruiting",Acerta Pharma BV ,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma",12/06/2016,[],no
0,both,"[{'id': 3969, 'name': 'papillary thyroid carcinoma', 'source': 'DOID'}, {'id': 3962, 'name': 'follicular thyroid carcinoma', 'source': 'DOID'}]",NCT02211222,Phase I,Approved for marketing,Eisai Inc. ,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer,03/19/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02211755,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 3063, 'therapyName': 'Bortezomib + Clofarabine'}]",Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors,08/27/2015,[],no
0,both,"[{'id': 12603, 'name': 'acute leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02212561,Phase Ib/II,Completed,St. Jude Children's Research Hospital ,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2345, 'therapyName': 'Cytarabine + Dexamethasone+ Methotrexate '}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome,03/04/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02212730,Phase I,Recruiting,Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031),05/08/2015,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02213042,Phase II,"Active, not recruiting",GlaxoSmithKline,"[{'id': 1414, 'therapyName': 'Trastuzumab + Lapatinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer,06/22/2017,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02213107,Phase II,"Active, not recruiting",University of Rochester ,"[{'id': 3067, 'therapyName': 'Dutasteride + Enzalutamide'}]",Enzalutamide & Dutasteride as 1st Line Treatment for Patients =/&gt; 65 Years Old With Prostate Cancer.,08/25/2017,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT02213289,Phase Ib/II,Recruiting,University of Chicago ,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1913, 'therapyName': 'FOLTAX'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 629, 'therapyName': 'AMG102'}]",PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,03/17/2015,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02213744,Phase II,Terminated,Merrimack Pharmaceuticals ,"[{'id': 1890, 'therapyName': 'Vinorelbine + Trastuzumab'}, {'id': 1409, 'therapyName': 'Capecitabine + Trastuzumab'}, {'id': 1889, 'therapyName': 'Gemcitabine + Trastuzumab'}, {'id': 1888, 'therapyName': 'MM-302 + Trastuzumab'}]",MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients,01/07/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02213926,Phase II,"Active, not recruiting",Acerta Pharma BV ,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","An Open-label, Phase 2 Study of ACP 196 in Subjects With Mantle Cell Lymphoma",02/09/2016,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 5825, 'name': 'adult lymphoma', 'source': 'DOID'}]",NCT02214147,Phase I,Completed,"Millennium Pharmaceuticals, Inc. ","[{'id': 626, 'therapyName': 'Alisertib'}]",Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function,08/30/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02215096,Phase I,Recruiting,GlaxoSmithKline ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 765, 'therapyName': 'GSK2636771'}]",Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer,08/26/2015,"[{'molecularProfile': {'id': 479, 'profileName': 'PTEN loss'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02215161,Phase II,"Active, not recruiting","University of California, San Francisco ","[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide,05/02/2017,[],no
0,both,[],NCT02215512,Phase I,"Active, not recruiting","EpicentRx, Inc. ","[{'id': 3680, 'therapyName': 'RRx-001'}]",Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases,07/06/2017,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02216409,Phase I,Recruiting,"Forty Seven, Inc. ","[{'id': 4947, 'therapyName': 'Hu5F9-G4'}]","Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody",11/19/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02217566,Phase II,"Active, not recruiting","Janssen Research & Development, LLC ","[{'id': 1805, 'therapyName': 'Abiraterone'}]","Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy",11/06/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02218606,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer,08/27/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02219711,Phase I,Recruiting,Mirati Therapeutics Inc. ,"[{'id': 1655, 'therapyName': 'MGCD516'}]",Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer,03/03/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02219724,Phase I,"Active, not recruiting","Genentech, Inc. ","[{'id': 2729, 'therapyName': 'MOXR0916'}]","A Phase I, Open-Label Study of MOXR0916 in Patients With Locally Advanced or Metastatic Solid Tumors",06/01/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02219737,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3360, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide + Rituximab'}]",Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,07/14/2017,[],yes
0,female,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}]",NCT02219789,Phase I,"Active, not recruiting",Mayo Clinic,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,04/02/2016,[],yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02220608,Phase I,Completed,Washington University School of Medicine ,"[{'id': 3345, 'therapyName': 'Bortezomib + Filgrastim'}]",Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma,02/08/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02220842,Phase I,Recruiting,Hoffmann-La Roche,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma,01/25/2015,[],no
0,both,"[{'id': 3275, 'name': 'thymoma', 'source': 'DOID'}]",NCT02220855,Phase II,Recruiting,Indiana University ,"[{'id': 680, 'therapyName': 'BKM120'}]",A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas,04/06/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02220894,Phase III,Recruiting,Merck Sharp & Dohme Corp. ,"[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042),07/25/2017,"[{'molecularProfile': {'id': 4138, 'profileName': 'EML4-ALK'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02221310,Phase II,Recruiting,New York Medical College ,"[{'id': 3932, 'therapyName': 'Busulfan + Cyclophosphamide + Gemtuzumab ozogamicin'}]",Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS,04/15/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02221739,Phase II,Completed,New York University School of Medicine ,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC),10/14/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02221882,Phase I,Completed,Eli Lilly and Company ,"[{'id': 1969, 'therapyName': 'LY3164530'}]",A Study of LY3164530 in Participants With Cancer,07/12/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02221960,Phase I,"Active, not recruiting",MedImmune LLC ,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3119, 'therapyName': 'MEDI6383'}]",A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors,06/22/2016,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02222688,Phase I,Recruiting,Thomas Kipps ,"[{'id': 4312, 'therapyName': 'Cirmtuzumab'}]",UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia,07/01/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02222922,Phase I,Recruiting,Pfizer,"[{'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 4421, 'therapyName': 'PF-06647020'}]",A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors,08/16/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02223247,Phase I,Completed,"3V Biosciences, Inc. ","[{'id': 3611, 'therapyName': 'TVB-2640'}]","A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors",08/15/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02223598,Phase I,Terminated,"Cleave Biosciences, Inc. ","[{'id': 1944, 'therapyName': 'CB-5083'}, {'id': 4513, 'therapyName': 'CB-5083 + Dexamethasone'}]",A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies  (CLC-102),06/20/2017,[],no
0,both,"[{'id': 7808, 'name': 'necrotic uveal melanoma', 'source': 'DOID'}, {'id': 6522, 'name': 'mixed cell uveal melanoma', 'source': 'DOID'}, {'id': 6566, 'name': 'posterior uveal melanoma', 'source': 'DOID'}, {'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT02223819,Phase II,Recruiting,"Memorial Sloan Kettering Cancer Center, Pfizer","[{'id': 706, 'therapyName': 'Crizotinib'}]",Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy,03/30/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02224781,Phase III,Recruiting,National Cancer Institute (NCI),"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,04/14/2016,"[{'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1208, 'profileName': 'HRAS mutant'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02225405,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 2372, 'therapyName': 'Cisplatin + Docetaxel + Nintedanib'}]","Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC)",04/10/2015,[],no
0,both,"[{'id': 12603, 'name': 'acute leukemia', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02225574,Phase Ib/II,Completed,"M.D. Anderson Cancer Center, Novartis","[{'id': 2219, 'therapyName': 'MEK162 + Nilotinib'}]","An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)",02/08/2017,[],yes
0,female,[],NCT02226276,Phase I,"Active, not recruiting",City of Hope Medical Center,[],Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer,03/18/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02226965,Phase II,"Active, not recruiting","ProNAi Therapeutics, Inc ","[{'id': 2581, 'therapyName': 'PNT2258'}]",Wolverine: PNT2258 for Treatment of Patients With r/r DLBCL,06/22/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02227251,Phase II,Recruiting,"Karyopharm Therapeutics, Inc ","[{'id': 1749, 'therapyName': 'Selinexor'}]",Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SADAL),12/31/2015,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02227667,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer,09/30/2015,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02227914,Phase Ib/II,Withdrawn,"Onyx Therapeutics, Inc. ","[{'id': 2422, 'therapyName': 'Oprozomib'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,11/06/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02227940,Phase I,Recruiting,Roswell Park Cancer Institute ,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2554, 'therapyName': 'Ceritinib + Gemcitabine'}]",Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer,04/21/2015,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 80146, 'name': 'B-cell childhood acute lymphoblastic leukemia', 'source': 'DOID'}]",NCT02228096,Phase II,Recruiting,Novartis Pharmaceuticals,"[{'id': 5981, 'therapyName': 'Tisagenlecleucel'}]",Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients,10/03/2017,[],yes
0,,[],NCT02228265,,Recruiting,OHSU Knight Cancer Institute ,[],Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Enzalutamide,05/01/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02228369,Phase I,"Active, not recruiting",AstraZeneca ,"[{'id': 660, 'therapyName': 'Osimertinib'}, {'id': 2912, 'therapyName': 'AZD3759'}]","Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer",03/29/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02228382,FDA approved,"Active, not recruiting",Pfizer ,"[{'id': 690, 'therapyName': 'Bosutinib'}]",Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors,09/29/2017,"[{'molecularProfile': {'id': 536, 'profileName': 'ABL1 T315I'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 3595, 'profileName': 'ABL1 V299L'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02228525,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes,05/11/2017,[],no
0,female,"[{'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}]",NCT02228681,Phase II,"Active, not recruiting",Gynecologic Oncology Group ,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 2401, 'therapyName': 'Medroxyprogesterone'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]",Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer,11/19/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02228811,Phase I,"Active, not recruiting",Deciphera Pharmaceuticals LLC ,"[{'id': 1656, 'therapyName': 'Altiratinib'}]",A Study of DCC-2701 in Participants With Advanced Solid Tumors,12/15/2016,[],no
0,,[],NCT02229136,,"Active, not recruiting",,[],Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus,09/20/2016,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02229149,Phase II,"Active, not recruiting",US Oncology Research ,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer",05/20/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02229981,Phase Ib/II,Recruiting,RedHill Biopharma Limited ,"[{'id': 3301, 'therapyName': 'ABC294640'}]",An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma,12/21/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02230306,Phase II,Terminated,Hussein Tawbi ,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases,04/07/2016,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02230319,Phase II,Unknown status,Medical Oncology & Hematology Associates of Northern Virginia ,"[{'id': 1103, 'therapyName': 'Paclitaxel'}]",Prevention of Paclitaxel Neuropathy With Cryotherapy,09/02/2017,[],no
0,both,"[{'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}]",NCT02231164,Phase III,Terminated,Boehringer Ingelheim ,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 831, 'therapyName': 'Nintedanib'}]",LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research,04/28/2016,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02231723,Phase I,"Active, not recruiting","Boston Biomedical, Inc ","[{'id': 2630, 'therapyName': 'BBI608 + Gemcitabine + nab-paclitaxel'}]",A Study of BBI608 in Combination With Gemcitabine and Nab-Paclitaxel in Adult Patients With Metastatic Pancreatic Adenocarcinoma,10/10/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02231749,Phase III,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214),05/14/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02231775,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Combi-Neo Study for Stage IV Melanoma,02/14/2017,[],no
0,,[],NCT02232230,Phase II,"Active, not recruiting",21st Century Oncology ,[],A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T,07/15/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02232243,Phase I,Recruiting,Peng Wang ,"[{'id': 1316, 'therapyName': 'Hydroxychloroquine'}]",HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors,10/19/2016,[],no
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}]",NCT02232620,Phase II,Recruiting,"Boston Biomedical, Inc ","[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors,03/29/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT02232633,Phase II,Recruiting,"Boston Biomedical, Inc ","[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer,05/06/2015,[],no
0,male,"[{'id': 10286, 'name': 'prostate carcinoma', 'source': 'DOID'}]",NCT02234115,Phase III,Completed,"Foreseeacer Pharmaceuticals, Inc.","[{'id': 795, 'therapyName': 'Leuprolide'}]","Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma",07/06/2017,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}]",NCT02234180,Phase II,Completed,Academic and Community Cancer Research United ,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy,02/08/2017,[],no
0,both,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT02234596,Phase II,"Active, not recruiting",Memorial Sloan Kettering Cancer Center,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Patients With Advanced Esophagogastric Cancer,05/19/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'excluded'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02234921,Phase I,Recruiting,UbiVac ,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Pilot Study of DRibble Vaccine for Prostate Cancer Patients,03/04/2016,[],no
0,both,"[{'id': 5015, 'name': 'fibrolamellar carcinoma', 'source': 'DOID'}]",NCT02234986,Phase II,"Active, not recruiting","CASI Pharmaceuticals, Inc. ","[{'id': 727, 'therapyName': 'ENMD-2076'}]","A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma",06/27/2017,[],no
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT02235324,Phase II,Withdrawn,University of Southern California ,"[{'id': 1841, 'therapyName': 'Aflibercept + Leucovorin + Fluorouracil'}, {'id': 624, 'therapyName': 'Aflibercept'}]","Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer",03/17/2015,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02235740,Phase I,Terminated,GlaxoSmithKline ,"[{'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1839, 'therapyName': 'Afuresertib + Carfilzomib'}]","A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)",05/05/2016,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02236000,Phase Ib/II,Recruiting,NSABP Foundation Inc ,"[{'id': 1906, 'therapyName': 'Neratinib + trastuzumab emtansine'}]",A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer,02/09/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02236013,Phase I,Recruiting,"Astellas Pharma Global Development, Inc. ","[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 2865, 'therapyName': 'Gilteritinib'}]",A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia,11/05/2015,[],yes
0,both,"[{'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}]",NCT02236195,Phase II,Completed,Mirati Therapeutics Inc. ,"[{'id': 3002, 'therapyName': 'Mocetinostat'}]",Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes,12/28/2016,[],yes
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02236572,Phase II,"Active, not recruiting",Yale University ,"[{'id': 735, 'therapyName': 'Everolimus'}]","Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score",12/06/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT02237157,Phase I,"Active, not recruiting",RenovoRx ,"[{'id': 755, 'therapyName': 'Gemcitabine'}]",A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer,03/25/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 5076, 'name': 'mixed glioma', 'source': 'DOID'}]",NCT02238496,Phase II,"Active, not recruiting",Andrew Lassman ,"[{'id': 2194, 'therapyName': 'Perifosine + Temsirolimus'}]",Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas,09/09/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02238522,Phase I,Withdrawn,Zenith Epigenetics Corp. ,[],Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML,12/25/2014,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02239900,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors,06/01/2016,[],no
0,both,"[{'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}, {'id': 4932, 'name': 'ampulla of Vater carcinoma', 'source': 'DOID'}, {'id': 3121, 'name': 'gallbladder cancer', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02240238,Phase Ib/II,Recruiting,"NanoCarrier Co., Ltd.","[{'id': 5626, 'therapyName': 'Gemcitabine + NC-6004'}]","Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer",05/05/2017,[],yes
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02240706,Phase II,Recruiting,Boehringer Ingelheim,"[{'id': 5537, 'therapyName': 'BI 836858'}]",Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes,07/06/2017,[],no
0,both,"[{'id': 712, 'name': 'refractory hematologic cancer', 'source': 'DOID'}]",NCT02240719,Phase I,Recruiting,"University of California, Davis ","[{'id': 2336, 'therapyName': 'Bendamustine + Everolimus'}]",Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer,03/10/2015,[],no
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT02241187,Phase I,Completed,Memorial Sloan-Kettering Cancer Center,"[{'id': 2145, 'therapyName': 'Cetuximab + PEGPH20'}]",Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection,10/27/2016,[],no
0,both,"[{'id': 1324, 'name': 'lung cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02241369,Phase I,Recruiting,Inovio Pharmaceuticals ,"[{'id': 5846, 'therapyName': 'INO-3106 + INO-9012'}]",Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies,06/13/2017,[],no
0,both,"[{'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT02241720,Phase II,Terminated,University of Utah ,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers,09/24/2016,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02242097,Phase II,Recruiting,Northwestern University ,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma,02/19/2016,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02242942,Phase III,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}, {'id': 3636, 'therapyName': 'GDC-0199 + Obinutuzumab'}]",A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia,09/03/2016,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02243371,Phase II,"Active, not recruiting",Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 2642, 'therapyName': 'GVAX pancreatic cancer vaccine  '}, {'id': 2641, 'therapyName': 'CRS-207'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab,09/03/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02243917,Phase I,"Active, not recruiting","Cleave Biosciences, Inc. ","[{'id': 1944, 'therapyName': 'CB-5083'}]",A Phase 1 Study Evaluating CB-5083 in Patients With Advanced Solid Tumors,06/20/2017,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT02244463,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer,07/30/2015,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02244489,Phase I,Terminated,Gilead Sciences,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 823, 'therapyName': 'Momelotinib'}]",Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma,04/19/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02246621,Phase III,"Active, not recruiting",Eli Lilly and Company,"[{'id': 1854, 'therapyName': 'Abemaciclib + Anastrozole + Letrozole'}, {'id': 1853, 'therapyName': 'Anastrozole + Letrozole'}]",A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer,10/22/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02247349,Phase Ib/II,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 4534, 'therapyName': 'BMS-986012'}, {'id': 4535, 'therapyName': 'BMS-986012 + Nivolumab'}]",BMS-986012 in Relapsed/Refractory SCLC,06/27/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02248090,Phase I,"Active, not recruiting",AstraZeneca ,"[{'id': 2997, 'therapyName': 'AZD9496'}]",AZD9496 First Time in Patients Ascending Dose Study,07/14/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT02248805,Phase I,Recruiting,MacroGenics ,"[{'id': 3093, 'therapyName': 'MGD007'}]",Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma,10/02/2015,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02249429,Phase Ib/II,Recruiting,PIQUR Therapeutics AG ,"[{'id': 2019, 'therapyName': 'PQR309'}]","Open-Label, Non Randomized Phase 2 Study With Safety Run-In",04/28/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02250326,Phase II,"Active, not recruiting",Celgene Corporation ,"[{'id': 1950, 'therapyName': 'Abraxane + Azacitidine'}, {'id': 619, 'therapyName': 'Abraxane'}]",Safety and Efficacy Study of Nab-Paclitaxel With CC-486 and Nab-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer,03/02/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02250781,Phase I,Recruiting,Rutgers,"[{'id': 1687, 'therapyName': 'ONC201'}]",Akt/ERK Inhibitor ONC201 in Treating Patients With Advanced Solid Tumors,03/12/2015,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 50626, 'name': 'gastrointestinal neuroendocrine tumor', 'source': 'DOID'}, {'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT02250885,Phase II,Completed,Gabrail Cancer Center Research ,"[{'id': 1749, 'therapyName': 'Selinexor'}]",KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors,11/05/2016,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 8144, 'name': 'pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma', 'source': 'DOID'}, {'id': 7230, 'name': 'postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma', 'source': 'DOID'}]",NCT02251548,Phase II,Recruiting,"Dana-Farber Cancer Institute, Pharmacyclics","[{'id': 2185, 'therapyName': 'Ibrutinib + Rituximab + Cyclophosphamide + Fludarabine'}]","A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia",04/12/2017,[],no
0,both,"[{'id': 4971, 'name': 'myelofibrosis', 'source': 'DOID'}]",NCT02251821,Phase II,Recruiting,Fred Hutchinson Cancer Research Center,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 2006, 'therapyName': 'Pacritinib'}, {'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis,08/20/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02252042,Phase III,"Active, not recruiting",Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040),05/03/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02252146,Phase Ib/II,Completed,"Idera Pharmaceuticals, Inc. ","[{'id': 2866, 'therapyName': 'IMO-8400'}]",Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88L265P Mutation,02/08/2017,"[{'molecularProfile': {'id': 6507, 'profileName': 'MYD88 L265P'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02252263,Phase I,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 2055, 'therapyName': 'Urelumab'}, {'id': 2583, 'therapyName': 'Lirilumab '}, {'id': 3343, 'therapyName': 'Elotuzumab'}]",A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma,04/22/2016,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02252887,Phase II,"Active, not recruiting",Memorial Sloan-Kettering Cancer Center,"[{'id': 1592, 'therapyName': 'Gemcitabine + Trastuzumab + Pertuzumab'}]","Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab-Based Therapy, TDM-1, and TDM-1 + Pertuzumab",05/05/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02253420,Phase I,Recruiting,Bayer,"[{'id': 995, 'therapyName': 'Copanlisib'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",COPANLISIB (BAY80-6946) Drug-drug Interaction Study in Advanced Solid Tumor Patients,02/27/2015,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02253992,Phase Ib/II,Recruiting,Bristol-Myers Squibb ,"[{'id': 2567, 'therapyName': 'Nivolumab + Urelumab'}]",Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma,04/22/2015,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02254239,Phase I,"Active, not recruiting",Mayo Clinic ,"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,08/23/2017,[],no
0,both,"[{'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT02254278,Phase II,"Active, not recruiting",NRG Oncology ,"[{'id': 700, 'therapyName': 'Cisplatin'}]",Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer,02/10/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02254551,Phase II,Terminated,"SCRI Development Innovations, LLC ","[{'id': 1954, 'therapyName': 'Bortezomib + Sonidegib'}]",Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma,12/12/2015,[],no
0,both,"[{'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02254772,Phase Ib/II,Completed,Ronald Levy ,"[{'id': 3848, 'therapyName': 'Ipilimumab + SD-101'}]","TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma",03/04/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02254785,Phase II,Recruiting,British Columbia Cancer Agency ,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer,05/06/2015,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02255097,Phase II,"Active, not recruiting",Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055),10/08/2015,[],no
0,both,"[{'id': 3620, 'name': 'central nervous system cancer', 'source': 'DOID'}]",NCT02255461,Phase I,Recruiting,Pediatric Brain Tumor Consortium ,"[{'id': 850, 'therapyName': 'Palbociclib'}]","Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors",04/06/2017,"[{'molecularProfile': {'id': 2395, 'profileName': 'RB1 positive'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02256111,Phase II,Recruiting,Duke University ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",EXTEND Exercise Trial,06/18/2015,[],no
0,both,"[{'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}]",NCT02256436,Phase III,"Active, not recruiting",Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)",10/14/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02257138,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1735, 'therapyName': 'Ruxolitinib + Decitabine'}]",Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML),02/17/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02257424,Phase Ib/II,Recruiting,Abramson Cancer Center of the University of Pennsylvania ,"[{'id': 2, 'therapyName': 'Trametinib'}]","The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma",02/27/2015,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 3744, 'name': 'cervical squamous cell carcinoma', 'source': 'DOID'}, {'id': 3702, 'name': 'cervical adenocarcinoma', 'source': 'DOID'}, {'id': 5636, 'name': 'cervical adenosquamous carcinoma', 'source': 'DOID'}]",NCT02257528,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1312, 'therapyName': 'Nivolumab'}]","Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer",06/23/2016,[],no
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}]",NCT02257541,Phase Ib/II,"Active, not recruiting",Memorial Sloan Kettering Cancer Center,"[{'id': 2284, 'therapyName': 'BGJ398 + Imatinib'}]",BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST),04/15/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02257567,Phase Ib/II,"Active, not recruiting",Hoffmann-La Roche ,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]",A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma,04/25/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02257619,Phase II,Terminated,Incyte Corporation ,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer,12/07/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02257736,Phase III,"Active, not recruiting","Janssen Research & Development, LLC ","[{'id': 1948, 'therapyName': 'ARN-509 + Abiraterone'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",An Efficacy and Safety Study of JNJ56021927 in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC),09/28/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02258451,Phase II,Recruiting,Bayer,"[{'id': 1966, 'therapyName': 'Exemestane + Everolimus'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer,12/02/2016,[],yes
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02258464,Phase II,Recruiting,Bayer ,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer,04/15/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02258607,Phase I,Terminated,Gilead Sciences ,"[{'id': 823, 'therapyName': 'Momelotinib'}, {'id': 1860, 'therapyName': 'Momelotinib + Trametinib'}]",Efficacy and Safety of Momelotinib and Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase,03/29/2017,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02259010,Phase I,"Active, not recruiting","Millennium Pharmaceuticals, Inc.","[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma,11/18/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 305, 'name': 'carcinoma', 'source': 'DOID'}, {'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02259114,Phase I,Completed,OncoEthix ,"[{'id': 2034, 'therapyName': 'OTX015'}]","A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors",03/29/2017,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02259231,Phase Ib/II,Recruiting,"Reata Pharmaceuticals, Inc. ","[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3062, 'therapyName': 'RTA 408'}]",RTA 408 Capsules in Patients With Melanoma - REVEAL,08/27/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02259582,Phase II,"Active, not recruiting","OncoMed Pharmaceuticals, Inc. ","[{'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 2007, 'therapyName': 'Demcizumab'}]","A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer",02/08/2017,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02259621,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC",05/07/2015,[],no
0,both,"[{'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT02259725,Phase II,Recruiting,University of Southern California ,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors,04/21/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02260440,Phase II,"Active, not recruiting",University of Pittsburgh ,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",A Phase 2 Study of MK-3475 in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer,06/10/2016,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02260531,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 998, 'therapyName': 'cabozantinib'}, {'id': 947, 'therapyName': 'Trastuzumab'}]",Cabozantinib + / - Trastuzumab In Breast Cancer Patients w/ Brain Metastases,01/26/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02260661,Phase I,Completed,AstraZeneca ,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 2013, 'therapyName': 'AZD8835'}]","Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours",10/12/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02261220,Phase I,"Active, not recruiting",MedImmune LLC ,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors,06/20/2017,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02261805,Phase Ib/II,Terminated,Georgetown University ,"[{'id': 3052, 'therapyName': 'Aldoxorubicin + Ganetespib'}]",A Phase I/II Study of Ganetespib in Combination With Doxorubicin,10/15/2016,[],no
0,both,"[{'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 8618, 'name': 'oral cavity cancer', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02262741,Phase I,"Active, not recruiting",MedImmune LLC ,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer",09/10/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02262910,Phase I,Recruiting,Aptevo Therapeutics ,"[{'id': 4651, 'therapyName': 'MOR209/ES414'}]",Study of MOR209/ES414 in Metastatic Castration-Resistant Prostate Cancer,09/12/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02263508,Phase Ib/II,Recruiting,Amgen ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2695, 'therapyName': 'talimogene laherparepvec '}]",MK-3475 With or Without Talimogene Laherparepvec in Unresected Melanoma,02/12/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02263898,Phase II,Withdrawn,Jonsson Comprehensive Cancer Center,"[{'id': 1100, 'therapyName': 'Binimetinib + Encorafenib'}]",Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations,12/23/2016,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02264613,Phase Ib/II,Recruiting,Aileron Therapeutics ,"[{'id': 2273, 'therapyName': 'ALRN-6924'}]",Safety Study of ALRN-6924 in Patients With Advanced Solid Tumors,03/04/2015,"[{'molecularProfile': {'id': 642, 'profileName': 'TP53 wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02264678,Phase Ib/II,Recruiting,AstraZeneca ,"[{'id': 2881, 'therapyName': 'AZD6738'}, {'id': 4737, 'therapyName': 'AZD6738 + Carboplatin'}, {'id': 4738, 'therapyName': 'AZD6738 + MEDI4736'}, {'id': 4739, 'therapyName': 'AZD6738 + Olaparib'}]",Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents,12/02/2016,"[{'molecularProfile': {'id': 11378, 'profileName': 'ATM loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1391, 'profileName': 'ATM dec exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 522, 'profileName': 'ATM inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 17614, 'profileName': 'ATM del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02264990,Phase III,"Active, not recruiting",AbbVie,"[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer Who Are Current or Former Smokers,07/30/2016,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}]",NCT02265341,Phase II,"Active, not recruiting",Mayo Clinic ,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions,10/04/2017,"[{'molecularProfile': {'id': 2969, 'profileName': 'FGFR2 fusion'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02265510,Phase I,Recruiting,Incyte Corporation ,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2747, 'therapyName': 'INCB052793'}, {'id': 688, 'therapyName': 'Bortezomib'}]","An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies",05/29/2015,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02265536,Phase I,Recruiting,Eli Lilly and Company,"[{'id': 2004, 'therapyName': 'LY3022855'}]",A Study of LY3022855 In Participants With Breast or Prostate Cancer,05/14/2015,[],no
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02266147,Phase Ib/II,Completed,Dynavax Technologies Corporation ,"[{'id': 3084, 'therapyName': 'SD-101'}]",Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma,09/01/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02266745,Phase I,Recruiting,Phosplatin Therapeutics ,"[{'id': 2920, 'therapyName': 'PT-112'}]",A Phase 1 Study of PT-112 Injection in Subjects With Advanced Solid Tumors,07/24/2015,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02267083,Phase II,Completed,Gem Pharmaceuticals ,"[{'id': 2041, 'therapyName': 'GPX-150'}]",Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma,02/24/2017,[],no
0,both,"[{'id': 3965, 'name': 'Merkel cell carcinoma', 'source': 'DOID'}]",NCT02267603,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer,05/13/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02268175,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate,11/26/2016,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02268370,Phase II,Recruiting,"University Health Network, Toronto ","[{'id': 717, 'therapyName': 'Dasatinib'}]",Treatment-free Remission Accomplished With Dasatinib in Patients With CML (TRAD),03/11/2016,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}, {'id': 4905, 'name': 'pancreatic carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02268825,Phase Ib/II,"Active, not recruiting",University of Utah,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase I/IIA Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers,09/29/2016,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02268851,Phase I,Recruiting,Dana-Farber Cancer Institute,"[{'id': 2044, 'therapyName': 'Ibrutinib + TGR-1202'}]",A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL,02/16/2015,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02269085,Phase Ib/II,"Active, not recruiting",M.D. Anderson Cancer Center ,"[{'id': 3282, 'therapyName': 'Carfilzomib + Ibrutinib'}]",A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma,12/09/2016,[],no
0,female,"[{'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 6170, 'name': 'ovarian carcinosarcoma', 'source': 'DOID'}]",NCT02269293,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 2640, 'therapyName': 'Carboplatin + Paclitaxel + Selinexor'}]","Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers",05/11/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02269579,Phase II,Recruiting,Celator Pharmaceuticals,"[{'id': 4341, 'therapyName': 'CPX-351'}]",Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment,07/12/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02269670,Phase II,"Active, not recruiting",Emory University,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1869, 'therapyName': 'Megestrol'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 633, 'therapyName': 'Anastrozole'}]",Everolimus and Hormone Therapy in Treating Patients With Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy,09/27/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}]",NCT02269943,Phase II,"Active, not recruiting",Celgene Corporation ,"[{'id': 651, 'therapyName': 'Azacitidine'}]",Safety and Efficacy of Oral Azacitidine in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma,12/25/2015,[],no
0,both,"[{'id': 3459, 'name': 'breast carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}]",NCT02270372,Phase I,Completed,Oncothyreon Inc. ,"[{'id': 2525, 'therapyName': 'Varlilumab'}, {'id': 3051, 'therapyName': 'ONT-10'}]",Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer,08/04/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02270463,Phase Ib/II,Recruiting,"Stemline Therapeutics, Inc. ","[{'id': 2005, 'therapyName': 'SL-401'}]",SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission,02/24/2015,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 12603, 'name': 'acute leukemia', 'source': 'DOID'}]",NCT02270788,Phase I,Completed,St. Jude Children's Research Hospital,"[{'id': 1865, 'therapyName': 'Methotrexate + Cytarabine + Leucovorin'}, {'id': 1864, 'therapyName': 'Crenolanib + Sorafenib'}]",Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies,10/04/2017,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02270814,Phase II,Recruiting,Washington University School of Medicine,"[{'id': 1957, 'therapyName': 'Abraxane + Carboplatin + Cetuximab'}, {'id': 1956, 'therapyName': 'Abraxane + Cisplatin + Cetuximab'}]","Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma",02/04/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02271139,Phase III,No longer available,"Genentech, Inc. ","[{'id': 698, 'therapyName': 'Alectinib'}]",Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Crizotinib,03/10/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02271906,Phase II,Terminated,M.D. Anderson Cancer Center,"[{'id': 623, 'therapyName': 'Afatinib'}]",The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting,08/23/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02272413,Phase III,"Active, not recruiting",Boehringer Ingelheim ,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin Plus Chemotherapy in Patients With Lung Cancer,05/20/2017,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}]",NCT02272686,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center ,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma,02/25/2017,[],yes
0,female,"[{'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}]",NCT02272790,Phase II,Recruiting,AstraZeneca,"[{'id': 1194, 'therapyName': 'MK-1775 + Carboplatin '}, {'id': 1279, 'therapyName': 'MK-1775 + Gemcitabine'}, {'id': 1567, 'therapyName': 'MK-1775 + Paclitaxel'}]","A Phase II Study Comparing AZD1775 + Chemotherapy Versus Chemotherapy Alone in Patients to Treat Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.",03/23/2017,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02272855,Phase II,"Active, not recruiting",Takara Bio Inc. ,"[{'id': 2003, 'therapyName': 'HF10 + Ipilimumab'}]",A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma,04/22/2016,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02272998,Phase II,Recruiting,Sameek Roychowdhury ,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib Hydrochloride in Treating Patients With Refractory Metastatic Cancers and Genetic Alterations,11/23/2015,"[{'molecularProfile': {'id': 2903, 'profileName': 'RET fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1219, 'profileName': 'FGFR2 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1668, 'profileName': 'KIT act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2294, 'profileName': 'RET act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2774, 'profileName': 'FLT3 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2838, 'profileName': 'ABL1 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1217, 'profileName': 'FGFR3 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2881, 'profileName': 'PDGFRA act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3329, 'profileName': 'FGFR3 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1218, 'profileName': 'FGFR1 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3147, 'profileName': 'FGFR2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 812, 'profileName': 'FGFR1 amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02273102,Phase I,Recruiting,University of Miami ,"[{'id': 6126, 'therapyName': 'Tranylcypromine + Tretinoin '}]",Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA),08/18/2017,[],no
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT02273219,Phase I,Recruiting,Gary Schwartz,"[{'id': 1861, 'therapyName': 'AEB071 + BYL719'}]",Trial of AEB071 in Combination With BYL719 in Patients With Melanoma,07/01/2015,[],no
0,,[],NCT02273362,,Recruiting,,[],Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver Undergoing Surgery,03/26/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02273375,Phase III,Recruiting,NCIC Clinical Trials Group ,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC,09/30/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 50749, 'name': 'peripheral T-cell lymphoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02273739,Phase Ib/II,Completed,"Agios Pharmaceuticals, Inc. ","[{'id': 2982, 'therapyName': 'Enasidenib'}]","Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation",08/20/2016,"[{'molecularProfile': {'id': 5912, 'profileName': 'IDH2 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 1798, 'name': 'pancreatic endocrine carcinoma', 'source': 'DOID'}]",NCT02273752,Phase II,Terminated,Emory University ,"[{'id': 735, 'therapyName': 'Everolimus'}]","Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer",01/14/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02273973,Phase II,Completed,"Genentech, Inc. ","[{'id': 1016, 'therapyName': 'GDC-0032'}]",Study of Neoadjuvant Letrozole + GDC-0032 Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI),05/11/2017,[],yes
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 1107, 'name': 'esophageal carcinoma', 'source': 'DOID'}, {'id': 5517, 'name': 'stomach carcinoma', 'source': 'DOID'}]",NCT02274012,Phase II,Withdrawn,Balazs Halmos ,"[{'id': 2441, 'therapyName': 'Afatinib + Paclitaxel'}]","Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer",04/12/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT02275039,Phase I,"Active, not recruiting",City of Hope Medical Center,"[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer,01/13/2017,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02275533,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy,06/19/2015,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02276443,,Recruiting,M.D. Anderson Cancer Center,[],Molecular Triaging and Diagnostic Imaging to Guide Neoadjuvant Therapy,11/11/2015,[],yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02277093,Phase II,Terminated,Washington University School of Medicine,"[{'id': 2006, 'therapyName': 'Pacritinib'}]",Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer,05/02/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02277184,Phase I,Terminated,"Julie E. Bauman, MD, MPH ","[{'id': 1955, 'therapyName': 'Ficlatuzumab + Cisplatin'}]","Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma",09/14/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02277197,Phase I,"Active, not recruiting","Julie E. Bauman, MD, MPH ","[{'id': 1959, 'therapyName': 'Ficlatuzumab + Cetuximab'}]",Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC),09/10/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02277457,Phase I,Withdrawn,University of Michigan Cancer Center ,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 4, 'therapyName': 'Erlotinib'}]","Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations",06/25/2016,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02278120,Phase III,"Active, not recruiting",Novartis Pharmaceuticals,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 790, 'therapyName': 'Ribociclib'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 633, 'therapyName': 'Anastrozole'}]","Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer",04/07/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02278133,Phase Ib/II,Completed,Novartis Pharmaceuticals,"[{'id': 2008, 'therapyName': 'LGK974 + LGX818 + Cetuximab'}]",Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations,10/10/2017,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02278185,Phase II,Recruiting,"University of Colorado, Denver ","[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2047, 'therapyName': 'Histrelin acetate'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer,10/22/2015,[],no
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT02278783,Phase II,Terminated,University of Utah ,"[{'id': 890, 'therapyName': 'Regorafenib'}]","Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer",08/04/2016,[],no
0,female,"[{'id': 3459, 'name': 'breast carcinoma', 'source': 'DOID'}]",NCT02278965,Phase I,"Active, not recruiting",Katherine D. Crew ,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer,07/21/2016,[],no
0,both,"[{'id': 9551, 'name': 'smoldering myeloma', 'source': 'DOID'}]",NCT02279394,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}]",Trial of Combination of Elotuzumab and Lenalidomide +/- Dexamethasone in High-Risk Smoldering Multiple Myeloma,01/24/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 6658, 'name': 'pulmonary large cell neuroendocrine carcinoma', 'source': 'DOID'}]",NCT02279433,Phase I,"Active, not recruiting",Daiichi Sankyo Inc. ,"[{'id': 4343, 'therapyName': 'DS6051b'}]","A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b",09/12/2017,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 11085, 'profileName': 'ROS1 rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02279719,Phase Ib/II,Recruiting,"Boston Biomedical, Inc ","[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2361, 'therapyName': 'BBI503 + Sorafenib'}, {'id': 2362, 'therapyName': 'BBI608 + Sorafenib'}]","A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma",03/12/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02279862,Phase II,Completed,Bristol-Myers Squibb,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive,06/02/2017,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02281084,Phase II,Recruiting,Celgene Corporation ,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes,05/27/2016,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02281279,Phase Ib/II,Withdrawn,Mayo Clinic ,"[{'id': 2349, 'therapyName': 'Lenalidomide + Rituximab + Romidepsin '}]","Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",08/12/2016,[],no
0,both,"[{'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT02281955,Phase II,Recruiting,UNC Lineberger Comprehensive Cancer Center,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC,02/17/2015,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 5744, 'name': 'ovary serous adenocarcinoma', 'source': 'DOID'}, {'id': 5828, 'name': 'endometrioid ovary carcinoma', 'source': 'DOID'}]",NCT02282020,Phase III,Recruiting,"AstraZeneca, Myriad Genetics","[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Treatment in Relapsed Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments.,03/07/2015,"[{'molecularProfile': {'id': 1282, 'profileName': 'BRCA1 inact mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1283, 'profileName': 'BRCA2 inact mut'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02282345,Phase II,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 682, 'therapyName': 'Talazoparib'}]",Neoadjuvant BMN673 for Patients With a BRCA Deleterious Mutation,08/05/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02282358,Phase Ib/II,"Active, not recruiting",Memorial Sloan Kettering Cancer Center ,"[{'id': 3002, 'therapyName': 'Mocetinostat'}]",Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma,04/07/2017,[],yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02282371,Phase I,Recruiting,Memorial Sloan-Kettering Cancer Center,"[{'id': 1837, 'therapyName': 'BYL719 + Cetuximab'}]",Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC),01/30/2015,[],no
0,both,"[{'id': 3565, 'name': 'meningioma', 'source': 'DOID'}]",NCT02282917,Phase I,Recruiting,Massachusetts Eye and Ear Infirmary,"[{'id': 987, 'therapyName': 'AR-42'}]",Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma,09/25/2015,[],yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02283177,Phase II,Recruiting,Arog Pharmaceuticals LLC ,"[{'id': 2637, 'therapyName': 'Crenolanib + Cytarabine + Daunorubicin'}]",A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations,05/07/2015,"[{'molecularProfile': {'id': 2774, 'profileName': 'FLT3 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1325, 'profileName': 'FLT3 rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02283320,Phase II,Completed,BIND Therapeutics ,"[{'id': 720, 'therapyName': 'Docetaxel'}]",A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer,04/19/2016,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT02283359,Phase I,Terminated,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 2588, 'therapyName': 'Irinotecan + Selinexor'}]",Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus,01/16/2016,[],no
0,female,"[{'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}]",NCT02283658,Phase II,"Active, not recruiting",Mayo Clinic ,"[{'id': 1621, 'therapyName': 'Everolimus + Letrozole'}]","Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer",06/08/2016,[],yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02284971,Phase I,Terminated,"James Larner, MD ","[{'id': 2525, 'therapyName': 'Varlilumab'}]",Pilot Study of SBRT and CDX-1127 in Prostate Cancer (Prostate-04),12/02/2016,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 1039, 'name': 'prolymphocytic leukemia', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02285244,Phase II,Withdrawn,James Blachly ,"[{'id': 621, 'therapyName': 'AEB071'}]","Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation",04/03/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02285439,Phase Ib/II,Recruiting,"Children's Hospital Los Angeles , Dana-Farber Cancer Institute","[{'id': 807, 'therapyName': 'Binimetinib'}]",MEK 162 for Children w/Progressive/Recurrent Cancer/Study for Children w/Low-Grade Gliomas/Other Ras/Raf/MAP Pathway Activated Tumors,04/26/2016,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 696, 'profileName': 'BRAF act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}]",NCT02285855,Phase II,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin in Non Small Cell Lung Cancer (NSCLC),02/26/2015,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02285959,Phase I,Recruiting,Erol Veznedaroglu ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme,02/20/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02286687,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center ,"[{'id': 682, 'therapyName': 'Talazoparib'}]",Phase II Study of BMN 673,02/09/2016,"[{'molecularProfile': {'id': 1213, 'profileName': 'PTEN mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1788, 'profileName': 'BRCA2 loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1787, 'profileName': 'BRCA1 loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3274, 'profileName': 'ATM mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2408, 'profileName': 'PTEN del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02286726,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 4341, 'therapyName': 'CPX-351'}]",Phase II CPX-351 in Acute Myeloid Leukemia (AML),07/12/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02286843,Phase I,Recruiting,Memorial Sloan-Kettering Cancer Center,"[{'id': 947, 'therapyName': 'Trastuzumab'}]","Can HER2 Targeted 89Zr-trastuzumab PET/CT Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?",10/05/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02286921,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2591, 'therapyName': 'Andriol'}]","Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance",04/28/2015,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02287025,FDA approved,Terminated,Bayer ,"[{'id': 890, 'therapyName': 'Regorafenib'}]",A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Out Comes?,05/24/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02287233,Phase I,"Active, not recruiting",AbbVie ,"[{'id': 3182, 'therapyName': 'Cytarabine + GDC-0199'}]",A Study Evaluating ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML),05/26/2017,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT02287727,Phase II,Withdrawn,Roswell Park Cancer Institute ,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment,10/14/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02288507,Phase I,Unknown status,University of Hawaii ,"[{'id': 920, 'therapyName': 'Sorafenib'}]",Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer,06/20/2017,[],no
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT02289144,Phase II,Recruiting,University of Texas Southwestern Medical Center ,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Ceritinib (LDK378) in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer,10/15/2015,"[{'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}]",NCT02289209,Phase II,Recruiting,Dan Zandberg ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck,05/08/2015,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02289222,Phase Ib/II,"Active, not recruiting",Ashraf Badros ,"[{'id': 3344, 'therapyName': 'Dexamethasone + Pembrolizumab + Pomalidomide'}]",Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma,11/05/2016,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02289690,Phase I,Recruiting,AbbVie ,"[{'id': 1544, 'therapyName': 'Carboplatin + Etoposide + Veliparib'}]",Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer,05/08/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02289833,Phase II,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]","A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer",11/09/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT02289898,Phase II,"Active, not recruiting","OncoMed Pharmaceuticals, Inc. ","[{'id': 2639, 'therapyName': 'Demcizumab + Gemcitabine + nab-paclitaxel'}]","Study of Gemcitabine, Abraxane Plus Placebo Versus Gemcitabine, Abraxane Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma",09/21/2016,[],no
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT02289950,Phase II,Recruiting,Morphotek ,"[{'id': 3230, 'therapyName': 'Farletuzumab'}]",A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer,12/18/2015,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}]",NCT02290951,Phase I,Recruiting,Regeneron Pharmaceuticals ,"[{'id': 6151, 'therapyName': 'REGN1979'}]",A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies,10/18/2017,[],yes
0,both,"[{'id': 2893, 'name': 'cervix carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02291055,Phase Ib/II,Recruiting,NCT02291055,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3090, 'therapyName': 'ADXS11-001'}]",Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head &amp; Neck Cancer,06/21/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02291913,Phase II,"Active, not recruiting","SCRI Development Innovations, LLC ","[{'id': 2267, 'therapyName': 'Everolimus + Tamoxifen'}, {'id': 2268, 'therapyName': 'Anastrozole + Everolimus'}, {'id': 1589, 'therapyName': 'Fulvestrant + Everolimus'}, {'id': 1621, 'therapyName': 'Everolimus + Letrozole'}, {'id': 2269, 'therapyName': 'Everolimus + Toremifene'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer,03/22/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02292173,Phase I,Recruiting,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 2197, 'therapyName': 'Sorafenib + Trametinib'}]",Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer,02/27/2015,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02292225,Phase I,Terminated,"Infinity Pharmaceuticals, Inc. ","[{'id': 2341, 'therapyName': 'Duvelisib + Obinutuzumab'}]",IPI-145 With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi,12/28/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02292550,Phase Ib/II,"Active, not recruiting",Novartis Pharmaceuticals ,"[{'id': 2638, 'therapyName': 'Ceritinib + LEE011'}]",Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.,09/08/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT02292758,Phase II,Recruiting,Academic and Community Cancer Research United ,"[{'id': 1923, 'therapyName': 'Bevacizumab + Cetuximab + Irinotecan'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}]","Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in KRAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer",03/17/2015,"[{'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1208, 'profileName': 'HRAS mutant'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 1790, 'name': 'malignant mesothelioma', 'source': 'DOID'}]",NCT02293005,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 626, 'therapyName': 'Alisertib'}]",Alisertib in Malignant Mesothelioma,02/18/2017,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT02293980,Phase I,"Active, not recruiting","Peloton Therapeutics, Inc. ","[{'id': 4146, 'therapyName': 'PT2385'}, {'id': 4347, 'therapyName': 'PT2385 + Nivolumab'}]","A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma",08/25/2017,[],no
0,,[],NCT02294006,Phase II,Unknown status,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano ",[],Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs,06/20/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02296112,Phase II,Recruiting,Vanderbilt-Ingram Cancer Center ,"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations,03/03/2015,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1196, 'profileName': 'NRAS G12X'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1198, 'profileName': 'NRAS Q61X'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1197, 'profileName': 'NRAS G13X'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 3287, 'profileName': 'BRAF fusion'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02296125,Phase III,"Active, not recruiting",AstraZeneca ,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 660, 'therapyName': 'Osimertinib'}, {'id': 751, 'therapyName': 'Gefitinib'}]",AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,06/15/2016,"[{'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT02296242,Phase Ib/II,Completed,"BioMed Valley Discoveries, Inc ","[{'id': 997, 'therapyName': 'BVD-523'}]",Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes,07/14/2017,"[{'molecularProfile': {'id': 1208, 'profileName': 'HRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}]",NCT02296684,Phase II,Recruiting,Washington University School of Medicine ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma,04/24/2015,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02296801,Phase II,Recruiting,NSABP Foundation Inc ,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 794, 'therapyName': 'Letrozole'}]",A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer,04/21/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1039, 'name': 'prolymphocytic leukemia', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02296918,Phase I,"Active, not recruiting",Acerta Pharma BV ,"[{'id': 3477, 'therapyName': 'Acalabrutinib + Obinutuzumab'}]",ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL,02/04/2016,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02297230,Phase Ib/II,Completed,New York University School of Medicine ,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1551, 'therapyName': 'Trastuzumab + Paclitaxel'}]",Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics,05/15/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02297698,Phase II,Recruiting,"Cancer Insight, LLC ","[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 3766, 'therapyName': 'E75'}]",Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients,01/16/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02298153,Phase I,"Active, not recruiting",Incyte Corporation ,"[{'id': 2636, 'therapyName': 'Atezolizumab + Epacadostat'}]",A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer,07/15/2017,[],no
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT02298348,Phase I,Recruiting,New Approaches to Neuroblastoma Therapy Consortium,"[{'id': 2360, 'therapyName': 'Cyclophosphamide + Sorafenib + Topotecan'}]",Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,04/11/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02298387,Phase I,"Active, not recruiting","OncoMed Pharmaceuticals, Inc. ","[{'id': 2732, 'therapyName': 'OMP-305B83 '}]",A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors,07/28/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02298959,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 2369, 'therapyName': 'Aflibercept + Pembrolizumab'}]",Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors,03/20/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02299141,Phase I,Recruiting,Washington University School of Medicine ,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer,06/15/2015,"[{'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1417, 'profileName': 'PDGFRA amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2346, 'profileName': 'KDR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3147, 'profileName': 'FGFR2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 812, 'profileName': 'FGFR1 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1215, 'profileName': 'PDGFRA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1185, 'profileName': 'FGFR2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3329, 'profileName': 'FGFR3 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3601, 'profileName': 'KDR amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1221, 'profileName': 'FGFR1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02299505,Phase I,Recruiting,Novartis Pharmaceuticals ,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC),05/08/2015,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02299518,Phase I,Recruiting,Bhavana Bhatnagar ,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}]",Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,05/13/2017,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02299635,Phase II,Terminated,Pfizer ,"[{'id': 859, 'therapyName': 'PF-03084014'}]",A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations,07/18/2015,[],yes
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02300545,Phase II,Recruiting,Washington University School of Medicine ,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy,08/31/2015,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}]",NCT02300610,Phase I,"Active, not recruiting",H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer,08/31/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02300935,Phase I,Withdrawn,"SCRI Development Innovations, LLC ","[{'id': 1268, 'therapyName': 'nab-paclitaxel + GSK1120212'}]",Study of Trametinib and Nab-paclitaxel in Patients With Melanoma,01/16/2016,[],no
0,both,"[{'id': 2994, 'name': 'germ cell cancer', 'source': 'DOID'}]",NCT02300987,Phase II,"Active, not recruiting",Novartis Pharmaceuticals ,"[{'id': 790, 'therapyName': 'Ribociclib'}]","A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression",02/25/2017,[],no
0,both,"[{'id': 5940, 'name': 'malignant peripheral nerve sheath tumor', 'source': 'DOID'}, {'id': 3382, 'name': 'liposarcoma', 'source': 'DOID'}, {'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}, {'id': 5485, 'name': 'synovial sarcoma', 'source': 'DOID'}, {'id': 1967, 'name': 'leiomyosarcoma', 'source': 'DOID'}, {'id': 4415, 'name': 'fibrous histiocytoma', 'source': 'DOID'}]",NCT02301039,Phase II,Recruiting,Sarcoma Alliance for Research through Collaboration ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas,06/01/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02301117,Phase I,Recruiting,"Taiho Oncology, Inc.","[{'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}]",A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment,07/05/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02301130,Phase I,"Active, not recruiting","Kyowa Hakko Kirin Pharma, Inc. ","[{'id': 2968, 'therapyName': 'Mogamulizumab '}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Study of Mogamulizumab + MEDI4736 and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors,10/12/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02301156,Phase III,"Active, not recruiting","TG Therapeutics, Inc.","[{'id': 2287, 'therapyName': 'Ublituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL),12/16/2016,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3234, 'name': 'central nervous system lymphoma', 'source': 'DOID'}]",NCT02301364,Phase II,Completed,Memorial Sloan Kettering Cancer Center. ,"[{'id': 680, 'therapyName': 'BKM120'}]",Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL),10/19/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02301988,Phase II,"Active, not recruiting","Genentech, Inc. ","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 747, 'therapyName': 'Ipatasertib'}]",A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer,07/14/2017,[],yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02302339,Phase II,Recruiting,Celldex Therapeutics ,"[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}]",A Study of Glembatumumab Vedotin in Patients With Advanced Melanoma,03/20/2016,[],no
0,both,"[{'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}]",NCT02302807,Phase III,"Active, not recruiting",Hoffmann-La Roche ,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MPDL3280A Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,03/03/2016,[],no
0,both,"[{'id': 5719, 'name': 'adrenal medulla cancer', 'source': 'DOID'}, {'id': 50773, 'name': 'paraganglioma', 'source': 'DOID'}]",NCT02302833,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Cabozantinib for Malignant Pheochromocytoma,02/19/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}, {'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 3620, 'name': 'central nervous system cancer', 'source': 'DOID'}]",NCT02303028,Phase Ib/II,Recruiting,The Hospital for Sick Children ,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours,03/20/2015,[],no
0,both,"[{'id': 2513, 'name': 'basal cell carcinoma', 'source': 'DOID'}]",NCT02303041,Phase I,"Active, not recruiting",Stanford University ,"[{'id': 1547, 'therapyName': 'BKM120 + Sonidegib'}]",Erismodegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma,06/15/2016,[],no
0,both,"[{'id': 1967, 'name': 'leiomyosarcoma', 'source': 'DOID'}]",NCT02303262,Phase II,Completed,Sarcoma Alliance for Research through Collaboration ,"[{'id': 3128, 'therapyName': 'Gemcitabine + Mocetinostat'}]",A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma,09/29/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02303392,Phase I,Recruiting,Jennifer Woyach ,"[{'id': 3579, 'therapyName': 'Ibrutinib + Selinexor'}]",Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma,06/20/2017,[],no
0,,[],NCT02303444,,Recruiting,Bayer ,[],An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors,08/27/2015,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT02303990,Phase I,Recruiting,Abramson Cancer Center of the University of Pennsylvania,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",RADVAX A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers,05/13/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02304393,Phase I,Recruiting,Hoffmann-La Roche ,"[{'id': 2672, 'therapyName': 'RO7009789'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of RO7009789 in Combination With MPDL3280A in Patients With Locally Advanced and Metastatic Solid Tumors,05/13/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02304419,Phase I,Completed,Eli Lilly and Company ,"[{'id': 2409, 'therapyName': 'Galunisertib'}]",A Study of Galunisertib on the Immune System in Participants With Cancer,10/06/2016,[],no
0,both,"[{'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}, {'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}, {'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}]",NCT02304458,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas,09/07/2016,[],no
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT02305186,Phase Ib/II,Recruiting,"Osama Rahma, MD ","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer,05/08/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02305563,Phase Ib/II,Recruiting,Bristol-Myers Squibb ,"[{'id': 6259, 'therapyName': 'Cytarabine + Ulocuplumab'}]",An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia,09/29/2017,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}]",NCT02305758,Phase II,Completed,AbbVie ,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 954, 'therapyName': 'Veliparib'}]",Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer,09/16/2017,[],no
0,,[],NCT02306135,,Terminated,Dartmouth-Hitchcock Medical Center ,[],Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer,04/28/2016,[],no
0,both,"[{'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}]",NCT02306161,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1433, 'therapyName': 'Vincristine + Doxorubicin + Cyclophosphamide + Ifosfamide + Etoposide'}, {'id': 746, 'therapyName': 'Ganitumab'}]",Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma,12/30/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02306291,Phase Ib/II,Recruiting,GlycoMimetics Incorporated ,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 4402, 'therapyName': 'GMI-1271'}]","Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML",07/22/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02306850,Phase II,Recruiting,St. Louis University ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma,05/13/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02307149,Phase I,Recruiting,Viralytics ,"[{'id': 2974, 'therapyName': 'coxsackievirus A21'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Study of Intratumoral CAVATAK (Coxsackievirus A21) and Ipilimumab in Patients With Advanced Melanoma,07/29/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02307240,Phase I,Recruiting,"Curis, Inc. ","[{'id': 709, 'therapyName': 'CUDC-907'}]","Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors",02/27/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT02307474,Phase I,Withdrawn,Case Comprehensive Cancer Center ,"[{'id': 848, 'therapyName': 'Pazopanib'}]",A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer,03/05/2016,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02308020,Phase II,Recruiting,Eli Lilly and Company ,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer That Has Spread to the Brain,05/28/2015,[],yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02308280,Phase II,Recruiting,Maisonneuve-Rosemont Hospital ,"[{'id': 688, 'therapyName': 'Bortezomib'}]",Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients,08/27/2015,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02308761,Phase I,Recruiting,Tensha Therapeutics ,"[{'id': 937, 'therapyName': 'TEN-010'}]",A Dose Escalation and Cohort Expansion Study of TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome,11/05/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02309177,Phase I,Recruiting,Celgene Corporation ,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2489, 'therapyName': 'Abraxane + Nivolumab'}]","Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer",04/07/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,both,[],NCT02309567,,Completed,Cumhuriyet University ,[],"Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?",11/02/2016,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02309580,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma,07/30/2015,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02311361,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer,07/29/2015,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02311582,Phase Ib/II,Recruiting,Washington University School of Medicine,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas,08/07/2015,[],no
0,both,"[{'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02311920,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Temozolomide in Combination With Ipilimumab and/or Nivolumab in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma,08/19/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02311933,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 3076, 'therapyName': 'Z-endoxifen HCl'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer",04/20/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02311998,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 3200, 'therapyName': 'Bosutinib + inotuzumab ozogamicin'}]",Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML),08/23/2016,"[{'molecularProfile': {'id': 536, 'profileName': 'ABL1 T315I'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT02312102,Phase I,Recruiting,Massachusetts General Hospital ,"[{'id': 3220, 'therapyName': 'Bortezomib + lenalidomide'}]",Phase I Study of Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation,12/01/2015,[],no
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT02312245,Phase II,Recruiting,"Mayo Clinic, National Cancer Institute (NCI)","[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",07/24/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02312557,Phase II,Recruiting,OHSU Knight Cancer Institute ,"[{'id': 2666, 'therapyName': 'Enzalutamide + Pembrolizumab'}]",Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide,02/15/2017,[],no
0,both,"[{'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02312804,Phase I,Withdrawn,The University of Texas Health Science Center at San Antonio ,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 674, 'therapyName': 'BGJ398'}]",Ph Ib/BGJ398/Cervix and Other Solid Tumors,02/26/2015,"[{'molecularProfile': {'id': 1185, 'profileName': 'FGFR2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1221, 'profileName': 'FGFR1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02313012,Phase I,Terminated,Celgene Corporation ,"[{'id': 2874, 'therapyName': 'CC-90003'}]",Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors,08/23/2016,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02313272,Phase I,Recruiting,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Phase I Trial of HFSRT With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas,12/01/2015,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02314052,Phase Ib/II,Terminated,"Dicerna Pharmaceuticals, Inc. ","[{'id': 3122, 'therapyName': 'DCR-MYC'}]","Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma",08/05/2017,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}]",NCT02314117,Phase III,"Active, not recruiting",Eli Lilly and Company ,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer,09/20/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'excluded'}]",yes
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02314156,Phase II,Recruiting,Northwestern University ,"[{'id': 2820, 'therapyName': 'Telapristone'}]",Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy,06/13/2016,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 7177, 'name': 'anal canal squamous cell carcinoma', 'source': 'DOID'}]",NCT02314169,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal,12/06/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02314364,Phase II,Recruiting,Massachusetts General Hospital ,[],A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC,08/21/2015,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1249, 'profileName': 'ROS1 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1676, 'profileName': 'ROS1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 2893, 'name': 'cervix carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02315066,Phase I,Recruiting,Pfizer ,"[{'id': 4333, 'therapyName': 'PF-04518600'}, {'id': 4448, 'therapyName': 'PF-04518600 + Utomilumab'}]",Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566,07/14/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 3234, 'name': 'central nervous system lymphoma', 'source': 'DOID'}]",NCT02315326,Phase Ib/II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 768, 'therapyName': 'Ibrutinib'}]","Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)",04/29/2016,[],no
0,female,"[{'id': 5304, 'name': 'ovarian clear cell adenocarcinoma', 'source': 'DOID'}]",NCT02315430,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",11/03/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02315534,Phase Ib/II,Recruiting,"Boston Biomedical, Inc ","[{'id': 2057, 'therapyName': 'BBI608'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma,05/27/2015,[],no
0,both,"[{'id': 50626, 'name': 'gastrointestinal neuroendocrine tumor', 'source': 'DOID'}, {'id': 1799, 'name': 'islet cell tumor', 'source': 'DOID'}]",NCT02315625,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery,08/28/2015,"[{'molecularProfile': {'id': 1215, 'profileName': 'PDGFRA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1214, 'profileName': 'KIT mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1213, 'profileName': 'PTEN mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 4973, 'profileName': 'VHL mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1209, 'profileName': 'AKT1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02315768,Phase Ib/II,Recruiting,"University of California, San Diego","[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.,01/29/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02316002,Phase II,Recruiting,Abramson Cancer Center of the University of Pennsylvania ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer,08/27/2015,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02316340,Phase II,Recruiting,The University of Texas Health Science Center at San Antonio ,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer,05/14/2015,[],no
0,female,"[{'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 5744, 'name': 'ovary serous adenocarcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT02316834,Phase I,"Active, not recruiting","M.D. Anderson Cancer Center, BioMarin Pharmaceutical","[{'id': 682, 'therapyName': 'Talazoparib'}]",POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer,02/25/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02317016,Phase I,"Active, not recruiting",AstraZeneca ,"[{'id': 660, 'therapyName': 'Osimertinib'}, {'id': 2928, 'therapyName': 'Rosuvastatin'}]","Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer",08/29/2015,"[{'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02317874,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 682, 'therapyName': 'Talazoparib'}]","PARP Inhibitor BMN-673, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",11/23/2016,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT02317991,Phase II,Recruiting,"SCRI Development Innovations, LLC ","[{'id': 2039, 'therapyName': 'Abraxane + Ramucirumab'}]",Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer,03/24/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02318277,Phase Ib/II,Recruiting,Incyte Corporation ,"[{'id': 3015, 'therapyName': 'INCB024360 + MEDI4736'}]",A Study of INCB024360 in Combination With MEDI4736 in Subjects With Selected Advanced Solid Tumors,08/11/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02318329,Phase I,Recruiting,"Five Prime Therapeutics, Inc. ","[{'id': 2933, 'therapyName': 'FPA144'}]","Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors",07/23/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02318368,Phase II,Terminated,"AVEO Pharmaceuticals, Inc, Biodesix","[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2169, 'therapyName': 'Ficlatuzumab + Erlotinib'}]","A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label",06/10/2017,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02318394,Phase I,"Active, not recruiting",MedImmune LLC ,"[{'id': 3838, 'therapyName': 'MEDI0562'}]",A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors,04/18/2017,[],no
0,both,"[{'id': 263, 'name': 'kidney cancer', 'source': 'DOID'}, {'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02318771,Phase I,Recruiting,Thomas Jefferson University ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Urothelial Cancer, Melanoma, and Non-Small Cell Lung Cancer",04/28/2015,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02318901,Phase Ib/II,"Active, not recruiting",Western Regional Medical Center ,"[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}, {'id': 1908, 'therapyName': 'Pembrolizumab + Trastuzumab'}, {'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer,06/28/2017,"[{'molecularProfile': {'id': 481, 'profileName': 'NRAS wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 4, 'profileName': 'BRAF wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3119, 'name': 'gastrointestinal system cancer', 'source': 'DOID'}]",NCT02319018,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 626, 'therapyName': 'Alisertib'}]",Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors,04/30/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02319044,Phase II,"Active, not recruiting",AstraZeneca ,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck",05/12/2016,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02319369,Phase I,Recruiting,Daiichi Sankyo Inc. ,"[{'id': 2079, 'therapyName': 'DS-3032b'}]","Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies",04/01/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02319824,Phase I,Completed,Fred Hutchinson Cancer Research Center ,[],NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy,01/13/2017,[],yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02319837,Phase III,Recruiting,"Medivation, Inc. ","[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK),05/07/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02320058,Phase II,Recruiting,Bristol-Myers Squibb ,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy (CheckMate 204),05/06/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02320305,Phase I,"Active, not recruiting",Mayo Clinic ,"[{'id': 3787, 'therapyName': 'MART-1 antigen'}, {'id': 3889, 'therapyName': 'GLA-SE + MART-1 antigen'}]",MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery,11/03/2016,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02321293,Phase I,Unknown status,Lady Davis Institute ,"[{'id': 2379, 'therapyName': 'Erlotinib + Gefitinib'}]",A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC,09/02/2017,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02321501,Phase I,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 2295, 'therapyName': 'Ceritinib + Everolimus'}, {'id': 789, 'therapyName': 'Ceritinib'}]",Phase I/Ib Dose Escalation and Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression,11/09/2016,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02321540,Phase Ib/II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer,02/18/2017,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02322281,Phase III,"Active, not recruiting","Clovis Oncology, Inc. ","[{'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1003, 'therapyName': 'CO1686'}]","TIGER-3 Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy",06/07/2016,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 4039, 'profileName': 'EGFR exon 20 ins'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT02322814,Phase II,Recruiting,Hoffmann-La Roche ,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1004, 'therapyName': 'Cobimetinib'}]",A Study of Cobimetinib in Combination With Paclitaxel as First-line Treatment for Patients With Metastatic Triple-negative Breast Cancer,02/27/2015,[],yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02323113,Phase Ib/II,Recruiting,"Millennium Pharmaceuticals, Inc. ","[{'id': 3146, 'therapyName': 'TAK-659'}]","Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)",10/31/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02323126,Phase II,Recruiting,Novartis Pharmaceuticals,"[{'id': 2443, 'therapyName': 'EGF816 + Nivolumab'}, {'id': 2444, 'therapyName': 'INC280 + Nivolumab'}]",Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer,02/01/2016,"[{'molecularProfile': {'id': 343, 'profileName': 'EGFR wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1240, 'profileName': 'MET positive'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02323191,Phase I,Recruiting,Hoffmann-La Roche ,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 2004, 'therapyName': 'LY3022855'}]",A Study of RO5509554 and MPDL3280A Administered in Combination in Patients With Advanced Solid Tumors,05/13/2015,[],yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02323230,Phase II,"Active, not recruiting","ImmunoVaccine Technologies, Inc. ","[{'id': 4280, 'therapyName': 'Cyclophosphamide + DPX-Survivac'}]",A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL,07/19/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02323607,Phase I,Suspended,Bhavana Bhatnagar,"[{'id': 3219, 'therapyName': 'Cytarabine + Daunorubicin + Pacritinib'}, {'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}]",Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations,07/08/2017,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02323880,Phase I,Recruiting,Children's Oncology Group ,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Study of Selinexor in Pediatric Solid Tumors,09/13/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02323906,Phase Ib/II,Terminated,Celgene Corporation,"[{'id': 2430, 'therapyName': 'Sorafenib + CC-122'}]",Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer,03/21/2017,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT02324582,Phase I,Recruiting,Southern Illinois University ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475/BCG in High Risk Superficial Bladder Cancer,02/11/2017,[],no
0,both,"[{'id': 3151, 'name': 'skin squamous cell carcinoma', 'source': 'DOID'}]",NCT02324608,Phase I,Recruiting,"Rutgers, The State University of New Jersey ","[{'id': 694, 'therapyName': 'Cetuximab'}]",Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer,07/15/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02324621,Phase I,Recruiting,"Rutgers, The State University of New Jersey, National Cancer Institute (NCI), Oncoceutics, Inc. ","[{'id': 1687, 'therapyName': 'ONC201'}]",Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors,02/26/2015,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02325401,Phase I,Recruiting,University of Cincinnati,"[{'id': 2205, 'therapyName': 'Cisplatin + Metformin'}]",Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma,04/08/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02325557,Phase Ib/II,Recruiting,"Advaxis, Inc. ","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3050, 'therapyName': 'ADXS31-142 '}]",ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046,08/25/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02325739,Phase Ib/II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 2031, 'therapyName': 'FGF401'}]",Safety and Efficacy of FGF401 in Patients With Solid Malignancies,03/11/2015,[],no
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02326844,Phase II,Terminated,National Cancer Institute (NCI),"[{'id': 682, 'therapyName': 'Talazoparib'}]","BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment",05/25/2017,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02326974,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1492, 'therapyName': 'T-DM1 + Pertuzumab'}]",T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA,01/27/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02327078,Phase Ib/II,Recruiting,Incyte Corporation ,"[{'id': 3059, 'therapyName': 'INCB024360 + Nivolumab'}]","A Study of the Safety, Tolerability, and Efficacy of INCB24360 Administered in Combination With Nivolumab in Select Advanced Cancers",09/26/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02327169,Phase I,Recruiting,"Millennium Pharmaceuticals, Inc. ","[{'id': 2175, 'therapyName': 'MLN0128 + MLN2480'}, {'id': 2176, 'therapyName': 'MLN2480 + Alisertib'}, {'id': 2177, 'therapyName': 'MLN2480 + Paclitaxel'}]",A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib or Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies,03/12/2015,[],no
0,both,"[{'id': 706, 'name': 'mature B-cell neoplasm', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 7061, 'name': 'precursor B lymphoblastic lymphoma/leukemia', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 285, 'name': 'hairy cell leukemia', 'source': 'DOID'}]",NCT02328014,Phase Ib/II,Recruiting,Acerta Pharma BV ,"[{'id': 3265, 'therapyName': 'ACP-319'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]","ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies",12/10/2015,[],no
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02329847,Phase Ib/II,Recruiting,"Janssen Research & Development, LLC ","[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Pharmacokinetic and Pharmacodynamic Study to Evaluate Safety and Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies,11/13/2015,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02330562,Phase I,Recruiting,Triphase Research and Development I Corporation ,"[{'id': 2166, 'therapyName': 'Bevacizumab + Marizomib'}]",Study of Marizomib With Bevacizumab in Bevacizumab-Na&#239;ve Subjects With WHO Grade IV Malignant Glioma,04/01/2015,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02331251,Phase Ib/II,"Active, not recruiting",Western Regional Medical Center ,"[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]",Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus),08/11/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02331368,Phase II,"Active, not recruiting",University of Michigan Cancer Center ,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma,05/04/2017,[],no
0,both,[],NCT02332655,Phase Ib/II,"Active, not recruiting","Anne Comi, MD","[{'id': 2632, 'therapyName': 'Cannabidiol'}]",Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome,01/13/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02332668,Phase Ib/II,Recruiting,Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (MK-3475-051/KEYNOTE-051)",04/22/2015,[],yes
0,,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02332850,,Recruiting,,"[{'id': 1624, 'therapyName': 'Carfilzomib'}]",SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma,10/19/2017,[],
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}]",NCT02332889,Phase Ib/II,Terminated,University of Louisville ,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",Phase I/II Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs,09/07/2016,[],no
0,both,[],NCT02332902,Phase II,Completed,"The University of Texas Health Science Center, Houston ","[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T,05/13/2016,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02332980,Phase II,Recruiting,Mayo Clinic ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma,03/27/2015,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02333162,Phase I,Recruiting,University of Chicago ,"[{'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}]","Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant",05/15/2015,[],no
0,both,"[{'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}]",NCT02334319,Phase I,Terminated,Emory University ,"[{'id': 745, 'therapyName': 'Ganetespib'}]",Ganetespib Window of Opportunity Study in Head and Neck Cancers,07/27/2016,[],no
0,both,"[{'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}]",NCT02334527,Phase II,Recruiting,UNC Lineberger Comprehensive Cancer Center ,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy,04/21/2016,"[{'molecularProfile': {'id': 1806, 'profileName': 'CDKN2A loss'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 2395, 'profileName': 'RB1 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02334735,Phase II,Recruiting,Nina Bhardwaj ,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 3012, 'therapyName': 'Melan-A/MART-1 peptide vaccine'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]",A Comparison of Matured Dendritic Cells and Montanide&#174; in Study Subjects With High Risk of Melanoma Recurrence,02/18/2016,[],no
0,female,"[{'id': 2870, 'name': 'endometrial adenocarcinoma', 'source': 'DOID'}]",NCT02335203,Phase II,"Active, not recruiting",Women and Infants Hospital of Rhode Island ,"[{'id': 2401, 'therapyName': 'Medroxyprogesterone'}]",The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy,03/22/2016,[],no
0,,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT02335411,Phase II,"Active, not recruiting",Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059),06/28/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}]",NCT02335424,Phase II,"Active, not recruiting",Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52),06/14/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02335814,Phase I,Terminated,"Flexus Biosciences, Inc. ","[{'id': 2529, 'therapyName': 'FLX925  '}]",First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia,09/29/2017,"[{'molecularProfile': {'id': 1325, 'profileName': 'FLT3 rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 5329, 'profileName': 'FLT3 D835X'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02335918,Phase Ib/II,Recruiting,Celldex Therapeutics ,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}]",A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors,04/10/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02335944,Phase Ib/II,Recruiting,Novartis Pharmaceuticals,"[{'id': 2445, 'therapyName': 'EGF816 + INC280'}]",Study of Safety and Efficacy of EGF816 in Combination With INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation.,02/01/2016,"[{'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02336087,Phase I,Recruiting,City of Hope Medical Center ,"[{'id': 2204, 'therapyName': 'Abraxane + Gemcitabine + Metformin'}]","Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Metastatic Pancreatic Cancer",01/23/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02336165,Phase II,"Active, not recruiting",Ludwig Institute for Cancer Research ,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2117, 'therapyName': 'Bevacizumab + MEDI4736'}]",Phase 2 Study of MEDI4736 in Patients With Glioblastoma,02/16/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02336451,Phase II,Recruiting,Novartis Pharmaceuticals,"[{'id': 789, 'therapyName': 'Ceritinib'}]",A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges,03/27/2015,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02336815,Phase II,Recruiting,"Karyopharm Therapeutics, Inc ","[{'id': 2479, 'therapyName': 'Dexamethasone + Selinexor'}]",Phase 2b Open-Label Single-Arm Selinexor (KPT-330) + Low-Dose Dexamethasone in Patients w/ Multiple Myeloma Quad-refractory to Previous Therapies,07/16/2015,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02336984,Phase Ib/II,"Active, not recruiting",Abramson Cancer Center of the University of Pennsylvania ,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 5222, 'therapyName': 'HER2-pulsed DC1 vaccine'}]",A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS,01/16/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT02337309,Phase I,Recruiting,New Approaches to Neuroblastoma Therapy Consortium,"[{'id': 915, 'therapyName': 'SF1126'}]",SF1126 for Patients With Relapsed or Refractory Neuroblastoma,08/18/2017,[],yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02337491,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Pembrolizumab +/- Bevacizumab for Recurrent GBM,01/21/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02337530,Phase II,"Active, not recruiting",NCIC Clinical Trials Group ,"[{'id': 913, 'therapyName': 'Selumetinib'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",Selumetinib in Patients Receiving Pemetrexed and Cisplatin in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer,05/31/2017,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02337686,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma,05/01/2015,[],no
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02337829,Phase II,Recruiting,Acerta Pharma BV ,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}]",ACP-196 in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL,01/29/2016,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02337985,Phase I,Recruiting,City of Hope Medical Center ,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma,02/25/2017,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02339168,Phase I,Recruiting,"University of California, Davis ","[{'id': 2202, 'therapyName': 'Enzalutamide + Metformin'}]",Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer,07/01/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02339324,Phase I,"Active, not recruiting",University of Pittsburgh ,"[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b,06/09/2017,[],no
0,both,"[{'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}]",NCT02339558,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer,10/07/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02339571,Phase II,Suspended,National Cancer Institute (NCI),"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,06/29/2017,[],no
0,both,"[{'id': 60318, 'name': 'acute promyelocytic leukemia', 'source': 'DOID'}]",NCT02339740,Phase III,Recruiting,Children's Oncology Group ,"[{'id': 3686, 'therapyName': 'Cytarabine + Dexamethasone + Idarubicin + Mitoxantrone'}, {'id': 3685, 'therapyName': 'Arsenic trioxide + Gemtuzumab ozogamicin + Tretinoin'}]",Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia,03/06/2016,[],yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02340117,Phase II,Recruiting,"SynerGene Therapeutics, Inc. ","[{'id': 2518, 'therapyName': 'SGT-53'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer,08/10/2015,[],no
0,both,"[{'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02340156,Phase II,Recruiting,"SynerGene Therapeutics, Inc. ","[{'id': 2518, 'therapyName': 'SGT-53'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma,08/11/2015,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02340221,Phase III,Recruiting,Hoffmann-La Roche ,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy,11/21/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02340611,Phase II,Recruiting,"University Health Network, Toronto ","[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib,06/18/2015,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02340780,Phase II,"Active, not recruiting",NCIC Clinical Trials Group ,"[{'id': 680, 'therapyName': 'BKM120'}]",Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia,02/08/2017,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT02340975,Phase Ib/II,Recruiting,MedImmune LLC ,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma",04/29/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02341456,Phase I,"Active, not recruiting",AstraZeneca,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours,05/26/2017,[],no
0,both,"[{'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1790, 'name': 'malignant mesothelioma', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT02341625,Phase Ib/II,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 4923, 'therapyName': 'BMS-986148'}, {'id': 4924, 'therapyName': 'BMS-986148 + Nivolumab'}]",A Study of BMS-986148 in Patients With Select Advanced Solid Tumors,07/03/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02342353,Phase Ib/II,Recruiting,Washington University School of Medicine ,"[{'id': 2382, 'therapyName': 'Erlotinib + Pacritinib'}]",Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI),07/15/2016,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02342379,Phase II,"Active, not recruiting",The University of Texas Health Science Center at San Antonio ,"[{'id': 2144, 'therapyName': 'Bevacizumab + Evofosfamide'}]",TH-302 in Combination With Bevacizumab for Glioblastoma,08/10/2017,[],no
0,both,"[{'id': 50743, 'name': 'mature T-cell and NK-cell lymphoma', 'source': 'DOID'}]",NCT02342782,Phase I,Recruiting,City of Hope Medical Center ,"[{'id': 2485, 'therapyName': '90Y basiliximab'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 2392, 'therapyName': 'Cytarabine + Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma,06/11/2015,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02343042,Phase Ib/II,Recruiting,"Karyopharm Therapeutics, Inc ","[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 2479, 'therapyName': 'Dexamethasone + Selinexor'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Phase 1b/2 Study of Selinexor (KPT-330) in Combination w/ Backbone Treatments for Resistant/Refractory Multiple Myeloma,10/27/2015,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}]",NCT02343120,Phase I,Recruiting,BeiGene ,"[{'id': 2544, 'therapyName': 'BGB-3111'}]",Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies,04/22/2015,[],no
0,both,"[{'id': 3382, 'name': 'liposarcoma', 'source': 'DOID'}]",NCT02343172,Phase Ib/II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 2481, 'therapyName': 'HDM201 + LEE011'}]",Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma,03/27/2015,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02343406,Phase II,Recruiting,AbbVie ,"[{'id': 2075, 'therapyName': 'Lomustine'}, {'id': 976, 'therapyName': 'ABT-414'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma,11/03/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02343536,Phase I,Recruiting,Celgene Corporation,"[{'id': 2488, 'therapyName': 'Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Phase 1, Open-label,Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma",04/07/2015,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02343549,Phase II,Recruiting,Ashley Love Sumrall ,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",LCI-NEU-NOV-001 Study of a Device Worn on the Head in Combination With Chemo to Treat Brain Cancer,03/12/2015,[],no
0,,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02343666,Phase I,Recruiting,Fred Hutchinson Cancer Research Center ,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 2556, 'therapyName': 'O6-benzylguanine'}]",HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection,09/09/2016,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02343679,Phase II,Withdrawn,"Anne Beaven, MD ","[{'id': 789, 'therapyName': 'Ceritinib'}]",Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies,02/08/2017,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02343718,Phase I,"Active, not recruiting",NCIC Clinical Trials Group ,"[{'id': 2492, 'therapyName': 'Temsirolimus + Vinblastine'}]",Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours,04/05/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02343939,Phase Ib/II,Recruiting,Gilead Sciences ,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 2522, 'therapyName': 'Entospletinib  '}]",Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML),06/25/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02343952,Phase II,"Active, not recruiting","Nasser Hanna, M.D. ","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Consolidation Pembrolizumab (MK-3475), Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC",12/14/2016,[],no
0,both,"[{'id': 1107, 'name': 'esophageal carcinoma', 'source': 'DOID'}, {'id': 3119, 'name': 'gastrointestinal system cancer', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 5517, 'name': 'stomach carcinoma', 'source': 'DOID'}]",NCT02344810,Phase Ib/II,Withdrawn,Eastern Cooperative Oncology Group,"[{'id': 1064, 'therapyName': 'AMG 337'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]","C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer",10/20/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 5828, 'name': 'endometrioid ovary carcinoma', 'source': 'DOID'}, {'id': 6212, 'name': 'ovarian endometrial cancer', 'source': 'DOID'}, {'id': 5746, 'name': 'ovarian serous cystadenocarcinoma', 'source': 'DOID'}, {'id': 5831, 'name': 'fallopian tube endometrioid adenocarcinoma', 'source': 'DOID'}, {'id': 4901, 'name': 'peritoneal serous adenocarcinoma', 'source': 'DOID'}, {'id': 5744, 'name': 'ovary serous adenocarcinoma', 'source': 'DOID'}, {'id': 5598, 'name': 'fallopian tube serous adenocarcinoma', 'source': 'DOID'}]",NCT02345265,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer",07/14/2017,"[{'molecularProfile': {'id': 1283, 'profileName': 'BRCA2 inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1282, 'profileName': 'BRCA1 inact mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 12603, 'name': 'acute leukemia', 'source': 'DOID'}]",NCT02345382,Phase I,Completed,Bayer,"[{'id': 4027, 'therapyName': 'BAY1143572'}]",Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia,08/24/2017,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02345772,Phase I,Terminated,Western Regional Medical Center ,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]","Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer",09/29/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02345824,Phase I,Recruiting,Dartmouth-Hitchcock Medical Center ,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Early-Phase Study to Assess Inhibitor LEE011 in Patients With Recurrent Glioblastoma or Anaplastic Glioma,03/24/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02346253,Phase Ib/II,Recruiting,Stanford University ,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 759, 'therapyName': 'Goserelin'}]",High-Dose Brachytherapy in Treating Patients With Prostate Cancer,03/30/2015,[],no
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT02346747,Phase II,"Active, not recruiting","Gradalis, Inc. ","[{'id': 1157, 'therapyName': 'FANG vaccine'}]",Phase II/III Trial of Maintenance Vigil for High Risk Stage III/IV Ovarian Cancer (VITAL),03/29/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 8923, 'name': 'skin melanoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}]",NCT02346955,Phase I,Terminated,Merck Sharp & Dohme Corp.,"[{'id': 4246, 'therapyName': 'CM-24'}, {'id': 4247, 'therapyName': 'CM-24 + Pembrolizumab'}]",Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001),03/17/2017,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT02348008,Phase Ib/II,"Active, not recruiting","Arkadiusz Z. Dudek, MD ","[{'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma,05/19/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02348216,Phase Ib/II,Recruiting,"Kite Pharma, Inc. ","[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1),12/07/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02348255,Phase II,Withdrawn,"University of California, Davis ","[{'id': 2371, 'therapyName': 'Bevacizumab + Carmustine'}]",NovoTTF-100A in Combination With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse,02/08/2017,[],no
0,female,"[{'id': 3744, 'name': 'cervical squamous cell carcinoma', 'source': 'DOID'}, {'id': 5636, 'name': 'cervical adenosquamous carcinoma', 'source': 'DOID'}, {'id': 3702, 'name': 'cervical adenocarcinoma', 'source': 'DOID'}]",NCT02348398,Phase II,Withdrawn,M.D. Anderson Cancer Center,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Phase II Study of Pazopanib and Topotecan in Cervical Cancer,08/17/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02348489,Phase III,"Active, not recruiting",Astex Pharmaceuticals ,"[{'id': 1949, 'therapyName': 'SGI-110'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 650, 'therapyName': 'Decitabine'}]","SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction",01/07/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02349139,Phase Ib/II,"Active, not recruiting",Asana BioSciences ,"[{'id': 2528, 'therapyName': 'CYP17 lyase inhibitor ASN001'}]","Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer",05/09/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02349633,Phase I,Recruiting,Pfizer ,"[{'id': 2527, 'therapyName': 'PF-06747775  '}]",Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M),02/01/2016,"[{'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02349867,Phase I,Recruiting,"Virginia Commonwealth University, National Cancer Institute (NCI)","[{'id': 2429, 'therapyName': 'Abraxane + Gemcitabine + Sorafenib + Vorinostat'}]","Gemcitabine Hydrochloride, Nab-Paclitaxel, Radiation Therapy, Sorafenib Tosylate,Vorinostat in Treating Previously Untreated Pancreatic Cancer Patients",05/28/2016,[],no
0,both,"[{'id': 363, 'name': 'uterine cancer', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1790, 'name': 'malignant mesothelioma', 'source': 'DOID'}]",NCT02349958,Phase II,Recruiting,Bay Area Gynecology Oncology,"[{'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy,02/08/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02350673,Phase I,Recruiting,Hoffmann-La Roche ,"[{'id': 2886, 'therapyName': 'RO6895882'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Intravenous RO6895882 and MPDL3280A Combination in Patients With Locally Advanced and/or Metastatic Solid Tumors,09/13/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02350764,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Evaluate the Mediators of Sensitivity and Resistance to Nivolumab in Patients With Advanced NSCLCs,04/22/2015,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02351037,Phase II,Terminated,Pharmacyclics ,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 712, 'therapyName': 'Cytarabine'}]",A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia,05/20/2017,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02351505,Phase II,Terminated,Erin Bertino ,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer,05/17/2016,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}]",NCT02351739,Phase II,"Active, not recruiting",Acerta Pharma BV ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum-refractory Metastatic Bladder Cancer,01/09/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02352025,Phase I,Recruiting,The University of Texas Health Science Center at San Antonio ,"[{'id': 2596, 'therapyName': 'S-equol  '}]",S-equol in Women With Triple Negative Breast Cancer,09/20/2017,[],yes
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02352558,Phase I,"Active, not recruiting","Boston Biomedical, Inc ","[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 2057, 'therapyName': 'BBI608'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]","A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies",12/22/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02352844,Phase II,"Active, not recruiting",Washington University School of Medicine ,"[{'id': 735, 'therapyName': 'Everolimus'}]","Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations",07/06/2017,"[{'molecularProfile': {'id': 1246, 'profileName': 'STK11 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02352948,Phase III,"Active, not recruiting",AstraZeneca,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2438, 'therapyName': 'Erlotinib + Gemcitabine + Vinorelbine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer",08/10/2016,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02353715,Phase I,Recruiting,Duke University ,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]","Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge), Abiraterone Acetate (Zytiga) or Enzalutamide (Xtandi) Undergoing Cardiopulmonary EXercise Testing",05/22/2015,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02353728,Phase II,Not yet recruiting,Weill Medical College of Cornell University ,"[{'id': 829, 'therapyName': 'Nilotinib'}]",Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy,03/26/2015,[],yes
0,male,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT02354131,Phase Ib/II,Recruiting,Nordic Society for Gynaecologic Oncology,"[{'id': 832, 'therapyName': 'Niraparib'}, {'id': 4254, 'therapyName': 'Bevacizumab + Niraparib'}]",Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer (AVANOVA),04/07/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02354547,Phase I,Recruiting,"SynerGene Therapeutics, Inc. ","[{'id': 3617, 'therapyName': 'SGT-53 + Cyclophosphamide + Topotecan'}]",A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors,02/25/2016,[],no
0,female,"[{'id': 4901, 'name': 'peritoneal serous adenocarcinoma', 'source': 'DOID'}, {'id': 5598, 'name': 'fallopian tube serous adenocarcinoma', 'source': 'DOID'}, {'id': 5744, 'name': 'ovary serous adenocarcinoma', 'source': 'DOID'}]",NCT02354586,Phase II,Recruiting,"Tesaro, Inc. ","[{'id': 832, 'therapyName': 'Niraparib'}]",A Study of Niraparib in Patients With Ovarian Cancer Who Have Received at Least Three Previous Chemotherapy Regimens,05/08/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02355431,Phase II,Withdrawn,Incyte Corporation ,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2406, 'therapyName': 'INCB039110'}]",INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations,11/18/2015,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02355535,Phase I,Recruiting,"Vanquish Oncology, Inc.","[{'id': 4602, 'therapyName': 'PAC-1'}]",Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies,10/13/2017,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02356159,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 2294, 'therapyName': 'Cytarabine + Fludarabine'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 2238, 'therapyName': 'Sirolimus + Tacrolimus + Methotrexate'}, {'id': 2292, 'therapyName': 'Doxorubicin + Etoposide + Fludarabine + Vincristine '}, {'id': 2291, 'therapyName': 'Cyclophosphamide + Fludarabine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation,05/06/2015,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1790, 'name': 'malignant mesothelioma', 'source': 'DOID'}]",NCT02357147,Phase II,"Active, not recruiting",Morphotek ,"[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 3513, 'therapyName': 'Amatuximab'}]",Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM). (ARTEMIS),02/08/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}, {'id': 3382, 'name': 'liposarcoma', 'source': 'DOID'}]",NCT02357810,Phase II,Recruiting,Northwestern University ,"[{'id': 1469, 'therapyName': 'Topotecan + Pazopanib'}]",Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas,03/12/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02357836,Phase I,Recruiting,University of Texas Southwestern Medical Center ,"[{'id': 1026, 'therapyName': 'Itraconazole'}]",Neoadjuvant Itraconazole in Non-small Cell Lung Cancer,07/08/2015,[],no
0,both,"[{'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}]",NCT02358031,Phase III,"Active, not recruiting",Merck Sharp & Dohme Corp. ,"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048),01/11/2017,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02358187,Phase II,Recruiting,University of Pittsburgh ,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",A Vaccine Trial for Low Grade Gliomas,08/11/2015,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02358200,Phase I,"Active, not recruiting","University of California, San Francisco ","[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 682, 'therapyName': 'Talazoparib'}]",Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer,01/06/2016,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT02358863,Phase I,Terminated,Georgetown University ,"[{'id': 4311, 'therapyName': 'Docetaxel + Irinotecan'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1835, 'therapyName': 'Docetaxel + Cisplatin'}, {'id': 1406, 'therapyName': 'Camptosar + Cisplatin'}, {'id': 4310, 'therapyName': 'Epirubicin + Docetaxel'}, {'id': 4309, 'therapyName': 'Capecitabine + Docetaxel'}]",Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach (mEGA),09/02/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02359019,Phase II,"Active, not recruiting",Barbara Ann Karmanos Cancer Institute ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy,12/01/2016,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02359565,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas",03/08/2017,[],no
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT02359851,Phase II,"Active, not recruiting",Vanderbilt-Ingram Cancer Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Advanced Uveal Melanoma,02/10/2017,[],no
0,,[],NCT02360059,,Terminated,,[],Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer,09/24/2016,[],no
0,both,"[{'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}]",NCT02360618,Phase II,Recruiting,London Health Sciences Centre ,"[{'id': 1829, 'therapyName': 'Metformin + Simvastatin'}]",Metformin and Simvastatin Use in Bladder Cancer,07/18/2016,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02362035,Phase Ib/II,"Active, not recruiting",Acerta Pharma BV ,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145)",05/23/2017,[],no
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT02362048,Phase II,"Active, not recruiting",Acerta Pharma BV ,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer,12/03/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02362594,Phase III,"Active, not recruiting",Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054),09/30/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02362997,Phase II,Recruiting,Dana-Farber Cancer Institute ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL,12/03/2015,[],no
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT02363283,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}]",Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma,09/09/2017,[],no
0,both,"[{'id': 3284, 'name': 'thymic carcinoma', 'source': 'DOID'}]",NCT02364076,Phase II,"Active, not recruiting",Georgetown University ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 in Patients With Thymic Carcinoma,05/31/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02364609,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 2435, 'therapyName': 'Afatinib + Pembrolizumab'}]",Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib,01/27/2016,"[{'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}]",yes
0,,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02364999,Phase III,"Active, not recruiting",Pfizer,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC,07/20/2017,"[{'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 4138, 'profileName': 'EML4-ALK'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3996, 'name': 'urinary system cancer', 'source': 'DOID'}]",NCT02365597,Phase II,Recruiting,"Janssen Research & Development, LLC ","[{'id': 1028, 'therapyName': 'JNJ-42756493'}]",An Efficacy and Safety Study of JNJ-42756493 in Participants With Urothelial Cancer,05/06/2015,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02365662,Phase I,Recruiting,AbbVie ,"[{'id': 2914, 'therapyName': 'ABBV-221'}]",A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor,07/20/2015,"[{'molecularProfile': {'id': 2419, 'profileName': 'EGFR over exp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}]",NCT02365766,Phase Ib/II,Recruiting," Christopher Hoimes, M.D. ","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Study of Neoadjuvant Pembrolizumab in Combination With Gemcitabine Based Therapy in Cis-eligible or -Ineligible Subjects With Urothelial Cancer,05/10/2016,[],no
0,both,"[{'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}]",NCT02365818,Phase II,"Active, not recruiting","Cold Genesys, Inc. ","[{'id': 2523, 'therapyName': 'CG0070'}]",Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade Non-Muscle Invasive Bladder Cancer After BCG Failure,11/09/2016,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02366130,Phase II,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 1198, 'therapyName': 'Denosumab'}]",Phase II Trial of Ra-223 Dichloride and Hormonal Treatment,07/29/2015,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02366143,Phase III,"Active, not recruiting",Hoffmann-La Roche ,"[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1489, 'therapyName': 'Nab-paclitaxel + Carboplatin + Bevacizumab'}, {'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}]",TBAA Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer,04/19/2017,[],no
0,both,[],NCT02366312,Phase II,"Active, not recruiting",The Bluestone Center for Clinical Research ,"[{'id': 956, 'therapyName': 'Vismodegib'}]","A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors",07/26/2016,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02366494,Phase I,Recruiting,Medical College of Wisconsin ,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Micro RNAs to Predict Response to Androgen Deprivation Therapy,08/05/2015,[],no
0,,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3074, 'name': 'giant cell glioblastoma', 'source': 'DOID'}]",NCT02366728,,Recruiting,,"[{'id': 5985, 'therapyName': 'Basiliximab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",DC Migration Study for Newly-Diagnosed GBM,07/27/2017,[],
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02366949,Phase I,Recruiting,Bayer,"[{'id': 3447, 'therapyName': 'BAY1217389 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel,02/16/2016,[],yes
0,both,"[{'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02367040,Phase III,Recruiting,Bayer ,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 995, 'therapyName': 'Copanlisib'}]",Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL),07/14/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02367456,Phase Ib/II,Recruiting,Pfizer ,"[{'id': 4177, 'therapyName': 'Azacitidine + PF-04449913'}]","A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients",06/23/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02367781,Phase III,"Active, not recruiting",Hoffmann-La Roche ,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer,04/20/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02367794,Phase III,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC),06/20/2017,[],no
0,both,[],NCT02367859,Phase I,Recruiting,Stanford University ,"[{'id': 3, 'therapyName': 'Dabrafenib'}]",Dabrafenib in Treating Patients With BRAF Mutated Ameloblastoma,08/01/2017,"[{'molecularProfile': {'id': 696, 'profileName': 'BRAF act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02368301,Phase I,Approved for marketing,Bristol-Myers Squibb ,"[{'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]",Expanded Access Treatment Protocol CA204-143,10/07/2016,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02368691,Phase II,Terminated,GTx,"[{'id': 5026, 'therapyName': 'enobosarm'}]",Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC),09/29/2017,[],yes
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}, {'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT02368886,Phase II,"Active, not recruiting",Academic and Community Cancer Research United ,"[{'id': 2350, 'therapyName': 'Clobetasol + Regorafenib'}]",Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer,07/14/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02368951,Phase I,Terminated,Bayer ,"[{'id': 2931, 'therapyName': 'BAY1187982'}]","Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)",09/01/2016,"[{'molecularProfile': {'id': 9798, 'profileName': 'FGFR2 positive'}, 'requirementType': 'required'}]",yes
0,both,[],NCT02368990,Phase I,Withdrawn,AstraZeneca ,[],T790M Mutation Positive 2nd Line STandard of cAre Registry,07/09/2015,[],no
0,both,"[{'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02369016,Phase III,"Active, not recruiting",Bayer ,"[{'id': 995, 'therapyName': 'Copanlisib'}]",Phase III Copanlisib in Rituximab-refractory iNHL,04/28/2017,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02369029,Phase I,Terminated,Bayer ,"[{'id': 2598, 'therapyName': 'BAY 1238097 '}]","BAY1238097, First in Man",02/12/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02369874,Phase III,"Active, not recruiting",AstraZeneca ,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer,08/09/2017,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02370238,Phase II,Recruiting,Dompé Farmaceutici S.p.A ,"[{'id': 2930, 'therapyName': 'Reparixin'}]",A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer,07/17/2015,[],yes
0,both,"[{'id': 2704, 'name': 'malignant giant cell tumor of the tendon sheath', 'source': 'DOID'}]",NCT02371369,Phase III,"Active, not recruiting",Daiichi Sankyo Inc. ,"[{'id': 874, 'therapyName': 'PLX3397'}]",PLX3397 Phase 3 Study for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS),10/20/2016,[],no
0,both,"[{'id': 5509, 'name': 'pediatric ependymoma', 'source': 'DOID'}, {'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}, {'id': 4202, 'name': 'brain stem glioma', 'source': 'DOID'}, {'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}]",NCT02372006,Phase I,Recruiting,Boehringer Ingelheim ,"[{'id': 623, 'therapyName': 'Afatinib'}]",Phase I Trial of Afatinib in Pediatric Tumours,05/20/2015,"[{'molecularProfile': {'id': 6309, 'profileName': 'ERBB4 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1216, 'profileName': 'ERBB2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1790, 'name': 'malignant mesothelioma', 'source': 'DOID'}]",NCT02372227,Phase I,Terminated,"Verastem, Inc. ","[{'id': 2464, 'therapyName': 'VS-5584 + VS-6063'}]","A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma",01/05/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02372240,Phase Ib/II,Suspended,Vivolux AB,"[{'id': 5099, 'therapyName': 'VLX1570 + Dexamethasone'}]",A Study of VLX1570 and Dexamethasone in Myeloma Patients,06/03/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02374099,Phase II,"Active, not recruiting",Celgene Corporation ,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant,06/07/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02375555,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute ,"[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM",11/03/2016,[],no
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT02375672,Phase II,"Active, not recruiting","Safi Shadha, M.D. ","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer,08/24/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02376166,Phase I,Completed,Matthew Galsky ,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin for Rising PSA Remote Trial,01/13/2017,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02376699,Phase I,Recruiting,"Seattle Genetics, Inc. ","[{'id': 5781, 'therapyName': 'Pembrolizumab + SEA-CD40'}, {'id': 5780, 'therapyName': 'SEA-CD40'}]",Safety Study of SEA-CD40 in Cancer Patients,05/26/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02379247,Phase Ib/II,Recruiting,University of Kansas ,"[{'id': 2503, 'therapyName': 'BYL719 + nab-paclitaxel'}]",BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer,04/06/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02379390,Phase II,Terminated,Sanofi ,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}]",Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enz (PRIMCAB),06/03/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02379416,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 2490, 'therapyName': 'Abraxane + Nilotinib'}]",Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors,04/03/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02379520,Phase I,Recruiting,Baylor College of Medicine,"[{'id': 5328, 'therapyName': 'Cyclophosphamide + Fludarabine phosphate + Nivolumab'}]","HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA (HESTIA)",02/15/2017,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02379585,Phase Ib/II,Terminated,Western Regional Medical Center ,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer,09/26/2015,[],yes
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02381080,Phase I,Completed,"Janssen Research & Development, LLC","[{'id': 3793, 'therapyName': 'Erythromycin + Ibrutinib + Voriconazole'}]",Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy,09/09/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02381236,Phase II,Completed,"GenSpera, Inc. ","[{'id': 4338, 'therapyName': 'mipsagargin'}]",G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer,02/25/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02381314,Phase I,Recruiting,MacroGenics ,"[{'id': 3058, 'therapyName': 'Ipilimumab + MGA271'}]",Safety Study of MGA271 in Combination With Ipilimumab in Refractory Cancer,08/26/2015,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}]",NCT02381535,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 645, 'therapyName': 'AT13387'}]",Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin,09/29/2016,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT02381548,Phase I,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 3197, 'therapyName': 'Belinostat + MK-1775'}]",Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia,10/14/2017,"[{'molecularProfile': {'id': 13812, 'profileName': 'CEBPA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 688, 'profileName': 'RUNX1 wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 8907, 'profileName': 'NPM1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02381886,Phase I,Suspended,Novartis Pharmaceuticals ,"[{'id': 2981, 'therapyName': 'IDH305'}]",A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations,12/01/2016,"[{'molecularProfile': {'id': 10006, 'profileName': 'IDH1 R132X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02382406,Phase Ib/II,Recruiting,Jyoti Patel ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Carboplatin/Nab-Paclitaxel and MK-3475 in NSCLC,03/09/2016,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02382549,Phase Ib/II,Recruiting,"Craig L Slingluff, Jr ","[{'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 2620, 'therapyName': '6MHP vaccine'}]",A Clinical Trial to Evaluate a Helper Peptide Vaccine Plus Vemurafenib in Melanoma,04/29/2016,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2, 'profileName': 'BRAF V600K'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02383212,Phase I,"Active, not recruiting",Regeneron Pharmaceuticals,"[{'id': 5722, 'therapyName': 'REGN2810 + Carboplatin + Docetaxel'}, {'id': 5721, 'therapyName': 'REGN2810 + Carboplatin + Pemetrexed'}, {'id': 5723, 'therapyName': 'REGN2810 + GM-CSF + Cyclophosphamide'}, {'id': 5718, 'therapyName': 'REGN2810 + Cyclophosphamide'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 5720, 'therapyName': 'REGN2810 + Carboplatin + Paclitaxel'}, {'id': 5719, 'therapyName': 'REGN2810 + Docetaxel'}]",Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies,09/19/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02383433,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 2491, 'therapyName': 'Gemcitabine + Regorafenib'}]",Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer,02/25/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT02383927,Phase II,Recruiting,"Kura Oncology, Inc. ","[{'id': 938, 'therapyName': 'Tipifarnib'}]",Phase II Study of Tipifarnib in Advanced Cancers With HRAS Mutations,07/08/2015,"[{'molecularProfile': {'id': 1208, 'profileName': 'HRAS mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02384239,Phase II,Recruiting,"University of California, San Francisco ","[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer,04/21/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02384382,Phase II,"Active, not recruiting","Medivation, Inc. ","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC),07/22/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02384746,Phase I,Recruiting,Dartmouth-Hitchcock Medical Center ,"[{'id': 2568, 'therapyName': 'Fulvestrant + Ixazomib'}]",Phase I Study of the Combination of MLN9708 and Fulvestrant,08/01/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02384954,Phase Ib/II,Recruiting,Altor Bioscience Corporation ,"[{'id': 3936, 'therapyName': 'ALT-803 + Rituximab'}]",ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab,04/22/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02385669,Phase Ib/II,Recruiting,"Craig L Slingluff, Jr ","[{'id': 2620, 'therapyName': '6MHP vaccine'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma,07/29/2015,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT02386111,Phase Ib/II,Terminated,Celldex Therapeutics ,"[{'id': 3057, 'therapyName': 'Sunitinib + Varlilumab'}]",A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma,03/18/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02386501,,Recruiting,,"[{'id': 4654, 'therapyName': 'ADXS31-164'}]",Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors,09/12/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT02386826,Phase I,Recruiting,"SCRI Development Innovations, LLC ","[{'id': 2600, 'therapyName': 'Bevacizumab + INC280'}]","INC280 Combined With Bevacizumab to Evaluate Glioblastoma Multiforme, Metastatic Colorectal Cancer, and Metastatic Renal Cell Carcinoma Patients",09/17/2016,"[{'molecularProfile': {'id': 1112, 'profileName': 'MET alterations'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 5363, 'name': 'myxoid liposarcoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 5485, 'name': 'synovial sarcoma', 'source': 'DOID'}]",NCT02387125,Phase I,Recruiting,Immune Design ,"[{'id': 4318, 'therapyName': 'CMB305'}]","A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1",06/19/2016,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02387216,Phase II,Recruiting,Merrimack Pharmaceuticals ,"[{'id': 820, 'therapyName': 'Seribantumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC,07/29/2015,"[{'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}]",NCT02387996,Phase II,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer,01/09/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02388906,Phase III,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238),10/07/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02389309,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 2697, 'therapyName': 'Cyclophosphamide + Dasatinib + Temsirolimus'}]","A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors",10/10/2015,[],no
0,both,"[{'id': 3748, 'name': 'esophagus squamous cell carcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}]",NCT02389751,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 745, 'therapyName': 'Ganetespib'}]",A Study of Ganetespib in Combination With Chemoradiation,12/18/2015,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02389764,Phase II,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib For HER2-negative Metastatic Inflammatory Breast Cancer (MIBC),06/26/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02390427,Phase I,Recruiting,Dana-Farber Cancer Institute ,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer,04/15/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}, {'id': 5151, 'name': 'plexiform neurofibroma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 12603, 'name': 'acute leukemia', 'source': 'DOID'}, {'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}, {'id': 3620, 'name': 'central nervous system cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02390752,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 874, 'therapyName': 'PLX3397'}]",PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN),09/07/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02391116,Phase II,"Active, not recruiting",Bayer ,"[{'id': 995, 'therapyName': 'Copanlisib'}]",Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL),02/03/2016,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02391480,Phase I,Recruiting,AbbVie,"[{'id': 4028, 'therapyName': 'ABBV-075'}]",A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer,04/29/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02391727,Phase I,Recruiting,"Synermore Biologics Co., Ltd.","[{'id': 5330, 'therapyName': 'SYN004'}]","Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors (SYN004_Ph_1)",02/15/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02392507,Phase II,Recruiting,Eli Lilly and Company,"[{'id': 2599, 'therapyName': 'Carboplatin + nab-paclitaxel + Necitumumab'}]",A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC,10/21/2015,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 12603, 'name': 'acute leukemia', 'source': 'DOID'}]",NCT02392572,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 1687, 'therapyName': 'ONC201'}]",ONC201 in Relapsed/Refractory Acute Leukemias and High-risk Myelodysplastic Syndromes (HR-MDS),11/07/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02392611,Phase I,"Active, not recruiting",Gilead Sciences ,"[{'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}]","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas",06/10/2017,[],no
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT02392676,Phase III,Withdrawn,AstraZeneca ,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations,05/03/2016,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02392793,Phase I,Recruiting,St. Jude Children's Research Hospital ,"[{'id': 1378, 'therapyName': 'Irinotecan + Talazoparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies,04/28/2015,[],no
0,both,"[{'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}]",NCT02393248,Phase Ib/II,Recruiting,Incyte Corporation ,"[{'id': 4176, 'therapyName': 'Cisplatin + Gemcitabine + INCB054828'}, {'id': 4174, 'therapyName': 'Docetaxel + INCB054828'}, {'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies",06/03/2016,"[{'molecularProfile': {'id': 1185, 'profileName': 'FGFR2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3329, 'profileName': 'FGFR3 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14910, 'profileName': 'FGFR1 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 812, 'profileName': 'FGFR1 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3147, 'profileName': 'FGFR2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2969, 'profileName': 'FGFR2 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14903, 'profileName': 'FGFR3 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1221, 'profileName': 'FGFR1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02393625,Phase I,Recruiting,Novartis Pharmaceuticals ,"[{'id': 2565, 'therapyName': 'Ceritinib + Nivolumab'}]",Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer,06/09/2015,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3962, 'name': 'follicular thyroid carcinoma', 'source': 'DOID'}]",NCT02393690,Phase II,Recruiting,Academic and Community Cancer Research United,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer,12/18/2015,[],no
0,both,"[{'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}, {'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT02393755,Phase Ib/II,"Active, not recruiting",Roswell Park Cancer Institute ,"[{'id': 2589, 'therapyName': 'Capecitabine + Nintedanib'}]",Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer,08/11/2017,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02393794,Phase Ib/II,"Active, not recruiting",Priyanka Sharma ,"[{'id': 2993, 'therapyName': 'Cisplatin + Romidepsin '}]",Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC),07/03/2017,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 2893, 'name': 'cervix carcinoma', 'source': 'DOID'}]",NCT02394652,Phase II,Recruiting,"University Health Network, Toronto ","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1031, 'therapyName': 'Metformin'}]",The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer,08/14/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02395172,Phase III,"Active, not recruiting","EMD Serono Research & Development Institute, Inc.","[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200),02/18/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}]",NCT02395601,Phase I,Recruiting,Constellation Pharmaceuticals ,"[{'id': 2733, 'therapyName': 'CPI-1205'}]",A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas,03/20/2016,[],no
0,both,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}]",NCT02395627,Phase II,Recruiting,Pamela Munster,"[{'id': 3114, 'therapyName': 'Pembrolizumab + Tamoxifen + vorinostat'}]",Reversing Hormone Therapy Resistance With Epigenetic-Immune Modification,10/07/2015,[],yes
0,both,[],NCT02395666,Phase II,"Active, not recruiting",Giselle Sholler ,[],Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission,09/09/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02396368,Phase I,Withdrawn,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 2699, 'therapyName': 'Tasquinimod'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer,11/21/2015,[],no
0,female,"[{'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}]",NCT02397083,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 735, 'therapyName': 'Everolimus'}]",Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer,09/26/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02397720,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 3196, 'therapyName': 'Azacitidine + Nivolumab'}]",A Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia,02/12/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02399085,Phase II,Recruiting,MorphoSys AG ,"[{'id': 5843, 'therapyName': 'Lenalidomide + MOR208'}]",A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL,06/02/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02399137,Phase II,"Active, not recruiting",Merrimack Pharmaceuticals,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1073, 'therapyName': 'MM-141'}]",A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer,06/28/2017,[],no
0,both,"[{'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT02399215,Phase II,Recruiting,Roswell Park Cancer Institute ,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors,05/20/2015,[],no
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}, {'id': 1788, 'name': 'peritoneal mesothelioma', 'source': 'DOID'}]",NCT02399371,Phase II,Recruiting,University of Chicago ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Malignant Mesothelioma,04/28/2015,[],no
0,both,"[{'id': 50688, 'name': 'anal canal cancer', 'source': 'DOID'}, {'id': 1993, 'name': 'rectum cancer', 'source': 'DOID'}]",NCT02399813,Phase Ib/II,"Active, not recruiting","Advaxis, Inc. ","[{'id': 3090, 'therapyName': 'ADXS11-001'}]",Phase 2 Study of ADXS11-001 in Subjects With Anal Cancer or Cancer of the Rectum,04/30/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02399943,Phase II,Recruiting,"University Health Network, Toronto ","[{'id': 1991, 'therapyName': 'Panitumumab + Trametinib'}]",A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer,06/27/2016,"[{'molecularProfile': {'id': 481, 'profileName': 'NRAS wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 4, 'profileName': 'BRAF wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02400242,Phase I,"Active, not recruiting",Acetylon Pharmaceuticals Incorporated ,"[{'id': 3311, 'therapyName': 'Citarinostat'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1622, 'therapyName': 'Pomalidomide'}]",Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma,06/20/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02400255,Phase II,Recruiting,"Arog Pharmaceuticals, Inc. ","[{'id': 705, 'therapyName': 'Crenolanib'}]",Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients,11/05/2015,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 5329, 'profileName': 'FLT3 D835X'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02400281,Phase Ib/II,Recruiting,"Arog Pharmaceuticals, Inc. ","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 705, 'therapyName': 'Crenolanib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}]",Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients,11/05/2015,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02400385,Phase II,Withdrawn,California Pacific Medical Center Research Institute ,"[{'id': 2626, 'therapyName': 'Nivolumab + Sunitinib'}]",A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma,02/08/2017,"[{'molecularProfile': {'id': 1214, 'profileName': 'KIT mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1324, 'profileName': 'KIT rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02400476,Phase II,Recruiting,"Puma Biotechnology, Inc. ","[{'id': 828, 'therapyName': 'Neratinib'}]",A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide,04/24/2015,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02400814,Phase I,Recruiting,"University of California, Davis ","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer,09/02/2016,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02401048,Phase Ib/II,"Active, not recruiting",Pharmacyclics ,"[{'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}]",A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas,10/12/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02401295,Phase I,Completed,University of Iowa ,"[{'id': 3433, 'therapyName': 'Celecoxib + Itraconazole + Tretinoin '}]","ATRA, Celecoxib, and Itraconazole as Maintenance",02/24/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02401347,Phase II,Recruiting,Melinda Telli ,"[{'id': 682, 'therapyName': 'Talazoparib'}]",Talazoparib Beyond BRCA (TBB) Trial,07/24/2017,"[{'molecularProfile': {'id': 3274, 'profileName': 'ATM mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1213, 'profileName': 'PTEN mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}]",NCT02401542,Phase II,Recruiting,"BioClin Therapeutics, Inc. ","[{'id': 2934, 'therapyName': 'B-701'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Phase 2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma,07/27/2015,"[{'molecularProfile': {'id': 9322, 'profileName': 'FGFR3 positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02401815,Phase Ib/II,Recruiting,Plexxikon ,"[{'id': 874, 'therapyName': 'PLX3397'}, {'id': 2602, 'therapyName': 'PLX9486'}]",A Study of PLX9486 as a Single Agent and in Combination With PLX3397 in Patients With Advanced Solid Tumors Including GIST,03/16/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02402036,Phase II,"Active, not recruiting",Georgetown University ,"[{'id': 890, 'therapyName': 'Regorafenib'}]",A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer,09/01/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02402348,Phase I,Terminated,West Virginia University ,"[{'id': 1031, 'therapyName': 'Metformin'}]","Pilot Study of Metformin in HNSCC to Investigate the Effects of MF, Tumor Genotype and MF-genotype Interactions, on Tumor Metabolism and Anoikis",11/10/2016,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02402712,Phase III,"Active, not recruiting",Hoffmann-La Roche ,"[{'id': 1978, 'therapyName': 'Pertuzumab + Trastuzumab + Docetaxel'}]",Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer,04/15/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02402764,Phase II,"Active, not recruiting",H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Phase 2 Trial of Selinexor (KPT-330) for Metastatic TNBC,04/12/2016,[],yes
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT02402920,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer,07/25/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02403193,Phase Ib/II,Recruiting,Palobiofarma SL ,"[{'id': 4741, 'therapyName': 'PBF-509 + PDR001'}, {'id': 4740, 'therapyName': 'PBF-509'}]",Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (AdenONCO),09/21/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02403271,Phase Ib/II,Completed,Pharmacyclics ,"[{'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}]",A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors,09/09/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02403310,Phase I,"Active, not recruiting",H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 1738, 'therapyName': 'Daunorubicin + Cytarabine'}, {'id': 1749, 'therapyName': 'Selinexor'}]",A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML,07/06/2016,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02403505,Phase II,"Active, not recruiting","Dr. Han Xu, President/CEO / PD / PI / Monitor / IRB Chair ","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1814, 'therapyName': 'Degarelix'}]",Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms,03/04/2017,[],no
0,both,"[{'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}]",NCT02403895,Phase II,Completed,AstraZeneca ,"[{'id': 991, 'therapyName': 'Vistusertib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",AZD2014 and Weekly Paclitaxel in Squamous NSCLC,02/08/2017,[],no
0,,"[{'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 50688, 'name': 'anal canal cancer', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02404441,Phase Ib/II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 2659, 'therapyName': 'PDR001'}]",Phase I/II Study of PDR001 in Patients With Advanced Malignancies,05/20/2015,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02404480,Phase I,Unknown status,PTC Therapeutics,"[{'id': 5407, 'therapyName': 'PTC596'}]",PTC596 in Patients With Advanced Solid Tumors,07/03/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02406508,Phase II,Recruiting,Delcath Systems Inc. ,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC,07/27/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02406521,Phase I,"Active, not recruiting",Dana-Farber Cancer Institute ,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases,09/16/2016,[],no
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02406742,Phase Ib/II,Recruiting,Celgene Corporation ,"[{'id': 1646, 'therapyName': 'Obinutuzumab'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2358, 'therapyName': 'CC-122'}]","A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Rituximab, Ibrutinib and Obinutuzumab in Subjects With Relapsed/Refractory CLL/SLL (ENHANCE)",02/25/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02407054,Phase II,Recruiting,Eli Lilly and Company ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer,05/08/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02407171,Phase Ib/II,Recruiting,Yale University,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC,10/02/2015,[],no
0,both,"[{'id': 5151, 'name': 'plexiform neurofibroma', 'source': 'DOID'}]",NCT02407405,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery,06/19/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02407990,Phase I,Recruiting,BeiGene,"[{'id': 5871, 'therapyName': 'BGB-A317'}]","Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors",06/19/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02408042,Phase Ib/II,Withdrawn,Western Regional Medical Center ,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 2352, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2486, 'therapyName': 'Brentuximab vedotin'}]",Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme),02/23/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 8632, 'name': ""Kaposi's sarcoma"", 'source': 'DOID'}]",NCT02408861,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors,02/20/2016,[],no
0,both,[],NCT02409134,Phase I,Recruiting,"Sung Choi, M.D. ",[],Cognitive Function and Patient-Reported Quality of Life Outcomes Investigation in Patients Taking Vorinostat,12/06/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02409342,Phase III,Recruiting,Hoffmann-La Roche ,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC),05/13/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02409355,Phase III,"Active, not recruiting",Hoffmann-La Roche ,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A Compared With Gemcitabine + Cisplatin or Carboplatin in Patients With Stage IV Squamous Non-Small Cell Lung Cancer,06/09/2016,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02410512,Phase I,Recruiting,"Genentech, Inc. ","[{'id': 2729, 'therapyName': 'MOXR0916'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors,05/20/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02411448,Phase III,Recruiting,Eli Lilly and Company ,"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC,05/23/2015,"[{'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3459, 'name': 'breast carcinoma', 'source': 'DOID'}]",NCT02411656,Phase II,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC),06/16/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'excluded'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02411786,Phase I,Recruiting,"University of Wisconsin, Madison ","[{'id': 4297, 'therapyName': 'pTVG-AR '}, {'id': 1873, 'therapyName': 'Sargramostim'}]",A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF,06/17/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02412371,Phase II,Recruiting,AbbVie ,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer,05/08/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02412462,Phase I,Completed,Alethia Biotherapeutics ,"[{'id': 4317, 'therapyName': 'AB-16B5'}]",Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy,06/29/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02412475,Phase I,"Active, not recruiting",Michael Burke ,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",Epigenetic Reprogramming in Relapse AML,08/19/2017,[],no
0,both,"[{'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}]",NCT02412670,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2668, 'therapyName': 'Aldoxorubicin + Cisplatin + Methotrexate + Vincristine'}]",Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer,08/21/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02412722,Phase I,"Active, not recruiting","Millennium Pharmaceuticals, Inc. ","[{'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","Safety, Tolerability, and Pharmacokinetics of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies",01/13/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02413827,Phase Ib/II,Terminated,Celldex Therapeutics ,"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}, {'id': 1324, 'therapyName': 'DEC-205-NY-ESO-1 fusion protein vaccine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma,03/08/2017,[],no
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT02413853,Phase II,Withdrawn,University of Southern California ,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1083, 'therapyName': 'Pri-724'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer,04/18/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02414139,Phase II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With Advanced Non-small Cell Lung Cancer Who Have Received One or Two Prior Lines of Therapy,07/17/2015,"[{'molecularProfile': {'id': 343, 'profileName': 'EGFR wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02414165,Phase II,"Active, not recruiting",Tocagen Inc. ,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5),02/10/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02414516,Phase I,Unknown status,Oncolys BioPharma Inc ,"[{'id': 2906, 'therapyName': 'OBP-801'}]",A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors,06/20/2017,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02414646,Phase II,Recruiting,Academic and Community Cancer Research United ,"[{'id': 947, 'therapyName': 'Trastuzumab'}]",Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer,06/02/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02414724,Phase I,Terminated,Roswell Park Cancer Institute ,"[{'id': 2898, 'therapyName': 'Gemcitabine + Ribociclib'}]",Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma,09/13/2016,[],no
0,both,"[{'id': 3664, 'name': 'mast cell neoplasm', 'source': 'DOID'}, {'id': 9254, 'name': 'mast-cell leukemia', 'source': 'DOID'}]",NCT02415608,Phase II,Recruiting,Jason Robert Gotlib ,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis,03/31/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02415621,Phase I,Recruiting,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 1805, 'therapyName': 'Abiraterone'}]",Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer,08/27/2015,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02415881,Phase I,Recruiting,Eben Rosenthal ,"[{'id': 845, 'therapyName': 'Panitumumab'}]",Phase I Panitumumab IRDye800 Optical Imaging Study,10/15/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02416908,Phase Ib/II,Recruiting,Washington University School of Medicine ,"[{'id': 1749, 'therapyName': 'Selinexor'}, {'id': 3178, 'therapyName': 'Cladribine + Cytarabine + Plerixafor'}]",Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia,11/05/2015,[],no
0,both,"[{'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}]",NCT02417701,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",TORC1/2 Inhibitor MLN0128 in Treating Patients With Stage IV or Recurrent Lung Cancer,10/12/2016,[],yes
0,both,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 3119, 'name': 'gastrointestinal system cancer', 'source': 'DOID'}]",NCT02417753,Phase II,Terminated,National Cancer Institute (NCI),"[{'id': 2782, 'therapyName': 'AZD9150 '}]","AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites",04/12/2016,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT02418000,Phase Ib/II,Terminated,Strategia Therapeutics,"[{'id': 1011, 'therapyName': 'E6201'}]",A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation,09/02/2017,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02419417,Phase Ib/II,Recruiting,Bristol-Myers Squibb ,"[{'id': 2811, 'therapyName': 'BMS986158'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Study of BMS-986158 in Subjects With Select Advanced Solid Tumors,06/27/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02419495,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1749, 'therapyName': 'Selinexor'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Selinexor in Combination With Standard Chemotherapy,06/22/2017,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02419560,Phase I,Suspended,"Craig Portell, MD ","[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL,03/21/2017,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02419755,Phase II,Terminated,St. Jude Children's Research Hospital,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies,01/07/2017,"[{'molecularProfile': {'id': 14079, 'profileName': 'KMT2A rearrange'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4202, 'name': 'brain stem glioma', 'source': 'DOID'}]",NCT02420613,Phase I,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 936, 'therapyName': 'Temsirolimus'}]",Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG),10/09/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02420652,Phase II,Recruiting,"Rutgers, The State University of New Jersey ","[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy,11/05/2015,[],no
0,both,"[{'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT02420691,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center ,"[{'id': 790, 'therapyName': 'Ribociclib'}]",LEE011 in Neuroendocrine Tumors of Foregut Origin,09/21/2016,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02420717,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 2046, 'therapyName': 'Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine '}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 3194, 'therapyName': 'Mercaptopurine + Methotrexate + Prednisone + Vincristine'}]",Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL),06/26/2016,[],yes
0,both,"[{'id': 50744, 'name': 'anaplastic large cell lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02420795,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 1687, 'therapyName': 'ONC201'}]",Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma,03/31/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02420821,Phase III,"Active, not recruiting",Hoffmann-La Roche ,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma,03/04/2017,[],no
0,both,"[{'id': 70004, 'name': 'myeloid neoplasm', 'source': 'DOID'}]",NCT02420860,Phase II,Recruiting,Boehringer Ingelheim,"[{'id': 5972, 'therapyName': 'Famotidine'}, {'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}, {'id': 1275, 'therapyName': 'Diphenhydramine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT),07/06/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02420912,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]","Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",03/11/2016,[],no
0,,[],NCT02421354,,Recruiting,,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Patients With Myelofibrosis,10/19/2017,[],
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02421939,Phase III,Recruiting,"Astellas Pharma Global Development, Inc. ","[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 3193, 'therapyName': 'Cytarabine + Fludarabine + Idarubicin'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation,11/08/2015,"[{'molecularProfile': {'id': 2774, 'profileName': 'FLT3 act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02422381,Phase Ib/II,Recruiting,Providence Health & Services ,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC),05/14/2015,[],no
0,,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02422589,Phase I,Recruiting,Novartis Pharmaceuticals ,"[{'id': 2505, 'therapyName': 'Warfarin'}, {'id': 2685, 'therapyName': 'Midazolam'}, {'id': 789, 'therapyName': 'Ceritinib'}]","A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors",12/06/2015,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1760, 'profileName': 'ALK amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02422615,Phase III,"Active, not recruiting",Novartis Pharmaceuticals ,"[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.,11/01/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02422979,Phase I,Recruiting,"Aspyrian Therapeutics, Inc. ","[{'id': 2918, 'therapyName': 'RM-1929'}]",Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer,07/17/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02423057,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 2907, 'therapyName': 'TdCyd'}]",Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors,07/22/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02423343,Phase Ib/II,Recruiting,Eli Lilly and Company ,"[{'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma",10/22/2015,[],no
0,both,"[{'id': 6086, 'name': 'malignant leptomeningeal tumor', 'source': 'DOID'}, {'id': 7912, 'name': 'mixed oligodendroglioma-astrocytoma', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}, {'id': 3565, 'name': 'meningioma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02423525,Phase I,Recruiting,"University of California, San Diego ","[{'id': 623, 'therapyName': 'Afatinib'}]",Safety Study of Afatinib for Brain Cancer,10/27/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 4159, 'name': 'skin cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02423863,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 2595, 'therapyName': 'poly ICLC  '}]","In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol",05/13/2015,[],no
0,female,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT02423902,Phase Ib/II,"Active, not recruiting",Ziopharm ,"[{'id': 4250, 'therapyName': 'Ad-RTS-IL-12 plus AL'}]",A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer,02/15/2017,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02423915,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}]",Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention,06/03/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02423954,Phase Ib/II,"Active, not recruiting",Western Regional Medical Center ,"[{'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus),06/28/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02424617,Phase Ib/II,Recruiting,BerGenBio AS ,"[{'id': 2684, 'therapyName': 'BGB-324 + Erlotinib'}]",A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer,05/14/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02425306,Phase Ib/II,Recruiting,"Craig L Slingluff, Jr ","[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2620, 'therapyName': '6MHP vaccine'}, {'id': 2595, 'therapyName': 'poly ICLC  '}]",Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma,02/08/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02425683,Phase II,"Active, not recruiting",US Oncology Research ,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX,05/20/2017,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02425891,Phase III,"Active, not recruiting",Hoffmann-La Roche ,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of MPDL3280A in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer,08/05/2017,[],yes
0,both,"[{'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}]",NCT02426125,Phase III,"Active, not recruiting",Eli Lilly and Company ,"[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer,04/13/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02426723,Phase I,Recruiting,JW Pharmaceutical,"[{'id': 3081, 'therapyName': 'CWP232291'}, {'id': 4036, 'therapyName': 'Dexamethasone + lenalidomide'}]",Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients,04/29/2016,[],no
0,both,"[{'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 119, 'name': 'vaginal cancer', 'source': 'DOID'}, {'id': 11615, 'name': 'penile cancer', 'source': 'DOID'}, {'id': 50688, 'name': 'anal canal cancer', 'source': 'DOID'}, {'id': 1245, 'name': 'vulva cancer', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT02426892,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors,02/18/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02427451,Phase Ib/II,"Active, not recruiting",Jeffrey Jones ,"[{'id': 3472, 'therapyName': 'GDC-0199 + Ibrutinib + Obinutuzumab'}]","Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia",06/20/2017,[],yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02427581,Phase I,Recruiting,Washington University School of Medicine ,"[{'id': 2595, 'therapyName': 'poly ICLC  '}]",Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy,10/09/2015,[],yes
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02427620,Phase II,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 2353, 'therapyName': 'Cyclophosphamide + Doxorubicin + Vincristine '}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3195, 'therapyName': 'Cytarabine + Methotrexate '}, {'id': 1642, 'therapyName': 'Leucovorin'}]",A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma,12/15/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02427893,Phase III,Withdrawn,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 1004, 'therapyName': 'Cobimetinib'}, {'id': 342, 'therapyName': 'Vemurafenib'}]",Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma,11/17/2016,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 5289, 'name': 'uterus leiomyosarcoma', 'source': 'DOID'}]",NCT02428192,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Advanced Uterine Leiomyosarcoma,06/07/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02428270,Phase II,Recruiting,"University Health Network, Toronto ","[{'id': 4205, 'therapyName': 'GSK2256098 + Trametinib'}]",A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer,06/02/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3963, 'name': 'thyroid carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02428712,Phase Ib/II,Recruiting,Plexxikon ,"[{'id': 1041, 'therapyName': 'PLX8394'}]","A Study of PLX8394 as a Single Agent in Patients With Advanced, Unresectable Solid Tumors",05/14/2015,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 696, 'profileName': 'BRAF act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4928, 'name': 'intrahepatic cholangiocarcinoma', 'source': 'DOID'}]",NCT02428855,Phase II,"Active, not recruiting",Massachusetts General Hospital ,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma,02/18/2017,"[{'molecularProfile': {'id': 1781, 'profileName': 'IDH1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 5912, 'profileName': 'IDH2 mutant'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02429193,Phase II,Recruiting,"University Health Network, Toronto ","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA (BARRIER-P),04/14/2016,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02429375,Phase Ib/II,"Active, not recruiting",Memorial Sloan Kettering Cancer Center ,"[{'id': 3264, 'therapyName': 'Brentuximab vedotin + Mocetinostat'}]",Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma,04/27/2017,[],no
0,both,"[{'id': 2994, 'name': 'germ cell cancer', 'source': 'DOID'}]",NCT02429466,Phase I,Recruiting,Costantine Albany ,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1949, 'therapyName': 'SGI-110'}]",Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors,09/01/2017,[],no
0,both,"[{'id': 1324, 'name': 'lung cancer', 'source': 'DOID'}]",NCT02429843,Phase I,Recruiting,University of Alabama at Birmingham ,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1242, 'therapyName': 'Carotuximab'}]",A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer,02/20/2016,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02430480,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 759, 'therapyName': 'Goserelin'}]",Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer,05/14/2015,[],no
0,,[],NCT02431169,,Recruiting,Washington University School of Medicine ,[],Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression,10/17/2015,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02431208,Phase I,Suspended,Hoffmann-La Roche ,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab (Anti-Programmed Death Ligand 1 [PD-L1] Antibody) Administered With or Without Lenalidomide in Participants With Multiple Myeloma (MM),09/30/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02431260,Phase I,"Active, not recruiting",Incyte Corporation ,"[{'id': 2812, 'therapyName': 'INCB054329'}]","An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies",05/12/2017,[],no
0,female,"[{'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT02431559,Phase Ib/II,Recruiting,Ludwig Institute for Cancer Research ,"[{'id': 3101, 'therapyName': 'Aldoxorubicin + MEDI4736 + Motolimod'}]","A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated",12/16/2016,[],no
0,both,[],NCT02431676,Phase II,"Active, not recruiting",Sidney Kimmel Comprehensive Cancer Center,[],Survivorship Promotion In Reducing IGF-1 Trial (SPIRIT),04/30/2017,[],no
0,both,"[{'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}, {'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02432274,Phase Ib/II,Recruiting,Eisai Limited ,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 792, 'therapyName': 'Lenvatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies,11/16/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02432326,Phase I,Recruiting,"Boston Biomedical, Inc ","[{'id': 1945, 'therapyName': 'BBI503'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors,05/15/2015,[],no
0,both,[],NCT02432560,Phase 0,Recruiting,"Children's Hospital Medical Center, Cincinnati ",[],Safety and Durability of Sirolimus for Treatment of LAM,07/22/2016,[],no
0,both,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT02432690,Phase II,"Active, not recruiting","Boston Biomedical, Inc ","[{'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation,03/14/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02432846,Phase II,Recruiting,Immunicum AB,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) (MERECA),03/10/2017,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 3587, 'name': 'pancreatic ductal carcinoma', 'source': 'DOID'}]",NCT02432963,Phase I,Recruiting,City of Hope Medical Center ,"[{'id': 1038, 'therapyName': 'MVAp53'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy,06/18/2016,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 6841, 'profileName': 'TP53 over exp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02434354,Phase I,Recruiting,Abramson Cancer Center of the University of Pennsylvania,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma,06/01/2015,[],no
0,,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02435121,Phase II,Completed,Sanofi ,"[{'id': 2159, 'therapyName': 'SAR125844'}]",A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification,02/13/2016,"[{'molecularProfile': {'id': 1629, 'profileName': 'MET amp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02435433,Phase III,Recruiting,Eli Lilly and Company ,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2),07/28/2015,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02435680,Phase II,"Active, not recruiting",Novartis Pharmaceuticals ,"[{'id': 2838, 'therapyName': 'MCS110'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC),10/04/2017,[],yes
0,both,"[{'id': 80146, 'name': 'B-cell childhood acute lymphoblastic leukemia', 'source': 'DOID'}]",NCT02435849,Phase II,Recruiting,Novartis Pharmaceuticals,"[{'id': 5981, 'therapyName': 'Tisagenlecleucel'}]",Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL (ELIANA),10/09/2017,[],yes
0,both,"[{'id': 2513, 'name': 'basal cell carcinoma', 'source': 'DOID'}, {'id': 4143, 'name': 'orbital cancer', 'source': 'DOID'}]",NCT02436408,FDA approved,Recruiting,University of Michigan Cancer Center ,"[{'id': 956, 'therapyName': 'Vismodegib'}]",VISmodegib for ORbital and Periocular Basal Cell Carcinoma,09/16/2015,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02436668,Phase II,"Active, not recruiting",Pharmacyclics ,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma",04/07/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}]",NCT02436707,Phase II,Recruiting,NCIC Clinical Trials Group ,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3391, 'therapyName': 'Cisplatin + Dexamethasone + Gemcitabine + Rituximab'}]",Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma,01/15/2016,[],yes
0,female,"[{'id': 3459, 'name': 'breast carcinoma', 'source': 'DOID'}]",NCT02436993,Phase II,Recruiting,"University of California, Irvine ","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting,05/20/2015,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02437071,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients,05/20/2015,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02437136,Phase Ib/II,Recruiting,Syndax Pharmaceuticals,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma,12/31/2015,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02437318,Phase III,Recruiting,Novartis Pharmaceuticals ,"[{'id': 691, 'therapyName': 'BYL719'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.,08/11/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}]",NCT02437370,Phase I,Recruiting,"University of California, Davis ","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer,08/28/2015,[],no
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT02437812,Phase II,Recruiting,Gynecologic Oncology Associates ,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1031, 'therapyName': 'Metformin'}]","Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma",05/19/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02438007,Phase III,Terminated,Tokai Pharmaceuticals ,"[{'id': 1508, 'therapyName': 'galeterone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC,01/11/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02438722,Phase II,Recruiting,Southwest Oncology Group ,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 694, 'therapyName': 'Cetuximab'}]","S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer",09/22/2016,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02439450,Phase I,Recruiting,Heat Biologics ,"[{'id': 2457, 'therapyName': 'HS-110'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,09/16/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02439723,Phase I,Not yet recruiting,AHS Cancer Control Alberta ,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients,05/20/2015,[],no
0,both,"[{'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT02440425,Phase II,Recruiting,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer,08/18/2015,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02440464,Phase II,Recruiting,"National Heart, Lung, and Blood Institute (NHLBI) ","[{'id': 3321, 'therapyName': 'Tacrolimus + Methotrexate'}, {'id': 1359, 'therapyName': 'Ixazomib'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 688, 'therapyName': 'Bortezomib'}]",Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302),11/23/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02441517,FDA approved,Terminated,"Astellas Pharma Global Development, Inc. ","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel Treatment in Patients Who Have Previously Received Enzalutamide,05/24/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02441686,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute ,"[{'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma",09/06/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02441946,Phase II,Completed,Eli Lilly and Company ,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 2700, 'therapyName': 'Loperamide'}, {'id': 633, 'therapyName': 'Anastrozole'}]","A Phase 2 Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer",05/19/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02442297,Phase I,Recruiting,Baylor College of Medicine ,"[{'id': 2940, 'therapyName': 'HER2 sensitized T-cells'}]",T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma,04/22/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02442414,Phase I,Unknown status,Sihuan Pharmaceutical Holdings Group Ltd. ,"[{'id': 2908, 'therapyName': 'Pirotinib'}]",A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors,06/20/2017,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02443077,Phase III,Recruiting,National Cancer Institute (NCI),"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma,09/27/2016,[],no
0,both,"[{'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT02443324,Phase I,"Active, not recruiting",Eli Lilly and Company,"[{'id': 2896, 'therapyName': 'Pembrolizumab + Ramucirumab'}]","A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium",09/29/2017,[],no
0,both,"[{'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}]",NCT02443337,Phase II,"Active, not recruiting",Eli Lilly and Company ,"[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3023414 and Necitumumab in Squamous Lung Cancer,01/24/2017,[],no
0,both,"[{'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT02443883,Phase II,"Active, not recruiting",Eli Lilly and Company ,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer,12/13/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02444741,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC),09/22/2015,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 4007, 'name': 'bladder carcinoma', 'source': 'DOID'}, {'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02444793,Phase I,Recruiting,Pfizer ,"[{'id': 6332, 'therapyName': 'Mogamulizumab + Utomilumab'}]",A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors,10/18/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02445248,Phase II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 5981, 'therapyName': 'Tisagenlecleucel'}]",Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients (JULIET),07/17/2017,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02446236,Phase I,Recruiting,Hackensack University Medical Center ,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]","Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)",01/10/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02446405,Phase III,"Active, not recruiting",University of Sydney ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer,03/29/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}, {'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}, {'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}]",NCT02446431,Phase I,Recruiting,Miller Children's & Women's Hospital Long Beach ,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence,09/07/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02446444,Phase III,Recruiting,University of Sydney ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer",05/28/2015,[],no
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02446457,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center ,"[{'id': 3279, 'therapyName': 'Pembrolizumab + Rituximab'}]",Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma,10/20/2017,[],no
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT02446600,Phase III,Recruiting,National Cancer Institute (NCI),"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",02/10/2016,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02446704,Phase Ib/II,"Active, not recruiting",Massachusetts General Hospital ,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy,05/10/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02447003,Phase II,"Active, not recruiting",Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086),02/25/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02448251,Phase Ib/II,Recruiting,"ACEA Biosciences, Inc. ","[{'id': 2909, 'therapyName': 'AC0010MA'}]","Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer",02/01/2016,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02448303,Phase II,"Active, not recruiting",Acerta Pharma BV ,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab Alone and In Combination With ACP-196 in Subjects With Advanced Non-small Cell Lung Cancer,05/10/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02448589,Phase I,Recruiting,"Taiho Oncology, Inc. ","[{'id': 1400, 'therapyName': 'TAS-119'}]",An Investigation of TAS-119 Monotherapy and in Combination With Docetaxel,10/04/2016,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02448771,Phase Ib/II,Recruiting,Dana-Farber Cancer Institute ,"[{'id': 2738, 'therapyName': 'Bazedoxifene + Palbociclib'}]",A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer,05/26/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02448810,Phase II,Terminated,Baxalta US Inc. ,"[{'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}, {'id': 2996, 'therapyName': 'Imalumab'}, {'id': 845, 'therapyName': 'Panitumumab'}]",Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer,06/06/2017,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT02449239,Phase III,Recruiting,Viventia Bio ,"[{'id': 6290, 'therapyName': 'Oportuzumab monatox'}]",Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG,10/09/2017,[],no
0,both,"[{'id': 3151, 'name': 'skin squamous cell carcinoma', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 8618, 'name': 'oral cavity cancer', 'source': 'DOID'}]",NCT02449681,Phase II,Terminated,Threshold Pharmaceuticals,"[{'id': 2910, 'therapyName': 'TH-4000'}]",Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS,02/28/2017,[],no
0,both,"[{'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}, {'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}, {'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}]",NCT02450175,Phase I,Unknown status,Sinai Hospital of Baltimore ,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 735, 'therapyName': 'Everolimus'}]","Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls",06/20/2017,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT02450331,Phase III,Recruiting,Hoffmann-La Roche,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]","IMvigor 010 Study: Anti-Programmed Death-Ligand 1 (PD-L1) Antibody MPDL3280A Treatment Versus Observation as Adjuvant Therapy in Patients With PD-L1 Positive, High Risk Muscle Invasive Bladder Cancer After Cystectomy",07/03/2015,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02450539,Phase II,"Active, not recruiting",Eli Lilly and Company ,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer,02/18/2017,[],no
0,both,"[{'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}]",NCT02450591,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations,06/25/2015,"[{'molecularProfile': {'id': 3321, 'profileName': 'EGFR S768I'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 6633, 'profileName': 'EGFR exon 19 ins'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1044, 'profileName': 'EGFR G719A'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 4039, 'profileName': 'EGFR exon 20 ins'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT02451423,Phase II,Recruiting,"University of California, San Francisco ","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Study of MPDL3280A in Bladder Cancer,06/02/2016,[],no
0,both,"[{'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02451553,Phase I,Recruiting,University of Washington ,"[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]","Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer",11/19/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02451852,Phase I,No longer available,AstraZeneca,"[{'id': 660, 'therapyName': 'Osimertinib'}]",AZD9291 US Expanded Access Program,01/22/2016,"[{'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02451865,Phase I,Withdrawn,Jonsson Comprehensive Cancer Center ,"[{'id': 2740, 'therapyName': 'Binimetinib + Docetaxel'}]","Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer",07/12/2016,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02451930,Phase I,"Active, not recruiting",Eli Lilly and Company ,"[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC,02/08/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02451943,Phase III,"Active, not recruiting",Eli Lilly and Company ,"[{'id': 3269, 'therapyName': 'Olaratumab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma,08/03/2016,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02451982,Phase Ib/II,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3622, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine '}]",Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer,03/04/2016,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02452008,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Study of TGF-Beta Receptor Inhibitor LY2157299 and Enzalutamide in Metastatic Castration-resistant Prostate Cancer,04/22/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02452268,Phase I,Recruiting,Novartis Pharmaceuticals,"[{'id': 6032, 'therapyName': 'PDR001 + NIZ985'}]",A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers,07/28/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02452281,Phase Ib/II,Withdrawn,Rabih Said ,"[{'id': 2973, 'therapyName': 'Vitespen'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma,01/26/2016,[],no
0,both,"[{'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 3587, 'name': 'pancreatic ductal carcinoma', 'source': 'DOID'}, {'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02452424,Phase Ib/II,"Active, not recruiting",Plexxikon,"[{'id': 2736, 'therapyName': 'Pembrolizumab + PLX3397'}]",A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,07/29/2017,[],yes
0,both,[],NCT02452463,Phase II,Recruiting,Roswell Park Cancer Institute ,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy,10/03/2016,[],no
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02452775,Phase I,Recruiting,Abramson Cancer Center of the University of Pennsylvania ,"[{'id': 3008, 'therapyName': 'OC-L'}]",Autologous OC-L Vaccine and Ovarian Cancer,08/11/2015,[],no
0,both,"[{'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT02452970,Phase II,"Active, not recruiting","EpicentRx, Inc. ","[{'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC),11/02/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02453282,Phase III,"Active, not recruiting",AstraZeneca ,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).,06/02/2016,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02453594,Phase II,"Active, not recruiting",Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087),03/12/2016,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02453620,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1541, 'therapyName': 'Entinostat'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer",11/14/2015,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02454010,Phase I,Recruiting,"Fujifilm Pharmaceuticals U.S.A., Inc. ","[{'id': 3833, 'therapyName': 'FF-21101(90Y)'}]",A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer,03/25/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}]",NCT02454179,Phase II,"Active, not recruiting",Acerta Pharma BV,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma,05/10/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02454270,Phase II,"Active, not recruiting","Janssen Research & Development, LLC ","[{'id': 4166, 'therapyName': 'JNJ-64052781'}]",A Dose Escalation Study of JNJ-64052781 in Participants With Relapsed or Refractory B-cell Malignancies,09/19/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02454842,Phase II,Terminated,Threshold Pharmaceuticals ,"[{'id': 2910, 'therapyName': 'TH-4000'}]","Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC",02/28/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02454933,Phase III,"Active, not recruiting",AstraZeneca ,"[{'id': 660, 'therapyName': 'Osimertinib'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours,03/24/2016,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}, {'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}, {'id': 2994, 'name': 'germ cell cancer', 'source': 'DOID'}, {'id': 305, 'name': 'carcinoma', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 3459, 'name': 'breast carcinoma', 'source': 'DOID'}, {'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}, {'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}, {'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT02454972,Phase II,Recruiting,PharmaMar ,"[{'id': 1195, 'therapyName': 'Lurbinectedin'}]",Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors,09/07/2016,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02455297,Phase II,Terminated,Bayer ,"[{'id': 995, 'therapyName': 'Copanlisib'}]",Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL),01/19/2017,[],no
0,both,"[{'id': 3962, 'name': 'follicular thyroid carcinoma', 'source': 'DOID'}]",NCT02456701,Phase I,Completed,"Kolltan Pharmaceuticals, Inc. ","[{'id': 2063, 'therapyName': 'CDX-3379 + Vemurafenib'}]",Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379,04/05/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02456857,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 936, 'therapyName': 'Temsirolimus'}]","Liposomal Doxorubicin, Bevacizumab and Temsirolimus (DAT) in Triple-Negative Breast Cancer (TNBC) Insensitive to Standard Neoadjuvant Chemotherapy",01/14/2016,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02456883,Phase I,Completed,"Astellas Pharma Global Development, Inc. ","[{'id': 2865, 'therapyName': 'Gilteritinib'}]","Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors",07/22/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02457351,Phase I,Completed,Bayer,"[{'id': 663, 'therapyName': 'BAY1000394'}, {'id': 1026, 'therapyName': 'Itraconazole'}]",Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study,05/24/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02457793,Phase I,Completed,"Genentech, Inc.","[{'id': 1004, 'therapyName': 'Cobimetinib'}, {'id': 2149, 'therapyName': 'GDC-0994'}]","A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors",04/08/2017,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02457910,Phase Ib/II,Recruiting,Vanderbilt-Ingram Cancer Center ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1016, 'therapyName': 'GDC-0032'}]",Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer,07/27/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 7497, 'name': 'brain ependymoma', 'source': 'DOID'}, {'id': 5503, 'name': 'spinal cord ependymoma', 'source': 'DOID'}, {'id': 2129, 'name': 'atypical teratoid rhabdoid tumor', 'source': 'DOID'}, {'id': 5648, 'name': 'choroid plexus carcinoma', 'source': 'DOID'}, {'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}]",NCT02458339,Phase I,Recruiting,"The University of Texas Health Science Center, Houston ","[{'id': 1639, 'therapyName': 'Methotrexate'}]",Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors,09/07/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02458638,Phase II,Recruiting,Hoffmann-La Roche ,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",An Open Label Study of MPDL3280A in Advanced Solid Tumors,07/24/2015,[],no
0,both,"[{'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}]",NCT02459119,Phase II,Recruiting,University of Alabama at Birmingham ,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477),06/12/2015,[],no
0,female,"[{'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT02459301,Phase I,"Active, not recruiting",NCIC Clinical Trials Group ,"[{'id': 3382, 'therapyName': 'IPH2201'}]","Dose-Ranging Study of IPH2201 in Patients With High Grade Serious CA of Ovarian, Fallopian Tube or Peritoneal Origin",04/22/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02460198,Phase II,"Active, not recruiting",Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164),09/27/2016,[],no
0,both,"[{'id': 263, 'name': 'kidney cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}]",NCT02460224,Phase Ib/II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 2887, 'therapyName': 'LAG525'}, {'id': 2659, 'therapyName': 'PDR001'}]",Safety and Efficay of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,11/11/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02460367,Phase Ib/II,Recruiting,NewLink Genetics Corporation,"[{'id': 3578, 'therapyName': 'Docetaxel + Indoximod'}]",Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer,02/19/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02460991,Phase I,Terminated,"CeloNova BioSciences, Inc. ","[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma,06/20/2017,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02462252,Phase II,Recruiting,"BioLineRx, Ltd. ","[{'id': 4411, 'therapyName': 'anti-thymocyte globulin + BKT140 + Cyclosporine + Methylprednisolone'}]","Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome",07/01/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02463032,Phase II,"Active, not recruiting",GTX,"[{'id': 5026, 'therapyName': 'enobosarm'}]",Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer,08/05/2017,[],yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02463799,Phase II,Recruiting,Johns Hopkins University ,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 2648, 'therapyName': 'Sipuleucel-T'}]",Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC,12/15/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02463994,Phase I,"Active, not recruiting",University of Michigan Cancer Center ,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC,03/21/2017,"[{'molecularProfile': {'id': 1102, 'profileName': 'EGFR positive'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1771, 'profileName': 'ROS1 positive'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 50744, 'name': 'anaplastic large cell lymphoma', 'source': 'DOID'}, {'id': 50749, 'name': 'peripheral T-cell lymphoma', 'source': 'DOID'}]",NCT02464228,Phase II,Recruiting,"Kura Oncology, Inc. ","[{'id': 938, 'therapyName': 'Tipifarnib'}]",Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma,04/15/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT02464657,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3192, 'therapyName': 'Cytarabine + Idarubicin + Nivolumab'}]",Nivolumab in Acute Myeloid Leukemia (AML),11/10/2015,[],no
0,both,[],NCT02464761,Phase I,Recruiting,Sunnybrook Health Sciences Centre ,"[{'id': 3319, 'therapyName': 'Verteporfin'}]",Photodynamic Therapy for the Treatment of Vertebral Metastases,01/29/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02465060,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 660, 'therapyName': 'Osimertinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 654, 'therapyName': 'AZD4547'}, {'id': 958, 'therapyName': 'VS-6063'}, {'id': 765, 'therapyName': 'GSK2636771'}]",NCI-MATCH Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas,01/30/2017,"[{'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1221, 'profileName': 'FGFR1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1664, 'profileName': 'SMO mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 11085, 'profileName': 'ROS1 rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1629, 'profileName': 'MET amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1243, 'profileName': 'ERBB2 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2969, 'profileName': 'FGFR2 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3287, 'profileName': 'BRAF fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1185, 'profileName': 'FGFR2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 479, 'profileName': 'PTEN loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 26413, 'profileName': 'MET del exon14'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 25004, 'profileName': 'MLH1 loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2408, 'profileName': 'PTEN del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 25000, 'profileName': 'GNAQ mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 24999, 'profileName': 'GNA11 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1214, 'profileName': 'KIT mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14910, 'profileName': 'FGFR1 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1213, 'profileName': 'PTEN mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1209, 'profileName': 'AKT1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14903, 'profileName': 'FGFR3 fusion'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT02466009,Phase II,Recruiting,University of Rochester ,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Regorafenib in Metastatic Colorectal Cancer,06/12/2015,[],no
0,both,"[{'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}]",NCT02466568,Phase Ib/II,Not yet recruiting,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung,06/12/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02466802,Phase I,Recruiting,Virginia Commonwealth University ,"[{'id': 890, 'therapyName': 'Regorafenib'}, {'id': 3066, 'therapyName': 'Sildenafil'}]",Study of Regorafenib and Sildenafil for Advanced Solid Tumors,10/19/2016,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02467270,Phase II,Recruiting,Ariad Pharmaceuticals ,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses,10/30/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02467361,Phase Ib/II,Recruiting,"Boston Biomedical, Inc ","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers,09/05/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02468661,Phase Ib/II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 1065, 'therapyName': 'Capmatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]","A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification",12/11/2015,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1629, 'profileName': 'MET amp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT02469415,Phase II,Terminated,M.D. Anderson Cancer Center,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2006, 'therapyName': 'Pacritinib'}]",Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS),06/10/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02469701,Phase II,"Active, not recruiting",howard safran ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",BrUOG 317: Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease,07/26/2017,[],no
0,both,"[{'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}]",NCT02470091,Phase II,Recruiting,Children's Oncology Group ,"[{'id': 1198, 'therapyName': 'Denosumab'}]",Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma,11/18/2015,[],no
0,female,"[{'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT02470585,Phase III,"Active, not recruiting",AbbVie ,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 954, 'therapyName': 'Veliparib'}]","Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",08/05/2017,[],no
0,female,[],NCT02470741,Phase III,"Active, not recruiting","University of California, San Francisco ",[],Pilot of Letrozole for Uterine Myomas (PLUM),01/18/2017,[],no
0,both,"[{'id': 314, 'name': 'tenosynovial giant cell tumor', 'source': 'DOID'}]",NCT02471716,Phase Ib/II,Recruiting,"Five Prime Therapeutics, Inc. ","[{'id': 2840, 'therapyName': 'FPA008'}]",Study of FPA008 in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor,07/02/2015,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02471846,Phase I,"Active, not recruiting","Genentech, Inc. ","[{'id': 2888, 'therapyName': 'GDC-0919'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors,08/08/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02471911,Phase I,Recruiting,Weill Medical College of Cornell University ,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3360, 'therapyName': 'Carboplatin + Etoposide + Ifosfamide + Rituximab'}, {'id': 1749, 'therapyName': 'Selinexor'}]",KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma,01/06/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02472145,Phase III,"Active, not recruiting","Janssen Research & Development, LLC ","[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 5909, 'therapyName': 'Decitabine + Talacotuzumab'}]",An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy,08/23/2017,[],yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02472275,Phase I,Recruiting,Barbara Ann Karmanos Cancer Institute ,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 874, 'therapyName': 'PLX3397'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1814, 'therapyName': 'Degarelix'}]","PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer",08/27/2015,[],no
0,both,[],NCT02472353,Phase II,Suspended,Avera McKennan Hospital & University Health Center ,[],Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer,05/17/2017,[],no
0,both,"[{'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}]",NCT02472392,Phase I,Completed,University of Louisville ,"[{'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma,12/07/2016,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02472977,Phase Ib/II,Terminated,Bristol-Myers Squibb ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2847, 'therapyName': 'Ulocuplumab'}]",Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors,03/14/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02473497,Expanded access,Available,Pfizer,"[{'id': 706, 'therapyName': 'Crizotinib'}]",Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients,01/27/2017,"[{'molecularProfile': {'id': 11085, 'profileName': 'ROS1 rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2096, 'profileName': 'MET act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 27139, 'profileName': 'ROS1 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2514, 'profileName': 'ETV6-NTRK3'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 18885, 'profileName': 'ALK act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}]",NCT02473731,Phase I,Completed,"Kolltan Pharmaceuticals, Inc. ","[{'id': 2054, 'therapyName': 'CDX-3379'}]",A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients,05/06/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02474173,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 645, 'therapyName': 'AT13387'}]",HSP90 Inhibitor AT13387 and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer,08/05/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02474355,Phase III,Recruiting,AstraZeneca ,"[{'id': 660, 'therapyName': 'Osimertinib'}]",Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC,12/29/2015,"[{'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02475213,Phase I,Recruiting,MacroGenics ,"[{'id': 2864, 'therapyName': 'MGA271 + Pembrolizumab'}]",Safety Study of MGA271 in Combination With Pembrolizumab in Refractory Cancer,08/28/2015,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02475382,Expanded access,No longer available,Bristol-Myers Squibb,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169),09/30/2016,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02475681,Phase III,"Active, not recruiting",Acerta Pharma BV ,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 1646, 'therapyName': 'Obinutuzumab'}]","Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL",02/17/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02476786,Phase II,Recruiting,Washington University School of Medicine ,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}]",Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score,01/20/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02476955,Phase I,Recruiting,ArQule ,"[{'id': 635, 'therapyName': 'ARQ092'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel,08/05/2015,[],no
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02476968,FDA approved,Recruiting,AstraZeneca ,"[{'id': 837, 'therapyName': 'Olaparib'}]",To Assess Efficacy of Olaparib Maintenance Monotherapy at Preventing or Delaying the Return of the Cancer,10/15/2015,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02477696,Phase III,Recruiting,Acerta Pharma BV ,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",Elevate CLL R/R: Study of ACP-196 Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia,02/04/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02477826,Phase III,Recruiting,Bristol-Myers Squibb ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","An Open-Label, Trial of Nivolumab and Nivolumab Plus Ipilimumab Versus Platinum Doublet Chemotherapy in Subjects With Stage IV Non-Small Cell Lung Cancer (NSCLC)",07/22/2015,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 1240, 'name': 'leukemia', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02477878,Phase I,Recruiting,Bellicum Pharmaceuticals,"[{'id': 5995, 'therapyName': 'BPX-601'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant,07/28/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02478164,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute ,"[{'id': 877, 'therapyName': 'Ponatinib'}]",Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma,08/11/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02478320,Phase II,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 975, 'therapyName': 'ABT-348'}]",Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors,08/24/2016,"[{'molecularProfile': {'id': 4974, 'profileName': 'CDKN2A mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 6542, 'profileName': 'CDKN2A del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 4897, 'name': 'bile duct carcinoma', 'source': 'DOID'}]",NCT02479178,Phase II,Terminated,BIND Therapeutics ,"[{'id': 3640, 'therapyName': 'BIND-014'}]","A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck  (iNSITE2)",04/15/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02481050,Phase II,"Active, not recruiting",Eisai Inc. ,"[{'id': 728, 'therapyName': 'Eribulin'}]",Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer,06/28/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02481154,Phase I,Recruiting,"Agios Pharmaceuticals, Inc. ","[{'id': 2995, 'therapyName': 'AG-881'}]","Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation",08/05/2015,"[{'molecularProfile': {'id': 5912, 'profileName': 'IDH2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1781, 'profileName': 'IDH1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02481830,Phase III,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 2951, 'therapyName': 'Amrubicin'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 942, 'therapyName': 'Topotecan'}]",Efficacy Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer,04/01/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02482168,Phase I,Recruiting,"Apexigen, Inc. ","[{'id': 3835, 'therapyName': 'APX005M'}]",Study of the CD40 Agonistic Monoclonal Antibody APX005M,04/22/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02482441,Phase I,Recruiting,"OncoMed Pharmaceuticals, Inc. ","[{'id': 4401, 'therapyName': 'Rosmantuzumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]","A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10",07/01/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02483247,Phase Ib/II,Recruiting,"Boston Biomedical, Inc ","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1945, 'therapyName': 'BBI503'}]",A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer,10/15/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02483858,Phase I,Recruiting,PIQUR Therapeutics AG ,"[{'id': 2019, 'therapyName': 'PQR309'}]",Study of Oral PQR309 in Patients With Advanced Solid Tumors,07/10/2015,[],no
0,both,"[{'id': 12603, 'name': 'acute leukemia', 'source': 'DOID'}]",NCT02484261,Phase I,Recruiting,Reuven Schore ,"[{'id': 3191, 'therapyName': 'Bortezomib + Pravastatin'}]",Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children,11/10/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02484404,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 2895, 'therapyName': 'Cediranib + Durvalumab'}, {'id': 2894, 'therapyName': 'Durvalumab + Olaparib'}]",Phase 1 and 2 Study of MEDI4736 in Combination With Olaparib or Cediranib for Advanced Solid Tumors and Recurrent Ovarian Cancer,07/10/2015,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02484430,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",TORC1/2 Inhibitor INK128 in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia,11/30/2016,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02485535,Phase I,Recruiting,University of Chicago ,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant,01/07/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02485652,Phase II,"Active, not recruiting",Hanmi Pharmaceutical Company Limited ,"[{'id': 2137, 'therapyName': 'HM61713'}]",Phase II Trial of HM61713 (BI 1482694) for the Treatment of >2nd Line T790M Mutation Positive Adenocarcinoma of the Lung (NSCLC),09/21/2016,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT02485990,Phase Ib/II,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)",04/22/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02486718,Phase III,Recruiting,Hoffmann-La Roche ,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer,08/27/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT02487095,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 2879, 'therapyName': 'VX-970'}, {'id': 942, 'therapyName': 'Topotecan'}]","Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer",07/28/2015,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02487459,Phase I,Not yet recruiting,Bellicum Pharmaceuticals,"[{'id': 6053, 'therapyName': 'BPX-501'}, {'id': 5992, 'therapyName': 'Rimiducid'}]",Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies,07/31/2017,"[{'molecularProfile': {'id': 27975, 'profileName': 'KMT2A fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}]",NCT02487979,Phase II,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}]",Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma,02/15/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02488408,Phase I,Recruiting,BerGenBio AS ,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2660, 'therapyName': 'BGB-324'}]",Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With AML,06/17/2016,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 119, 'name': 'vaginal cancer', 'source': 'DOID'}, {'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 3965, 'name': 'Merkel cell carcinoma', 'source': 'DOID'}, {'id': 5517, 'name': 'stomach carcinoma', 'source': 'DOID'}, {'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}, {'id': 1294, 'name': 'vulva carcinoma', 'source': 'DOID'}, {'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}]",NCT02488759,Phase Ib/II,Recruiting,Bristol-Myers Squibb ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358),10/16/2015,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT02489006,Phase II,Recruiting,"University Health Network, Toronto","[{'id': 837, 'therapyName': 'Olaparib'}]","A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer",07/22/2017,[],no
0,,[],NCT02489058,,Recruiting,"University Health Network, Toronto ",[],A Study of Long-Term Responders on Olaparib (OLALA),06/24/2016,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02489123,Phase I,Recruiting,University of Washington,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma,02/19/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02489318,Phase III,"Active, not recruiting","Janssen Research & Development, LLC ","[{'id': 1947, 'therapyName': 'ARN-509'}]",A Phase 3 Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With Low-Volume mHSPC,08/23/2017,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02489357,Phase I,"Active, not recruiting",Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer",11/23/2016,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02489448,Phase Ib/II,Recruiting,Yale University ,"[{'id': 3100, 'therapyName': 'MEDI4736 + nab-paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer,12/04/2015,[],yes
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT02489903,Phase II,Recruiting,"EpicentRx, Inc. ","[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 3680, 'therapyName': 'RRx-001'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 619, 'therapyName': 'Abraxane'}]","RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens",03/25/2016,[],no
0,both,[],NCT02490878,Phase II,Recruiting,Alliance for Clinical Trials in Oncology ,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases,06/19/2017,[],no
0,both,"[{'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}]",NCT02490930,Phase I,Completed,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 3610, 'therapyName': 'Fingolimod'}]",A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma,09/14/2017,[],no
0,female,"[{'id': 5750, 'name': 'uterine corpus serous adenocarcinoma', 'source': 'DOID'}]",NCT02491099,Phase II,Recruiting,Yale University ,"[{'id': 623, 'therapyName': 'Afatinib'}]",A Phase II Evaluation of Afatinib,07/10/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02491411,Phase I,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel,06/02/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02492711,Phase III,Recruiting,MacroGenics ,"[{'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 808, 'therapyName': 'MGAH22'}]",Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer,09/08/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02492737,Phase I,"Active, not recruiting","Agios Pharmaceuticals, Inc. ","[{'id': 2995, 'therapyName': 'AG-881'}]",Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation,01/05/2017,"[{'molecularProfile': {'id': 5912, 'profileName': 'IDH2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1781, 'profileName': 'IDH1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02493361,Phase II,"Active, not recruiting",Alain Algazi ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2990, 'therapyName': 'IL-12 gene'}]",Trial of pIL-12/MK-3475 in Metastatic Melanoma,10/05/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02493751,Phase I,"Active, not recruiting",Pfizer ,"[{'id': 3145, 'therapyName': 'Avelumab + Axitinib'}]",A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer,08/26/2017,[],no
0,both,"[{'id': 2643, 'name': 'perivascular epithelioid cell tumor', 'source': 'DOID'}]",NCT02494570,Phase II,Recruiting,"Aadi, LLC ","[{'id': 3380, 'therapyName': 'Nab-Rapamycin'}]",A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa,01/14/2016,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT02494583,Phase III,"Active, not recruiting",Merck Sharp & Dohme Corp. ,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062),05/10/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02494713,Phase II,Recruiting,"The University of Texas Health Science Center, Houston ","[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 2858, 'therapyName': 'Ketoconazole'}]",Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer,10/21/2015,[],no
0,both,"[{'id': 7061, 'name': 'precursor B lymphoblastic lymphoma/leukemia', 'source': 'DOID'}]",NCT02494882,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 3218, 'therapyName': 'Dasatinib + Dexamethasone + Ruxolitinib'}]",Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older,11/16/2015,[],yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02494921,Phase Ib/II,Recruiting,Rahul Aggarwal,"[{'id': 3113, 'therapyName': 'Docetaxel + Filgrastim + Prednisone + Ribociclib'}]",LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC,10/07/2015,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02495103,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 2959, 'therapyName': 'Metformin + Vandetanib'}]",Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma,07/27/2015,[],no
0,both,"[{'id': 50749, 'name': 'peripheral T-cell lymphoma', 'source': 'DOID'}]",NCT02495415,Phase II,Recruiting,"CerRx, Inc.","[{'id': 2731, 'therapyName': 'Fenretinide'}]",Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas,10/04/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02495636,Phase II,Withdrawn,Yale University ,"[{'id': 4204, 'therapyName': 'Atezolizumab + DEC-205-NY-ESO-1 fusion protein vaccine'}]","Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer",06/23/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}]",NCT02496208,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors,07/27/2015,[],no
0,both,[],NCT02496585,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 831, 'therapyName': 'Nintedanib'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis,10/03/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02496663,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 826, 'therapyName': 'Necitumumab'}, {'id': 660, 'therapyName': 'Osimertinib'}]",EGFR Inhibitor AZD9291 and Necitumumab in Treating Patients With EGFR-Positive Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor,03/29/2016,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02497638,Phase II,Recruiting,"University Health Network, Toronto ","[{'id': 1576, 'therapyName': 'Atorvastatin + Metformin'}]",LIpitor and biGuanide to Androgen Delay Trial,04/14/2016,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02498600,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",05/26/2017,[],no
0,,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02498613,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,05/07/2016,"[{'molecularProfile': {'id': 518, 'profileName': 'BRCA1 wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 442, 'profileName': 'BRCA2 wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02498665,Phase I,Recruiting,"Boston Biomedical, Inc ","[{'id': 4320, 'therapyName': 'DSP-7888'}]",A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies,06/19/2016,[],no
0,both,"[{'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}]",NCT02499120,Phase II,Recruiting,Pfizer ,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}]",Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer,04/21/2016,[],no
0,both,"[{'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02499328,Phase Ib/II,Recruiting,AstraZeneca ,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}, {'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2782, 'therapyName': 'AZD9150 '}]",Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck,06/27/2016,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02499770,Phase Ib/II,"Active, not recruiting","G1 Therapeutics, Inc. ","[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 3074, 'therapyName': 'Trilaciclib'}]",G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC),07/08/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02499835,Phase Ib/II,Recruiting,"University of Wisconsin, Madison ","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer",08/01/2015,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 1240, 'name': 'leukemia', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02499861,Phase Ib/II,Recruiting,St. Justine's Hospital ,"[{'id': 1734, 'therapyName': 'Genistein + Decitabine'}]",Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies,08/26/2015,[],no
0,both,"[{'id': 2994, 'name': 'germ cell cancer', 'source': 'DOID'}]",NCT02499952,Phase II,"Active, not recruiting","Nasser Hanna, M.D. ","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors,01/11/2017,[],no
0,both,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT02500043,Phase III,Recruiting,"Taiho Oncology, Inc. ","[{'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}]",Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer,06/19/2016,[],no
0,both,"[{'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}]",NCT02500121,Phase II,Recruiting,Matthew Galsky ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Testing the PD-1 Inhibitor Pembrolizumab After Initial Chemotherapy in Patients With Metastatic Bladder Cancer,11/18/2015,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}]",NCT02500199,Phase I,Recruiting,"Jiangsu HengRui Medicine Co., Ltd. ","[{'id': 3082, 'therapyName': 'Pyrotinib'}]",Open Label Oral Use of Pyrotinib in Patients With HER2 Positive Solid Tumors Who Failed Prior HER2 Targeted Therapy,09/18/2015,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1216, 'profileName': 'ERBB2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}]",NCT02500407,Phase I,Recruiting,"Genentech, Inc.","[{'id': 6305, 'therapyName': 'Atezolizumab + BTCT4465A'}]",A Safety and Pharmacokinetic Study of BTCT4465A as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL),10/09/2017,[],yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02500576,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 5683, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine + Mesna + Pembrolizumab'}]","MK-3475 With Lymphodepletion, TIL and High or Low Dose Interleukin-2 (IL-2)",05/18/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02500797,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma,10/05/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02500901,Phase I,"Active, not recruiting","Paul Mathew, MD ","[{'id': 832, 'therapyName': 'Niraparib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC),05/14/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02501096,Phase Ib/II,Recruiting,Eisai Inc. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 792, 'therapyName': 'Lenvatinib'}]",Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors,09/30/2016,[],no
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02501473,Phase Ib/II,Recruiting,Immune Design ,"[{'id': 3577, 'therapyName': 'GLA-SE + Pembrolizumab'}]",Study of Intratumoral G100 Therapy in Patients With Or Without Pembrolizumab With Follicular Non-Hodgkin's Lymphoma,02/19/2016,[],no
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT02501902,Phase I,Recruiting,Pfizer,"[{'id': 3112, 'therapyName': 'nab-paclitaxel + Palbociclib'}]",Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC,12/06/2015,[],no
0,both,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02502266,Phase II,Suspended,National Cancer Institute (NCI),"[{'id': 942, 'therapyName': 'Topotecan'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1001, 'therapyName': 'Cediranib'}]","Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",06/20/2017,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 5074, 'name': 'malignant ependymoma', 'source': 'DOID'}, {'id': 1319, 'name': 'brain cancer', 'source': 'DOID'}, {'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}]",NCT02502708,Phase I,Recruiting,NewLink Genetics Corporation ,"[{'id': 2976, 'therapyName': 'indoximod'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors",10/21/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02503358,Phase I,Recruiting,OHSU Knight Cancer Institute ,"[{'id': 913, 'therapyName': 'Selumetinib'}, {'id': 619, 'therapyName': 'Abraxane'}]",Selumetinib and Nab-Paclitaxel (Albumin-stabilized Nanoparticle Formulation) as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer,09/30/2016,"[{'molecularProfile': {'id': 1676, 'profileName': 'ROS1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02503709,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 2727, 'therapyName': 'AT7519'}, {'id': 645, 'therapyName': 'AT13387'}]",Hsp90 Inhibitor AT13387 and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,04/23/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02503722,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 2994, 'therapyName': 'AZD9291 + MLN0128'}]",TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor,10/19/2016,"[{'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02503774,Phase I,Recruiting,MedImmune LLC ,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3089, 'therapyName': 'MEDI9447'}]",MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors,09/29/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02504489,Phase III,Recruiting,BeyondSpring Pharmaceuticals Inc. ,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 3679, 'therapyName': 'Docetaxel + Plinabulin'}]",Plinabulin (P) + Docetaxel (D) vs D as 2nd-Line Chemo in Patients With Advanced NSCLC With at Least 1 Large Lung Lesion,03/11/2016,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 263, 'name': 'kidney cancer', 'source': 'DOID'}]",NCT02504892,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 735, 'therapyName': 'Everolimus'}]",Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer,07/30/2015,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02506114,Phase II,Recruiting,"University of California, San Francisco","[{'id': 4892, 'therapyName': 'PROSTVAC-V/F'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 4895, 'therapyName': 'PROSTVAC-V/F + Ipilimumab'}]",Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer,05/22/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02506153,Phase III,"Active, not recruiting",National Cancer Institute (NCI),"[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",High-Dose Recombinant Interferon Alfa-2B or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery,08/22/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02506517,Phase II,Recruiting,"University Health Network, Toronto ","[{'id': 623, 'therapyName': 'Afatinib'}]",A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene,06/23/2016,[],no
0,both,"[{'id': 70004, 'name': 'myeloid neoplasm', 'source': 'DOID'}, {'id': 3721, 'name': 'plasmacytoma', 'source': 'DOID'}, {'id': 6536, 'name': 'plasma cell neoplasm', 'source': 'DOID'}]",NCT02506959,Phase II,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma,12/29/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02507570,Phase II,"Active, not recruiting","Carolina Research Professionals, LLC ","[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis,08/24/2016,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02507583,Phase I,Recruiting,Thomas Jefferson University ,"[{'id': 4325, 'therapyName': 'IGF-1R/AS ODN'}]",Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma,06/19/2016,[],yes
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02508038,Phase I,Recruiting,"University of Wisconsin, Madison ","[{'id': 2971, 'therapyName': 'Zoledronic acid'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}]", Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa,02/02/2016,[],no
0,both,"[{'id': 1993, 'name': 'rectum cancer', 'source': 'DOID'}, {'id': 219, 'name': 'colon cancer', 'source': 'DOID'}]",NCT02508077,Phase II,Terminated,City of Hope Medical Center ,"[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 845, 'therapyName': 'Panitumumab'}]",FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer,09/20/2017,"[{'molecularProfile': {'id': 4, 'profileName': 'BRAF wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 575, 'profileName': 'HRAS wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 481, 'profileName': 'NRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02508246,Phase I,Recruiting,University of Washington ,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}]","AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck",08/27/2015,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT02508467,Phase I,Recruiting,Blueprint Medicines Corporation ,"[{'id': 3165, 'therapyName': 'BLU-554'}]",A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma,11/08/2015,[],no
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02508532,Phase I,Recruiting,Blueprint Medicines Corporation,"[{'id': 2941, 'therapyName': 'BLU-285'}]",Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors,10/15/2015,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02508636,Phase II,Recruiting,"University of California, San Francisco ","[{'id': 3180, 'therapyName': 'Enzalutamide + Leuprolide'}]",Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate,11/05/2015,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02508870,Phase I,Recruiting,Hoffmann-La Roche,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]","A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes",02/25/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02510950,Phase I,Recruiting,Washington University School of Medicine ,"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 1141, 'therapyName': 'Temozolomide'}]",Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma,11/21/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02511106,Phase III,Recruiting,AstraZeneca ,"[{'id': 660, 'therapyName': 'Osimertinib'}]","AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy",02/01/2016,"[{'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3368, 'name': ""bone Ewing's sarcoma"", 'source': 'DOID'}, {'id': 4232, 'name': ""extraosseous Ewing's sarcoma"", 'source': 'DOID'}]",NCT02511132,Phase II,"Active, not recruiting","Gradalis, Inc. ","[{'id': 1157, 'therapyName': 'FANG vaccine'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",Randomized Phase IIb Trial of Vigil Versus Gemcitabine + Docetaxel for Ewing's Sarcoma,08/30/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02511184,Phase I,Recruiting,Pfizer ,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients,10/20/2015,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02511405,Phase III,"Active, not recruiting",Vascular Biogenics Ltd. operating as VBL Therapeutics ,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 2276, 'therapyName': 'VB-111'}]","A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)",01/07/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02511795,Phase I,Recruiting,AstraZeneca ,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 837, 'therapyName': 'Olaparib'}]",AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors,09/10/2015,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02512172,Phase I,Recruiting,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}, {'id': 5728, 'therapyName': 'Romidepsin + Pembrolizumab'}, {'id': 5782, 'therapyName': 'Azacitidine + Pembrolizumab + Romidepsin'}]",A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer,05/26/2017,[],no
0,both,"[{'id': 1240, 'name': 'leukemia', 'source': 'DOID'}]",NCT02512926,Phase I,Recruiting,Phoenix Children's Hospital ,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 1136, 'therapyName': 'Etoposide'}]",Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children,08/05/2015,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02513394,Phase III,Recruiting,"Alliance Foundation Trials, LLC. ","[{'id': 850, 'therapyName': 'Palbociclib'}]",PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer (PALLAS),04/21/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02513472,Phase Ib/II,"Active, not recruiting",Eisai Inc. ,"[{'id': 3080, 'therapyName': 'Eribulin + Pembrolizumab'}]",Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC),02/08/2017,[],yes
0,both,"[{'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}]",NCT02513563,Phase II,Recruiting,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 822, 'therapyName': 'MK-1775'}]",AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer,09/17/2015,[],no
0,both,"[{'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}]",NCT02513667,Phase II,Recruiting,University of Texas Southwestern Medical Center ,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma,11/16/2015,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02514083,Phase II,Recruiting,"National Heart, Lung, and Blood Institute (NHLBI) ","[{'id': 3633, 'therapyName': 'Fludarabine + Ibrutinib'}]",A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),02/26/2016,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02514174,FDA approved,Recruiting,Boehringer Ingelheim ,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older,08/20/2015,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02514382,Phase I,Recruiting,University of Southern California ,"[{'id': 3432, 'therapyName': 'Bortezomib + Dexamethasone + Reolysin'}]","Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma",01/21/2016,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02514447,Phase Ib/II,Recruiting,"G1 Therapeutics, Inc. ","[{'id': 3074, 'therapyName': 'Trilaciclib'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of G1T28 in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy,09/06/2015,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT02514551,Phase II,"Active, not recruiting",Eli Lilly and Company ,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer,05/20/2017,[],no
0,both,"[{'id': 3965, 'name': 'Merkel cell carcinoma', 'source': 'DOID'}]",NCT02514824,Phase Ib/II,Recruiting,Dana-Farber Cancer Institute ,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma,10/22/2015,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}]",NCT02516241,Phase III,Recruiting,AstraZeneca ,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of MEDI4736 With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer,09/12/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02516813,Phase I,Recruiting,EMD Serono ,"[{'id': 3616, 'therapyName': 'MSC2490484A '}]","Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy",03/11/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02517398,Phase I,Recruiting,"EMD Serono Research & Development Institute, Inc. ","[{'id': 5860, 'therapyName': 'M7824'}]",MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors,06/12/2017,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 5603, 'name': 'acute T cell leukemia', 'source': 'DOID'}]",NCT02518113,Phase Ib/II,Recruiting,Eli Lilly and Company ,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2958, 'therapyName': 'LY3039478'}]",A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL,12/01/2015,[],no
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02518555,Phase II,"Active, not recruiting",Farrukh Awan ,"[{'id': 768, 'therapyName': 'Ibrutinib'}]","Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",09/21/2017,"[{'molecularProfile': {'id': 17613, 'profileName': 'TP53 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 17614, 'profileName': 'ATM del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02518750,Phase II,Recruiting,St. Jude Children's Research Hospital,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3217, 'therapyName': 'Cyclophosphamide + Etoposide'}, {'id': 3216, 'therapyName': 'Cytarabine + Methotrexate + Prednisone'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma,12/12/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02518958,Phase I,"Active, not recruiting","EpicentRx, Inc. ","[{'id': 1312, 'therapyName': 'Nivolumab'}]","A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab",07/06/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02519322,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma,07/19/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02519348,Phase II,Recruiting,MedImmune LLC ,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma",12/29/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02520011,Phase II,Recruiting,"Tolero Pharmaceuticals, Inc. ","[{'id': 628, 'therapyName': 'Alvocidib'}, {'id': 2393, 'therapyName': 'Cytarabine + Mitoxantrone'}]",Alvocidib Biomarker-driven Phase 2 AML Study,01/29/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02520063,Phase Ib/II,Recruiting,University of Alabama at Birmingham ,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 1242, 'therapyName': 'Carotuximab'}, {'id': 735, 'therapyName': 'Everolimus'}]","Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer",02/24/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}]",NCT02520115,Phase I,Recruiting,Barbara Ann Karmanos Cancer Institute ,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1076, 'therapyName': 'Valproic acid'}]",Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer,08/25/2015,[],no
0,both,"[{'id': 686, 'name': 'liver carcinoma', 'source': 'DOID'}, {'id': 3121, 'name': 'gallbladder cancer', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT02520141,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",Ramucirumab for Advanced Pre-treated Biliary Cancers,12/31/2015,[],no
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02520154,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer,07/08/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02520752,Phase I,Completed,Novartis Pharmaceuticals ,"[{'id': 2685, 'therapyName': 'Midazolam'}, {'id': 1065, 'therapyName': 'Capmatinib'}]",A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors,10/19/2017,"[{'molecularProfile': {'id': 1112, 'profileName': 'MET alterations'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02520778,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 3065, 'therapyName': 'Navitoclax + Osimertinib'}]",EGFR Inhibitor AZD9291 and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer,04/09/2016,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50749, 'name': 'peripheral T-cell lymphoma', 'source': 'DOID'}]",NCT02520791,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 4762, 'therapyName': 'MEDI-570'}]",Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma,09/25/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02521051,Phase Ib/II,Recruiting,Massachusetts General Hospital ,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 698, 'therapyName': 'Alectinib'}]","Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer",02/18/2016,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT02521090,Phase Ib/II,Withdrawn,Barbara Ann Karmanos Cancer Institute ,"[{'id': 1012, 'therapyName': 'EGFRBi-armed autologous activated T cells'}]",EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma,02/16/2016,[],no
0,both,"[{'id': 14250, 'name': 'Down syndrome', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02521493,Phase III,Recruiting,Children's Oncology Group ,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 5912, 'therapyName': 'Asparaginase Erwinia chrysanthemi'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2206, 'therapyName': 'Asparaginase'}]",Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome,09/25/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02521870,Phase I,Recruiting,Dynavax Technologies Corporation ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3084, 'therapyName': 'SD-101'}]",A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma,09/22/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02522715,Phase Ib/II,Recruiting,OHSU Knight Cancer Institute ,"[{'id': 3056, 'therapyName': 'Cabazitaxel + Enzalutamide'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Hormone-Resistant Prostate Cancer",08/26/2015,[],no
0,both,"[{'id': 3565, 'name': 'meningioma', 'source': 'DOID'}]",NCT02523014,Phase II,Recruiting,Alliance for Clinical Trials in Oncology ,"[{'id': 3078, 'therapyName': 'GSK2256098'}, {'id': 956, 'therapyName': 'Vismodegib'}]",A Study Looking at Targeted Therapy According to Tumor Markers for People With Meningiomas,09/06/2015,"[{'molecularProfile': {'id': 1664, 'profileName': 'SMO mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02523469,Phase Ib/II,Recruiting,John Wrangle ,"[{'id': 3061, 'therapyName': 'ALT-803 + Nivolumab'}]","ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer",01/23/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02524119,Phase II,Recruiting,University of Texas Southwestern Medical Center ,"[{'id': 790, 'therapyName': 'Ribociclib'}]",LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma (LEE001),06/11/2016,"[{'molecularProfile': {'id': 2395, 'profileName': 'RB1 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02525692,Phase II,Recruiting,"Oncoceutics, Inc. ","[{'id': 1687, 'therapyName': 'ONC201'}]",Oral ONC201 in Adult Recurrent Glioblastoma,01/23/2016,"[{'molecularProfile': {'id': 5912, 'profileName': 'IDH2 mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1781, 'profileName': 'IDH1 mutant'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02525757,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",MPDL3280A With Chemoradiation for Lung Cancer,02/02/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02526017,Phase I,Recruiting,"Five Prime Therapeutics, Inc. ","[{'id': 2840, 'therapyName': 'FPA008'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of FPA008 in Combination With Nivolumab in Patients With Selected Advance Cancers,08/26/2015,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02527174,Phase I,Withdrawn,University of Alberta ,"[{'id': 3213, 'therapyName': 'Cytarabine + Idarubicin + Volasertib'}]",A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia (VIAC),04/06/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02527434,Phase II,"Active, not recruiting",AstraZeneca ,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Tremelimumab in Patients With Advanced Solid Tumors,02/08/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02528357,Phase I,Recruiting,GlaxoSmithKline ,"[{'id': 5177, 'therapyName': 'GSK3174998'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors,01/09/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02528643,Phase II,"Active, not recruiting","Astellas Pharma Global Development, Inc. ","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma,03/18/2017,[],no
0,both,"[{'id': 4971, 'name': 'myelofibrosis', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02528877,Phase I,Withdrawn,City of Hope Medical Center ,"[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3181, 'therapyName': 'Ruxolitinib + Sirolimus + Tacrolimus'}]","Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis",09/16/2016,[],no
0,both,"[{'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02529072,Phase I,Terminated,Gary Archer Ph.D. ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With DC Vaccines for Recurrent Brain Tumors,10/03/2017,[],no
0,both,"[{'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02529553,Phase I,Recruiting,Eli Lilly and Company ,"[{'id': 3164, 'therapyName': 'LY3076226'}]",A Study of LY3076226 in Participants With Advanced or Metastatic Cancer,11/10/2015,"[{'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02530125,Phase II,"Active, not recruiting",Northwestern University ,"[{'id': 3338, 'therapyName': 'Pidilizumab'}]",Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission,01/06/2017,[],yes
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}]",NCT02530437,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1587, 'therapyName': 'Taladegib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","A Phase 1B/2 Study of LY2940680 in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction",03/10/2017,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02530463,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS),05/19/2017,[],no
0,both,"[{'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT02530476,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 3189, 'therapyName': 'Selinexor + Sorafenib'}]","Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia",05/17/2017,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02530489,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}]",Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A,06/20/2017,[],yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02530502,Phase Ib/II,"Active, not recruiting",Northwestern University ,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma,11/03/2016,[],no
0,both,"[{'id': 4971, 'name': 'myelofibrosis', 'source': 'DOID'}, {'id': 8761, 'name': 'megakaryocytic leukemia', 'source': 'DOID'}]",NCT02530619,Phase I,Recruiting,Northwestern University ,"[{'id': 626, 'therapyName': 'Alisertib'}]",Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia,12/01/2015,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02531308,Phase II,Terminated,Rush University Medical Center,"[{'id': 1031, 'therapyName': 'Metformin'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 897, 'therapyName': 'Rituximab'}]",Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL),02/08/2017,[],no
0,both,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02531516,Phase III,Recruiting,"Aragon Pharmaceuticals, Inc.","[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",An Efficacy and Safety Study of JNJ-56021927 (ARN-509) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy,12/25/2015,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02531932,Phase II,Recruiting,Amy Tiersten ,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 735, 'therapyName': 'Everolimus'}]",Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer,08/30/2015,[],yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02532010,Phase II,"Active, not recruiting",Weill Medical College of Cornell University ,"[{'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}, {'id': 3176, 'therapyName': 'Pacritinib + Cytarabine'}]",Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML,02/20/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02532114,Phase I,Recruiting,University of Washington ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 3072, 'therapyName': 'Niclosamide'}]","Niclosamide and Enzalutamide in Treating Patients With Androgen Receptor Splice Variant-Positive, Castration-Resistant, Metastatic Prostate Cancer",01/08/2016,[],yes
0,both,"[{'id': 8584, 'name': 'Burkitt lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02532192,Phase I,Withdrawn,M.D. Anderson Cancer Center ,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1689, 'therapyName': 'Fluconazole'}, {'id': 1078, 'therapyName': 'Belinostat'}]","A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma",01/07/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02532231,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Acute Myeloid Leukemia (AML) in Remission at High Risk for Relapse,11/08/2015,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02532257,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]",Study of Ibrutinib in Combination With Rituximab and Lenalidomide,04/13/2016,[],yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02533115,Expanded access,Approved for marketing,Celator Pharmaceuticals ,"[{'id': 4341, 'therapyName': 'CPX-351'}]",EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML,08/23/2017,[],no
0,both,"[{'id': 8923, 'name': 'skin melanoma', 'source': 'DOID'}]",NCT02535078,Phase Ib/II,Recruiting,Immunocore Ltd ,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3847, 'therapyName': 'IMCgp100'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma,04/07/2016,[],no
0,both,"[{'id': 50749, 'name': 'peripheral T-cell lymphoma', 'source': 'DOID'}]",NCT02535247,Phase II,Suspended,Fox Chase Cancer Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma,06/20/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02535286,Phase Ib/II,Recruiting,"TG Therapeutics, Inc. ","[{'id': 3475, 'therapyName': 'Pembrolizumab + TGR-1202 + Ublituximab'}]",Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL,02/04/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02535338,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 3071, 'therapyName': 'Erlotinib + Onalespib'}]",Erlotinib Hydrochloride and Hsp90 Inhibitor AT13387 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer,10/18/2017,"[{'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 4039, 'profileName': 'EGFR exon 20 ins'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT02535533,Phase I,Recruiting,University of Iowa ,"[{'id': 3474, 'therapyName': 'Axitinib + Selenomethionine'}]",SLM + Axitinib for Clear Cell RCC,11/10/2016,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 7061, 'name': 'precursor B lymphoblastic lymphoma/leukemia', 'source': 'DOID'}, {'id': 1037, 'name': 'lymphoblastic leukemia', 'source': 'DOID'}, {'id': 715, 'name': 'T-cell leukemia', 'source': 'DOID'}]",NCT02535806,Phase II,Terminated,Children's Mercy Hospital Kansas City ,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults,07/22/2017,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02536339,Phase II,"Active, not recruiting","Genentech, Inc. ","[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy,07/20/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}]",NCT02536495,Phase Ib/II,Withdrawn,Erin Bertino ,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer,10/31/2015,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02536794,Phase II,Suspended,Northwestern University ,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer,10/04/2017,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02537223,Phase I,Recruiting,"University Health Network, Toronto ","[{'id': 691, 'therapyName': 'BYL719'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer,06/23/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02537418,Phase I,"Active, not recruiting",NCIC Clinical Trials Group ,"[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Receiving Standard Chemotherapy Regimens,09/12/2017,[],no
0,female,"[{'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT02537444,Phase II,"Active, not recruiting",Acerta Pharma BV ,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer (KEYNOTE191),06/25/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02537561,Phase I,Withdrawn,Washington University School of Medicine ,"[{'id': 682, 'therapyName': 'Talazoparib'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors,02/12/2016,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02537613,Phase I,Recruiting,Dana-Farber Cancer Institute,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,02/04/2016,[],no
0,female,[],NCT02538484,Phase I,Recruiting,Andrew Brenner ,[],Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects,10/27/2016,[],no
0,both,"[{'id': 8850, 'name': 'salivary gland cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 5515, 'name': 'nasal cavity squamous cell carcinoma', 'source': 'DOID'}, {'id': 50619, 'name': 'paranasal sinus cancer', 'source': 'DOID'}, {'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}]",NCT02538510,Phase Ib/II,"Active, not recruiting",University of Washington ,"[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]",Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery,08/26/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02538614,Phase Ib/II,Terminated,Gilead Sciences ,"[{'id': 4396, 'therapyName': 'BI 836826 + Idelalisib '}]",Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia,08/02/2017,[],no
0,both,"[{'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 1324, 'name': 'lung cancer', 'source': 'DOID'}]",NCT02538627,Phase I,Terminated,Merrimack Pharmaceuticals ,"[{'id': 820, 'therapyName': 'Seribantumab'}, {'id': 821, 'therapyName': 'MM-151'}]",Phase 1 Combination Study of MM-151 and MM-121,09/06/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02538666,Phase III,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]","A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451)",10/20/2017,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02538926,Phase II,Not yet recruiting,University of Washington ,"[{'id': 770, 'therapyName': 'Imatinib'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3212, 'therapyName': 'Doxorubicin + Etoposide + Vincristine '}, {'id': 2206, 'therapyName': 'Asparaginase'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",11/16/2015,"[{'molecularProfile': {'id': 536, 'profileName': 'ABL1 T315I'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14098, 'profileName': 'ABL1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,[],NCT02539459,Phase II,Recruiting,Fox Chase Cancer Center ,"[{'id': 735, 'therapyName': 'Everolimus'}]",Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus,10/22/2015,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02540161,Phase II,Recruiting,Annick Desjardins ,"[{'id': 931, 'therapyName': 'SYM004'}]",Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma,11/04/2015,"[{'molecularProfile': {'id': 447, 'profileName': 'EGFR amp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 50933, 'name': 'ovarian serous carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02540291,Phase I,Recruiting,Eisai Inc.,"[{'id': 5694, 'therapyName': 'E7046'}]",Study of E7046 in Subjects With Selected Advanced Malignancies,05/26/2017,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02540330,Phase II,Recruiting,"Atossa Genetics, Inc. ","[{'id': 744, 'therapyName': 'Fulvestrant'}]",PK Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy,03/05/2016,[],yes
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT02540356,Phase Ib/II,Terminated,Baxalta US Inc,"[{'id': 2996, 'therapyName': 'Imalumab'}]",Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer,10/05/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02540876,Phase I,Recruiting,University of Chicago ,"[{'id': 975, 'therapyName': 'ABT-348'}]",Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery,01/13/2016,"[{'molecularProfile': {'id': 1806, 'profileName': 'CDKN2A loss'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 4974, 'profileName': 'CDKN2A mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 6542, 'profileName': 'CDKN2A del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02541565,Phase I,Recruiting,University of Washington ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 897, 'therapyName': 'Rituximab'}]",Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma,06/02/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02541604,Phase I,Recruiting,Hoffmann-La Roche ,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors",12/19/2015,[],no
0,male,"[{'id': 5518, 'name': 'penis squamous cell carcinoma', 'source': 'DOID'}]",NCT02541903,Phase II,Recruiting,University of Alabama at Birmingham ,"[{'id': 623, 'therapyName': 'Afatinib'}]",Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma,11/14/2015,[],no
0,both,"[{'id': 8691, 'name': 'mycosis fungoides', 'source': 'DOID'}, {'id': 8541, 'name': ""Sezary's disease"", 'source': 'DOID'}]",NCT02542124,Phase II,Recruiting,Neumedicines Inc.,"[{'id': 5262, 'therapyName': 'Interleukin-12'}]",NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT),02/13/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02542293,Phase III,Recruiting,AstraZeneca ,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Study of 1st Line Therapy Study of MEDI4736 With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).,12/11/2015,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02543255,Phase II,Recruiting,"University Health Network, Toronto ","[{'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 3079, 'therapyName': 'Abiraterone + Leuprolide + Prednisone'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial),12/03/2016,[],no
0,both,"[{'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02543645,Phase Ib/II,Terminated,Celldex Therapeutics ,"[{'id': 3086, 'therapyName': 'Atezolizumab + Varlilumab'}]",A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer,03/18/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02544633,Phase II,Recruiting,Mirati Therapeutics Inc. ,"[{'id': 809, 'therapyName': 'MGCD265'}]",Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET,11/08/2015,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 13844, 'profileName': 'MET mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02545283,Phase III,Recruiting,Hoffmann-La Roche ,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 4395, 'therapyName': 'Cytarabine + Idasanutlin'}]",A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia,07/14/2016,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT02545504,Phase III,"Active, not recruiting",Gilead Sciences ,"[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3320, 'therapyName': 'GS-5745'}]",GS-5745 With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma,06/09/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02546531,Phase I,Recruiting,Washington University School of Medicine ,"[{'id': 3083, 'therapyName': 'Defactinib + Gemcitabine + Pembrolizumab'}]",Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer,01/13/2016,[],no
0,both,"[{'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}]",NCT02546661,Phase I,Recruiting,AstraZeneca,"[{'id': 654, 'therapyName': 'AZD4547'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer",10/27/2016,"[{'molecularProfile': {'id': 3514, 'profileName': 'FGFR3 Y373C'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1737, 'profileName': 'FGFR3 R248C'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2969, 'profileName': 'FGFR2 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1736, 'profileName': 'FGFR3 S249C'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14910, 'profileName': 'FGFR1 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3539, 'profileName': 'FGFR3 G380R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2897, 'profileName': 'FGFR3 G370C'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 10071, 'profileName': 'FGFR3-TACC3'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14903, 'profileName': 'FGFR3 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 3526, 'profileName': 'FGFR3 S371C'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02546986,Phase II,"Active, not recruiting",Celgene Corporation ,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer,08/31/2016,"[{'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02547675,Phase I,No longer available,"Clovis Oncology, Inc. ","[{'id': 1003, 'therapyName': 'CO1686'}]",Rociletinib (CO-1686) USA Expanded Access Program,03/22/2016,"[{'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 4039, 'profileName': 'EGFR exon 20 ins'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02548962,Phase Ib/II,Recruiting,Pharmacyclics ,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}]",Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma,04/29/2016,[],no
0,female,"[{'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}]",NCT02549209,Phase II,Recruiting,"Mario Javier Pineda, MD ","[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Pembro/Carbo/Taxol in Endometrial Cancer,09/12/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02549651,Phase I,Recruiting,MedImmune LLC ,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}]",MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023),07/26/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02549937,Phase I,Recruiting,Hutchison Medipharma Limited ,"[{'id': 3666, 'therapyName': 'Sulfatinib'}]","A Multi-Center, Open-Label Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors",03/20/2016,[],no
0,female,"[{'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}]",NCT02549989,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 1069, 'therapyName': 'LY3023414'}]",Study of LY3023414 for the Treatment of Recurrent,09/22/2015,"[{'molecularProfile': {'id': 1281, 'profileName': 'AKT1 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 479, 'profileName': 'PTEN loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 743, 'profileName': 'PIK3CA act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT02550743,Phase I,Recruiting,howard safran ,"[{'id': 1535, 'therapyName': 'BYL719 + Capecitabine'}]","BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study",06/07/2016,[],no
0,both,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02551055,Phase I,Terminated,"Millennium Pharmaceuticals, Inc.","[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 626, 'therapyName': 'Alisertib'}, {'id': 3146, 'therapyName': 'TAK-659'}, {'id': 1033, 'therapyName': 'MLN1117'}]","MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma",03/11/2017,[],no
0,both,"[{'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02551159,Phase III,"Active, not recruiting",AstraZeneca ,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1914, 'therapyName': 'Cetuximab + Carboplatin + Fluorouracil'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN,05/10/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02551185,Phase I,Recruiting,Acetylon Pharmaceuticals Incorporated ,"[{'id': 3311, 'therapyName': 'Citarinostat'}]",ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors,04/22/2016,[],no
0,both,"[{'id': 12603, 'name': 'acute leukemia', 'source': 'DOID'}]",NCT02551718,Phase I,Recruiting,University of Washington,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 3159, 'therapyName': 'Bexarotene'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 623, 'therapyName': 'Afatinib'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 2, 'therapyName': 'Trametinib'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 789, 'therapyName': 'Ceritinib'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1571, 'therapyName': 'Cabazitaxel'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1327, 'therapyName': 'Pralatrexate'}]",High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia,10/13/2017,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02553460,Phase II,Recruiting,St. Jude Children's Research Hospital,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I,11/16/2015,[],no
0,both,"[{'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}]",NCT02553642,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260),09/18/2015,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02553941,Phase I,Recruiting,"University of California, Davis ","[{'id': 3632, 'therapyName': 'Azacitidine + Ibrutinib'}]",Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome,04/29/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02554812,Phase I,Recruiting,Pfizer ,"[{'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}]",A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley),10/10/2017,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02555189,Phase Ib/II,Recruiting,Thomas Jefferson University ,"[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression",12/03/2015,"[{'molecularProfile': {'id': 2395, 'profileName': 'RB1 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}]",NCT02555644,Phase I,Recruiting,Eli Lilly and Company ,"[{'id': 1651, 'therapyName': 'Prexasertib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer,02/27/2016,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02555657,Phase III,"Active, not recruiting",Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119),03/07/2017,[],yes
0,both,[],NCT02555878,Phase III,Recruiting,"Janssen Research & Development, LLC ","[{'id': 4119, 'therapyName': 'Rivaroxaban'}]",A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants,01/12/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60061, 'name': 'cutaneous T cell lymphoma', 'source': 'DOID'}]",NCT02556463,Phase I,Recruiting,MedImmune LLC,"[{'id': 5457, 'therapyName': 'MEDI9197'}, {'id': 5458, 'therapyName': 'MEDI9197 + MEDI4736'}]",A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and Palliative Radiation in Subjects With Solid Tumors,03/30/2017,[],no
0,both,"[{'id': 2226, 'name': 'myeloproliferative neoplasm', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}, {'id': 1039, 'name': 'prolymphocytic leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 6536, 'name': 'plasma cell neoplasm', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02556931,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 4228, 'therapyName': 'Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus'}]","Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies",06/02/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02557321,Phase Ib/II,Recruiting,Provectus Pharmaceuticals ,"[{'id': 879, 'therapyName': 'PV-10'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma,10/23/2015,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02557516,Phase Ib/II,Recruiting,Innate Pharma ,"[{'id': 3382, 'therapyName': 'IPH2201'}]",Combination Study of IPH2201 With Ibrutinib in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia,01/29/2016,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02558140,Phase I,Recruiting,Hoffmann-La Roche ,"[{'id': 4330, 'therapyName': 'RO6874813'}]",A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors,06/20/2016,[],yes
0,both,"[{'id': 3587, 'name': 'pancreatic ductal carcinoma', 'source': 'DOID'}]",NCT02558894,Phase II,Completed,NCT02558894,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 1652, 'therapyName': 'Tremelimumab'}]",Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma,08/19/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02559024,Phase I,"Active, not recruiting",Providence Health & Services ,"[{'id': 1653, 'therapyName': 'MEDI6469'}]",Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer,09/21/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}]",NCT02559492,Phase I,"Active, not recruiting", Incyte Corporation,"[{'id': 3096, 'therapyName': 'INCB039110 + INCB024360'}, {'id': 3097, 'therapyName': 'INCB039110 + INCB050465'}]",INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors,07/14/2017,[],yes
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT02559674,Phase Ib/II,Recruiting,Altor Bioscience Corporation ,"[{'id': 3095, 'therapyName': 'ALT-803 + Gemcitabine + nab-paclitaxel'}]",ALT-803 in Patients With Advanced Pancreatic Cancer Conjunction With Gemcitabine and Nab-Paclitaxel,08/23/2016,[],no
0,both,"[{'id': 3748, 'name': 'esophagus squamous cell carcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT02559687,Phase II,"Active, not recruiting",Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180),03/10/2017,[],no
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 4163, 'name': 'ganglioneuroblastoma', 'source': 'DOID'}]",NCT02559778,Phase I,Recruiting,Giselle Sholler,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2629, 'therapyName': 'Eflornithine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 717, 'therapyName': 'Dasatinib'}]",Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,10/05/2015,[],yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02560012,Phase II,Terminated,"The University of Texas Health Science Center, Houston ","[{'id': 735, 'therapyName': 'Everolimus'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 848, 'therapyName': 'Pazopanib'}]",Personalized Targeted Inhibitors Treatment in Renal Cell Cancer,08/05/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02560025,Phase II,"Active, not recruiting",Massachusetts General Hospital ,"[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML,08/19/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02560051,Phase II,Recruiting,"The University of Texas Health Science Center, Houston","[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 3087, 'therapyName': 'Aldoxorubicin + Docetaxel + Estramustine + Ketoconazole'}]",Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,11/14/2015,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02560779,Phase Ib/II,Recruiting,Tracon Pharmaceuticals Inc. ,"[{'id': 2389, 'therapyName': 'Carotuximab + Sorafenib'}]",Trial of TRC105 and Sorafenib in Patients With HCC,01/29/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02561455,Phase Ib/II,"Active, not recruiting","Astellas Pharma Global Development, Inc. ","[{'id': 2865, 'therapyName': 'Gilteritinib'}]",Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial,06/20/2017,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02561832,Phase I,Completed,AstraZeneca ,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]","A Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin in Patients With HER-2 Negative Breast Cancer",02/16/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 3664, 'name': 'mast cell neoplasm', 'source': 'DOID'}]",NCT02561988,Phase I,Recruiting,Blueprint Medicines Corporation ,"[{'id': 2941, 'therapyName': 'BLU-285'}]",Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies,03/25/2016,"[{'molecularProfile': {'id': 1215, 'profileName': 'PDGFRA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1214, 'profileName': 'KIT mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02562443,Phase III,Recruiting,"Onconova Therapeutics, Inc. ","[{'id': 1046, 'therapyName': 'rigosertib'}]",Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE),06/27/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02562755,Phase III,Recruiting,"SillaJen, Inc. ","[{'id': 3341, 'therapyName': 'JX-594'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone,12/29/2015,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02562898,Phase Ib/II,Recruiting,Margaret Tempero ,"[{'id': 3259, 'therapyName': 'Gemcitabine + Ibrutinib + Paclitaxel'}]",Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer,12/03/2015,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02563002,Phase III,Recruiting,Merck Sharp & Dohme Corp. ,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177),03/06/2016,[],no
0,both,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02563548,Phase I,Recruiting,Halozyme Therapeutics ,"[{'id': 5779, 'therapyName': 'PEGPH20 + Pembrolizumab'}]",Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab,05/26/2017,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02563925,Phase I,"Active, not recruiting",Memorial Sloan Kettering Cancer Center ,"[{'id': 1652, 'therapyName': 'Tremelimumab'}]",Brain Irradiation and Tremelimumab in Metastatic Breast Cancer,12/23/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3620, 'name': 'central nervous system cancer', 'source': 'DOID'}]",NCT02564198,Phase I,Recruiting,Eli Lilly and Company ,"[{'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors,01/09/2016,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3748, 'name': 'esophagus squamous cell carcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}]",NCT02564263,Phase III,Recruiting,Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2282, 'therapyName': 'Docetaxel + Irinotecan + Paclitaxel'}]",Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181),12/20/2015,[],no
0,both,"[{'id': 50458, 'name': 'juvenile myelomonocytic leukemia', 'source': 'DOID'}, {'id': 4971, 'name': 'myelofibrosis', 'source': 'DOID'}, {'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02564536,Phase I,Withdrawn,Washington University School of Medicine ,"[{'id': 3177, 'therapyName': 'Pacritinib + Decitabine'}]",Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS),05/09/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02564614,Phase I,"Active, not recruiting",Hoffmann-La Roche,"[{'id': 3612, 'therapyName': 'EZN-2968'}]","A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)",07/12/2017,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT02564900,Phase I,Recruiting,"Daiichi Sankyo Co., Ltd. ","[{'id': 4844, 'therapyName': 'DS-8201a'}]",Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors,10/30/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 20976, 'profileName': 'ERBB2 dec exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02565758,Phase I,Recruiting,AbbVie ,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 3846, 'therapyName': 'ABBV-085'}]","ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Cancer Tumors",03/25/2016,[],no
0,both,"[{'id': 10286, 'name': 'prostate carcinoma', 'source': 'DOID'}]",NCT02565901,Phase Ib/II,Recruiting,University of Washington ,"[{'id': 3111, 'therapyName': 'Carboplatin + Docetaxel + Sirolimus '}]","Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer",03/29/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02565992,Phase I,Recruiting,Viralytics ,"[{'id': 3136, 'therapyName': 'coxsackievirus A21 + Pembrolizumab'}]",Phase I Study of Intratumoral CAVATAK and Pembrolizumab in Subjects With Advanced Melanoma,10/16/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02566772,Phase I,Recruiting,"Taiho Oncology, Inc. ","[{'id': 4329, 'therapyName': 'TAS3681'}]",Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer,07/05/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02567396,Phase I,Withdrawn,National Cancer Institute (NCI),"[{'id': 682, 'therapyName': 'Talazoparib'}]",Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction,04/18/2017,[],no
0,both,"[{'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}]",NCT02567409,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 3110, 'therapyName': 'Cisplatin + Gemcitabine + VX-970'}]",Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer,10/01/2016,[],no
0,both,"[{'id': 50619, 'name': 'paranasal sinus cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02567422,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 3109, 'therapyName': 'Cisplatin + VX-970'}]","VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma",09/09/2016,[],no
0,both,"[{'id': 3246, 'name': 'embryonal rhabdomyosarcoma', 'source': 'DOID'}, {'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}, {'id': 4051, 'name': 'alveolar rhabdomyosarcoma', 'source': 'DOID'}]",NCT02567435,Phase III,Suspended,National Cancer Institute (NCI) ,"[{'id': 1435, 'therapyName': 'Vincristine + Dactinomycin + Cyclophosphamide'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Combination Chemotherapy and Irinotecan Hydrochloride or Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma,10/04/2016,[],no
0,both,"[{'id': 60061, 'name': 'cutaneous T cell lymphoma', 'source': 'DOID'}, {'id': 50743, 'name': 'mature T-cell and NK-cell lymphoma', 'source': 'DOID'}, {'id': 50749, 'name': 'peripheral T-cell lymphoma', 'source': 'DOID'}]",NCT02567656,Phase I,Recruiting,Rhizen Pharmaceuticals SA ,"[{'id': 2020, 'therapyName': 'RP6530'}]",Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma,01/15/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02568046,Phase Ib/II,"Active, not recruiting",Symphogen A/S ,"[{'id': 3949, 'therapyName': 'FOLFIRI + SYM004'}]",Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients,01/20/2017,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 481, 'profileName': 'NRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 50744, 'name': 'anaplastic large cell lymphoma', 'source': 'DOID'}]",NCT02568267,Phase II,Recruiting,"Ignyta, Inc. ","[{'id': 1455, 'therapyName': 'Entrectinib'}]","Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements  (STARTRK-2)",10/20/2015,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 11085, 'profileName': 'ROS1 rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT02568449,Phase II,Recruiting,Barbara Ann Karmanos Cancer Institute ,"[{'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent,07/01/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02568943,Phase I,Available,Novartis Pharmaceuticals ,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}]","An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma",12/29/2015,[],no
0,both,"[{'id': 5041, 'name': 'esophageal cancer', 'source': 'DOID'}]",NCT02569242,Phase III,"Active, not recruiting",Ono Pharmaceutical Co. Ltd,"[{'id': 3045, 'therapyName': 'Docetaxel + Paclitaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer,09/29/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02569320,Phase I,Suspended,Yvonne Efebera ,"[{'id': 4299, 'therapyName': 'AR-42 + Dexamethasone + Pomalidomide'}]",HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma,07/07/2017,[],no
0,both,"[{'id': 1240, 'name': 'leukemia', 'source': 'DOID'}, {'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}]",NCT02569476,Phase I,Recruiting,BeiGene ,"[{'id': 4682, 'therapyName': 'BGB-3111 + Obinutuzumab'}]",BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies,09/11/2016,[],no
0,female,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}]",NCT02569801,Phase II,"Active, not recruiting","Genentech, Inc. ","[{'id': 2150, 'therapyName': 'GDC-0810'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",A Study of GDC-0810 Versus Fulvestrant in Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy,03/10/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT02570308,Phase I,Recruiting,Immunocore Ltd ,"[{'id': 3847, 'therapyName': 'IMCgp100'}]",A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma,05/27/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02570542,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 1756, 'therapyName': 'Plerixafor'}, {'id': 3359, 'therapyName': 'Carmustine + Cytarabine + Etoposide + Melphalan'}]",Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL),01/04/2016,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02570711,Phase II,Terminated,Acerta Pharma BV,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer,04/22/2016,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02571036,Phase I,Recruiting,Deciphera Pharmaceuticals LLC ,"[{'id': 4316, 'therapyName': 'DCC-2618'}]","A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies",06/17/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02571530,Phase I,Recruiting,North Shore Long Island Jewish Health System ,"[{'id': 947, 'therapyName': 'Trastuzumab'}]",Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer,10/14/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT02571725,Phase Ib/II,Recruiting,New Mexico Cancer Care Alliance ,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 837, 'therapyName': 'Olaparib'}]",PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer,02/26/2016,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02572167,Phase Ib/II,"Active, not recruiting","Seattle Genetics, Inc. ","[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma,10/03/2017,[],no
0,both,"[{'id': 50744, 'name': 'anaplastic large cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02572453,Phase II,Recruiting,National Cancer Institute (NCI) ,"[{'id': 645, 'therapyName': 'AT13387'}]","AT13387 in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma",05/06/2016,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02572687,Phase I,Recruiting,Eli Lilly and Company ,"[{'id': 3257, 'therapyName': 'MEDI4736 + Ramucirumab'}]",A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies,03/19/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02573220,Phase I,Withdrawn,University of Chicago ,"[{'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer,12/10/2016,"[{'molecularProfile': {'id': 481, 'profileName': 'NRAS wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 575, 'profileName': 'HRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02573324,Phase II,Recruiting,AbbVie ,"[{'id': 976, 'therapyName': 'ABT-414'}, {'id': 1141, 'therapyName': 'Temozolomide'}]",A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification,10/16/2015,"[{'molecularProfile': {'id': 447, 'profileName': 'EGFR amp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02573363,Phase I,Recruiting,University of Chicago ,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia,11/05/2015,[],no
0,both,"[{'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}]",NCT02573493,Phase II,Recruiting,Washington University School of Medicine ,"[{'id': 3126, 'therapyName': 'Cisplatin + nab-paclitaxel'}, {'id': 3127, 'therapyName': 'Cetuximab + nab-paclitaxel'}]",Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC),04/15/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02574078,Phase I,Recruiting,Bristol-Myers Squibb ,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2114, 'therapyName': 'Bevacizumab + Pemetrexed'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",A Master Protocol Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (CheckMate 370),02/16/2016,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02574533,Phase I,Completed,"Gradalis, Inc. ","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1157, 'therapyName': 'FANG vaccine'}]",Pilot Study of Vigil + Pembrolizumab for Advanced Melanoma,09/29/2017,[],yes
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}]",NCT02574663,Phase I,"Active, not recruiting","TG Therapeutics, Inc. ","[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors,06/30/2017,[],no
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1319, 'name': 'brain cancer', 'source': 'DOID'}, {'id': 184, 'name': 'bone cancer', 'source': 'DOID'}, {'id': 5176, 'name': ""renal Wilms' tumor"", 'source': 'DOID'}]",NCT02574728,Phase II,Recruiting,Emory University ,"[{'id': 3143, 'therapyName': 'Celecoxib + Cyclophosphamide + Etoposide + Sirolimus'}]",Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors,10/21/2015,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT02575222,Phase I,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma,03/02/2016,[],no
0,both,"[{'id': 1798, 'name': 'pancreatic endocrine carcinoma', 'source': 'DOID'}]",NCT02575300,Phase II,Recruiting,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors,10/20/2015,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02575339,Phase Ib/II,Recruiting,"Bert O'Neil, MD ","[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}]",MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma,07/23/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02575404,Phase I,Recruiting,Providence Health & Services,"[{'id': 2975, 'therapyName': 'GR-MD-02'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",GR-MD-02 Plus Pembrolizumab in Melanoma Patients,05/21/2016,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02575508,Phase Ib/II,Withdrawn,Roswell Park Cancer Institute ,"[{'id': 3142, 'therapyName': 'BGJ398 + Fluorouracil + Irinotecan + Oxaliplatin'}]",Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer,05/21/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02575781,Phase I,Recruiting,Sanofi ,"[{'id': 4026, 'therapyName': 'SAR428926'}]",A Study of SAR428926 in Patients With Advanced Solid Tumors,04/29/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02575807,Phase Ib/II,Recruiting,"Aduro Biotech, Inc. ","[{'id': 2575, 'therapyName': 'Epacadostat'}, {'id': 2641, 'therapyName': 'CRS-207'}]","Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer",11/23/2016,[],no
0,both,"[{'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02576275,Phase III,Withdrawn,"Infinity Pharmaceuticals, Inc. ","[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 1024, 'therapyName': 'Duvelisib'}]",A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA),07/01/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02576301,Phase Ib/II,Recruiting,OXiGENE ,"[{'id': 3524, 'therapyName': 'OXi4503'}, {'id': 3887, 'therapyName': 'Cytarabine + OXi4503'}]",Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS,03/31/2016,[],no
0,both,"[{'id': 8850, 'name': 'salivary gland cancer', 'source': 'DOID'}, {'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 3620, 'name': 'central nervous system cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT02576431,Phase II,Recruiting,"Loxo Oncology, Inc. ","[{'id': 2650, 'therapyName': 'LOXO-101'}]",Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors,10/20/2015,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02576444,Phase II,Recruiting,Yale University ,"[{'id': 3140, 'therapyName': 'MK-1775 + Olaparib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 3141, 'therapyName': 'Olaparib + Vistusertib'}, {'id': 3139, 'therapyName': 'AZD5363 + Olaparib'}]",OLAParib COmbinations,07/24/2017,"[{'molecularProfile': {'id': 1209, 'profileName': 'AKT1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 13314, 'profileName': 'PTEN dec exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1246, 'profileName': 'STK11 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 479, 'profileName': 'PTEN loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3274, 'profileName': 'ATM mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 60901, 'name': ""Waldenstroem's macroglobulinemia"", 'source': 'DOID'}, {'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 1039, 'name': 'prolymphocytic leukemia', 'source': 'DOID'}, {'id': 50749, 'name': 'peripheral T-cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02576496,Phase I,Recruiting,Mundipharma-EDO GmbH ,"[{'id': 6104, 'therapyName': 'EDO-S101'}]","Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies",09/18/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02576509,Phase III,Recruiting,Bristol-Myers Squibb ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 920, 'therapyName': 'Sorafenib'}]",A Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma,05/11/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02576574,Phase III,Recruiting,EMD Serono ,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100),10/27/2015,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02576665,Phase I,Recruiting,Tocagen Inc. ,"[{'id': 3211, 'therapyName': 'Toca 511 + Toca FC'}]","A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Solid Tumors (Toca6)",08/05/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02576977,Phase III,Suspended,Merck Sharp & Dohme Corp. ,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183),06/20/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02576990,Phase II,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Primary Mediastinal Large B-cell Lymphoma (MK-3475-170/KEYNOTE-170),04/29/2016,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02577406,Phase III,Recruiting,Celgene Corporation ,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 2982, 'therapyName': 'Enasidenib'}]",An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation (IDHENTIFY),12/02/2015,"[{'molecularProfile': {'id': 5912, 'profileName': 'IDH2 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02578680,Phase III,"Active, not recruiting",Merck Sharp & Dohme Corp. ,"[{'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Non-squamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189),02/24/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02578797,Phase I,"Active, not recruiting",NCT02578797,"[{'id': 1947, 'therapyName': 'ARN-509'}]",A JNJ-56021927 (ARN-509) QT/QTc Study,05/31/2017,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02579226,Phase I,Recruiting,AstraZeneca ,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 3547, 'therapyName': 'AZD2811'}]","A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors",03/06/2016,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT02579811,Phase II,Recruiting,Case Comprehensive Cancer Center ,"[{'id': 649, 'therapyName': 'Axitinib'}]",Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer,01/13/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02579824,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 2079, 'therapyName': 'DS-3032b'}]",DS-3032b for Relapsed and/or Refractory (RR) Myeloma,09/09/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02579863,Phase III,Suspended,Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1164, 'therapyName': 'lenalidomide'}]",Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185),06/20/2017,[],no
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02580058,Phase III,"Active, not recruiting",Pfizer ,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3144, 'therapyName': 'Avelumab'}]",A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer,09/15/2017,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}]",NCT02580448,Phase Ib/II,Recruiting,Innocrin Pharmaceutical ,"[{'id': 2822, 'therapyName': 'VT-464'}]","A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer",10/29/2015,"[{'molecularProfile': {'id': 530, 'profileName': 'ERBB2 wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02580708,Phase Ib/II,Completed,"Clovis Oncology, Inc. ","[{'id': 2, 'therapyName': 'Trametinib'}, {'id': 1003, 'therapyName': 'CO1686'}]",A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC),07/27/2016,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 4039, 'profileName': 'EGFR exon 20 ins'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1629, 'profileName': 'MET amp'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}]",NCT02581059,Phase II,Recruiting,Hoosier Cancer Research Network ,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Efficacy of Ginseng for Patients on Regorafenib,06/02/2016,[],no
0,both,[],NCT02581137,Phase II,"Active, not recruiting",National Cancer Institute (NCI) ,[],Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion,07/14/2017,[],no
0,male,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT02581215,Phase II,Recruiting,"Walid Shaib, MD ","[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1903, 'therapyName': 'FOLFIRINOX'}]",Phase II Randomized Trial of FOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer,08/14/2016,[],no
0,both,"[{'id': 8541, 'name': ""Sezary's disease"", 'source': 'DOID'}, {'id': 50749, 'name': 'peripheral T-cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02581631,Phase Ib/II,Recruiting,Bristol-Myers Squibb ,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436),01/09/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02581787,Phase Ib/II,Recruiting,Maximilian Diehn ,"[{'id': 2707, 'therapyName': 'fresolimumab'}]",SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer,09/16/2016,[],no
0,both,"[{'id': 8923, 'name': 'skin melanoma', 'source': 'DOID'}]",NCT02581930,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma,09/03/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02581943,Phase II,Suspended,National Cancer Institute (NCI),"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer,07/12/2017,[],no
0,both,"[{'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}]",NCT02581982,Phase II,Recruiting,Comprehensive Cancer Center of Wake Forest University ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer,03/24/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02582749,Phase II,Recruiting,"Ajjai Alva, MD ","[{'id': 4618, 'therapyName': 'Bicalutamide + Ra 223'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases,08/29/2016,[],no
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT02583477,Phase Ib/II,Recruiting,AstraZeneca ,"[{'id': 3099, 'therapyName': 'AZD5069 + MEDI4736'}, {'id': 3163, 'therapyName': 'Gemcitabine + MEDI4736 + nab-paclitaxel'}]",Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma,08/02/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02583893,Phase II,Recruiting,Thomas Jefferson University ,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1752, 'therapyName': 'Mitoxantrone + Etoposide + Cytarabine'}]",Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia,12/18/2015,"[{'molecularProfile': {'id': 15350, 'profileName': 'RUNX1-RUNX1T1'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1816, 'name': 'angiosarcoma', 'source': 'DOID'}, {'id': 5940, 'name': 'malignant peripheral nerve sheath tumor', 'source': 'DOID'}, {'id': 1907, 'name': 'malignant fibroxanthoma', 'source': 'DOID'}, {'id': 1967, 'name': 'leiomyosarcoma', 'source': 'DOID'}, {'id': 6193, 'name': 'epithelioid sarcoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 3355, 'name': 'fibrosarcoma', 'source': 'DOID'}, {'id': 5485, 'name': 'synovial sarcoma', 'source': 'DOID'}]",NCT02584309,Phase II,Recruiting,Washington University School of Medicine,"[{'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 4140, 'therapyName': 'Doxorubicin + Olaratumab'}]",Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma,01/03/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02584634,Phase I,Recruiting,Pfizer,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 869, 'therapyName': 'PF-06463922'}]","Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)",12/31/2015,[],no
0,both,"[{'id': 5940, 'name': 'malignant peripheral nerve sheath tumor', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02584647,Phase Ib/II,Recruiting,Gary Schwartz ,"[{'id': 3155, 'therapyName': 'PLX3397 + Sirolimus'}]",Combination of PLX3397 and Sirolimus in Unresectable Sarcoma (Phase 1) and Malignant Peripheral Nerve Sheath Tumors (Phase 2),10/27/2015,[],no
0,both,"[{'id': 3965, 'name': 'Merkel cell carcinoma', 'source': 'DOID'}]",NCT02584829,Phase Ib/II,Suspended,Fred Hutchinson Cancer Research Center ,"[{'id': 3156, 'therapyName': 'IFN-B'}, {'id': 3144, 'therapyName': 'Avelumab'}]",Localized Radiation Therapy or Recombinant Interferon Beta and MSB0010718C With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma,09/29/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02584933,FDA approved,Recruiting,Novartis Pharmaceuticals,"[{'id': 789, 'therapyName': 'Ceritinib'}]",Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study,02/13/2016,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02585973,Phase I,Recruiting,UNC Lineberger Comprehensive Cancer Center ,"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]",Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC,07/12/2016,[],no
0,both,"[{'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}]",NCT02586207,Phase I,Recruiting,Sanford Health ,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",Pembrolizumab in Combination With CRT for LA-SCCHN,01/14/2017,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02586675,Phase I,"Active, not recruiting",H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 3175, 'therapyName': 'LEE001 + Tamoxifen'}]",TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer,05/19/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02586857,Phase Ib/II,Recruiting,Acerta Pharma BV ,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}]","A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)",02/25/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02586987,Phase I,Recruiting,AstraZeneca ,"[{'id': 3162, 'therapyName': 'MEDI4736 + Selumetinib'}]","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 in Patients With Advanced Solid Tumours",01/07/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02587598,Phase Ib/II,Recruiting,Incyte Corporation ,"[{'id': 3696, 'therapyName': 'INCB053914'}]",Study of INCB053914 in Subjects With Advanced Malignancies,03/25/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02587962,Phase Ib/II,Recruiting,Medivir ,"[{'id': 6160, 'therapyName': 'Birinapant  + Pembrolizumab'}]",Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors,09/05/2017,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02588105,Phase I,Recruiting,AstraZeneca ,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 3557, 'therapyName': 'AZD0156'}]",Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer,02/19/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02588261,Phase III,"Active, not recruiting","Astellas Pharma Global Development, Inc. ","[{'id': 1082, 'therapyName': 'ASP8273'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations,06/20/2017,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02589145,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2558, 'therapyName': 'Busulfan + Melphalan'}, {'id': 3278, 'therapyName': 'Enoxaparin'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}]",Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype,06/25/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02589522,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 2879, 'therapyName': 'VX-970'}]",VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer,07/27/2016,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}]",NCT02589717,FDA approved,Approved for marketing,"Genentech, Inc.","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy,08/13/2016,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02591615,Phase II,Recruiting,"Alliance Foundation Trials, LLC. ","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}]",Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC,03/25/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02591654,Phase I,Recruiting,Columbia University ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",MRI/PET Imaging to Assess Response to Pembrolizumab in Metastatic Melanoma,10/30/2015,[],no
0,both,[],NCT02592356,Phase I,Recruiting,M.D. Anderson Cancer Center ,[],Tyrosine Kinase Inhibitors (TKI) and Body Composition,11/18/2015,[],no
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT02592551,Phase II,Recruiting,Baylor College of Medicine ,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma,06/05/2016,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02593175,Phase II,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 3386, 'therapyName': 'Carboplatin + Paclitaxel + Panitumumab'}]","Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy",08/30/2016,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02593708,Phase I,Unknown status,Michelle Melisko ,"[{'id': 3187, 'therapyName': 'Neratinib + Paclitaxel + Pertuzumab + Trastuzumab'}]","Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+",10/03/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02594072,Phase I,Recruiting,University of British Columbia ,"[{'id': 759, 'therapyName': 'Goserelin'}]",Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT) (ASSERT),07/18/2016,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 8632, 'name': ""Kaposi's sarcoma"", 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02595866,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms",03/31/2016,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02595892,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 2879, 'therapyName': 'VX-970'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Gemcitabine Hydrochloride Alone or With VX-970 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",08/31/2016,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02595905,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 954, 'therapyName': 'Veliparib'}]",Cisplatin With or Without Veliparib in Treating Patients With Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer,07/13/2016,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT02595918,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With HIgh-Risk Non-Metastatic Kidney Cancer,07/30/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02595931,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 2883, 'therapyName': 'VX-970 + Irinotecan'}]",VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,06/14/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02595944,Phase III,Recruiting,National Cancer Institute (NCI),"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (ANVIL),07/14/2016,"[{'molecularProfile': {'id': 343, 'profileName': 'EGFR wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 391, 'profileName': 'ALK wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02596035,FDA approved,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374),12/17/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02596971,Phase I,Recruiting,Hoffmann-La Roche ,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}, {'id': 3266, 'therapyName': 'Cyclophosphamide + Doxorubicin + Prednisone + Vincristine '}, {'id': 1231, 'therapyName': 'Bendamustine'}]",Safety and Efficacy of MPDL3280A in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Diffuse Large B-Cell Lymphoma,01/15/2016,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT02597036,Phase I,"Active, not recruiting",Eli Lilly and Company ,"[{'id': 3562, 'therapyName': 'LY3127804 '}, {'id': 886, 'therapyName': 'Ramucirumab'}]",A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors,10/05/2017,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02598427,Phase I,Recruiting,Duke University ,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer,06/23/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}]",NCT02598557,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 738, 'therapyName': 'Exemestane'}]",Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer,12/23/2016,[],yes
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02598661,Phase III,Recruiting,"Janssen Research & Development, LLC ","[{'id': 3710, 'therapyName': 'Imetelstat'}]",Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS),06/02/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02598960,Phase Ib/II,Recruiting,Bristol-Myers Squibb ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3559, 'therapyName': 'BMS-986156'}]",A Study of BMS-986156 Given Alone and in Combination With Nivolumab in Subjects With Advanced Solid Tumors,02/19/2016,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02599324,Phase Ib/II,Recruiting,Pharmacyclics ,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 694, 'therapyName': 'Cetuximab'}]",A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors,03/26/2016,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1102, 'profileName': 'EGFR positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02599363,Phase I,Recruiting,Abramson Cancer Center of the University of Pennsylvania,"[{'id': 3206, 'therapyName': 'Paclitaxel + Ribociclib'}]",A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer,02/04/2016,"[{'molecularProfile': {'id': 2395, 'profileName': 'RB1 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02599402,Phase III,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma,08/05/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02599454,Phase I,Recruiting,"University of California, Davis ","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer,02/19/2016,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT02599649,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 2583, 'therapyName': 'Lirilumab '}]",Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS),04/07/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02599714,Phase Ib/II,Recruiting,AstraZeneca ,"[{'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 991, 'therapyName': 'Vistusertib'}]",Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer (PASTOR),01/09/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02599779,Phase II,Recruiting,Sunnybrook Health Sciences Centre ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients,12/31/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}]",NCT02600897,Phase Ib/II,Recruiting,Hoffmann-La Roche,"[{'id': 4394, 'therapyName': 'lenalidomide + Obinutuzumab + Polatuzumab Vedotin'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",07/14/2016,[],yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02601014,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7,09/29/2017,[],no
0,both,"[{'id': 4415, 'name': 'fibrous histiocytoma', 'source': 'DOID'}, {'id': 1967, 'name': 'leiomyosarcoma', 'source': 'DOID'}, {'id': 5940, 'name': 'malignant peripheral nerve sheath tumor', 'source': 'DOID'}, {'id': 5485, 'name': 'synovial sarcoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02601209,Phase Ib/II,Suspended,National Cancer Institute (NCI),"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}]",Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma,08/09/2017,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02601313,Phase II,Recruiting,"Kite Pharma, Inc.","[{'id': 5098, 'therapyName': 'KTE-C19 + Fludarabine phosphate + Cyclophosphamide'}]",A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2),12/13/2016,[],no
0,both,"[{'id': 3672, 'name': 'rhabdoid cancer', 'source': 'DOID'}, {'id': 4838, 'name': 'myoepithelial carcinoma', 'source': 'DOID'}, {'id': 5861, 'name': 'myxoid chondrosarcoma', 'source': 'DOID'}, {'id': 4464, 'name': 'collecting duct carcinoma', 'source': 'DOID'}, {'id': 6193, 'name': 'epithelioid sarcoma', 'source': 'DOID'}, {'id': 8353, 'name': 'epithelioid malignant peripheral nerve sheath tumor', 'source': 'DOID'}, {'id': 5485, 'name': 'synovial sarcoma', 'source': 'DOID'}]",NCT02601937,Phase I,Recruiting,"Epizyme, Inc. ","[{'id': 2683, 'therapyName': 'Tazemetostat'}]",A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma,05/11/2016,"[{'molecularProfile': {'id': 13297, 'profileName': 'SMARCB1 loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 13296, 'profileName': 'SMARCB1 mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3672, 'name': 'rhabdoid cancer', 'source': 'DOID'}, {'id': 5485, 'name': 'synovial sarcoma', 'source': 'DOID'}]",NCT02601950,Phase II,Recruiting,"Epizyme, Inc.","[{'id': 2683, 'therapyName': 'Tazemetostat'}]","A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma",05/11/2016,"[{'molecularProfile': {'id': 13297, 'profileName': 'SMARCB1 loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 13296, 'profileName': 'SMARCB1 mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT02602327,Phase I,Recruiting,"University of California, San Francisco ","[{'id': 2426, 'therapyName': 'trifluridine/tipiracil hydrochloride'}]",Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases,12/06/2016,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02603419,Phase I,Recruiting,Pfizer ,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS),06/27/2016,[],no
0,both,"[{'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}]",NCT02603432,Phase III,Recruiting,Pfizer,"[{'id': 3144, 'therapyName': 'Avelumab'}]",A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100),05/19/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02603887,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab for Smoldering Multiple Myeloma (SMM),09/21/2017,[],no
0,both,"[{'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}]",NCT02604511,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute ,"[{'id': 768, 'therapyName': 'Ibrutinib'}]","Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing",01/13/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02605044,Phase III,Recruiting,AB Science ,"[{'id': 804, 'therapyName': 'Masitinib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer,12/03/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02605083,Phase Ib/II,Recruiting,Effector Therapeutics ,"[{'id': 4005, 'therapyName': 'eFT508'}]",A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors,04/29/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02605356,Phase Ib/II,Withdrawn,Bayer ,"[{'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma,10/08/2016,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02605486,Phase Ib/II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 3252, 'therapyName': 'Bicalutamide + Palbociclib'}]",Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC),12/08/2015,"[{'molecularProfile': {'id': 530, 'profileName': 'ERBB2 wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02605694,Phase II,Withdrawn,"Infinity Pharmaceuticals, Inc.","[{'id': 3389, 'therapyName': 'Duvelisib + Rituximab'}, {'id': 2195, 'therapyName': 'R-CHOP'}]",Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO),08/01/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02605746,Phase I,Recruiting,"St. Joseph's Hospital and Medical Center, Phoenix ","[{'id': 789, 'therapyName': 'Ceritinib'}]",Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis,06/05/2016,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}]",NCT02605863,Phase II,Recruiting,University of Rochester ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide for Bladder Cancer Chemoprevention,12/08/2015,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02605915,Phase I,Recruiting,Hoffmann-La Roche ,"[{'id': 3250, 'therapyName': 'Atezolizumab + Trastuzumab'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 856, 'therapyName': 'Pertuzumab'}]",Safety and Pharmacokinetics of Atezolizumab in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab in Participants With HER2-Positive Breast Cancer,12/08/2015,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}]",NCT02605967,Phase II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 2659, 'therapyName': 'PDR001'}]",Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma,04/28/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02606123,Phase Ib/II,"Active, not recruiting",ESSA Pharmaceuticals ,"[{'id': 5611, 'therapyName': 'EPI-506'}]",Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer,10/05/2017,[],no
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}]",NCT02606305,Phase I,Recruiting,"ImmunoGen, Inc. ","[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3232, 'therapyName': 'IMGN853'}]","Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer",12/12/2015,[],no
0,both,"[{'id': 3382, 'name': 'liposarcoma', 'source': 'DOID'}]",NCT02606461,Phase II,Recruiting,"Karyopharm Therapeutics, Inc ","[{'id': 1749, 'therapyName': 'Selinexor'}]",KCP-330-020 SEAL (Selinexor in Advanced Liposarcoma) (SEAL),02/25/2016,[],no
0,both,"[{'id': 4202, 'name': 'brain stem glioma', 'source': 'DOID'}, {'id': 6726, 'name': 'fibrillary astrocytoma', 'source': 'DOID'}, {'id': 5076, 'name': 'mixed glioma', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02607124,Phase Ib/II,Recruiting,"Children's Hospital Medical Center, Cincinnati ","[{'id': 790, 'therapyName': 'Ribociclib'}]",Administration of Ribociclib Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG),04/16/2016,[],no
0,both,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02607228,Phase Ib/II,Recruiting,Gilead Sciences ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}]","Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer",02/19/2016,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT02607553,Phase II,Completed,"GenSpera, Inc. ","[{'id': 4338, 'therapyName': 'mipsagargin'}]",Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA,02/25/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02607813,Phase I,Recruiting,Novartis Pharmaceuticals ,"[{'id': 4443, 'therapyName': 'LXH 254 + PDR001'}, {'id': 4442, 'therapyName': 'LXH 254'}]",Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations,12/15/2016,"[{'molecularProfile': {'id': 1238, 'profileName': 'MAP2K1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02608125,Phase I,Recruiting,"Principia Biopharma, Inc. ","[{'id': 3583, 'therapyName': 'PRN1371'}]",A Dose Escalation and Dose Expansion Study of PRN1371 in Adult Patients With Advanced Solid Tumors,12/11/2016,"[{'molecularProfile': {'id': 812, 'profileName': 'FGFR1 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14910, 'profileName': 'FGFR1 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1185, 'profileName': 'FGFR2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3329, 'profileName': 'FGFR3 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1221, 'profileName': 'FGFR1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14903, 'profileName': 'FGFR3 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2969, 'profileName': 'FGFR2 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3147, 'profileName': 'FGFR2 amp'}, 'requirementType': 'partial'}]",yes
0,female,[],NCT02608216,Phase I,Recruiting,University of Pennsylvania ,[],[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer,12/10/2015,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02608229,Phase I,Recruiting,Washington University School of Medicine ,"[{'id': 3249, 'therapyName': 'BVD-523 + Gemcitabine + nab-paclitaxel'}]",BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer,06/09/2016,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02608268,Phase Ib/II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 2659, 'therapyName': 'PDR001'}, {'id': 3560, 'therapyName': 'MBG453'}]",Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,02/19/2016,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02608385,Phase I,"Active, not recruiting",University of Chicago ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors,05/12/2017,[],no
0,female,"[{'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT02608684,Phase II,Recruiting,Cedars-Sinai Medical Center ,"[{'id': 3248, 'therapyName': 'Cisplatin + Gemcitabine + Pembrolizumab'}]",A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer,02/09/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02609503,Phase II,Recruiting,UNC Lineberger Comprehensive Cancer Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin,06/02/2016,[],no
0,both,"[{'id': 5363, 'name': 'myxoid liposarcoma', 'source': 'DOID'}, {'id': 5485, 'name': 'synovial sarcoma', 'source': 'DOID'}]",NCT02609984,Phase II,"Active, not recruiting",Immune Design ,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3273, 'therapyName': 'G305 + ID-LV305'}]",Trial of CMB305 and Atezolizumab in Patients With Sarcoma,07/03/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02610075,Phase I,Recruiting,AstraZeneca ,"[{'id': 822, 'therapyName': 'MK-1775'}]",Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.,12/18/2015,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02610361,Phase I,"Active, not recruiting",BeiGene ,"[{'id': 4025, 'therapyName': 'BGB-283'}]",Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors,08/23/2016,"[{'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02610777,Phase II,"Active, not recruiting","Millennium Pharmaceuticals, Inc. ","[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1688, 'therapyName': 'MLN4924'}]","An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)",06/30/2017,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02611063,Phase I,Recruiting,"Stefanie Sarantopoulos, MD, PhD. ","[{'id': 1528, 'therapyName': 'Fostamatinib'}]",Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant,02/19/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}]",NCT02611323,Phase Ib/II,Recruiting,Hoffmann-La Roche,"[{'id': 4227, 'therapyName': 'Obinutuzumab + Polatuzumab Vedotin + Venetoclax'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",06/03/2016,[],yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02611908,Phase I,Recruiting,Michael Choi ,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.,06/29/2016,[],no
0,both,"[{'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}]",NCT02611960,Phase II,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4203, 'therapyName': 'Capecitabine + Docetaxel + Gemcitabine'}]","Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122, KEYNOTE-122)",06/02/2016,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}]",NCT02612194,Phase II,Recruiting,Earle Burgess ,"[{'id': 706, 'therapyName': 'Crizotinib'}]",LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer,03/06/2016,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02612285,Phase II,Terminated,Esanex Inc. ,"[{'id': 866, 'therapyName': 'SNX-5422'}]",Study of SNX-5422 in TP53 Null Cancers,11/05/2016,"[{'molecularProfile': {'id': 630, 'profileName': 'TP53 loss'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02612311,Phase III,"Active, not recruiting","TG Therapeutics, Inc. ","[{'id': 2287, 'therapyName': 'Ublituximab'}, {'id': 1648, 'therapyName': 'Obinutuzumab + Chlorambucil'}, {'id': 2022, 'therapyName': 'TGR-1202'}]",Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia,10/20/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02612779,Phase II,"Active, not recruiting",Bristol-Myers Squibb,"[{'id': 3355, 'therapyName': 'Elotuzumab + Dexamethasone + Pomalidomide'}]",A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone (EPd) in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide,09/07/2017,[],no
0,female,[],NCT02613416,Phase II,Recruiting,Stony Brook University ,[],Denosumab and Breast Imaging,12/09/2015,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02613598,Phase I,Recruiting,University of Michigan Cancer Center ,"[{'id': 3262, 'therapyName': 'Bortezomib + Ruxolitinib'}]",Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma,06/03/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02613650,Phase I,Recruiting,University of Utah ,"[{'id': 3247, 'therapyName': 'Binimetinib + FOLFIRI'}]",A Trial of FOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers,02/18/2017,"[{'molecularProfile': {'id': 14911, 'profileName': 'KRAS positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02614066,Phase Ib/II,Recruiting,"Kite Pharma, Inc. ","[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Study Evaluating KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3) (ZUMA-3),10/30/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02614456,Phase I,Recruiting,Fox Chase Cancer Center ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1733, 'therapyName': 'interferon gamma '}]",Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors,12/15/2015,[],no
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02614508,Phase I,"Active, not recruiting",Emory University ,"[{'id': 3630, 'therapyName': 'BKM120 + Ibrutinib'}, {'id': 3629, 'therapyName': 'BKM120 + Ofatumumab'}]",Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,09/20/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02614794,Phase II,Recruiting,Oncothyreon Inc. ,"[{'id': 3340, 'therapyName': 'ARRY-380 + Capecitabine + Trastuzumab'}, {'id': 1409, 'therapyName': 'Capecitabine + Trastuzumab'}]",Study of ONT-380 vs Placebo in Combo w/ Capecitabine & Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer,02/04/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02614859,Phase II,Recruiting,Fox Chase Cancer Center ,"[{'id': 1507, 'therapyName': 'Bicalutamide'}, {'id': 1031, 'therapyName': 'Metformin'}]",Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients,12/12/2015,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02616185,Phase I,Recruiting,Pfizer ,"[{'id': 3565, 'therapyName': 'PF-06755990 + PF-06755992 + Sunitinib + Tremelimumab'}]",A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR),08/12/2017,[],no
0,,[],NCT02616211,,"Active, not recruiting",Mayo Clinic ,[],An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors,03/04/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02616393,Phase II,Recruiting,"Kadmon Corporation, LLC ","[{'id': 967, 'therapyName': 'XL647'}]","Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases",12/09/2015,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02616640,Phase I,"Active, not recruiting",Celgene Corporation ,"[{'id': 1622, 'therapyName': 'Pomalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma,09/29/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02617277,Phase I,Recruiting,AstraZeneca ,"[{'id': 3414, 'therapyName': 'MEDI4736 + MK-1775'}]","Safety, Tolerability and Pharmacokinetics of AZD1775 Plus MEDI4736 in Patients With Advanced Solid Tumours",01/14/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02617589,Phase III,Recruiting,Bristol-Myers Squibb ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Study of Nivolumab Versus Temozolomide, Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) (CheckMate 498)",03/15/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02617849,Phase II,Recruiting,Wilson Miller ,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma,07/12/2016,[],no
0,both,"[{'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}]",NCT02619253,Phase Ib/II,Recruiting,Roberto Pili ,"[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]",Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma,04/07/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02619669,Phase I,Recruiting,Dartmouth-Hitchcock Medical Center ,"[{'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 794, 'therapyName': 'Letrozole'}]",Neoadjuvant Run-In Study With TAK-228 (MLN0128) Followed by Letrozole/TAK-228 (MLN0128) in Women With High-Risk ER+/HER2- Breast Cancer,05/11/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02619864,Phase Ib/II,Recruiting,Canadian Cancer Trials Group ,"[{'id': 991, 'therapyName': 'Vistusertib'}]",mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme,12/28/2016,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02620423,Phase I,"Active, not recruiting",Oncolytics Biotech ,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 893, 'therapyName': 'Reolysin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab With REOLYSIN and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma,03/29/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02620800,Phase Ib/II,Recruiting,Celgene Corporation ,"[{'id': 3621, 'therapyName': 'FABLOx'}]","Study of 5-fluorouracil (5-FU), Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer",02/25/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02620839,Phase I,Recruiting,Pamela Munster,"[{'id': 5627, 'therapyName': 'Alpelisib + Cisplatin'}]",Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies,05/05/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02620865,Phase Ib/II,Suspended,Barbara Ann Karmanos Cancer Institute,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 2278, 'therapyName': 'Fluorouracil + Leucovorin'}]",Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer,02/19/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02621021,Phase II,Recruiting,National Cancer Institute (NCI) ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab,06/21/2016,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT02621151,Phase II,Recruiting,New York University School of Medicine ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}]","Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder",06/25/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02621398,Phase I,Suspended,"Rutgers, The State University of New Jersey ","[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer",09/29/2017,[],no
0,female,[],NCT02621957,Phase I,Completed,"Genentech, Inc. ",[],Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential,03/05/2016,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02624258,Phase I,Recruiting,University of Pennsylvania ,"[{'id': 6000, 'therapyName': 'RNA CART19 cells'}]","Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma",07/17/2017,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02624388,Phase II,Recruiting,University of Virginia ,"[{'id': 757, 'therapyName': 'Genistein'}]",Study of Genistein in Pediatric Oncology Patients (UVA-Gen001),08/13/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02624570,Phase I,Available,Novartis Pharmaceuticals ,"[{'id': 810, 'therapyName': 'Midostaurin'}]",Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy.,03/25/2016,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02624700,Phase II,Recruiting,Virginia Commonwealth University ,"[{'id': 1482, 'therapyName': 'Pemetrexed + Sorafenib'}]",Study of Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer,02/02/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02624986,Phase Ib/II,Recruiting,Hoffmann-La Roche,"[{'id': 4393, 'therapyName': 'Idasanutlin + Obinutuzumab'}]",A Study of Obinutuzumab With Idasanutlin in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL),07/14/2016,[],yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02625480,Phase Ib/II,Recruiting,"Kite Pharma, Inc. ","[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-4),10/30/2016,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT02625610,Phase III,Recruiting,EMD Serono ,"[{'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}]",Avelumab in First-Line Gastric Cancer (JAVELIN Gastric 100),12/22/2015,[],no
0,both,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT02625623,Phase III,"Active, not recruiting",EMD Serono ,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1074, 'therapyName': 'Irinotecan'}]",Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300),05/09/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02625857,Phase I,"Active, not recruiting","Janssen Research & Development, LLC ","[{'id': 4889, 'therapyName': 'JNJ-64041809'}]","Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer",10/07/2017,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT02625961,Phase II,Recruiting,Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057),03/11/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02626000,Phase Ib/II,Recruiting,Amgen ,"[{'id': 4035, 'therapyName': 'Pembrolizumab + talimogene laherparepvec '}]",Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck,05/11/2016,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT02626130,Phase I,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 1652, 'therapyName': 'Tremelimumab'}]",Pilot Study of Presurgical Tremelimumab With or Without Cryoablation in Patients With Metastatic Renal Cell Carcinoma (RCC),04/02/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02626234,Phase I,Completed,Novartis Pharmaceuticals ,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors,06/01/2017,"[{'molecularProfile': {'id': 1112, 'profileName': 'MET alterations'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02626338,Phase Ib/II,Recruiting,"Arog Pharmaceuticals, Inc. ","[{'id': 4024, 'therapyName': 'Crenolanib + Cytarabine + Mitoxantrone'}]",Pilot Study of Crenolanib Combined With Cytarabine and Mitoxantrone in Subjects With R/R AML,04/29/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT02626364,Phase II,Recruiting,"Arog Pharmaceuticals, Inc. ","[{'id': 705, 'therapyName': 'Crenolanib'}]",Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification,07/30/2016,"[{'molecularProfile': {'id': 1417, 'profileName': 'PDGFRA amp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02626455,Phase III,Recruiting,Bayer ,"[{'id': 1631, 'therapyName': 'Vincristine'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 3388, 'therapyName': 'Aldoxorubicin +Cyclophosphamide + Prednisone + Rituximab + Vincristine'}, {'id': 995, 'therapyName': 'Copanlisib'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 897, 'therapyName': 'Rituximab'}]",Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL),01/15/2016,[],yes
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02626507,Phase I,Recruiting,Eastchester Center for Cancer Care ,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 1040, 'therapyName': 'PF-05212384'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer,05/05/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02627274,Phase I,Recruiting,Hoffmann-La Roche,"[{'id': 5364, 'therapyName': 'RO6874281'}]","A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 in Participants With Advanced and/or Metastatic Solid Tumors",03/16/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02627430,Phase I,Withdrawn,National Cancer Institute (NCI),"[{'id': 3317, 'therapyName': 'Onalespib + Talazoparib'}]","Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer",07/27/2016,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02627443,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2879, 'therapyName': 'VX-970'}]","Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",11/10/2016,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02627963,Phase III,"Active, not recruiting","AVEO Pharmaceuticals, Inc. ","[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1055, 'therapyName': 'Tivozanib'}]",A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC,08/18/2017,[],no
0,both,"[{'id': 4897, 'name': 'bile duct carcinoma', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 3963, 'name': 'thyroid carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1790, 'name': 'malignant mesothelioma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}, {'id': 8850, 'name': 'salivary gland cancer', 'source': 'DOID'}, {'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}, {'id': 3500, 'name': 'gallbladder adenocarcinoma', 'source': 'DOID'}, {'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}, {'id': 2893, 'name': 'cervix carcinoma', 'source': 'DOID'}, {'id': 1294, 'name': 'vulva carcinoma', 'source': 'DOID'}, {'id': 6126, 'name': 'anal canal carcinoma', 'source': 'DOID'}]",NCT02628067,Phase II,Recruiting,Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158),01/15/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02628574,Phase I,Recruiting,"GITR, Inc. ","[{'id': 3613, 'therapyName': 'TRX518'}]",Dose Escalation Study of TRX518 in Adults With Advanced Solid Tumors,02/25/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02628704,Phase II,Withdrawn,"Karyopharm Therapeutics, Inc ","[{'id': 2985, 'therapyName': 'Carfilzomib + Dexamethasone + Selinexor'}]","Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma",03/31/2017,[],no
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02629809,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 3627, 'therapyName': 'Cyclophosphamide + Fludarabine + Obinutuzumab'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)",03/23/2016,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02630186,Phase Ib/II,"Active, not recruiting","Clovis Oncology, Inc. ","[{'id': 3575, 'therapyName': 'Atezolizumab + CO1686'}]",A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC,05/19/2016,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 4039, 'profileName': 'EGFR exon 20 ins'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02630420,Phase I,Not yet recruiting,Yale University,"[{'id': 3790, 'therapyName': 'Cetuximab + Savolitinib'}]",Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer,03/20/2016,"[{'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'excluded'}]",yes
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02630693,Phase II,"Active, not recruiting",Canadian Cancer Trials Group ,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]","Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer",02/14/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}]",NCT02630823,Phase I,Recruiting,Washington University School of Medicine ,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",MK-3475 Immunotherapy in Endometrial Carcinoma,02/12/2016,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02631044,Phase I,Recruiting,"Juno Therapeutics, Inc.","[{'id': 5980, 'therapyName': 'JCAR017'}]",Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL),09/05/2017,[],yes
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02631577,Phase I,Suspended,Hoffmann-La Roche ,"[{'id': 3387, 'therapyName': 'Atezolizumab + lenalidomide + Obinutuzumab'}]",A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma,10/04/2017,[],yes
0,both,"[{'id': 4897, 'name': 'bile duct carcinoma', 'source': 'DOID'}, {'id': 4948, 'name': 'gallbladder carcinoma', 'source': 'DOID'}]",NCT02631590,Phase II,Recruiting,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 3315, 'therapyName': 'BAY80-6946 + Cisplatin + Gemcitabine'}]",Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma,07/01/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02631733,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 3314, 'therapyName': 'Irinotecan + Veliparib'}]",Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery,05/23/2017,[],yes
0,both,"[{'id': 715, 'name': 'T-cell leukemia', 'source': 'DOID'}]",NCT02631746,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma,06/09/2016,[],no
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT02631876,Phase II,Recruiting,"ImmunoGen, Inc. ","[{'id': 3574, 'therapyName': 'Doxil + Paclitaxel'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3232, 'therapyName': 'IMGN853'}]","PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer",11/09/2016,[],yes
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02632045,Phase II,Recruiting,Kevin Kalinsky ,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 790, 'therapyName': 'Ribociclib'}]",Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ H2N- Advanced Breast Cancer,03/19/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT02632071,Phase I,Recruiting,Kevin Kalinsky ,"[{'id': 3313, 'therapyName': 'ACY-1215 + nab-paclitaxel'}]",Phase I of ACY-1215 + Nab-paclitaxel in Breast Cancer,03/22/2016,[],no
0,both,"[{'id': 2615, 'name': 'papilloma', 'source': 'DOID'}]",NCT02632344,Phase II,Recruiting,Massachusetts General Hospital ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement",04/29/2016,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}]",NCT02632409,Phase III,Recruiting,Bristol-Myers Squibb,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Adjuvant Nivolumab Versus Placebo Post-Surgical Removal of High Risk Invasive Urothelial Carcinoma,03/10/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02632448,Phase Ib/II,Recruiting,Esperas Pharma Inc. ,"[{'id': 4420, 'therapyName': 'LY2880070 + Gemcitabine'}, {'id': 4315, 'therapyName': 'LY2880070'}]",A Study of LY2880070 in Patients With Advanced or Metastatic Cancer,07/05/2016,[],yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02632708,Phase I,Recruiting,"Agios Pharmaceuticals, Inc. ","[{'id': 1491, 'therapyName': 'AG-120'}, {'id': 2982, 'therapyName': 'Enasidenib'}, {'id': 3431, 'therapyName': 'Cytarabine + Daunorubicin + Etoposide + Mitoxantrone'}]",Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation,01/21/2016,"[{'molecularProfile': {'id': 1781, 'profileName': 'IDH1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 5912, 'profileName': 'IDH2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02632721,Phase II,Recruiting,Boehringer Ingelheim ,"[{'id': 5540, 'therapyName': 'BI 836858 + Decitabine'}, {'id': 650, 'therapyName': 'Decitabine'}]",A Study to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML),04/19/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02633059,Phase Ib/II,Recruiting,Mayo Clinic ,"[{'id': 4392, 'therapyName': 'Dexamethasone + Idasanutlin + Ixazomib'}]","Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma",06/27/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02634827,Phase II,Recruiting,Mayo Clinic ,"[{'id': 1769, 'therapyName': 'Decitabine + Midostaurin'}]",Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation,02/19/2016,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02635061,Phase I,Recruiting,Acetylon Pharmaceuticals Incorporated ,"[{'id': 3312, 'therapyName': 'ACY-241 + Ipilimumab + Nivolumab'}]",Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer,04/07/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02635074,Phase I,Recruiting,Steven E. Coutre ,"[{'id': 3573, 'therapyName': 'Cytarabine + Idarubicin + Ibrutinib'}]","Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",08/26/2017,[],no
0,female,"[{'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}]",NCT02635360,Phase II,Recruiting,Linda R Duska ,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer,07/14/2016,[],no
0,both,"[{'id': 8850, 'name': 'salivary gland cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 4007, 'name': 'bladder carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02636036,Phase I,Recruiting,PsiOxus Therapeutics Ltd ,"[{'id': 3620, 'therapyName': 'Enadenotucirev + Pembrolizumab'}]",Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors,02/25/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02636322,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 2482, 'therapyName': 'Cyclophosphamide + Doxorubicin + Etoposide + Vincristine '}, {'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}, {'id': 2188, 'therapyName': 'Prednisone'}]","A Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Dose Adjusted Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma",04/01/2016,[],no
0,female,"[{'id': 60074, 'name': 'ductal carcinoma in situ', 'source': 'DOID'}]",NCT02636582,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 5152, 'therapyName': 'Nelipepimut-S Plus GM-CSF'}]",Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer,03/09/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02636725,Phase II,Recruiting,Breelyn Wilky ,"[{'id': 2494, 'therapyName': 'Axitinib + Pembrolizumab'}]",Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas,04/01/2016,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02637375,Phase I,Withdrawn,University of Chicago ,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 745, 'therapyName': 'Ganetespib'}]",A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer,06/01/2016,[],yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 305, 'name': 'carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02637531,Phase I,Recruiting,"Infinity Pharmaceuticals, Inc. ","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3363, 'therapyName': 'IPI-549'}]","A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",01/06/2016,[],no
0,both,"[{'id': 8418, 'name': 'congenital fibrosarcoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3620, 'name': 'central nervous system cancer', 'source': 'DOID'}]",NCT02637687,Phase I,Recruiting,"Loxo Oncology, Inc. ","[{'id': 2650, 'therapyName': 'LOXO-101'}]",Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors,12/28/2015,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02638090,Phase Ib/II,Recruiting,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1077, 'therapyName': 'Vorinostat'}]",Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC),02/27/2016,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 4907, 'name': 'small intestine carcinoma', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT02638909,Phase II,Recruiting,"Criterium, Inc. ","[{'id': 789, 'therapyName': 'Ceritinib'}]",Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies,04/22/2016,"[{'molecularProfile': {'id': 18885, 'profileName': 'ALK act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02639026,Phase I,Recruiting,Abramson Cancer Center of the University of Pennsylvania,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers",12/31/2015,[],no
0,both,"[{'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}]",NCT02639065,Phase II,Recruiting,"Shadia Jalal, MD ","[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Study of Durvalumab (MEDI4736) in Esophageal Cancer,05/03/2016,[],no
0,both,"[{'id': 1788, 'name': 'peritoneal mesothelioma', 'source': 'DOID'}, {'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02639091,Phase I,Recruiting,Bayer,"[{'id': 4617, 'therapyName': 'Anetumab ravtansine + Cisplatin + Pemetrexed'}]",Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors,08/29/2016,[],no
0,both,"[{'id': 2513, 'name': 'basal cell carcinoma', 'source': 'DOID'}]",NCT02639117,Phase I,Recruiting,University of Arizona,"[{'id': 956, 'therapyName': 'Vismodegib'}]",Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas,04/14/2016,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02639182,Phase II,Recruiting,"Agensys, Inc. ","[{'id': 4220, 'therapyName': 'AGS-16C3F'}, {'id': 649, 'therapyName': 'Axitinib'}]",A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma,06/02/2016,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02639234,Phase II,Withdrawn,"Gradalis, Inc. ","[{'id': 3572, 'therapyName': 'FANG vaccine + Nivolumab'}]",Vigil + Nivolumab in Advanced Non-Small Cell Lung Cancer,05/06/2017,[],no
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 2129, 'name': 'atypical teratoid rhabdoid tumor', 'source': 'DOID'}, {'id': 5151, 'name': 'plexiform neurofibroma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3246, 'name': 'embryonal rhabdomyosarcoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 3193, 'name': 'peripheral nerve sheath neoplasm', 'source': 'DOID'}, {'id': 3672, 'name': 'rhabdoid cancer', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02639546,Phase I,Recruiting,Hoffmann-La Roche,"[{'id': 1004, 'therapyName': 'Cobimetinib'}]",iMATRIXcobi: Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Patients With Previously Treated Solid Tumors,04/26/2016,[],yes
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02639559,Phase II,Recruiting,Washington University School of Medicine ,"[{'id': 2849, 'therapyName': 'BKT140'}]",Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies,04/05/2016,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02639910,Phase II,Recruiting,MorphoSys AG,"[{'id': 5785, 'therapyName': 'MOR208 + Venetoclax'}, {'id': 5784, 'therapyName': 'Idelalisib + MOR208'}]",Study to Evaluate Efficacy and Safety of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS),05/26/2017,[],no
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02640209,Phase I,Recruiting,University of Pennsylvania ,"[{'id': 5999, 'therapyName': 'CART19 cells'}]",Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL),07/17/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02640508,Phase II,Recruiting,Virginia G. Kaklamani ,"[{'id': 3352, 'therapyName': 'Eribulin + Lenvatinib'}]",Eribulin and Lenvatinib in Advanced Solid Tumors,07/23/2016,[],no
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02640833,Phase I,Withdrawn,AbbVie ,"[{'id': 3624, 'therapyName': 'GDC-0199 + Duvelisib'}]","A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor",07/27/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02641093,Phase II,Recruiting,Trisha Wise-Draper,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma,01/07/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02642016,Phase I,Recruiting,"Kolltan Pharmaceuticals, Inc. ","[{'id': 4037, 'therapyName': 'CDX-0158'}]",A Study to Evaluate the Safety and Pharmacokinetics of KTN0158 in Adult Patients With Advanced Solid Tumors,04/29/2016,"[{'molecularProfile': {'id': 851, 'profileName': 'KIT positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02642042,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1264, 'therapyName': 'Docetaxel + Trametinib'}]",Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV Non-small Cell Lung Cancer,09/07/2017,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'required'}]",yes
0,female,[],NCT02642094,Phase I,Recruiting,The University of Texas Health Science Center at San Antonio ,[],Aging Mammary Stem Cells and Breast Cancer Prevention,10/08/2016,[],no
0,both,"[{'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}]",NCT02642809,Phase I,Recruiting, Washington University School of Medicine ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With Locally Delivered Radiation Therapy for the Initial Treatment of Metastatic Esophageal Cancers,06/10/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02642913,Phase Ib/II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 920, 'therapyName': 'Sorafenib'}]",Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients,12/31/2015,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02642939,Phase II,Recruiting,"Check, Jerome H., M.D., Ph.D.","[{'id': 2603, 'therapyName': 'Mifepristone'}]",Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer,12/31/2015,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02642965,Phase Ib/II,Recruiting,Children's Oncology Group ,"[{'id': 4391, 'therapyName': 'CPX-351 + Cytarabine + Filgrastim + Fludarabine '}]","Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia",05/13/2017,[],no
0,both,"[{'id': 263, 'name': 'kidney cancer', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 3965, 'name': 'Merkel cell carcinoma', 'source': 'DOID'}, {'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 60061, 'name': 'cutaneous T cell lymphoma', 'source': 'DOID'}]",NCT02643303,Phase Ib/II,Recruiting,Ludwig Institute for Cancer Research ,"[{'id': 3385, 'therapyName': 'MEDI4736 + poly ICLC '}, {'id': 1652, 'therapyName': 'Tremelimumab'}]","A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",04/26/2017,[],no
0,both,"[{'id': 8618, 'name': 'oral cavity cancer', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}]",NCT02643550,Phase Ib/II,Recruiting,Innate Pharma ,"[{'id': 3383, 'therapyName': 'Cetuximab + IPH2201'}]",Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,01/15/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02643667,Phase Ib/II,Recruiting,Lawrence Fong ,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Study of Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer,06/12/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02644122,Phase II,Recruiting,Ezra Cohen,"[{'id': 915, 'therapyName': 'SF1126'}]",SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes,01/03/2017,"[{'molecularProfile': {'id': 1209, 'profileName': 'AKT1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1213, 'profileName': 'PTEN mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02644369,Phase II,Recruiting,"University Health Network, Toronto ","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors,03/24/2016,[],yes
0,both,"[{'id': 1319, 'name': 'brain cancer', 'source': 'DOID'}, {'id': 3672, 'name': 'rhabdoid cancer', 'source': 'DOID'}, {'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}, {'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}, {'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02644460,Phase I,Recruiting,Cynthia Wetmore ,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors,02/11/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02644967,Phase Ib/II,Recruiting,"Idera Pharmaceuticals, Inc. ","[{'id': 4244, 'therapyName': 'IMO-2125 + Ipilimumab'}, {'id': 4245, 'therapyName': 'IMO-2125 + Pembrolizumab'}]",A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma,06/05/2016,[],no
0,both,"[{'id': 3744, 'name': 'cervical squamous cell carcinoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 363, 'name': 'uterine cancer', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}]",NCT02646319,Phase II,"Active, not recruiting",Mayo Clinic ,"[{'id': 3380, 'therapyName': 'Nab-Rapamycin'}]",Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations,09/21/2017,"[{'molecularProfile': {'id': 1246, 'profileName': 'STK11 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1209, 'profileName': 'AKT1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02646748,Phase I,Recruiting,Incyte Corporation ,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2406, 'therapyName': 'INCB039110'}]",Pembrolizumab Combined With INCB039110 and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors,02/06/2016,[],yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02648282,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 4473, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine + Pembrolizumab'}]","Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer",07/18/2016,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02648477,Phase II,Recruiting,City of Hope Medical Center ,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer,03/12/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 305, 'name': 'carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02648490,Phase I,Recruiting,"Henlix, Inc ","[{'id': 3939, 'therapyName': 'Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron'}, {'id': 3938, 'therapyName': 'HLX07'}]","An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers",02/08/2017,"[{'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT02648633,Phase I,Terminated,University of Virginia ,"[{'id': 4219, 'therapyName': 'Nivolumab + Valproic acid'}]",Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma,06/01/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02648711,Phase I,"Active, not recruiting",Cerulean Pharma Inc. ,"[{'id': 708, 'therapyName': 'CRLX101'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",Alternative Dosing for CRLX101 Alone and With Avastin in Advanced Solid Tumors,04/21/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02648724,Phase Ib/II,Recruiting,Symphogen A/S ,"[{'id': 4322, 'therapyName': 'SYM015'}]",Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies,06/19/2016,"[{'molecularProfile': {'id': 1629, 'profileName': 'MET amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3565, 'name': 'meningioma', 'source': 'DOID'}]",NCT02648997,Phase II,Recruiting,Dana-Farber Cancer Institute ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma,03/09/2016,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02649387,Phase II,Recruiting,Mayo Clinic,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy (MERIT),02/25/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02649530,Phase II,Withdrawn,University of Michigan Cancer Center ,"[{'id': 1937, 'therapyName': 'LGK974'}]","An Open Label, Non-randomized Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma",10/01/2016,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT02649673,Phase Ib/II,Recruiting,"SCRI Development Innovations, LLC ","[{'id': 3845, 'therapyName': 'LCL161 + Topotecan'}]",LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies,03/31/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02649686,Phase I,"Active, not recruiting",Canadian Cancer Trials Group,"[{'id': 4218, 'therapyName': 'MEDI4736 + Trastuzumab'}]",Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab,04/22/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02649764,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 3535, 'therapyName': 'Cytarabine + Fludarabine + Prexasertib'}]",LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS),05/07/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02649790,Phase Ib/II,Recruiting,Karyopharm Therapeutics Inc,"[{'id': 5687, 'therapyName': 'KPT-8602'}]","Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma",07/03/2017,[],no
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 3620, 'name': 'central nervous system cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02650401,Phase I,Recruiting,"Ignyta, Inc. ","[{'id': 1455, 'therapyName': 'Entrectinib'}]",Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors,01/14/2016,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 11085, 'profileName': 'ROS1 rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02650635,Phase I,"Active, not recruiting",Mayo Clinic ,"[{'id': 3413, 'therapyName': 'Cyclophosphamide + Pegfilgrastim + VTX-2337'}]","TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors",10/20/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02650713,Phase I,Recruiting,Hoffmann-La Roche ,"[{'id': 3412, 'therapyName': 'Atezolizumab + RO6958688 '}]","A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors",01/27/2016,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02650752,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 1399, 'therapyName': 'Lapatinib + Capecitabine'}]",Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases,01/15/2016,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02650804,Phase II,Recruiting,"Berg, LLC ","[{'id': 5759, 'therapyName': 'BPM 31510'}, {'id': 5842, 'therapyName': 'BPM 31510 + Gemcitabine'}]",BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients,06/02/2017,[],no
0,female,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02650999,Phase Ib/II,Recruiting,Abramson Cancer Center of the University of Pennsylvania ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas,02/19/2016,[],no
0,both,"[{'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}, {'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}, {'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT02651415,Phase II,"Active, not recruiting",British Columbia Cancer Agency,"[{'id': 3410, 'therapyName': 'Perindopril + Regorafenib'}]",Phase II Study of Perindopril and Regorafenib in mCRC,07/14/2017,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02651610,Phase II,Withdrawn,Peregrine Pharmaceuticals,"[{'id': 3545, 'therapyName': 'Bavituximab'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]",Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer,07/12/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02651662,Phase I,Recruiting,Regeneron Pharmaceuticals,"[{'id': 5656, 'therapyName': 'REGN2810'}, {'id': 6152, 'therapyName': 'REGN1979 + REGN2810'}]",Study of REGN2810 and REGN1979 in Patients With Lymphoma,09/01/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02651727,Phase I,Terminated,"Verastem, Inc. ","[{'id': 4342, 'therapyName': 'Gemcitabine + nab-paclitaxel + VS-4718'}]","Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects",02/08/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02652455,Phase I,Recruiting,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 2055, 'therapyName': 'Urelumab'}]","Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma",03/05/2016,[],no
0,both,[],NCT02652468,Phase I,Recruiting,"University of Wisconsin, Madison ",[],TCR-alpha/beta and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma,04/22/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02652871,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 3470, 'therapyName': 'Cytarabine + Idarubicin + LY2510924'}]","A Phase 1b, Open-label Study of LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia",05/12/2016,[],no
0,both,"[{'id': 3620, 'name': 'central nervous system cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02653196,Phase II,Terminated,Montefiore Medical Center,"[{'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1205, 'therapyName': 'Alemtuzumab'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 3948, 'therapyName': 'Cyclosporine + Mycophenolate mofetil + Tacrolimus'}]",A Multi-Institutional Phase II Feasibility Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors,08/18/2017,[],no
0,both,[],NCT02653612,Phase I,Recruiting,VA Office of Research and Development ,[],Intraoperative Imaging of Pulmonary Adenocarcinoma,01/14/2016,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02654119,Phase II,Recruiting,University of Nebraska ,"[{'id': 1898, 'therapyName': 'Cyclophosphamide + Paclitaxel + Trastuzumab '}]","Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery",06/18/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02654132,Phase II,"Active, not recruiting",Bristol-Myers Squibb,"[{'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}, {'id': 3343, 'therapyName': 'Elotuzumab'}]",Trial of Elotuzumab With or Without Pomalidomide and Low-dose Dexamethasone to Treat Refractory and Relapsed and Refractory Multiple Myeloma,05/16/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02654587,Phase III,"Active, not recruiting",OSE Immunotherapeutics ,"[{'id': 4327, 'therapyName': 'OSE 2101 '}, {'id': 4328, 'therapyName': 'Docetaxel + Pemetrexed'}]",Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC (ATALANTE 1),08/16/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02654639,Phase II,"Active, not recruiting",Georgetown University ,"[{'id': 3682, 'therapyName': 'Bevacizumab + trifluridine/tipiracil hydrochloride'}]",Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer,09/01/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02654990,Phase II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 1604, 'therapyName': 'Panobinostat + Bortezomib + Dexamethasone'}]",Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma,05/27/2016,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02655016,Phase III,Recruiting,"Tesaro, Inc. ","[{'id': 832, 'therapyName': 'Niraparib'}]",A Study of Niraparib Maintenance Treatment in Patients With HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy,04/14/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02655458,Phase I,Completed,Hearn Jay Cho ,"[{'id': 3430, 'therapyName': 'Elotuzumab + lenalidomide'}]",Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma,08/19/2017,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02655601,Phase Ib/II,Recruiting,"BioMimetix JV, LLC ","[{'id': 5841, 'therapyName': 'BMX-001 + Temozolomide'}, {'id': 1141, 'therapyName': 'Temozolomide'}]","Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001",06/02/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 263, 'name': 'kidney cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}]",NCT02655822,Phase I,Recruiting,"Corvus Pharmaceuticals, Inc. ","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 3571, 'therapyName': 'CPI-444 '}]",Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers,02/23/2016,[],yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02656303,Phase II,Recruiting,"TG Therapeutics, Inc. ","[{'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}]",An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304,02/04/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02656706,Phase II,Recruiting,howard safran ,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial,07/20/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02656849,Phase II,Withdrawn,Dana-Farber Cancer Institute,"[{'id': 663, 'therapyName': 'BAY1000394'}]","BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors",07/02/2016,[],yes
0,both,"[{'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}]",NCT02657005,Phase I,Recruiting,"Tokalas, Inc. ","[{'id': 4314, 'therapyName': 'TK216'}]",TK216 in Patients With Relapsed or Refractory Ewing Sarcoma,06/17/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02657343,Phase Ib/II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 790, 'therapyName': 'Ribociclib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 1402, 'therapyName': 'trastuzumab emtansine'}]","An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.",04/07/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT02657369,Phase II,Recruiting,Eisai Inc. ,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC),10/26/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02657434,Phase III,Recruiting,Hoffmann-La Roche,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer,01/21/2016,"[{'molecularProfile': {'id': 2446, 'profileName': 'ALK fusion'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT02657486,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 674, 'therapyName': 'BGJ398'}]",BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder,01/21/2016,"[{'molecularProfile': {'id': 1217, 'profileName': 'FGFR3 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14903, 'profileName': 'FGFR3 fusion'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3973, 'name': 'thyroid medullary carcinoma', 'source': 'DOID'}]",NCT02657551,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 890, 'therapyName': 'Regorafenib'}]",A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer,04/14/2016,[],no
0,both,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02657889,Phase Ib/II,Recruiting,"Tesaro, Inc. ","[{'id': 3935, 'therapyName': 'Niraparib + Pembrolizumab'}]",Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or Ovarian Cancer (KEYNOTE-162),04/15/2016,[],yes
0,female,"[{'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}]",NCT02657928,Phase II,Recruiting,Mayo Clinic ,"[{'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal or Endometrial Cancer",07/13/2016,"[{'molecularProfile': {'id': 2395, 'profileName': 'RB1 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02658019,Phase II,Recruiting,Lynn Feun ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma,05/03/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02658084,Phase Ib/II,Recruiting,University of Miami ,"[{'id': 3429, 'therapyName': 'Trastuzumab emtansine + Vinorelbine'}]",Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer,04/13/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02658097,Phase II,Recruiting,Case Comprehensive Cancer Center,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC",05/22/2017,[],no
0,both,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02658214,Phase I,Recruiting,AstraZeneca ,"[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors,04/08/2017,[],yes
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02658279,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype,01/27/2016,"[{'molecularProfile': {'id': 17286, 'profileName': 'MLH1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 17288, 'profileName': 'MSH6 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02658396,Phase I,Withdrawn,Dana-Farber Cancer Institute ,"[{'id': 3427, 'therapyName': 'Bortezomib + GO-203-2C'}]",GO-203-2C + Bortezomib For Relapsed Or Refractory MM,12/14/2016,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02658890,Phase Ib/II,Recruiting,Bristol-Myers Squibb ,"[{'id': 3569, 'therapyName': 'BMS-986205 + Nivolumab'}]","Safety, Tolerability, Pharmacokinetic/Pharmacodynamic and Preliminary Efficacy Study of BMS-986205 Administered in Combination With Nivolumab in Advanced Cancers",02/27/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02658929,Phase I,Recruiting,bluebird bio,"[{'id': 5278, 'therapyName': 'bb2121'}]",Study of bb2121 in Multiple Myeloma,02/13/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02659020,Phase Ib/II,Recruiting,Eli Lilly and Company ,"[{'id': 3269, 'therapyName': 'Olaratumab'}, {'id': 1439, 'therapyName': 'Gemcitabine + Docetaxel'}]",A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma,03/03/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02659059,Phase II,Recruiting,Bristol-Myers Squibb ,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab Plus Ipilimumab to Treat First Line Stage IV Non-Small Cell Lung Cancer (CheckMate568),04/15/2016,[],no
0,female,"[{'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT02659241,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 822, 'therapyName': 'MK-1775'}]",A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer,02/09/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02659514,Phase II,Recruiting,"Spectrum Pharmaceuticals, Inc ","[{'id': 1042, 'therapyName': 'poziotinib'}]",Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer,04/15/2016,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02659540,Phase I,Recruiting,Ludwig Institute for Cancer Research ,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma,08/11/2016,[],no
0,female,"[{'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT02661815,Phase I,"Active, not recruiting",Dana-Farber Cancer Institute,"[{'id': 3469, 'therapyName': 'ACY-1215 + Paclitaxel'}, {'id': 667, 'therapyName': 'Bevacizumab'}]","A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer",03/02/2017,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02662296,Phase II,Withdrawn,Fred Hutchinson Cancer Research Center ,"[{'id': 1023, 'therapyName': 'Idelalisib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]","Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant",09/29/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02663271,Phase II,Recruiting,University of Florida ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma,08/16/2016,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02663518,Phase I,Recruiting,Trillium Therapeutics Inc.,"[{'id': 5338, 'therapyName': 'TTI-621'}]",A Trial of TTI-621 for Patients With Hematologic Malignancies,03/01/2017,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02663908,Phase III,Recruiting,Ferring Pharmaceuticals ,"[{'id': 1814, 'therapyName': 'Degarelix'}, {'id': 795, 'therapyName': 'Leuprolide'}]",A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease,03/05/2016,[],no
0,both,"[{'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}]",NCT02664077,Phase III,Recruiting,NSABP Foundation Inc ,"[{'id': 890, 'therapyName': 'Regorafenib'}]",A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer (ARGO),06/11/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02664181,Phase II,Recruiting,Case Comprehensive Cancer Center,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 5910, 'therapyName': 'Decitabine + Nivolumab + Tetrahydrouridine'}]",Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer (PRECISE),08/26/2017,[],no
0,both,"[{'id': 4085, 'name': 'trophoblastic neoplasm', 'source': 'DOID'}]",NCT02664961,Phase II,Recruiting,Tracon Pharmaceuticals Inc. ,"[{'id': 1243, 'therapyName': 'Bevacizumab + TRC105'}]",Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN),11/13/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02665143,Phase Ib/II,Recruiting,Yale University ,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 831, 'therapyName': 'Nintedanib'}]",A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia,06/22/2016,[],no
0,both,"[{'id': 5517, 'name': 'stomach carcinoma', 'source': 'DOID'}, {'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 4905, 'name': 'pancreatic carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02665416,Phase I,Recruiting,Hoffmann-La Roche ,"[{'id': 3468, 'therapyName': 'RO5520985 + RO7009789'}]","Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors",02/18/2016,[],yes
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02665650,Phase I,Recruiting,Affimed GmbH ,"[{'id': 4390, 'therapyName': 'AFM13 + Pembrolizumab'}]",Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,06/27/2016,[],yes
0,female,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02666105,Phase II,Recruiting,"Masonic Cancer Center, University of Minnesota ","[{'id': 738, 'therapyName': 'Exemestane'}]",Exemestane in Post-Menopausal Women With NSCLC,08/17/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02666209,Phase I,No longer available,Dana-Farber Cancer Institute,"[{'id': 3556, 'therapyName': 'Bortezomib + Dexamethasone + Ulocuplumab'}, {'id': 3555, 'therapyName': 'Dexamethasone + lenalidomide + Ulocuplumab'}]",Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma,08/29/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02666950,Phase II,Recruiting,Mayo Clinic ,"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 712, 'therapyName': 'Cytarabine'}]",WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome,06/29/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02667587,Phase II,Recruiting,Bristol-Myers Squibb,"[{'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 3724, 'therapyName': 'Nivolumab + Temozolomide'}]","Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer).",04/09/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02667873,Phase I,Recruiting,"Stemline Therapeutics, Inc. ","[{'id': 6223, 'therapyName': 'SL-801'}]",A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors,09/25/2017,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT02667886,Phase Ib/II,Recruiting,X4 Pharmaceuticals ,"[{'id': 649, 'therapyName': 'Axitinib'}, {'id': 3570, 'therapyName': 'X4P-001'}]",Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma,02/19/2016,[],no
0,,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02668653,Phase III,Recruiting,Daiichi Sankyo Inc. ,"[{'id': 3543, 'therapyName': 'Cytarabine + Daunorubicin + Idarubicin'}, {'id': 882, 'therapyName': 'Quizartinib'}]",Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) AML,10/20/2016,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02668666,Phase II,Recruiting,"Oana Danciu, MD ","[{'id': 3542, 'therapyName': 'Palbociclib + Tamoxifen'}]",Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer,07/08/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02668770,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 5741, 'therapyName': 'Ipilumumab + Lefitolimod'}]",Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies,05/22/2017,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02669173,Phase I,Recruiting,Case Comprehensive Cancer Center ,"[{'id': 2097, 'therapyName': 'Bevacizumab + Capecitabine'}]",Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma,04/29/2016,[],no
0,both,"[{'id': 3234, 'name': 'central nervous system lymphoma', 'source': 'DOID'}]",NCT02669511,Phase II,Recruiting,PIQUR Therapeutics AG ,"[{'id': 2019, 'therapyName': 'PQR309'}]",PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma,06/19/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02669914,Phase II,Recruiting,Washington University School of Medicine,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors,09/16/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02670044,Phase Ib/II,Recruiting,Hoffmann-La Roche,"[{'id': 4171, 'therapyName': 'Cobimetinib + Venetoclax'}, {'id': 4172, 'therapyName': 'RO5503781 + Venetoclax'}]",A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy,05/27/2016,[],no
0,both,"[{'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02671955,Phase I,Terminated,"Janssen Research & Development, LLC ","[{'id': 3614, 'therapyName': 'JNJ-61610588 '}]","A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer",08/26/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02672475,Phase I,Recruiting,Vanderbilt-Ingram Cancer Center ,"[{'id': 3541, 'therapyName': 'Galunisertib + Paclitaxel'}]",Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer,04/08/2016,[],yes
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT02672917,Phase I,Recruiting,"MabVax Therapeutics, Inc.","[{'id': 5712, 'therapyName': 'MVT-5873'}]",Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies,05/26/2017,[],no
0,both,"[{'id': 660, 'name': 'adrenal cortex cancer', 'source': 'DOID'}]",NCT02673333,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma,02/17/2016,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02673398,Phase II,Recruiting,City of Hope Medical Center ,"[{'id': 828, 'therapyName': 'Neratinib'}]",Neratinib in Treating Older Patients With Locally Advanced or Metastatic HER2-Positive Breast Cancer,11/02/2016,"[{'molecularProfile': {'id': 18585, 'profileName': 'ERBB2 L755_E757del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3128, 'profileName': 'ERBB2 D769H'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3960, 'profileName': 'ERBB2 G776V'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 18584, 'profileName': 'ERBB2 L869R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 18583, 'profileName': 'ERBB2 E757A'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 17958, 'profileName': 'ERBB2 L841V'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3234, 'profileName': 'ERBB2 V777L'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3151, 'profileName': 'ERBB2 L755S'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3278, 'profileName': 'ERBB2 G778_P780dup'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3148, 'profileName': 'ERBB2 Y772_A775dup'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1243, 'profileName': 'ERBB2 act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 314, 'name': 'tenosynovial giant cell tumor', 'source': 'DOID'}]",NCT02673736,Phase I,"Active, not recruiting",Plexxikon ,"[{'id': 4332, 'therapyName': 'PLX73086'}]",A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor,08/05/2017,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT02674061,Phase II,"Active, not recruiting",Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100),09/03/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02674555,Phase I,Withdrawn,"Astellas Pharma Global Development, Inc.","[{'id': 1082, 'therapyName': 'ASP8273'}]","A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors",07/29/2017,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02674568,Phase II,"Active, not recruiting",Stemcentrx ,"[{'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY),06/20/2017,[],yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02674750,Phase II,Recruiting,"Curis, Inc. ","[{'id': 4447, 'therapyName': 'CUDC-907 + Rituximab'}, {'id': 709, 'therapyName': 'CUDC-907'}]",Study to Evaluate the Efficacy and Safety of CUDC-907 With and Without Rituximab in Patients With RR MYC-Altered DLBCL,07/14/2016,[],yes
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02675231,Phase II,Recruiting,Eli Lilly and Company ,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 744, 'therapyName': 'Fulvestrant'}]","A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer",05/28/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 1324, 'name': 'lung cancer', 'source': 'DOID'}, {'id': 3996, 'name': 'urinary system cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02675829,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers,06/29/2017,"[{'molecularProfile': {'id': 3284, 'profileName': 'ERBB2 S310F'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 11379, 'profileName': 'ERBB2 V659E'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3278, 'profileName': 'ERBB2 G778_P780dup'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 24125, 'profileName': 'ERBB2 G776delinsVC'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3148, 'profileName': 'ERBB2 Y772_A775dup'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1243, 'profileName': 'ERBB2 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3234, 'profileName': 'ERBB2 V777L'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3151, 'profileName': 'ERBB2 L755S'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 27295, 'profileName': 'ERBB2 L755A'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02676323,Phase Ib/II,Recruiting,St. Jude Children's Research Hospital ,"[{'id': 3732, 'therapyName': 'Cytarabine + Fludarabine + Leucovorin + Panobinostat'}]",Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome,03/11/2016,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}]",NCT02676986,Phase II,Recruiting,Queen Mary University of London,"[{'id': 6183, 'therapyName': 'Enzalutamide + Exemestane'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB)",09/11/2017,[],yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02677038,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 837, 'therapyName': 'Olaparib'}]",Ph II Olaparib for BRCAness Phenotype in Pancreatic Cancer,10/03/2017,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2075, 'profileName': 'BRCA1 negative'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2076, 'profileName': 'BRCA2 negative'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3620, 'name': 'central nervous system cancer', 'source': 'DOID'}]",NCT02677116,Phase I,Recruiting,Eli Lilly and Company ,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 3618, 'therapyName': 'Irinotecan + Vincristine'}, {'id': 3269, 'therapyName': 'Olaratumab'}]",A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer,09/02/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02677896,Phase III,Recruiting,"Astellas Pharma Global Development, Inc. ","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC),07/27/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 2226, 'name': 'myeloproliferative neoplasm', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02677922,Phase Ib/II,Recruiting,Celgene Corporation ,"[{'id': 4002, 'therapyName': 'AG-120 + Azacitidine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}]",A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML),04/22/2016,"[{'molecularProfile': {'id': 5912, 'profileName': 'IDH2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 22039, 'profileName': 'IDH2 R172X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 10006, 'profileName': 'IDH1 R132X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 22038, 'profileName': 'IDH2 R140X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1781, 'profileName': 'IDH1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02677948,Phase Ib/II,Withdrawn,University of Michigan Cancer Center ,"[{'id': 3623, 'therapyName': 'Ibrutinib + Pacritinib'}]",Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),09/07/2017,[],no
0,both,[],NCT02678572,Phase III,Recruiting,Delcath Systems Inc. ,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma,02/25/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02679131,Phase I,Recruiting,"Spectrum Pharmaceuticals, Inc ","[{'id': 1078, 'therapyName': 'Belinostat'}]","To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.",04/22/2016,[],no
0,both,"[{'id': 8923, 'name': 'skin melanoma', 'source': 'DOID'}]",NCT02680184,Phase I,Recruiting,Checkmate Pharmaceuticals ,"[{'id': 4001, 'therapyName': 'Pembrolizumab + QbG10'}]",Clinical Study of CMP-001 in Combination With Pembrolizumab,10/22/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02680795,Phase I,Recruiting,"Spectrum Pharmaceuticals, Inc ","[{'id': 1078, 'therapyName': 'Belinostat'}]","To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes",04/22/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02680951,Phase I,Recruiting,Emory University ,"[{'id': 3731, 'therapyName': 'Cytarabine + Dasatinib + Fludarabine  + Idarubicin'}]",Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia,03/31/2016,[],no
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02681237,Phase I,Recruiting,"University Health Network, Toronto","[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer,03/17/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 70004, 'name': 'myeloid neoplasm', 'source': 'DOID'}]",NCT02681302,Phase Ib/II,Recruiting,Hackensack University Medical Center ,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence (CPIT001),09/21/2016,"[{'molecularProfile': {'id': 17613, 'profileName': 'TP53 del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02681549,Phase II,Recruiting,Yale University ,"[{'id': 2119, 'therapyName': 'Bevacizumab + Pembrolizumab'}]",Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer,10/02/2016,[],yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02684006,Phase III,Recruiting,Pfizer ,"[{'id': 3145, 'therapyName': 'Avelumab + Axitinib'}, {'id': 930, 'therapyName': 'Sunitinib'}]",A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101),04/15/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02684032,Phase I,Recruiting,Pfizer,"[{'id': 794, 'therapyName': 'Letrozole'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 4034, 'therapyName': 'Gedatolisib + Palbociclib'}]",A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer,12/15/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02684162,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1949, 'therapyName': 'SGI-110'}]",SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT),06/25/2016,[],no
0,female,"[{'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}]",NCT02684227,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 3681, 'therapyName': 'Carboplatin + Enzalutamide + Paclitaxel'}]",Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer,09/02/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02684253,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)",03/06/2016,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02684292,Phase III,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204),06/26/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02684461,Phase II,Recruiting,UNC Lineberger Comprehensive Cancer Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel,09/25/2016,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 4138, 'profileName': 'EML4-ALK'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02684617,Phase I,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 4225, 'therapyName': 'Dinaciclib + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies  (MK-3475-155) (KEYNOTE-155),06/02/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02685267,Phase II,"Active, not recruiting",Prostate Cancer Clinical Trials Consortium ,"[{'id': 4681, 'therapyName': 'Docetaxel + Enzalutamide + Prednisone'}, {'id': 2462, 'therapyName': 'Docetaxel + Prednisone'}]",Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (Doce/Enza),09/16/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02685397,Phase II,Recruiting,Sir Mortimer B. Davis - Jewish General Hospital ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 759, 'therapyName': 'Goserelin'}, {'id': 795, 'therapyName': 'Leuprolide'}]",Management of Castration-Resistant Prostate Cancer With Oligometastases,02/08/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02685826,Phase I,Suspended,Celgene Corporation ,"[{'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3934, 'therapyName': 'lenalidomide + MEDI4736'}]",A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma,09/30/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02686164,Phase I,"Active, not recruiting",Eisai Inc. ,"[{'id': 3730, 'therapyName': 'Lenvatinib + Midazolam'}]",Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors,12/15/2016,[],no
0,both,"[{'id': 1984, 'name': 'rectal neoplasm', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}]",NCT02687009,Phase I,Recruiting,"Michael Morse, MD ","[{'id': 3072, 'therapyName': 'Niclosamide'}]",A Study of Niclosamide in Patients With Resectable Colon Cancer,04/28/2017,[],no
0,both,[],NCT02687230,Phase I,Recruiting,"MabVax Therapeutics, Inc.",[],Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1,05/26/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02688088,Phase I,Recruiting,Eli Lilly and Company ,"[{'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 3729, 'therapyName': 'Caffeine + Dextromethorphan + Midazolam + Warfarin'}]",A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body,03/31/2016,[],no
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT02688608,Phase II,Recruiting,University of Texas Southwestern Medical Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer,10/27/2016,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT02688712,Phase II,Recruiting,Providence Health & Services,"[{'id': 5788, 'therapyName': 'Capecitabine + Galunisertib'}, {'id': 5789, 'therapyName': 'Fluorouracil + Galunisertib'}, {'id': 2409, 'therapyName': 'Galunisertib'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer,05/26/2017,[],no
0,both,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT02689284,Phase Ib/II,Recruiting,MacroGenics ,"[{'id': 3728, 'therapyName': 'MGAH22 + Pembrolizumab'}]","Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer",03/31/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02689336,Phase II,Recruiting,Washington University School of Medicine ,"[{'id': 3726, 'therapyName': 'Erlotinib + Temozolomide'}]",Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors,08/16/2016,"[{'molecularProfile': {'id': 1216, 'profileName': 'ERBB2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 591, 'profileName': 'JAK2 V617F'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02689427,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 3725, 'therapyName': 'Enzalutamide + Paclitaxel'}]",Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC),09/24/2016,[],yes
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02689440,FDA approved,Recruiting,M.D. Anderson Cancer Center,"[{'id': 717, 'therapyName': 'Dasatinib'}]",Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib,04/22/2016,[],yes
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02689921,Phase II,Recruiting,Midwestern Regional Medical Center ,"[{'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 738, 'therapyName': 'Exemestane'}]",NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT),10/30/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT02690558,Phase II,Recruiting,UNC Lineberger Comprehensive Cancer Center,"[{'id': 3248, 'therapyName': 'Cisplatin + Gemcitabine + Pembrolizumab'}]",Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy,05/26/2017,[],no
0,both,"[{'id': 2513, 'name': 'basal cell carcinoma', 'source': 'DOID'}]",NCT02690948,Phase II,Recruiting,Anne Chang ,"[{'id': 3727, 'therapyName': 'Pembrolizumab + Vismodegib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer,03/11/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02692755,Phase II,Recruiting,Georgetown University,"[{'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]",Palbociclib / Letrozole in African American Women With HR+ HER2- Breast Cancer (PALINA),07/18/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02693535,Phase II,Recruiting,American Society of Clinical Oncology ,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 690, 'therapyName': 'Bosutinib'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 694, 'therapyName': 'Cetuximab'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 4, 'therapyName': 'Erlotinib'}]",TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer,12/19/2016,"[{'molecularProfile': {'id': 3287, 'profileName': 'BRAF fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1214, 'profileName': 'KIT mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3601, 'profileName': 'KDR amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 13844, 'profileName': 'MET mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2346, 'profileName': 'KDR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3274, 'profileName': 'ATM mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 17614, 'profileName': 'ATM del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1806, 'profileName': 'CDKN2A loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1228, 'profileName': 'CSF1R mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1676, 'profileName': 'ROS1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 481, 'profileName': 'NRAS wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1282, 'profileName': 'BRCA1 inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 20513, 'profileName': 'SRC mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1215, 'profileName': 'PDGFRA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 20512, 'profileName': 'KDR over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1283, 'profileName': 'BRCA2 inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 4, 'profileName': 'BRAF wild-type'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 60074, 'name': 'ductal carcinoma in situ', 'source': 'DOID'}]",NCT02694809,Phase II,Recruiting,Northwestern University ,"[{'id': 5928, 'therapyName': 'Conjugated estrogens/bazedoxifene'}]",Conjugated Estrogens/Bazedoxifene in Treating Patients With Ductal Carcinoma in Situ Undergoing Surgery,06/26/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02694822,Phase I,Recruiting,Agenus Inc.,"[{'id': 5695, 'therapyName': 'AGEN1884'}]","AGEN-1884, an Anti-CTLA-4 Antibody, in Advanced Solid Cancers",05/26/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02695290,Phase III,Terminated,Boehringer Ingelheim ,"[{'id': 623, 'therapyName': 'Afatinib'}]",Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3),07/03/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02696993,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}]",Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-small Cell Lung Cancer,12/21/2016,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 2870, 'name': 'endometrial adenocarcinoma', 'source': 'DOID'}]",NCT02697591,Phase Ib/II,Recruiting,Incyte Corporation ,"[{'id': 4321, 'therapyName': 'INCAGN01876'}]","An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors",06/22/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 60463, 'name': 'NUT midline carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02698176,Phase I,Terminated,Merck Sharp & Dohme Corp.,"[{'id': 2034, 'therapyName': 'OTX015'}]",A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006),05/25/2017,[],yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02698189,Phase I,"Active, not recruiting",Merck Sharp & Dohme Corp.,"[{'id': 2034, 'therapyName': 'OTX015'}]",A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005),02/08/2017,[],no
0,both,"[{'id': 2513, 'name': 'basal cell carcinoma', 'source': 'DOID'}]",NCT02699723,Phase I,Not yet recruiting,Jean Yuh Tang ,"[{'id': 3791, 'therapyName': 'Arsenic trioxide + Itraconazole'}]",Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer,03/20/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 8584, 'name': 'Burkitt lymphoma', 'source': 'DOID'}]",NCT02700022,Phase I,"Active, not recruiting",UNC Lineberger Comprehensive Cancer Center ,"[{'id': 626, 'therapyName': 'Alisertib'}, {'id': 3395, 'therapyName': 'R-EPOCH'}]",A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas,07/15/2017,[],yes
0,,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02700841,Phase II,Recruiting,Emory University ,"[{'id': 5344, 'therapyName': 'Melphalan + PVX-410'}]",Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation,02/20/2017,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02701400,Phase II,Recruiting,Emory University ,"[{'id': 3840, 'therapyName': 'MEDI0562 + Tremelimumab'}]",Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer,04/19/2016,[],no
0,both,"[{'id': 8584, 'name': 'Burkitt lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02701673,Phase Ib/II,Withdrawn,M.D. Anderson Cancer Center,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1078, 'therapyName': 'Belinostat'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1207, 'therapyName': 'Melphalan'}]",Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma,05/05/2016,[],no
0,both,"[{'id': 3969, 'name': 'papillary thyroid carcinoma', 'source': 'DOID'}, {'id': 3962, 'name': 'follicular thyroid carcinoma', 'source': 'DOID'}]",NCT02702388,Phase II,Recruiting,Eisai Inc. ,"[{'id': 792, 'therapyName': 'Lenvatinib'}]","Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 20 mg or 14 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile",05/19/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02702401,Phase II,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240),06/27/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02702414,Phase II,"Active, not recruiting",Merck Sharp & Dohme Corp.,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224),02/10/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02702492,Phase I,Recruiting,"Karyopharm Therapeutics, Inc ","[{'id': 4662, 'therapyName': 'KPT-9274'}, {'id': 4688, 'therapyName': 'KPT-9274 + Niacin'}]",PAK4 and NAMPT in Patients With Solid MAlignancies or NHL (PANAMA) (PANAMA),09/12/2016,[],no
0,both,[],NCT02702960,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,[],"Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)",05/19/2016,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02703272,Phase III,Recruiting,"Janssen Research & Development, LLC ","[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 4307, 'therapyName': 'Carboplatin + Dexamethasone + Etoposide + Ifosfamide + Rituximab'}, {'id': 4308, 'therapyName': 'Carboplatin + Dexamethasone + Idarubicin + Ifosfamide + Rituximab + Vincristine'}]",A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma,07/19/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02703571,Phase Ib/II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 4472, 'therapyName': 'Ribociclib + Trametinib'}]",Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors,07/18/2016,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02703623,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 3844, 'therapyName': 'Cabazitaxel + Carboplatin'}]",A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO),05/21/2016,[],no
0,both,"[{'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}]",NCT02703714,Phase II,Recruiting,Robin Kate Kelley ,"[{'id': 4217, 'therapyName': 'Pembrolizumab + Sargramostim'}]",Pembrolizumab and GM-CSF in Biliary Cancer,06/02/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02703779,Phase II,Recruiting,University of Kansas Medical Center ,"[{'id': 688, 'therapyName': 'Bortezomib'}, {'id': 3933, 'therapyName': 'Filgrastim + Plerixafor'}]",Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM),04/15/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02705105,Phase Ib/II,Recruiting,"Kyowa Hakko Kirin Pharma, Inc. ","[{'id': 3843, 'therapyName': 'Mogamulizumab + Nivolumab'}]",Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors,03/25/2016,[],no
0,both,"[{'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}]",NCT02705339,Phase II,Withdrawn,Washington University School of Medicine ,"[{'id': 1003, 'therapyName': 'CO1686'}]",Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC),05/19/2016,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02705469,Phase I,"Active, not recruiting",Zenith Epigenetics Corp.,"[{'id': 4032, 'therapyName': 'ZEN003694'}]",A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer,08/15/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02705482,Phase I,Recruiting,MedImmune LLC ,"[{'id': 3840, 'therapyName': 'MEDI0562 + Tremelimumab'}, {'id': 3839, 'therapyName': 'MEDI0562 + MEDI4736'}]",A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors,04/16/2016,[],no
0,female,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02705963,Phase I,Recruiting,Novartis Pharmaceuticals ,"[{'id': 2, 'therapyName': 'Trametinib'}]",A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors,09/25/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02706353,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 3836, 'therapyName': 'APX005M + Pembrolizumab'}]",APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma,06/09/2017,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02706405,Phase I,Recruiting,Fred Hutchinson Cancer Research Center ,"[{'id': 4365, 'therapyName': 'Cyclophosphamide + JCAR014 + MEDI4736'}]",JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma,12/15/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02706626,Phase II,Recruiting,"Criterium, Inc. ","[{'id': 634, 'therapyName': 'AP26113'}]",Trial of Brigatinib After Treatment With Second-Generation ALK Inhibitors,03/27/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02706691,Phase II,Not yet recruiting,University of Chicago ,"[{'id': 674, 'therapyName': 'BGJ398'}]","Pan FGFR Kinase Inhibitor BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer",04/19/2017,"[{'molecularProfile': {'id': 3147, 'profileName': 'FGFR2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 812, 'profileName': 'FGFR1 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1276, 'profileName': 'FGFR1 rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1221, 'profileName': 'FGFR1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1317, 'profileName': 'FGFR2 rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1318, 'profileName': 'FGFR3 rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1185, 'profileName': 'FGFR2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3329, 'profileName': 'FGFR3 amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT02707666,Phase I,Recruiting,University of Chicago ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}]",A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma,06/21/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02708641,Phase II,Recruiting,Michael Boyiadzis ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients 60 With AML,07/03/2017,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02708680,Phase Ib/II,Recruiting,Syndax Pharmaceuticals,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5129, 'therapyName': 'Entinostat + Atezolizumab'}]",Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In,12/27/2016,[],yes
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02709083,Phase II,Recruiting,Emory University ,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 770, 'therapyName': 'Imatinib'}]","Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia",10/22/2016,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02709889,Phase Ib/II,Recruiting,Stemcentrx ,"[{'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors,09/12/2016,[],yes
0,both,"[{'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 3748, 'name': 'esophagus squamous cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02710396,Phase II,Recruiting,Columbia University ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Genetic Predictors of Benefit to Pembrolizumab,04/15/2016,"[{'molecularProfile': {'id': 343, 'profileName': 'EGFR wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 391, 'profileName': 'ALK wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02711137,Phase Ib/II,Recruiting,Incyte Corporation ,"[{'id': 4319, 'therapyName': 'INCB057643 '}]","A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies",06/19/2016,[],no
0,both,"[{'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}, {'id': 3502, 'name': 'ampulla of Vater adenocarcinoma', 'source': 'DOID'}, {'id': 3121, 'name': 'gallbladder cancer', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT02711553,Phase II,"Active, not recruiting",Eli Lilly and Company,"[{'id': 886, 'therapyName': 'Ramucirumab'}, {'id': 1030, 'therapyName': 'LY2801653'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}]",A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer,08/17/2017,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02711956,Phase I,Recruiting,Zenith Epigenetics Corp. ,"[{'id': 4033, 'therapyName': 'Enzalutamide + ZEN003694'}]",A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer,12/07/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02712723,Phase II,Recruiting,Qamar Khan ,"[{'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]","Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer",04/15/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02712905,Phase Ib/II,Recruiting,Incyte Corporation,"[{'id': 5464, 'therapyName': 'INCB059872'}]","An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies",03/29/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02713373,Phase Ib/II,Recruiting,Roswell Park Cancer Institute ,"[{'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery,08/18/2016,"[{'molecularProfile': {'id': 481, 'profileName': 'NRAS wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT02713386,Phase Ib/II,Recruiting,NRG Oncology ,"[{'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]","Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",10/27/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT02713529,Phase Ib/II,Recruiting,Amgen ,"[{'id': 4170, 'therapyName': 'AMG820 + Pembrolizumab'}]",Safety Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer,05/27/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02713828,Phase Ib/II,Recruiting,"PrECOG, LLC. ","[{'id': 3597, 'therapyName': 'Glembatumumab vedotin'}]","Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung",04/29/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02713867,Phase III,Recruiting,Bristol-Myers Squibb ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks (CheckMate 384)",04/28/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02714218,Phase III,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma",02/08/2017,[],no
0,,[],NCT02715284,,Recruiting,,"[{'id': 6320, 'therapyName': 'TSR-042'}]","A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors",10/19/2017,[],
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT02715531,Phase I,Recruiting,Hoffmann-La Roche,"[{'id': 3947, 'therapyName': 'Atezolizumab + Gemcitabine + nab-paclitaxel'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",A Study of the Safety and Tolerability of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors,04/15/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02716038,Phase II,Recruiting,Columbia University ,"[{'id': 3946, 'therapyName': 'Atezolizumab + Carboplatin + nab-Paclitaxel'}]","Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC",06/30/2016,[],no
0,both,[],NCT02716077,Phase I,Recruiting,Abramson Cancer Center of the University of Pennsylvania,[],Early FDG PET in Melanoma,05/26/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02716116,Phase Ib/II,Recruiting,Ariad Pharmaceuticals ,"[{'id': 3981, 'therapyName': 'AP32788'}]",A Trial of AP32788 in Non-Small Cell Lung Cancer,06/03/2016,"[{'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 22000, 'profileName': 'ERBB2 exon 20 ins'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 4039, 'profileName': 'EGFR exon 20 ins'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1243, 'profileName': 'ERBB2 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02716805,Phase I,"Active, not recruiting",Ludwig Institute for Cancer Research,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Phase 1 Study to Assess Safety & Tolerability of Tremelimumab & Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant",09/06/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02716948,Phase I,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Stereotactic Radiosurgery and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine,04/15/2016,[],no
0,both,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02716974,Phase I,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 3945, 'therapyName': 'Bicalutamide + Docetaxel + Leuprolide'}]",A Study of Definitive Therapy to Treat Prostate Cancer,10/04/2016,[],no
0,both,"[{'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}]",NCT02717156,Phase II,Recruiting,University of Southern California,"[{'id': 3944, 'therapyName': 'sEphB4-HSA + Pembrolizumab'}]",Recombinant EphB4-HSA Fusion Protein and Pembrolizumab in Treating Patients With Metastatic or Recurrent Urothelial Cancer That Is Refractory to Certain Chemotherapy Drugs,03/25/2017,[],no
0,both,"[{'id': 4202, 'name': 'brain stem glioma', 'source': 'DOID'}]",NCT02717455,Phase I,Recruiting,Pediatric Brain Tumor Consortium ,"[{'id': 1080, 'therapyName': 'Panobinostat'}]",Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma,06/19/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02717611,Phase II,"Active, not recruiting",Acerta Pharma BV ,"[{'id': 1605, 'therapyName': 'Acalabrutinib'}]",A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy,08/15/2017,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02717624,Phase I,"Active, not recruiting",Acerta Pharma BV ,"[{'id': 3996, 'therapyName': 'Acalabrutinib + Bendamustine + Rituximab'}]",A Study of ACP-196 in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma,04/18/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02718066,Phase Ib/II,Recruiting,HUYA Bioscience International ,"[{'id': 4689, 'therapyName': 'Chidamide + Nivolumab'}]","Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer",09/12/2016,[],no
0,both,"[{'id': 4971, 'name': 'myelofibrosis', 'source': 'DOID'}]",NCT02718300,Phase II,Recruiting,Incyte Corporation ,"[{'id': 4224, 'therapyName': 'INCB050465 + Ruxolitinib'}]",A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis,10/01/2016,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT02718417,Phase III,Recruiting,Pfizer,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100),06/03/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02718833,Phase II,Recruiting,Massachusetts General Hospital ,"[{'id': 4031, 'therapyName': 'Bortezomib + Dexamethasone + Elotuzumab + Panobinostat'}]","A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma",06/22/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02718911,Phase I,Recruiting,Eli Lilly and Company,"[{'id': 4216, 'therapyName': 'LY3022855 + Tremelimumab'}, {'id': 4215, 'therapyName': 'LY3022855 + MEDI4736'}]",A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors,07/14/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02719015,Phase Ib/II,Not yet recruiting,M.D. Anderson Cancer Center ,"[{'id': 3943, 'therapyName': 'Pembrolizumab + rAd.CD40L'}]",Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma,04/15/2016,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02719574,Phase I,Recruiting,"Forma Therapeutics, Inc. ","[{'id': 4336, 'therapyName': 'FT-2102'}, {'id': 4449, 'therapyName': 'FT-2102 + Azacitidine'}]",Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With AML or MDS With an IDH1 Mutation,07/14/2016,"[{'molecularProfile': {'id': 10006, 'profileName': 'IDH1 R132X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02719613,Phase II,Recruiting,Bristol-Myers Squibb ,"[{'id': 4533, 'therapyName': 'Bortezomib + Elotuzumab + Dexamethasone + lenalidomide'}]",Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab,08/07/2016,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02719691,Phase I,Recruiting,"University of Colorado, Denver ","[{'id': 4214, 'therapyName': 'Alisertib + MLN0128'}]",Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,06/02/2016,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02720068,Phase I,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 4213, 'therapyName': 'MK-4280 + Pembrolizumab'}, {'id': 4212, 'therapyName': 'MK-4280'}]",Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-4280-001),06/02/2016,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02720185,Phase II,Recruiting,"University of Wisconsin, Madison ","[{'id': 717, 'therapyName': 'Dasatinib'}]",The Window of Opportunity of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR,08/04/2016,"[{'molecularProfile': {'id': 1102, 'profileName': 'EGFR positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3948, 'name': 'adrenocortical carcinoma', 'source': 'DOID'}]",NCT02720484,Phase II,"Active, not recruiting",Northwestern University ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer,05/31/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02720510,Phase II,Recruiting,Novartis Pharmaceuticals,"[{'id': 1080, 'therapyName': 'Panobinostat'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)",09/12/2016,[],no
0,both,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02721433,FDA approved,Recruiting,Ottawa Hospital Research Institute ,"[{'id': 4784, 'therapyName': 'Denosumab + pamidronate + Zoledronic acid'}]",4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases (REaCT-BTA),10/04/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02721459,Phase I,Recruiting,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 3995, 'therapyName': 'Cobimetinib + XL888 + Vemurafenib'}]",XL888 + Vemurafenib + Cobimetinib for Unresectable B Rapidly Accelerated Fibrosarcoma (BRAF) Mutated Stage III/IV Melanoma,08/13/2016,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3948, 'name': 'adrenocortical carcinoma', 'source': 'DOID'}, {'id': 11615, 'name': 'penile cancer', 'source': 'DOID'}, {'id': 3275, 'name': 'thymoma', 'source': 'DOID'}, {'id': 305, 'name': 'carcinoma', 'source': 'DOID'}, {'id': 3151, 'name': 'skin squamous cell carcinoma', 'source': 'DOID'}, {'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 5719, 'name': 'adrenal medulla cancer', 'source': 'DOID'}, {'id': 2998, 'name': 'testicular cancer', 'source': 'DOID'}, {'id': 50773, 'name': 'paraganglioma', 'source': 'DOID'}]",NCT02721732,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors,08/18/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02721875,Phase I,Terminated,Boehringer Ingelheim ,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 957, 'therapyName': 'Volasertib'}]",Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes,12/22/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02721979,Phase II,Not yet recruiting,University of Washington ,"[{'id': 1947, 'therapyName': 'ARN-509'}]",ARN-509 in Treating Patients With Prostate Cancer Who Are in Active Surveillance,06/28/2017,[],no
0,both,"[{'id': 1035, 'name': 'natural killer cell leukemia', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 8584, 'name': 'Burkitt lymphoma', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 12603, 'name': 'acute leukemia', 'source': 'DOID'}, {'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 50744, 'name': 'anaplastic large cell lymphoma', 'source': 'DOID'}, {'id': 2226, 'name': 'myeloproliferative neoplasm', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}, {'id': 1039, 'name': 'prolymphocytic leukemia', 'source': 'DOID'}]",NCT02722668,Phase II,Recruiting,"Masonic Cancer Center, University of Minnesota ","[{'id': 2281, 'therapyName': 'Cyclophosphamide + Fludarabine + Mycophenolate mofetil'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}]",UCB Transplant for Hematological DIseases Using a Non Myeloablative Prep,05/19/2017,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02722941,Phase II,Recruiting,H. Lee Moffitt Cancer Center and Research Institute,"[{'id': 1080, 'therapyName': 'Panobinostat'}]",Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT),06/14/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02722954,Phase I,"Active, not recruiting","OncoMed Pharmaceuticals, Inc. ","[{'id': 3994, 'therapyName': 'Demcizumab + Pembrolizumab'}]",A Study of Demcizumab Plus Pembrolizumab +/- Chemotherapy,04/15/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02723006,Phase I,Recruiting,"Millennium Pharmaceuticals, Inc. ","[{'id': 4198, 'therapyName': 'MLN2480 + Nivolumab'}, {'id': 4200, 'therapyName': 'MLN1202 + Nivolumab'}, {'id': 4202, 'therapyName': 'Ipilimumab + Nivolumab + Vedolizumab '}]","Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma",06/03/2016,"[{'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02723435,Phase II,Not yet recruiting,Stanford University ,"[{'id': 810, 'therapyName': 'Midostaurin'}]",Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant,04/22/2016,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02723864,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 3993, 'therapyName': 'Cisplatin + Veliparib + VX-970'}]","Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors",04/22/2016,[],no
0,both,"[{'id': 4007, 'name': 'bladder carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 1749, 'name': 'squamous cell carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 1542, 'name': 'head and neck carcinoma', 'source': 'DOID'}, {'id': 1107, 'name': 'esophageal carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}, {'id': 1520, 'name': 'colon carcinoma', 'source': 'DOID'}, {'id': 2893, 'name': 'cervix carcinoma', 'source': 'DOID'}, {'id': 10286, 'name': 'prostate carcinoma', 'source': 'DOID'}]",NCT02723955,Phase I,Recruiting,GlaxoSmithKline ,"[{'id': 4409, 'therapyName': 'GSK3359609'}, {'id': 4410, 'therapyName': 'GSK3359609 + Pembrolizumab'}]",Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1),07/26/2016,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02723994,Phase II,Recruiting,Incyte Corporation ,"[{'id': 2188, 'therapyName': 'Prednisone'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 2346, 'therapyName': 'Mercaptopurine + Thioguanine'}, {'id': 2394, 'therapyName': 'Asparaginase + Cytarabine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 1848, 'therapyName': 'Cyclophosphamide + Methotrexate + Vincristine + Pegaspargase '}]",A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia,09/13/2016,"[{'molecularProfile': {'id': 26237, 'profileName': 'JAK2 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1181, 'profileName': 'JAK2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02724020,Phase II,Recruiting,"Millennium Pharmaceuticals, Inc. ","[{'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}, {'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 735, 'therapyName': 'Everolimus'}]",MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma,07/31/2016,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02724878,Phase II,Recruiting,Dana-Farber Cancer Institute ,"[{'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma,09/14/2016,[],no
0,female,"[{'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}]",NCT02725268,Phase II,Recruiting,"Millennium Pharmaceuticals, Inc. ","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1282, 'therapyName': 'Sapanisertib'}, {'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]","Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer",07/16/2016,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02725489,Phase II,Recruiting,Mary Crowley Medical Research Center ,"[{'id': 4388, 'therapyName': 'FANG vaccine + MEDI4736'}]",Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil in Advanced Breast Cancer,06/27/2016,[],yes
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02725541,Phase II,Withdrawn,The Methodist Hospital System ,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}]",Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer,06/25/2016,"[{'molecularProfile': {'id': 20976, 'profileName': 'ERBB2 dec exp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT02726399,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 3998, 'therapyName': 'Ramucirumab + Trastuzumab'}]",Ramucirumab With Trastuzumab and Capecitabine/Cisplatin in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer,04/22/2016,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02726581,Phase III,"Active, not recruiting",Bristol-Myers Squibb,"[{'id': 3343, 'therapyName': 'Elotuzumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 3792, 'therapyName': 'Dexamethasone + Pomalidomide'}]","Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma",09/07/2017,[],no
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT02726997,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]",Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer,07/12/2016,[],no
0,both,"[{'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02728050,Phase Ib/II,Recruiting,University of Washington ,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 4363, 'therapyName': 'Cladribine + Cytarabine + Filgrastim + Mitoxantrone'}]","Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome",12/15/2016,[],no
0,female,"[{'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}]",NCT02728258,Phase II,Suspended,NRG Oncology ,"[{'id': 995, 'therapyName': 'Copanlisib'}]",Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer,08/24/2017,"[{'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'required'}]",yes
0,both,[],NCT02728700,Phase Ib/II,Recruiting,Stanford University ,[],Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT,01/12/2017,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT02728830,Phase I,Recruiting,"Stephanie Gaillard, M.D. ","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers,10/22/2016,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02729194,Phase I,"Active, not recruiting",University of Michigan Cancer Center ,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma,10/19/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02729298,Phase I,Recruiting,"Tolero Pharmaceuticals, Inc.","[{'id': 3826, 'therapyName': 'TP-0903'}]",First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors,12/13/2016,[],no
0,female,[],NCT02729701,Phase II,Recruiting,University of Kansas Medical Center ,"[{'id': 5928, 'therapyName': 'Conjugated estrogens/bazedoxifene'}]",Pilot Study of the Effect of Duavee on Benign Breast Tissue Proliferation,07/03/2017,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02729896,Phase Ib/II,Recruiting,Hoffmann-La Roche,"[{'id': 4362, 'therapyName': 'Atezolizumab + Obinutuzumab + Polatuzumab Vedotin'}]","A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)",07/14/2016,[],yes
0,both,"[{'id': 50744, 'name': 'anaplastic large cell lymphoma', 'source': 'DOID'}]",NCT02729961,Phase Ib/II,Not yet recruiting,University of Washington ,"[{'id': 4169, 'therapyName': 'Brentuximab vedotin + Ceritinib'}]",Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma,06/03/2016,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02730130,Phase II,"Active, not recruiting",Memorial Sloan Kettering Cancer Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients,07/27/2017,[],yes
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02730195,Phase II,Recruiting,Emory University ,"[{'id': 3125, 'therapyName': 'Pioglitazone'}]",Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia,07/05/2016,"[{'molecularProfile': {'id': 14098, 'profileName': 'ABL1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02730247,Phase II,Recruiting,"Liza Villaruz, MD ","[{'id': 2039, 'therapyName': 'Abraxane + Ramucirumab'}]",Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC),09/18/2017,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 6271, 'name': 'gastric cardia adenocarcinoma', 'source': 'DOID'}]",NCT02730546,Phase Ib/II,Suspended,Mayo Clinic ,"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery",09/06/2017,[],no
0,both,"[{'id': 8923, 'name': 'skin melanoma', 'source': 'DOID'}, {'id': 6367, 'name': 'acral lentiginous melanoma', 'source': 'DOID'}]",NCT02731729,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy,04/22/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02731742,Phase I,Recruiting,Merck Sharp & Dohme Corp. ,"[{'id': 4471, 'therapyName': 'MK-1966 + SD-101'}]",Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001),07/18/2016,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02732119,Phase Ib/II,Recruiting,Novartis Pharmaceuticals,"[{'id': 2265, 'therapyName': 'LEE011 + Everolimus + Exemestane'}]",Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor. (TRINITI-1),06/23/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT02732938,Phase I,"Active, not recruiting",Pfizer,"[{'id': 4340, 'therapyName': 'Gemcitabine + nab-paclitaxel + PF-04136309'}]",Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i),05/25/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}]",NCT02733042,Phase Ib/II,Recruiting,Celgene Corporation,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 4278, 'therapyName': 'lenalidomide + MEDI4736 + Rituximab'}, {'id': 4279, 'therapyName': 'Bendamustine + MEDI4736 + Rituximab'}, {'id': 2573, 'therapyName': 'Ibrutinib + MEDI4736'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia (FUSION NHL 001)",06/11/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02733250,Phase Ib/II,Recruiting,Centre hospitalier de l'Université de Montréal (CHUM) ,"[{'id': 4023, 'therapyName': 'nab-paclitaxel + Pembrolizumab'}]",Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer (URCOH-PMS-001),03/18/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02734004,Phase Ib/II,"Active, not recruiting",AstraZeneca,"[{'id': 2894, 'therapyName': 'Durvalumab + Olaparib'}]",A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA),06/20/2017,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 22423, 'profileName': 'ATM negative'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02734160,Phase I,Recruiting,Eli Lilly and Company,"[{'id': 4211, 'therapyName': 'Galunisertib + MEDI4736'}]",A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer,07/19/2016,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02734290,Phase Ib/II,Recruiting,Providence Health & Services ,"[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}, {'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}]",Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer,05/21/2016,[],yes
0,both,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}]",NCT02734615,Phase I,Recruiting,Novartis Pharmaceuticals ,"[{'id': 4441, 'therapyName': 'Alpelisib + LSZ 102'}, {'id': 4440, 'therapyName': 'LSZ 102 + Ribociclib'}, {'id': 4439, 'therapyName': 'LSZ 102'}]",Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers,07/12/2016,[],yes
0,both,[],NCT02735083,Phase I,Recruiting,Institut de Recherches Internationales Servier ,[],A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Malignancies Who Have Been Previously Administered With UCART19,07/17/2017,[],no
0,both,"[{'id': 2513, 'name': 'basal cell carcinoma', 'source': 'DOID'}]",NCT02735356,Phase I,"Active, not recruiting",Jean Yuh Tang ,"[{'id': 1026, 'therapyName': 'Itraconazole'}]",Topical Itraconazole in Treating Patients With Basal Cell Cancer,07/19/2017,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02735980,Phase II,Recruiting,Eli Lilly and Company,"[{'id': 1651, 'therapyName': 'Prexasertib'}]",A Study of LY2606368 in Participants With Extensive Stage Disease Small Cell Lung Cancer,10/06/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02736123,Phase Ib/II,Withdrawn,University of Pittsburgh ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone,09/21/2017,[],no
0,female,"[{'id': 13223, 'name': 'uterine fibroid', 'source': 'DOID'}]",NCT02736435,Phase III,Not yet recruiting,Thunder Bay Regional Research Institute ,"[{'id': 795, 'therapyName': 'Leuprolide'}]",Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound,04/29/2016,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02736617,Phase II,Recruiting,OHSU Knight Cancer Institute,"[{'id': 3476, 'therapyName': 'Ibrutinib + Obinutuzumab'}]",Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma,11/29/2016,[],yes
0,both,"[{'id': 50523, 'name': 'adult T-cell leukemia', 'source': 'DOID'}]",NCT02737046,Phase II,Recruiting,University of Miami ,"[{'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 2624, 'therapyName': 'peginterferon alfa-2b'}, {'id': 4361, 'therapyName': 'Belinostat + Zidovudine'}]",Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma,11/17/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02737072,Phase I,"Active, not recruiting",Eli Lilly and Company,"[{'id': 4210, 'therapyName': 'LY2510924 + MEDI4736'}]",A Study of LY2510924 and Durvalumab in Participants With Solid Tumors,07/29/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02737475,Phase Ib/II,Recruiting,Bristol-Myers Squibb,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 4030, 'therapyName': 'BMS-986178'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of BMS-986178 Monotherapy or in Combination With Nivolumab or Ipilimumab in Subjects With Advanced Solid Tumors,06/28/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02737501,Phase III,"Active, not recruiting",Ariad Pharmaceuticals ,"[{'id': 634, 'therapyName': 'AP26113'}, {'id': 706, 'therapyName': 'Crizotinib'}]",ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients,08/09/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT02737787,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 4020, 'therapyName': 'Nivolumab + WT1 vaccine'}]",A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer,08/09/2016,[],yes
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02738866,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}]",Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor,08/05/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02740270,Phase I,Recruiting,Novartis Pharmaceuticals ,"[{'id': 4469, 'therapyName': 'GWN 323 + PDR001'}, {'id': 4468, 'therapyName': 'GWN 323'}]",Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas,07/18/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02740920,Phase II,Recruiting,Canadian Cancer Trials Group ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Assessment of Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography (CT) Texture Analysis as a Predictive Biomarker,01/13/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02740985,Phase I,Recruiting,AstraZeneca ,"[{'id': 4223, 'therapyName': 'AZD4635'}, {'id': 4349, 'therapyName': 'AZD4635 + MEDI4736'}]",A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies,07/02/2016,[],no
0,both,"[{'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02741570,Phase III,Recruiting,Bristol-Myers Squibb ,"[{'id': 4168, 'therapyName': 'Carboplatin + Cetuximab + Cisplatin + Fluorouracil'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,08/10/2016,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02742090,Phase II,Recruiting,"TG Therapeutics, Inc. ","[{'id': 2022, 'therapyName': 'TGR-1202'}]",Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy,06/21/2016,[],no
0,both,"[{'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3074, 'name': 'giant cell glioblastoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02743078,Phase II,Recruiting,"RTOG Foundation, Inc. ","[{'id': 667, 'therapyName': 'Bevacizumab'}]",Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma,04/19/2017,[],no
0,both,"[{'id': 1107, 'name': 'esophageal carcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT02743494,Phase III,Recruiting,Bristol-Myers Squibb,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal or Gastroesophageal Junction Cancer (CheckMate 577),06/23/2016,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02743546,Phase I,Withdrawn,"Janssen Research & Development, LLC ","[{'id': 4167, 'therapyName': 'Ibrutinib + JNJ-64052781'}]","Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of JNJ-64052781 Plus Ibrutinib in Lymphoma",10/10/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02743611,Phase I,Recruiting,Bellicum Pharmaceuticals ,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 5991, 'therapyName': 'BPX-701'}]",Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms,07/31/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02743637,Phase I,Recruiting,"SynDevRx, Inc. ","[{'id': 4326, 'therapyName': 'SDX-7320'}]",A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors (SDX-0101),06/19/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02743819,Phase II,Recruiting,University of Chicago ,"[{'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}]",Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody,07/19/2016,[],no
0,,[],NCT02744287,,Recruiting,,[],Prostate Stem Cell Antigen (PSCA)-Specific CAR T Cells In Subjects With Non-Resectable Pancreatic Cancer,07/10/2017,[],
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02744612,Phase II,Recruiting,City of Hope Medical Center ,"[{'id': 4300, 'therapyName': 'Brentuximab vedotin + Ibrutinib'}]",Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,06/23/2016,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02745769,Phase I,Recruiting,Eli Lilly and Company ,"[{'id': 4208, 'therapyName': 'LY2801653 + Ramucirumab'}, {'id': 4209, 'therapyName': 'Abemaciclib + Ramucirumab'}]",A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents,10/26/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02746081,Phase I,Recruiting,Bayer ,"[{'id': 3987, 'therapyName': 'BAY 1436032'}]",Phase I Study of BAY1436032 in Isocitrate Dehydrogenase-1 (IDH1)-Mutant Advanced Solid Tumors,06/25/2016,"[{'molecularProfile': {'id': 10006, 'profileName': 'IDH1 R132X'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02746328,Phase II,"Active, not recruiting",GTx,"[{'id': 5026, 'therapyName': 'enobosarm'}]",Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass,08/05/2017,[],yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02746952,Phase I,Recruiting,Servier ,"[{'id': 5997, 'therapyName': 'UCART19'}]",Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia (CALM),07/17/2017,[],yes
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02747004,Phase II,Recruiting,Eli Lilly and Company,"[{'id': 4387, 'therapyName': 'Abemaciclib + Loperamide'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 2256, 'therapyName': 'Abemaciclib + Tamoxifen'}]",A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (nextMONARCH 1),09/21/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02747537,Phase II,Recruiting,Washington University School of Medicine ,"[{'id': 1323, 'therapyName': 'Sorafenib + Irinotecan'}]",Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan,08/16/2016,"[{'molecularProfile': {'id': 2346, 'profileName': 'KDR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1208, 'profileName': 'HRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1181, 'profileName': 'JAK2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1214, 'profileName': 'KIT mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1215, 'profileName': 'PDGFRA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1238, 'profileName': 'MAP2K1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02747797,Phase II,Withdrawn,"eresa Helsten, MD ","[{'id': 1029, 'therapyName': 'Lucitanib'}]","Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations",11/03/2016,"[{'molecularProfile': {'id': 1185, 'profileName': 'FGFR2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1215, 'profileName': 'PDGFRA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1221, 'profileName': 'FGFR1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2346, 'profileName': 'KDR mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 4051, 'name': 'alveolar rhabdomyosarcoma', 'source': 'DOID'}, {'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}, {'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}]",NCT02748135,Phase Ib/II,Recruiting,Oncurious NV ,"[{'id': 4704, 'therapyName': 'TB-403'}]",A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma,09/21/2016,[],no
0,both,"[{'id': 8923, 'name': 'skin melanoma', 'source': 'DOID'}, {'id': 50929, 'name': 'mucosal melanoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02748564,Phase II,Recruiting,"Rutgers, The State University of New Jersey ","[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,04/08/2017,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02748889,Phase Ib/II,Terminated,Giuseppe Giaccone,"[{'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}, {'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}]",Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer,07/14/2017,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 5041, 'name': 'esophageal cancer', 'source': 'DOID'}]",NCT02749513,Phase I,Recruiting,Dallas VA Medical Center ,"[{'id': 1026, 'therapyName': 'Itraconazole'}]",Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients,05/06/2016,[],no
0,both,"[{'id': 8850, 'name': 'salivary gland cancer', 'source': 'DOID'}]",NCT02749903,Phase II,Recruiting,Alliance for Clinical Trials in Oncology ,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers,06/26/2016,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02750215,Phase II,"Active, not recruiting",Massachusetts General Hospital ,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor,09/29/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2096, 'profileName': 'MET act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02750358,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer,05/21/2016,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02750514,Phase II,Recruiting,Bristol-Myers Squibb,"[{'id': 1813, 'therapyName': 'Dasatinib + Nivolumab'}, {'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Test Combination Treatments in People With Advanced Non-Small Cell Lung Cancer,06/02/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02752035,Phase II,Recruiting,"Astellas Pharma Global Development, Inc. ","[{'id': 2865, 'therapyName': 'Gilteritinib'}, {'id': 651, 'therapyName': 'Azacitidine'}]","A Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation in Patients Not Eligible for Intensive Induction Chemotherapy",07/01/2016,"[{'molecularProfile': {'id': 5329, 'profileName': 'FLT3 D835X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 24703, 'profileName': 'FLT3 I836X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 19128, 'profileName': 'FLT3 exon 14 ins'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02752074,Phase III,"Active, not recruiting",Incyte Corporation ,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma,09/07/2017,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02752685,Phase II,Recruiting,New York University School of Medicine ,"[{'id': 4023, 'therapyName': 'nab-paclitaxel + Pembrolizumab'}]",Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer,06/08/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02753127,Phase III,Recruiting,"Boston Biomedical, Inc ","[{'id': 1315, 'therapyName': 'FOLFIRI'}, {'id': 2057, 'therapyName': 'BBI608'}]",A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C),07/01/2016,[],no
0,both,"[{'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}]",NCT02753309,Phase 0,Recruiting,The University of Texas Health Science Center at San Antonio ,"[{'id': 917, 'therapyName': 'Sirolimus'}]",A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer,09/12/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02753686,Phase I,Recruiting,Novartis Pharmaceuticals,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 1966, 'therapyName': 'Exemestane + Everolimus'}]",Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight),05/06/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02754141,Phase Ib/II,Recruiting,Bristol-Myers Squibb ,"[{'id': 4195, 'therapyName': 'BMS-986179 + Nivolumab'}]",A Study of BMS-986179 Administered in Combination With Nivolumab in Advanced Cancers,06/28/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02754362,Phase II,Enrolling by invitation,New York University School of Medicine ,"[{'id': 2595, 'therapyName': 'poly ICLC  '}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma,09/01/2017,[],no
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT02754726,Phase II,Recruiting,HonorHealth Research Institute ,"[{'id': 4087, 'therapyName': 'Cisplatin + Gemcitabine + nab-paclitaxel + Nivolumab + Paricalcitol'}]",Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma,05/06/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02754856,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 4097, 'therapyName': 'Bevacizumab + MEDI4736 + Tremelimumab + FOLFOX'}]",Tremelimumab (Anti-CTLA-4) Plus MEDI4736 (Anti-PD-L1) in Resectable Colorectal Cancer Liver Metastases.,04/01/2017,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02755272,Phase II,Recruiting,Fox Chase Cancer Center,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer,08/04/2016,[],yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02755597,Phase III,Recruiting,AbbVie,"[{'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}, {'id': 3436, 'therapyName': 'Bortezomib + Dexamethasone + GDC-0199\t'}]",A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy,12/12/2016,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02756247,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 3630, 'therapyName': 'BKM120 + Ibrutinib'}]",A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma,08/23/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02756364,Phase II,Recruiting,"Millennium Pharmaceuticals, Inc. ","[{'id': 1581, 'therapyName': 'MLN0128 + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy,09/25/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02756572,Phase I,Recruiting,University of Washington,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 1650, 'therapyName': 'Cyclosporine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5215, 'therapyName': 'mitoxantrone hydrochloride'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia,01/16/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02756611,Phase III,Recruiting,AbbVie ,"[{'id': 1562, 'therapyName': 'Venetoclax'}]",A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Are Refractory or Intolerant to B-cell Receptor Inhibitors,07/12/2016,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02756897,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL),07/12/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02756962,Phase II,Recruiting,Washington University School of Medicine ,"[{'id': 810, 'therapyName': 'Midostaurin'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance,08/04/2017,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 19128, 'profileName': 'FLT3 exon 14 ins'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02757326,Phase Ib/II,Recruiting,RedHill Biopharma Limited ,"[{'id': 3301, 'therapyName': 'ABC294640'}]",ABC294640 in Refractory / Relapsed Multiple Myeloma,02/24/2017,[],no
0,both,"[{'id': 3119, 'name': 'gastrointestinal system cancer', 'source': 'DOID'}]",NCT02757391,Phase I,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 4193, 'therapyName': 'Aldesleukin + Cyclophosphamide + Pembrolizumab'}]",T Cell Immunotherapy Plus Anti-PD1 Antibody in Advanced Solid Malignancies,06/02/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02758132,Phase I,Terminated,University of Hawaii ,"[{'id': 4182, 'therapyName': 'Abiraterone + Denosumab + Enzalutamide + Prednisone'}, {'id': 4183, 'therapyName': 'Denosumab + Enzalutamide'}]","Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases",07/22/2017,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02758717,Phase II,Recruiting,Academic and Community Cancer Research United ,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma,06/02/2016,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02759016,Phase I,Recruiting,Boehringer Ingelheim ,"[{'id': 4277, 'therapyName': 'BI 836826 + Ibrutinib'}]","Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Who Have Received at Least One Prior Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib",06/29/2016,[],no
0,both,"[{'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}]",NCT02759575,Phase Ib/II,Recruiting,Nooshin Hashemi-Sadraei ,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma,05/27/2016,[],no
0,both,"[{'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}]",NCT02759835,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 660, 'therapyName': 'Osimertinib'}]","Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib",05/27/2016,"[{'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02760030,Phase II,Recruiting,Ohio State University Comprehensive Cancer Center ,"[{'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}]",Fulvestrant and Palbociclib in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery,05/27/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02760485,Phase Ib/II,Recruiting,Incyte Corporation,"[{'id': 5151, 'therapyName': 'Ibrutinib + INCB039110'}]",A Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,01/14/2017,[],no
0,both,"[{'id': 3151, 'name': 'skin squamous cell carcinoma', 'source': 'DOID'}]",NCT02760498,Phase II,Recruiting,Regeneron Pharmaceuticals,"[{'id': 5656, 'therapyName': 'REGN2810'}]",Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma,05/22/2017,[],no
0,both,"[{'id': 1790, 'name': 'malignant mesothelioma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02760797,Phase I,Recruiting,Hoffmann-La Roche ,"[{'id': 4181, 'therapyName': 'Emactuzumab + RO7009789'}]",A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors,05/27/2016,[],no
0,both,"[{'id': 4465, 'name': 'papillary renal cell carcinoma', 'source': 'DOID'}]",NCT02761057,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 2161, 'therapyName': 'Savolitinib'}, {'id': 998, 'therapyName': 'cabozantinib'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 930, 'therapyName': 'Sunitinib'}]","Cabozantinib-S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer",05/27/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02761694,Phase I,Recruiting,ArQule ,"[{'id': 4331, 'therapyName': 'ARQ 751'}]","Phase 1 Study of ARQ 751 in Solid Tumors With AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations or PTEN-null",07/14/2016,"[{'molecularProfile': {'id': 743, 'profileName': 'PIK3CA act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1209, 'profileName': 'AKT1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 479, 'profileName': 'PTEN loss'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02762006,Phase I,Recruiting,Brian Rini ,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma,01/07/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02762513,Phase II,Recruiting,University of Michigan Cancer Center ,"[{'id': 649, 'therapyName': 'Axitinib'}]",Expansion Trial for Axitinib In Head And Neck Cancer,09/02/2016,[],no
0,both,"[{'id': 7936, 'name': 'precursor T-lymphoblastic lymphoma/leukemia refractory', 'source': 'DOID'}, {'id': 5602, 'name': 'T-cell adult acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02763384,Phase II,Recruiting,Washington University School of Medicine ,"[{'id': 4275, 'therapyName': 'BKT140 + Nelarabine'}]",BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma,12/15/2016,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02763579,Phase III,Recruiting,Hoffmann-La Roche ,"[{'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133),05/27/2016,[],no
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT02764333,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 4180, 'therapyName': 'MEDI4736 + TPIV 200'}]",TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer,05/27/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02764541,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS),05/27/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT02764593,Phase I,Recruiting,"RTOG Foundation, Inc. ","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4760, 'therapyName': 'Cisplatin + Nivolumab'}, {'id': 4761, 'therapyName': 'Cetuximab + Nivolumab'}]",Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma,09/25/2016,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02766478,Phase II,Recruiting,Emory University ,"[{'id': 757, 'therapyName': 'Genistein'}]",Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer,10/10/2017,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT02766582,Phase II,Recruiting,Medical College of Wisconsin ,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]",Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer,11/19/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02766699,Phase I,Recruiting,Engeneic Pty Limited,"[{'id': 5331, 'therapyName': 'EGFR(V)-EDV-Dox'}]","A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) (CerebralEDV)",02/15/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02767804,Phase III,Recruiting,"Xcovery Holding Company, LLC","[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 961, 'therapyName': 'X-396'}]",eXalt3: Study Comparing X-396 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients,07/02/2016,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02767934,Phase II,Recruiting,University of Washington ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia,01/24/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02768363,Phase II,Recruiting,"Advantagene, Inc. ","[{'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}, {'id': 5171, 'therapyName': 'Valacyclovir'}]",Randomized Controlled Trial of ProstAtak Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES),06/19/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02768389,Phase I,Recruiting,Case Comprehensive Cancer Center ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma,09/16/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02768558,Phase III,Recruiting,"RTOG Foundation, Inc. ","[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 4922, 'therapyName': 'Cisplatin + Etoposide + Nivolumab'}]",Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC,11/06/2016,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02768701,Phase II,Recruiting,UNC Lineberger Comprehensive Cancer Center ,"[{'id': 4891, 'therapyName': 'Cyclophosphamide + Pembrolizumab'}]",Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer,10/30/2016,[],yes
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT02768766,Phase I,Recruiting,Richard D. Carvajal ,"[{'id': 913, 'therapyName': 'Selumetinib'}]",Intermittent Selumetinib for Uveal Melanoma,12/17/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02768792,Phase II,Recruiting,UNC Lineberger Comprehensive Cancer Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML,05/18/2017,[],no
0,both,"[{'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT02769520,Phase II,Recruiting,Ezra Cohen ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck",12/15/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02769962,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 4348, 'therapyName': 'CRLX101 + Olaparib'}]","Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer",01/03/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02770014,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 4, 'therapyName': 'Erlotinib'}]",Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer,01/24/2017,"[{'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02770391,Phase II,Recruiting,Case Comprehensive Cancer Center ,"[{'id': 4207, 'therapyName': 'ARN-509 + Leuprolide'}]",ARN-509 and Leuprolide in Intermediate and High-risk Prostate Cancer,12/14/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02771197,Phase II,Recruiting,"Northside Hospital, Inc. ","[{'id': 2237, 'therapyName': 'Fludarabine + Melphalan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant,11/08/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02771626,Phase Ib/II,Recruiting,"Calithera Biosciences, Inc ","[{'id': 4274, 'therapyName': 'CB-839 + Nivolumab'}]",Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors,09/16/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02772588,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 4206, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide'}]",AASUR in High Risk Prostate Cancer,06/02/2016,[],no
0,both,"[{'id': 5074, 'name': 'malignant ependymoma', 'source': 'DOID'}]",NCT02774421,Phase I,Recruiting,"University of Colorado, Denver ","[{'id': 1891, 'therapyName': 'Trastuzumab + Sargramostim'}]",Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma,12/14/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02774681,Phase II,Recruiting,Northwestern University ,"[{'id': 3041, 'therapyName': 'Palbociclib + Trastuzumab'}]",Palbociclib in Treating Patients With Metastatic HER-2 Positive or Triple-Negative Breast Cancer With Brain Metastasis,06/03/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02775292,Phase I,Recruiting,Jonsson Comprehensive Cancer Center ,"[{'id': 3409, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine '}, {'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1",04/27/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02775435,Phase III,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407),06/27/2016,[],no
0,both,"[{'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02775812,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]","Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma",10/12/2017,[],no
0,both,"[{'id': 3162, 'name': 'malignant spindle cell melanoma', 'source': 'DOID'}]",NCT02775851,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery,10/26/2016,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02775903,Phase II,Recruiting,Celgene Corporation ,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML),07/14/2016,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02776917,Phase I,Not yet recruiting,"Barbara Parker, MD ","[{'id': 4313, 'therapyName': 'Cirmtuzumab + Paclitaxel'}]","Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer",06/17/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 2596, 'name': 'larynx cancer', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}]",NCT02777385,Phase II,Recruiting,University of Pittsburgh ,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}]",Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer,06/10/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02778685,Phase II,Recruiting,City of Hope Medical Center ,"[{'id': 4222, 'therapyName': 'Letrozole + Palbociclib + Pembrolizumab'}]","Pembrolizumab, Letrozole, and Palbociclib in Treating Patients With Stage IV Estrogen Receptor Positive Breast Cancer With Stable Disease That Has Not Responded to Letrozole and Palbociclib",10/05/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02779283,Phase I,Recruiting,OHSU Knight Cancer Institute ,"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia,06/05/2016,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02779751,Phase II,Recruiting,Eli Lilly and Company ,"[{'id': 4242, 'therapyName': 'Abemaciclib + Pembrolizumab'}]",A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer,11/26/2016,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02779777,Phase II,Recruiting,"Kura Oncology, Inc. ","[{'id': 938, 'therapyName': 'Tipifarnib'}]","Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes",06/26/2016,[],no
0,both,"[{'id': 4517, 'name': 'skin angiosarcoma', 'source': 'DOID'}, {'id': 5680, 'name': 'embryonal testis carcinoma', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}]",NCT02780011,Phase I,Not yet recruiting,The Methodist Hospital System ,"[{'id': 4301, 'therapyName': 'Alisertib + Brentuximab vedotin'}]",Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies,06/17/2016,[],yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02780024,Phase II,Recruiting,McGill University Health Center ,"[{'id': 1031, 'therapyName': 'Metformin'}]","Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM",06/02/2016,[],no
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT02780128,Phase I,Recruiting,Yael P Mosse ,"[{'id': 2186, 'therapyName': 'HDM201'}, {'id': 2638, 'therapyName': 'Ceritinib + LEE011'}, {'id': 2, 'therapyName': 'Trametinib'}]",Next Generation Personalized Neuroblastoma Therapy,07/31/2016,[],no
0,both,"[{'id': 50931, 'name': 'parotid gland adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 7198, 'name': 'maxillary sinus adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 60219, 'name': 'lymph node adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4868, 'name': 'prostate adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4867, 'name': 'cervical adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4870, 'name': 'lacrimal gland adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4869, 'name': 'laryngeal adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4872, 'name': 'lung adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 2764, 'name': 'ethmoid sinus adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4875, 'name': 'trachea adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4878, 'name': 'esophageal adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4877, 'name': 'breast adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4879, 'name': ""Bartholin's gland adenoid cystic carcinoma"", 'source': 'DOID'}, {'id': 50930, 'name': 'sublingual gland adenoid cystic carcinoma', 'source': 'DOID'}]",NCT02780310,Phase II,"Active, not recruiting",Memorial Sloan Kettering Cancer Center ,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma,06/09/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02780609,Phase Ib/II,Recruiting,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 4221, 'therapyName': 'Dexamethasone + Melphalan + Selinexor'}]",Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma,06/28/2017,[],no
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT02780700,Phase II,Terminated,Boehringer Ingelheim ,"[{'id': 2589, 'therapyName': 'Capecitabine + Nintedanib'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2],12/13/2016,[],no
0,both,[],NCT02780713,Phase I,Completed,AstraZeneca ,"[{'id': 2997, 'therapyName': 'AZD9496'}]",A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects (PK),11/09/2016,[],no
0,both,"[{'id': 3620, 'name': 'central nervous system cancer', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02780804,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1541, 'therapyName': 'Entinostat'}]",Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors,02/08/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02781506,Phase II,Recruiting,University of Texas Southwestern Medical Center ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab and Stereotactic Ablative Radiation Therapy Versus Nivolumab Alone for Metastatic Renal Cancer,07/01/2016,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02782403,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 4241, 'therapyName': 'Axitinib + Bosutinib'}]","Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases",03/22/2017,"[{'molecularProfile': {'id': 536, 'profileName': 'ABL1 T315I'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02782546,Phase II,Recruiting,Washington University School of Medicine ,[],Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation,02/08/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02783599,Phase I,Recruiting,Eli Lilly and Company,"[{'id': 4140, 'therapyName': 'Doxorubicin + Olaratumab'}]",A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma,10/26/2016,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02783625,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 4240, 'therapyName': 'Bortezomib + Duvelisib'}, {'id': 4239, 'therapyName': 'Duvelisib + romidepsin '}]",Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas,06/05/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02784158,Phase I,No longer available,Ariad Pharmaceuticals,"[{'id': 634, 'therapyName': 'AP26113'}]",An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer,06/02/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT02784171,Phase II,Recruiting,Canadian Cancer Trials Group ,"[{'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma,11/19/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02784483,Phase I,Recruiting,Yale University ,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]","Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma",06/04/2016,[],no
0,both,"[{'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 219, 'name': 'colon cancer', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02784795,Phase I,Recruiting,Eli Lilly and Company ,"[{'id': 4374, 'therapyName': 'Cisplatin + Gemcitabine + LY3039478'}, {'id': 4375, 'therapyName': 'Carboplatin + Gemcitabine + LY3039478'}, {'id': 4372, 'therapyName': 'LY3039478 + LY3023414'}, {'id': 4373, 'therapyName': 'Abemaciclib + LY3039478'}, {'id': 4371, 'therapyName': 'LY3039478 + Taladegib'}, {'id': 2958, 'therapyName': 'LY3039478'}, {'id': 1069, 'therapyName': 'LY3023414'}]",A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,12/14/2016,"[{'molecularProfile': {'id': 14278, 'profileName': 'NOTCH1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 4725, 'profileName': 'NOTCH1 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 24429, 'profileName': 'NOTCH1 dec exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 4730, 'profileName': 'NOTCH1 over exp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02785068,Phase I,Withdrawn,Merrimack Pharmaceuticals ,"[{'id': 4532, 'therapyName': 'Fluorouracil + Irinotecan + Leucovorin + MM-151'}]",Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer,01/13/2017,"[{'molecularProfile': {'id': 481, 'profileName': 'NRAS wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 4, 'profileName': 'BRAF wild-type'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT02785250,Phase I,Recruiting,"ImmunoVaccine Technologies, Inc. ","[{'id': 4238, 'therapyName': 'Cyclophosphamide + DPX-Survivac + INCB024360 '}]",Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer,06/04/2016,[],no
0,both,"[{'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}]",NCT02785913,Phase II,"Active, not recruiting",Southwest Oncology Group ,"[{'id': 1016, 'therapyName': 'GDC-0032'}]",Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches,02/08/2017,[],no
0,both,"[{'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}]",NCT02785939,Phase II,"Active, not recruiting",Southwest Oncology Group ,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Lung-MAP: Palbociclib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches,02/08/2017,[],no
0,both,"[{'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}]",NCT02785952,Phase III,Recruiting,Southwest Oncology Group ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers,06/04/2016,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 1240, 'name': 'leukemia', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02786485,Phase I,Not yet recruiting,Bellicum Pharmaceuticals,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6053, 'therapyName': 'BPX-501'}]",Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT,07/31/2017,[],no
0,both,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02787005,Phase II,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Chemotherapy (MK-3475-199/KEYNOTE-199),02/08/2017,[],no
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02787369,Phase I,"Active, not recruiting",Dana-Farber Cancer Institute,"[{'id': 4273, 'therapyName': 'ACY-1215 + Idelalisib '}, {'id': 4272, 'therapyName': 'ACY-1215 + Ibrutinib'}]",ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL,05/31/2017,[],no
0,both,"[{'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}]",NCT02788201,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 4, 'therapyName': 'Erlotinib'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 640, 'therapyName': 'Arsenic trioxide'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1133, 'therapyName': 'Mitomycin C'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1767, 'therapyName': 'Cladribine'}, {'id': 1013, 'therapyName': 'epirubicin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1137, 'therapyName': 'Bleomycin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 751, 'therapyName': 'Gefitinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 2075, 'therapyName': 'Lomustine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 781, 'therapyName': 'Ixabepilone'}, {'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 649, 'therapyName': 'Axitinib'}, {'id': 2950, 'therapyName': 'Estramustine'}, {'id': 1941, 'therapyName': 'Floxuridine'}, {'id': 787, 'therapyName': 'Lapatinib'}, {'id': 1811, 'therapyName': 'Carmustine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 829, 'therapyName': 'Nilotinib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 956, 'therapyName': 'Vismodegib'}, {'id': 953, 'therapyName': 'Vandetanib'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 2601, 'therapyName': 'Dactinomycin'}, {'id': 936, 'therapyName': 'Temsirolimus'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 1075, 'therapyName': 'romidepsin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 3035, 'therapyName': 'Chlorambucil'}, {'id': 3161, 'therapyName': 'Pentostatin'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 1750, 'therapyName': 'Hydroxyurea'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1877, 'therapyName': 'Tretinoin  '}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 4305, 'therapyName': 'Teniposide'}, {'id': 720, 'therapyName': 'Docetaxel'}, {'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 4304, 'therapyName': 'Streptozocin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1231, 'therapyName': 'Bendamustine'}, {'id': 4303, 'therapyName': 'Mechlorethamine'}, {'id': 4302, 'therapyName': 'Mitotane'}]",Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,09/14/2016,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}]",NCT02788279,Phase III,"Active, not recruiting",Hoffmann-La Roche ,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma,06/28/2017,[],no
0,female,"[{'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT02788708,Phase I,Recruiting,Floor Backes ,"[{'id': 4236, 'therapyName': 'Lenvatinib + Paclitaxel'}]",Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer,10/26/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02788773,Phase II,Recruiting,Canadian Cancer Trials Group ,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer,12/20/2016,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02788981,Phase II,Recruiting,University of Chicago ,"[{'id': 4350, 'therapyName': 'Mifepristone + Nab-paclitaxel'}, {'id': 619, 'therapyName': 'Abraxane'}]","A Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer",04/15/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02789345,Phase I,Recruiting,Eli Lilly and Company,"[{'id': 4379, 'therapyName': 'Osimertinib + Ramucirumab'}, {'id': 4380, 'therapyName': 'Necitumumab + Osimertinib'}]",A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer,11/05/2016,"[{'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02789657,Phase II,Recruiting,William Sikov ,"[{'id': 4235, 'therapyName': 'Carboplatin + Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}]",BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.,05/25/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,,"[{'id': 50458, 'name': 'juvenile myelomonocytic leukemia', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}, {'id': 8683, 'name': 'myeloid sarcoma', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02790515,Phase II,Recruiting,St. Jude Children's Research Hospital ,"[{'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1844, 'therapyName': 'anti-thymocyte globulin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,06/12/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02791334,Phase I,Recruiting,Eli Lilly and Company,"[{'id': 4370, 'therapyName': 'LY3300054 + Necitumumab'}, {'id': 4369, 'therapyName': 'LY3300054 + Ramucirumab'}, {'id': 4368, 'therapyName': 'LY3300054'}]",A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors  (PACT),07/01/2016,[],no
0,both,[],NCT02791594,Phase I,Recruiting,Abramson Cancer Center of the University of Pennsylvania ,[],Imaging FDG Flare in Melanoma,06/10/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02791919,Phase I,Withdrawn,National Cancer Institute (NCI),"[{'id': 822, 'therapyName': 'MK-1775'}, {'id': 4271, 'therapyName': 'Cytarabine + Filgrastim + Fludarabine'}]","Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia",01/10/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02792114,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 5992, 'therapyName': 'Rimiducid'}, {'id': 6029, 'therapyName': 'Mesothelin CAR-T cells'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",T-Cell Therapy for Advanced Breast Cancer,07/28/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT02792192,Phase Ib/II,Recruiting,Hoffmann-La Roche ,"[{'id': 4456, 'therapyName': 'Atezolizumab + BCG solution'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-risk Non-muscle-invasive Bladder Cancer (NMIBC) Participants,07/17/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02792465,Phase I,Recruiting,"University Health Network, Toronto ","[{'id': 5853, 'therapyName': 'CFI-402257'}]",A Study of Investigational Drug CFI-402257 in Patients With Advanced Cancers,06/20/2017,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02792725,Expanded access,Available,Eli Lilly and Company,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer,11/19/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02793219,Phase II,Not yet recruiting,"The University of Texas Health Science Center, Houston ","[{'id': 4270, 'therapyName': 'Docetaxel + Sipuleucel-T'}]",Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer,06/10/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 3620, 'name': 'central nervous system cancer', 'source': 'DOID'}]",NCT02793466,Phase I,Recruiting,Children's Hospital Los Angeles ,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab in Pediatric and Adolescent Patients,07/20/2016,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 12603, 'name': 'acute leukemia', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 80147, 'name': 'lymphoblastic lymphoma', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02793544,Phase II,Recruiting,Center for International Blood and Marrow Transplant Research,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 917, 'therapyName': 'Sirolimus'}, {'id': 1845, 'therapyName': 'Mycophenolate mofetil'}, {'id': 5682, 'therapyName': 'Mesna'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide,07/06/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02793583,Phase II,Recruiting,"TG Therapeutics, Inc. ","[{'id': 2022, 'therapyName': 'TGR-1202'}, {'id': 2319, 'therapyName': 'TGR-1202 + Ublituximab'}]",Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 and TGR-1202 Alone in Patients With Previously Treated Diffuse Large B-Cell Lymphoma (UNITY-DLBCL),06/10/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02793765,Phase II,Not yet recruiting,"The University of Texas Health Science Center, Houston ","[{'id': 4270, 'therapyName': 'Docetaxel + Sipuleucel-T'}]",Docetaxel Followed by Provenge in Metastatic Prostate Cancer,06/10/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02794571,Phase I,Recruiting,"Genentech, Inc. ","[{'id': 4269, 'therapyName': 'Atezolizumab + MTIG7192A '}, {'id': 4268, 'therapyName': 'MTIG7192A '}]",Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors,06/10/2016,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02794883,Phase II,Recruiting,Northwestern University ,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma,09/24/2016,[],no
0,both,"[{'id': 2596, 'name': 'larynx cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 10811, 'name': 'nasal cavity cancer', 'source': 'DOID'}, {'id': 50619, 'name': 'paranasal sinus cancer', 'source': 'DOID'}, {'id': 3571, 'name': 'liver cancer', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}, {'id': 5041, 'name': 'esophageal cancer', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}, {'id': 8618, 'name': 'oral cavity cancer', 'source': 'DOID'}]",NCT02795156,Phase II,Recruiting,"SCRI Development Innovations, LLC ","[{'id': 623, 'therapyName': 'Afatinib'}, {'id': 890, 'therapyName': 'Regorafenib'}]",Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations,12/19/2016,"[{'molecularProfile': {'id': 1221, 'profileName': 'FGFR1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 6309, 'profileName': 'ERBB4 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1216, 'profileName': 'ERBB2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1215, 'profileName': 'PDGFRA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1185, 'profileName': 'FGFR2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1214, 'profileName': 'KIT mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14910, 'profileName': 'FGFR1 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2903, 'profileName': 'RET fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3287, 'profileName': 'BRAF fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2969, 'profileName': 'FGFR2 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1232, 'profileName': 'RET mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14098, 'profileName': 'ABL1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 812, 'profileName': 'FGFR1 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3147, 'profileName': 'FGFR2 amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02795429,Phase Ib/II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 2659, 'therapyName': 'PDR001'}, {'id': 4492, 'therapyName': 'INC280 + PDR001'}]",Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC,07/22/2016,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02795819,Phase I,Suspended,Virginia Commonwealth University ,"[{'id': 4267, 'therapyName': 'AR-42 + Pazopanib'}]",Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer,11/26/2016,[],no
0,both,"[{'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT02795858,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 4266, 'therapyName': 'Octreotide + Ramucirumab'}]","A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors",08/05/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02796352,Phase II,Terminated,Ahmad Tarhini ,"[{'id': 1167, 'therapyName': 'Aldesleukin'}]",A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study,08/22/2017,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02796898,Phase Ib/II,Recruiting,"Tyme, Inc ","[{'id': 5866, 'therapyName': 'SM88'}]","Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer",06/19/2017,[],no
0,both,"[{'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02798406,Phase II,Recruiting,"DNAtrix, Inc. ","[{'id': 4408, 'therapyName': 'DNX-2401 + Pembrolizumab'}]",Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE),07/01/2016,[],no
0,both,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02799095,Phase I,Recruiting,"Alkermes, Inc. ","[{'id': 4298, 'therapyName': 'ALKS 4230'}]",A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors,07/26/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02799602,Phase III,Recruiting,Bayer,"[{'id': 836, 'therapyName': 'ODM-201'}, {'id': 4921, 'therapyName': 'Docetaxel + ODM-201'}]",ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer (ARASENS),12/29/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02799745,Phase II,Recruiting,"Astellas Pharma Global Development, Inc. ","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) (ENACT),06/26/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3078, 'name': 'grade III astrocytoma', 'source': 'DOID'}, {'id': 5076, 'name': 'mixed glioma', 'source': 'DOID'}]",NCT02800486,Phase II,Recruiting,Northwell Health ,"[{'id': 694, 'therapyName': 'Cetuximab'}]","Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA",07/14/2016,"[{'molecularProfile': {'id': 2419, 'profileName': 'EGFR over exp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02801097,Phase I,Recruiting,"EpicentRx, Inc. ","[{'id': 4323, 'therapyName': 'Irinotecan + RRx-001'}]","A Phase I, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer  (PAYLOAD) (PAYLOAD)",09/12/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02801578,Phase I,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL),06/22/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02802163,Phase Ib/II,Withdrawn,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 4367, 'therapyName': 'Carfilzomib + Dexamethasone + lenalidomide + Panobinostat'}]","Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat",04/26/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02803203,Phase Ib/II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 4366, 'therapyName': 'Bevacizumab + Osimertinib'}]",Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers,07/01/2016,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02805660,Phase Ib/II,Recruiting,Mirati Therapeutics Inc. ,"[{'id': 4378, 'therapyName': 'MEDI4736 + Mocetinostat'}]",Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC,07/14/2016,[],no
0,both,"[{'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}]",NCT02807272,Phase II,Recruiting,"Kura Oncology, Inc. ","[{'id': 938, 'therapyName': 'Tipifarnib'}]",Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia (CMML),11/06/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02807454,Phase Ib/II,"Active, not recruiting",Celgene Corporation ,"[{'id': 4531, 'therapyName': 'Daratumumab + Dexamethasone + MEDI4736 + Pomalidomide'}, {'id': 4530, 'therapyName': 'Daratumumab + MEDI4736'}]",A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma (FUSIONMM-003),09/29/2017,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}]",NCT02807636,Phase III,Recruiting,Hoffmann-La Roche ,"[{'id': 4450, 'therapyName': 'Atezolizumab + Carboplatin + Gemcitabine'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",The Effect of Atezolizumab in Combination With Gemcitabine/Carboplatin and Gemcitabine/Carboplatin Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy,07/14/2016,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02807805,Phase II,Recruiting,"University of California, Davis ","[{'id': 4377, 'therapyName': 'Abiraterone + Niclosamide + Prednisone'}]","Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer",09/13/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}, {'id': 4905, 'name': 'pancreatic carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02807844,Phase Ib/II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 5072, 'therapyName': 'MCS110 + PDR001'}]",Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies,12/08/2016,[],yes
0,both,"[{'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}]",NCT02808143,Phase I,Recruiting,Northwestern University,"[{'id': 4457, 'therapyName': 'BCG solution + Pembrolizumab'}]",Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer,02/24/2017,[],no
0,both,"[{'id': 3620, 'name': 'central nervous system cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02808650,Phase I,Recruiting,Children's Oncology Group,"[{'id': 1651, 'therapyName': 'Prexasertib'}]",Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors,03/01/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02810457,Phase III,Recruiting,Centus Biotherapeutics Limited ,"[{'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]",Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer (AVANA),10/03/2016,"[{'molecularProfile': {'id': 4138, 'profileName': 'EML4-ALK'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02811497,Phase II,Recruiting,"University Health Network, Toronto ","[{'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}]",Study of Azacitidine and Durvalumab in Advanced Solid Tumors (METADUR),09/13/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02811809,Phase II,Not yet recruiting,Robert J Amato ,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 4207, 'therapyName': 'ARN-509 + Leuprolide'}]",Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer,10/30/2016,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02811861,Phase III,Recruiting,Eisai Inc. ,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma,10/04/2016,[],no
0,both,"[{'id': 1245, 'name': 'vulva cancer', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 11615, 'name': 'penile cancer', 'source': 'DOID'}, {'id': 14110, 'name': 'anus cancer', 'source': 'DOID'}, {'id': 119, 'name': 'vaginal cancer', 'source': 'DOID'}]",NCT02812056,Phase I,Withdrawn,M.D. Anderson Cancer Center,"[{'id': 4214, 'therapyName': 'Alisertib + MLN0128'}]",Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies,03/29/2017,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}]",NCT02812420,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy",03/10/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02812524,Phase I,Recruiting,Providence Health & Services,"[{'id': 779, 'therapyName': 'Ipilimumab'}]",Ipilimumab for Head and Neck Cancer Patients,06/20/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02812667,Phase I,Recruiting,"Lyudmila Bazhenova, M.D. ","[{'id': 4512, 'therapyName': 'Nivolumab + Plinabulin'}]",Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC),12/07/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02812693,Phase Ib/II,Recruiting,Joanne Jeter ,"[{'id': 4376, 'therapyName': 'Imatinib + Pembrolizumab'}]",Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification,11/09/2016,"[{'molecularProfile': {'id': 1214, 'profileName': 'KIT mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 473, 'profileName': 'KIT amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02812875,Phase I,Recruiting,"Curis, Inc.","[{'id': 5885, 'therapyName': 'CA-170'}]","A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas",06/19/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02814669,Phase I,Recruiting,Hoffmann-La Roche,"[{'id': 4881, 'therapyName': 'Atezolizumab + Ra 223'}]",Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor,10/30/2016,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02815059,Phase I,Recruiting,University of Utah ,"[{'id': 4438, 'therapyName': 'Dasatinib + Ibrutinib + Prednisone'}]","Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone",09/30/2016,[],yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02815397,Phase II,Recruiting,Rush University Medical Center ,"[{'id': 1031, 'therapyName': 'Metformin'}]",DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma,07/01/2016,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02815592,Phase Ib/II,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 4563, 'therapyName': 'BMS-986012 + Cisplatin + Etoposide'}, {'id': 4564, 'therapyName': 'BMS-986012 + Carboplatin + Etoposide'}]",Trial of BMS-986012 in Combination With Platinum and Etoposide,06/20/2017,[],no
0,both,"[{'id': 255, 'name': 'hemangioma', 'source': 'DOID'}, {'id': 1967, 'name': 'leiomyosarcoma', 'source': 'DOID'}, {'id': 5485, 'name': 'synovial sarcoma', 'source': 'DOID'}, {'id': 3315, 'name': 'lipoma', 'source': 'DOID'}, {'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}, {'id': 1816, 'name': 'angiosarcoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02815995,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes,08/18/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02816021,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma,02/16/2017,[],no
0,both,"[{'id': 50929, 'name': 'mucosal melanoma', 'source': 'DOID'}, {'id': 8923, 'name': 'skin melanoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02818023,Phase I,Recruiting,University of Pittsburgh ,"[{'id': 4406, 'therapyName': 'Pembrolizumab + Vemurafenib'}]",Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib Advanced Melanoma,07/21/2016,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02818920,Phase II,Recruiting,Neal Ready,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Neoadjuvant Pembrolizumab,02/09/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02819518,Phase III,Recruiting,Merck Sharp & Dohme Corp. ,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355),08/11/2016,[],yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02819804,Phase I,Recruiting,Northwestern University ,"[{'id': 1813, 'therapyName': 'Dasatinib + Nivolumab'}]",Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,08/30/2016,[],yes
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02819999,Phase I,Recruiting,Stemcentrx,"[{'id': 4827, 'therapyName': 'Rovalpituzumab Tesirine + Cisplatin + Etoposide'}, {'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer,10/13/2016,[],yes
0,female,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}]",NCT02820961,Phase I,Recruiting,Syndax Pharmaceuticals ,"[{'id': 4437, 'therapyName': 'Entinostat + Exemestane'}]",Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer,07/12/2016,[],yes
0,both,"[{'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02821754,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC),10/21/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02823405,Phase I,Recruiting,X4 Pharmaceuticals ,"[{'id': 4436, 'therapyName': 'Pembrolizumab + X4P-001'}]",Neoadjuvant X4P-001 and Pembrolizumab in Patients With Resectable Melanoma (X4P-001-MELA),07/08/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02823574,Phase II,Recruiting,Bristol-Myers Squibb,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,10/01/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02823990,Phase II,Recruiting,"University of California, Davis ","[{'id': 4435, 'therapyName': 'MVA-MUC1-IL2 vaccine + Nivolumab'}]",TG4010 and Nivolumab in Patients With Lung Cancer,12/21/2016,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 18885, 'profileName': 'ALK act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02824029,Phase II,Recruiting,Barbara Ann Karmanos Cancer Institute ,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,07/08/2016,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1788, 'name': 'peritoneal mesothelioma', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02824042,Phase I,Recruiting,Bayer,"[{'id': 4594, 'therapyName': 'Anetumab ravtansine + Itraconazole'}, {'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole,12/04/2016,[],yes
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02824575,Phase I,Recruiting,Montefiore Medical Center ,"[{'id': 4433, 'therapyName': 'Paclitaxel + Rebastinib'}, {'id': 4434, 'therapyName': 'Eribulin + Rebastinib'}]",Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer,08/13/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02826161,Phase III,Terminated,"Boston Biomedical, Inc","[{'id': 2586, 'therapyName': 'BBI608 + Paclitaxel'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L)",07/12/2017,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02826434,Phase I,Recruiting,Massachusetts General Hospital ,"[{'id': 4466, 'therapyName': 'MEDI4736 + PVX-410 + poly ICLC '}]",Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer,10/26/2016,[],yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02826486,Phase II,Recruiting,"BioLineRx, Ltd. ","[{'id': 4757, 'therapyName': 'BKT140 + Pembrolizumab'}, {'id': 2849, 'therapyName': 'BKT140'}]",Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202) (COMBAT),10/04/2016,[],no
0,both,"[{'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT02827838,Phase I,Recruiting,Comprehensive Cancer Center of Wake Forest University ,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer,02/08/2017,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02827877,Phase I,Recruiting,City of Hope Medical Center ,"[{'id': 1389, 'therapyName': 'Trastuzumab + Pertuzumab'}]",Copper (Cu) 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer,10/20/2016,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02827968,Phase I,Recruiting,"3D Medicines (Sichuan) Co., Ltd. ","[{'id': 6140, 'therapyName': 'KN035'}]",Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors,09/01/2017,[],no
0,both,"[{'id': 3571, 'name': 'liver cancer', 'source': 'DOID'}]",NCT02828124,Phase Ib/II,"Active, not recruiting",Bristol-Myers Squibb ,"[{'id': 5628, 'therapyName': 'BMS-986183'}, {'id': 5629, 'therapyName': 'BMS-986183 + Nivolumab'}]",A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer,07/28/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02829723,Phase Ib/II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 2844, 'therapyName': 'BLZ945'}, {'id': 5071, 'therapyName': 'BLZ945 + PDR001'}]",Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors,12/08/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}]",NCT02829840,Phase Ib/II,Withdrawn,M.D. Anderson Cancer Center ,"[{'id': 4464, 'therapyName': 'Azacitidine + Ponatinib'}]","Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)",06/03/2017,"[{'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4948, 'name': 'gallbladder carcinoma', 'source': 'DOID'}, {'id': 50625, 'name': 'biliary tract neoplasm', 'source': 'DOID'}]",NCT02829918,Phase II,Recruiting,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers,09/21/2016,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02829931,Phase I,Recruiting,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Hypofractionated Stereotactic Irradiation With Nivolumab in Patients With Recurrent High Grade Gliomas,08/12/2016,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 5517, 'name': 'stomach carcinoma', 'source': 'DOID'}, {'id': 1107, 'name': 'esophageal carcinoma', 'source': 'DOID'}]",NCT02830594,Phase II,Recruiting,City of Hope Medical Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer",10/08/2016,[],no
0,both,"[{'id': 5574, 'name': 'VIPoma', 'source': 'DOID'}, {'id': 3973, 'name': 'thyroid medullary carcinoma', 'source': 'DOID'}, {'id': 1799, 'name': 'islet cell tumor', 'source': 'DOID'}, {'id': 5719, 'name': 'adrenal medulla cancer', 'source': 'DOID'}, {'id': 3892, 'name': 'insulinoma', 'source': 'DOID'}, {'id': 3950, 'name': 'adrenal carcinoma', 'source': 'DOID'}, {'id': 4430, 'name': 'somatostatinoma', 'source': 'DOID'}, {'id': 3965, 'name': 'Merkel cell carcinoma', 'source': 'DOID'}, {'id': 50925, 'name': 'small intestine carcinoid neuroendocrine tumor', 'source': 'DOID'}, {'id': 7402, 'name': 'L-cell glucagon-like peptide producing tumor', 'source': 'DOID'}, {'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}, {'id': 5577, 'name': 'gastrinoma', 'source': 'DOID'}]",NCT02831179,Phase I,Withdrawn,Vanderbilt-Ingram Cancer Center ,"[{'id': 4463, 'therapyName': 'Capecitabine + Veliparib + Temozolomide'}]","Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",09/29/2017,[],no
0,both,"[{'id': 3565, 'name': 'meningioma', 'source': 'DOID'}]",NCT02831257,Phase II,"Active, not recruiting",Massachusetts General Hospital ,"[{'id': 991, 'therapyName': 'Vistusertib'}]",AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas,09/29/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02831491,Phase II,Withdrawn,Eli Lilly and Company,"[{'id': 1423, 'therapyName': 'Ramucirumab + Docetaxel'}]",A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer,12/03/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02831686,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 4500, 'therapyName': 'Dexamethasone + Ixazomib + Selinexor'}]","A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma",06/01/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02831933,Phase II,Recruiting,"Eric Bernicker, MD ","[{'id': 4462, 'therapyName': 'AdV-tk + Nivolumab'}]",Trial of Stereotactic Body Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma (ENSIGN),02/18/2017,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT02833233,Phase I,Recruiting, Memorial Sloan Kettering Cancer Center ,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer,07/29/2016,[],no
0,female,"[{'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT02833506,Phase I,Not yet recruiting,Roswell Park Cancer Institute ,"[{'id': 4460, 'therapyName': 'NY-ESO-1 peptide vaccine + Sirolimus'}, {'id': 2696, 'therapyName': 'NY-ESO-1 peptide vaccine'}]","Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",07/17/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02833610,Phase II,Recruiting,Massachusetts General Hospital,"[{'id': 1198, 'therapyName': 'Denosumab'}]",A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency,02/21/2017,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02833701,Phase I,Recruiting,University of Nebraska,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma,07/18/2016,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02833883,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 4459, 'therapyName': 'CC-115 + Enzalutamide'}]","Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer",08/23/2016,[],no
0,both,"[{'id': 4440, 'name': 'seminoma', 'source': 'DOID'}, {'id': 50904, 'name': 'salivary gland carcinoma', 'source': 'DOID'}, {'id': 3030, 'name': 'mucinous adenocarcinoma', 'source': 'DOID'}, {'id': 50773, 'name': 'paraganglioma', 'source': 'DOID'}, {'id': 5345, 'name': 'testicular non-seminomatous germ cell cancer', 'source': 'DOID'}, {'id': 11615, 'name': 'penile cancer', 'source': 'DOID'}, {'id': 2156, 'name': 'ovarian germ cell cancer', 'source': 'DOID'}, {'id': 3307, 'name': 'teratoma', 'source': 'DOID'}, {'id': 4715, 'name': 'gastric neuroendocrine neoplasm', 'source': 'DOID'}, {'id': 2024, 'name': 'placental choriocarcinoma', 'source': 'DOID'}, {'id': 3559, 'name': 'pseudomyxoma peritonei', 'source': 'DOID'}, {'id': 13159, 'name': 'scrotum squamous cell carcinoma', 'source': 'DOID'}, {'id': 50918, 'name': 'vaginal carcinoma', 'source': 'DOID'}, {'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}, {'id': 5742, 'name': 'pancreatic acinar cell adenocarcinoma', 'source': 'DOID'}, {'id': 6126, 'name': 'anal canal carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 3963, 'name': 'thyroid carcinoma', 'source': 'DOID'}, {'id': 3706, 'name': 'fallopian tube adenocarcinoma', 'source': 'DOID'}, {'id': 3193, 'name': 'peripheral nerve sheath neoplasm', 'source': 'DOID'}, {'id': 3702, 'name': 'cervical adenocarcinoma', 'source': 'DOID'}, {'id': 1540, 'name': 'parathyroid carcinoma', 'source': 'DOID'}, {'id': 3713, 'name': 'ovary adenocarcinoma', 'source': 'DOID'}, {'id': 3711, 'name': 'bladder adenocarcinoma', 'source': 'DOID'}, {'id': 3596, 'name': 'placental site trophoblastic tumor', 'source': 'DOID'}, {'id': 4236, 'name': 'carcinosarcoma', 'source': 'DOID'}, {'id': 4876, 'name': 'trachea carcinoma', 'source': 'DOID'}, {'id': 5516, 'name': 'gastric squamous cell carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 138, 'name': 'vaginal squamous tumor', 'source': 'DOID'}, {'id': 660, 'name': 'adrenal cortex cancer', 'source': 'DOID'}, {'id': 3603, 'name': 'mucinous cystadenocarcinoma', 'source': 'DOID'}, {'id': 5531, 'name': 'ovarian squamous cell carcinoma', 'source': 'DOID'}, {'id': 3608, 'name': 'appendix adenocarcinoma', 'source': 'DOID'}, {'id': 3606, 'name': 'ovarian mucinous adenocarcinoma', 'source': 'DOID'}, {'id': 4757, 'name': 'sex cord-stromal neoplasm', 'source': 'DOID'}, {'id': 5539, 'name': 'ureter squamous cell carcinoma', 'source': 'DOID'}, {'id': 5410, 'name': 'pulmonary neuroendocrine tumor', 'source': 'DOID'}, {'id': 3744, 'name': 'cervical squamous cell carcinoma', 'source': 'DOID'}, {'id': 2602, 'name': 'chondroma', 'source': 'DOID'}, {'id': 3114, 'name': 'serous cystadenocarcinoma', 'source': 'DOID'}, {'id': 4906, 'name': 'small intestine adenocarcinoma', 'source': 'DOID'}, {'id': 8618, 'name': 'oral cavity cancer', 'source': 'DOID'}, {'id': 3750, 'name': 'urethra squamous cell carcinoma', 'source': 'DOID'}, {'id': 4901, 'name': 'peritoneal serous adenocarcinoma', 'source': 'DOID'}, {'id': 4916, 'name': 'pituitary carcinoma', 'source': 'DOID'}, {'id': 2098, 'name': 'vulva adenocarcinoma', 'source': 'DOID'}, {'id': 6193, 'name': 'epithelioid sarcoma', 'source': 'DOID'}, {'id': 4015, 'name': 'spindle cell carcinoma', 'source': 'DOID'}, {'id': 4910, 'name': 'urethra adenocarcinoma', 'source': 'DOID'}, {'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}, {'id': 50619, 'name': 'paranasal sinus cancer', 'source': 'DOID'}, {'id': 2870, 'name': 'endometrial adenocarcinoma', 'source': 'DOID'}, {'id': 2101, 'name': 'vulva squamous cell carcinoma', 'source': 'DOID'}, {'id': 4931, 'name': 'nasal cavity carcinoma', 'source': 'DOID'}, {'id': 4930, 'name': 'nasal cavity adenocarcinoma', 'source': 'DOID'}, {'id': 50626, 'name': 'gastrointestinal neuroendocrine tumor', 'source': 'DOID'}, {'id': 3905, 'name': 'lung carcinoma', 'source': 'DOID'}, {'id': 4928, 'name': 'intrahepatic cholangiocarcinoma', 'source': 'DOID'}, {'id': 4159, 'name': 'skin cancer', 'source': 'DOID'}, {'id': 4926, 'name': 'bronchiolo-alveolar adenocarcinoma', 'source': 'DOID'}, {'id': 50892, 'name': 'adrenal gland pheochromocytoma', 'source': 'DOID'}, {'id': 4682, 'name': 'extrahepatic bile duct carcinoma', 'source': 'DOID'}, {'id': 4938, 'name': 'ureter adenocarcinoma', 'source': 'DOID'}, {'id': 200, 'name': 'giant cell tumor', 'source': 'DOID'}, {'id': 1107, 'name': 'esophageal carcinoma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}, {'id': 3025, 'name': 'acinar cell carcinoma', 'source': 'DOID'}, {'id': 14545, 'name': 'seminal vesicle adenocarcinoma', 'source': 'DOID'}]",NCT02834013,Phase 0,Recruiting,National Cancer Institute (NCI),"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Rare Tumors,01/20/2017,[],no
0,both,"[{'id': 219, 'name': 'colon cancer', 'source': 'DOID'}]",NCT02834052,Phase Ib/II,Not yet recruiting,Samir N. Khleif ,"[{'id': 4458, 'therapyName': 'Pembrolizumab + poly ICLC '}]",Pembrolizumab + Poly-ICLC in MRP Colon Cancer,07/29/2016,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02834247,Phase I,Recruiting,"Millennium Pharmaceuticals, Inc. ","[{'id': 4680, 'therapyName': 'Nivolumab + TAK-659'}]",A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors,09/11/2016,[],yes
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02834403,Phase Ib/II,Recruiting,"Polly A. Niravath, MD","[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 6123, 'therapyName': 'Docetaxel + L-NMMA'}, {'id': 6096, 'therapyName': 'L-NMMA'}]",L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients,08/18/2017,[],yes
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT02834975,Phase II,Recruiting,University of Miami ,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).",12/17/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02835729,Phase Ib/II,Recruiting,NewLink Genetics Corporation ,"[{'id': 1606, 'therapyName': 'Cytarabine + Idarubicin'}, {'id': 4499, 'therapyName': 'Cytarabine + Idarubicin + indoximod'}]",A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia,08/12/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}, {'id': 2893, 'name': 'cervix carcinoma', 'source': 'DOID'}]",NCT02835833,Phase I,Recruiting,University of Alabama at Birmingham ,"[{'id': 4498, 'therapyName': 'Bevacizumab + Nintedanib'}]",Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors,07/26/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02837029,Phase I,Recruiting,Northwestern University ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer,07/28/2016,[],no
0,male,"[{'id': 7958, 'name': 'sarcomatoid penile squamous cell carcinoma', 'source': 'DOID'}]",NCT02837042,Phase II,Recruiting,University of Alabama at Birmingham ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma,12/30/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02837263,Phase I,Recruiting,"University of Wisconsin, Madison ","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer,10/14/2016,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}, {'id': 4465, 'name': 'papillary renal cell carcinoma', 'source': 'DOID'}]",NCT02837991,Phase Ib/II,Recruiting,Celldex Therapeutics,"[{'id': 5774, 'therapyName': 'CDX-014'}]","A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Advanced or Metastatic Renal Cell Carcinoma",05/26/2017,[],no
0,both,"[{'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}]",NCT02839681,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma,06/02/2017,[],yes
0,both,"[{'id': 2994, 'name': 'germ cell cancer', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02839694,Phase I,Withdrawn,National Cancer Institute (NCI),"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}, {'id': 4592, 'therapyName': 'Decitabine + Tetrahydrouridine + Celecoxib'}]",Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy,04/30/2017,[],no
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02839707,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 4496, 'therapyName': 'Atezolizumab + Bevacizumab + Doxil'}, {'id': 4495, 'therapyName': 'Atezolizumab + Doxil'}, {'id': 1673, 'therapyName': 'Doxil + Bevacizamub'}]","Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",06/28/2017,[],no
0,both,"[{'id': 962, 'name': 'neurofibroma', 'source': 'DOID'}]",NCT02839720,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Dermal Neurofibroma,06/20/2017,[],yes
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02840409,Phase II,Recruiting,The Hospital for Sick Children,"[{'id': 2635, 'therapyName': 'Vinblastine'}, {'id': 5178, 'therapyName': 'Bevacizumab + Vinblastine'}]",Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG),01/09/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02840994,Phase Ib/II,Recruiting,"Bavarian Nordic, Inc.","[{'id': 5244, 'therapyName': 'CV301 + Nivolumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer,02/03/2017,[],no
0,both,"[{'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}]",NCT02841748,Phase II,Recruiting,University of Chicago ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study",05/31/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02842125,Phase I,Recruiting,"MultiVir, Inc. ","[{'id': 5879, 'therapyName': 'Ad5CMV-p53 gene + Capecitabine'}]",Safety and Efficacy of Intra-Arterial Ad-p53 in Liver Metastases of Solid Tumors,06/12/2017,"[{'molecularProfile': {'id': 2836, 'profileName': 'TP53 positive'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 642, 'profileName': 'TP53 wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 70004, 'name': 'myeloid neoplasm', 'source': 'DOID'}]",NCT02843074,Phase II,Recruiting,"SCRI Development Innovations, LLC ","[{'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]","Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients",11/19/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02844439,Phase II,"Active, not recruiting","Kadmon Corporation, LLC ","[{'id': 967, 'therapyName': 'XL647'}]",Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma,09/29/2017,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT02844816,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer,02/17/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02845297,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (?65 Years) AML Patients,07/31/2016,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT02845323,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 2055, 'therapyName': 'Urelumab'}, {'id': 2567, 'therapyName': 'Nivolumab + Urelumab'}]",Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder,08/02/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02846376,Phase I,Recruiting,Hackensack University Medical Center ,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002),08/18/2017,"[{'molecularProfile': {'id': 28205, 'profileName': 'FLT3 positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02846623,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1975, 'therapyName': 'Atezolizumab + Obinutuzumab'}]",Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib in Patients With Relapsed Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL),02/08/2017,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02846766,Phase II,Not yet recruiting,"Teresa Helsten, MD ","[{'id': 792, 'therapyName': 'Lenvatinib'}]",Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling,07/31/2016,"[{'molecularProfile': {'id': 25719, 'profileName': 'FGFR3 inact mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1221, 'profileName': 'FGFR1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 25717, 'profileName': 'FGFR1 inact mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 25718, 'profileName': 'FGFR2 inact mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1185, 'profileName': 'FGFR2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3329, 'profileName': 'FGFR3 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3147, 'profileName': 'FGFR2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 812, 'profileName': 'FGFR1 amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02846792,Phase Ib/II,Recruiting,University of Washington ,"[{'id': 4512, 'therapyName': 'Nivolumab + Plinabulin'}]","Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer",01/24/2017,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02846935,Phase 0,Recruiting,Yogen Saunthararajah ,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}]",p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies,04/27/2017,[],no
0,both,"[{'id': 3382, 'name': 'liposarcoma', 'source': 'DOID'}]",NCT02846987,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",Study of Abemaciclib in Dedifferentiated Liposarcoma,07/31/2016,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 4905, 'name': 'pancreatic carcinoma', 'source': 'DOID'}]",NCT02847000,Phase 0,Recruiting,Yogen Saunthararajah ,"[{'id': 3567, 'therapyName': 'Decitabine + Tetrahydrouridine'}]",p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer,04/19/2017,[],no
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}]",NCT02847429,Phase III,Recruiting,"Arog Pharmaceuticals, Inc. ","[{'id': 705, 'therapyName': 'Crenolanib'}]",Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST,08/26/2016,"[{'molecularProfile': {'id': 604, 'profileName': 'PDGFRA D842V'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3565, 'name': 'meningioma', 'source': 'DOID'}]",NCT02847559,Phase II,Recruiting,Northwestern University ,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma,08/11/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02848651,Phase II,Recruiting,"Genentech, Inc. ","[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab (MPDL3280A) as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Clinical Evaluation of Novel Blood-Based Diagnostics [B-F1RST],09/11/2016,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02849496,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4511, 'therapyName': 'Atezolizumab + Veliparib'}, {'id': 954, 'therapyName': 'Veliparib'}]",Veliparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer,11/30/2016,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02849990,Phase II,Recruiting,University of Washington ,"[{'id': 4510, 'therapyName': 'Abiraterone + ARN-509 + Degarelix + Indomethacin + Prednisone'}]","Androgen Receptor Antagonist ARN-509, Abiraterone Acetate, Prednisone, Degarelix, and Indomethacin in Treating Patients With Localized Prostate Cancer Before Surgery",04/15/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02852655,Phase 0,"Active, not recruiting",Dana-Farber Cancer Institute ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma",09/16/2017,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}]",NCT02853305,Phase III,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}]",Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361),09/25/2016,[],no
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT02853318,Phase II,Recruiting,Roswell Park Cancer Institute ,"[{'id': 4528, 'therapyName': 'Bevacizumab + Cyclophosphamide + Pembrolizumab'}]","Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",09/09/2016,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02853331,Phase III,Recruiting,Merck Sharp & Dohme Corp. ,"[{'id': 2494, 'therapyName': 'Axitinib + Pembrolizumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426),10/04/2016,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02853344,Phase II,Recruiting,Merck Sharp & Dohme Corp. ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427),10/30/2016,[],no
0,female,"[{'id': 3702, 'name': 'cervical adenocarcinoma', 'source': 'DOID'}, {'id': 5636, 'name': 'cervical adenosquamous carcinoma', 'source': 'DOID'}, {'id': 3744, 'name': 'cervical squamous cell carcinoma', 'source': 'DOID'}]",NCT02853604,Phase III,Recruiting,"Advaxis, Inc. ","[{'id': 3090, 'therapyName': 'ADXS11-001'}]",Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer (AIM2CERV),10/30/2016,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02854436,Phase II,Suspended,"Janssen Research & Development, LLC ","[{'id': 832, 'therapyName': 'Niraparib'}]",An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies,06/10/2017,[],no
0,,[],NCT02855086,Phase Ib/II,Terminated,Eben Rosenthal ,[],Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery,07/18/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02855125,Phase II,Recruiting,"Taiho Oncology, Inc. ","[{'id': 1407, 'therapyName': 'TS-1'}, {'id': 4527, 'therapyName': 'TAS-114 + TS-1'}]",A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1,09/28/2016,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT02855944,Phase III,Recruiting,"Clovis Oncology, Inc. ","[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 906, 'therapyName': 'Rucaparib'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1103, 'therapyName': 'Paclitaxel'}]","ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients",10/17/2016,"[{'molecularProfile': {'id': 1283, 'profileName': 'BRCA2 inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1282, 'profileName': 'BRCA1 inact mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT02856568,Phase I,Withdrawn,Mayo Clinic ,"[{'id': 4526, 'therapyName': 'ACY-1215 + Cisplatin + Gemcitabine'}]","Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma",05/31/2017,[],no
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02857270,Phase I,Recruiting,Eli Lilly and Company,"[{'id': 4588, 'therapyName': 'LY3214996'}, {'id': 4590, 'therapyName': 'LY3214996 + nab-paclitaxel + Gemcitabine'}, {'id': 4589, 'therapyName': 'LY3214996 + Midazolam'}, {'id': 4591, 'therapyName': 'LY3214996 + Abemaciclib'}]",A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer,10/08/2016,"[{'molecularProfile': {'id': 1208, 'profileName': 'HRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3234, 'name': 'central nervous system lymphoma', 'source': 'DOID'}, {'id': 12253, 'name': 'testicular lymphoma', 'source': 'DOID'}]",NCT02857426,Phase II,Recruiting,Bristol-Myers Squibb,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) (CheckMate 647),06/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02858310,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 4562, 'therapyName': 'Aldesleukin + Cyclophosphamide + Fludarabine + Pembrolizumab'}]",E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers,08/14/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02858869,Phase 0,Recruiting,Emory University ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases,10/22/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02859324,Phase Ib/II,Recruiting,Celgene Corporation,"[{'id': 4611, 'therapyName': 'CC-122 + Nivolumab'}]",A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC),09/17/2016,[],no
0,both,"[{'id': 2615, 'name': 'papilloma', 'source': 'DOID'}]",NCT02859454,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab for People With Recurrent Respiratory Papillomatosis,09/18/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02860000,Phase II,Recruiting,Mayo Clinic ,"[{'id': 4561, 'therapyName': 'Alisertib + Fulvestrant'}, {'id': 626, 'therapyName': 'Alisertib'}]","Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer",07/12/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1790, 'name': 'malignant mesothelioma', 'source': 'DOID'}]",NCT02860286,Phase II,"Active, not recruiting","Epizyme, Inc.","[{'id': 2683, 'therapyName': 'Tazemetostat'}]",Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma,07/26/2017,[],yes
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT02860546,Phase II,"Active, not recruiting","Taiho Oncology, Inc. ","[{'id': 4560, 'therapyName': 'Nivolumab + trifluridine/tipiracil hydrochloride'}]",A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC,07/25/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02860676,Phase I,Enrolling by invitation,"University of California, San Diego ","[{'id': 4312, 'therapyName': 'Cirmtuzumab'}]",Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961,03/02/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 219, 'name': 'colon cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02860780,Phase I,Completed,Eli Lilly and Company,"[{'id': 4587, 'therapyName': 'Prexasertib + Ralimetinib'}]",A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer,09/06/2017,"[{'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02861040,Phase I,Withdrawn,Northwestern University ,"[{'id': 4781, 'therapyName': 'Vincristine + Volasertib'}]",Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia,12/16/2016,[],yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02861573,Phase I,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 5343, 'therapyName': 'Dexamethasone + Docetaxel + Pembrolizumab + Prednisone'}, {'id': 5342, 'therapyName': 'Olaparib + Pembrolizumab'}, {'id': 2666, 'therapyName': 'Enzalutamide + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365),02/20/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02861898,Phase Ib/II,Recruiting,Northwell Health ,"[{'id': 4559, 'therapyName': 'Cetuximab + Mannitol'}]",Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma,08/14/2016,"[{'molecularProfile': {'id': 2419, 'profileName': 'EGFR over exp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02862275,Phase 0,Recruiting,National Cancer Institute (NCI),"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer,03/10/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02863991,Phase II,Recruiting,"Oncoceutics, Inc. ","[{'id': 1687, 'therapyName': 'ONC201'}]",Oral ONC201 in Relapsed/Refractory Multiple Myeloma,03/15/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02864251,Phase III,Recruiting,Bristol-Myers Squibb,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}]","A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy (CheckMate722)",10/30/2016,"[{'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02864316,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure,12/30/2016,[],no
0,both,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT02864381,Phase II,"Active, not recruiting",Gilead Sciences ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4736, 'therapyName': 'GS-5745 + Nivolumab'}]",GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma,06/09/2017,[],no
0,both,"[{'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}]",NCT02864992,Phase II,Recruiting,"EMD Serono Research & Development Institute, Inc. ","[{'id': 1398, 'therapyName': 'MSC2156119J'}]",Tepotinib Phase II Study in Lung Adenocarcinoma Harbouring MET Exon 14 (METex14) Skipping Alterations,08/13/2016,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 24383, 'profileName': 'MET exon 14'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 4039, 'profileName': 'EGFR exon 20 ins'}, 'requirementType': 'excluded'}]",yes
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT02865811,Phase II,"Active, not recruiting",Dana-Farber Cancer Institute,"[{'id': 4558, 'therapyName': 'Doxil + Pembrolizumab'}]","Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer",08/22/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 3620, 'name': 'central nervous system cancer', 'source': 'DOID'}, {'id': 3973, 'name': 'thyroid medullary carcinoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 660, 'name': 'adrenal cortex cancer', 'source': 'DOID'}, {'id': 5176, 'name': ""renal Wilms' tumor"", 'source': 'DOID'}, {'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}, {'id': 4233, 'name': 'clear cell sarcoma', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 687, 'name': 'hepatoblastoma', 'source': 'DOID'}, {'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}, {'id': 4239, 'name': 'alveolar soft part sarcoma', 'source': 'DOID'}]",NCT02867592,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 998, 'therapyName': 'cabozantinib'}]","Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",06/20/2017,"[{'molecularProfile': {'id': 2294, 'profileName': 'RET act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1629, 'profileName': 'MET amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2096, 'profileName': 'MET act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 5392, 'profileName': 'MET over exp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02867618,Phase Ib/II,Recruiting,Changchun Deng ,"[{'id': 4598, 'therapyName': 'Carfilzomib + TGR-1202'}]",Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma,02/18/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02868632,Phase I,Recruiting,New York University School of Medicine ,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer",10/03/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02869295,Phase I,Recruiting,Nektar Therapeutics,"[{'id': 5075, 'therapyName': 'NKTR-214'}]",A Phase 1 Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors,04/07/2017,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02869633,Phase II,Recruiting,Vanderbilt-Ingram Cancer Center ,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant,10/19/2016,"[{'molecularProfile': {'id': 14278, 'profileName': 'NOTCH1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02869789,Phase III,Recruiting,Bristol-Myers Squibb,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers,10/04/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02870920,Phase II,"Active, not recruiting",Canadian Cancer Trials Group ,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies,07/03/2017,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02871791,Phase Ib/II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 4597, 'therapyName': 'Exemestane + Everolimus + Palbociclib'}]",Palbociclib With Everolimus + Exemestane In BC,08/26/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02871843,Phase I,Recruiting,"EpicentRx, Inc. ","[{'id': 4596, 'therapyName': 'RRx-001 + Temozolomide'}]",Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1),07/06/2017,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}]",NCT02872116,Phase III,Recruiting,Bristol-Myers Squibb,"[{'id': 1597, 'therapyName': 'Capecitabine + Oxaliplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer (CheckMate649),10/14/2016,[],no
0,both,"[{'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}]",NCT02872714,Phase II,Recruiting,Incyte Corporation ,"[{'id': 4173, 'therapyName': 'INCB054828'}]",A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma,12/13/2016,"[{'molecularProfile': {'id': 14910, 'profileName': 'FGFR1 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3147, 'profileName': 'FGFR2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 812, 'profileName': 'FGFR1 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2969, 'profileName': 'FGFR2 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14903, 'profileName': 'FGFR3 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1221, 'profileName': 'FGFR1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1185, 'profileName': 'FGFR2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3329, 'profileName': 'FGFR3 amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02873195,Phase II,Recruiting,Academic and Community Cancer Research United ,"[{'id': 2097, 'therapyName': 'Bevacizumab + Capecitabine'}, {'id': 1202, 'therapyName': 'Atezolizumab + Bevacizumab + Capecitabine'}]",Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer,10/19/2017,[],no
0,both,"[{'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}]",NCT02873819,Phase II,Recruiting,Gliknik Inc. ,"[{'id': 4614, 'therapyName': 'MAGE-A3 vaccine'}, {'id': 4615, 'therapyName': 'Cyclophosphamide + poly ICLC  + Sargramostim'}]",Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity,04/08/2017,[],no
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT02873962,Phase II,Recruiting, Dana-Farber Cancer Institute,"[{'id': 2111, 'therapyName': 'Bevacizumab + Nivolumab'}]",A Phase II Study Of Nivolumab/ Bevacizumab,03/02/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02873975,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1651, 'therapyName': 'Prexasertib'}]",A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency,10/20/2016,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2007, 'profileName': 'RB1 loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3274, 'profileName': 'ATM mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 16574, 'profileName': 'FBXW7 mutant'}, 'requirementType': 'partial'}]",yes
0,,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02874404,Phase II,Recruiting,"Matthew Lunning, MD","[{'id': 2044, 'therapyName': 'Ibrutinib + TGR-1202'}]",TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma,12/10/2016,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 363, 'name': 'uterine cancer', 'source': 'DOID'}]",NCT02874430,Phase II,Recruiting,Thomas Jefferson University,"[{'id': 4610, 'therapyName': 'Metformin + Doxycycline'}]",Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer,08/29/2016,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02874664,Phase I,Recruiting,Stemcentrx ,"[{'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}]",A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer,02/20/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02874742,Phase II,Recruiting,"Janssen Research & Development, LLC ","[{'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}]","Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma",09/09/2016,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 50749, 'name': 'peripheral T-cell lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 8584, 'name': 'Burkitt lymphoma', 'source': 'DOID'}]",NCT02875002,Phase I,Not yet recruiting,Yale University,"[{'id': 4826, 'therapyName': 'Belinostat + Volasertib'}]",Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas,10/17/2016,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02875067,Phase Ib/II,Recruiting,New York University School of Medicine,"[{'id': 3322, 'therapyName': 'lenalidomide + Pembrolizumab'}]","Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma",12/27/2016,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02875548,Phase II,Recruiting,"Epizyme, Inc. ","[{'id': 2683, 'therapyName': 'Tazemetostat'}]",Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study,09/18/2017,[],no
0,both,"[{'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}]",NCT02875613,Phase II,Recruiting,"Assuntina Sacco, M.D. ","[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer,10/30/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02876003,Phase II,Withdrawn,"GenSpera, Inc","[{'id': 4338, 'therapyName': 'mipsagargin'}]",Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma,02/25/2017,[],yes
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02876107,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 3386, 'therapyName': 'Carboplatin + Paclitaxel + Panitumumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC),10/08/2016,[],yes
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT02876224,Phase I,Recruiting,Hoffmann-La Roche,"[{'id': 4609, 'therapyName': 'Cobimetinib + Bevacizumab + Atezolizumab'}]",Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors,10/05/2016,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02876302,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 4679, 'therapyName': 'Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib'}]",Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer,04/30/2017,[],yes
0,both,[],NCT02877082,Phase II,Terminated,Emory University ,[],"Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients",08/08/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02878785,Phase Ib/II,Recruiting,University of Maryland ,"[{'id': 5531, 'therapyName': 'Decitabine + Talazoparib'}]",Decitabine and Talazoparib in Untreated AML and R/R AML (1565GCC) ,04/12/2017,[],no
0,both,"[{'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}, {'id': 50934, 'name': 'ovarian clear cell carcinoma', 'source': 'DOID'}, {'id': 7177, 'name': 'anal canal squamous cell carcinoma', 'source': 'DOID'}, {'id': 50904, 'name': 'salivary gland carcinoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 50929, 'name': 'mucosal melanoma', 'source': 'DOID'}, {'id': 6367, 'name': 'acral lentiginous melanoma', 'source': 'DOID'}, {'id': 305, 'name': 'carcinoma', 'source': 'DOID'}]",NCT02879162,Phase II,Recruiting,Canadian Cancer Trials Group ,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours,12/10/2016,[],yes
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT02879318,Phase II,Recruiting,Canadian Cancer Trials Group,"[{'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma",12/02/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02879617,Phase II,Recruiting,"Liza Villaruz, MD ","[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients,03/27/2017,"[{'molecularProfile': {'id': 11085, 'profileName': 'ROS1 rearrange'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 12603, 'name': 'acute leukemia', 'source': 'DOID'}]",NCT02879695,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 4613, 'therapyName': 'Blinatumomab + Ipilimumab + Nivolumab'}]",Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia,05/26/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02879760,Phase Ib/II,Recruiting,"Turnstone Biologics, Inc.","[{'id': 5085, 'therapyName': 'Pembrolizumab + Ad-MAGEA3 + MG1-MAGEA3'}]",Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients,12/12/2016,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02879994,Phase II,Recruiting,Jonsson Comprehensive Cancer Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer",06/02/2017,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}]",NCT02880020,Phase II,Recruiting,Jonsson Comprehensive Cancer Center,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery,12/23/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02880228,Phase II,"Active, not recruiting",Mayo Clinic ,"[{'id': 4612, 'therapyName': 'Dexamethasone + lenalidomide + Pembrolizumab'}]","Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant",07/12/2017,[],no
0,both,"[{'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}]",NCT02880345,Phase 0,Not yet recruiting,Abramson Cancer Center of the University of Pennsylvania ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",RADVAX: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy,08/28/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT02880371,Phase Ib/II,Recruiting,Array BioPharma,"[{'id': 4608, 'therapyName': 'ARRY-382 + Pembrolizumab'}]",A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors,09/21/2016,[],yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02881242,Phase II,Not yet recruiting,Jonsson Comprehensive Cancer Center ,"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer,08/28/2016,[],no
0,both,"[{'id': 50610, 'name': 'oral cavity carcinoma in situ', 'source': 'DOID'}]",NCT02882282,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias,06/20/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02882321,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 6267, 'therapyName': 'IACS-010759'}]",Study of IACS-010759 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML),10/09/2017,[],no
0,both,"[{'id': 7061, 'name': 'precursor B lymphoblastic lymphoma/leukemia', 'source': 'DOID'}]",NCT02883049,Phase III,Suspended,National Cancer Institute (NCI),"[{'id': 717, 'therapyName': 'Dasatinib'}, {'id': 4685, 'therapyName': 'Dexamethasone + Doxorubicin'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1746, 'therapyName': 'Clofarabine'}]",Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations,09/13/2017,[],yes
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02883062,Phase II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}, {'id': 1203, 'therapyName': 'Atezolizumab + Carboplatin + Paclitaxel'}]","Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer",09/11/2016,[],yes
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT02884648,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 667, 'therapyName': 'Bevacizumab'}]",Bevacizumab in Ovarian Cancer Patients With Disease at Second-look Surgery,11/17/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02885324,Phase II,Recruiting,Indiana University ,"[{'id': 998, 'therapyName': 'cabozantinib'}]",Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children,05/23/2017,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT02885649,Phase 0,Not yet recruiting,"Rutgers, The State University of New Jersey ","[{'id': 1262, 'therapyName': 'Enzalutamide'}]",Enzalutamide Before Surgery in Treating Patients With Kidney Cancer,09/11/2016,[],yes
0,both,"[{'id': 9551, 'name': 'smoldering myeloma', 'source': 'DOID'}]",NCT02886065,Phase I,Recruiting,Massachusetts General Hospital,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 5082, 'therapyName': 'PVX-410 + MEDI4736'}, {'id': 5081, 'therapyName': 'PVX-410 + MEDI4736 + lenalidomide'}]","A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma",01/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02886585,Phase II,Recruiting,Massachusetts General Hospital ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab In Central Nervous System Metastases,12/09/2016,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02887976,Phase III,Not yet recruiting,"GU Research Network, LLC ","[{'id': 4678, 'therapyName': 'Abiraterone + Methylprednisolone'}]",Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201,09/11/2016,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT02888665,Phase Ib/II,Recruiting,Fred Hutchinson Cancer Research Center ,"[{'id': 4690, 'therapyName': 'Doxorubicin + Pembrolizumab'}]",Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery,12/17/2016,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02888743,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer,06/20/2017,"[{'molecularProfile': {'id': 7744, 'profileName': 'MSH6 loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 25004, 'profileName': 'MLH1 loss'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02889861,Phase Ib/II,Recruiting,Immunocore Ltd ,"[{'id': 3847, 'therapyName': 'IMCgp100'}]",IMCgp100-401 Rollover Study,03/29/2017,[],no
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 50934, 'name': 'ovarian clear cell carcinoma', 'source': 'DOID'}, {'id': 5828, 'name': 'endometrioid ovary carcinoma', 'source': 'DOID'}]",NCT02889900,Phase II,Recruiting,AstraZeneca,"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO),01/25/2017,"[{'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02890069,Phase I,Recruiting,Novartis Pharmaceuticals,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5312, 'therapyName': 'PDR001 + Everolimus'}, {'id': 5313, 'therapyName': 'PDR001 + Panobinostat'}]","A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat",02/12/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02890329,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 5738, 'therapyName': 'Decitabine + Ipilimumab'}]",Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia,05/26/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02890355,,Recruiting,,"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1315, 'therapyName': 'FOLFIRI'}]",FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer,09/12/2016,[],no
0,both,"[{'id': 8691, 'name': 'mycosis fungoides', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02890368,Phase I,Recruiting,Trillium Therapeutics Inc.,"[{'id': 5338, 'therapyName': 'TTI-621'}]",Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides,02/28/2017,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT02891161,Phase Ib/II,Recruiting,Monika Joshi ,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder,12/07/2016,[],no
0,,[],NCT02891603,Phase Ib/II,Recruiting,H. Lee Moffitt Cancer Center and Research Institute ,[],A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression,04/05/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}, {'id': 5517, 'name': 'stomach carcinoma', 'source': 'DOID'}]",NCT02892123,Phase I,Recruiting,Zymeworks Inc.,"[{'id': 6240, 'therapyName': 'ZW25'}]",Trial of ZW25 in Patients With Advanced HER2-expressing Cancers,09/29/2017,"[{'molecularProfile': {'id': 343, 'profileName': 'EGFR wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 391, 'profileName': 'ALK wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1249, 'profileName': 'ROS1 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}]",NCT02892201,Phase II,Recruiting,Yale University ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in HNSCC With Residual Disease After Radiation,09/23/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02892318,Phase I,Recruiting,Hoffmann-La Roche ,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}]",A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML),11/03/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02892734,Phase II,Recruiting,Northwestern University ,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer,09/12/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02893917,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1971, 'therapyName': 'Cediranib + Olaparib'}, {'id': 837, 'therapyName': 'Olaparib'}]",Olaparib With or Without Cediranib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,04/06/2017,[],no
0,both,"[{'id': 1798, 'name': 'pancreatic endocrine carcinoma', 'source': 'DOID'}]",NCT02893930,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery,02/08/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02896335,Phase II,Recruiting,Massachusetts General Hospital ,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Palbociclib In Progressive Brain Metastases,12/09/2016,"[{'molecularProfile': {'id': 1806, 'profileName': 'CDKN2A loss'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02897375,Phase I,Recruiting,Emory University ,"[{'id': 4734, 'therapyName': 'Cisplatin + Palbociclib'}, {'id': 4735, 'therapyName': 'Carboplatin + Palbociclib'}]",Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors,11/05/2016,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}]",NCT02897765,Phase I,Recruiting,"Neon Therapeutics, Inc.","[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 4733, 'therapyName': 'NEO-PV-01 + poly ICLC'}]","A Personalized Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer",10/05/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02897778,Phase I,Completed,Syndax Pharmaceuticals ,"[{'id': 1541, 'therapyName': 'Entinostat'}]",Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors,04/18/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02898116,Phase Ib/II,Recruiting,Ludwig Institute for Cancer Research ,"[{'id': 4730, 'therapyName': 'MEDI4736 + X-396'}, {'id': 961, 'therapyName': 'X-396'}]","A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer",03/07/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5598, 'name': 'fallopian tube serous adenocarcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 50933, 'name': 'ovarian serous carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 4901, 'name': 'peritoneal serous adenocarcinoma', 'source': 'DOID'}]",NCT02898207,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 4729, 'therapyName': 'Olaparib + Onalespib'}]","Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer",06/20/2017,[],yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02899052,Phase II,Recruiting,AbbVie,"[{'id': 5268, 'therapyName': 'Carfilzomib + Dexamethasone + Venetoclax'}]",Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM),01/31/2017,[],no
0,both,"[{'id': 263, 'name': 'kidney cancer', 'source': 'DOID'}]",NCT02899078,Phase Ib/II,Recruiting,"University of California, Davis ","[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer,11/22/2016,[],no
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT02899195,Phase II,Recruiting,"PrECOG, LLC. ","[{'id': 5630, 'therapyName': 'Cisplatin + Durvalumab + Pemetrexed'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505),05/05/2017,[],no
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT02899299,Phase III,Recruiting,Bristol-Myers Squibb,"[{'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (CheckMate743),11/17/2016,[],no
0,both,"[{'id': 50875, 'name': 'small cell neuroendocrine carcinoma', 'source': 'DOID'}]",NCT02899728,Phase II,Suspended,National Cancer Institute (NCI),"[{'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]","Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer",06/01/2017,[],no
0,female,"[{'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}]",NCT02899793,Phase II,Recruiting,Yale University ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer,10/01/2016,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02900157,Phase I,"Active, not recruiting",MedImmune LLC ,"[{'id': 4727, 'therapyName': 'MEDI4736 + MEDI9090'}]",Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors,03/14/2017,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02900469,Phase 0,Recruiting,New York University School of Medicine ,"[{'id': 1198, 'therapyName': 'Denosumab'}]",Safety Study of Denosumab to Treat Breast Cancer,11/19/2016,[],no
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT02900560,Phase II,Recruiting,Translational Research in Oncology,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer,01/16/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02900664,Phase I,Recruiting,Novartis Pharmaceuticals,"[{'id': 5399, 'therapyName': 'PDR001 + EGF816'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 5398, 'therapyName': 'PDR001 + Trametinib'}, {'id': 5395, 'therapyName': 'PDR001 + Canakinumab'}]","A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)",03/01/2017,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT02901548,Phase II,Recruiting,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder,02/18/2017,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT02901899,Phase II,Recruiting,Northwestern University ,"[{'id': 4725, 'therapyName': 'Pembrolizumab + SGI-110'}]","Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",11/26/2016,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02902484,Phase Ib/II,Not yet recruiting,University of Texas Southwestern Medical Center,"[{'id': 4723, 'therapyName': 'Nintedanib + Gemcitabine + nab-paclitaxel'}, {'id': 831, 'therapyName': 'Nintedanib'}]",Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer,09/21/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02903160,Phase II,Recruiting,Icahn School of Medicine at Mount Sinai ,"[{'id': 4759, 'therapyName': 'Abiraterone + Cabazitaxel + Carboplatin + Enzalutamide + Prednisone'}]","Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)",10/12/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02903368,Phase II,Recruiting,Dana-Farber Cancer Institute ,"[{'id': 3079, 'therapyName': 'Abiraterone + Leuprolide + Prednisone'}, {'id': 4758, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide + Prednisone'}]",Neoadjuvant And Adjuvant Abiraterone Acetate + Aptilutamide Prostate Cancer Undergoing Prostatectomy,02/10/2017,[],no
0,both,"[{'id': 9551, 'name': 'smoldering myeloma', 'source': 'DOID'}]",NCT02903381,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 5128, 'therapyName': 'Nivolumab + Lenalidomide + Dexamethasone'}]",Nivolumab + Lenalidomide + Dexamethasone In SMM,12/27/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02903914,Phase I,Recruiting,"Calithera Biosciences, Inc","[{'id': 4722, 'therapyName': 'CB-1158 + Nivolumab'}, {'id': 4721, 'therapyName': 'CB-1158'}]",Arginase Inhibitor CB-1158 in Patients With Solid Tumors,09/21/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02904226,Phase Ib/II,Recruiting,"Jounce Therapeutics, Inc.","[{'id': 4720, 'therapyName': 'JTX-2011 + Nivolumab'}, {'id': 4719, 'therapyName': 'JTX-2011'}]",Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors (ICONIC),09/19/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02904954,Phase II,Recruiting,Weill Medical College of Cornell University,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer,01/03/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02905318,Phase II,Recruiting,Canadian Cancer Trials Group ,"[{'id': 850, 'therapyName': 'Palbociclib'}]",Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer,03/11/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02905994,Phase I,Withdrawn,Massachusetts General Hospital,"[{'id': 3213, 'therapyName': 'Cytarabine + Idarubicin + Volasertib'}]",Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia,02/18/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02906059,Phase I,Recruiting,New York University School of Medicine,"[{'id': 1361, 'therapyName': 'MK-1775 + Irinotecan'}]","Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer",12/09/2016,"[{'molecularProfile': {'id': 1193, 'profileName': 'KRAS G13X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1196, 'profileName': 'NRAS G12X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 26332, 'profileName': 'KRAS K117X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1197, 'profileName': 'NRAS G13X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 26333, 'profileName': 'KRAS A146X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 26334, 'profileName': 'NRAS A146X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1192, 'profileName': 'KRAS G12X'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02906332,Phase II,"Active, not recruiting",Hackensack University Medical Center,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1390, 'therapyName': 'Dexamethasone'}]",Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM),08/10/2017,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 80147, 'name': 'lymphoblastic lymphoma', 'source': 'DOID'}]",NCT02906371,Phase I,Recruiting,University of Pennsylvania,"[{'id': 5647, 'therapyName': 'Tocilizumab'}]",Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome,05/19/2017,[],yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02906397,Phase I,Recruiting,Abramson Cancer Center of the University of Pennsylvania ,"[{'id': 2409, 'therapyName': 'Galunisertib'}]",A Phase I Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC),08/01/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02906605,Phase II,Withdrawn,"Janssen Research & Development, LLC ","[{'id': 1947, 'therapyName': 'ARN-509'}, {'id': 4890, 'therapyName': 'ARN-509 + JNJ-64041809'}]","A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer",11/23/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02906670,Phase Ib/II,Recruiting,Symphogen A/S,"[{'id': 3885, 'therapyName': 'Pan-HER'}]",Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies,02/15/2017,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02906696,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 690, 'therapyName': 'Bosutinib'}]",Bosutinib Dose-Optimization Study in Chronic Myeloid Leukemia (CML),11/02/2016,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02907099,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 4757, 'therapyName': 'BKT140 + Pembrolizumab'}]",Pembrolizumab and BL-8040 in Metastatic Pancreatic Cancer,12/06/2016,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}]",NCT02907359,Phase III,Recruiting,Astex Pharmaceuticals ,"[{'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1949, 'therapyName': 'SGI-110'}]",Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs,10/30/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02907918,Phase II,Recruiting,Washington University School of Medicine,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 4756, 'therapyName': 'Letrozole + Palbociclib + Trastuzumab'}]",Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer (PALTAN),07/06/2017,[],yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02908672,Phase III,Recruiting,Hoffmann-La Roche,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}]",A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Participants With Metastatic or Unresectable Locally Advanced Melanoma,02/08/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02909452,Phase I,Recruiting,Syndax Pharmaceuticals,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors,09/25/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 8584, 'name': 'Burkitt lymphoma', 'source': 'DOID'}, {'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT02909777,Phase I,Recruiting,Dana-Farber Cancer Institute,"[{'id': 709, 'therapyName': 'CUDC-907'}]","Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma",05/26/2017,[],yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02909972,Phase I,Recruiting,Aileron Therapeutics ,"[{'id': 4755, 'therapyName': 'ALRN-6924 + Cytarabine'}, {'id': 2273, 'therapyName': 'ALRN-6924'}]",Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome,09/25/2016,"[{'molecularProfile': {'id': 642, 'profileName': 'TP53 wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT02910583,Phase II,"Active, not recruiting",Pharmacyclics LLC. ,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Ibrutinib Plus Venetoclax in Patients With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma,08/23/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02910700,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 4753, 'therapyName': 'Nivolumab + Trametinib'}, {'id': 4754, 'therapyName': 'Dabrafenib + Nivolumab + Trametinib'}]",Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma,12/14/2016,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}]",NCT02912559,Phase III,Recruiting,National Cancer Institute (NCI),"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair or Microsatellite Instability,09/16/2017,"[{'molecularProfile': {'id': 7744, 'profileName': 'MSH6 loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 17286, 'profileName': 'MLH1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 17288, 'profileName': 'MSH6 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 25004, 'profileName': 'MLH1 loss'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}]",NCT02912572,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 3144, 'therapyName': 'Avelumab'}]","Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer",03/02/2017,[],yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02912754,Phase Ib/II,Not yet recruiting,Sunnybrook Health Sciences Centre,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 4768, 'therapyName': 'Ibrutinib + Ruxolitinib'}]",Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients,09/26/2016,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02913196,Phase I,Recruiting,Weill Medical College of Cornell University,"[{'id': 4767, 'therapyName': 'Abiraterone + ARN-509 + Docetaxel + Prednisone'}]","Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC",12/09/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02913313,Phase Ib/II,Recruiting,Bristol-Myers Squibb ,"[{'id': 4888, 'therapyName': 'BMS-986207 + Nivolumab'}, {'id': 4887, 'therapyName': 'BMS-986207 '}]",A Study to Evaluate the Safety and Tolerability of Monoclonal Antibody BMS-986207 Alone and in Combination With Nivolumab in Advanced (Solid Tumor) Cancers,12/02/2016,[],no
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT02913417,Phase Ib/II,Recruiting,"David Minor, MD","[{'id': 4769, 'therapyName': 'Yttrium-90 + Nivolumab + Ipilimumab'}]","Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases",12/13/2016,[],no
0,both,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}]",NCT02913430,Phase II,Recruiting,University of Pittsburgh,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Phase II Treatment of Metastatic Breast Cancer With Fulvestrant or Tamoxifen,11/06/2016,[],yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02914327,Phase I,Recruiting,Esanex Inc.,"[{'id': 4780, 'therapyName': 'Ibrutinib + SNX-5422'}]",Safety and Activity of SNX-5422 Plus Ibrutinib in CLL,02/15/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02915172,Phase I,Withdrawn,M.D. Anderson Cancer Center,"[{'id': 4779, 'therapyName': 'Capecitabine + Lenvatinib'}]",Lenvatinib and Capecitabine in Patients With Advanced Malignancies,06/27/2017,[],no
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT02915523,Phase Ib/II,Recruiting,Syndax Pharmaceuticals ,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 5559, 'therapyName': 'Avelumab + Entinostat'}]",Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer,04/19/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02915666,Phase I,Recruiting,University of Texas Southwestern Medical Center ,"[{'id': 4778, 'therapyName': 'Dabrafenib + Digoxin + Trametinib'}]",A Clinical Trial of Patients With Melanoma,11/24/2016,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4471, 'name': 'chromophobe renal cell carcinoma', 'source': 'DOID'}, {'id': 4465, 'name': 'papillary renal cell carcinoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 4464, 'name': 'collecting duct carcinoma', 'source': 'DOID'}]",NCT02915783,Phase II,Recruiting,Eisai Inc.,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]",A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease,03/14/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02917993,Phase Ib/II,Recruiting,Incyte Corporation ,"[{'id': 4777, 'therapyName': 'INCB039110 + Osimertinib'}]",An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer,11/05/2016,"[{'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT02918162,Phase II,Recruiting,Paul Oberstein ,"[{'id': 4776, 'therapyName': 'Capecitabine + Epirubicin + Oxaliplatin + Pembrolizumab'}]",Perioperative Chemo and Pembrolizumab in Gastric Cancer,02/08/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02919449,Phase I,Recruiting,"Vyriad, Inc.","[{'id': 6127, 'therapyName': 'MV-NIS + Atezolizumab'}]",Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer,08/18/2017,[],no
0,both,"[{'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}]",NCT02919683,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity,11/17/2016,[],no
0,both,"[{'id': 14110, 'name': 'anus cancer', 'source': 'DOID'}]",NCT02919969,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Refractory Metastatic Anal Cancer,11/26/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02920008,Phase III,Recruiting,Astex Pharmaceuticals,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1949, 'therapyName': 'SGI-110'}]","Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia",03/29/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02920450,Phase Ib/II,Recruiting,University of Florida,"[{'id': 4785, 'therapyName': 'Gedatolisib + Paclitaxel + Carboplatin'}]","Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC",05/17/2017,"[{'molecularProfile': {'id': 479, 'profileName': 'PTEN loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2095, 'profileName': 'PTEN inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 743, 'profileName': 'PIK3CA act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02920996,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1030, 'therapyName': 'LY2801653'}]",Merestinib In Non-Small Cell Lung Cancer And Solid Tumors,11/17/2016,"[{'molecularProfile': {'id': 24383, 'profileName': 'MET exon 14'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT02921256,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 954, 'therapyName': 'Veliparib'}, {'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}, {'id': 4838, 'therapyName': 'Capecitabine + Veliparib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer,10/18/2016,[],no
0,female,"[{'id': 2893, 'name': 'cervix carcinoma', 'source': 'DOID'}]",NCT02921269,Phase II,Suspended,National Cancer Institute (NCI) ,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]","Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer",09/29/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02921919,Phase II,Recruiting,"Medivation, Inc.","[{'id': 682, 'therapyName': 'Talazoparib'}]",Open-Label Extension and Safety Study of Talazoparib,02/09/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02922777,Phase I,Recruiting,University of Texas Southwestern Medical Center,"[{'id': 5973, 'therapyName': 'BGB-324 + Docetaxel'}]",Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.,07/06/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02923180,Phase I,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 2863, 'therapyName': 'MGA271'}]",Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer,06/27/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 2870, 'name': 'endometrial adenocarcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT02923349,Phase Ib/II,Recruiting,Incyte Europe Sàrl ,"[{'id': 5831, 'therapyName': 'INCAGN01949'}]","A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors",06/02/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02923531,Phase Ib/II,Recruiting,X4 Pharmaceuticals ,"[{'id': 4837, 'therapyName': 'Nivolumab + X4P-001'}]",Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma,11/05/2016,[],no
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT02923739,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 4836, 'therapyName': 'Bevacizumab + Emactuzumab + Paclitaxel'}, {'id': 2123, 'therapyName': 'Bevacizumab + Paclitaxel'}]","Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT",05/10/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02923921,Phase III,Recruiting,ARMO BioSciences ,"[{'id': 5849, 'therapyName': 'AM0010 + mFOLFOX-6'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",Study of AM0010 With FOLFOX Compared to FOLFOX Alone Second-line Tx in Pts With Metastatic Pancreatic Cancer,06/03/2017,[],no
0,both,"[{'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02924038,Phase I,Recruiting,"University of California, San Francisco ","[{'id': 4835, 'therapyName': 'IMA950 + poly ICLC '}, {'id': 2525, 'therapyName': 'Varlilumab'}]",A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG),01/24/2017,[],yes
0,both,"[{'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}]",NCT02924233,Phase Ib/II,Withdrawn,Symphogen A/S ,"[{'id': 4833, 'therapyName': 'Nivolumab + SYM004'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer,02/28/2017,"[{'molecularProfile': {'id': 447, 'profileName': 'EGFR amp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT02924376,Phase II,Recruiting,Incyte Corporation ,"[{'id': 4173, 'therapyName': 'INCB054828'}]",Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy,10/16/2016,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02924766,Phase I,Recruiting,"Janssen Research & Development, LLC ","[{'id': 4832, 'therapyName': 'ARN-509 + Niraparib'}]",A Safety and Pharmacokinetics Study of Niraparib Plus Apalutamide in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE),11/05/2016,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02924883,Phase II,"Active, not recruiting",Hoffmann-La Roche ,"[{'id': 947, 'therapyName': 'Trastuzumab'}, {'id': 3250, 'therapyName': 'Atezolizumab + Trastuzumab'}]",A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy,09/29/2017,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02925104,Phase I,Recruiting,Novartis Pharmaceuticals,"[{'id': 1065, 'therapyName': 'Capmatinib'}]","A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.",05/26/2017,"[{'molecularProfile': {'id': 1629, 'profileName': 'MET amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 27373, 'profileName': 'MET fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 13844, 'profileName': 'MET mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}]",NCT02925533,Phase I,Terminated,Dana-Farber Cancer Institute ,"[{'id': 4831, 'therapyName': 'B-701 + Pembrolizumab'}]",Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract,06/28/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02926768,Phase Ib/II,Recruiting,"Checkpoint Therapeutics, Inc.","[{'id': 5329, 'therapyName': 'CK-101'}]",Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors,02/24/2017,"[{'molecularProfile': {'id': 4039, 'profileName': 'EGFR exon 20 ins'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02926833,Phase Ib/II,Recruiting,"Kite Pharma, Inc. ","[{'id': 4830, 'therapyName': 'Atezolizumab + KTE-C19'}]",A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6),10/16/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02927262,Phase III,Recruiting,"Astellas Pharma Global Development, Inc. ","[{'id': 2865, 'therapyName': 'Gilteritinib'}]","A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission",12/07/2016,"[{'molecularProfile': {'id': 19128, 'profileName': 'FLT3 exon 14 ins'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02927301,Phase II,Recruiting,"Genentech, Inc. ","[{'id': 1201, 'therapyName': 'Atezolizumab'}]","A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Stage IB, II, or IIIA Resectable and Untreated Non-Small Cell Lung Cancer (NSCLC)",01/13/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02927340,Phase II,Recruiting,Massachusetts General Hospital ,"[{'id': 869, 'therapyName': 'PF-06463922'}]",A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions,10/28/2016,"[{'molecularProfile': {'id': 11085, 'profileName': 'ROS1 rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02927769,Phase II,Recruiting,Bristol-Myers Squibb,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}, {'id': 5055, 'therapyName': 'Brentuximab vedotin + Bendamustine'}]","A Study of Nivolumab + Brentuximab Vedotin in Children, Adolescents, and Young Adults With Classic Hodgkin Lymphoma (cHL) After Failure of First Line Therapy, Followed by Brentuximab Vedotin + Bendamustine for Participants With a Suboptimal Response (CheckMate 744)",03/31/2017,[],no
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02927964,Phase Ib/II,Recruiting,Ronald Levy ,"[{'id': 4828, 'therapyName': 'Ibrutinib + SD-101 + Radiotherapy'}]","TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma",12/02/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02928029,Phase Ib/II,Recruiting,Bayer,"[{'id': 6161, 'therapyName': 'Bortezomib + Dexamethasone + radium Ra 223 dichloride'}]",Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma,09/05/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02928224,Phase III,Recruiting,Array BioPharma ,"[{'id': 1916, 'therapyName': 'Cetuximab + Encorafenib'}, {'id': 4886, 'therapyName': 'Binimetinib + Cetuximab + LGX818'}, {'id': 1874, 'therapyName': 'Cetuximab + Irinotecan'}, {'id': 2180, 'therapyName': 'Cetuximab + FOLFIRI'}]",Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC),10/30/2016,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3996, 'name': 'urinary system cancer', 'source': 'DOID'}]",NCT02928406,Phase III,Recruiting,Hoffmann-La Roche,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract,03/07/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02928575,Phase II,Recruiting,Bassam Abdulkarim,"[{'id': 4905, 'therapyName': 'Sunitinib + Temozolomide'}]","Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma",11/01/2016,[],no
0,both,"[{'id': 60074, 'name': 'ductal carcinoma in situ', 'source': 'DOID'}, {'id': 3010, 'name': 'lobular neoplasia', 'source': 'DOID'}]",NCT02928978,Phase II,Not yet recruiting,Julie Nangia,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib for Premalignant Breast Disease,06/19/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02929576,Phase III,Withdrawn,"Medivation, Inc.","[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 3725, 'therapyName': 'Enzalutamide + Paclitaxel'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR)",06/06/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02929862,Phase Ib/II,Recruiting,Lycera Corp.,"[{'id': 5812, 'therapyName': 'LYC-55716'}]",Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer,06/03/2017,[],no
0,both,"[{'id': 4905, 'name': 'pancreatic carcinoma', 'source': 'DOID'}]",NCT02930902,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 4903, 'therapyName': 'Pembrolizumab + Paricalcitol'}, {'id': 4904, 'therapyName': 'Pembrolizumab + Paricalcitol + Gemcitabine + nab-paclitaxel'}]",Preoperative Pilot Study to Assess Safety and Immunological Effect of Pembrolizumab (Keytruda) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer,02/24/2017,[],no
0,both,"[{'id': 3620, 'name': 'central nervous system cancer', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1240, 'name': 'leukemia', 'source': 'DOID'}]",NCT02932280,Phase Ib/II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 828, 'therapyName': 'Neratinib'}]",Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment,11/14/2016,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02933255,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 4895, 'therapyName': 'PROSTVAC-V/F + Ipilimumab'}, {'id': 4893, 'therapyName': 'PROSTVAC-V/F + Nivolumab + Ipilimumab'}, {'id': 4894, 'therapyName': 'PROSTVAC-V/F + Nivolumab'}]",PROSTVAC in Combination With Nivolumab and/or Ipilimumab in Men With Prostate Cancer,03/18/2017,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3565, 'name': 'meningioma', 'source': 'DOID'}]",NCT02933736,Phase 0,Recruiting,"St. Joseph's Hospital and Medical Center, Phoenix","[{'id': 790, 'therapyName': 'Ribociclib'}]",Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients,11/14/2016,"[{'molecularProfile': {'id': 21978, 'profileName': 'RB1 negative'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 2395, 'profileName': 'RB1 positive'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1806, 'profileName': 'CDKN2A loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1101, 'profileName': 'RB1 wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02934503,Phase II,Recruiting,New York University School of Medicine ,"[{'id': 6184, 'therapyName': 'Carboplatin + Cisplatin + Etoposide + Pembrolizumab'}]",Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC),09/11/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02934568,Phase II,Recruiting,Novartis Pharmaceuticals,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Ribociclib (LEE011) Rollover Study for Continued Access,12/02/2016,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02935205,Phase Ib/II,Not yet recruiting,"University of California, Davis","[{'id': 4876, 'therapyName': 'Enzalutamide + Indomethacin'}]",Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer,10/31/2016,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT02935309,Phase I,Recruiting,H. Lee Moffitt Cancer Center and Research Institute,"[{'id': 4779, 'therapyName': 'Capecitabine + Lenvatinib'}]",Phase I Study of Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma,10/31/2016,[],no
0,both,"[{'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02935361,Phase Ib/II,Recruiting,University of Southern California,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}]",Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed,01/25/2017,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02935543,Phase II,Recruiting,University of Pennsylvania ,"[{'id': 5999, 'therapyName': 'CART19 cells'}]",CART19 in Patient With ALL,07/17/2017,[],yes
0,both,"[{'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}]",NCT02935634,Phase II,Recruiting,Bristol-Myers Squibb,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (FRACTION-GC),12/12/2016,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02935790,Phase I,Completed,Acetylon Pharmaceuticals Incorporated ,"[{'id': 3312, 'therapyName': 'ACY-241 + Ipilimumab + Nivolumab'}]",Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab,08/25/2017,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02935907,Phase I,Recruiting,Ascentage Pharma Group Inc. ,"[{'id': 5826, 'therapyName': 'APG-115'}]",APG-115 in Patients With Advanced Solid Tumors or Lymphomas,06/03/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02936102,Phase I,Recruiting,Novartis Pharmaceuticals ,"[{'id': 4971, 'therapyName': 'FAZ053'}, {'id': 4972, 'therapyName': 'FAZ053 + PDR001'}]",A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,11/19/2016,[],yes
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02936206,Phase I,Recruiting,Icahn School of Medicine at Mount Sinai,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Examination of Breast Cancer Cells of Pre-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.,08/08/2017,[],yes
0,both,"[{'id': 5719, 'name': 'adrenal medulla cancer', 'source': 'DOID'}, {'id': 50872, 'name': 'large cell neuroendocrine carcinoma', 'source': 'DOID'}, {'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}, {'id': 50773, 'name': 'paraganglioma', 'source': 'DOID'}, {'id': 3973, 'name': 'thyroid medullary carcinoma', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 3965, 'name': 'Merkel cell carcinoma', 'source': 'DOID'}]",NCT02936323,,Recruiting,,"[{'id': 5819, 'therapyName': 'PEN-221'}]",PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers,06/03/2017,[],yes
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02936752,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure,04/07/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02937272,Phase I,Recruiting,Eli Lilly and Company ,"[{'id': 5811, 'therapyName': 'LY3200882'}]",A Study of LY3200882 in Participants With Solid Tumors,06/03/2017,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02937675,Phase Ib/II,Recruiting,Effector Therapeutics ,"[{'id': 4005, 'therapyName': 'eFT508'}]",A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies,11/06/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02938793,Phase II,Recruiting,Greenville Health System ,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors,01/31/2017,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02939274,Phase II,Recruiting,Rogers Sciences Inc.,"[{'id': 3319, 'therapyName': 'Verteporfin'}]","An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne) for the Treatment of Cutaneous Metastases of Breast Cancer",02/24/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02939300,Phase II,Recruiting,Massachusetts General Hospital ,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma,03/07/2017,[],no
0,both,"[{'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT02939651,Phase II,Recruiting,Namrata Vijayvergia ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of Pembrolizumab in Patients With Neuroendocrine Tumors,10/30/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02939807,Phase II,Recruiting,RedHill Biopharma Limited,"[{'id': 3301, 'therapyName': 'ABC294640'}]",A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular Carcinoma,02/26/2017,[],no
0,both,[],NCT02940223,Phase II,Recruiting,M.D. Anderson Cancer Center,[],Effects of Fish Oil and Physical Activity on Fatigue in Colorectal Cancer Patients Receiving Regorafenib,07/31/2017,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT02940301,Phase II,Recruiting,Ohio State University Comprehensive Cancer Center ,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma,12/22/2016,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02940496,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab (MK-3475) in Hepatocellular Carcinoma,12/14/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02941601,Phase II,Withdrawn,Eli Lilly and Company,"[{'id': 4973, 'therapyName': 'Necitumumab + Gemcitabine + Carboplatin'}]",A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC),11/23/2016,"[{'molecularProfile': {'id': 1102, 'profileName': 'EGFR positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02941926,Phase III,Recruiting,Novartis Pharmaceuticals,"[{'id': 5310, 'therapyName': 'Ribociclib + Letrozole + Goserelin'}]",Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC,02/14/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02942095,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 4885, 'therapyName': 'Erlotinib + Ixazomib'}]",Phase I Study of Ixazomib and Erlotinib in Solid Tumors,03/10/2017,"[{'molecularProfile': {'id': 1193, 'profileName': 'KRAS G13X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1192, 'profileName': 'KRAS G12X'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}]",NCT02942264,Phase Ib/II,Recruiting,National Cancer Institute (NCI) ,"[{'id': 5836, 'therapyName': 'TG02'}, {'id': 5851, 'therapyName': 'Temozolomide + TG02'}]",TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma,06/13/2017,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02942290,Phase II,Recruiting,AbbVie,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}]",A Study Evaluating Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Participants With Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS),09/29/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02942355,Phase II,Recruiting,Antoinette Tan,"[{'id': 4974, 'therapyName': 'Anastrozole + Palbociclib'}]",Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer,11/19/2016,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT02943317,Phase I,Recruiting,"Verastem, Inc. ","[{'id': 958, 'therapyName': 'VS-6063'}, {'id': 3144, 'therapyName': 'Avelumab'}]","Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer",11/06/2016,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02943473,Phase II,Recruiting,Icahn School of Medicine at Mount Sinai ,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients,11/17/2016,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT02943603,Phase II,Withdrawn,"Weijing Sun, MD, FACP ","[{'id': 1161, 'therapyName': 'mFOLFOX-6 + Pembrolizumab'}]",A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach,09/29/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02944396,Phase II,Recruiting,AbbVie,"[{'id': 5054, 'therapyName': 'Carboplatin + Paclitaxel + Pemetrexed + Veliparib'}, {'id': 5053, 'therapyName': 'Carboplatin + Paclitaxel + Pemetrexed + Nivolumab + Veliparib'}]",Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC),12/02/2016,[],no
0,male,[],NCT02946996,Phase II,Recruiting,Medical University of South Carolina,[],Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy,02/14/2017,[],no
0,,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02947165,Phase I,Recruiting,Novartis Pharmaceuticals ,"[{'id': 5632, 'therapyName': 'NIS793 + PDR001'}, {'id': 5631, 'therapyName': 'NIS793'}]",Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.,05/05/2017,[],yes
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02947347,Phase III,Recruiting,Pharmacyclics LLC.,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3280, 'therapyName': 'Ibrutinib + Rituximab'}]",Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma,03/21/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02947386,Phase Ib/II,Recruiting,Roswell Park Cancer Institute ,"[{'id': 4920, 'therapyName': 'Nimotuzumab + Nivolumab'}]",Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer,07/03/2017,[],no
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT02947685,Phase III,Recruiting,"Alliance Foundation Trials, LLC.","[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 856, 'therapyName': 'Pertuzumab'}, {'id': 794, 'therapyName': 'Letrozole'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 947, 'therapyName': 'Trastuzumab'}]","Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)",06/13/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT02948101,Phase II,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 5848, 'therapyName': 'Cyclophosphamide + PD 0360324'}]",Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer,06/02/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02948283,Phase 0,Recruiting,City of Hope Medical Center ,"[{'id': 4919, 'therapyName': 'Metformin + Ritonavir'}]",Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia,03/14/2017,[],no
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT02948426,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 4975, 'therapyName': 'interferon gamma + peginterferon alfa-2b'}]","Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer",11/19/2016,[],no
0,both,"[{'id': 50926, 'name': 'jejunal adenocarcinoma', 'source': 'DOID'}, {'id': 10816, 'name': 'duodenum adenocarcinoma', 'source': 'DOID'}, {'id': 10153, 'name': 'ileum cancer', 'source': 'DOID'}]",NCT02949219,Phase II,Recruiting,Academic and Community Cancer Research United,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery,06/20/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02949284,Phase II,Recruiting,"Rutgers, The State University of New Jersey","[{'id': 1947, 'therapyName': 'ARN-509'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]","Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery",06/23/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02949700,Phase Ib/II,Recruiting,Baylor College of Medicine,"[{'id': 2205, 'therapyName': 'Cisplatin + Metformin'}]",Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma,04/07/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02949843,Phase II,Recruiting,Comprehensive Cancer Center of Wake Forest University,"[{'id': 4918, 'therapyName': 'Nivolumab + Pembrolizumab'}]",Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations,03/15/2017,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1249, 'profileName': 'ROS1 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2446, 'profileName': 'ALK fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2096, 'profileName': 'MET act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1243, 'profileName': 'ERBB2 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2294, 'profileName': 'RET act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 696, 'profileName': 'BRAF act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02950038,Phase II,Withdrawn,M.D. Anderson Cancer Center,"[{'id': 3198, 'therapyName': 'Ibrutinib + Nivolumab'}]",Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC),02/14/2017,[],no
0,both,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02950064,Phase I,Recruiting,Placon Therapeutics ,"[{'id': 6336, 'therapyName': 'BTP-114'}]",A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations,10/18/2017,"[{'molecularProfile': {'id': 3274, 'profileName': 'ATM mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 8584, 'name': 'Burkitt lymphoma', 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02950220,Phase I,Recruiting,Kami Maddocks,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma,01/19/2017,[],yes
0,,[],NCT02950766,,Not yet recruiting,,"[{'id': 779, 'therapyName': 'Ipilimumab'}]","A Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma",05/18/2017,[],
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02951156,Phase III,Recruiting,Pfizer,"[{'id': 5088, 'therapyName': 'Avelumab + Azacitidine + Utomilumab'}, {'id': 5087, 'therapyName': 'Avelumab + Rituximab + Utomilumab'}, {'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 5090, 'therapyName': 'Gemcitabine + Oxaliplatin + Rituximab'}, {'id': 5089, 'therapyName': 'Avelumab + Bendamustine + Rituximab'}]","Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)",02/18/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02951819,Phase II,Recruiting,"Janssen Scientific Affairs, LLC ","[{'id': 4951, 'therapyName': 'Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone'}]",A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma,12/20/2016,[],no
0,both,"[{'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02952248,Phase I,Recruiting,Boehringer Ingelheim,"[{'id': 5692, 'therapyName': 'BI 754091'}]",A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours,05/26/2017,[],no
0,both,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}, {'id': 10286, 'name': 'prostate carcinoma', 'source': 'DOID'}]",NCT02952534,Phase II,Recruiting,"Clovis Oncology, Inc.","[{'id': 906, 'therapyName': 'Rucaparib'}]",A Study of Rucaparib in Patients With MetA Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2),01/03/2017,"[{'molecularProfile': {'id': 522, 'profileName': 'ATM inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1282, 'profileName': 'BRCA1 inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1283, 'profileName': 'BRCA2 inact mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT02952573,Phase II,Recruiting,"University Health Network, Toronto ","[{'id': 4950, 'therapyName': 'Dexamethasone + JNJ-42756493'}]",Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement,07/28/2017,"[{'molecularProfile': {'id': 9322, 'profileName': 'FGFR3 positive'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02952586,Phase III,Recruiting,Pfizer,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 5052, 'therapyName': 'Avelumab + Cisplatin'}]",Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100),01/24/2017,[],no
0,both,"[{'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT02952729,Phase I,Recruiting,Mersana Therapeutics,"[{'id': 5834, 'therapyName': 'XMT-1522'}]",Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2,06/02/2017,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02952989,Phase I,Recruiting,"Seattle Genetics, Inc. ","[{'id': 5896, 'therapyName': 'SGN-2FF'}]",A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors,06/26/2017,[],no
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT02953457,Phase Ib/II,Recruiting,Roswell Park Cancer Institute ,"[{'id': 4949, 'therapyName': 'MEDI4736 + Olaparib + Tremelimumab'}]","Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRAC2 Mutation",07/03/2017,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02953509,Phase Ib/II,Recruiting,"Forty Seven, Inc. ","[{'id': 4955, 'therapyName': 'Hu5F9-G4 + Rituximab'}]",Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma,11/19/2016,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02953561,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 5372, 'therapyName': 'Avelumab + Azacitidine'}]",Avelumab (antiPDL1) and Azacytidine in Acute Myeloid Leukemia (AML),02/26/2017,[],no
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}]",NCT02953782,Phase Ib/II,Recruiting,"Forty Seven, Inc. ","[{'id': 4948, 'therapyName': 'Cetuximab + Hu5F9-G4'}]",Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer,11/19/2016,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02953860,Phase II,Recruiting,Anthony Elias,"[{'id': 4940, 'therapyName': 'Enzalutamide + Fulvestrant'}]",Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer,07/03/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02954406,Phase I,Recruiting,"Millennium Pharmaceuticals, Inc.","[{'id': 5150, 'therapyName': 'Lenalidomide + TAK-659'}, {'id': 5149, 'therapyName': 'Ibrutinib + TAK-659'}, {'id': 5148, 'therapyName': 'Gemcitabine + TAK-659'}, {'id': 5147, 'therapyName': 'Bendamustine + Rituximab + TAK-659'}, {'id': 5146, 'therapyName': 'Bendamustine + TAK-659'}]","A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma",05/06/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02954523,Phase Ib/II,Recruiting,Giuseppe Giaccone ,"[{'id': 4946, 'therapyName': 'Dasatinib + Osimertinib'}]",Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations,11/13/2016,"[{'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT02954536,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 4945, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab'}]",Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer,11/13/2016,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02954653,Phase I,Recruiting,Pfizer ,"[{'id': 6087, 'therapyName': 'PF-06747143'}, {'id': 6092, 'therapyName': 'Cytarabine + Daunorubicin + PF-06747143'}, {'id': 6093, 'therapyName': 'Azacitidine + Decitabine + PF-06747143'}]","A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia",08/04/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02954874,Phase III,Recruiting,National Cancer Institute (NCI),"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer,11/30/2016,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02954991,Phase II,Recruiting,Mirati Therapeutics Inc. ,"[{'id': 4943, 'therapyName': 'MGCD516 + Nivolumab'}, {'id': 4944, 'therapyName': 'Mocetinostat + Nivolumab'}, {'id': 4942, 'therapyName': 'MGCD265 + Nivolumab'}]","Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer",11/15/2016,[],no
0,both,"[{'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}, {'id': 50626, 'name': 'gastrointestinal neuroendocrine tumor', 'source': 'DOID'}]",NCT02955069,Phase II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 2659, 'therapyName': 'PDR001'}]","Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin",02/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02955251,Phase I,Recruiting,AbbVie ,"[{'id': 5051, 'therapyName': 'ABBV-428 + Nivolumab'}, {'id': 5050, 'therapyName': 'ABBV-428'}]","A Study Evaluating Safety and Pharmacokinetics, and the Recommended Phase 2 Dose (RPTD) of ABBV-428 in Participants With Advanced Solid Tumors",12/01/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02955290,Phase Ib/II,Recruiting,Roswell Park Cancer Institute ,"[{'id': 4941, 'therapyName': 'CIMAvax-EGF + Nivolumab'}]",CIMAvax Vaccine and Nivolumab in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer,12/29/2016,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02955394,Phase II,Recruiting,Anthony Elias ,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 4940, 'therapyName': 'Enzalutamide + Fulvestrant'}]",Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer,10/17/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02955446,Expanded access,No longer available,"University of Colorado, Denver","[{'id': 859, 'therapyName': 'PF-03084014'}]",Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies,06/20/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02955758,Phase II,Recruiting,Joel Neal ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer,02/24/2017,[],no
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02956382,Phase Ib/II,Recruiting,Georgetown University,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma,12/27/2016,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02956798,Phase II,Not yet recruiting,University of Texas Southwestern Medical Center ,"[{'id': 848, 'therapyName': 'Pazopanib'}]",Pazopanib Vs. Local Therapy for Renal Cancer With Metastases,11/13/2016,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02957968,Phase II,Recruiting,Virginia Commonwealth University,"[{'id': 1495, 'therapyName': 'Paclitaxel + Doxorubicin + Cyclophosphamide'}, {'id': 5729, 'therapyName': 'Doxorubicin + Cyclophosphamide + Paclitaxel + Carboplatin'}]",Neoadj Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca,05/26/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02959437,Phase Ib/II,Recruiting,Incyte Corporation ,"[{'id': 5477, 'therapyName': 'Azacitidine + INCB024360 + Pembrolizumab'}]",Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206),03/27/2017,[],no
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT02959463,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma,05/04/2017,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02960022,Phase II,Recruiting,"Astellas Pharma Global Development, Inc.","[{'id': 5371, 'therapyName': 'Enzalutamide + Abiraterone + Prednisone'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]",A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study,03/01/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 3459, 'name': 'breast carcinoma', 'source': 'DOID'}, {'id': 3905, 'name': 'lung carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 5041, 'name': 'esophageal cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 4905, 'name': 'pancreatic carcinoma', 'source': 'DOID'}]",NCT02960594,Phase I,Recruiting,Inovio Pharmaceuticals,"[{'id': 5844, 'therapyName': 'INO-1400 + INO-9012'}, {'id': 5807, 'therapyName': 'INO-1400'}]",hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse,06/02/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02961283,Phase I,Recruiting,Asana BioSciences,"[{'id': 5827, 'therapyName': 'ASN003'}]",Study of ASN003 in Subjects With Advanced Solid Tumors,06/02/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 479, 'profileName': 'PTEN loss'}, 'requirementType': 'partial'}]",yes
0,both,[],NCT02961374,Phase II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 4, 'therapyName': 'Erlotinib'}]",Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer,11/19/2016,"[{'molecularProfile': {'id': 5414, 'profileName': 'APC mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02961816,Phase II,Withdrawn,M.D. Anderson Cancer Center,"[{'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 4976, 'therapyName': 'Busulfan + Gemcitabine + Melphalan + Panobinostat'}, {'id': 4977, 'therapyName': 'Dexamethasone + Filgrastim + Palifermin + Rituximab'}]",Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma,04/22/2017,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}]",NCT02962063,Phase Ib/II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]","Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer",11/21/2016,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02962804,Phase II,Not yet recruiting,University of Kansas Medical Center,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC),11/21/2016,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT02963090,Phase II,Recruiting,"Alliance Foundation Trials, LLC. ","[{'id': 5532, 'therapyName': 'Pembrolizumab + Topotecan'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer,04/12/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02963610,Phase Ib/II,Recruiting,Fox Chase Cancer Center,"[{'id': 3322, 'therapyName': 'lenalidomide + Pembrolizumab'}]",Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer,04/07/2017,[],no
0,both,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 5041, 'name': 'esophageal cancer', 'source': 'DOID'}, {'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}, {'id': 4226, 'name': 'endometrial stromal sarcoma', 'source': 'DOID'}, {'id': 50626, 'name': 'gastrointestinal neuroendocrine tumor', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 5289, 'name': 'uterus leiomyosarcoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}, {'id': 1245, 'name': 'vulva cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 6171, 'name': 'uterine carcinosarcoma', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 1790, 'name': 'malignant mesothelioma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}, {'id': 119, 'name': 'vaginal cancer', 'source': 'DOID'}]",NCT02963831,Phase Ib/II,Recruiting,Ludwig Institute for Cancer Research,"[{'id': 4978, 'therapyName': 'ONCOS-102 + MEDI4736'}]","A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",09/12/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02964013,Phase I,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 5218, 'therapyName': 'MK-7684'}, {'id': 5219, 'therapyName': 'MK-7684 + Pembrolizumab'}]",Study of MK-7684 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001),01/16/2017,[],no
0,both,"[{'id': 263, 'name': 'kidney cancer', 'source': 'DOID'}]",NCT02964078,Phase II,Recruiting,H. Lee Moffitt Cancer Center and Research Institute,"[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer,04/14/2017,[],no
0,female,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT02964507,Phase II,Recruiting,GlaxoSmithKline,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 5242, 'therapyName': 'GSK525762 + Fulvestrant'}]",Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer,02/18/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3151, 'name': 'skin squamous cell carcinoma', 'source': 'DOID'}]",NCT02964559,Phase II,Recruiting,Emory University,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer,02/10/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02965417,Phase II,Withdrawn,Symphogen A/S,"[{'id': 931, 'therapyName': 'SYM004'}]",Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients,01/20/2017,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02965716,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 4035, 'therapyName': 'Pembrolizumab + talimogene laherparepvec '}]",Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma,10/06/2017,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}]",NCT02965885,Phase I,Recruiting,"Taiho Oncology, Inc. ","[{'id': 2768, 'therapyName': 'TAS-116'}]",A Study of TAS-116 in Patients With Solid Tumors,09/01/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02966587,Phase II,Not yet recruiting,University of Washington,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer,11/20/2016,[],no
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT02966730,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy,11/21/2016,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02966782,Phase I,Recruiting,"Genentech, Inc.","[{'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}, {'id': 1562, 'therapyName': 'Venetoclax'}]",A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure,05/22/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02967692,Phase III,Recruiting,Novartis Pharmaceuticals,"[{'id': 6023, 'therapyName': 'Dabrafenib + Trametinib + PDR001'}, {'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]","A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma",07/27/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02968940,Phase III,Recruiting,New York University School of Medicine,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma,02/15/2017,"[{'molecularProfile': {'id': 5912, 'profileName': 'IDH2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1781, 'profileName': 'IDH1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 70004, 'name': 'myeloid neoplasm', 'source': 'DOID'}]",NCT02969837,Phase II,Recruiting,University of Chicago ,"[{'id': 5033, 'therapyName': 'Carfilzomib + Elotuzumab + Dexamethasone + lenalidomide'}]","Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma",09/21/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02970318,Phase III,Recruiting,Acerta Pharma BV ,"[{'id': 2324, 'therapyName': 'Bendamustine + Idelalisib + Rituximab'}, {'id': 1605, 'therapyName': 'Acalabrutinib'}]",A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL,12/01/2016,[],no
0,both,"[{'id': 5041, 'name': 'esophageal cancer', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}]",NCT02970539,Phase I,Recruiting,Kinex Pharmaceuticals Inc ,"[{'id': 5032, 'therapyName': 'Oraxol + Ramucirumab'}]","Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers",05/16/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02970981,Phase II,Not yet recruiting,New York University School of Medicine,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma,11/30/2016,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02971501,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 660, 'therapyName': 'Osimertinib'}, {'id': 4366, 'therapyName': 'Bevacizumab + Osimertinib'}]",Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases,09/14/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 6263, 'name': 'inflammatory breast carcinoma', 'source': 'DOID'}]",NCT02971748,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy,02/08/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02971761,Phase II,Recruiting,City of Hope Medical Center,"[{'id': 5027, 'therapyName': 'enobosarm + Pembrolizumab'}]",Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer,05/05/2017,[],yes
0,both,"[{'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 3748, 'name': 'esophagus squamous cell carcinoma', 'source': 'DOID'}]",NCT02971956,Phase II,Not yet recruiting,Dana-Farber Cancer Institute,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer,11/30/2016,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}, {'id': 11239, 'name': 'appendix cancer', 'source': 'DOID'}]",NCT02972034,Phase I,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 5269, 'therapyName': 'MK-8353 + Pembrolizumab'}]",Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013),01/31/2017,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT02972840,Phase III,Recruiting,Acerta Pharma BV,"[{'id': 2323, 'therapyName': 'Bendamustine + Rituximab'}, {'id': 3996, 'therapyName': 'Acalabrutinib + Bendamustine + Rituximab'}]",A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma,04/12/2017,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 50743, 'name': 'mature T-cell and NK-cell lymphoma', 'source': 'DOID'}]",NCT02973113,Phase I,Recruiting,Baylor College of Medicine,"[{'id': 5058, 'therapyName': 'EB-VST cells + Nivolumab'}]","Nivolumab With Epstein Barr Virus Specific T Cells (EB-VSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) (PREVALE)",03/04/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT02973399,Phase I,Recruiting,Esanex Inc.,"[{'id': 4780, 'therapyName': 'Ibrutinib + SNX-5422'}]",Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL,02/15/2017,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT02973711,Phase Ib/II,Recruiting,University of Michigan Cancer Center,"[{'id': 1116, 'therapyName': 'Ruxolitinib + Nilotinib'}]",A Phase I/II Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML,06/20/2017,[],no
0,both,"[{'id': 3962, 'name': 'follicular thyroid carcinoma', 'source': 'DOID'}, {'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}, {'id': 3969, 'name': 'papillary thyroid carcinoma', 'source': 'DOID'}, {'id': 8161, 'name': 'thyroid Hurthle cell carcinoma', 'source': 'DOID'}]",NCT02973997,Phase II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery,12/10/2016,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02974621,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1971, 'therapyName': 'Cediranib + Olaparib'}]",Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma,10/03/2017,[],no
0,both,"[{'id': 50743, 'name': 'mature T-cell and NK-cell lymphoma', 'source': 'DOID'}, {'id': 60061, 'name': 'cutaneous T cell lymphoma', 'source': 'DOID'}]",NCT02974647,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma,12/01/2016,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT02974738,Phase I,Recruiting,"Peloton Therapeutics, Inc. ","[{'id': 5820, 'therapyName': 'PT 2977'}]",A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors,10/03/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02974803,Phase II,Not yet recruiting,Canadian Cancer Trials Group,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}]",Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases,07/27/2017,"[{'molecularProfile': {'id': 16857, 'profileName': 'HRAS act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 16855, 'profileName': 'KRAS act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 16856, 'profileName': 'NRAS act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02975882,Phase I,"Active, not recruiting",Children's Oncology Group,"[{'id': 5030, 'therapyName': 'Nab-Rapamycin + Temozolomide + Irinotecan'}]","Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors",10/19/2017,[],no
0,male,"[{'id': 10286, 'name': 'prostate carcinoma', 'source': 'DOID'}]",NCT02975934,Phase III,Recruiting,"Clovis Oncology, Inc","[{'id': 906, 'therapyName': 'Rucaparib'}]",A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency,01/16/2017,"[{'molecularProfile': {'id': 522, 'profileName': 'ATM inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1283, 'profileName': 'BRCA2 inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1282, 'profileName': 'BRCA1 inact mut'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02977468,Phase I,Recruiting,Eileen Connolly,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT),05/24/2017,[],yes
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT02977689,Phase II,Not yet recruiting,New York University School of Medicine,"[{'id': 2981, 'therapyName': 'IDH305'}]",Trial of IDH305 in IDH1 Mutant Grade II or III Glioma,09/29/2017,"[{'molecularProfile': {'id': 10006, 'profileName': 'IDH1 R132X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02977780,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1000, 'therapyName': 'CC-115'}, {'id': 5028, 'therapyName': 'Abemaciclib + Temozolomide'}, {'id': 1141, 'therapyName': 'Temozolomide'}, {'id': 5029, 'therapyName': 'Neratinib + Temozolomide'}]",INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT),01/11/2017,"[{'molecularProfile': {'id': 1253, 'profileName': 'IDH1 R132H'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT02978235,Phase Ib/II,Recruiting,"Taiho Oncology, Inc.","[{'id': 5897, 'therapyName': 'TAS4464'}]",A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma,07/03/2017,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02978404,Phase II,Recruiting,Centre hospitalier de l'Université de Montréal (CHUM),"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases,07/13/2017,[],no
0,both,"[{'id': 50929, 'name': 'mucosal melanoma', 'source': 'DOID'}, {'id': 6367, 'name': 'acral lentiginous melanoma', 'source': 'DOID'}]",NCT02978443,Phase II,Recruiting,Georgetown University,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab,05/31/2017,[],no
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT02978547,Phase II,Not yet recruiting,British Columbia Cancer Agency,"[{'id': 1031, 'therapyName': 'Metformin'}]",The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma (Metformin 001),12/13/2016,[],no
0,both,"[{'id': 3149, 'name': 'keratoacanthoma', 'source': 'DOID'}, {'id': 7566, 'name': 'eccrine porocarcinoma', 'source': 'DOID'}, {'id': 4871, 'name': 'cutaneous adenocystic carcinoma', 'source': 'DOID'}, {'id': 5063, 'name': 'basosquamous carcinoma', 'source': 'DOID'}, {'id': 3030, 'name': 'mucinous adenocarcinoma', 'source': 'DOID'}, {'id': 5590, 'name': 'aggressive digital papillary adenocarcinoma', 'source': 'DOID'}, {'id': 2513, 'name': 'basal cell carcinoma', 'source': 'DOID'}, {'id': 3151, 'name': 'skin squamous cell carcinoma', 'source': 'DOID'}, {'id': 4304, 'name': 'signet ring basal cell carcinoma', 'source': 'DOID'}, {'id': 3965, 'name': 'Merkel cell carcinoma', 'source': 'DOID'}, {'id': 50749, 'name': 'peripheral T-cell lymphoma', 'source': 'DOID'}, {'id': 3450, 'name': ""cutaneous Paget's disease"", 'source': 'DOID'}, {'id': 50744, 'name': 'anaplastic large cell lymphoma', 'source': 'DOID'}, {'id': 3896, 'name': 'hidradenoma', 'source': 'DOID'}, {'id': 50743, 'name': 'mature T-cell and NK-cell lymphoma', 'source': 'DOID'}, {'id': 4934, 'name': 'apocrine sweat gland cancer', 'source': 'DOID'}, {'id': 5569, 'name': 'malignant syringoma', 'source': 'DOID'}, {'id': 4866, 'name': 'salivary gland adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 5570, 'name': 'malignant acrospiroma', 'source': 'DOID'}, {'id': 4840, 'name': 'sebaceous carcinoma', 'source': 'DOID'}, {'id': 8691, 'name': 'mycosis fungoides', 'source': 'DOID'}, {'id': 2095, 'name': 'sweat gland cancer', 'source': 'DOID'}, {'id': 8541, 'name': ""Sezary's disease"", 'source': 'DOID'}, {'id': 60061, 'name': 'cutaneous T cell lymphoma', 'source': 'DOID'}, {'id': 2072, 'name': 'vulvar squamous tumor', 'source': 'DOID'}, {'id': 7960, 'name': 'malignant spiradenoma', 'source': 'DOID'}, {'id': 5667, 'name': 'sweat gland carcinoma', 'source': 'DOID'}]",NCT02978625,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 5080, 'therapyName': 'Talimogene laherparepvec + Nivolumab'}]",Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers,10/04/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02978716,Phase II,Recruiting,"G1 Therapeutics, Inc.","[{'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 5737, 'therapyName': 'Carboplatin + Gemcitabine + Trilaciclib'}]","Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)",05/22/2017,[],yes
0,both,"[{'id': 4239, 'name': 'alveolar soft part sarcoma', 'source': 'DOID'}, {'id': 5485, 'name': 'synovial sarcoma', 'source': 'DOID'}, {'id': 3382, 'name': 'liposarcoma', 'source': 'DOID'}, {'id': 5940, 'name': 'malignant peripheral nerve sheath tumor', 'source': 'DOID'}, {'id': 4051, 'name': 'alveolar rhabdomyosarcoma', 'source': 'DOID'}]",NCT02978859,Phase II,Recruiting,Gary Schwartz,"[{'id': 1655, 'therapyName': 'MGCD516'}]",MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas,12/11/2016,[],no
0,both,"[{'id': 1816, 'name': 'angiosarcoma', 'source': 'DOID'}]",NCT02979899,Phase III,Recruiting,Tracon Pharmaceuticals Inc.,"[{'id': 848, 'therapyName': 'Pazopanib'}, {'id': 1431, 'therapyName': 'TRC105 + Pazopanib'}]",A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS),02/17/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02979977,Phase II,Recruiting,Aarti Bhatia,"[{'id': 4190, 'therapyName': 'Afatinib + Cetuximab'}]",Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck,03/29/2017,[],no
0,male,"[{'id': 219, 'name': 'colon cancer', 'source': 'DOID'}]",NCT02980029,Phase I,Recruiting,Mark Evers,"[{'id': 3611, 'therapyName': 'TVB-2640'}]",Pharmacodynamic Effects of Fatty Acid Synthase (FASN) Inhibition With TVB-2640 in Resectable Colon Cancer,01/16/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02981108,Phase Ib/II,Recruiting,"Jiangsu Hansoh Pharmaceutical Co., Ltd.","[{'id': 5830, 'therapyName': 'HS-10296'}]","A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC",06/02/2017,"[{'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02981303,Phase II,Recruiting,Biothera,"[{'id': 5174, 'therapyName': 'Imprime PGG + Pembrolizumab'}]",Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer,01/09/2017,[],yes
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT02981342,Phase II,Recruiting,Eli Lilly and Company,"[{'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 802, 'therapyName': 'Abemaciclib'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 5175, 'therapyName': 'Abemaciclib + LY3023414'}, {'id': 5176, 'therapyName': 'Abemaciclib + Galunisertib'}]",A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma,01/19/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02981524,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 5079, 'therapyName': 'Cyclophosphamide + GVAX colorectal cancer vaccine + Pembrolizumab'}]",Phase 2 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer,05/31/2017,[],no
0,both,"[{'id': 80146, 'name': 'B-cell childhood acute lymphoblastic leukemia', 'source': 'DOID'}]",NCT02981628,Phase II,Recruiting,Children's Oncology Group,"[{'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia,06/07/2017,[],yes
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 706, 'name': 'mature B-cell neoplasm', 'source': 'DOID'}]",NCT02981914,Phase 0,Recruiting,University of Chicago,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation,04/15/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT02981940,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",A Study of Abemaciclib in Recurrent Glioblastoma,02/08/2017,"[{'molecularProfile': {'id': 1101, 'profileName': 'RB1 wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 6542, 'profileName': 'CDKN2A del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1781, 'profileName': 'IDH1 mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 5912, 'profileName': 'IDH2 mutant'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT02982720,Phase II,Recruiting,Georgetown University,"[{'id': 2625, 'therapyName': 'peginterferon alfa-2b + Pembrolizumab'}]",Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron,09/30/2017,[],no
0,both,"[{'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}, {'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}, {'id': 2154, 'name': 'nephroblastoma', 'source': 'DOID'}, {'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}]",NCT02982941,Phase I,Recruiting,MacroGenics,"[{'id': 2863, 'therapyName': 'MGA271'}]",Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors,06/02/2017,[],yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02982954,Phase III,Recruiting,Bristol-Myers Squibb,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920),01/09/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02983006,Phase I,Recruiting,New York University School of Medicine,"[{'id': 5078, 'therapyName': 'DS-8273a + Nivolumab'}]",Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma,12/11/2016,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02983045,Phase Ib/II,Recruiting,Nektar Therapeutics,"[{'id': 5076, 'therapyName': 'NKTR-214 + Nivolumab'}]",A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) in Patients With Select Advanced or Metastatic Solid Tumors (PIVOT-02),12/11/2016,[],no
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02983578,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 3098, 'therapyName': 'AZD9150 + MEDI4736'}]","AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer",03/04/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT02983604,Phase Ib/II,Recruiting,Gilead Sciences,"[{'id': 738, 'therapyName': 'Exemestane'}, {'id': 5074, 'therapyName': 'GS-5829 + Fulvestrant'}, {'id': 3561, 'therapyName': 'GS-5829 + Exemestane'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",GS-5829 in Combination With Exemestane or Fulvestrant Comparing With Exemestane or Fulvestrant Alone in Women With Advanced Estrogen Receptor Positive HER2- Breast Cancer,01/14/2017,[],yes
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 50933, 'name': 'ovarian serous carcinoma', 'source': 'DOID'}]",NCT02983799,Phase II,Recruiting,AstraZeneca,"[{'id': 837, 'therapyName': 'Olaparib'}]",Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status,01/19/2017,"[{'molecularProfile': {'id': 442, 'profileName': 'BRCA2 wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 518, 'profileName': 'BRCA1 wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT02984683,Phase II,Recruiting,Sanofi,"[{'id': 5825, 'therapyName': 'SAR566658'}]",Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer,06/02/2017,[],yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT02985125,Phase Ib/II,Recruiting,Georgetown University,"[{'id': 5073, 'therapyName': 'Ribociclib + Everolimus'}]",LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy,06/09/2017,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT02985554,Phase I,Recruiting,University of Chicago,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies,04/15/2017,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02985658,Phase I,Available,University of Washington,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 954, 'therapyName': 'Veliparib'}, {'id': 1685, 'therapyName': 'Vinorelbine'}]",Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer,12/13/2016,"[{'molecularProfile': {'id': 1216, 'profileName': 'ERBB2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02985957,Phase II,Recruiting, Bristol-Myers Squibb,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer,03/30/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02987166,Phase I,Recruiting,"James Larner, MD","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",HDCRT Plus Pembrolizumab in Advanced Malignancies (UVA-AM-001),03/29/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02987504,Phase I,Suspended,Alexion Pharmaceuticals ,"[{'id': 5535, 'therapyName': 'Samalizumab'}]",Study of Samalizumab in Patients With Advanced Cancer,08/05/2017,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT02987543,Phase III,Recruiting,AstraZeneca,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 1805, 'therapyName': 'Abiraterone'}]",Study of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study),02/16/2017,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3274, 'profileName': 'ATM mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02987829,Phase Ib/II,Recruiting,Tracon Pharmaceuticals Inc.,"[{'id': 5770, 'therapyName': 'TRC253'}]","A Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients",05/26/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 3357, 'name': 'extraosseous osteosarcoma', 'source': 'DOID'}, {'id': 1967, 'name': 'leiomyosarcoma', 'source': 'DOID'}, {'id': 4415, 'name': 'fibrous histiocytoma', 'source': 'DOID'}, {'id': 3250, 'name': 'pleomorphic rhabdomyosarcoma', 'source': 'DOID'}, {'id': 5940, 'name': 'malignant peripheral nerve sheath tumor', 'source': 'DOID'}, {'id': 5702, 'name': 'pleomorphic liposarcoma', 'source': 'DOID'}, {'id': 1816, 'name': 'angiosarcoma', 'source': 'DOID'}]",NCT02987959,Phase II,Recruiting,Fox Chase Cancer Center,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas,03/21/2017,"[{'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1213, 'profileName': 'PTEN mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 479, 'profileName': 'PTEN loss'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02987998,Phase I,Recruiting,"Nathan Pennell, MD, PhD","[{'id': 5145, 'therapyName': 'Cisplatin + Etoposide + Pembrolizumab'}]",Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC,06/06/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02988440,Phase I,Recruiting,Novartis Pharmaceuticals ,"[{'id': 5590, 'therapyName': 'PDR001 + Sorafenib'}]",Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients,04/28/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02988817,Phase Ib/II,Recruiting,Genmab ,"[{'id': 5864, 'therapyName': 'HuMax-Axl-ADC'}]",HuMax-AXL-ADC Safety Study in Patients With Solid Tumors,08/21/2017,[],no
0,both,"[{'id': 2994, 'name': 'germ cell cancer', 'source': 'DOID'}]",NCT02988843,Phase II,Recruiting,"Masonic Cancer Center, University of Minnesota","[{'id': 5144, 'therapyName': 'Bevacizumab + Brentuximab vedotin'}]",Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors,05/04/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02988960,Phase I,Recruiting,AbbVie,"[{'id': 5143, 'therapyName': 'ABBV-927 + Nivolumab'}, {'id': 5142, 'therapyName': 'ABBV-927'}]","A Study of ABBV-927, an Immunotherapy, in Participants With Advanced Solid Tumors",03/10/2017,[],no
0,both,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}]",NCT02988986,Phase II,Recruiting,"Millennium Pharmaceuticals, Inc.","[{'id': 5141, 'therapyName': 'MLN0128 + Tamoxifen'}]","TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer",04/26/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}]",NCT02989584,Phase Ib/II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 5140, 'therapyName': 'Atezolizumab + Cisplatin + Gemcitabine'}]",A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer,01/03/2017,[],no
0,both,"[{'id': 3302, 'name': 'chordoma', 'source': 'DOID'}]",NCT02989636,Phase I,Recruiting,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 1312, 'therapyName': 'Nivolumab'}]","Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma",04/21/2017,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT02989714,Phase Ib/II,Recruiting,University of Michigan Cancer Center,"[{'id': 5139, 'therapyName': 'Aldesleukin + Nivolumab'}]","Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer",02/25/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT02989844,Phase II,Recruiting,"Masonic Cancer Center, University of Minnesota","[{'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.035: Relapse Prophylaxis With ALT-803 for AML and MDS Pts Following Allo HSCT,04/18/2017,[],no
0,both,"[{'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT02989857,Phase III,Recruiting,"Agios Pharmaceuticals, Inc.","[{'id': 1491, 'therapyName': 'AG-120'}]",Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy),02/08/2017,"[{'molecularProfile': {'id': 1781, 'profileName': 'IDH1 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT02989870,Phase I,Recruiting,H. Lee Moffitt Cancer Center and Research Institute,"[{'id': 5138, 'therapyName': 'Bavituximab + Sorafenib'}]",Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma,03/30/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT02990416,Phase Ib/II,Not yet recruiting,Angimmune LLC,"[{'id': 5137, 'therapyName': 'A-dmDT390-bisFv(UCHT1) + Pembrolizumab'}]",A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma,01/03/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT02990468,Phase I,Recruiting,"BioMimetix JV, LLC","[{'id': 5840, 'therapyName': 'BMX-001 + Cisplatin'}]","A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer (BMX-HN)",06/02/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02990481,Phase I,Recruiting,"Toray Industries, Inc","[{'id': 5835, 'therapyName': 'TRK-950'}]",A Study of TRK-950 in Patients With Advanced Solid Tumors,06/02/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT02991196,Phase I,Terminated,Daiichi Sankyo Inc.,"[{'id': 5078, 'therapyName': 'DS-8273a + Nivolumab'}]",Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer,10/03/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02991651,Phase I,Recruiting,Io Therapeutics ,"[{'id': 5135, 'therapyName': 'Erlotinib + IRX4204'}]",Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC,01/03/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}]",yes
0,both,[],NCT02991807,Phase Ib/II,Recruiting,Boston Children’s Hospital,[],RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome (PTEN),06/19/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT02991911,Phase I,Recruiting,MedImmune LLC,"[{'id': 5217, 'therapyName': 'Enzalutamide + MEDI3726'}, {'id': 5216, 'therapyName': 'MEDI3726'}]",A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer,01/16/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT02992483,Phase I,Recruiting,Novartis Pharmaceuticals ,"[{'id': 5814, 'therapyName': 'MIK665'}]","Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma",07/20/2017,[],no
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}]",NCT02992522,Phase I,Recruiting,Beth Christian,"[{'id': 5133, 'therapyName': 'Lenalidomide + Obinutuzumab + Venetoclax'}]","Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",03/04/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02992964,Phase Ib/II,Recruiting,The Hospital for Sick Children,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers,04/07/2017,[],no
0,female,"[{'id': 60074, 'name': 'ductal carcinoma in situ', 'source': 'DOID'}]",NCT02993159,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 5132, 'therapyName': 'Afimoxifene'}, {'id': 1456, 'therapyName': 'Tamoxifen'}]",Tamoxifen Citrate or Afimoxifene in Treating Patients With Estrogen Receptor Positive Breast Cancer,08/22/2017,[],yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02993523,Phase III,Recruiting,AbbVie,"[{'id': 1637, 'therapyName': 'GDC-0199 + Azacitidine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Elderly Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy,01/09/2017,[],no
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT02993731,Phase III,Recruiting,"Boston Biomedical, Inc","[{'id': 2630, 'therapyName': 'BBI608 + Gemcitabine + nab-paclitaxel'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P),02/12/2017,[],no
0,both,"[{'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 50865, 'name': 'tongue squamous cell carcinoma', 'source': 'DOID'}]",NCT02993991,Phase I,Not yet recruiting,"University Health Network, Toronto","[{'id': 4378, 'therapyName': 'MEDI4736 + Mocetinostat'}]",Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity,01/03/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02994953,Phase I,Recruiting,EMD Serono,"[{'id': 5131, 'therapyName': 'Avelumab + NHS-IL12'}]","A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12)",01/24/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT02996110,Phase II,Recruiting,Bristol-Myers Squibb,"[{'id': 4197, 'therapyName': 'BMS-986016 + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (FRACTION-RCC),02/10/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT02996474,Phase Ib/II,Recruiting,"National Heart, Lung, and Blood Institute (NHLBI)","[{'id': 5127, 'therapyName': 'Pembrolizumab + Decitabine'}]",Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia,02/10/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT02996825,Phase I,Recruiting,City of Hope Medical Center,"[{'id': 3232, 'therapyName': 'IMGN853'}]","Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer",06/02/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02997163,Phase I,Recruiting,Pfizer,"[{'id': 682, 'therapyName': 'Talazoparib'}]",An Open-Label Pharmacokinetics and Safety Study of Talazoparib,08/08/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT02997176,Phase I,Recruiting,"Medivation, Inc.","[{'id': 682, 'therapyName': 'Talazoparib'}]",An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800),01/03/2017,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}]",NCT02997228,Phase III,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1484, 'therapyName': 'Bevacizumab + Oxaliplatin + Leucovorin + Fluorouracil'}, {'id': 5126, 'therapyName': 'Bevacizumab + Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin'}]","Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Microsatellite Instability-High Metastatic Colorectal Cancer",12/27/2016,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT02997761,Phase II,Recruiting,"University of California, Davis","[{'id': 5125, 'therapyName': 'Blinatumomab + Ibrutinib'}]",Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia,07/12/2017,[],no
0,both,"[{'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT02998268,Phase II,Recruiting,Weill Medical College of Cornell University,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma,05/10/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT02998476,Phase II,Recruiting,Incyte Corporation,"[{'id': 3088, 'therapyName': 'INCB050465 '}]",A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202),06/02/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT02998528,Phase III,Recruiting,Bristol-Myers Squibb,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 5241, 'therapyName': 'Cisplatin + Vinorelbine + Gemcitabine + Docetaxel + Pemetrexed + Carboplatin'}]",A Neoadjuvant Study of Nivolumab and Ipilimumab Compared to Chemotherapy Doublet in Early Stage Non-Small Cell Lung Cancer (NSCLC) (CheckMate 816),01/20/2017,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT02999477,Phase I,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 619, 'therapyName': 'Abraxane'}]",A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer,03/29/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4932, 'name': 'ampulla of Vater carcinoma', 'source': 'DOID'}, {'id': 10021, 'name': 'duodenum cancer', 'source': 'DOID'}, {'id': 4906, 'name': 'small intestine adenocarcinoma', 'source': 'DOID'}]",NCT03000179,Phase II,Recruiting,Vanderbilt-Ingram Cancer Center,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma,03/09/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03000257,Phase I,Recruiting,AbbVie,"[{'id': 5766, 'therapyName': 'ABBV-181'}]",A Study of ABBV-181 in Participants With Advanced Solid Tumors,05/26/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03000452,Phase II,"Active, not recruiting",Celgene ,"[{'id': 4530, 'therapyName': 'Daratumumab + MEDI4736'}]",A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (FUSION-MM-005),09/29/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03001882,Phase II,Recruiting,Bristol-Myers Squibb,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC),03/18/2017,[],no
0,both,"[{'id': 3969, 'name': 'papillary thyroid carcinoma', 'source': 'DOID'}, {'id': 7089, 'name': 'tall cell variant papillary carcinoma', 'source': 'DOID'}, {'id': 8161, 'name': 'thyroid Hurthle cell carcinoma', 'source': 'DOID'}, {'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT03002623,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 709, 'therapyName': 'CUDC-907'}]",CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer,02/15/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03003468,Phase Ib/II,Recruiting,Lawrence Feldman,"[{'id': 5174, 'therapyName': 'Imprime PGG + Pembrolizumab'}]",Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Chemotherapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017,01/09/2017,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT03003520,Phase II,Recruiting,Celgene,"[{'id': 5350, 'therapyName': 'MEDI4736 + R2-CHOP'}, {'id': 5349, 'therapyName': 'MEDI4736 + Rituximab + Doxorubicin + Vincristine + Cyclophosphamide + Prednisone'}]",A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma,02/21/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03003676,Phase I,Recruiting,Targovax Oy,"[{'id': 5173, 'therapyName': 'Cyclophosphamide + ONCOS-102 + Pembrolizumab'}]","A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade",01/13/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03004105,Phase II,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 3162, 'therapyName': 'MEDI4736 + Selumetinib'}]",MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC),01/09/2017,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03004183,Phase II,Recruiting,"Jenny C. Chang, MD","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC,08/09/2017,[],yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03004287,Phase II,Recruiting,University of Arkansas,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1624, 'therapyName': 'Carfilzomib'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1164, 'therapyName': 'lenalidomide'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1475, 'therapyName': 'Thalidomide'}]",2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy,07/12/2017,[],no
0,female,"[{'id': 3459, 'name': 'breast carcinoma', 'source': 'DOID'}]",NCT03004534,Phase 0,Recruiting,Translational Research in Oncology,"[{'id': 836, 'therapyName': 'ODM-201'}]",A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of ODM-201,08/08/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT03005002,Phase I,Recruiting,City of Hope Medical Center,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver,09/13/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03005639,Phase II,Recruiting,Inova Health Care Services,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma,01/09/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03005782,Phase I,Recruiting,Regeneron Pharmaceuticals,"[{'id': 5736, 'therapyName': 'REGN3767 + REGN2810'}, {'id': 5735, 'therapyName': 'REGN3767'}]",Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers,05/22/2017,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03006172,Phase I,Recruiting,Hoffmann-La Roche,"[{'id': 5182, 'therapyName': 'GDC-0077 + Letrozole + Palbociclib'}, {'id': 5181, 'therapyName': 'GDC-0077'}, {'id': 5184, 'therapyName': 'GDC-0077 + Fulvestrant'}, {'id': 5183, 'therapyName': 'GDC-0077 + Letrozole'}]","To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",01/13/2017,"[{'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT03006302,Phase II,Not yet recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 5169, 'therapyName': 'CRS-207 + INCB024360 + Pembrolizumab'}, {'id': 5170, 'therapyName': 'CRS-207 + Cyclophosphamide + GVAX panc vaccine + INCB024360 + Pembrolizumab'}]","Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer",01/09/2017,[],no
0,both,"[{'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}]",NCT03006848,Phase II,Recruiting,St. Jude Children's Research Hospital,"[{'id': 3144, 'therapyName': 'Avelumab'}]",A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma,01/09/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT03006926,Phase I,Recruiting,"Eisai Co., Ltd. ","[{'id': 4782, 'therapyName': 'Lenvatinib + Pembrolizumab'}]",A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma,09/18/2017,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT03007147,Phase III,Recruiting,Children's Oncology Group,"[{'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 1441, 'therapyName': 'Ifosfamide'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 5167, 'therapyName': 'Methylprednisolone'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 5168, 'therapyName': 'Prednisolone'}, {'id': 1009, 'therapyName': 'Doxorubicin'}]",Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia,09/01/2017,[],yes
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT03007407,Phase II,Recruiting,NSABP Foundation Inc ,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy,10/03/2017,[],no
0,both,[],NCT03007719,,Recruiting,Lawrence Fong,[],[18F]F-AraG Imaging in Bladder Cancer Patients + Atezolizumab,04/11/2017,[],no
0,both,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03007732,Phase II,Suspended,Lawrence Fong,"[{'id': 5166, 'therapyName': 'Pembrolizumab + SD-101'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Combination With Intratumoral SD-101 Therapy,10/18/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT03007979,Phase II,Recruiting,Washington University School of Medicine,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 2922, 'therapyName': 'Palbociclib + Letrozole'}]",Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer,06/27/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03008187,Phase Ib/II,Suspended,Selvita S.A.,"[{'id': 3693, 'therapyName': 'SEL24-B489'}]",SEL24 in Patients With AML,10/11/2017,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 5517, 'name': 'stomach carcinoma', 'source': 'DOID'}]",NCT03008278,Phase Ib/II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 5165, 'therapyName': 'Olaparib + Ramucirumab'}]",Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery,01/09/2017,[],no
0,both,"[{'id': 50773, 'name': 'paraganglioma', 'source': 'DOID'}, {'id': 50892, 'name': 'adrenal gland pheochromocytoma', 'source': 'DOID'}, {'id': 50936, 'name': 'extra-adrenal pheochromocytoma', 'source': 'DOID'}]",NCT03008369,Phase II,Recruiting,Mayo Clinic,"[{'id': 792, 'therapyName': 'Lenvatinib'}]",Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery,06/07/2017,[],no
0,female,"[{'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}]",NCT03008408,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 5180, 'therapyName': 'Ribociclib + Everolimus + Letrozole'}]","Phase II Ribociclib, Everolimus and Letrozole in Endometrial Cancer",08/23/2017,[],no
0,both,"[{'id': 1816, 'name': 'angiosarcoma', 'source': 'DOID'}, {'id': 4136, 'name': 'myxosarcoma', 'source': 'DOID'}, {'id': 5940, 'name': 'malignant peripheral nerve sheath tumor', 'source': 'DOID'}, {'id': 3382, 'name': 'liposarcoma', 'source': 'DOID'}, {'id': 5702, 'name': 'pleomorphic liposarcoma', 'source': 'DOID'}, {'id': 1967, 'name': 'leiomyosarcoma', 'source': 'DOID'}, {'id': 6193, 'name': 'epithelioid sarcoma', 'source': 'DOID'}, {'id': 3250, 'name': 'pleomorphic rhabdomyosarcoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 3355, 'name': 'fibrosarcoma', 'source': 'DOID'}, {'id': 5485, 'name': 'synovial sarcoma', 'source': 'DOID'}]",NCT03009201,Phase I,Recruiting,OHSU Knight Cancer Institute,"[{'id': 5179, 'therapyName': 'Doxorubicin + Ribociclib'}]",Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery,04/13/2017,"[{'molecularProfile': {'id': 2395, 'profileName': 'RB1 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03009240,Phase I,Recruiting,City of Hope Medical Center ,"[{'id': 5214, 'therapyName': 'Decitabine + MLN4924'}]",Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia,07/12/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03009981,Phase III,Recruiting,"Alliance Foundation Trials, LLC.","[{'id': 5523, 'therapyName': 'Abiraterone + ARN-509 + Degarelix + Prednisone'}, {'id': 5524, 'therapyName': 'ARN-509 + Degarelix'}, {'id': 1814, 'therapyName': 'Degarelix'}]",A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer,04/07/2017,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03010176,Phase I,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 5348, 'therapyName': 'MK-1454 + Pembrolizumab'}, {'id': 5347, 'therapyName': 'MK-1454'}]",Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001),02/21/2017,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT03011034,Phase II,Recruiting,"Janssen Research & Development, LLC","[{'id': 5809, 'therapyName': 'Talacotuzumab'}, {'id': 1630, 'therapyName': 'Daratumumab'}]",Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment,07/06/2017,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT03011372,Phase II,Recruiting,Incyte Corporation,"[{'id': 4173, 'therapyName': 'INCB054828'}]",A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement,03/07/2017,"[{'molecularProfile': {'id': 1276, 'profileName': 'FGFR1 rearrange'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50749, 'name': 'peripheral T-cell lymphoma', 'source': 'DOID'}, {'id': 60061, 'name': 'cutaneous T cell lymphoma', 'source': 'DOID'}, {'id': 8541, 'name': ""Sezary's disease"", 'source': 'DOID'}, {'id': 8691, 'name': 'mycosis fungoides', 'source': 'DOID'}]",NCT03011814,Phase Ib/II,"Active, not recruiting",City of Hope Medical Center,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 3934, 'therapyName': 'lenalidomide + MEDI4736'}]",Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma,09/08/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03012230,Phase I,Not yet recruiting,Mayo Clinic,"[{'id': 5227, 'therapyName': 'Pembrolizumab + Ruxolitinib'}]",Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer,01/19/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03012321,Phase II,Recruiting,Northwestern University,"[{'id': 5226, 'therapyName': 'Abiraterone + Prednisone + Olaparib'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}, {'id': 837, 'therapyName': 'Olaparib'}]","Abiraterone Acetate, Olaparib, and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer With DNA Repair Defects",03/21/2017,"[{'molecularProfile': {'id': 3274, 'profileName': 'ATM mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14074, 'profileName': 'BRCA1 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 17614, 'profileName': 'ATM del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 11671, 'profileName': 'BRCA2 del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03012477,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1725, 'therapyName': 'MK-1775 + Cisplatin'}]",CISPLATIN + AZD-1775 In Breast Cancer,01/24/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT03013218,Phase I,Recruiting,"Alexo Therapeutics, Inc.","[{'id': 5211, 'therapyName': 'ALX148'}, {'id': 5212, 'therapyName': 'ALX148 + Atezolizumab'}, {'id': 5213, 'therapyName': 'ALX148 + Trastuzumab'}]",A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma,02/11/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT03013491,Phase II,Recruiting,CytomX Therapeutics,"[{'id': 5209, 'therapyName': 'CX-072 + Ipilimumab'}, {'id': 5210, 'therapyName': 'CX-072 + Vemurafenib'}, {'id': 5208, 'therapyName': 'CX-072'}]",A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas,01/15/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03013998,Phase Ib/II,Recruiting,"Beat AML, LLC ","[{'id': 4003, 'therapyName': 'Azacitidine + Enasidenib'}, {'id': 5539, 'therapyName': 'Azacitidine + Entospletinib'}, {'id': 5536, 'therapyName': 'Cytarabine + Daunorubicin + Samalizumab'}, {'id': 5538, 'therapyName': 'Azacitidine + BI 836858'}]",Study of Biomarker-Based Treatment of Acute Myeloid Leukemia,04/12/2017,[],no
0,both,"[{'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT03014297,Phase I,Recruiting,Lowell Anthony,"[{'id': 5207, 'therapyName': 'Everolimus + Fosbretabulin'}]",Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression,03/15/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03014648,Phase II,Recruiting,University of Pittsburgh,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC),09/09/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT03014804,Phase II,Not yet recruiting,Jonsson Comprehensive Cancer Center,"[{'id': 5205, 'therapyName': 'DCVax-L'}, {'id': 5206, 'therapyName': 'DCVax-L + Nivolumab'}]",Dendritic Cell-Autologous Lung Tumor Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma,01/15/2017,[],no
0,female,"[{'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}]",NCT03015129,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer,01/13/2017,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03015740,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 4943, 'therapyName': 'MGCD516 + Nivolumab'}]",MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC),04/26/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03015792,Phase Ib/II,Recruiting,Mayo Clinic,"[{'id': 5240, 'therapyName': 'Ibrutinib + Lenalidomide + Dexamethasone'}]","Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant",03/17/2017,[],no
0,both,"[{'id': 8543, 'name': ""Hodgkin's lymphoma, lymphocytic-histiocytic predominance"", 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 8584, 'name': 'Burkitt lymphoma', 'source': 'DOID'}, {'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT03015896,Phase Ib/II,Suspended,Kami Maddocks,"[{'id': 5239, 'therapyName': 'Lenalidomide + Nivolumab'}]",Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma,09/15/2017,[],no
0,both,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03016312,Phase III,Recruiting,Hoffmann-La Roche,"[{'id': 5204, 'therapyName': 'Atezolizumab + Enzalutamide'}, {'id': 1262, 'therapyName': 'Enzalutamide'}]","IMbassador250: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen",01/15/2017,[],no
0,female,"[{'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}]",NCT03016338,Phase II,Not yet recruiting,"University Health Network, Toronto","[{'id': 832, 'therapyName': 'Niraparib'}]",Study of Niraparib in Recurrent Endometrial Cancer,01/16/2017,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT03016377,Phase I,Not yet recruiting,UNC Lineberger Comprehensive Cancer Center,"[{'id': 3585, 'therapyName': 'Anti-CD19 CAR T'}]",Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia,08/08/2017,[],yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT03016741,FDA approved,Recruiting,Vanderbilt-Ingram Cancer Center,"[{'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 2748, 'therapyName': 'Abiraterone + Prednisone'}]",Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer,06/19/2017,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT03016871,Phase II,Recruiting,City of Hope Medical Center,"[{'id': 5198, 'therapyName': 'Nivolumab + Etoposide + Ifosfamide + Carboplatin'}]","Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma",04/26/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03017833,Phase I,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 5197, 'therapyName': 'MLN0128 + Metformin'}]",Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers,01/13/2017,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT03018080,Phase II,Recruiting,Antoinette Tan,"[{'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}]",Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer (PePPy),06/20/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,[],NCT03018223,,Recruiting,,[],Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT,07/27/2017,[],no
0,female,"[{'id': 2870, 'name': 'endometrial adenocarcinoma', 'source': 'DOID'}]",NCT03018249,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 2401, 'therapyName': 'Medroxyprogesterone'}, {'id': 5203, 'therapyName': 'Medroxyprogesterone + Entinostat'}]",Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer,08/31/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT03018288,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 5221, 'therapyName': 'Pembrolizumab + Temozolomide'}, {'id': 5220, 'therapyName': 'Pembrolizumab + Temozolomide + Vitespen'}]",Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM),03/24/2017,"[{'molecularProfile': {'id': 576, 'profileName': 'IDH1 wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 577, 'profileName': 'IDH2 wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT03018405,Phase I,Recruiting,Celyad (formerly named Cardio3 BioSciences) ,"[{'id': 5998, 'therapyName': 'NKR-2 cells'}]",A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK),07/17/2017,[],yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03019003,Phase Ib/II,Recruiting,Massachusetts General Hospital,"[{'id': 5199, 'therapyName': 'MEDI4736 + Azacitidine + Tremelimumab'}]","A Phase IB/II Study With Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients",03/23/2017,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT03020030,Phase III,Recruiting,Dana-Farber Cancer Institute,"[{'id': 3160, 'therapyName': 'Nelarabine'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents,07/29/2017,[],yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03021460,Phase II,Suspended,Mayo Clinic,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery,06/20/2017,[],no
0,both,"[{'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}]",NCT03021993,Phase II,Recruiting,David Neskey,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer,06/20/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03022409,Phase I,Not yet recruiting,AstraZeneca,"[{'id': 837, 'therapyName': 'Olaparib'}, {'id': 2881, 'therapyName': 'AZD6738'}]",A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC),01/20/2017,[],no
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT03022565,Phase I,Not yet recruiting,Nicolas Acquavella,"[{'id': 1077, 'therapyName': 'Vorinostat'}]",Vorinostat in Patients With Class 2 High Risk Uveal Melanoma,01/27/2017,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT03022825,Phase II,Recruiting,Altor Bioscience Corporation,"[{'id': 5238, 'therapyName': 'ALT-803 + BCG solution'}]",QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer,06/07/2017,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 80147, 'name': 'lymphoblastic lymphoma', 'source': 'DOID'}]",NCT03023046,Phase II,Recruiting,University of Washington,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 770, 'therapyName': 'Imatinib'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 1631, 'therapyName': 'Vincristine'}]","Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",03/04/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 3277, 'name': 'thymus cancer', 'source': 'DOID'}, {'id': 734, 'name': 'urethra cancer', 'source': 'DOID'}, {'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}, {'id': 3275, 'name': 'thymoma', 'source': 'DOID'}, {'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT03023319,Phase I,Recruiting,Nagla Karim,"[{'id': 5237, 'therapyName': 'Bosutinib + Pemetrexed'}]",Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors,01/27/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03023423,Phase Ib/II,Recruiting,"Janssen Research & Development, LLC","[{'id': 5236, 'therapyName': 'Atezolizumab + Daratumumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (DARZALEX),01/19/2017,[],no
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT03023722,Phase II,Recruiting,Howard Hochster,"[{'id': 4593, 'therapyName': 'Anetumab ravtansine'}]",Phase II Anetumab Ravtansine as 2nd Line Treatment for Pancreatic Cancer,05/16/2017,[],yes
0,both,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03024216,Phase I,Recruiting,University of Hawaii,"[{'id': 5642, 'therapyName': 'Atezolizumab + Sipuleucel-T'}]",Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer,05/12/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03024437,Phase Ib/II,"Active, not recruiting",Roberto Pili,"[{'id': 5129, 'therapyName': 'Entinostat + Atezolizumab'}, {'id': 5235, 'therapyName': 'Atezolizumab + Entinostat + Bevacizumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma,06/09/2017,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 4473, 'name': 'sarcomatoid renal cell carcinoma', 'source': 'DOID'}]",NCT03024996,Phase III,Recruiting,Hoffmann-La Roche,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy (IMmotion010),01/27/2017,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT03025035,Phase II,Recruiting,Monica Mita,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Advanced BRCA-mutated Breast Cancer,06/10/2017,"[{'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03025256,Phase I,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD),01/27/2017,[],no
0,both,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT03026062,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1652, 'therapyName': 'Tremelimumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Durvalumab and Tremelimumab in Combo Versus Sequential,05/23/2017,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT03026166,Phase I,Recruiting,AbbVie,"[{'id': 5640, 'therapyName': 'Rovalpituzumab Tesirine + Nivolumab + Ipilimumab'}, {'id': 5641, 'therapyName': 'Rovalpituzumab Tesirine + Nivolumab'}]",A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer,05/07/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03026517,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 5270, 'therapyName': 'Dabrafenib + Trametinib + Phenformin'}]",Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma,01/31/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT03027388,Phase I,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 3514, 'therapyName': 'LB-100'}]","Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma",02/03/2017,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT03028103,Phase I,Recruiting,"Epizyme, Inc.","[{'id': 5267, 'therapyName': 'Tazemetostat + Fluconazole'}, {'id': 5285, 'therapyName': 'Repaglinide + Omeprazole + Tazemetostat'}]","Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, the Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma Subjects",06/22/2017,[],no
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 4001, 'name': 'ovarian carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}]",NCT03029403,Phase II,Not yet recruiting,"University Health Network, Toronto","[{'id': 5266, 'therapyName': 'Pembrolizumab + DPX-Survivac + Cyclophosphamide'}]","Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer",01/30/2017,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT03029598,Phase Ib/II,Recruiting,University of Washington,"[{'id': 5265, 'therapyName': 'Carboplatin + Pembrolizumab'}]","Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",04/08/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03029780,Phase II,Recruiting,Bristol-Myers Squibb,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma,02/21/2017,[],no
0,both,"[{'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}]",NCT03029832,Phase II,"Active, not recruiting","Genentech, Inc.","[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5451, 'therapyName': 'Atezolizumab + MOXR0916'}]",A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy,09/08/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03030261,Phase II,Not yet recruiting,Washington University School of Medicine,"[{'id': 1207, 'therapyName': 'Melphalan'}, {'id': 3355, 'therapyName': 'Elotuzumab + Dexamethasone + Pomalidomide'}]","Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma",02/03/2017,[],no
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT03030287,Phase I,Recruiting,"OncoMed Pharmaceuticals, Inc.","[{'id': 5264, 'therapyName': 'OMP-305B83 + Paclitaxel'}]","A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer",02/03/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03030378,Phase I,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 5263, 'therapyName': 'Pembrolizumab + Interleukin-12'}]",Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors,01/30/2017,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03030417,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 5749, 'therapyName': 'LMP744'}]",Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas,05/26/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03030885,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 5804, 'therapyName': '131I-MIP-1095'}]",Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC),06/02/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT03031691,Phase I,"Active, not recruiting","OncoMed Pharmaceuticals, Inc.","[{'id': 5261, 'therapyName': 'Brontictuzumab + Trifluridine'}]",A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer,06/03/2017,[],no
0,male,[],NCT03031821,Phase III,Not yet recruiting,Canadian Urologic Oncology Group,[],Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome,02/09/2017,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT03032107,Phase I,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1909, 'therapyName': 'Pembrolizumab + trastuzumab emtansine'}]",A Study Of Pembrolizumab In Combination With Trastuzumab-DM1,02/24/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT03032406,Phase II,Recruiting,Abramson Cancer Center of the University of Pennsylvania,"[{'id': 2231, 'therapyName': 'Everolimus + Hydroxychloroquine'}, {'id': 735, 'therapyName': 'Everolimus'}, {'id': 1316, 'therapyName': 'Hydroxychloroquine'}]","CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer",02/03/2017,[],yes
0,both,"[{'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}]",NCT03032484,Phase II,Recruiting,The University of Texas Health Science Center at San Antonio,"[{'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 5260, 'therapyName': 'Bevacizumab + TVB-2640'}]",TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma,08/10/2017,[],no
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT03033225,Phase II,Recruiting,Mayo Clinic,"[{'id': 3319, 'therapyName': 'Verteporfin'}]",EUS-guided PDT in Pancreatic Tumors,04/28/2017,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT03033511,Phase III,Recruiting,AbbVie,"[{'id': 5307, 'therapyName': 'Rovalpituzumab Tesirine + Dexamethasone'}]",A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) (MERU),02/28/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03033576,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That is Stage IV or Stage III and Cannot Be Removed by Surgery,07/22/2017,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT03033914,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 5296, 'therapyName': 'Dacarbazine + Doxorubicin + Vinblastine + Nivolumab'}, {'id': 5295, 'therapyName': 'Bleomycin + Dacarbazine + Doxorubicin + Vinblastine + Nivolumab'}]",A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma,02/09/2017,[],no
0,both,"[{'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT03034200,Phase II,Recruiting,Peter Anderson,"[{'id': 1687, 'therapyName': 'ONC201'}]",Phase 2 Study of ONC201 in Neuroendocrine Tumors,07/29/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03035253,Phase I,Recruiting,"OncoMed Pharmaceuticals, Inc.","[{'id': 5297, 'therapyName': 'FOLFIRI + OMP-305B83'}]",A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer,02/09/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT03035279,Phase I,Recruiting,AbbVie,"[{'id': 5748, 'therapyName': 'SC-006'}]",A Study of SC-006 in Subjects With Advanced Cancer,05/26/2017,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT03035331,Phase Ib/II,Recruiting,Mayo Clinic,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma",04/12/2017,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT03035630,Phase II,Recruiting,Guru Sonpavde,"[{'id': 3144, 'therapyName': 'Avelumab'}, {'id': 930, 'therapyName': 'Sunitinib'}]",Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma,08/10/2017,[],no
0,both,[],NCT03035890,Phase I,Recruiting,West Virginia University ,[],Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer,05/26/2017,[],no
0,both,"[{'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}]",NCT03036098,Phase III,Recruiting,Bristol-Myers Squibb,"[{'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}]",Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care Chemotherapy in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer,03/30/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03036488,Phase III,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 1087, 'therapyName': 'Epirubicin + Cyclophosphamide'}, {'id': 1977, 'therapyName': 'Doxorubicin + Cyclophosphamide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1124, 'therapyName': 'Paclitaxel + Carboplatin'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522),03/30/2017,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT03036904,Phase I,Recruiting,Weill Medical College of Cornell University,"[{'id': 5294, 'therapyName': 'Venetoclax + DA-EPOCH-R'}]",Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (V+DA-EPOCH-R),04/30/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3973, 'name': 'thyroid medullary carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03037385,Phase I,Recruiting,Blueprint Medicines Corporation,"[{'id': 5530, 'therapyName': 'BLU-667'}]","Phase 1 Study of BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors",04/12/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 18885, 'profileName': 'ALK act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 27139, 'profileName': 'ROS1 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1249, 'profileName': 'ROS1 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1232, 'profileName': 'RET mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1326, 'profileName': 'RET rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2446, 'profileName': 'ALK fusion'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT03037645,Phase Ib/II,Recruiting,Sunesis Pharmaceuticals,"[{'id': 5281, 'therapyName': 'SNS-062'}]","Safety, PK, PD, and Antitumor Activity of SNS-062 in B Lymphoid Cancers",05/19/2017,[],no
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT03038100,Phase III,Recruiting,Hoffmann-La Roche,"[{'id': 2370, 'therapyName': 'Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel'}, {'id': 1152, 'therapyName': 'Bevacizumab + Carboplatin + Paclitaxel'}]","A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (IMagyn050)",03/09/2017,[],no
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT03038477,Phase II,Recruiting,"University of Colorado, Denver","[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection,05/31/2017,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}]",NCT03038672,Phase II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 2526, 'therapyName': 'Nivolumab + Varlilumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas,02/09/2017,[],no
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT03039114,Phase I,Recruiting,Incyte Corporation,"[{'id': 6260, 'therapyName': 'Bendamustine + INCB050465 + Obinutuzumab'}]",Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102),09/29/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03040973,FDA approved,Recruiting,Novartis Pharmaceuticals,"[{'id': 1065, 'therapyName': 'Capmatinib'}]",Roll-over Study for Patients With cMET-dependent Malignancies Who Previously Completed a Novartis Capmatinib Study,08/25/2017,"[{'molecularProfile': {'id': 1629, 'profileName': 'MET amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2096, 'profileName': 'MET act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 5392, 'profileName': 'MET over exp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT03040986,Phase II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 913, 'therapyName': 'Selumetinib'}]",Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations,02/06/2017,"[{'molecularProfile': {'id': 1732, 'profileName': 'KRAS G12R'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 8618, 'name': 'oral cavity cancer', 'source': 'DOID'}, {'id': 2596, 'name': 'larynx cancer', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT03040999,Phase III,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 3256, 'therapyName': 'Cisplatin + Pembrolizumab'}, {'id': 700, 'therapyName': 'Cisplatin'}]",Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412),03/30/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03041181,Phase II,Recruiting,"Nasser Hanna, M.D.","[{'id': 5288, 'therapyName': 'Docetaxel + Nivolumab'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Docetaxel Plus Nivolumab or Docetaxel Alone in Patients With Advanced Non-squamous NSCLC Previously Treated With Nivolumab,02/06/2017,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT03041311,Phase II,Recruiting,"G1 Therapeutics, Inc.","[{'id': 5541, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide + Trilaciclib'}, {'id': 4164, 'therapyName': 'Atezolizumab + Carboplatin + Etoposide'}]","Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)",05/05/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT03041636,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Administration of Jakafi (Ruxolitinib) to Patients With High-Risk Chronic Lymphocytic Leukemia (CLL),03/14/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03041688,Phase I,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 6185, 'therapyName': 'AMG 232 + Decitabine'}]","MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia",09/11/2017,"[{'molecularProfile': {'id': 642, 'profileName': 'TP53 wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4051, 'name': 'alveolar rhabdomyosarcoma', 'source': 'DOID'}, {'id': 3246, 'name': 'embryonal rhabdomyosarcoma', 'source': 'DOID'}]",NCT03041701,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 5287, 'therapyName': 'Dasatinib + Ganitumab'}]",Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma,03/01/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03042013,Phase II,Withdrawn,"Astellas Pharma Global Development, Inc.","[{'id': 1082, 'therapyName': 'ASP8273'}]",A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study,07/12/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT03042611,Phase III,Recruiting,LSK BioPartners Inc.,"[{'id': 986, 'therapyName': 'Apatinib'}]",Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer,06/19/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 4971, 'name': 'myelofibrosis', 'source': 'DOID'}]",NCT03042689,Phase I,Not yet recruiting,Massachusetts General Hospital,"[{'id': 890, 'therapyName': 'Regorafenib'}]",Study of Regorafenib in Patients With Advanced Myeloid Malignancies,02/06/2017,[],no
0,female,"[{'id': 50933, 'name': 'ovarian serous carcinoma', 'source': 'DOID'}]",NCT03042702,Phase II,Recruiting,Cellceutix Corporation,"[{'id': 2999, 'therapyName': 'thioureidobutyronitrile'}]",A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer,02/21/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT03042819,Phase I,Recruiting,"University Health Network, Toronto","[{'id': 5286, 'therapyName': 'Selinexor + Doxorubicin'}]",Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas,06/01/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03042910,Phase I,Completed,"Medivation, Inc. ","[{'id': 682, 'therapyName': 'Talazoparib'}]",A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors,08/23/2017,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}, {'id': 234, 'name': 'colon adenocarcinoma', 'source': 'DOID'}]",NCT03043313,Phase II,Recruiting,Academic and Community Cancer Research United,"[{'id': 1560, 'therapyName': 'ARRY-380 + Trastuzumab'}]",Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER)Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER) (MOUNTAINEER),07/06/2017,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 481, 'profileName': 'NRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT03043599,Phase Ib/II,Recruiting,H. Lee Moffitt Cancer Center and Research Institute,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer,02/16/2017,[],no
0,both,"[{'id': 50626, 'name': 'gastrointestinal neuroendocrine tumor', 'source': 'DOID'}, {'id': 1798, 'name': 'pancreatic endocrine carcinoma', 'source': 'DOID'}]",NCT03043664,Phase Ib/II,Recruiting,Duke University,"[{'id': 6129, 'therapyName': 'Lanreotide Depot + Pembrolizumab'}]",Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors (PLANET),08/18/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03043807,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 3945, 'therapyName': 'Bicalutamide + Docetaxel + Leuprolide'}]",A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy,03/23/2017,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT03043872,Phase III,Recruiting,AstraZeneca,"[{'id': 5305, 'therapyName': 'MEDI4736 + Tremelimumab + Carboplatin + Cisplatin + Etoposide'}, {'id': 5306, 'therapyName': 'MEDI4736 + Carboplatin + Cisplatin + Etoposide'}, {'id': 4728, 'therapyName': 'Carboplatin + Cisplatin + Etoposide'}]",Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian),04/26/2017,[],no
0,both,"[{'id': 5041, 'name': 'esophageal cancer', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT03044613,Phase I,Recruiting,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 5304, 'therapyName': 'Nivolumab + Ipilimumab + Carboplatin + Paclitaxel'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Nivolumab or Nivolumab/Ipilimumab Prior to Chemoradiation Plus Nivolumab With II/III Gastro/Esophageal Cancer,06/20/2017,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03044730,Phase II,Recruiting,Northwestern University,"[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}]",Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery,06/09/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT03045328,Phase Ib/II,Recruiting,Steven E. Coutre,"[{'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL,10/05/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03047135,Phase II,Recruiting,,"[{'id': 837, 'therapyName': 'Olaparib'}]","Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis",05/04/2017,"[{'molecularProfile': {'id': 522, 'profileName': 'ATM inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1283, 'profileName': 'BRCA2 inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1282, 'profileName': 'BRCA1 inact mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}]",NCT03047213,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations,06/19/2017,[],yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT03047473,Phase II,Recruiting,Clinique Neuro-Outaouais,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme (SEJ),03/30/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03048136,Phase III,Not yet recruiting,Bristol-Myers Squibb,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955),05/26/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03048500,Phase II,Not yet recruiting,Northwestern University,"[{'id': 5302, 'therapyName': 'Metformin + Nivolumab'}]",Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery,02/11/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03049618,Phase II,Recruiting,University of Southern California,"[{'id': 3944, 'therapyName': 'sEphB4-HSA + Pembrolizumab'}]","Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475",03/29/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 4451, 'name': 'renal carcinoma', 'source': 'DOID'}]",NCT03050060,Phase II,Recruiting,University of Washington,"[{'id': 5301, 'therapyName': 'Nelfinavir + Nivolumab'}]","Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, and Nivolumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer",06/20/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03050216,Phase II,Recruiting,"Masonic Cancer Center, University of Minnesota","[{'id': 5300, 'therapyName': 'ALT-803 + Cyclophosphamide + Fludarabine phosphate'}]",Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML,05/19/2017,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT03050398,Phase III,Recruiting,Novartis Pharmaceuticals,"[{'id': 1568, 'therapyName': 'LEE011 + Letrozole'}]",A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib,05/29/2017,[],no
0,both,"[{'id': 3620, 'name': 'central nervous system cancer', 'source': 'DOID'}]",NCT03050450,Phase I,Recruiting,Johns Hopkins All Children's Hospital,"[{'id': 5337, 'therapyName': 'Lenalidomide + Vorinostat'}]",Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors,02/19/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03050554,Phase Ib/II,Recruiting,Andrew Sharabi,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC),03/23/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT03050814,Phase II,Suspended,National Cancer Institute (NCI),"[{'id': 1524, 'therapyName': 'Fluorouracil + Bevacizumab + Capecitabine + Leucovorin + Oxaliplatin'}, {'id': 5336, 'therapyName': 'Ad-CEA + Bevacizumab + FOLFOX'}]",Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer,08/08/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03051035,Phase I,Recruiting,"Kura Oncology, Inc.","[{'id': 5747, 'therapyName': 'KO-947'}]",First-in-Human Study of KO-947 in Non-Hematological Malignancies,05/26/2017,"[{'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1208, 'profileName': 'HRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT03051659,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 728, 'therapyName': 'Eribulin'}, {'id': 3080, 'therapyName': 'Eribulin + Pembrolizumab'}]",A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer,03/25/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT03051672,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC,04/18/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT03052127,Phase I,Recruiting,Aura Biosciences,"[{'id': 5828, 'therapyName': 'AU-011'}]",Phase 1B Study in Subjects With Small to Medium Primary Choroidal Melanoma,06/02/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03052205,Phase I,Recruiting,"Idera Pharmaceuticals, Inc.","[{'id': 4243, 'therapyName': 'IMO-2125'}]",A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors,05/17/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03052569,Expanded access,Temporarily not available,"Ignyta, Inc.","[{'id': 1002, 'therapyName': 'CEP-32496'}]",Expanded Access to RXDX-105 for Cancers With RET Alterations,09/06/2017,"[{'molecularProfile': {'id': 1232, 'profileName': 'RET mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03052608,Phase III,Recruiting,Pfizer ,"[{'id': 869, 'therapyName': 'PF-06463922'}, {'id': 706, 'therapyName': 'Crizotinib'}]",A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC,04/30/2017,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}]",NCT03053440,Phase III,Recruiting,BeiGene,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 2544, 'therapyName': 'BGB-3111'}]",A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM),03/01/2017,[],no
0,both,"[{'id': 1996, 'name': 'rectum adenocarcinoma', 'source': 'DOID'}]",NCT03053544,Phase II,Recruiting,Sunnybrook Health Sciences Centre,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer,02/19/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03054038,Phase I,Recruiting,Vanderbilt-Ingram Cancer Center,"[{'id': 5363, 'therapyName': 'Afatinib + Necitumumab'}]",Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer,09/06/2017,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT03054363,Phase Ib/II,Not yet recruiting,"University of Colorado, Denver","[{'id': 5334, 'therapyName': 'ARRY-380 + Palbociclib + Letrozole'}]","Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer",02/24/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT03054909,Phase I,Not yet recruiting,"Masonic Cancer Center, University of Minnesota","[{'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-2.021: Phase I of IP Followed by SQ ALT-803 for Ovarian Cancer,02/19/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03055013,Phase III,Recruiting,National Cancer Institute (NCI),"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PROSPER),02/19/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT03056001,Phase II,Recruiting,Edward Kim,"[{'id': 4690, 'therapyName': 'Doxorubicin + Pembrolizumab'}]","Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma",05/12/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT03056339,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 6217, 'therapyName': 'Cyclophosphamide + Fludarabine phosphate + iC9/CAR.19/IL15-Transduced CB-NK'}]",Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies,09/18/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT03056599,,Recruiting,,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1299, 'therapyName': 'Interferon alfa-2b '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 728, 'therapyName': 'Eribulin'}, {'id': 1733, 'therapyName': 'interferon gamma '}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 3420, 'therapyName': 'trabectedin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 720, 'therapyName': 'Docetaxel'}]",Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma,05/26/2017,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT03056755,Phase II,Recruiting,Novartis Pharmaceuticals ,"[{'id': 5929, 'therapyName': 'Alpelisib + Fulvestrant'}, {'id': 1553, 'therapyName': 'Letrozole + BYL719'}]","Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant",06/29/2017,"[{'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT03056833,Phase I,Recruiting,University of Michigan Cancer Center,"[{'id': 5333, 'therapyName': 'LEE011 + Carboplatin + Paclitaxel'}]",Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer,06/20/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03057106,Phase II,Recruiting,Canadian Cancer Trials Group,"[{'id': 700, 'therapyName': 'Cisplatin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC,03/31/2017,"[{'molecularProfile': {'id': 2446, 'profileName': 'ALK fusion'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03057145,Phase I,Recruiting,Khanh Do,"[{'id': 5332, 'therapyName': 'Olaparib + Prexasertib'}]",Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors,04/05/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03057613,Phase II,Recruiting,Case Comprehensive Cancer Center,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck,05/18/2017,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT03057795,Phase II,Recruiting,City of Hope Medical Center,"[{'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]",Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma,04/07/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT03059147,Phase I,Recruiting,"SignalRX Pharmaceuticals, Inc.","[{'id': 915, 'therapyName': 'SF1126'}]",A Study of Single Agent SF1126 Inhibitor in Patients With Advanced Hepatocellular Carcinoma,06/02/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03059485,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 5369, 'therapyName': 'DC/AML Vaccine'}, {'id': 5370, 'therapyName': 'DC/AML Vaccine + MEDI4736'}]",DC/AML Fusion Cell Vaccine vs DC/AML Fusion Cell Vaccine Plus Durvalumab vs Observation in Patients Who Achieve a Chemotherapy-induced Remission,07/06/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03059823,Phase I,Recruiting,MacroGenics,"[{'id': 5813, 'therapyName': 'MGA012'}]",A Phase 1 Study of MGA012 in Patients With Advanced Solid Tumors,06/02/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT03061188,Phase I,Recruiting,Northwestern University,"[{'id': 5368, 'therapyName': 'Veliparib + Nivolumab'}]",Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes,06/03/2017,"[{'molecularProfile': {'id': 3274, 'profileName': 'ATM mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT03061812,Phase III,Recruiting,AbbVie ,"[{'id': 3544, 'therapyName': 'Rovalpituzumab Tesirine'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (TAHOE),05/02/2017,[],yes
0,both,"[{'id': 8541, 'name': ""Sezary's disease"", 'source': 'DOID'}, {'id': 8691, 'name': 'mycosis fungoides', 'source': 'DOID'}]",NCT03063632,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 5367, 'therapyName': 'Pembrolizumab + interferon gamma'}]",Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome,10/19/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03063762,Phase I,Recruiting,Hoffmann-La Roche,"[{'id': 5365, 'therapyName': 'RO6874281 + Obinutuzumab + Atezolizumab'}, {'id': 5366, 'therapyName': 'RO6874281 + Obinutuzumab + Atezolizumab + Bevacizumab'}]","Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)",09/06/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03063944,Phase I,"Active, not recruiting",Sidney Kimmel Cancer Center at Thomas Jefferson University,"[{'id': 5794, 'therapyName': 'Decitabine + OPB-111077'}]",STAT Inhibitor OPB-111077 and Decitabine in Treating Patients With Acute Myeloid Leukemia That Is Refractory or Newly Diagnosed and Ineligible for Intensive Chemotherapy,10/05/2017,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT03064490,Phase II,Recruiting,Duke University,"[{'id': 2103, 'therapyName': 'Carboplatin + Paclitaxel + Pembrolizumab'}]","Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)",08/02/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03064854,Phase I,Recruiting,Novartis Pharmaceuticals,"[{'id': 6027, 'therapyName': 'Carboplatin + Paclitaxel + PDR001'}, {'id': 6026, 'therapyName': 'Cisplatin + Pemetrexed + PDR001'}, {'id': 6025, 'therapyName': 'Cisplatin + Gemcitabine + PDR001'}, {'id': 6024, 'therapyName': 'Pemetrexed + PDR001 + Cisplatin + Carboplatin'}]","PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)",07/27/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 343, 'profileName': 'EGFR wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 11085, 'profileName': 'ROS1 rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT03064867,Phase I,Recruiting,"Paolo Caimi, MD","[{'id': 5404, 'therapyName': 'Venetoclax + Rituximab + Ifosfamide + Carboplatin + Etoposide'}]",Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma,09/06/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}, {'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03065062,Phase I,Recruiting,Dana-Farber Cancer Institute,"[{'id': 4034, 'therapyName': 'Gedatolisib + Palbociclib'}]","Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors",03/15/2017,"[{'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 479, 'profileName': 'PTEN loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1191, 'profileName': 'PIK3CA amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03065179,Phase II,Recruiting,University of Texas Southwestern Medical Center,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients,06/23/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03065387,Phase I,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 5401, 'therapyName': 'Neratinib + Everolimus'}, {'id': 5402, 'therapyName': 'Neratinib + Palbociclib'}, {'id': 5403, 'therapyName': 'Neratinib + Trametinib'}]","Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation",03/03/2017,"[{'molecularProfile': {'id': 1216, 'profileName': 'ERBB2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 447, 'profileName': 'EGFR amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 6309, 'profileName': 'ERBB4 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4971, 'name': 'myelofibrosis', 'source': 'DOID'}, {'id': 2224, 'name': 'essential thrombocythemia', 'source': 'DOID'}, {'id': 4960, 'name': 'bone marrow cancer', 'source': 'DOID'}]",NCT03065400,Phase II,Recruiting,John Mascarenhas,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",PD-1 Inhibition in Advanced Myeloproliferative Neoplasms,06/30/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03066206,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1042, 'therapyName': 'poziotinib'}]",Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC),03/22/2017,"[{'molecularProfile': {'id': 4039, 'profileName': 'EGFR exon 20 ins'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1048, 'profileName': 'EGFR V769_D770insASV'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1049, 'profileName': 'EGFR D770_N771insSVD'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3086, 'profileName': 'EGFR H773_V774insNPH'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 23636, 'profileName': 'EGFR D770_N771insNPG'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 27329, 'profileName': 'EGFR exon20'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03066661,Expanded access,Available,"Ignyta, Inc.","[{'id': 1455, 'therapyName': 'Entrectinib'}]","Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions",03/10/2017,"[{'molecularProfile': {'id': 2446, 'profileName': 'ALK fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1249, 'profileName': 'ROS1 fusion'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT03066778,Phase III,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 2585, 'therapyName': 'Cisplatin + Etoposide'}, {'id': 5145, 'therapyName': 'Cisplatin + Etoposide + Pembrolizumab'}, {'id': 2604, 'therapyName': 'Carboplatin + Etoposide + Pembrolizumab'}, {'id': 1791, 'therapyName': 'Carboplatin + Etoposide'}]",A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604),05/26/2017,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT03067051,Phase I,Recruiting,SpectraCure AB,"[{'id': 3319, 'therapyName': 'Verteporfin'}]",Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System,04/28/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03068351,Phase I,Recruiting,Hoffmann-La Roche ,"[{'id': 937, 'therapyName': 'TEN-010'}, {'id': 5957, 'therapyName': 'Daratumumab + TEN-010'}]",Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma,07/03/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03068455,Phase III,Recruiting,Bristol-Myers Squibb,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Nivolumab in Combination With Ipilimumab Compared to Nivolumab or Ipilimumab Alone in Treatment of Patients After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915),04/12/2017,[],no
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT03068624,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 5733, 'therapyName': 'Aldesleukin + Cyclophosphamide + Ipilimumab'}]",Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma,09/13/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03069352,Phase III,Recruiting,AbbVie,"[{'id': 3182, 'therapyName': 'Cytarabine + GDC-0199'}, {'id': 712, 'therapyName': 'Cytarabine'}]",A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy,08/08/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT03069378,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 4035, 'therapyName': 'Pembrolizumab + talimogene laherparepvec '}]",A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma,03/16/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT03069469,Phase I,Recruiting,Deciphera Pharmaceuticals LLC,"[{'id': 5760, 'therapyName': 'DCC-3014'}]",Study of DCC-3014 in Patients With Advanced Malignancies,05/26/2017,[],no
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT03069950,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 5476, 'therapyName': 'Floxiuridine + Panitumumab + Dexamethasone + FOLFIRI'}]",Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver,03/30/2017,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 481, 'profileName': 'NRAS wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 4, 'profileName': 'BRAF wild-type'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 575, 'profileName': 'HRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT03070002,Phase II,Recruiting,Northwestern University,"[{'id': 1198, 'therapyName': 'Denosumab'}]","Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells",03/29/2017,[],yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03070093,Expanded access,Available,"Astellas Pharma Global Development, Inc. ","[{'id': 2865, 'therapyName': 'Gilteritinib'}]",Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD),04/28/2017,"[{'molecularProfile': {'id': 24703, 'profileName': 'FLT3 I836X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 19128, 'profileName': 'FLT3 exon 14 ins'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1227, 'profileName': 'FLT3 mutant'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 5329, 'profileName': 'FLT3 D835X'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT03070301,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 5073, 'therapyName': 'Ribociclib + Everolimus'}]",A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors,03/21/2017,[],no
0,both,"[{'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}]",NCT03070392,Phase II,Recruiting,Immunocore Ltd,"[{'id': 1154, 'therapyName': 'Dacarbazine'}, {'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 3847, 'therapyName': 'IMCgp100'}]",Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma,07/03/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03070886,Phase III,Recruiting,NRG Oncology,"[{'id': 5450, 'therapyName': 'Bicalutamide + Docetaxel + Flutamide + Goserelin + Leuprolide + Nilutamide'}, {'id': 5449, 'therapyName': 'Bicalutamide + Flutamide + Goserelin + Leuprolide + Nilutamide'}]",Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery,03/21/2017,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03071276,Phase II,Recruiting,St. Jude Children's Research Hospital,"[{'id': 5448, 'therapyName': 'Selinexor + Fludarabine phosphate + Cytarabine + Methotrexate + Prednisone'}]",Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia,03/15/2017,[],no
0,both,"[{'id': 3965, 'name': 'Merkel cell carcinoma', 'source': 'DOID'}]",NCT03071406,Phase II,Recruiting,H. Lee Moffitt Cancer Center and Research Institute,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma,03/15/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03071757,Phase I,Recruiting,AbbVie,"[{'id': 5446, 'therapyName': 'ABBV-368'}, {'id': 5447, 'therapyName': 'ABBV-368 + Nivolumab'}]","A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",04/01/2017,[],no
0,both,"[{'id': 3565, 'name': 'meningioma', 'source': 'DOID'}]",NCT03071874,Phase II,Recruiting,Massachusetts General Hospital,"[{'id': 991, 'therapyName': 'Vistusertib'}]",Phase II Study Of Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas,09/30/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT03072043,Phase Ib/II,Recruiting,H. Lee Moffitt Cancer Center and Research Institute,"[{'id': 5445, 'therapyName': 'APR-246 + Azacitidine'}]",Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms,05/09/2017,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3973, 'name': 'thyroid medullary carcinoma', 'source': 'DOID'}]",NCT03072160,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer,06/02/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03072238,Phase III,Recruiting,Hoffmann-La Roche,"[{'id': 1805, 'therapyName': 'Abiraterone'}, {'id': 5438, 'therapyName': 'Abiraterone + Ipatasertib'}]","Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer",05/16/2017,[],no
0,female,"[{'id': 120, 'name': 'female reproductive organ cancer', 'source': 'DOID'}]",NCT03073525,Phase II,Recruiting,"Gradalis, Inc. ","[{'id': 5558, 'therapyName': 'Atezolizumab + FANG vaccine'}]",Trial of Atezolizumab and Vigil for Advanced Gynecological Cancers (A Companion Study to CL-PTL-119),06/24/2017,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT03074006,Phase Ib/II,Not yet recruiting,"MedPacto, Inc.","[{'id': 3011, 'therapyName': 'TEW 7197'}]",Dose Escalation and Proof-of-Concept Studies of TEW-7197 Monotherapy in Patients With Myelodysplastic Syndrome (MDS),07/06/2017,[],no
0,both,"[{'id': 3382, 'name': 'liposarcoma', 'source': 'DOID'}, {'id': 1967, 'name': 'leiomyosarcoma', 'source': 'DOID'}]",NCT03074318,Phase Ib/II,Recruiting,Fred Hutchinson Cancer Research Center,"[{'id': 5444, 'therapyName': 'Avelumab + trabectedin'}]",Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery,10/03/2017,[],no
0,both,"[{'id': 1798, 'name': 'pancreatic endocrine carcinoma', 'source': 'DOID'}, {'id': 7958, 'name': 'sarcomatoid penile squamous cell carcinoma', 'source': 'DOID'}, {'id': 2101, 'name': 'vulva squamous cell carcinoma', 'source': 'DOID'}, {'id': 138, 'name': 'vaginal squamous tumor', 'source': 'DOID'}, {'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}, {'id': 7177, 'name': 'anal canal squamous cell carcinoma', 'source': 'DOID'}, {'id': 3608, 'name': 'appendix adenocarcinoma', 'source': 'DOID'}, {'id': 3965, 'name': 'Merkel cell carcinoma', 'source': 'DOID'}, {'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}, {'id': 1788, 'name': 'peritoneal mesothelioma', 'source': 'DOID'}, {'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT03074513,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Atezolizumab and Bevacizumab in Rare Solid Tumors,03/17/2017,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT03075527,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma,04/21/2017,[],no
0,both,"[{'id': 8691, 'name': 'mycosis fungoides', 'source': 'DOID'}, {'id': 50749, 'name': 'peripheral T-cell lymphoma', 'source': 'DOID'}, {'id': 50744, 'name': 'anaplastic large cell lymphoma', 'source': 'DOID'}, {'id': 50523, 'name': 'adult T-cell leukemia', 'source': 'DOID'}, {'id': 50743, 'name': 'mature T-cell and NK-cell lymphoma', 'source': 'DOID'}]",NCT03075553,Phase II,Recruiting,Mayo Clinic,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma,05/24/2017,"[{'molecularProfile': {'id': 24175, 'profileName': 'ALK negative'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}]",NCT03075696,Phase I,Recruiting,Hoffmann-La Roche,"[{'id': 6162, 'therapyName': 'Obinutuzumab + RO7082859 + Tocilizumab'}]","A Dose Escalation Study of RO7082859, Administered After a Fixed, Single Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma",09/05/2017,[],no
0,both,"[{'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT03075826,Phase II,Recruiting,Weill Medical College of Cornell University,"[{'id': 1949, 'therapyName': 'SGI-110'}]",A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms,03/15/2017,[],no
0,both,"[{'id': 3910, 'name': 'lung adenocarcinoma', 'source': 'DOID'}]",NCT03076164,Phase Ib/II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 1265, 'therapyName': 'Erlotinib + Trametinib'}]",A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib,03/15/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03076203,Phase I,Recruiting,Thomas Jefferson University,"[{'id': 5436, 'therapyName': 'Niraparib + radium Ra 223 dichloride'}]",Radium Ra 223 Dichloride and Niraparib in Treating Patients With Hormone- Resistant Prostate Cancer Metastatic to the Bone,09/29/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03076281,Phase II,Recruiting,Sidney Kimmel Cancer Center at Thomas Jefferson University,"[{'id': 1391, 'therapyName': 'Doxycycline'}, {'id': 4610, 'therapyName': 'Metformin + Doxycycline'}, {'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery,09/06/2017,[],no
0,both,"[{'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 5517, 'name': 'stomach carcinoma', 'source': 'DOID'}, {'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}, {'id': 1107, 'name': 'esophageal carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03076372,Phase I,Recruiting,Merrimack Pharmaceuticals,"[{'id': 5758, 'therapyName': 'MM-310'}]",A Study Evaluating MM-310 in Patients With Solid Tumors,05/26/2017,[],no
0,both,"[{'id': 3275, 'name': 'thymoma', 'source': 'DOID'}, {'id': 3284, 'name': 'thymic carcinoma', 'source': 'DOID'}]",NCT03076554,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 3144, 'therapyName': 'Avelumab'}]",A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy,03/15/2017,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT03077828,Phase II,Recruiting,Northwestern University,"[{'id': 5435, 'therapyName': 'Pembrolizumab + Etoposide + Carboplatin + Ifosfamide'}]",Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma,04/26/2017,[],no
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT03078400,Phase I,Recruiting,"Splash Pharmaceuticals, Inc.","[{'id': 5763, 'therapyName': 'SPL-108'}]",Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer,05/26/2017,[],no
0,,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT03078751,Phase III,Recruiting,Novartis Pharmaceuticals,"[{'id': 790, 'therapyName': 'Ribociclib'}]",Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer (EarLEE-1),07/03/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT03079687,Expanded access,Approved for marketing,AstraZeneca,"[{'id': 837, 'therapyName': 'Olaparib'}]","Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.",09/16/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT03080311,Phase I,Recruiting,Ascentage Pharma Group Inc.,"[{'id': 5757, 'therapyName': 'APG-1252'}]",A Study of APG-1252 in Patients With SCLC or Other Solid Tumors,05/29/2017,[],no
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT03080974,Phase II,Recruiting,University of Louisville ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma,10/04/2017,[],no
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT03081494,Phase I,Recruiting,Novartis Pharmaceuticals ,"[{'id': 5930, 'therapyName': 'PDR001 + Regorafenib'}]",Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer,06/26/2017,[],no
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT03081702,Phase Ib/II,Not yet recruiting,"University Health Network, Toronto","[{'id': 5495, 'therapyName': 'Hydroxychloroquine + Itraconazole'}]","A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer",03/30/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT03082209,Phase I,Recruiting,AbbVie,"[{'id': 5756, 'therapyName': 'ABBV-621'}]",A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies,05/29/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03082300,Phase I,Terminated,"Astellas Pharma Global Development, Inc.","[{'id': 1082, 'therapyName': 'ASP8273'}]",A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations,07/19/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03082534,Phase II,Recruiting,Assuntina G. Sacco,"[{'id': 1910, 'therapyName': 'Pembrolizumab + Cetuximab'}]",Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma,03/31/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03083808,Phase II,Recruiting,Greg Durm,"[{'id': 5497, 'therapyName': 'Pembrolizumab + Gemcitabine'}, {'id': 5496, 'therapyName': 'Docetaxel + Pembrolizumab'}, {'id': 5498, 'therapyName': 'Pemetrexed + Pembrolizumab'}, {'id': 854, 'therapyName': 'Pemetrexed'}]",Phase II Trial of Continuation Therapy in Advanced NSCLC,03/30/2017,[],no
0,both,"[{'id': 3996, 'name': 'urinary system cancer', 'source': 'DOID'}]",NCT03084471,Phase III,Recruiting,AstraZeneca,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies. (STRONG)",04/26/2017,[],no
0,both,"[{'id': 8923, 'name': 'skin melanoma', 'source': 'DOID'}]",NCT03084640,Phase Ib/II,Recruiting,Checkmate Pharmaceuticals,"[{'id': 4001, 'therapyName': 'Pembrolizumab + QbG10'}]",Phase 1b Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma,06/19/2017,[],no
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT03085056,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 5493, 'therapyName': 'Trametinib + Paclitaxel'}]",Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer,03/29/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03085095,Phase III,Recruiting,Myovant Sciences GmbH,"[{'id': 5492, 'therapyName': 'Relugolix'}, {'id': 795, 'therapyName': 'Leuprolide'}]",A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO),03/28/2017,[],no
0,,[],NCT03085147,,Recruiting,,"[{'id': 837, 'therapyName': 'Olaparib'}]",A Dye for the Detection of Cancer of the Tongue and Mouth,06/16/2017,[],
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03085719,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN,05/03/2017,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT03085849,Phase I,Recruiting,Catherine Shu,"[{'id': 5488, 'therapyName': 'SGI-110 + MEDI4736 + Tremelimumab'}]",SGI-110 Plus Durvalumab/Tremelimumab in SCLC,03/28/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03085914,Phase Ib/II,Recruiting,Incyte Corporation,"[{'id': 5483, 'therapyName': 'INCB024360 + Nivolumab + mFOLFOX6'}, {'id': 5484, 'therapyName': 'INCB024360 + Nivolumab + Gemcitabine + nab-paclitaxel'}, {'id': 5485, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Paclitaxel'}, {'id': 5486, 'therapyName': 'INCB024360 + Pembrolizumab + Carboplatin + Pemetrexed'}, {'id': 5487, 'therapyName': 'INCB024360 + Pembrolizumab + Cyclophosphamide'}]",A Study of Epacadostat in Combination With a PD-1 Inhibitor and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207),05/25/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT03086369,Phase Ib/II,Recruiting,Eli Lilly and Company,"[{'id': 5482, 'therapyName': 'Olaratumab + nab-paclitaxel + Gemcitabine'}, {'id': 1779, 'therapyName': 'Nab-paclitaxel + Gemcitabine'}]",A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer,06/28/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03086733,Phase II,Recruiting,"University Health Network, Toronto","[{'id': 1031, 'therapyName': 'Metformin'}]",Phase II Lung Metcore - Preoperative Metformin for Lung Cancer (Metcore),03/30/2017,[],no
0,both,"[{'id': 50931, 'name': 'parotid gland adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 50930, 'name': 'sublingual gland adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 7198, 'name': 'maxillary sinus adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 60219, 'name': 'lymph node adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4868, 'name': 'prostate adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4869, 'name': 'laryngeal adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4870, 'name': 'lacrimal gland adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4866, 'name': 'salivary gland adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4867, 'name': 'cervical adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 2764, 'name': 'ethmoid sinus adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4877, 'name': 'breast adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4878, 'name': 'esophageal adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4879, 'name': ""Bartholin's gland adenoid cystic carcinoma"", 'source': 'DOID'}, {'id': 4872, 'name': 'lung adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4875, 'name': 'trachea adenoid cystic carcinoma', 'source': 'DOID'}]",NCT03087019,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,04/27/2017,[],no
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT03087071,Phase II,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 845, 'therapyName': 'Panitumumab'}, {'id': 2, 'therapyName': 'Trametinib'}]",Panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer,03/30/2017,"[{'molecularProfile': {'id': 27387, 'profileName': 'KRAS exon 3'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 27386, 'profileName': 'KRAS exon 2'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 27389, 'profileName': 'NRAS exon 2'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 27388, 'profileName': 'KRAS exon 4'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 12766, 'profileName': 'EGFR S492R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 27391, 'profileName': 'NRAS exon 4'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 27390, 'profileName': 'NRAS exon 3'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03087448,Phase Ib/II,Recruiting,"University of California, San Francisco","[{'id': 6303, 'therapyName': 'Ceritinib + Trametinib'}]",Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC),10/09/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 11085, 'profileName': 'ROS1 rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT03087591,Phase I,Recruiting,Wake Forest University Health Sciences,"[{'id': 5751, 'therapyName': 'APN401'}]","APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery",05/29/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03087760,Phase II,Recruiting,Abramson Cancer Center of the University of Pennsylvania,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer,03/27/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03088176,Phase I,Recruiting,West Cancer Center,"[{'id': 5481, 'therapyName': 'talimogene laherparepvec + Dabrafenib + Trametinib'}]",Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma,06/28/2017,"[{'molecularProfile': {'id': 696, 'profileName': 'BRAF act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT03088878,Phase Ib/II,Not yet recruiting,"University of California, San Diego","[{'id': 5480, 'therapyName': 'Cirmtuzumab + Ibrutinib'}, {'id': 768, 'therapyName': 'Ibrutinib'}]",A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies,03/27/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03088930,Phase II,Not yet recruiting,"University of Colorado, Denver","[{'id': 706, 'therapyName': 'Crizotinib'}]",Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer,03/27/2017,"[{'molecularProfile': {'id': 11085, 'profileName': 'ROS1 rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 27373, 'profileName': 'MET fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 24383, 'profileName': 'MET exon 14'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3120, 'profileName': 'MET Y1003*'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 8923, 'name': 'skin melanoma', 'source': 'DOID'}]",NCT03089606,Phase II,Recruiting,UNC Lineberger Comprehensive Cancer Center,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker,07/12/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03089645,Phase I,Recruiting,MedImmune LLC ,"[{'id': 5588, 'therapyName': 'MEDI5083'}, {'id': 5589, 'therapyName': 'MEDI4736 + MEDI5083'}]",MEDI5083 Alone and in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors,04/28/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03090165,Phase Ib/II,Recruiting,"Ruth O'Regan, M.D.","[{'id': 5479, 'therapyName': 'Ribociclib + Bicalutamide'}]",Ribociclib and Bicalutamide in AR+ TNBC,04/06/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03090737,Phase II,Recruiting,Bristol-Myers Squibb,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 907),07/12/2017,[],no
0,both,"[{'id': 4465, 'name': 'papillary renal cell carcinoma', 'source': 'DOID'}]",NCT03091192,Phase III,Recruiting,AstraZeneca,"[{'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2161, 'therapyName': 'Savolitinib'}]",Savolitinib vs. Sunitinib in MET-driven PRCC,08/15/2017,"[{'molecularProfile': {'id': 4973, 'profileName': 'VHL mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 2096, 'profileName': 'MET act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03091257,Phase I,Recruiting,Massachusetts General Hospital,"[{'id': 1066, 'therapyName': 'Trametinib + Dabrafenib'}, {'id': 3, 'therapyName': 'Dabrafenib'}, {'id': 2, 'therapyName': 'Trametinib'}]",A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma,05/10/2017,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03091478,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Patients With Leptomeningeal Disease,04/28/2017,[],no
0,both,"[{'id': 9053, 'name': 'bladder carcinoma in situ', 'source': 'DOID'}, {'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}]",NCT03091660,Phase III,Recruiting,Southwest Oncology Group,"[{'id': 5478, 'therapyName': 'BCG Tokyo-172 Strain Solution'}, {'id': 4455, 'therapyName': 'BCG solution'}]",Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer,07/31/2017,[],no
0,both,"[{'id': 1907, 'name': 'malignant fibroxanthoma', 'source': 'DOID'}, {'id': 5702, 'name': 'pleomorphic liposarcoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}, {'id': 3355, 'name': 'fibrosarcoma', 'source': 'DOID'}, {'id': 4235, 'name': 'spindle cell sarcoma', 'source': 'DOID'}]",NCT03092323,Phase II,Recruiting,Sarcoma Alliance for Research through Collaboration,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032),07/28/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03092453,Phase I,Recruiting,University of Pennsylvania ,"[{'id': 4891, 'therapyName': 'Cyclophosphamide + Pembrolizumab'}]",Dendritic Cell Vaccination in Patients With Advanced Melamona,05/03/2017,[],no
0,both,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}]",NCT03092635,Phase I,Recruiting,Medical University of South Carolina,"[{'id': 5908, 'therapyName': 'OPC + Metformin'}]",AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy,06/19/2017,[],yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT03092674,Phase II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 1736, 'therapyName': 'Decitabine + Cytarabine'}, {'id': 2471, 'therapyName': 'Azacitidine + Midostaurin'}, {'id': 3196, 'therapyName': 'Azacitidine + Nivolumab'}, {'id': 651, 'therapyName': 'Azacitidine'}]","Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",04/12/2017,[],yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03092856,Phase II,Recruiting,University of Southern California,"[{'id': 649, 'therapyName': 'Axitinib'}, {'id': 5522, 'therapyName': 'Axitinib + PF-04518600'}]",Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer,07/22/2017,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03092934,Phase Ib/II,Recruiting,AurKa Pharma Inc.,"[{'id': 5753, 'therapyName': 'AK-01'}]",A Study of AK-01 in Solid Tumors,05/29/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT03093116,Phase Ib/II,Recruiting,"TP Therapeutics, Inc.","[{'id': 3950, 'therapyName': 'TPX-0005'}]","A Study of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements",04/07/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 11085, 'profileName': 'ROS1 rearrange'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT03093155,Phase II,Recruiting,Yale University ,"[{'id': 1122, 'therapyName': 'Bevacizumab + Ixabepilone'}, {'id': 781, 'therapyName': 'Ixabepilone'}]",Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab,04/12/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03093272,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 795, 'therapyName': 'Leuprolide'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 5521, 'therapyName': 'ARN-509 + Docetaxel'}]",A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer,08/05/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03093428,Phase II,Recruiting,Dana-Farber Cancer Institute ,"[{'id': 5542, 'therapyName': 'Pembrolizumab + Ra 223'}, {'id': 2001, 'therapyName': 'radium Ra 223 dichloride'}]",Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC,06/20/2017,[],no
0,both,"[{'id': 4932, 'name': 'ampulla of Vater carcinoma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}, {'id': 3121, 'name': 'gallbladder cancer', 'source': 'DOID'}, {'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}]",NCT03093870,Phase II,Not yet recruiting,Aslan Pharmaceuticals ,"[{'id': 5543, 'therapyName': 'Capecitabine + Varlitinib'}, {'id': 1105, 'therapyName': 'Capecitabine'}]",Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer,04/12/2017,[],no
0,both,"[{'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}]",NCT03093922,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 5140, 'therapyName': 'Atezolizumab + Cisplatin + Gemcitabine'}]",A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer,04/13/2017,[],no
0,both,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT03094052,Phase II,Recruiting,"University of California, San Francisco","[{'id': 828, 'therapyName': 'Neratinib'}, {'id': 2700, 'therapyName': 'Loperamide'}, {'id': 5906, 'therapyName': 'Crofelemer'}, {'id': 4359, 'therapyName': 'Neratinib + Trastuzumab'}]","Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy",06/19/2017,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 305, 'name': 'carcinoma', 'source': 'DOID'}]",NCT03094169,Phase I,Recruiting,Formation Biologics,"[{'id': 5755, 'therapyName': 'AVID100'}]",AVID100 in Advanced Epithelial Carcinomas,05/30/2017,"[{'molecularProfile': {'id': 1102, 'profileName': 'EGFR positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT03094611,Phase II,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia,04/13/2017,[],yes
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT03094637,Phase II,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Azacitidine and Pembrolizumab for Patients With Myelodysplastic Syndrome (MDS),04/13/2017,[],no
0,both,"[{'id': 3192, 'name': 'neurilemmoma', 'source': 'DOID'}, {'id': 5074, 'name': 'malignant ependymoma', 'source': 'DOID'}, {'id': 12689, 'name': 'acoustic neuroma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3565, 'name': 'meningioma', 'source': 'DOID'}]",NCT03095248,Phase II,Recruiting,"Children's Hospital Medical Center, Cincinnati","[{'id': 913, 'therapyName': 'Selumetinib'}]",Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors,05/12/2017,[],yes
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT03095352,Phase II,Recruiting,"University of California, San Francisco","[{'id': 5265, 'therapyName': 'Carboplatin + Pembrolizumab'}]","A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease",10/06/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03095612,Phase Ib/II,Not yet recruiting,University of Texas Southwestern Medical Center,"[{'id': 5534, 'therapyName': 'Docetaxel + Selinexor'}]",Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC),04/12/2017,"[{'molecularProfile': {'id': 1194, 'profileName': 'KRAS Q61X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1193, 'profileName': 'KRAS G13X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1192, 'profileName': 'KRAS G12X'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 4906, 'name': 'small intestine adenocarcinoma', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT03095781,Phase I,Recruiting,Emory University,"[{'id': 5533, 'therapyName': 'Pembrolizumab + XL888'}]",Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer,07/08/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03097328,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1282, 'therapyName': 'Sapanisertib'}]",Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma,10/12/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT03098160,Phase I,Recruiting,Threshold Pharmaceuticals ,"[{'id': 5745, 'therapyName': 'Evofosfamide + Ipilimumab'}]",Immunotherapy Study of Evofosfamide in Combination With Ipilimumab,05/26/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03098550,Phase Ib/II,Recruiting,Bristol-Myers Squibb,"[{'id': 5520, 'therapyName': 'Daratumumab + Nivolumab '}]",A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread,07/13/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03098836,Phase II,Recruiting,"Daniel George, MD","[{'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}]",Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer,07/28/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03099109,Phase I,Recruiting,Eli Lilly and Company ,"[{'id': 5556, 'therapyName': 'LY3321367'}, {'id': 5557, 'therapyName': 'LY3300054 + LY3321367'}]",A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors,04/25/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03099161,Phase I,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 5518, 'therapyName': 'Preladenant'}, {'id': 5519, 'therapyName': 'Pembrolizumab + Preladenant'}]",Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062),06/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03099174,Phase I,Recruiting,Boehringer Ingelheim,"[{'id': 5514, 'therapyName': 'Abemaciclib + Xentuzumab'}, {'id': 5515, 'therapyName': 'Abemaciclib + Letrozole + Xentuzumab'}, {'id': 5516, 'therapyName': 'Abemaciclib + Anastrozole + Xentuzumab'}, {'id': 5517, 'therapyName': 'Abemaciclib + Fulvestrant + Xentuzumab'}]",This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.,05/19/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT03099356,Phase II,Recruiting,University of Michigan Cancer Center,"[{'id': 5513, 'therapyName': 'Sirolimus + Cyclophosphamide'}]","Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer",05/26/2017,[],no
0,female,"[{'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}]",NCT03099499,Phase II,Recruiting,Fox Chase Cancer Center,"[{'id': 1687, 'therapyName': 'ONC201'}]",Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer,07/28/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT03099564,Phase I,Recruiting,Hoosier Cancer Research Network,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab Plus Y90 Radioembolization in HCC Subjects,04/07/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03101254,Phase Ib/II,Recruiting,Dana-Farber Cancer Institute ,"[{'id': 5512, 'therapyName': 'Cobimetinib + LY3022855 + Vemurafenib'}]",LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma,07/18/2017,"[{'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}]",NCT03101566,Phase II,Recruiting,University of Michigan Cancer Center,"[{'id': 5511, 'therapyName': 'Cisplatin + Gemcitabine + Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer,09/07/2017,[],no
0,female,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT03101748,Phase Ib/II,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 3187, 'therapyName': 'Neratinib + Paclitaxel + Pertuzumab + Trastuzumab'}, {'id': 1505, 'therapyName': 'Paclitaxel + Neratinib + Doxorubicin + Cyclophosphamide'}]",3HT With Taxol for Metastatic Breast Cancer,04/12/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03101839,Phase I,Recruiting,AstraZeneca,"[{'id': 5914, 'therapyName': 'AZD4785'}]",Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours,06/26/2017,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03102606,Phase II,Recruiting,BeyondSpring Pharmaceuticals Inc. ,"[{'id': 3678, 'therapyName': 'Plinabulin'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]",Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1),04/28/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03104270,Phase II,Recruiting,Oncotherapeutics ,"[{'id': 5555, 'therapyName': 'Carfilzomib + Elotuzumab + Dexamethasone + Pomalidomide'}]",Combination Study for High Risk Multiple Myeloma Patients,04/18/2017,[],no
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT03104439,Phase II,Recruiting,Massachusetts General Hospital ,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer,06/01/2017,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT03104491,Phase Ib/II,Recruiting,Leland Metheny ,"[{'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia,09/06/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}]",NCT03104699,Phase Ib/II,Recruiting,Agenus Inc.,"[{'id': 5693, 'therapyName': 'AGEN2034'}]",Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer,05/29/2017,[],no
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT03105336,Phase II,Recruiting,"Kite Pharma, Inc. ","[{'id': 4829, 'therapyName': 'KTE-C19'}]",A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5),06/07/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03106077,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 3232, 'therapyName': 'IMGN853'}]",Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC),06/09/2017,[],yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03106415,Phase Ib/II,Recruiting,Mayo Clinic ,"[{'id': 5568, 'therapyName': 'Binimetinib + Pembrolizumab'}]",Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer,09/30/2017,[],yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03106428,Phase I,Recruiting,MedImmune LLC,"[{'id': 5762, 'therapyName': 'MEDI7247'}]",A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies,05/29/2017,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 6166, 'name': 'prostatic urethra urothelial carcinoma', 'source': 'DOID'}, {'id': 9053, 'name': 'bladder carcinoma in situ', 'source': 'DOID'}]",NCT03106610,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy,07/12/2017,[],no
0,both,"[{'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT03106779,Phase III,Recruiting,Novartis Pharmaceuticals ,"[{'id': 690, 'therapyName': 'Bosutinib'}, {'id': 2484, 'therapyName': 'ABL001'}]","Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs",09/25/2017,"[{'molecularProfile': {'id': 3595, 'profileName': 'ABL1 V299L'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 536, 'profileName': 'ABL1 T315I'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT03107182,Phase II,Recruiting,University of Chicago,"[{'id': 5581, 'therapyName': 'Dexamethasone + Diphenhydramine + Famotidine + 5FU + Hydroxyurea + Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",Oropharyngeal Tumor Induction Chemotherapy and Response-stratified Locoregional Therapy Trial in Order to Minimize Long-term Adverse Events,07/12/2017,"[{'molecularProfile': {'id': 1974, 'profileName': 'CDKN2A positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT03107780,Phase I,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 1452, 'therapyName': 'AMG 232'}]",MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma,05/29/2017,"[{'molecularProfile': {'id': 642, 'profileName': 'TP53 wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}]",NCT03107988,Phase I,Recruiting,New Approaches to Neuroblastoma Therapy Consortium ,"[{'id': 5580, 'therapyName': 'PF-06463922 + Cyclophosphamide + Topotecan'}, {'id': 869, 'therapyName': 'PF-06463922'}]",Study of Lorlatinib (PF-06463922),09/22/2017,"[{'molecularProfile': {'id': 2446, 'profileName': 'ALK fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1760, 'profileName': 'ALK amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 18885, 'profileName': 'ALK act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT03108066,Phase II,"Active, not recruiting","Peloton Therapeutics, Inc.","[{'id': 4146, 'therapyName': 'PT2385'}]",PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma,09/06/2017,"[{'molecularProfile': {'id': 6849, 'profileName': 'VHL inact mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 4906, 'name': 'small intestine adenocarcinoma', 'source': 'DOID'}, {'id': 3608, 'name': 'appendix adenocarcinoma', 'source': 'DOID'}, {'id': 3151, 'name': 'skin squamous cell carcinoma', 'source': 'DOID'}]",NCT03108131,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",Cobimetinib and Atezolizumab in Advanced Rare Tumors,04/27/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03109015,Phase II,Recruiting,Duke University ,"[{'id': 930, 'therapyName': 'Sunitinib'}]",Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing (ASSET),10/08/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03109158,Phase Ib/II,Recruiting,"NanoCarrier Co., Ltd. ","[{'id': 5578, 'therapyName': 'Cetuximab + Fluorouracil + NC-6004'}]",NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,04/27/2017,[],no
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}]",NCT03109301,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 913, 'therapyName': 'Selumetinib'}]",A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST),04/17/2017,"[{'molecularProfile': {'id': 1214, 'profileName': 'KIT mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1215, 'profileName': 'PDGFRA mutant'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 11934, 'name': 'head and neck cancer', 'source': 'DOID'}]",NCT03109873,Phase I,Recruiting,Sidney Kimmel Cancer Center at Thomas Jefferson University,"[{'id': 1031, 'therapyName': 'Metformin'}]",Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer,04/17/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03110107,Phase Ib/II,Recruiting,Bristol-Myers Squibb,"[{'id': 779, 'therapyName': 'Ipilimumab'}, {'id': 5552, 'therapyName': 'BMS-986218 + Nivolumab'}, {'id': 5551, 'therapyName': 'BMS-986218'}]",First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors,05/04/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT03110354,Phase I,Recruiting,Daiichi Sankyo Inc.,"[{'id': 5691, 'therapyName': 'DS-3201b'}]",DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL),06/19/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03110562,Phase III,Recruiting,Karyopharm Therapeutics Inc,"[{'id': 5639, 'therapyName': 'Selinexor + Bortezomib + Dexamethasone'}, {'id': 2470, 'therapyName': 'Bortezomib + Dexamethasone'}]","Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma (BOSTON)",05/12/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03110822,Phase I,Recruiting,Oncotherapeutics,"[{'id': 5550, 'therapyName': 'Methylprednisolone + Lenalidomide + Ruxolitinib'}]","A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients",04/17/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03110978,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I or Isolated Lung Parenchymal Recurrent Non-small Cell Lung Cancer: I-SABR,06/28/2017,[],no
0,both,"[{'id': 4932, 'name': 'ampulla of Vater carcinoma', 'source': 'DOID'}, {'id': 4607, 'name': 'biliary tract cancer', 'source': 'DOID'}]",NCT03111732,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 5549, 'therapyName': 'Capecitabine + Oxaliplatin + Pembrolizumab'}]","Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)",06/20/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03111901,Phase Ib/II,Not yet recruiting,"William Grosh, MD","[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer,04/17/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03111992,Phase I,Recruiting,Novartis Pharmaceuticals,"[{'id': 5311, 'therapyName': 'PDR001 + LCL161'}, {'id': 5397, 'therapyName': 'PDR001 + CJM112'}, {'id': 2659, 'therapyName': 'PDR001'}]","Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma",08/18/2017,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT03112174,Phase III,Recruiting,Pharmacyclics LLC.,"[{'id': 768, 'therapyName': 'Ibrutinib'}, {'id': 3392, 'therapyName': 'GDC-0199 + Ibrutinib'}]",Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO),08/21/2017,[],yes
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT03112590,Phase Ib/II,Recruiting,H. Lee Moffitt Cancer Center and Research Institute,"[{'id': 5548, 'therapyName': 'Interferon gamma + Paclitaxel + Pertuzumab + Trastuzumab'}]",Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer,05/03/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03113188,Phase I,Recruiting,CanBas Co. Ltd. ,"[{'id': 6186, 'therapyName': 'CBP501 + Cisplatin + Nivolumab'}]","CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors",09/11/2017,[],no
0,female,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT03113487,Phase II,Not yet recruiting,City of Hope Medical Center,"[{'id': 5547, 'therapyName': 'MVAp53 + Pembrolizumab'}]","P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",04/17/2017,[],no
0,both,"[{'id': 3382, 'name': 'liposarcoma', 'source': 'DOID'}, {'id': 1967, 'name': 'leiomyosarcoma', 'source': 'DOID'}]",NCT03114527,Phase II,Recruiting,Fox Chase Cancer Center,"[{'id': 5073, 'therapyName': 'Ribociclib + Everolimus'}]",Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS),10/17/2017,"[{'molecularProfile': {'id': 2395, 'profileName': 'RB1 positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}]",NCT03115801,Phase II,Recruiting,Weill Medical College of Cornell University,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers,04/17/2017,[],no
0,both,"[{'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT03116971,Phase Ib/II,Recruiting,"EMD Serono Research & Development Institute, Inc.","[{'id': 5546, 'therapyName': 'MSC2490484A  + Cisplatin + Etoposide'}, {'id': 3616, 'therapyName': 'MSC2490484A '}]",Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED),05/13/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03117309,Phase II,Recruiting,"Michael B. Atkins, MD","[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma,08/10/2017,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 80147, 'name': 'lymphoblastic lymphoma', 'source': 'DOID'}]",NCT03117751,Phase II,Recruiting,St. Jude Children's Research Hospital ,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1876, 'therapyName': 'Blinatumomab '}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 907, 'therapyName': 'Ruxolitinib'}, {'id': 2188, 'therapyName': 'Prednisone'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 717, 'therapyName': 'Dasatinib'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1638, 'therapyName': 'Pegaspargase'}]",Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma,04/28/2017,[],no
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03118349,Phase I,Recruiting,"MabVax Therapeutics, Inc.","[{'id': 5801, 'therapyName': 'MVT-1075 + MVT-5873'}]",Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy,06/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03119428,Phase I,Recruiting,"OncoMed Pharmaceuticals, Inc.","[{'id': 5696, 'therapyName': 'OMP-313M32'}]",A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors,05/29/2017,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT03119467,Phase I,Recruiting,Rhizen Pharmaceuticals SA ,"[{'id': 5761, 'therapyName': 'RP4010'}]","Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma",09/01/2017,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT03120676,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma,04/28/2017,[],no
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT03120832,Phase I,Recruiting,"Panacea Pharmaceuticals, Inc.","[{'id': 5704, 'therapyName': 'PAN-301-1'}]",Phase 1 Trial of PAN-301-1 in Cancer Patients,05/29/2017,[],yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03121352,Phase I,Recruiting,Case Comprehensive Cancer Center ,"[{'id': 5591, 'therapyName': 'Carboplatin + nab-paclitaxel + Pembrolizumab'}]","Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer",06/03/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03121417,Phase II,Recruiting,Emory University,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic Non-small Cell Lung Cancer,08/15/2017,[],no
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT03121677,Phase I,Not yet recruiting,Washington University School of Medicine ,"[{'id': 5592, 'therapyName': 'Nivolumab + poly ICLC + Rituximab'}]",Personalized Synthetic Long Peptide Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma,04/28/2017,[],no
0,both,"[{'id': 60108, 'name': 'brain glioma', 'source': 'DOID'}]",NCT03122197,Phase I,Recruiting,University of Cincinnati,"[{'id': 794, 'therapyName': 'Letrozole'}]",Study of Letrozole in Recurrent Gliomas,07/28/2017,[],no
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT03122496,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer,05/04/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT03122509,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer",05/05/2017,[],no
0,both,"[{'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT03122548,Phase II,Recruiting,"Aduro Biotech, Inc.","[{'id': 5716, 'therapyName': 'CRS-207 + Pembrolizumab'}]","Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers",05/22/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03122717,Phase I,Recruiting,Dana-Farber Cancer Institute,"[{'id': 5616, 'therapyName': 'Gefitinib + Osimertinib'}]",Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer,08/12/2017,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}]",NCT03123055,Phase I,Recruiting,"BioClin Therapeutics, Inc.","[{'id': 5615, 'therapyName': 'B-701 + Atezolizumab'}]",A Study of B-701 in Combination With Atezolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma (U22),05/05/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03123744,Phase II,Not yet recruiting,"Razelle Kurzrock, MD","[{'id': 850, 'therapyName': 'Palbociclib'}]",Histology-Independent Study of Palbociclib in Patients With Advanced Cancer,05/04/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03123783,Phase Ib/II,Recruiting,"Apexigen, Inc.","[{'id': 5608, 'therapyName': 'APX005M + Nivolumab'}]",CD40 Agonistic Antibody APX005M in Combination With Nivolumab,05/20/2017,[],no
0,,"[{'id': 80146, 'name': 'B-cell childhood acute lymphoblastic leukemia', 'source': 'DOID'}]",NCT03123939,Phase II,Available,Novartis Pharmaceuticals ,"[{'id': 5981, 'therapyName': 'Tisagenlecleucel'}]",Expanded Treatment Protocol in Acute Lymphoblastic Leukemia,07/15/2017,[],yes
0,male,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT03123978,Phase I,Recruiting,"University of California, Davis","[{'id': 5607, 'therapyName': 'Niclosamide + Enzalutamide'}]",Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer,09/29/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03125200,Phase I,Recruiting,ADC Therapeutics SARL,"[{'id': 5689, 'therapyName': 'ADCT-502'}]",Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression,06/02/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03125239,Phase I,Recruiting,"Jacqueline Garcia, MD ","[{'id': 5744, 'therapyName': 'LY2801653 + LY2874455'}]",Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia,08/12/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03125902,Phase III,Recruiting,Hoffmann-La Roche,"[{'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131),06/20/2017,[],yes
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT03125928,Phase II,Recruiting,Fox Chase Cancer Center,"[{'id': 5600, 'therapyName': 'Atezolizumab + Paclitaxel + Trastuzumab + Pertuzumab'}]","Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer",06/09/2017,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT03126019,Phase II,Recruiting,Incyte Corporation,"[{'id': 3088, 'therapyName': 'INCB050465 '}, {'id': 1023, 'therapyName': 'Idelalisib'}]","An Open-Label, Randomized Study Comparing INCB050465 to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)",07/19/2017,[],no
0,both,"[{'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}, {'id': 5041, 'name': 'esophageal cancer', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 10534, 'name': 'stomach cancer', 'source': 'DOID'}]",NCT03126110,Phase Ib/II,Recruiting,Incyte Corporation,"[{'id': 5599, 'therapyName': 'INCAGN01876 + Nivolumab + Ipilimumab'}, {'id': 5598, 'therapyName': 'INCAGN01876 + Nivolumab'}, {'id': 5597, 'therapyName': 'INCAGN01876 + Ipilimumab'}]","Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies",05/02/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03126331,Phase II,Recruiting,Case Comprehensive Cancer Center,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Intermittent Nivolumab in Metastatic Renal Cell Carcinoma Patients,08/10/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03126461,Phase II,Not yet recruiting,University of Texas Southwestern Medical Center,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients,05/01/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT03126591,Phase I,Recruiting,Eli Lilly and Company,"[{'id': 5715, 'therapyName': 'Olaratumab + Pembrolizumab'}]",A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma,07/12/2017,[],no
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT03126630,Phase Ib/II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 5596, 'therapyName': 'Pembrolizumab + Anetumab ravtansine'}]",Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma,05/01/2017,[],yes
0,both,"[{'id': 769, 'name': 'neuroblastoma', 'source': 'DOID'}, {'id': 5193, 'name': 'nodular ganglioneuroblastoma', 'source': 'DOID'}]",NCT03126916,Phase III,Not yet recruiting,Children's Oncology Group,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1425, 'therapyName': '131I-MIBG'}, {'id': 1873, 'therapyName': 'Sargramostim'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1206, 'therapyName': 'Busulfan'}, {'id': 5595, 'therapyName': 'Isotretinoin'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 2563, 'therapyName': 'Thiotepa'}, {'id': 706, 'therapyName': 'Crizotinib'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1092, 'therapyName': 'Carboplatin'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 942, 'therapyName': 'Topotecan'}, {'id': 2286, 'therapyName': 'Dinutuximab  '}]",Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma,05/05/2017,[],yes
0,both,"[{'id': 219, 'name': 'colon cancer', 'source': 'DOID'}, {'id': 1993, 'name': 'rectum cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03127098,Phase Ib/II,"Active, not recruiting","NantCell, Inc. ","[{'id': 6239, 'therapyName': 'ALT-803 + ETBX-011'}]","QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer",10/06/2017,[],no
0,,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03127735,Phase I,Recruiting,Bayer ,"[{'id': 5698, 'therapyName': 'BAY1436032'}]",BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML),06/23/2017,"[{'molecularProfile': {'id': 1781, 'profileName': 'IDH1 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT03128034,Phase Ib/II,Recruiting,Fred Hutchinson Cancer Research Center,"[{'id': 5714, 'therapyName': 'Cyclosporine + Fludarabine phosphate + Mycophenolate mofetil + Sirolimus'}]","211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome",09/15/2017,[],no
0,both,"[{'id': 3078, 'name': 'grade III astrocytoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT03128047,Phase I,Recruiting,Hackensack University Medical Center,"[{'id': 2115, 'therapyName': 'Bevacizumab + Temozolomide'}]",HUMC 1612: Optune NovoTTF-200A System,05/01/2017,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT03128619,Phase Ib/II,Recruiting,Jonsson Comprehensive Cancer Center,"[{'id': 5594, 'therapyName': 'Copanlisib + Palbociclib + Letrozole'}, {'id': 5593, 'therapyName': 'Copanlisib + Letrozole'}]","Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer",09/06/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT03128879,Phase II,"Active, not recruiting",M.D. Anderson Cancer Center,"[{'id': 5876, 'therapyName': 'Allopurinol + Ibrutinib + Venetoclax'}]",Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL),09/06/2017,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'partial'}]",yes
0,both,[],NCT03129061,Phase I,Recruiting,"CellSight Technologies, Inc. ",[],Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN),05/26/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03130439,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 802, 'therapyName': 'Abemaciclib'}]","Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer",06/10/2017,"[{'molecularProfile': {'id': 2395, 'profileName': 'RB1 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03130764,Phase II,Not yet recruiting,Adrian Sacher,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC,05/12/2017,"[{'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 5074, 'name': 'malignant ependymoma', 'source': 'DOID'}, {'id': 3620, 'name': 'central nervous system cancer', 'source': 'DOID'}, {'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}]",NCT03130959,Phase II,Recruiting,Bristol-Myers Squibb,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908),06/20/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03131037,Phase I,Recruiting,"Advantagene, Inc.","[{'id': 5172, 'therapyName': 'AdV-tk + Valacyclovir'}]",Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer,06/19/2017,[],no
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03131206,Phase Ib/II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 698, 'therapyName': 'Alectinib'}]",A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer,07/27/2017,"[{'molecularProfile': {'id': 2294, 'profileName': 'RET act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1326, 'profileName': 'RET rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03131908,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 3518, 'therapyName': 'GSK2636771 + Pembrolizumab'}]",Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss,07/19/2017,"[{'molecularProfile': {'id': 479, 'profileName': 'PTEN loss'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03132454,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 5637, 'therapyName': 'Palbociclib + Decitabine'}, {'id': 5636, 'therapyName': 'Palbociclib + Dexamethasone'}, {'id': 850, 'therapyName': 'Palbociclib'}, {'id': 5638, 'therapyName': 'Palbociclib + Sorafenib'}]",Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias,08/05/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT03132467,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 Antibody (Tremelimumab) in HR+/HER2- Breast Cancer,06/20/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 2513, 'name': 'basal cell carcinoma', 'source': 'DOID'}]",NCT03132636,Phase II,Recruiting,Regeneron Pharmaceuticals,"[{'id': 5656, 'therapyName': 'REGN2810'}]","PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy",06/27/2017,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 50747, 'name': 'lymphoplasmacytic lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT03133221,Phase II,Not yet recruiting,University of Maryland ,"[{'id': 1023, 'therapyName': 'Idelalisib'}]",1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation,05/26/2017,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}]",NCT03133390,Phase II,Recruiting,New York University School of Medicine,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients,10/13/2017,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT03134131,Expanded access,Available,"Oncoceutics, Inc.","[{'id': 1687, 'therapyName': 'ONC201'}]",Expanded Access Program for ONC201 to Treat Recurrent Histone H3 Mutant Glioma,05/08/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03134638,Phase I,Recruiting,Syros Pharmaceuticals,"[{'id': 5700, 'therapyName': 'SY-1365'}]",A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors,05/29/2017,[],yes
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT03135171,Phase I,Recruiting,University of Michigan Cancer Center,"[{'id': 5648, 'therapyName': 'Pertuzumab + Tocilizumab + Trastuzumab'}]",Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab,05/26/2017,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT03135262,Phase Ib/II,Recruiting,Hoffmann-La Roche,"[{'id': 5646, 'therapyName': 'Idasanutlin + Rituximab + Venetoclax'}, {'id': 5644, 'therapyName': 'Idasanutlin + Obinutuzumab + Venetoclax'}, {'id': 5645, 'therapyName': 'Idasanutlin + Obinutuzumab + Rituximab + Venetoclax'}]",A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL),05/08/2017,[],yes
0,both,"[{'id': 1800, 'name': 'neuroendocrine carcinoma', 'source': 'DOID'}]",NCT03136055,Phase II,Recruiting,"University of California, San Francisco","[{'id': 5643, 'therapyName': 'Irinotecan + Pembrolizumab'}, {'id': 4021, 'therapyName': 'Paclitaxel + Pembrolizumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas,07/22/2017,[],no
0,both,"[{'id': 1037, 'name': 'lymphoblastic leukemia', 'source': 'DOID'}, {'id': 80147, 'name': 'lymphoblastic lymphoma', 'source': 'DOID'}, {'id': 8584, 'name': 'Burkitt lymphoma', 'source': 'DOID'}]",NCT03136146,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1136, 'therapyName': 'Etoposide'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1090, 'therapyName': 'Ofatumumab'}, {'id': 1746, 'therapyName': 'Clofarabine'}, {'id': 1476, 'therapyName': 'Pegfilgrastim'}]","Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)",08/15/2017,[],no
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}]",NCT03136406,Phase Ib/II,Recruiting," NantCell, Inc. ","[{'id': 1018, 'therapyName': 'GI-4000'}, {'id': 1642, 'therapyName': 'Leucovorin'}, {'id': 3144, 'therapyName': 'Avelumab'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 667, 'therapyName': 'Bevacizumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1105, 'therapyName': 'Capecitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1715, 'therapyName': 'Fluorouracil'}, {'id': 6163, 'therapyName': 'ETBX-011'}, {'id': 3060, 'therapyName': 'ALT-803'}]",QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy,09/05/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT03136497,Phase I,Recruiting,Hackensack University Medical Center ,"[{'id': 5777, 'therapyName': 'Ibrutinib + Rituximab + Venetoclax'}]",A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL),07/29/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03137771,Phase II,Recruiting,NRG Oncology,"[{'id': 720, 'therapyName': 'Docetaxel'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 4, 'therapyName': 'Erlotinib'}]",Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,05/05/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT03138161,Phase Ib/II,Recruiting,"Sarcoma Oncology Research Center, LLC","[{'id': 5800, 'therapyName': 'trabectedin + Ipilimumab + Nivolumab'}]","Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma",05/29/2017,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT03138499,Phase III,Recruiting,Bristol-Myers Squibb,"[{'id': 2486, 'therapyName': 'Brentuximab vedotin'}, {'id': 3263, 'therapyName': 'Brentuximab vedotin + Nivolumab'}]","Phase III Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,",06/24/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT03138512,Phase III,Recruiting,Bristol-Myers Squibb,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (CheckMate 914),07/14/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03138889,Phase I,Recruiting,Nektar Therapeutics,"[{'id': 5625, 'therapyName': 'NKTR-214 + Pembrolizumab'}]",A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Metastatic Urothelial Bladder Cancer or Metastatic Non-Small Cell Lung Cancer,06/20/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}, {'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}, {'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}, {'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT03139331,Phase I,Recruiting,"University of California, San Francisco","[{'id': 5635, 'therapyName': 'Pazopanib + Irinotecan + Temozolomide'}]",PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma,09/06/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03139370,Phase I,Recruiting,"Kite Pharma, Inc.","[{'id': 5803, 'therapyName': 'KITE-718'}]",A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers,09/01/2017,[],yes
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT03139747,Phase II,Recruiting,Abramson Cancer Center of the University of Pennsylvania,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]",UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone,05/05/2017,[],no
0,both,"[{'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT03139916,Phase II,Recruiting,Massachusetts General Hospital,"[{'id': 5634, 'therapyName': 'Bavituximab + Temozolomide'}]",Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma,06/20/2017,"[{'molecularProfile': {'id': 577, 'profileName': 'IDH2 wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 576, 'profileName': 'IDH1 wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT03140670,Phase II,Recruiting,Abramson Cancer Center of the University of Pennsylvania,"[{'id': 906, 'therapyName': 'Rucaparib'}]",Rucaparib in BRCA1/2 or PALB2 Mutated Pancreatic Cancer,05/12/2017,"[{'molecularProfile': {'id': 1283, 'profileName': 'BRCA2 inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1282, 'profileName': 'BRCA1 inact mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT03141034,Phase II,Not yet recruiting,Washington University School of Medicine,"[{'id': 5633, 'therapyName': 'Irinotecan + Ramucirumab'}]",Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma,05/05/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT03141177,Phase III,Recruiting,Bristol-Myers Squibb,"[{'id': 2068, 'therapyName': 'Cabozantinib + Ipilimumab + Nivolumab'}, {'id': 930, 'therapyName': 'Sunitinib'}, {'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",A Study of Nivolumab Combined With Cabozantinib or Nivolumab and Ipilimumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER),08/05/2017,[],no
0,both,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT03141671,Phase II,Not yet recruiting,Dana-Farber Cancer Institute,"[{'id': 5742, 'therapyName': 'Bicalutamide + Gonadorelin'}, {'id': 5743, 'therapyName': 'Abiraterone + ARN-509 + Gonadorelin + Prednisone'}]",Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509),05/22/2017,[],no
0,both,"[{'id': 4239, 'name': 'alveolar soft part sarcoma', 'source': 'DOID'}]",NCT03141684,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery,09/07/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03142334,Phase III,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564),07/28/2017,[],no
0,both,"[{'id': 5625, 'name': 'esophageal adenosquamous carcinoma', 'source': 'DOID'}, {'id': 3748, 'name': 'esophagus squamous cell carcinoma', 'source': 'DOID'}]",NCT03143153,Phase III,Recruiting,Bristol-Myers Squibb,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 5799, 'therapyName': 'Nivolumab + Cisplatin + Fluorouacil'}]",A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (CheckMate 648),06/23/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT03143270,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer,05/26/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03143985,Phase I,Recruiting,Case Comprehensive Cancer Center ,"[{'id': 5875, 'therapyName': 'Pomalidomide + TEW 7197'}]",TEW-7197 in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma,09/06/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03144245,Phase I,Recruiting,"Amphivena Therapeutics, Inc.","[{'id': 5711, 'therapyName': 'AMV-564'}]",Study of AMV564 in Patients With AML,06/02/2017,[],no
0,both,"[{'id': 9261, 'name': 'nasopharynx carcinoma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}, {'id': 5041, 'name': 'esophageal cancer', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 50933, 'name': 'ovarian serous carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03144661,Phase I,Recruiting,Incyte Corporation,"[{'id': 5832, 'therapyName': 'INCB062079'}]",An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies,06/20/2017,[],yes
0,both,"[{'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}]",NCT03144674,Phase II,Recruiting,Incyte Corporation,"[{'id': 3088, 'therapyName': 'INCB050465 '}]",A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204),09/29/2017,[],no
0,both,"[{'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}]",NCT03144778,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO),07/14/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03145181,Phase I,Recruiting," Janssen Research & Development, LLC ","[{'id': 5708, 'therapyName': 'JNJ-64007957'}]","Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma",06/20/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT03145558,Phase II,Not yet recruiting,Teclison Ltd.,"[{'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 3028, 'therapyName': 'tirapazamine'}]",TATE Versus TACE in Intermediate Stage HCC (TATE),05/18/2017,[],no
0,both,"[{'id': 50904, 'name': 'salivary gland carcinoma', 'source': 'DOID'}, {'id': 4866, 'name': 'salivary gland adenoid cystic carcinoma', 'source': 'DOID'}]",NCT03146650,Phase II,Recruiting,Northwestern University,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab and Ipilimumab in Treating Patients With Metastatic Recurrent Major or Minor Salivary Gland Cancer,06/03/2017,[],no
0,both,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03147196,Phase II,Recruiting,Mayo Clinic,"[{'id': 5686, 'therapyName': 'Raloxifene + Bicalutamide'}, {'id': 5685, 'therapyName': 'Raloxifene'}, {'id': 1507, 'therapyName': 'Bicalutamide'}]",Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery,06/29/2017,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT03147287,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 3205, 'therapyName': 'Fulvestrant + Palbociclib'}, {'id': 5684, 'therapyName': 'Fulvestrant + Palbociclib + Avelumab'}, {'id': 744, 'therapyName': 'Fulvestrant'}]",Palbociclib After CDK and Endocrine Therapy (PACE),09/06/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT03147612,Phase II,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 5682, 'therapyName': 'Mesna'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 897, 'therapyName': 'Rituximab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 877, 'therapyName': 'Ponatinib'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 712, 'therapyName': 'Cytarabine'}]",Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),05/26/2017,[],yes
0,both,"[{'id': 50909, 'name': 'MALT lymphoma', 'source': 'DOID'}, {'id': 50748, 'name': 'marginal zone B-cell lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 60901, 'name': ""Waldenstroem's macroglobulinemia"", 'source': 'DOID'}]",NCT03147885,Phase Ib/II,Recruiting,Barbara Ann Karmanos Cancer Institute ,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma,09/11/2017,[],no
0,both,"[{'id': 175, 'name': 'vascular cancer', 'source': 'DOID'}]",NCT03148275,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 2, 'therapyName': 'Trametinib'}]","Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery",05/22/2017,[],no
0,,[],NCT03148327,,Recruiting,,[],Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy,10/19/2017,[],
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03148418,Phase II,Not yet recruiting,Hoffmann-La Roche,"[{'id': 1201, 'therapyName': 'Atezolizumab'}]",A Study in Participants Previously Enrolled in a Genentech? and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study,05/17/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03148795,Phase II,Recruiting,Pfizer,"[{'id': 682, 'therapyName': 'Talazoparib'}]",A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer,07/28/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT03149003,Phase II,Recruiting,"Boston Biomedical, Inc","[{'id': 5986, 'therapyName': 'Bevicizumab + DSP-7888'}, {'id': 667, 'therapyName': 'Bevacizumab'}]",A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD201G),07/12/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03149029,Phase II,Not yet recruiting,Massachusetts General Hospital,"[{'id': 1449, 'therapyName': 'Pembrolizumab + Dabrafenib + Trametinib'}, {'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}]",Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma,05/17/2017,"[{'molecularProfile': {'id': 4, 'profileName': 'BRAF wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT03149120,Phase II,Withdrawn,New York University School of Medicine,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 5681, 'therapyName': 'Nivolumab + Pazopanib'}]",Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas,09/06/2017,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT03149159,Phase II,Not yet recruiting,Medical University of South Carolina,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab",05/22/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03149549,Phase Ib/II,Recruiting,CytomX Therapeutics,"[{'id': 5709, 'therapyName': 'CX-2009'}]",PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors,06/06/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03149822,Phase Ib/II,Not yet recruiting,"University of Colorado, Denver","[{'id': 5680, 'therapyName': 'Pembrolizumab + Cabozantinib'}]",Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma,05/17/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03150056,Phase I,Recruiting,GlaxoSmithKline,"[{'id': 6034, 'therapyName': 'Abiraterone + GSK525762'}, {'id': 6035, 'therapyName': 'Enzalutamide + GSK525762'}, {'id': 2188, 'therapyName': 'Prednisone'}]",Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer,07/28/2017,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT03150329,Phase I,Recruiting,City of Hope Medical Center,"[{'id': 3077, 'therapyName': 'Pembrolizumab + Vorinostat'}]","Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma",07/22/2017,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT03150693,Phase III,Recruiting,Alliance for Clinical Trials in Oncology ,"[{'id': 897, 'therapyName': 'Rituximab'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1640, 'therapyName': 'Mercaptopurine'}, {'id': 1639, 'therapyName': 'Methotrexate'}, {'id': 1783, 'therapyName': 'Cyclophosphamide + Cytarabine'}, {'id': 1641, 'therapyName': 'Thioguanine'}, {'id': 3628, 'therapyName': 'Allopurinol'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1631, 'therapyName': 'Vincristine'}, {'id': 3199, 'therapyName': 'inotuzumab ozogamicin'}]",Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia,06/12/2017,[],yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 6552, 'name': 'gastric small cell carcinoma', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}]",NCT03150810,Phase Ib/II,Recruiting,"BeiGene USA, Inc. ","[{'id': 6124, 'therapyName': 'BGB-290 + Temozolomide'}]","Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors",08/21/2017,[],yes
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT03150836,Phase II,Withdrawn,"Terence Friedlander, MD","[{'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer",10/20/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT03150862,Phase Ib/II,Recruiting,"BeiGene USA, Inc. ","[{'id': 2947, 'therapyName': 'BGB-290'}, {'id': 6124, 'therapyName': 'BGB-290 + Temozolomide'}]",A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma,08/18/2017,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT03151304,Phase II,Recruiting,Helsinn Healthcare SA,"[{'id': 5987, 'therapyName': 'Azacitidine + Pracinostat'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes,07/12/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03151408,Phase III,Recruiting,Helsinn Healthcare SA,"[{'id': 651, 'therapyName': 'Azacitidine'}, {'id': 5987, 'therapyName': 'Azacitidine + Pracinostat'}]",An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia,08/08/2017,[],no
0,both,"[{'id': 1993, 'name': 'rectum cancer', 'source': 'DOID'}]",NCT03152370,Phase I,Recruiting,Eisai Inc.,"[{'id': 5798, 'therapyName': 'E7046 + mFOLFOX-6'}, {'id': 5805, 'therapyName': 'Capecitabine + E7046'}]",Preoperative Radiotherapy and E7046 in Rectum Cancer (PRAER 1),09/06/2017,[],no
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT03153202,Phase Ib/II,Recruiting,Joshua Brody ,"[{'id': 4917, 'therapyName': 'Pembrolizumab + Ibrutinib'}]",Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL),07/22/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT03153410,Phase I,Not yet recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 5778, 'therapyName': 'Cyclophosphamide + GVAX pancreatic cancer vaccine + LY3022855 + Pembrolizumab'}]","Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas",05/26/2017,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT03153462,Expanded access,Available,"Kite Pharma, Inc.","[{'id': 5098, 'therapyName': 'KTE-C19 + Fludarabine phosphate + Cyclophosphamide'}]",Axicabtagene Ciloleucel Expanded Access Study,09/29/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03153982,Phase II,Not yet recruiting,"University of California, San Francisco ","[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib in Operable Head and Neck Cancer,05/22/2017,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}]",NCT03154281,Phase I,Not yet recruiting,Avera McKennan Hospital & University Health Center,"[{'id': 5732, 'therapyName': 'Niraparib + Everolimus'}]",Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast,05/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03154294,Phase I,Not yet recruiting,Avera McKennan Hospital & University Health Center,"[{'id': 5731, 'therapyName': 'Paclitaxel + MLN0128 + MLN1117'}]",Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors,05/20/2017,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60073, 'name': 'lymphatic system cancer', 'source': 'DOID'}, {'id': 3620, 'name': 'central nervous system cancer', 'source': 'DOID'}]",NCT03155620,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 2683, 'therapyName': 'Tazemetostat'}, {'id': 2650, 'therapyName': 'LOXO-101'}, {'id': 1069, 'therapyName': 'LY3023414'}, {'id': 342, 'therapyName': 'Vemurafenib'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 913, 'therapyName': 'Selumetinib'}, {'id': 961, 'therapyName': 'X-396'}]",Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Advanced Refractory Solid Tumors or Lymphomas,07/29/2017,"[{'molecularProfile': {'id': 3639, 'profileName': 'MAP2K1 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 16855, 'profileName': 'KRAS act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 27863, 'profileName': 'EZH2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 16857, 'profileName': 'HRAS act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 696, 'profileName': 'BRAF act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 16856, 'profileName': 'NRAS act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2446, 'profileName': 'ALK fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 13296, 'profileName': 'SMARCB1 mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3274, 'profileName': 'ATM mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 743, 'profileName': 'PIK3CA act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1249, 'profileName': 'ROS1 fusion'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT03155997,Phase III,Recruiting,Eli Lilly and Company,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",A Study to Compare Treatment After Surgery of Abemaciclib (LY2835219) Combined With Standard Endocrine Therapy Versus Endocrine Therapy Alone in Participants With Breast Cancer,07/28/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT03156114,Phase I,Recruiting,Boehringer Ingelheim,"[{'id': 5692, 'therapyName': 'BI 754091'}, {'id': 5690, 'therapyName': 'BI 754111'}]",This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.,06/29/2017,"[{'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3907, 'name': 'lung squamous cell carcinoma', 'source': 'DOID'}]",NCT03157089,Phase II,Not yet recruiting,Boehringer Ingelheim,"[{'id': 2435, 'therapyName': 'Afatinib + Pembrolizumab'}]",Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung (LUX-Lung IO),05/22/2017,[],no
0,both,"[{'id': 3973, 'name': 'thyroid medullary carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03157128,Phase I,Recruiting,"Loxo Oncology, Inc.","[{'id': 5702, 'therapyName': 'LOXO-292'}]","Phase 1 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET-Fusion Lung Cancer and Medullary Thyroid Cancer",05/26/2017,"[{'molecularProfile': {'id': 2903, 'profileName': 'RET fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 11085, 'profileName': 'ROS1 rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1232, 'profileName': 'RET mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 2994, 'name': 'germ cell cancer', 'source': 'DOID'}, {'id': 1660, 'name': 'malignant pineal area germ cell neoplasm', 'source': 'DOID'}]",NCT03158064,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]","Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors",05/26/2017,[],no
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}]",NCT03158103,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 5730, 'therapyName': 'Binimetinib + PLX3397'}]",A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST),05/22/2017,"[{'molecularProfile': {'id': 602, 'profileName': 'PDGFRA wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 582, 'profileName': 'KIT wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03158129,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection,06/20/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03158883,Phase I,Recruiting,"University of California, Davis ","[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients,10/08/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03159117,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 5707, 'therapyName': ' PF-06688992'}]",Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma,05/26/2017,[],no
0,female,[],NCT03159195,,Recruiting,Pfizer,[],Ibrance Real World Insights [IRIS] (IRIS),07/28/2017,[],no
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT03160079,Phase Ib/II,Recruiting,"Matthew Wieduwilt, M.D., Ph.D.","[{'id': 5839, 'therapyName': 'Blinatumomab + Pembrolizumab'}]",Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts,08/09/2017,[],no
0,both,"[{'id': 50749, 'name': 'peripheral T-cell lymphoma', 'source': 'DOID'}]",NCT03161223,Phase Ib/II,Not yet recruiting,Columbia University ,"[{'id': 5882, 'therapyName': 'Durvalumab + Romidepsin'}, {'id': 4178, 'therapyName': 'Azacitidine + MEDI4736'}, {'id': 5881, 'therapyName': 'Azacitidine + Durvalumab + Romidepsin'}, {'id': 5880, 'therapyName': 'Durvalumab + Pralatrexate + Romidepsin'}]","Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma",06/12/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03161431,Phase I,Not yet recruiting,"Syntrix Biosystems, Inc. ","[{'id': 5786, 'therapyName': 'SX-682'}, {'id': 5787, 'therapyName': 'Pembrolizumab + SX-682'}]",SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab,05/26/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03162224,Phase Ib/II,Recruiting,MedImmune LLC ,"[{'id': 5791, 'therapyName': 'Durvalumab + MEDI0457'}]",Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer,09/06/2017,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 60901, 'name': ""Waldenstroem's macroglobulinemia"", 'source': 'DOID'}, {'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT03162536,Phase I,Recruiting,ArQule ,"[{'id': 5224, 'therapyName': 'ARQ 531'}]","Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies",09/01/2017,[],no
0,female,"[{'id': 3706, 'name': 'fallopian tube adenocarcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT03162562,Phase I,Recruiting,OncoQuest Inc. ,"[{'id': 5792, 'therapyName': 'Oregovomab + poly ICLC '}]",The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer,06/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}]",NCT03162627,Phase I,Recruiting,M.D. Anderson Cancer Center,"[{'id': 5793, 'therapyName': 'Olaparib + Selumetinib'}]",Selumetinib and Olaparib in Solid Tumors,08/08/2017,"[{'molecularProfile': {'id': 1208, 'profileName': 'HRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03162731,Phase I,Recruiting,Sidney Kimmel Cancer Center at Thomas Jefferson University,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer",05/26/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 8692, 'name': 'myeloid leukemia', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 8683, 'name': 'myeloid sarcoma', 'source': 'DOID'}]",NCT03164057,Phase II,Recruiting,St. Jude Children's Research Hospital ,"[{'id': 1136, 'therapyName': 'Etoposide'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 5153, 'therapyName': 'dexrazoxane'}, {'id': 1006, 'therapyName': 'Daunorubicin'}, {'id': 1022, 'therapyName': 'Idarubicin'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 2206, 'therapyName': 'Asparaginase'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 920, 'therapyName': 'Sorafenib'}, {'id': 1740, 'therapyName': 'Mitoxantrone'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 651, 'therapyName': 'Azacitidine'}]",A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,05/26/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03164603,Phase I,Recruiting,NewLink Genetics Corporation,"[{'id': 5815, 'therapyName': 'NLG802'}]","NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors",07/08/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03164616,Phase III,Recruiting,AstraZeneca ,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1857, 'therapyName': 'Cisplatin + Pemetrexed'}, {'id': 1602, 'therapyName': 'Carboplatin + Pemetrexed'}, {'id': 1467, 'therapyName': 'Gemcitabine + Cisplatin'}, {'id': 2667, 'therapyName': 'Carboplatin + Gemcitabine'}, {'id': 1356, 'therapyName': 'Durvalumab'}, {'id': 2634, 'therapyName': 'Carboplatin + nab-paclitaxel'}]",Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). (POSEIDON),06/20/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 2446, 'profileName': 'ALK fusion'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03164772,Phase Ib/II,Not yet recruiting,Ludwig Institute for Cancer Research,"[{'id': 5818, 'therapyName': 'BI 1361849 + Durvalumab + Tremelimumab'}]",Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC,05/30/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}, {'id': 50936, 'name': 'extra-adrenal pheochromocytoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 5138, 'name': 'leiomyomatosis', 'source': 'DOID'}, {'id': 50892, 'name': 'adrenal gland pheochromocytoma', 'source': 'DOID'}, {'id': 50773, 'name': 'paraganglioma', 'source': 'DOID'}]",NCT03165721,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1949, 'therapyName': 'SGI-110'}]","A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer",09/06/2017,"[{'molecularProfile': {'id': 582, 'profileName': 'KIT wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 602, 'profileName': 'PDGFRA wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 1107, 'name': 'esophageal carcinoma', 'source': 'DOID'}, {'id': 3748, 'name': 'esophagus squamous cell carcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT03165994,Phase II,Recruiting,"University of California, San Francisco","[{'id': 5797, 'therapyName': 'APX005M + Paclitaxel + Carboplatin'}]",APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers,10/19/2017,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT03166085,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 5796, 'therapyName': 'PU-H71 + nab-paclitaxel'}]",PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer,05/30/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03166254,Phase I,Not yet recruiting,Washington University School of Medicine,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer,05/27/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03166631,Phase I,Recruiting,Boehringer Ingelheim ,"[{'id': 6263, 'therapyName': 'BI 754091 + BI 891065'}, {'id': 6262, 'therapyName': 'BI 891065'}]",A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread,09/29/2017,"[{'molecularProfile': {'id': 18885, 'profileName': 'ALK act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1249, 'profileName': 'ROS1 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 447, 'profileName': 'EGFR amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2446, 'profileName': 'ALK fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 11085, 'profileName': 'ROS1 rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1676, 'profileName': 'ROS1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 27139, 'profileName': 'ROS1 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03168100,Phase II,Recruiting,University of Arkansas ,"[{'id': 3342, 'therapyName': 'Bortezomib + Dexamethasone + lenalidomide'}, {'id': 3353, 'therapyName': 'Elotuzumab + Dexamethasone + Lenalidomide'}]","2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma",10/07/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03168438,Phase I,Recruiting,Adaptimmune,"[{'id': 5877, 'therapyName': 'NY-ESO-1-c259T'}, {'id': 5878, 'therapyName': 'NY-ESO-1-c259T + Pembrolizumab'}]",NY-ESO-1-c259T Alone and in Combination With Pembrolizumab for Multiple Myeloma,06/20/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03168464,Phase Ib/II,Recruiting,Weill Medical College of Cornell University,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632),09/06/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03170206,Phase Ib/II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 850, 'therapyName': 'Palbociclib'}, {'id': 807, 'therapyName': 'Binimetinib'}, {'id': 5838, 'therapyName': 'Binimetinib + Palbociclib'}]",Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer,07/29/2017,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT03170960,Phase Ib/II,Recruiting,Exelixis,"[{'id': 6094, 'therapyName': 'Atezolizumab + Cabozantinib'}]",Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,08/10/2017,[],no
0,both,"[{'id': 734, 'name': 'urethra cancer', 'source': 'DOID'}, {'id': 4007, 'name': 'bladder carcinoma', 'source': 'DOID'}, {'id': 4939, 'name': 'ureter carcinoma', 'source': 'DOID'}]",NCT03171025,Phase II,Recruiting,University of Utah ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT),07/28/2017,[],no
0,both,"[{'id': 4878, 'name': 'esophageal adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4877, 'name': 'breast adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4879, 'name': ""Bartholin's gland adenoid cystic carcinoma"", 'source': 'DOID'}, {'id': 2764, 'name': 'ethmoid sinus adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4875, 'name': 'trachea adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4870, 'name': 'lacrimal gland adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4869, 'name': 'laryngeal adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4872, 'name': 'lung adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4871, 'name': 'cutaneous adenocystic carcinoma', 'source': 'DOID'}, {'id': 4866, 'name': 'salivary gland adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4868, 'name': 'prostate adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 4867, 'name': 'cervical adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 7198, 'name': 'maxillary sinus adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 50619, 'name': 'paranasal sinus cancer', 'source': 'DOID'}, {'id': 60219, 'name': 'lymph node adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 8850, 'name': 'salivary gland cancer', 'source': 'DOID'}, {'id': 50931, 'name': 'parotid gland adenoid cystic carcinoma', 'source': 'DOID'}, {'id': 50930, 'name': 'sublingual gland adenoid cystic carcinoma', 'source': 'DOID'}]",NCT03172624,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer,06/02/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03172754,Phase Ib/II,Recruiting,Fox Chase Cancer Center,"[{'id': 5837, 'therapyName': 'Axitinib + Nivolumab'}]",Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma,06/20/2017,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03172936,Phase I,Recruiting,Novartis Pharmaceuticals ,"[{'id': 6219, 'therapyName': 'MIW815 + PDR001'}]",Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas,09/19/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03173248,Phase III,Recruiting,"Agios Pharmaceuticals, Inc. ","[{'id': 4002, 'therapyName': 'AG-120 + Azacitidine'}, {'id': 1491, 'therapyName': 'AG-120'}]",Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation (AGILE),07/03/2017,"[{'molecularProfile': {'id': 1781, 'profileName': 'IDH1 mutant'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}]",NCT03173560,Phase II,Recruiting,Eisai Inc. ,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]",Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With Renal Cell Carcinoma,09/29/2017,[],no
0,both,"[{'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 1664, 'name': 'pineoblastoma', 'source': 'DOID'}, {'id': 2626, 'name': 'choroid plexus papilloma', 'source': 'DOID'}, {'id': 3302, 'name': 'chordoma', 'source': 'DOID'}, {'id': 4202, 'name': 'brain stem glioma', 'source': 'DOID'}, {'id': 3565, 'name': 'meningioma', 'source': 'DOID'}, {'id': 5648, 'name': 'choroid plexus carcinoma', 'source': 'DOID'}, {'id': 6128, 'name': 'gliomatosis cerebri', 'source': 'DOID'}, {'id': 2129, 'name': 'atypical teratoid rhabdoid tumor', 'source': 'DOID'}, {'id': 5074, 'name': 'malignant ependymoma', 'source': 'DOID'}, {'id': 2132, 'name': 'brain sarcoma', 'source': 'DOID'}, {'id': 50902, 'name': 'medulloblastoma', 'source': 'DOID'}]",NCT03173950,Phase II,Recruiting,National Cancer Institute (NCI) ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers,07/03/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT03174197,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 5872, 'therapyName': 'Atezolizumab + Temozolomide'}]",Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM),07/03/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03174275,Phase II,Not yet recruiting,UNC Lineberger Comprehensive Cancer Center,"[{'id': 5873, 'therapyName': 'Carboplatin + Cisplatin + Durvalumab + Paclitaxel'}, {'id': 3997, 'therapyName': 'Carboplatin + Durvalumab + Paclitaxel'}]","Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma",06/12/2017,[],no
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT03175172,Phase II,Recruiting,"Aduro Biotech, Inc. ","[{'id': 5716, 'therapyName': 'CRS-207 + Pembrolizumab'}]",Evaluation of CRS-207 With Pembrolizumab in Previously Treated MPM,06/12/2017,[],no
0,,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 5517, 'name': 'stomach carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03175224,Phase I,Recruiting,"CBT Pharmaceuticals, Inc. ","[{'id': 5963, 'therapyName': 'CBT-101'}]",CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation,09/06/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 5392, 'profileName': 'MET over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 24383, 'profileName': 'MET exon 14'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1629, 'profileName': 'MET amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03175432,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}]",Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases  (BEAT-MBM),06/20/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03178071,Expanded access,Available,Pfizer,"[{'id': 869, 'therapyName': 'PF-06463922'}]",Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer Harboring Specific Molecular Alterations,10/18/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT03178201,Phase II,Recruiting,Changchun Deng ,"[{'id': 2022, 'therapyName': 'TGR-1202'}]",TGR1202 in Relapsed and Refractory Follicular Lymphoma,06/12/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03178552,Phase II,Recruiting,Hoffmann-La Roche ,"[{'id': 4686, 'therapyName': 'Carboplatin + Cisplatin + Gemcitabine'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 4616, 'therapyName': 'Carboplatin + Cisplatin + Pemetrexed'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST),10/12/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03178851,Phase I,Recruiting,Hoffmann-La Roche ,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study Evaluating Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy,06/12/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'excluded'}]",yes
0,,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}]",NCT03179436,Phase I,Recruiting,Merck Sharp & Dohme Corp. ,"[{'id': 6039, 'therapyName': 'MK-1308 + Pembrolizumab'}]","Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)",07/28/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1202, 'profileName': 'EGFR mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT03179904,Phase II,Recruiting,Mayo Clinic ,"[{'id': 5874, 'therapyName': 'Paclitaxel + Trastuzumab + TVB-2640'}]","FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer",09/29/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT03179917,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma,06/20/2017,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT03179930,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 3354, 'therapyName': 'Entinostat + Pembrolizumab'}]",Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas,06/12/2017,[],no
0,both,"[{'id': 3963, 'name': 'thyroid carcinoma', 'source': 'DOID'}]",NCT03181100,Phase II,Recruiting,M.D. Anderson Cancer Center ,"[{'id': 619, 'therapyName': 'Abraxane'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 4595, 'therapyName': 'Atezolizumab + Bevacizumab'}, {'id': 3049, 'therapyName': 'Atezolizumab + nab-paclitaxel'}, {'id': 4825, 'therapyName': 'Atezolizumab + Vemurafenib + Cobimetinib'}, {'id': 5606, 'therapyName': 'Atezolizumab + Paclitaxel'}]",Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas,08/08/2017,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 481, 'profileName': 'NRAS wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 575, 'profileName': 'HRAS wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 4, 'profileName': 'BRAF wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1208, 'profileName': 'HRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT03181126,Phase I,Not yet recruiting,AbbVie ,"[{'id': 6187, 'therapyName': 'Navitoclax + Venetoclax'}]",A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed Acute Lymphoblastic Leukemia,09/11/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03181308,Phase I,Recruiting,Tracon Pharmaceuticals Inc.,"[{'id': 6334, 'therapyName': 'Carotuximab + Nivolumab'}]",Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC,10/18/2017,"[{'molecularProfile': {'id': 18885, 'profileName': 'ALK act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 27139, 'profileName': 'ROS1 act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03184558,Phase II,Recruiting,BerGenBio ASA ,"[{'id': 5964, 'therapyName': 'BGB-324 + Pembrolizumab'}]",BGB324 in Combination With Pembrolizumab in Patients With TNBC,08/05/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03184571,Phase II,Recruiting,BerGenBio ASA ,"[{'id': 5964, 'therapyName': 'BGB-324 + Pembrolizumab'}]",BGB324 in Combination With Pembrolizumab in Patients With Advanced NSCLC,09/29/2017,[],no
0,both,"[{'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT03184870,Phase Ib/II,Recruiting,Bristol-Myers Squibb ,"[{'id': 5905, 'therapyName': 'BMS-813160 + Fluorouracil + Irinotecan + Leucovorin'}, {'id': 5903, 'therapyName': 'BMS-813160 + Nivolumab'}, {'id': 5904, 'therapyName': 'BMS-813160 + Gemcitabine + nab-paclitaxel'}, {'id': 5902, 'therapyName': 'BMS-813160'}]",A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors,08/12/2017,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03187288,Phase I,Not yet recruiting,"University Health Network, Toronto","[{'id': 4029, 'therapyName': 'CFI-400945'}]",A Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,06/19/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}, {'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}, {'id': 1324, 'name': 'lung cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03188965,Phase I,Recruiting,Bayer ,"[{'id': 5962, 'therapyName': 'BAY1895344'}]",First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas,07/22/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03189186,Phase I,Recruiting,"University of California, Irvine ","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas,06/26/2017,[],no
0,both,"[{'id': 3748, 'name': 'esophagus squamous cell carcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}]",NCT03189719,Phase III,Recruiting,Merck Sharp & Dohme Corp. ,"[{'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}]",First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590),09/01/2017,[],no
0,both,"[{'id': 3371, 'name': 'chondrosarcoma', 'source': 'DOID'}, {'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}, {'id': 1907, 'name': 'malignant fibroxanthoma', 'source': 'DOID'}, {'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}, {'id': 3382, 'name': 'liposarcoma', 'source': 'DOID'}]",NCT03190174,Phase Ib/II,Recruiting,"Sarcoma Oncology Research Center, LLC ","[{'id': 5931, 'therapyName': 'Nab-Rapamycin + Nivolumab'}]",Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma,09/06/2017,[],no
0,both,"[{'id': 1800, 'name': 'neuroendocrine carcinoma', 'source': 'DOID'}]",NCT03190213,Phase II,Not yet recruiting,University of Utah,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma (Pembro NEC),06/29/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03190278,Phase I,Suspended,Cellectis S.A. ,"[{'id': 5994, 'therapyName': 'UCART123'}]",Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia,09/15/2017,[],no
0,both,"[{'id': 50458, 'name': 'juvenile myelomonocytic leukemia', 'source': 'DOID'}]",NCT03190915,Phase II,Recruiting,National Cancer Institute (NCI) ,"[{'id': 2, 'therapyName': 'Trametinib'}]",Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia,10/13/2017,"[{'molecularProfile': {'id': 1208, 'profileName': 'HRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 9821, 'profileName': 'PTPN11 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 13184, 'profileName': 'CBL mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03190941,Phase I,Recruiting,National Cancer Institute (NCI),"[{'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 6061, 'therapyName': 'anti-KRAS G12V mTCR cells'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*1101 Patients,07/31/2017,"[{'molecularProfile': {'id': 1127, 'profileName': 'KRAS G12V'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2794, 'profileName': 'HRAS G12V'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3354, 'profileName': 'NRAS G12V'}, 'requirementType': 'partial'}]",yes
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT03190967,Phase Ib/II,Recruiting,National Cancer Institute (NCI) ,"[{'id': 1402, 'therapyName': 'trastuzumab emtansine'}, {'id': 5932, 'therapyName': 'Temozolomide + Trastuzumab emtansine'}]",T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery,09/19/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03191149,Phase II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 660, 'therapyName': 'Osimertinib'}]",Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations,06/26/2017,"[{'molecularProfile': {'id': 4039, 'profileName': 'EGFR exon 20 ins'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03191786,Phase III,Recruiting,Hoffmann-La Roche ,"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}]",A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy,09/06/2017,"[{'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 2446, 'profileName': 'ALK fusion'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT03192202,Phase Ib/II,Recruiting,Ahmed Sawas ,"[{'id': 4389, 'therapyName': 'AFM13'}]",AFM13 in Relapsed/Refractory Cutaneous Lymphomas,09/01/2017,[],yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03192345,Phase I,Recruiting,Sanofi ,"[{'id': 5934, 'therapyName': 'SAR439459 + REGN2810'}, {'id': 5933, 'therapyName': 'SAR439459'}]","A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors",06/29/2017,[],no
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT03193190,Phase Ib/II,Recruiting,Hoffmann-La Roche,"[{'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 5940, 'therapyName': 'Gemcitabine + Nab-Paclitaxel + mFOLFOX-6'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC),06/29/2017,[],no
0,both,"[{'id': 3284, 'name': 'thymic carcinoma', 'source': 'DOID'}, {'id': 3275, 'name': 'thymoma', 'source': 'DOID'}]",NCT03193437,Phase II,Not yet recruiting,Georgetown University,"[{'id': 1749, 'therapyName': 'Selinexor'}]",Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy,06/29/2017,[],no
0,female,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03193853,Phase II,Recruiting,Baylor Research Institute,"[{'id': 3126, 'therapyName': 'Cisplatin + nab-paclitaxel'}, {'id': 1283, 'therapyName': 'MLN1117 + Sapanisertib'}]",TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer,06/29/2017,[],yes
0,both,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}]",NCT03193918,Phase I,Recruiting,"Arog Pharmaceuticals, Inc.","[{'id': 5943, 'therapyName': 'Crenolanib + Paclitaxel + Ramucirumab'}]",Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma,06/29/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03194373,Phase II,Recruiting,University of Michigan Cancer Center,"[{'id': 4735, 'therapyName': 'Carboplatin + Palbociclib'}]",Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,09/29/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03194867,Phase Ib/II,Not yet recruiting,Sanofi ,"[{'id': 6335, 'therapyName': 'Isatuximab + REGN2810'}]",Isatuximab in Combination With REGN2810 in Relapsed/Refractory Multiple Myeloma (RRMM) Patients,10/18/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT03194893,Phase III,Recruiting,Hoffmann-La Roche,"[{'id': 706, 'therapyName': 'Crizotinib'}, {'id': 698, 'therapyName': 'Alectinib'}]",A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer,07/03/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1326, 'profileName': 'RET rearrange'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03194932,Phase I,Recruiting,St. Jude Children's Research Hospital ,"[{'id': 712, 'therapyName': 'Cytarabine'}]",Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia,07/12/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03195699,Phase I,Not yet recruiting,"StemMed, Ltd., USA ","[{'id': 5961, 'therapyName': 'C188-9'}]","Phase I Study of Oral STAT3 Inhibitor, C188-9, in Patients With Advanced Cancers",07/03/2017,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 4914, 'name': 'esophagus adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT03196232,Phase II,Recruiting,Pamela L. Kunz,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]",Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer,09/22/2017,[],no
0,both,"[{'id': 3721, 'name': 'plasmacytoma', 'source': 'DOID'}]",NCT03196401,Phase I,Suspended,Memorial Sloan Kettering Cancer Center,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",A Study of Immunotherapy Plus Radiation Therapy to Stimulate Immunity in Solitary Bone Plasmacytoma,09/20/2017,[],no
0,both,"[{'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}, {'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT03197506,Phase II,Recruiting,Mayo Clinic,"[{'id': 5221, 'therapyName': 'Pembrolizumab + Temozolomide'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma,09/21/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03197935,Phase III,Recruiting,Hoffmann-La Roche,"[{'id': 1476, 'therapyName': 'Pegfilgrastim'}, {'id': 1009, 'therapyName': 'Doxorubicin'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1632, 'therapyName': 'Filgrastim'}, {'id': 619, 'therapyName': 'Abraxane'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}]",A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031),07/18/2017,[],yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03199040,Phase I,Not yet recruiting,Washington University School of Medicine,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy,07/06/2017,[],yes
0,both,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT03199885,Phase III,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 1549, 'therapyName': 'Pertuzumab + Trastuzumab + Paclitaxel'}, {'id': 5956, 'therapyName': 'Paclitaxel + Pembrolizumab + Pertuzumab + Trastuzumab'}]","Paclitaxel, Trastuzumab, and Pertuzumab With or Without Pembrolizumab in Treating Patients With Metastatic Breast Cancer",06/30/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03200847,Phase Ib/II,Not yet recruiting,"University of Colorado, Denver","[{'id': 5988, 'therapyName': 'Pembrolizumab + Tretinoin'}]",Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma,07/12/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03201250,Phase Ib/II,Not yet recruiting,"Muhamed Baljevic, MD","[{'id': 6330, 'therapyName': 'Cabozantinib + Carfilzomib + Dexamethasone'}]",Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma,10/17/2017,[],no
0,both,"[{'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT03201458,Phase II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery,07/06/2017,[],no
0,both,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}]",NCT03201913,Phase I,Not yet recruiting,"TTC Oncology, LLC ","[{'id': 5960, 'therapyName': 'TTC-352'}]",Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy,07/03/2017,[],yes
0,female,"[{'id': 6263, 'name': 'inflammatory breast carcinoma', 'source': 'DOID'}]",NCT03202316,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 5970, 'therapyName': 'Atezolizumab + Cobimetinib + Eribulin'}]",Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer,09/06/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03202940,Phase Ib/II,Recruiting,Massachusetts General Hospital,"[{'id': 5971, 'therapyName': 'Alectinib + Cobimetinib'}]",A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC,08/12/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT03203304,Phase I,Recruiting,University of Chicago ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma,09/13/2017,[],no
0,both,"[{'id': 1035, 'name': 'natural killer cell leukemia', 'source': 'DOID'}]",NCT03203369,Phase I,Suspended,Cellectis S.A. ,"[{'id': 5994, 'therapyName': 'UCART123'}]",Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN (ABC123),09/15/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03203473,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study),10/12/2017,[],no
0,both,"[{'id': 6354, 'name': 'CLL/SLL', 'source': 'DOID'}]",NCT03204188,Phase II,Recruiting,"National Heart, Lung, and Blood Institute (NHLBI) ","[{'id': 6154, 'therapyName': 'Fludarabine + Ibrutinib + Pembrolizumab'}]","Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",09/29/2017,"[{'molecularProfile': {'id': 434, 'profileName': 'TP53 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 14278, 'profileName': 'NOTCH1 mutant'}, 'requirementType': 'partial'}]",yes
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03204812,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Tremelimumab + Durvalumab Chemotherapy Naive CRPC,07/19/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT03205046,Phase Ib/II,Recruiting,Acerta Pharma BV ,"[{'id': 6188, 'therapyName': 'Acalabrutinib + Vistusertib'}]",A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies,09/11/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 50933, 'name': 'ovarian serous carcinoma', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT03205176,Phase I,Recruiting,AstraZeneca,"[{'id': 4910, 'therapyName': 'AZD5153'}]",Phase I Study of AZD5153 in Patients With Relapsed or Refractory Solid Tumors and Lymphomas,07/20/2017,[],no
0,female,"[{'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}]",NCT03206047,Phase Ib/II,Recruiting,National Cancer Institute (NCI) ,"[{'id': 4693, 'therapyName': 'Atezolizumab + SGI-110'}, {'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 5982, 'therapyName': 'Atezolizumab + SGI-110 + DEC-205-NY-ESO-1 fusion protein vaccine'}]","Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",10/03/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT03206073,Phase Ib/II,Recruiting,National Cancer Institute (NCI),"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer,10/07/2017,[],no
0,female,"[{'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 363, 'name': 'uterine cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 4236, 'name': 'carcinosarcoma', 'source': 'DOID'}]",NCT03206177,Phase I,Recruiting,University of Oklahoma ,"[{'id': 6265, 'therapyName': 'Carboplatin + Galunisertib + Paclitaxel'}]",Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary,10/03/2017,[],no
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03206203,Phase II,Recruiting,Vanderbilt-Ingram Cancer Center,"[{'id': 5983, 'therapyName': 'Atezolizumab + Carboplatin'}, {'id': 1092, 'therapyName': 'Carboplatin'}]",Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer,08/02/2017,[],yes
0,female,"[{'id': 4901, 'name': 'peritoneal serous adenocarcinoma', 'source': 'DOID'}, {'id': 5301, 'name': 'fallopian tube clear cell adenocarcinoma', 'source': 'DOID'}, {'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 5831, 'name': 'fallopian tube endometrioid adenocarcinoma', 'source': 'DOID'}, {'id': 1963, 'name': 'fallopian tube carcinoma', 'source': 'DOID'}, {'id': 5598, 'name': 'fallopian tube serous adenocarcinoma', 'source': 'DOID'}, {'id': 1791, 'name': 'peritoneal carcinoma', 'source': 'DOID'}]",NCT03206645,Phase I,Recruiting,University of Oklahoma ,"[{'id': 6266, 'therapyName': 'Carboplatin + Paclitaxel + PTC596'}]",PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy,09/29/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03207334,Phase II,Not yet recruiting,University of Florida,"[{'id': 6095, 'therapyName': 'Cytarabine + Midostaurin'}]",iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-BMT-AML-001),08/08/2017,[],no
0,both,"[{'id': 1790, 'name': 'malignant mesothelioma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 6039, 'name': 'uveal melanoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03207347,Phase II,Not yet recruiting,University of Florida ,"[{'id': 832, 'therapyName': 'Niraparib'}]",A Trial of Niraparib in BAP1 and Other DNA Double-Strand Break Repair Deficient Neoplasms (UF-STO-ETI-001),07/07/2017,"[{'molecularProfile': {'id': 1213, 'profileName': 'PTEN mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1205, 'profileName': 'BRCA1 mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1781, 'profileName': 'IDH1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1206, 'profileName': 'BRCA2 mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 5912, 'profileName': 'IDH2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3274, 'profileName': 'ATM mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT03207529,Phase I,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 3751, 'therapyName': 'BYL719 + Enzalutamide'}]",Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer,07/10/2017,"[{'molecularProfile': {'id': 18161, 'profileName': 'PTEN positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}]",NCT03207555,Phase II,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL),07/10/2017,[],no
0,both,"[{'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}]",NCT03208712,Phase I,Not yet recruiting,University of Michigan Cancer Center ,"[{'id': 4881, 'therapyName': 'Atezolizumab + Ra 223'}]",Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy,07/10/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03209401,Phase I,Not yet recruiting,Georgetown University ,"[{'id': 5984, 'therapyName': 'Carboplatin + Niraparib'}]",Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies,07/11/2017,"[{'molecularProfile': {'id': 23602, 'profileName': 'ATRX inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1282, 'profileName': 'BRCA1 inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 2095, 'profileName': 'PTEN inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1283, 'profileName': 'BRCA2 inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 522, 'profileName': 'ATM inact mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT03210662,Phase II,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Fractionated External Beam Radiotherapy (EBRT) in Patients With Non-Hodgkin Lymphoma (NHL),07/28/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 3405, 'name': 'histiocytosis', 'source': 'DOID'}]",NCT03210714,Phase II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 1028, 'therapyName': 'JNJ-42756493'}]","Pediatric MATCH: Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations",07/31/2017,"[{'molecularProfile': {'id': 1222, 'profileName': 'FGFR3 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1221, 'profileName': 'FGFR1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1185, 'profileName': 'FGFR2 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT03211117,Phase II,Recruiting,Mayo Clinic,"[{'id': 6040, 'therapyName': 'Docetaxel + Doxorubicin + Pembrolizumab'}]","Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer",09/06/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT03211416,Phase Ib/II,Recruiting,Roswell Park Cancer Institute ,"[{'id': 6041, 'therapyName': 'Pembrolizumab + Sorafenib'}]",Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer,09/19/2017,[],no
0,both,"[{'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT03211988,Phase II,Not yet recruiting,Edward Gelmann ,"[{'id': 1541, 'therapyName': 'Entinostat'}]",Entinostat Neuroendocrine (NE) Tumor,07/28/2017,[],no
0,both,"[{'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03212274,Phase II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 837, 'therapyName': 'Olaparib'}]","Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations",07/28/2017,"[{'molecularProfile': {'id': 5912, 'profileName': 'IDH2 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1781, 'profileName': 'IDH1 mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03213041,Phase II,Recruiting,Northwestern University,"[{'id': 5265, 'therapyName': 'Carboplatin + Pembrolizumab'}]",Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer,10/03/2017,[],yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT03213626,Phase II,Not yet recruiting,Bert Howard O'Neil,"[{'id': 1255, 'therapyName': 'Cabozantinib + Erlotinib'}]",Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma,07/28/2017,"[{'molecularProfile': {'id': 5392, 'profileName': 'MET over exp'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 2419, 'profileName': 'EGFR over exp'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 3405, 'name': 'histiocytosis', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03213652,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 961, 'therapyName': 'X-396'}]","Pediatric MATCH: Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations",07/29/2017,"[{'molecularProfile': {'id': 2446, 'profileName': 'ALK fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1249, 'profileName': 'ROS1 fusion'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1267, 'profileName': 'ALK mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3405, 'name': 'histiocytosis', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT03213665,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 2683, 'therapyName': 'Tazemetostat'}]","Pediatric MATCH: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations",07/29/2017,"[{'molecularProfile': {'id': 2517, 'profileName': 'EZH2 act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 26056, 'profileName': 'SMARCB1 inact mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03213678,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 1069, 'therapyName': 'LY3023414'}]","Pediatric MATCH: PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations",08/08/2017,"[{'molecularProfile': {'id': 743, 'profileName': 'PIK3CA act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3405, 'name': 'histiocytosis', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT03213691,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 913, 'therapyName': 'Selumetinib'}]","Pediatric MATCH: Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations",07/29/2017,"[{'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1208, 'profileName': 'HRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 24999, 'profileName': 'GNA11 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 25000, 'profileName': 'GNAQ mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}]",yes
0,,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03213704,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 2650, 'therapyName': 'LOXO-101'}]","Pediatric MATCH: Trk Inhibitor LOXO-101 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions",07/31/2017,[],yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT03214250,Phase Ib/II,Recruiting,Parker Institute for Cancer Immunotherapy ,"[{'id': 6047, 'therapyName': 'Gemcitabine + nab-paclitaxel + Nivolumab'}, {'id': 6048, 'therapyName': 'APX005M + Gemcitabine + nab-paclitaxel'}, {'id': 6049, 'therapyName': 'APX005M + Gemcitabine + nab-paclitaxel + Nivolumab'}]",Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma,10/03/2017,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03214562,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 6329, 'therapyName': 'Cytarabine + Filgrastim + Fludarabine + Idarubicin + Venetoclax'}]",Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML),10/17/2017,[],no
0,both,"[{'id': 3962, 'name': 'follicular thyroid carcinoma', 'source': 'DOID'}, {'id': 3969, 'name': 'papillary thyroid carcinoma', 'source': 'DOID'}, {'id': 8161, 'name': 'thyroid Hurthle cell carcinoma', 'source': 'DOID'}]",NCT03215095,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers,07/28/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT03215264,Phase Ib/II,Not yet recruiting,Abramson Cancer Center of the University of Pennsylvania ,"[{'id': 6052, 'therapyName': 'Entinostat + Hydroxychloroquine + Regorafenib'}]","Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer",10/05/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03215511,Phase Ib/II,Recruiting,"Loxo Oncology, Inc.","[{'id': 5917, 'therapyName': 'LOXO-195'}]",Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusions or Non-fusion NTRK Cancers,07/28/2017,[],yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03215706,Phase III,Recruiting,Bristol-Myers Squibb,"[{'id': 6132, 'therapyName': 'Carboplatin + Cisplatin + Paclitaxel + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA),08/21/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'excluded'}]",yes
0,,[],NCT03215810,,Recruiting,,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1166, 'therapyName': 'Fludarabine'}]",Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer,10/14/2017,[],
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT03216499,Phase II,Recruiting,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 4146, 'therapyName': 'PT2385'}]",HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma,08/18/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03217071,Phase II,Recruiting,Sue Yom,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer,09/06/2017,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03217253,Phase I,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 2683, 'therapyName': 'Tazemetostat'}]",Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction,07/31/2017,[],no
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT03217266,Phase I,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 1452, 'therapyName': 'AMG 232'}]",MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma,07/28/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}]",NCT03217747,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 5052, 'therapyName': 'Avelumab + Cisplatin'}, {'id': 6044, 'therapyName': 'Avelumab + PF-04518600 + Utomilumab'}, {'id': 6043, 'therapyName': 'Avelumab + Utomilumab'}, {'id': 6045, 'therapyName': 'Avelumab + PF-04518600'}]",Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies,08/12/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03217838,Phase Ib/II,Recruiting,AstraZeneca,"[{'id': 3547, 'therapyName': 'AZD2811'}]","Safety, Tolerability, and Efficacy of AZD2811 Nanoparticles in Patients With Relapsed AML/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients.",09/25/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03218826,Phase I,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 6046, 'therapyName': 'AZD8186 + Docetaxel'}]",PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery,07/28/2017,"[{'molecularProfile': {'id': 429, 'profileName': 'PIK3CA mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 2095, 'profileName': 'PTEN inact mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT03219047,Phase I,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",The EXPLORE Trial: Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response,07/28/2017,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03219268,Phase I,Recruiting,MacroGenics,"[{'id': 6060, 'therapyName': 'MGD013'}]",A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms,09/06/2017,[],no
0,both,"[{'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}]",NCT03219333,Phase II,Recruiting,"Astellas Pharma Global Development, Inc.","[{'id': 4125, 'therapyName': 'Enfortumab vedotin'}]",A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201),10/08/2017,[],no
0,both,"[{'id': 50929, 'name': 'mucosal melanoma', 'source': 'DOID'}]",NCT03220009,Phase II,Not yet recruiting,National Cancer Institute (NCI) ,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma",07/28/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3405, 'name': 'histiocytosis', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT03220035,Phase II,Recruiting,National Cancer Institute (NCI) ,"[{'id': 342, 'therapyName': 'Vemurafenib'}]","Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations",07/29/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03220477,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 6042, 'therapyName': 'Mocetinostat + Pembrolizumab + SGI-110'}]",Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.,08/10/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}, {'id': 3565, 'name': 'meningioma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3234, 'name': 'central nervous system lymphoma', 'source': 'DOID'}, {'id': 5074, 'name': 'malignant ependymoma', 'source': 'DOID'}]",NCT03220646,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.,07/28/2017,"[{'molecularProfile': {'id': 1781, 'profileName': 'IDH1 mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1101, 'profileName': 'RB1 wild-type'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1806, 'profileName': 'CDKN2A loss'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 576, 'profileName': 'IDH1 wild-type'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 5409, 'name': 'lung small cell carcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}, {'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03221400,Phase Ib/II,Recruiting,Tarveda Therapeutics ,"[{'id': 4842, 'therapyName': 'STA-8666'}]",PEN-866 in Patients With Advanced Solid Malignancies,07/28/2017,[],no
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT03221426,Phase III,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 3999, 'therapyName': 'Capecitabine + Cisplatin'}, {'id': 6050, 'therapyName': 'Capecitabine + Cisplatin + Pembrolizumab'}, {'id': 6051, 'therapyName': 'Cisplatin + Fluorouracil + Pembrolizumab'}, {'id': 1833, 'therapyName': 'Cisplatin + Fluorouracil'}]",Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585),09/30/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03221634,Phase II,Not yet recruiting,Merck Sharp & Dohme Corp. ,"[{'id': 6115, 'therapyName': 'Daratumumab + Pembrolizumab'}]",Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668),08/18/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT03222076,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956),10/03/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03223155,Phase I,Recruiting,University of Chicago,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer",09/15/2017,[],no
0,both,"[{'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}]",NCT03223610,Phase I,Not yet recruiting,National Cancer Institute (NCI) ,"[{'id': 6189, 'therapyName': 'Ibrutinib + Lenalidomide + Obinutuzumab + Prednisone + Venetoclax'}]","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma",09/11/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT03223779,Phase Ib/II,Not yet recruiting,Massachusetts General Hospital,"[{'id': 4586, 'therapyName': 'Trifluridine'}]",Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer,07/31/2017,[],no
0,both,"[{'id': 3847, 'name': 'papillary craniopharyngioma', 'source': 'DOID'}]",NCT03224767,Phase II,Recruiting,Alliance for Clinical Trials in Oncology ,"[{'id': 1657, 'therapyName': 'Vemurafenib + Cobimetinib'}]",Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma,08/18/2017,"[{'molecularProfile': {'id': 1, 'profileName': 'BRAF V600E'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03224871,Phase I,Recruiting,"University of California, Davis","[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1167, 'therapyName': 'Aldesleukin'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.,09/06/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03225105,Phase I,Recruiting,"EMD Serono Research & Development Institute, Inc.","[{'id': 6059, 'therapyName': 'M3541'}]",M3541 in Combination With Radiotherapy in Subjects With Solid Tumors,09/12/2017,[],no
0,both,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03225547,Phase II,Not yet recruiting,University of Chicago ,"[{'id': 6030, 'therapyName': 'Mifepristone + Pembrolizumab'}]",Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer,07/28/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03225664,Phase Ib/II,Not yet recruiting,M.D. Anderson Cancer Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}]",BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC),07/28/2017,[],no
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT03226249,Phase II,Not yet recruiting,Northwestern University ,"[{'id': 6157, 'therapyName': 'Dacarbazine + Doxorubicin + Pembrolizumab +Vinblastine'}]",PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma,09/01/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03227432,Phase II,Not yet recruiting,Dana-Farber Cancer Institute ,"[{'id': 6118, 'therapyName': 'Dexamethasone + Elotuzumab + Nivolumab + Pomalidomide'}, {'id': 6117, 'therapyName': 'Elotuzumab + Nivolumab'}]",An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma,08/18/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03228186,Phase II,Not yet recruiting,University of Michigan Cancer Center ,"[{'id': 6033, 'therapyName': 'Docetaxel + MLN4924'}]",Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer,07/28/2017,[],no
0,both,"[{'id': 7474, 'name': 'malignant pleural mesothelioma', 'source': 'DOID'}]",NCT03228537,Phase I,Not yet recruiting,National Cancer Institute (NCI) ,"[{'id': 6036, 'therapyName': 'Atezolizumab + Cisplatin + Pemetrexed'}]","Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma",07/28/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03228667,Phase II,Not yet recruiting,Altor Bioscience Corporation,"[{'id': 3061, 'therapyName': 'ALT-803 + Nivolumab'}, {'id': 6037, 'therapyName': 'ALT-803 + Pembrolizumab'}]","QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy",07/28/2017,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 1240, 'name': 'leukemia', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03229200,FDA approved,Recruiting,Pharmacyclics Switzerland GmbH,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.,08/21/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT03229278,Phase I,Recruiting,"Rutgers, The State University of New Jersey","[{'id': 6055, 'therapyName': 'Nivolumab + Pembrolizumab + Trigriluzole'}]",Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma,10/19/2017,[],no
0,both,"[{'id': 4928, 'name': 'intrahepatic cholangiocarcinoma', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT03230318,Phase III,Recruiting,ArQule,"[{'id': 2900, 'therapyName': 'ARQ 087'}]",ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma,07/31/2017,"[{'molecularProfile': {'id': 2969, 'profileName': 'FGFR2 fusion'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5151, 'name': 'plexiform neurofibroma', 'source': 'DOID'}]",NCT03231306,Phase II,Not yet recruiting,University of Alabama at Birmingham,"[{'id': 807, 'therapyName': 'Binimetinib'}]",Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas (NF108-BINI),07/31/2017,[],yes
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT03232307,Phase II,Not yet recruiting,M.D. Anderson Cancer Center ,"[{'id': 1610, 'therapyName': 'Rituximab + Lenalidomide + Ibrutinib'}]",Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL),09/19/2017,[],yes
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3405, 'name': 'histiocytosis', 'source': 'DOID'}]",NCT03233204,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 837, 'therapyName': 'Olaparib'}]","Pediatric MATCH: Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes",08/08/2017,"[{'molecularProfile': {'id': 1283, 'profileName': 'BRCA2 inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1282, 'profileName': 'BRCA1 inact mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 522, 'profileName': 'ATM inact mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}]",NCT03233347,Phase II,Not yet recruiting,Academic and Community Cancer Research United ,"[{'id': 6328, 'therapyName': 'Brentuximab vedotin + Dacarbazine + Doxorubicin + Nivolumab + Vinblastine'}]","Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma",10/17/2017,[],no
0,both,"[{'id': 12239, 'name': 'anal margin squamous cell carcinoma', 'source': 'DOID'}]",NCT03233711,Phase II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer,08/08/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03233724,Phase Ib/II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","The Immune Checkpoint Inhibitor Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung Cancer",08/08/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 18885, 'profileName': 'ALK act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 60061, 'name': 'cutaneous T cell lymphoma', 'source': 'DOID'}]",NCT03235869,Phase I,Not yet recruiting,University of Michigan Cancer Center ,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma,08/18/2017,[],no
0,both,"[{'id': 2531, 'name': 'hematologic cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03236857,Phase I,Not yet recruiting,AbbVie,"[{'id': 1562, 'therapyName': 'Venetoclax'}]",A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies,08/08/2017,[],yes
0,both,"[{'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03236935,Phase I,Not yet recruiting,Jorge G. Darcourt,"[{'id': 6097, 'therapyName': 'L-NMMA + Pembrolizumab'}]",Phase Ib of L-NMMA and Pembrolizumab,08/08/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03237390,Phase I,Recruiting,Mayo Clinic,"[{'id': 2898, 'therapyName': 'Gemcitabine + Ribociclib'}]",Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors,09/29/2017,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT03237572,Phase I,Recruiting,"Patrick Dillon, MD","[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer (Breast-48),09/29/2017,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}, {'id': 5974, 'name': 'renal pelvis transitional cell carcinoma', 'source': 'DOID'}, {'id': 6888, 'name': 'ureter transitional cell carcinoma', 'source': 'DOID'}, {'id': 4013, 'name': 'urethra transitional cell carcinoma', 'source': 'DOID'}]",NCT03237780,Phase II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 1201, 'therapyName': 'Atezolizumab'}, {'id': 6098, 'therapyName': 'Atezolizumab + Eribulin'}]",Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer,08/08/2017,[],no
0,both,"[{'id': 3459, 'name': 'breast carcinoma', 'source': 'DOID'}]",NCT03238196,Phase I,Recruiting,Vanderbilt-Ingram Cancer Center,"[{'id': 6099, 'therapyName': 'JNJ-42756493 + Fulvestrant + Palbociclib'}]","Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer",08/16/2017,"[{'molecularProfile': {'id': 3329, 'profileName': 'FGFR3 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 3147, 'profileName': 'FGFR2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 812, 'profileName': 'FGFR1 amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4972, 'name': 'myelodysplastic/myeloproliferative neoplasm', 'source': 'DOID'}, {'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}]",NCT03238248,Phase II,Recruiting,Vanderbilt-Ingram Cancer Center ,"[{'id': 6164, 'therapyName': 'Azacitidine + MLN4924'}]",Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors,10/03/2017,[],no
0,both,"[{'id': 8533, 'name': 'hypopharynx cancer', 'source': 'DOID'}, {'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 2876, 'name': 'laryngeal squamous cell carcinoma', 'source': 'DOID'}, {'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 50619, 'name': 'paranasal sinus cancer', 'source': 'DOID'}, {'id': 5515, 'name': 'nasal cavity squamous cell carcinoma', 'source': 'DOID'}]",NCT03238365,Phase I,Recruiting,Sidney Kimmel Cancer Center at Thomas Jefferson University,"[{'id': 6100, 'therapyName': 'Nivolumab + Tadalafil'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery,09/21/2017,[],no
0,female,"[{'id': 3459, 'name': 'breast carcinoma', 'source': 'DOID'}]",NCT03238495,Phase II,Recruiting,Qamar Khan,"[{'id': 1879, 'therapyName': 'Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}, {'id': 6101, 'therapyName': 'Metformin + Pertuzumab + Trastuzumab + Carboplatin + Docetaxel'}]",Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer,08/09/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03238638,Phase II,Not yet recruiting,University of Chicago,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]","A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy",08/08/2017,[],no
0,female,"[{'id': 3459, 'name': 'breast carcinoma', 'source': 'DOID'}]",NCT03238703,FDA approved,Not yet recruiting,Fred Hutchinson Cancer Research Center,"[{'id': 1456, 'therapyName': 'Tamoxifen'}, {'id': 738, 'therapyName': 'Exemestane'}, {'id': 4419, 'therapyName': 'Toremifine'}, {'id': 633, 'therapyName': 'Anastrozole'}, {'id': 794, 'therapyName': 'Letrozole'}]","Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer",08/10/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03239145,Phase I,Recruiting,Dana-Farber Cancer Institute,"[{'id': 6102, 'therapyName': 'Pembrolizumab + Trebananib'}]",Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor,09/06/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03239340,Phase III,Not yet recruiting,AstraZeneca,"[{'id': 660, 'therapyName': 'Osimertinib'}]",A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib,10/17/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 4039, 'profileName': 'EGFR exon 20 ins'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}]",NCT03240016,Phase II,Not yet recruiting,University of Michigan Cancer Center ,"[{'id': 4023, 'therapyName': 'nab-paclitaxel + Pembrolizumab'}]",Abraxane With Anti-PD1/PDL1 in Cisplatin-ineligible Patients With Advanced Urothelial Cancer,08/18/2017,[],no
0,,[],NCT03240211,,Not yet recruiting,,"[{'id': 650, 'therapyName': 'Decitabine'}, {'id': 1327, 'therapyName': 'Pralatrexate'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL,10/19/2017,[],
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03240861,Phase I,Not yet recruiting,Jonsson Comprehensive Cancer Center,"[{'id': 6116, 'therapyName': 'Busulfan + Fludarabine'}, {'id': 3933, 'therapyName': 'Filgrastim + Plerixafor'}, {'id': 1167, 'therapyName': 'Aldesleukin'}]",Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer (NYESO SCT),08/18/2017,[],yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03241173,Phase Ib/II,Not yet recruiting,Incyte Corporation ,"[{'id': 6120, 'therapyName': 'INCAGN01949 + Ipilimumab'}, {'id': 6119, 'therapyName': 'INCAGN01949 + Nivolumab'}, {'id': 6121, 'therapyName': 'INCAGN01949 + Ipilimumab + Nivolumab'}]",A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies,08/18/2017,[],no
0,female,"[{'id': 2871, 'name': 'endometrial carcinoma', 'source': 'DOID'}, {'id': 1970, 'name': 'fallopian tube carcinosarcoma', 'source': 'DOID'}, {'id': 4226, 'name': 'endometrial stromal sarcoma', 'source': 'DOID'}, {'id': 5289, 'name': 'uterus leiomyosarcoma', 'source': 'DOID'}, {'id': 6170, 'name': 'ovarian carcinosarcoma', 'source': 'DOID'}, {'id': 363, 'name': 'uterine cancer', 'source': 'DOID'}, {'id': 6171, 'name': 'uterine carcinosarcoma', 'source': 'DOID'}]",NCT03241745,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",A Study of Nivolumab in Selected Uterine Cancer Patients,08/18/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT03241810,Phase II,Recruiting,Merrimack Pharmaceuticals,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6327, 'therapyName': 'Fulvestrant + Seribantumab'}]",Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC),10/17/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03241927,Phase II,Recruiting,Nina Bhardwaj ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT),08/18/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03242915,Phase II,Recruiting,University of Michigan Cancer Center ,"[{'id': 2105, 'therapyName': 'Carboplatin +  Pembrolizumab + Pemetrexed '}]",Pembrolizumab in Combination With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) With Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs),10/20/2017,"[{'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1051, 'profileName': 'EGFR L861Q'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3321, 'profileName': 'EGFR S768I'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1207, 'profileName': 'EGFR G719X'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03243331,Phase I,Not yet recruiting,Kathy Miller,"[{'id': 6110, 'therapyName': 'Gedatolisib + PF-06647020'}]",An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer,08/14/2017,[],yes
0,both,"[{'id': 6477, 'name': 'invasive bladder transitional cell carcinoma', 'source': 'DOID'}]",NCT03244384,Phase III,Recruiting,National Cancer Institute (NCI),"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer,09/30/2017,[],no
0,both,"[{'id': 3247, 'name': 'rhabdomyosarcoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}, {'id': 3369, 'name': 'Ewing sarcoma', 'source': 'DOID'}]",NCT03245151,Phase Ib/II,Not yet recruiting,Eisai Inc. ,"[{'id': 1713, 'therapyName': 'Everolimus + Lenvatinib'}]","Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors",08/14/2017,[],no
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT03245541,Phase Ib/II,Recruiting,Cedars-Sinai Medical Center ,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Durvalumab and Stereotactive Ablative Body Radiotherapy in Advanced Pancreatic Adenocarcinoma (DurvaRad),09/01/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03245736,Phase II,Recruiting,Genmab ,"[{'id': 6113, 'therapyName': 'Tisotumab Vedotin'}]",Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.,08/14/2017,[],no
0,female,"[{'id': 2152, 'name': 'ovary epithelial cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT03245892,Phase I,Recruiting,Memorial Sloan Kettering Cancer Center ,"[{'id': 5303, 'therapyName': 'Nivolumab + Carboplatin + Paclitaxel'}]",A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer,08/14/2017,[],no
0,both,[],NCT03246906,Phase II,Not yet recruiting,Fred Hutchinson Cancer Research Center,[],Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation,08/18/2017,[],no
0,both,"[{'id': 1781, 'name': 'thyroid cancer', 'source': 'DOID'}]",NCT03246958,Phase II,Recruiting,Dana-Farber Cancer Institute,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab Plus Ipilimumab in Thyroid Cancer,10/12/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03247088,Phase Ib/II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 6122, 'therapyName': 'Busulfan + Sorafenib + Fludarabine'}, {'id': 1148, 'therapyName': 'Cyclophosphamide'}, {'id': 1843, 'therapyName': 'Tacrolimus'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation,08/18/2017,[],no
0,,"[{'id': 162, 'name': 'cancer', 'source': 'DOID'}]",NCT03247283,,Recruiting,,"[{'id': 3568, 'therapyName': 'BMS-986205'}]",Pharmacokinetics and Metabolism Study in Healthy Male Participants,08/24/2017,[],
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03247712,Phase Ib/II,Not yet recruiting,Providence Health & Services,"[{'id': 1312, 'therapyName': 'Nivolumab'}]",Neoadjuvant Immunoradiotherapy in Head & Neck Cancer,08/18/2017,[],no
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03248479,Phase I,Not yet recruiting,"Forty Seven, Inc.","[{'id': 6133, 'therapyName': 'Azacitidine + Hu5F9-G4'}, {'id': 4947, 'therapyName': 'Hu5F9-G4'}]",Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies,08/21/2017,[],no
0,both,"[{'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT03248492,Phase II,Recruiting,"Daiichi Sankyo, Inc. ","[{'id': 4844, 'therapyName': 'DS-8201a'}]",DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,09/05/2017,"[{'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT03249792,Phase I,Recruiting,Merck Sharp & Dohme Corp.,"[{'id': 6131, 'therapyName': 'MK-2118 + Pembrolizumab'}, {'id': 6130, 'therapyName': 'MK-2118'}]",Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) in the Treatment of Adults With Advance/Metastatic Solid Tumors or Lymphomas (MK-2118-001),09/30/2017,[],no
0,both,"[{'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT03250273,Phase II,Not yet recruiting,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 6114, 'therapyName': 'Entinostat + Nivolumab'}]",A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma,08/21/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT03250299,Phase I,Recruiting,Sidney Kimmel Comprehensive Cancer Center,"[{'id': 4908, 'therapyName': 'BAL101553'}]",Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma,08/21/2017,[],no
0,female,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}]",NCT03250676,Phase Ib/II,Recruiting,H3 Biomedicine Inc.,"[{'id': 6150, 'therapyName': 'H3B-6545'}]","Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer",09/08/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03251924,Phase Ib/II,Recruiting,Bristol-Myers Squibb,"[{'id': 6136, 'therapyName': 'BMS-986226 + Nivolumab'}, {'id': 6135, 'therapyName': 'BMS-986226 + Ipilimumab'}, {'id': 6134, 'therapyName': 'BMS-986226'}]",A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors,09/20/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03253679,Phase II,Not yet recruiting,National Cancer Institute (NCI) ,"[{'id': 822, 'therapyName': 'MK-1775'}]",WEE1 Inhibitor AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification,09/01/2017,[],yes
0,both,"[{'id': 8557, 'name': 'oropharynx cancer', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03254927,Phase II,Not yet recruiting,Celldex Therapeutics ,"[{'id': 2061, 'therapyName': 'Cetuximab + CDX-3379'}]",A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma,09/01/2017,[],no
0,both,"[{'id': 5822, 'name': 'gray zone lymphoma', 'source': 'DOID'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT03255018,Phase II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extra-Nodal Diffuse Large B-cell Lymphomas",09/01/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT03255096,Phase I,Recruiting,Hoffmann-La Roche ,"[{'id': 6179, 'therapyName': 'Rituximab + TEN-010 + Venetoclax'}]","A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)",09/08/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03256045,Phase II,Not yet recruiting,University of Washington,"[{'id': 6289, 'therapyName': 'Carfilzomib + Dexamethasone + Panobinostat'}]","Panobinostat, Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma",10/03/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03256136,Phase II,Not yet recruiting,Massachusetts General Hospital ,"[{'id': 6159, 'therapyName': 'Carboplatin + Nivolumab + Pemetrexed'}, {'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]","A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer",09/01/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 370, 'profileName': 'EGFR T790M'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT03257163,Phase II,Recruiting,"Rutgers, The State University of New Jersey","[{'id': 4022, 'therapyName': 'Capecitabine + Pembrolizumab'}]","Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer",10/07/2017,[],no
0,female,"[{'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}]",NCT03257267,Phase III,Recruiting,Regeneron Pharmaceuticals,"[{'id': 1074, 'therapyName': 'Irinotecan'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1685, 'therapyName': 'Vinorelbine'}, {'id': 854, 'therapyName': 'Pemetrexed'}, {'id': 5656, 'therapyName': 'REGN2810'}, {'id': 942, 'therapyName': 'Topotecan'}]",Study of REGN2810 in Adults With Cervical Cancer,10/08/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03257722,Phase Ib/II,Recruiting,Zhonglin Hao ,"[{'id': 6145, 'therapyName': 'Idelalisib + Pembrolizumab'}]",Pembrolizumab + Idelalisib for Lung Cancer Study,09/30/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 1793, 'name': 'pancreatic cancer', 'source': 'DOID'}, {'id': 4947, 'name': 'cholangiocarcinoma', 'source': 'DOID'}]",NCT03257761,Phase I,Not yet recruiting,University of Southern California ,"[{'id': 6146, 'therapyName': 'Durvalumab + SGI-110'}]","Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer",09/01/2017,[],no
0,both,"[{'id': 50866, 'name': 'oral squamous cell carcinoma', 'source': 'DOID'}, {'id': 50921, 'name': 'pharynx squamous cell carcinoma', 'source': 'DOID'}]",NCT03258008,Phase II,Not yet recruiting,M.D. Anderson Cancer Center ,"[{'id': 6148, 'therapyName': 'ISA101b + Utomilumab'}]",Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer,09/08/2017,[],no
0,both,"[{'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT03258398,Phase II,Recruiting,Effector Therapeutics ,"[{'id': 6238, 'therapyName': 'Avelumab + eFT508'}, {'id': 4005, 'therapyName': 'eFT508'}]",A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer,09/25/2017,[],no
0,,[],NCT03258515,,Recruiting,,[],A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers,10/05/2017,[],
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03258554,Phase II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 694, 'therapyName': 'Cetuximab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin,09/08/2017,[],no
0,both,"[{'id': 4006, 'name': 'bladder urothelial carcinoma', 'source': 'DOID'}]",NCT03258593,Phase I,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 6291, 'therapyName': 'Durvalumab + Oportuzumab monatox'}]",Durvalumab and Vicinium in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG),10/03/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03259425,Phase II,Not yet recruiting,University of Utah ,"[{'id': 6149, 'therapyName': 'HF10 + Nivolumab'}]","Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma",09/08/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 8567, 'name': ""Hodgkin's lymphoma"", 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT03259503,Phase Ib/II,Not yet recruiting,M.D. Anderson Cancer Center ,"[{'id': 1206, 'therapyName': 'Busulfan'}, {'id': 837, 'therapyName': 'Olaparib'}, {'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 2373, 'therapyName': 'Palifermin'}, {'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1207, 'therapyName': 'Melphalan'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 3277, 'therapyName': 'Pyridoxine'}, {'id': 897, 'therapyName': 'Rituximab'}]",Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas,09/01/2017,[],no
0,both,"[{'id': 962, 'name': 'neurofibroma', 'source': 'DOID'}]",NCT03259633,Expanded access,Available,AstraZeneca ,"[{'id': 913, 'therapyName': 'Selumetinib'}]",An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1,09/01/2017,[],yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT03259867,Phase II,Recruiting,Teclison Ltd. ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 1447, 'therapyName': 'Pembrolizumab'}]",Combination of TATE and PD-1 Inhibitor in Liver Cancer,09/01/2017,[],no
0,both,"[{'id': 4467, 'name': 'renal clear cell carcinoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03260504,Phase I,Not yet recruiting,University of Washington ,"[{'id': 4165, 'therapyName': 'Aldesleukin + Pembrolizumab'}]",Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer,09/08/2017,[],no
0,male,"[{'id': 10286, 'name': 'prostate carcinoma', 'source': 'DOID'}]",NCT03261999,Phase III,Recruiting,"Foresee Pharmaceuticals Co., Ltd.","[{'id': 795, 'therapyName': 'Leuprolide'}]","Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer",09/12/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03262779,Phase II,Recruiting,Yale University,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.,09/01/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT03263026,Phase III,Not yet recruiting,Denovo Biopharma LLC ,"[{'id': 2195, 'therapyName': 'R-CHOP'}, {'id': 1682, 'therapyName': 'Enzastaurin'}]",Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1,09/08/2017,[],yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT03263429,Phase Ib/II,Recruiting,Vanderbilt-Ingram Cancer Center,"[{'id': 6158, 'therapyName': 'CB-839 + Irinotecan + Panitumumab'}]",Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer,09/01/2017,"[{'molecularProfile': {'id': 496, 'profileName': 'KRAS wild-type'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}]",NCT03263572,Phase II,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 6155, 'therapyName': 'Blinatumomab + Cytarabine + Dexamethasone + Methotrexate + Ponatinib'}, {'id': 6156, 'therapyName': 'Blinatumomab + Dexamethasone + Ponatinib'}]",Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL),09/01/2017,[],yes
0,male,"[{'id': 10286, 'name': 'prostate carcinoma', 'source': 'DOID'}]",NCT03263650,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 3844, 'therapyName': 'Cabazitaxel + Carboplatin'}, {'id': 837, 'therapyName': 'Olaparib'}]",Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC,10/05/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03263936,Phase I,Recruiting,Therapeutic Advances in Childhood Leukemia Consortium ,"[{'id': 1077, 'therapyName': 'Vorinostat'}, {'id': 650, 'therapyName': 'Decitabine'}, {'id': 712, 'therapyName': 'Cytarabine'}, {'id': 1166, 'therapyName': 'Fludarabine'}, {'id': 1632, 'therapyName': 'Filgrastim'}]",Epigenetic Reprogramming in Relapse/Refractory AML,09/08/2017,[],no
0,both,"[{'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03264066,Phase II,Not yet recruiting,Hoffmann-La Roche,"[{'id': 6094, 'therapyName': 'Atezolizumab + Cabozantinib'}]",A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors,09/01/2017,[],no
0,both,"[{'id': 3498, 'name': 'pancreatic ductal adenocarcinoma', 'source': 'DOID'}]",NCT03264404,Phase II,Recruiting,Columbia University,"[{'id': 2496, 'therapyName': 'Azacitidine + Pembrolizumab'}]",Azacitidine and Pembrolizumab in Pancreatic Cancer,09/22/2017,[],no
0,,"[{'id': 12603, 'name': 'acute leukemia', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}, {'id': 8552, 'name': 'chronic myeloid leukemia', 'source': 'DOID'}]",NCT03267186,Phase II,Recruiting,Andrew Rezvani ,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant,10/13/2017,[],no
0,both,"[{'id': 3565, 'name': 'meningioma', 'source': 'DOID'}]",NCT03267836,Phase I,Not yet recruiting,Washington University School of Medicine ,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma,09/19/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03267888,Phase I,Not yet recruiting,Emory University,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma,10/03/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03268057,Phase Ib/II,Recruiting,Vaccinex Inc.,"[{'id': 6153, 'therapyName': 'Avelumab + VX15/2503'}]",VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer,10/14/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT03269669,Phase II,Recruiting,National Cancer Institute (NCI),"[{'id': 6257, 'therapyName': 'Obinutuzumab + CHOP'}, {'id': 6302, 'therapyName': 'Lenalidomide + Obinutuzumab\t'}, {'id': 6301, 'therapyName': 'Obinutuzumab + TGR-1202'}, {'id': 2188, 'therapyName': 'Prednisone'}]","Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",10/08/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03270176,Phase I,Recruiting,Debiopharm International SA ,"[{'id': 6178, 'therapyName': 'AT-406 + Avelumab'}]",A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy,10/07/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT03271047,Phase Ib/II,Recruiting,Array BioPharma ,"[{'id': 6326, 'therapyName': 'Binimetinib + Ipilimumab + Nivolumab'}, {'id': 6325, 'therapyName': 'Binimetinib + Nivolumab'}]",Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation,10/17/2017,"[{'molecularProfile': {'id': 1208, 'profileName': 'HRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 3, 'profileName': 'NRAS mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3965, 'name': 'Merkel cell carcinoma', 'source': 'DOID'}]",NCT03271372,Phase III,Not yet recruiting,University of Washington ,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Adjuvant Avelumab in Merkel Cell Cancer (ADAM),09/08/2017,[],no
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03272464,Phase I,Not yet recruiting,Massachusetts General Hospital ,"[{'id': 6176, 'therapyName': 'Dabrafenib + INCB039110 + Trametinib'}]",Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.,09/08/2017,"[{'molecularProfile': {'id': 465, 'profileName': 'BRAF mutant'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 499, 'profileName': 'BRAF V600E/K'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03273153,Phase III,Recruiting,Hoffmann-La Roche ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}]",A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma,10/19/2017,"[{'molecularProfile': {'id': 1186, 'profileName': 'BRAF V600X'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 7379, 'name': 'adrenal medulla carcinoma', 'source': 'DOID'}]",NCT03274258,Phase II,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma,09/08/2017,"[{'molecularProfile': {'id': 13297, 'profileName': 'SMARCB1 loss'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 707, 'name': 'B-cell lymphoma', 'source': 'DOID'}]",NCT03274492,Phase III,Not yet recruiting,Hoffmann-La Roche ,"[{'id': 4226, 'therapyName': 'Polatuzumab Vedotin'}, {'id': 6177, 'therapyName': 'R-CHP'}, {'id': 2195, 'therapyName': 'R-CHOP'}]","A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma",09/08/2017,"[{'molecularProfile': {'id': 1772, 'profileName': 'ALK positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03274661,Phase II,Not yet recruiting,Baptist Health South Florida ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab Activity in Patients With HR Competent and Deficient Tumors,09/08/2017,[],no
0,,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03275597,Phase I,Not yet recruiting,"University of Wisconsin, Madison ","[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition,09/08/2017,"[{'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03276832,Phase I,Not yet recruiting,Mayo Clinic ,"[{'id': 6220, 'therapyName': 'Imiquimod + Pembrolizumab'}]",Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma,09/19/2017,[],no
0,both,"[{'id': 5744, 'name': 'ovary serous adenocarcinoma', 'source': 'DOID'}, {'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}, {'id': 50861, 'name': 'colorectal adenocarcinoma', 'source': 'DOID'}]",NCT03277209,Phase I,Recruiting,Weill Medical College of Cornell University,"[{'id': 1756, 'therapyName': 'Plerixafor'}]","To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas",09/19/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}, {'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03277352,Phase Ib/II,Not yet recruiting,Incyte Biosciences International Sàrl,"[{'id': 6277, 'therapyName': 'Epacadostat + INCAGN01876 + Pembrolizumab'}]",INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies,10/03/2017,[],no
0,female,"[{'id': 120, 'name': 'female reproductive organ cancer', 'source': 'DOID'}]",NCT03277482,Phase I,Not yet recruiting,Dana-Farber Cancer Institute ,"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]","Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer",09/19/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3071, 'name': 'gliosarcoma', 'source': 'DOID'}]",NCT03277638,Phase Ib/II,Not yet recruiting,Case Comprehensive Cancer Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma,09/25/2017,[],no
0,both,"[{'id': 50626, 'name': 'gastrointestinal neuroendocrine tumor', 'source': 'DOID'}, {'id': 5410, 'name': 'pulmonary neuroendocrine tumor', 'source': 'DOID'}]",NCT03278379,Phase II,Not yet recruiting,Sunnybrook Health Sciences Centre,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in G2-3 NET (NET-002),09/25/2017,[],no
0,both,"[{'id': 50626, 'name': 'gastrointestinal neuroendocrine tumor', 'source': 'DOID'}, {'id': 5410, 'name': 'pulmonary neuroendocrine tumor', 'source': 'DOID'}]",NCT03278405,Phase Ib/II,Not yet recruiting,Sunnybrook Health Sciences Centre ,"[{'id': 3144, 'therapyName': 'Avelumab'}]",Avelumab in G3 NEC (NET-001),09/25/2017,[],no
0,both,"[{'id': 50749, 'name': 'peripheral T-cell lymphoma', 'source': 'DOID'}]",NCT03278782,Phase Ib/II,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 1075, 'therapyName': 'romidepsin'}, {'id': 5728, 'therapyName': 'Romidepsin + Pembrolizumab'}]",Study of Pembrolizumab (MK-3475) in Combination With Romidepsin,09/25/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03279250,Phase II,Recruiting,M.D. Anderson Cancer Center,"[{'id': 759, 'therapyName': 'Goserelin'}, {'id': 2050, 'therapyName': 'Triptorelin'}, {'id': 2649, 'therapyName': 'Abiraterone + ARN-509 + Prednisone'}, {'id': 795, 'therapyName': 'Leuprolide'}, {'id': 1947, 'therapyName': 'ARN-509'}]",Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence,10/19/2017,[],no
0,both,"[{'id': 3565, 'name': 'meningioma', 'source': 'DOID'}]",NCT03279692,Phase II,Not yet recruiting,Massachusetts General Hospital,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma,09/29/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT03280563,Phase Ib/II,Not yet recruiting,Hoffmann-La Roche,"[{'id': 6269, 'therapyName': 'Atezolizumab + Ipatasertib'}, {'id': 6270, 'therapyName': 'Atezolizumab + Bevacizumab + Exemestane'}, {'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6271, 'therapyName': 'Atezolizumab + Bevacizumab + Fulvestrant'}, {'id': 6272, 'therapyName': 'Atezolizumab + Bevacizumab + Tamoxifen'}, {'id': 6273, 'therapyName': 'Atezolizumab + Ipatasertib + Fulvestrant'}, {'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 6268, 'therapyName': 'Atezolizumab + Fulvestrant'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer,09/29/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 3717, 'name': 'gastric adenocarcinoma', 'source': 'DOID'}]",NCT03281369,Phase Ib/II,Not yet recruiting,Hoffmann-La Roche,"[{'id': 1343, 'therapyName': 'Atezolizumab + Cobimetinib'}, {'id': 6274, 'therapyName': 'mFOLFOX-6 + Atezolizumab + Cobimetinib'}, {'id': 6275, 'therapyName': 'mFOLFOX-6 + Atezolizumab'}, {'id': 6276, 'therapyName': 'Atezolizumab + Linagliptin'}, {'id': 5941, 'therapyName': 'Atezolizumab + PEGPH20'}, {'id': 5942, 'therapyName': 'Atezolizumab + BKT140'}, {'id': 1721, 'therapyName': 'Ramucirumab + Paclitaxel'}, {'id': 5850, 'therapyName': 'mFOLFOX-6'}]",A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA),09/29/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 4074, 'name': 'pancreatic adenocarcinoma', 'source': 'DOID'}]",NCT03281382,Phase I,Recruiting,Henry Ford Health System,"[{'id': 6283, 'therapyName': 'Ad5-yCD/mutTKSR39rep-hIL12 '}]",Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer,10/02/2017,[],no
0,both,"[{'id': 1907, 'name': 'malignant fibroxanthoma', 'source': 'DOID'}, {'id': 3347, 'name': 'osteosarcoma', 'source': 'DOID'}, {'id': 5702, 'name': 'pleomorphic liposarcoma', 'source': 'DOID'}, {'id': 1816, 'name': 'angiosarcoma', 'source': 'DOID'}, {'id': 3371, 'name': 'chondrosarcoma', 'source': 'DOID'}, {'id': 1967, 'name': 'leiomyosarcoma', 'source': 'DOID'}]",NCT03282344,Phase II,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 5076, 'therapyName': 'NKTR-214 + Nivolumab'}]",A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma,09/29/2017,[],no
0,both,"[{'id': 50746, 'name': 'mantle cell lymphoma', 'source': 'DOID'}]",NCT03282396,Phase II,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 768, 'therapyName': 'Ibrutinib'}]",Ibrutinib in Newly Diagnosed Mantle Cell Lymphoma With Low-Risk Disease,09/29/2017,[],yes
0,both,"[{'id': 1040, 'name': 'chronic lymphocytic leukemia', 'source': 'DOID'}, {'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}]",NCT03283137,Phase I,Not yet recruiting,University of Chicago ,"[{'id': 6237, 'therapyName': 'Pembrolizumab + TGR-1202'}]",Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL,09/25/2017,[],no
0,both,"[{'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}]",NCT03283605,Phase Ib/II,Not yet recruiting,Centre hospitalier de l'Université de Montréal (CHUM),"[{'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}]",Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas,09/29/2017,[],no
0,,[],NCT03283631,,Not yet recruiting,,[],Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM,09/14/2017,[],
0,both,"[{'id': 1115, 'name': 'sarcoma', 'source': 'DOID'}]",NCT03283696,Phase I,Recruiting,Eli Lilly and Company,"[{'id': 6292, 'therapyName': 'Doxorubicin + Ifosfamide + Mesna + Olaratumab'}]","A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma",10/20/2017,[],no
0,both,[],NCT03283917,Phase I,Not yet recruiting,M.D. Anderson Cancer Center,[],"Study of Daratumumab, Ixazomib, and Dexamethasone in Previously Treated Amyloid Light Chain (AL) Amyloidosis",10/02/2017,[],no
0,female,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}, {'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}]",NCT03283943,Phase I,Not yet recruiting,British Columbia Cancer Agency ,"[{'id': 1356, 'therapyName': 'Durvalumab'}]",PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.,09/25/2017,[],no
0,female,"[{'id': 3458, 'name': 'breast adenocarcinoma', 'source': 'DOID'}]",NCT03284957,Phase Ib/II,Recruiting,Sanofi ,"[{'id': 6293, 'therapyName': 'SAR439859'}, {'id': 6294, 'therapyName': 'Palbociclib + SAR439859'}]",Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer,10/03/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03285321,Phase II,Recruiting,"Greg Durm, MD ","[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}, {'id': 1312, 'therapyName': 'Nivolumab'}]",Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC),09/25/2017,[],no
0,female,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT03285412,,Not yet recruiting,,"[{'id': 790, 'therapyName': 'Ribociclib'}]","CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer",09/25/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,,"[{'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}]",NCT03285607,Phase I,Not yet recruiting,Washington University School of Medicine ,"[{'id': 6236, 'therapyName': 'Cyclophosphamide + Doxorubicin + Paclitaxel + MCS110'}]","MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer",09/25/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 50908, 'name': 'myelodysplastic syndrome', 'source': 'DOID'}, {'id': 9952, 'name': 'acute lymphocytic leukemia', 'source': 'DOID'}, {'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03286114,Phase I,Not yet recruiting,University of Michigan Cancer Center ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab,09/25/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03286296,Phase I,Recruiting,Livzon Pharmaceutical Group Inc.,"[{'id': 6281, 'therapyName': 'LZM009'}]",LZM009 to Treat Patients With Advanced Solid Tumors,10/02/2017,"[{'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03286530,Phase II,Not yet recruiting,Massachusetts General Hospital ,"[{'id': 907, 'therapyName': 'Ruxolitinib'}]",Ruxolitinib + Allogeneic Stem Cell Transplantation in AML,09/24/2017,[],no
0,both,"[{'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}]",NCT03287050,Phase I,Not yet recruiting,University of Michigan Cancer Center,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma",09/24/2017,[],no
0,both,"[{'id': 5517, 'name': 'stomach carcinoma', 'source': 'DOID'}, {'id': 4944, 'name': 'gastroesophageal junction adenocarcinoma', 'source': 'DOID'}, {'id': 1107, 'name': 'esophageal carcinoma', 'source': 'DOID'}]",NCT03288350,Phase II,Not yet recruiting,McGill University Health Center,"[{'id': 1930, 'therapyName': 'Cisplatin + Docetaxel + Fluorouracil'}, {'id': 3144, 'therapyName': 'Avelumab'}]",mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA),09/24/2017,[],no
0,both,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03288493,Phase I,Recruiting,"Poseida Therapeutics, Inc. ","[{'id': 6280, 'therapyName': 'P-BCMA-101 CAR-T cells'}]",P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM),10/02/2017,[],no
0,female,"[{'id': 60075, 'name': 'estrogen-receptor positive breast cancer', 'source': 'DOID'}]",NCT03289039,,Not yet recruiting,,"[{'id': 828, 'therapyName': 'Neratinib'}, {'id': 5705, 'therapyName': 'Fulvestrant + Neratinib'}]","A Phase 2 Study of Neratinib With or Without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer",09/24/2017,"[{'molecularProfile': {'id': 1270, 'profileName': 'ERBB2 over exp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'required'}, {'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}]",NCT03289741,FDA approved,Recruiting,Memorial Sloan Kettering Cancer Center,"[{'id': 6279, 'therapyName': 'Lanreotide Depot + Octreotide'}]",A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide,10/03/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}, {'id': 4362, 'name': 'cervical cancer', 'source': 'DOID'}, {'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}, {'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}, {'id': 2671, 'name': 'transitional cell carcinoma', 'source': 'DOID'}, {'id': 3151, 'name': 'skin squamous cell carcinoma', 'source': 'DOID'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}, {'id': 14110, 'name': 'anus cancer', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 3965, 'name': 'Merkel cell carcinoma', 'source': 'DOID'}, {'id': 4450, 'name': 'renal cell carcinoma', 'source': 'DOID'}]",NCT03289962,Phase I,Not yet recruiting,"Genentech, Inc. ","[{'id': 6234, 'therapyName': 'RO7198457'}, {'id': 6235, 'therapyName': 'Atezolizumab + RO7198457'}]",A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,09/24/2017,[],yes
0,both,"[{'id': 169, 'name': 'neuroendocrine tumor', 'source': 'DOID'}, {'id': 1800, 'name': 'neuroendocrine carcinoma', 'source': 'DOID'}]",NCT03290079,Phase II,Not yet recruiting,H. Lee Moffitt Cancer Center and Research Institute ,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas,09/24/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT03290937,Phase I,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 6288, 'therapyName': 'Cetuximab + Irinotecan + Utomilumab'}]","Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer",10/02/2017,[],no
0,both,"[{'id': 9253, 'name': 'gastrointestinal stromal tumor', 'source': 'DOID'}]",NCT03291054,Phase II,Not yet recruiting,Richard D. Carvajal ,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]",Epacadostat and Pembrolizumab in Patients With GIST,10/02/2017,[],no
0,both,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03291938,Phase I,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 6267, 'therapyName': 'IACS-010759'}]",Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma,09/29/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03292133,Phase II,Not yet recruiting,Massachusetts General Hospital ,"[{'id': 6287, 'therapyName': 'EGF816 + Gefitinib'}]",A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer,10/02/2017,"[{'molecularProfile': {'id': 367, 'profileName': 'EGFR exon 19 del'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 369, 'profileName': 'EGFR L858R'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'required'}]",yes
0,both,"[{'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 60081, 'name': 'triple-receptor negative breast cancer', 'source': 'DOID'}]",NCT03292172,Phase I,Not yet recruiting,Hoffmann-La Roche,"[{'id': 6286, 'therapyName': 'Atezolizumab + TEN-010'}]","A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer",10/02/2017,[],yes
0,both,"[{'id': 1725, 'name': 'peritoneum cancer', 'source': 'DOID'}, {'id': 60080, 'name': 'Her2-receptor negative breast cancer', 'source': 'DOID'}, {'id': 2394, 'name': 'ovarian cancer', 'source': 'DOID'}, {'id': 1964, 'name': 'fallopian tube cancer', 'source': 'DOID'}]",NCT03294694,Phase I,Not yet recruiting,Dana-Farber Cancer Institute ,"[{'id': 6285, 'therapyName': 'Fulvestrant + PDR001 + Ribociclib'}, {'id': 6284, 'therapyName': 'PDR001 + Ribociclib'}]",Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer,10/02/2017,"[{'molecularProfile': {'id': 1184, 'profileName': 'ERBB2 neg'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3284, 'name': 'thymic carcinoma', 'source': 'DOID'}, {'id': 3275, 'name': 'thymoma', 'source': 'DOID'}]",NCT03295227,Phase I,Not yet recruiting,M.D. Anderson Cancer Center,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma,10/02/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}, {'id': 3069, 'name': 'astrocytoma', 'source': 'DOID'}, {'id': 3181, 'name': 'oligodendroglioma', 'source': 'DOID'}, {'id': 3070, 'name': 'malignant glioma', 'source': 'DOID'}]",NCT03295396,Phase II,Not yet recruiting,"Oncoceutics, Inc.","[{'id': 1687, 'therapyName': 'ONC201'}]",ONC201 in Adults With Recurrent High-grade Glioma,10/02/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03295942,Phase I,Recruiting,"OncoMed Pharmaceuticals, Inc. ","[{'id': 6264, 'therapyName': 'OMP-336B11'}]",A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors,09/29/2017,[],no
0,both,"[{'id': 3068, 'name': 'glioblastoma multiforme', 'source': 'DOID'}]",NCT03296696,Phase I,Not yet recruiting,Amgen ,"[{'id': 6261, 'therapyName': 'AMG 596'}]",Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma,09/29/2017,[],no
0,both,"[{'id': 60060, 'name': 'non-Hodgkin lymphoma', 'source': 'DOID'}, {'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}, {'id': 50873, 'name': 'follicular lymphoma', 'source': 'DOID'}]",NCT03297424,Phase Ib/II,Recruiting,Plexxikon,"[{'id': 6324, 'therapyName': 'PLX2853'}]",A Study of PLX2853 in Advanced Malignancies.,10/17/2017,[],no
0,male,"[{'id': 2526, 'name': 'prostate adenocarcinoma', 'source': 'DOID'}]",NCT03298087,Phase II,Not yet recruiting,VA Office of Research and Development ,"[{'id': 4206, 'therapyName': 'Abiraterone + ARN-509 + Leuprolide'}]",Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer,10/08/2017,[],no
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT03298451,Phase III,Not yet recruiting,AstraZeneca,"[{'id': 920, 'therapyName': 'Sorafenib'}, {'id': 2439, 'therapyName': 'Durvalumab + Tremelimumab'}, {'id': 1356, 'therapyName': 'Durvalumab'}]",Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma,10/08/2017,[],no
0,both,"[{'id': 11054, 'name': 'urinary bladder cancer', 'source': 'DOID'}]",NCT03298958,Phase III,Not yet recruiting,The University of Texas Health Science Center at San Antonio ,"[{'id': 917, 'therapyName': 'Sirolimus'}]",Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer,10/08/2017,[],no
0,both,"[{'id': 9119, 'name': 'acute myeloid leukemia', 'source': 'DOID'}]",NCT03298984,Phase I,Not yet recruiting,"Tolero Pharmaceuticals, Inc. ","[{'id': 6300, 'therapyName': 'Alvocidib + Cytarabine + Daunorubicin'}]",Ph I Study of Alvocidib and Cytarabine/Duanorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).,10/07/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03299088,Phase I,Not yet recruiting,"University of California, Davis","[{'id': 1450, 'therapyName': 'Pembrolizumab + Trametinib'}]",Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations,10/07/2017,"[{'molecularProfile': {'id': 448, 'profileName': 'KRAS mutant'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 684, 'name': 'hepatocellular carcinoma', 'source': 'DOID'}]",NCT03299946,Phase I,Not yet recruiting,Sidney Kimmel Comprehensive Cancer Center ,"[{'id': 2067, 'therapyName': 'Cabozantinib + Nivolumab'}]",Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC),10/07/2017,[],no
0,female,"[{'id': 1380, 'name': 'endometrial cancer', 'source': 'DOID'}]",NCT03300557,Phase II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 738, 'therapyName': 'Exemestane'}]",Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer,10/07/2017,[],no
0,,[],NCT03301168,,Recruiting,,[],Safety Study of Gene Modified Donor T-cells Following TCR + Alpha Beta Depleted Stem Cell Transplant,10/19/2017,[],
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}, {'id': 5520, 'name': 'head and neck squamous cell carcinoma', 'source': 'DOID'}, {'id': 1909, 'name': 'melanoma', 'source': 'DOID'}]",NCT03301896,Phase I,Not yet recruiting,Novartis Pharmaceuticals,"[{'id': 6299, 'therapyName': 'LHC165 + PDR001'}, {'id': 6298, 'therapyName': 'LHC165'}]",Phase I/Ib Study of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,10/07/2017,[],no
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03302234,Phase III,Not yet recruiting,Merck Sharp & Dohme Corp.,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}, {'id': 2106, 'therapyName': 'Ipilimumab + Pembrolizumab '}]",Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598),10/07/2017,"[{'molecularProfile': {'id': 423, 'profileName': 'EGFR act mut'}, 'requirementType': 'excluded'}, {'molecularProfile': {'id': 1248, 'profileName': 'ALK rearrange'}, 'requirementType': 'excluded'}]",yes
0,both,"[{'id': 3908, 'name': 'non-small cell lung carcinoma', 'source': 'DOID'}]",NCT03302247,Phase II,Not yet recruiting,Fox Chase Cancer Center ,"[{'id': 1312, 'therapyName': 'Nivolumab'}, {'id': 6297, 'therapyName': 'Gemcitabine + Nivolumab'}]",Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy,10/07/2017,[],no
0,female,"[{'id': 60079, 'name': 'Her2-receptor positive breast cancer', 'source': 'DOID'}]",NCT03304080,Phase Ib/II,Not yet recruiting,Icahn School of Medicine at Mount Sinai ,"[{'id': 6323, 'therapyName': 'Anastrozole + Palbociclib + Pertuzumab + Trastuzumab'}]","Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast",10/17/2017,"[{'molecularProfile': {'id': 531, 'profileName': 'ERBB2 amp'}, 'requirementType': 'partial'}, {'molecularProfile': {'id': 1187, 'profileName': 'ERBB2 positive'}, 'requirementType': 'partial'}]",yes
0,both,"[{'id': 3965, 'name': 'Merkel cell carcinoma', 'source': 'DOID'}]",NCT03304639,Phase II,Not yet recruiting,National Cancer Institute (NCI),"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]",Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer,10/17/2017,[],no
0,both,"[{'id': 50745, 'name': 'diffuse large B-cell lymphoma', 'source': 'DOID'}]",NCT03305445,Phase Ib/II,Not yet recruiting,Icahn School of Medicine at Mount Sinai,"[{'id': 1627, 'therapyName': 'Nivolumab + Ipilimumab'}]",Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL,10/17/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03306420,Phase I,Recruiting,"EMD Serono Research & Development Institute, Inc.","[{'id': 6317, 'therapyName': 'MS201408-0005A + MS201408-0005B'}, {'id': 6318, 'therapyName': 'MS201408-0005A + MS201408-0005C'}, {'id': 6314, 'therapyName': 'MS201408-0005A'}]",First-in-Human Study of MS201408-0005A as Single Agent and in Combinations,10/17/2017,[],no
0,both,"[{'id': 9256, 'name': 'colorectal cancer', 'source': 'DOID'}]",NCT03307603,Phase Ib/II,Not yet recruiting,Case Comprehensive Cancer Center,"[{'id': 6319, 'therapyName': 'Yttrium-90 + Nivolumab'}]",Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer,10/17/2017,[],no
0,both,"[{'id': 10000003, 'name': 'Advanced Solid Tumor', 'source': 'JAX'}]",NCT03307785,Phase I,Recruiting,"Tesaro, Inc. ","[{'id': 6322, 'therapyName': 'Carboplatin + Paclitaxel + TSR-042'}, {'id': 6321, 'therapyName': 'Niraparib + TSR-042'}]",Study of Niraparib or Carboplatin-Paclitaxel in Combination With TSR-042,10/18/2017,[],no
0,,[],NCT03308942,,Recruiting,,"[{'id': 832, 'therapyName': 'Niraparib'}]","Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer",10/19/2017,[],
0,,"[{'id': 10283, 'name': 'prostate cancer', 'source': 'DOID'}, {'id': 1612, 'name': 'breast cancer', 'source': 'DOID'}]",NCT03310541,,Recruiting,,"[{'id': 744, 'therapyName': 'Fulvestrant'}, {'id': 1262, 'therapyName': 'Enzalutamide'}, {'id': 655, 'therapyName': 'AZD5363'}]",AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations,10/19/2017,[],
0,,[],NCT03310567,,Not yet recruiting,,"[{'id': 4088, 'therapyName': 'Epacadostat + Pembrolizumab'}]",A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma,10/19/2017,[],
0,,"[{'id': 162, 'name': 'cancer', 'source': 'DOID'}]",NCT03310879,,Not yet recruiting,,"[{'id': 802, 'therapyName': 'Abemaciclib'}]",A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6,10/19/2017,[],
0,,"[{'id': 60058, 'name': 'lymphoma', 'source': 'DOID'}]",NCT03311412,,Not yet recruiting,,[],Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies or Lymphomas,10/19/2017,[],
0,,[],NCT03311958,,Not yet recruiting,,[],Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance,10/19/2017,[],
0,,[],NCT03313778,,Recruiting,,"[{'id': 1447, 'therapyName': 'Pembrolizumab'}]","Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors",10/19/2017,[],
0,,[],NCT03314181,,Not yet recruiting,,"[{'id': 1562, 'therapyName': 'Venetoclax'}, {'id': 688, 'therapyName': 'Bortezomib'}, {'id': 1390, 'therapyName': 'Dexamethasone'}, {'id': 1630, 'therapyName': 'Daratumumab'}]","A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma",10/19/2017,[],
0,,[],NCT03314935,,Not yet recruiting,,"[{'id': 755, 'therapyName': 'Gemcitabine'}, {'id': 1104, 'therapyName': 'Oxaliplatin'}, {'id': 1103, 'therapyName': 'Paclitaxel'}, {'id': 700, 'therapyName': 'Cisplatin'}, {'id': 1642, 'therapyName': 'Leucovorin'}]",A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors,10/19/2017,[],
0,,"[{'id': 9538, 'name': 'multiple myeloma', 'source': 'DOID'}]",NCT03315026,,Not yet recruiting,,"[{'id': 3485, 'therapyName': 'siltuximab'}]",Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis,10/19/2017,[],
